Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - GAMG [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - hTERT-RPE1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - JURKAT [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - OE19 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - SuSa [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"	"Single Cell Type RNA - Alveolar cells type 1 [NX]"	"Single Cell Type RNA - Alveolar cells type 2 [NX]"	"Single Cell Type RNA - B-cells [NX]"	"Single Cell Type RNA - Basal glandular cells [NX]"	"Single Cell Type RNA - Basal keratinocytes [NX]"	"Single Cell Type RNA - Bipolar cells [NX]"	"Single Cell Type RNA - Cardiomyocytes [NX]"	"Single Cell Type RNA - Cholangiocytes [NX]"	"Single Cell Type RNA - Ciliated cells [NX]"	"Single Cell Type RNA - Club cells [NX]"	"Single Cell Type RNA - Collecting duct cells [NX]"	"Single Cell Type RNA - Cone photoreceptor cells [NX]"	"Single Cell Type RNA - Cytotrophoblasts [NX]"	"Single Cell Type RNA - Distal tubular cells [NX]"	"Single Cell Type RNA - Ductal cells [NX]"	"Single Cell Type RNA - Early spermatids [NX]"	"Single Cell Type RNA - Endothelial cells [NX]"	"Single Cell Type RNA - Enterocytes [NX]"	"Single Cell Type RNA - Erythroid cells [NX]"	"Single Cell Type RNA - Exocrine glandular cells [NX]"	"Single Cell Type RNA - Extravillous trophoblasts [NX]"	"Single Cell Type RNA - Fibroblasts [NX]"	"Single Cell Type RNA - Glandular cells [NX]"	"Single Cell Type RNA - granulocytes [NX]"	"Single Cell Type RNA - Hepatocytes [NX]"	"Single Cell Type RNA - Hofbauer cells [NX]"	"Single Cell Type RNA - Horizontal cells [NX]"	"Single Cell Type RNA - Intestinal endocrine cells [NX]"	"Single Cell Type RNA - Ito cells [NX]"	"Single Cell Type RNA - Kupffer cells [NX]"	"Single Cell Type RNA - Late spermatids [NX]"	"Single Cell Type RNA - Leydig cells [NX]"	"Single Cell Type RNA - Macrophages [NX]"	"Single Cell Type RNA - Melanocytes [NX]"	"Single Cell Type RNA - monocytes [NX]"	"Single Cell Type RNA - Mucus-secreting cells [NX]"	"Single Cell Type RNA - Muller glia cells [NX]"	"Single Cell Type RNA - Pancreatic endocrine cells [NX]"	"Single Cell Type RNA - Paneth cells [NX]"	"Single Cell Type RNA - Peritubular cells [NX]"	"Single Cell Type RNA - Proximal tubular cells [NX]"	"Single Cell Type RNA - Rod photoreceptor cells [NX]"	"Single Cell Type RNA - Sertoli cells [NX]"	"Single Cell Type RNA - Smooth muscle cells [NX]"	"Single Cell Type RNA - Spermatocytes [NX]"	"Single Cell Type RNA - Spermatogonia [NX]"	"Single Cell Type RNA - Suprabasal keratinocytes [NX]"	"Single Cell Type RNA - Syncytiotrophoblasts [NX]"	"Single Cell Type RNA - T-cells [NX]"	"Single Cell Type RNA - Undifferentiated cells [NX]"	"Single Cell Type RNA - Urothelial cells [NX]"
ABI1	"ABI-1, E3B1, SSH3BP1"	ENSG00000136754	"Abl interactor 1"	Q8IZP0	10	26746593-26861087	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Basal keratinocytes: 218.7;Suprabasal keratinocytes: 236.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008375, HPA068407"	Approved		Approved	"Plasma membrane"		NA	NA		400000	"Plasma membrane"		"CAB008375: AB_592744, HPA068407: AB_2685983"	"unprognostic (2.83e-3)"	"unprognostic (8.69e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.96e-1)"	"unprognostic (2.51e-2)"	"unprognostic (9.24e-3)"	"unprognostic (1.88e-3)"	"unprognostic (2.03e-1)"	"unprognostic (6.04e-2)"	"unprognostic (4.38e-1)"	"unprognostic (2.40e-2)"	"unprognostic (5.48e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.18e-1)"	24.0	14.0	32.0	28.1	32.6	54.1	21.4	28.2	35.5	22.5	22.7	19.8	14.8	24.8	23.9	15.4	45.1	20.3	21.6	14.1	47.3	23.1	21.9	17.8	22.5	32.1	25.0	26.4	25.3	17.0	19.1	14.4	22.7	20.9	19.1	24.8	26.7	30.9	17.0	16.6	33.0	26.0	21.6	27.5	25.5	23.9	12.4	20.5	43.5	18.8	27.3	40.9	25.2	30.3	36.1	26.8	51.5	28.0	20.5	44.5	31.5	23.7	13.3	10.9	10.7	16.6	20.4	16.4	24.1	16.4	17.8	20.8	15.6	28.1	43.6	12.4	25.5	11.4	26.7	13.1	15.6	19.9	29.1	11.7	19.1	9.1	11.0	11.3	9.2	19.4	13.9	19.9	17.4	10.4	20.8	21.5	14.6	14.1	27.9	18.2	10.2	21.7	8.8	9.0	14.8	6.4	23.6	20.3	28.1	18.9	11.0	9.1	9.7	20.0	19.6	20.1	14.6	12.6	14.8	26.7	13.7	16.8	17.3	12.3	6.3	10.0	51.9	19.7	23.8	9.8	35.5	23.8	51.5	27.0	28.0	25.8	36.1	25.9	30.0	26.8	28.6	24.4	26.5	37.9	20.5	26.7	22.3	44.5	31.5	32.0	32.6	28.2	31.9	47.3	23.1	25.0	26.4	20.9	20.5	38.7	33.6	47.0	115.9	218.7	9.0	20.7	33.1	77.6	58.0	24.4	2.0	30.2	11.6	46.6	9.9	39.4	52.3	0.0	46.0	39.6	47.2	106.9	56.6	23.6	68.6	15.9	43.1	35.0	76.6	4.2	20.4	67.7	87.7	83.8	48.7	42.6	61.4	46.3	20.8	31.5	9.7	32.3	49.1	12.1	8.5	236.6	64.5	62.5	39.1	163.3
ABL1	"ABL, c-ABL, JTK7, p150"	ENSG00000097007	"ABL proto-oncogene 1, non-receptor tyrosine kinase"	P00519	9	130713946-130887675	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis"	"DNA-binding, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002686, HPA027251, HPA027280, HPA028409"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"		Yes	No			Nucleoplasm	"Nuclear bodies"	"CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011"	"unprognostic (4.82e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.55e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.75e-3)"	"unprognostic (1.89e-3)"	"unprognostic (2.34e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.06e-1)"	20.1	11.6	12.4	15.0	18.1	10.7	22.0	6.7	16.0	28.9	34.3	29.1	12.1	11.9	26.6	16.9	21.4	20.8	30.9	14.2	10.3	8.4	9.9	6.7	13.8	8.7	24.1	9.4	24.2	12.2	27.7	14.5	13.6	17.1	27.3	15.8	19.4	14.6	18.0	10.8	14.2	17.0	66.6	14.3	10.8	21.9	9.8	21.2	5.8	19.5	11.4	9.1	35.8	31.9	3.1	3.1	1.1	5.0	2.4	2.6	1.6	7.2	16.1	17.2	20.8	25.3	30.9	6.3	12.7	19.9	14.9	12.6	12.6	9.4	11.9	7.3	16.8	15.3	14.0	8.7	11.7	11.0	7.4	5.4	7.8	27.4	10.7	17.3	11.9	10.9	22.5	12.9	26.6	16.5	20.8	20.6	15.4	43.5	9.5	18.1	13.7	15.1	9.8	19.1	11.3	11.9	17.5	22.3	12.8	15.1	8.5	16.1	20.1	21.3	8.3	10.2	10.5	16.2	11.0	23.6	57.2	14.8	21.8	19.9	2.9	6.8	15.9	23.5	9.9	18.1	0.2	2.1	1.1	2.0	1.2	2.6	3.1	2.0	1.9	2.0	1.4	1.9	1.7	0.2	2.4	5.0	3.1	0.9	1.6	12.4	18.1	6.7	16.0	10.3	8.4	24.1	9.4	17.1	21.2	8.9	9.9	4.2	6.4	8.1	6.2	5.8	12.7	5.3	5.7	14.0	11.8	11.3	1.7	12.6	3.1	14.3	15.4	0.0	9.5	3.5	27.8	8.1	2.3	13.4	13.7	9.5	21.2	20.3	13.7	7.4	25.9	6.5	5.0	3.6	15.7	15.7	14.3	20.3	24.1	8.4	9.7	19.4	21.0	11.9	13.6	5.9	12.7	7.9	19.1	6.4
ABL2	"ABLL, ARG"	ENSG00000143322	"ABL proto-oncogene 2, non-receptor tyrosine kinase"	P42684	1	179099327-179229684	"Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins"	"Cell adhesion"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Cone photoreceptor cells: 157.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 32.3;TIME: 30.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001866, CAB017106, HPA072754"	Uncertain		Approved	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"CAB017106: , HPA001866: AB_1078082, HPA072754: AB_2732212"	"unprognostic (3.05e-1)"	"prognostic unfavorable (3.50e-4)"	"unprognostic (1.07e-1)"	"unprognostic (4.71e-2)"	"unprognostic (9.45e-2)"	"unprognostic (8.23e-3)"	"unprognostic (1.91e-2)"	"unprognostic (4.81e-3)"	"unprognostic (1.26e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.73e-1)"	"prognostic unfavorable (1.78e-7)"	"unprognostic (4.76e-2)"	"unprognostic (4.14e-2)"	"unprognostic (6.08e-2)"	"prognostic unfavorable (8.40e-4)"	14.3	5.2	8.6	7.4	13.7	3.7	8.3	14.9	10.6	9.2	6.6	5.8	4.5	4.0	5.4	4.7	3.9	4.3	18.8	6.8	9.7	3.9	4.9	4.3	11.5	3.7	6.5	6.1	5.6	8.4	9.2	8.4	6.1	8.1	5.1	5.2	5.8	4.5	4.4	5.2	6.6	3.7	6.9	6.2	3.9	4.7	9.2	8.6	3.6	5.8	3.1	3.6	6.7	11.2	2.8	2.0	3.8	1.2	1.8	2.2	0.6	10.1	5.6	3.7	2.5	3.2	7.4	2.3	11.3	9.3	13.9	10.1	4.1	3.1	5.9	8.4	8.0	9.6	5.1	5.4	3.8	19.8	3.7	4.9	2.8	5.1	2.0	5.9	3.1	0.9	6.8	5.0	19.8	32.3	6.0	15.4	3.0	6.7	1.7	18.1	2.7	2.5	1.7	3.6	2.0	1.8	3.7	6.3	2.9	4.7	1.6	2.3	5.2	9.4	3.0	23.2	5.9	2.7	2.6	30.1	14.5	10.8	6.9	18.1	3.1	3.9	6.1	6.8	1.8	13.9	3.8	1.2	0.4	2.2	0.4	1.0	1.8	1.4	1.4	0.9	2.8	1.9	2.0	2.6	1.8	0.5	2.0	0.8	0.6	8.6	13.7	14.9	10.6	9.7	3.9	6.5	6.1	8.1	8.6	20.8	26.6	12.4	33.8	41.7	36.0	7.0	17.8	6.7	10.3	10.4	157.1	7.7	10.0	12.7	14.0	46.7	9.7	0.0	11.9	6.7	36.0	32.7	16.2	14.5	21.0	23.8	25.9	33.7	32.7	21.4	14.1	36.5	65.8	12.6	9.6	9.8	30.1	14.4	12.7	8.4	34.1	6.5	29.3	18.2	26.3	33.5	8.7	10.1	13.9	20.7
ACKR3	"CMKOR1, CXCR7, GPR159, RDC1"	ENSG00000144476	"Atypical chemokine receptor 3"	P25106	2	236567787-236582358	"Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Basal keratinocytes: 19.6;Club cells: 21.6;Endothelial cells: 44.5;Fibroblasts: 27.8;Ito cells: 17.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"NK-cells: 6.1;T-cells: 6.1"	"Cell line enhanced"	"Detected in some"		"HeLa: 23.4;MCF7: 17.2;RT4: 68.3;SiHa: 20.9;U-2197: 71.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA032003, HPA049718"	Approved		Supported	"Vesicles,Plasma membrane"		NA	NA			"Vesicles, Plasma membrane"		"HPA032003: AB_2674107, HPA049718: AB_2680859"	"unprognostic (1.65e-2)"	"prognostic unfavorable (4.64e-4)"	"unprognostic (2.50e-1)"	"unprognostic (1.92e-3)"	"unprognostic (2.10e-1)"	"unprognostic (1.23e-1)"	"unprognostic (7.34e-3)"	"unprognostic (1.55e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.35e-1)"	"unprognostic (9.70e-3)"	"unprognostic (6.69e-2)"	"prognostic unfavorable (1.76e-6)"	"prognostic unfavorable (2.01e-4)"	"unprognostic (9.71e-2)"	"unprognostic (8.57e-3)"	"prognostic unfavorable (2.93e-4)"	56.1	2.9	5.4	6.9	5.6	1.7	28.5	2.2	6.4	10.7	15.2	8.9	9.1	5.7	9.9	20.4	23.6	14.6	15.3	30.2	8.4	3.0	3.8	29.6	10.9	7.2	3.8	6.5	19.3	25.7	2.2	10.7	59.6	8.4	14.2	12.8	25.2	8.9	8.9	36.4	16.0	15.7	32.6	7.2	70.9	12.6	9.4	5.5	0.2	34.3	22.3	8.6	59.2	17.8	1.0	0.2	0.1	0.5	6.1	6.1	0.6	0.0	0.0	1.4	0.0	2.4	0.0	10.0	0.5	0.3	0.5	1.0	0.1	0.0	0.0	1.1	0.0	3.8	14.7	0.0	5.2	0.0	0.0	0.0	0.0	23.4	0.0	0.0	0.0	0.0	0.6	13.4	0.0	0.0	3.3	2.4	0.0	0.2	0.0	0.0	17.2	0.0	0.0	2.3	0.0	0.1	0.0	1.6	0.1	0.0	68.3	0.0	0.0	20.9	0.1	0.0	5.5	0.0	0.0	0.0	0.1	5.4	71.8	0.0	0.3	0.0	0.0	0.2	1.4	0.1	0.0	0.1	0.0	4.1	0.3	6.1	0.6	2.1	5.0	0.2	1.0	1.8	2.3	0.1	6.1	0.5	0.0	3.1	0.6	5.4	5.6	2.2	6.4	8.4	3.0	3.8	6.5	8.4	5.5	8.9	4.5	0.5	0.1	19.6	1.3	6.9	0.0	6.7	21.6	0.0	0.0	0.0	0.0	0.2	1.0	44.5	0.7	0.0	9.3	0.2	27.8	0.2	5.8	0.9	0.8	0.0	0.0	17.8	2.5	0.2	1.4	4.0	1.7	1.0	0.0	0.0	0.9	0.8	1.1	0.6	0.0	0.0	15.0	0.3	0.4	13.9	0.2	0.0	0.0	0.9
ACSL3	"ACS3, FACL3, PRO2194"	ENSG00000123983	"Acyl-CoA synthetase long chain family member 3"	O95573	2	222860934-222944639	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid metabolism, Lipid metabolism"	Ligase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	4	"parathyroid gland: 206.1"	"Cell type enhanced"	"Detected in all"	9	"Horizontal cells: 494.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 94.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011315, HPA071021"	Approved		Approved	"Nucleoli,Nucleoli rim,Lipid droplets"		NA	NA			"Nucleoli, Nucleoli rim"	"Lipid droplets"	"HPA011315: AB_1848344, HPA071021: AB_2686335"	"unprognostic (1.87e-1)"	"unprognostic (5.64e-2)"	"unprognostic (2.36e-1)"	"unprognostic (9.35e-3)"	"unprognostic (7.53e-2)"	"unprognostic (2.07e-2)"	"prognostic unfavorable (2.75e-4)"	"prognostic unfavorable (8.78e-4)"	"unprognostic (3.90e-2)"	"unprognostic (2.50e-1)"	"unprognostic (2.64e-1)"	"unprognostic (4.26e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.36e-1)"	"unprognostic (2.72e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.60e-1)"	14.7	17.0	22.8	9.9	26.0	16.3	51.5	19.4	45.9	15.3	16.5	16.1	11.6	12.7	10.9	18.4	28.3	9.0	11.8	22.7	20.9	22.8	17.9	22.3	15.6	10.5	19.6	21.2	11.7	10.3	206.1	8.8	19.1	24.4	44.4	16.7	14.4	34.2	15.5	19.1	11.4	12.7	12.2	22.2	9.7	28.3	13.7	14.2	13.5	17.3	11.2	8.7	14.6	15.4	15.0	22.5	21.8	16.8	16.6	20.1	16.5	10.1	17.9	27.4	29.8	12.0	29.8	7.6	12.9	33.6	15.5	32.7	16.1	26.1	4.8	7.5	12.3	33.5	29.9	5.9	28.7	20.1	8.7	11.2	11.4	14.5	17.9	26.5	7.5	5.6	15.3	40.8	25.6	44.7	11.9	16.8	8.5	21.5	18.6	21.8	21.5	14.6	8.8	13.9	23.0	9.3	8.0	23.2	8.2	22.3	41.6	14.5	10.7	7.6	20.6	94.2	22.1	10.3	18.4	11.6	10.4	16.6	8.9	9.4	6.6	3.2	16.8	11.1	7.1	31.4	16.6	14.6	21.8	20.1	16.8	19.3	11.6	12.8	14.6	15.7	15.0	18.7	16.7	21.8	16.6	15.9	22.5	9.5	16.5	22.8	26.0	19.4	45.9	20.9	22.8	19.6	21.2	24.4	14.2	32.8	58.5	16.4	65.8	41.3	91.7	51.2	40.8	37.5	44.3	34.9	72.6	32.9	6.6	28.6	31.0	38.3	33.1	23.3	27.3	8.4	36.3	113.5	26.5	47.9	33.5	494.2	20.1	36.2	50.2	18.9	24.2	42.9	45.5	32.5	32.3	205.8	32.5	38.6	33.6	12.5	51.8	45.3	51.8	50.2	49.9	42.7	50.7	27.7	46.5	102.1
ACVR1	"ACVR1A, ACVRLK2, ALK2, SKR1"	ENSG00000115170	"Activin A receptor type 1"	Q04771	2	157736444-157875862	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007505, HPA046514"	Approved		Uncertain	Nucleoli,Cytosol		NA	NA			Nucleoli	Cytosol	"HPA007505: AB_1844752, HPA046514: AB_2732526"	"unprognostic (6.99e-2)"	"unprognostic (3.32e-2)"	"unprognostic (3.02e-1)"	"unprognostic (1.19e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.09e-2)"	"unprognostic (3.66e-3)"	"unprognostic (1.08e-1)"	"unprognostic (3.99e-1)"	"unprognostic (3.20e-1)"	"unprognostic (2.65e-2)"	"unprognostic (4.29e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.43e-3)"	"unprognostic (3.17e-1)"	"unprognostic (1.76e-2)"	"prognostic unfavorable (5.17e-4)"	18.9	9.2	18.0	10.0	12.7	1.6	38.7	15.3	12.2	25.2	14.4	7.4	8.4	8.9	24.8	26.8	11.0	16.6	20.5	18.8	18.7	8.6	21.7	18.9	22.5	15.1	10.4	7.9	18.5	12.3	11.3	17.0	14.2	12.3	16.8	10.5	14.3	18.1	13.6	15.6	12.8	11.5	29.2	12.3	9.2	11.8	8.8	10.9	7.5	34.0	14.6	6.9	16.1	32.5	1.4	2.4	3.8	2.6	1.9	10.0	1.6	2.1	4.3	5.0	6.5	25.4	26.5	7.0	15.4	25.6	12.4	13.2	3.4	4.8	0.0	7.1	16.6	12.0	6.0	3.6	8.3	13.3	14.7	3.1	8.7	2.5	4.9	20.1	0.6	10.4	33.2	15.8	25.3	32.3	16.2	13.4	2.4	3.2	2.4	15.5	3.8	0.1	0.2	7.5	3.0	7.8	1.4	6.7	1.8	16.0	8.1	4.4	5.5	5.9	3.4	21.1	8.2	1.8	2.3	19.3	18.8	6.2	9.2	5.8	1.6	1.2	0.1	19.3	0.5	20.2	3.8	2.6	0.2	1.1	1.7	1.2	1.4	7.8	2.5	1.8	0.8	3.1	1.5	0.8	1.9	2.3	2.4	10.0	1.6	18.0	12.7	15.3	12.2	18.7	8.6	10.4	7.9	12.3	10.9	8.9	7.0	0.8	6.8	8.8	7.5	9.2	12.7	6.7	9.1	7.0	0.0	7.0	5.0	8.4	0.5	13.5	3.1	0.0	15.5	4.4	11.6	8.9	4.7	12.1	6.5	3.2	4.1	17.2	11.6	1.1	18.7	7.7	3.3	3.6	5.2	6.1	14.7	3.5	14.9	15.3	1.5	12.9	15.5	0.5	2.5	6.6	8.8	1.0	3.5	7.6
ACVR2A	"ACTRII, ACVR2"	ENSG00000121989	"Activin A receptor type 2A"	P27037	2	147844517-147930826	"Cancer-related genes, Enzymes, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HHSteC: 21.0;RH-30: 17.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA046997	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA046997: AB_10970077"	"unprognostic (4.55e-2)"	"unprognostic (2.26e-2)"	"unprognostic (2.09e-1)"	"unprognostic (7.34e-3)"	"unprognostic (2.75e-1)"	"unprognostic (1.17e-1)"	"unprognostic (4.41e-3)"	"unprognostic (8.73e-3)"	"unprognostic (1.30e-2)"	"unprognostic (3.61e-1)"	"unprognostic (1.34e-2)"	"unprognostic (1.52e-1)"	"prognostic favorable (1.62e-4)"	"unprognostic (1.16e-1)"	"unprognostic (1.40e-1)"	"unprognostic (3.95e-1)"	"unprognostic (3.99e-2)"	12.0	6.0	13.6	8.2	9.9	3.8	10.7	14.5	14.2	10.2	14.1	4.7	9.7	10.4	9.3	9.9	13.6	7.6	17.7	5.6	10.0	9.0	9.0	10.3	7.5	4.7	5.9	10.6	7.6	9.8	8.6	15.9	10.6	7.3	12.2	9.1	7.6	12.2	12.0	19.6	29.5	17.8	13.8	5.4	6.5	9.3	11.0	6.4	1.5	9.5	6.9	6.8	13.5	11.8	0.7	3.0	0.5	3.6	7.7	4.6	1.4	1.3	1.6	10.0	3.7	5.9	3.8	4.1	3.1	3.7	5.3	9.3	4.3	6.0	0.0	2.8	4.9	1.9	4.7	9.1	4.5	6.8	1.0	5.5	0.6	2.8	7.4	21.0	0.6	0.7	6.3	5.7	3.4	6.8	4.1	4.0	1.2	1.4	2.6	3.6	3.5	0.3	0.5	11.3	4.0	2.6	0.1	17.5	0.9	4.2	8.5	9.9	5.6	2.6	3.1	3.8	4.5	1.9	1.0	3.1	4.9	5.8	4.6	2.1	0.7	0.2	1.8	3.0	0.3	3.9	0.4	3.0	0.5	1.2	3.6	0.5	0.3	4.6	2.1	2.3	0.7	3.0	0.7	0.1	7.7	3.1	3.0	0.4	1.4	13.6	9.9	14.5	14.2	10.0	9.0	5.9	10.6	7.3	6.4	6.0	6.5	0.5	6.7	26.4	15.8	7.8	10.2	8.1	11.4	7.0	13.7	3.9	1.7	5.0	4.1	9.8	13.2	0.0	5.6	2.1	13.5	6.7	0.0	8.6	4.7	11.1	8.6	12.9	9.4	0.8	9.2	7.6	10.1	8.2	13.8	3.7	6.3	8.6	10.6	5.0	8.5	32.3	14.4	13.8	12.8	26.1	4.5	5.1	8.5	7.1
AFDN	"AF-6, AF6, MLLT4"	ENSG00000130396	"Afadin, adherens junction formation factor"	P55196	6	167826922-167972023	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Cell adhesion"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Alveolar cells type 1: 157.8;Alveolar cells type 2: 72.9;Ciliated cells: 85.6;Club cells: 75.1;Collecting duct cells: 90.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868"	Approved		Enhanced	"Nucleoplasm,Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane, Cell Junctions"	Nucleoplasm	"CAB013496: , HPA030212: AB_10599291, HPA030213: AB_10601340, HPA030214: AB_10601005, HPA030215: AB_10601556, HPA049868: AB_2680924"	"prognostic unfavorable (7.43e-5)"	"unprognostic (2.66e-3)"	"unprognostic (2.07e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.13e-1)"	"unprognostic (9.06e-2)"	"unprognostic (4.12e-1)"	"unprognostic (3.12e-2)"	"unprognostic (4.12e-1)"	"unprognostic (1.09e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.73e-2)"	"unprognostic (5.56e-2)"	"unprognostic (5.43e-3)"	"unprognostic (1.59e-1)"	"unprognostic (4.72e-2)"	"unprognostic (5.68e-2)"	17.0	7.4	14.9	13.0	17.2	1.8	23.5	17.8	19.3	19.6	26.3	16.1	25.5	22.2	15.8	17.7	59.5	27.9	18.2	13.9	15.6	7.2	20.6	29.3	26.3	5.1	17.1	12.5	16.2	29.7	16.4	27.4	18.7	16.1	20.9	27.2	15.3	38.6	18.6	12.7	24.8	42.3	17.4	13.0	13.5	21.1	16.3	15.2	2.1	25.7	13.7	24.5	16.3	27.9	3.5	0.6	2.9	0.5	0.0	1.2	0.0	18.9	5.9	41.5	14.8	4.0	3.4	30.9	7.7	4.0	6.7	8.3	25.3	11.9	3.4	14.3	4.6	10.5	9.1	17.2	15.8	12.0	21.4	17.8	0.1	2.5	19.1	6.1	2.1	9.1	2.4	10.7	11.2	26.5	10.7	12.3	7.4	38.0	13.3	4.3	8.1	0.2	0.1	10.1	27.1	2.7	12.3	10.9	14.4	12.2	9.3	19.2	11.7	7.8	29.8	11.8	40.5	3.5	0.8	18.0	3.1	15.1	13.4	12.7	0.2	16.1	6.9	9.3	4.4	27.2	0.0	0.5	0.0	1.0	0.5	0.6	3.5	1.2	0.4	0.6	2.7	0.0	0.5	2.9	0.0	0.3	0.0	0.6	0.0	14.9	17.2	17.8	19.3	15.6	7.2	17.1	12.5	16.1	15.2	157.8	72.9	0.0	0.0	0.0	0.0	0.0	0.0	85.6	75.1	90.7	0.0	27.0	18.3	58.2	0.0	0.0	0.0	0.0	34.2	28.5	0.0	0.0	8.1	0.0	16.2	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	19.0	0.0	0.0	52.1	0.0	0.0	23.8	0.0	0.0	0.0	0.0	0.0	0.0	35.2	0.0	0.0	0.0
AFF1	"AF-4, AF4, MLLT2, PBM1"	ENSG00000172493	"AF4/FMR2 family member 1"	P51825	4	86935002-87141054	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 121.7"	"Cell type enhanced"	"Detected in many"	6	"Cone photoreceptor cells: 212.1;Rod photoreceptor cells: 150.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA069947			Approved	Nucleoplasm,Mitochondria		No	No			"Nucleoplasm, Mitochondria"		"HPA069947: AB_2686219"	"unprognostic (1.01e-1)"	"unprognostic (7.56e-2)"	"unprognostic (2.57e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.79e-1)"	"unprognostic (6.23e-2)"	"unprognostic (6.09e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.24e-1)"	"unprognostic (8.32e-3)"	"unprognostic (5.86e-2)"	"unprognostic (1.33e-2)"	"unprognostic (4.41e-1)"	"unprognostic (2.55e-1)"	"unprognostic (2.71e-2)"	33.7	16.6	8.0	11.8	9.5	19.5	26.5	6.5	12.2	20.2	21.0	10.5	18.9	11.1	27.4	16.6	15.8	18.6	15.3	22.4	10.3	5.3	27.6	15.5	18.4	12.9	9.3	5.5	24.7	19.0	28.6	18.5	121.7	9.5	16.8	14.3	27.0	16.0	25.6	58.8	18.6	16.2	20.3	11.5	13.9	15.0	6.7	10.3	17.0	38.8	21.1	13.9	19.5	26.5	11.3	14.6	21.1	5.4	5.1	8.8	2.8	7.9	7.3	6.1	6.4	10.1	12.1	8.6	8.0	11.8	6.1	9.2	7.7	14.8	9.0	11.0	9.8	7.8	3.6	9.6	12.1	8.5	15.4	3.8	18.8	19.1	6.4	7.8	18.0	14.9	9.8	8.8	10.5	9.3	8.9	22.5	7.6	11.5	25.6	2.6	2.1	16.2	5.2	8.1	13.3	2.6	12.9	3.6	11.5	18.1	7.6	13.9	2.5	12.3	8.1	3.9	13.4	4.8	15.1	11.3	11.4	10.4	6.9	4.4	22.2	12.3	15.6	9.4	20.8	4.1	3.5	5.4	11.7	6.7	4.1	7.4	8.0	8.8	6.6	6.0	11.3	4.7	4.4	21.1	5.1	2.2	14.6	7.5	2.8	8.0	9.5	6.5	12.2	10.3	5.3	9.3	5.5	9.5	10.3	38.7	57.2	25.4	12.5	21.4	44.7	96.4	40.8	40.2	31.8	87.2	212.1	0.9	3.3	11.6	6.6	38.8	30.8	46.7	10.9	3.8	14.6	24.9	23.3	27.7	11.3	17.5	31.0	65.1	43.0	5.4	27.0	25.6	21.9	8.2	40.8	22.0	11.1	31.7	26.9	40.9	150.1	25.8	15.6	3.5	6.4	27.7	27.5	15.2	25.3	14.4
AFF3	"LAF4, MLLT2-like"	ENSG00000144218	"AF4/FMR2 family member 3"	P51826	2	99545419-100142739	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 43.6"	"Cell type enhanced"	"Detected in many"	10	"B-cells: 79.7;Horizontal cells: 44.5"	"Cancer enhanced"	"Detected in many"		"breast cancer: 11.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"memory B-cell: 16.2;naive B-cell: 27.5;plasmacytoid DC: 12.8"	"Group enriched"	"Detected in many"	16	"B-cells: 27.5;dendritic cells: 12.8"	"Cell line enhanced"	"Detected in many"		"Daudi: 23.7;U-698: 35.1"	"Low region specificity"	"Detected in all"							"HPA044512, HPA053379"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA044512: AB_10795984, HPA053379: AB_2682133"	"unprognostic (1.05e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.30e-1)"	"unprognostic (4.88e-3)"	"unprognostic (1.02e-1)"	"unprognostic (4.98e-5)"	"unprognostic (1.11e-3)"	"unprognostic (3.04e-2)"	"unprognostic (8.75e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.95e-3)"	"unprognostic (7.57e-2)"	"prognostic unfavorable (5.64e-4)"	"unprognostic (6.40e-3)"	"unprognostic (6.79e-2)"	"unprognostic (3.69e-2)"	"unprognostic (7.87e-3)"	3.2	2.4	6.0	40.2	6.1	10.3	16.6	20.5	9.9	4.2	4.2	1.8	0.8	1.2	8.9	1.7	4.1	4.1	2.3	4.9	6.3	6.2	1.8	2.4	7.6	23.3	5.4	6.8	7.5	1.1	0.3	5.2	6.9	4.4	18.9	2.3	5.5	6.6	3.3	1.0	1.0	5.9	8.6	6.6	43.6	4.8	6.0	2.5	34.7	1.7	0.7	42.0	7.4	2.7	27.5	12.8	0.2	0.2	0.9	1.2	0.4	0.1	0.0	10.0	3.5	0.0	0.4	0.0	1.4	0.3	3.0	1.0	0.0	0.0	23.7	0.1	1.5	7.6	0.1	0.2	0.0	1.8	6.0	2.9	0.0	0.1	0.0	0.2	0.1	6.8	0.6	0.0	6.2	0.1	7.7	0.0	1.3	0.1	0.0	0.0	0.1	1.9	0.3	1.3	0.0	1.6	3.2	0.0	0.1	0.0	0.0	9.9	3.5	0.1	0.1	6.4	1.3	11.9	10.9	3.9	9.5	2.6	0.3	1.5	0.2	0.0	35.1	8.8	0.8	0.8	0.2	0.2	0.0	0.0	0.2	0.2	16.2	0.1	0.0	2.9	27.5	1.2	0.0	0.1	0.9	0.2	12.8	0.0	0.4	6.0	6.1	20.5	9.9	6.3	6.2	5.4	6.8	4.4	2.5	6.0	29.7	79.7	0.4	1.5	15.0	9.6	0.0	0.0	6.8	0.0	11.8	0.2	0.0	0.0	25.7	1.2	0.0	0.0	0.0	0.1	4.7	14.7	0.0	0.8	1.4	44.5	22.0	0.6	7.0	28.0	10.0	12.9	13.5	0.0	0.3	8.9	0.0	0.0	19.8	0.8	1.4	0.0	6.9	5.1	7.0	1.1	0.1	2.2	0.0	0.1
AFF4	"AF5Q31, MCEF"	ENSG00000072364	"AF4/FMR2 family member 4"	Q9UHB7	5	132875379-132963634	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Disease mutation, Dwarfism, Obesity, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023690, HPA029634"	Approved		Supported	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			"Nucleoplasm, Nucleoli fibrillar center"		"HPA023690: AB_1844633, HPA029634: AB_2673129"	"unprognostic (3.24e-2)"	"unprognostic (1.86e-2)"	"unprognostic (6.17e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.99e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.56e-2)"	"unprognostic (7.37e-2)"	"unprognostic (1.18e-1)"	"unprognostic (6.13e-2)"	"unprognostic (4.94e-2)"	"unprognostic (3.52e-1)"	"unprognostic (1.16e-2)"	"unprognostic (2.77e-2)"	"unprognostic (3.25e-2)"	"prognostic unfavorable (6.44e-4)"	"unprognostic (1.69e-1)"	22.9	29.6	22.8	19.1	38.7	38.3	23.6	37.8	25.6	26.2	21.8	25.2	22.1	14.6	27.6	19.5	29.8	20.8	26.8	21.3	18.7	18.7	25.7	24.2	24.8	19.6	19.0	19.7	34.0	24.9	48.8	40.1	20.4	18.3	26.7	18.5	27.5	25.2	25.1	32.1	22.2	17.8	24.4	18.8	17.3	24.8	17.6	24.4	26.6	33.9	15.7	19.2	26.3	24.7	8.7	5.2	12.2	4.9	3.8	5.5	1.5	16.8	13.6	18.7	20.7	14.4	17.5	14.7	18.2	19.6	16.8	21.5	20.0	11.1	8.5	21.7	23.8	20.4	8.4	15.0	22.5	28.2	6.1	9.7	10.6	18.5	7.1	18.5	3.7	11.0	20.4	15.1	29.1	29.6	18.1	16.1	7.8	7.5	7.3	20.9	6.4	10.2	3.9	7.2	5.0	5.5	6.8	18.3	3.2	14.6	23.7	14.6	15.4	20.7	5.1	20.6	27.0	10.7	6.0	22.6	20.2	17.2	17.8	19.3	10.1	17.2	7.8	19.0	6.9	13.8	12.2	2.4	3.8	5.5	2.0	4.1	7.7	5.1	3.7	2.9	8.7	5.3	4.6	5.2	3.8	4.9	5.2	2.5	1.5	22.8	38.7	37.8	25.6	18.7	18.7	19.0	19.7	18.3	24.4	74.5	31.6	45.5	71.7	70.7	71.8	55.7	68.8	48.2	73.9	55.8	149.2	32.2	6.6	46.4	222.1	55.8	54.9	0.0	40.0	37.0	72.8	98.0	41.6	20.2	36.3	74.7	93.7	57.1	46.7	140.8	64.2	53.7	65.8	30.7	46.2	72.9	61.9	60.4	63.3	26.2	136.3	77.6	56.1	34.9	20.1	75.7	58.5	51.1	37.9	92.8
AKT1	"AKT, PKB, PRKBA, RAC"	ENSG00000142208	"AKT serine/threonine kinase 1"	P31749	14	104769349-104795751	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Neurogenesis, Sugar transport, Translation regulation, Transport"	"Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 30.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 30.7"	"Cell line enhanced"	"Detected in all"		"MCF7: 115.3"	"Low region specificity"	"Detected in all"							"HPA002891, CAB003765"	Supported		Supported	Nucleoplasm,Microtubules		NA	NA			Nucleoplasm	Microtubules	"CAB003765: AB_562035, HPA002891: AB_1078123"	"unprognostic (3.30e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.84e-1)"	"unprognostic (3.70e-1)"	"unprognostic (9.17e-3)"	"unprognostic (1.55e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.47e-1)"	"prognostic favorable (4.83e-4)"	"unprognostic (3.58e-2)"	"unprognostic (1.90e-2)"	"prognostic favorable (2.12e-4)"	"unprognostic (7.14e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.41e-1)"	31.7	45.4	22.9	24.2	23.6	20.3	40.0	20.9	29.5	24.7	32.6	20.0	30.8	22.5	27.0	21.5	33.0	25.5	30.3	47.7	22.9	19.1	26.3	49.2	31.3	21.0	22.1	14.7	25.9	43.0	20.3	16.7	28.4	21.5	31.1	18.2	25.3	30.4	36.1	23.8	20.4	24.0	40.5	17.5	35.4	32.6	16.2	18.8	26.3	32.7	22.4	29.3	36.7	35.9	3.2	5.2	30.7	5.8	5.7	6.2	3.0	15.4	30.8	25.5	37.9	19.7	20.5	28.5	28.4	34.6	42.0	33.7	20.2	18.7	18.7	21.9	38.9	21.4	20.1	18.0	26.4	18.3	42.6	7.3	14.1	18.4	21.7	21.9	23.0	36.9	29.3	22.3	21.0	14.0	20.2	31.4	18.4	12.3	20.8	26.9	115.3	28.9	29.4	6.6	30.3	22.1	27.3	23.6	12.7	19.4	38.4	29.3	24.3	23.7	31.0	17.8	11.9	40.6	34.3	25.0	28.2	13.5	40.1	28.5	22.6	10.9	16.1	23.8	19.5	33.9	3.3	5.3	30.7	5.4	5.2	4.0	2.9	4.8	6.2	3.6	3.2	2.5	5.7	11.8	5.7	5.8	5.2	4.7	3.0	22.9	23.6	20.9	29.5	22.9	19.1	22.1	14.7	21.5	18.8	14.9	24.3	13.4	13.8	11.0	24.3	13.8	40.8	5.3	11.4	21.0	11.8	15.1	11.6	21.0	1.2	19.6	22.2	0.0	30.3	25.7	18.8	34.2	2.3	38.4	20.2	39.7	28.8	24.5	23.7	3.1	26.4	18.1	10.1	17.2	36.1	35.8	43.4	17.3	29.0	13.9	24.0	25.8	11.8	0.9	5.1	12.2	19.6	18.1	26.9	30.8
AKT2		ENSG00000105221	"AKT serine/threonine kinase 2"	P31751	19	40230317-40285536	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Carbohydrate metabolism, Glucose metabolism, Glycogen biosynthesis, Glycogen metabolism, Sugar transport, Translation regulation, Transport"	"Developmental protein, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Diabetes mellitus, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Rod photoreceptor cells: 109.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004204, HPA064521"	Uncertain		Supported	Nucleoplasm,Vesicles,Cytosol		NA	NA			"Nucleoplasm, Vesicles, Cytosol"		"CAB004204: AB_626659, HPA064521: AB_2685278"	"unprognostic (6.13e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.56e-1)"	"prognostic unfavorable (1.05e-6)"	"unprognostic (2.85e-1)"	"unprognostic (6.40e-3)"	"unprognostic (9.59e-2)"	"unprognostic (1.22e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.49e-2)"	"unprognostic (3.02e-1)"	"prognostic unfavorable (4.74e-4)"	"unprognostic (1.30e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.28e-1)"	"unprognostic (6.16e-2)"	"unprognostic (2.00e-1)"	31.1	20.3	15.4	17.6	15.2	21.3	18.2	46.3	18.2	23.3	18.2	23.4	21.2	12.3	22.8	28.0	22.1	22.7	14.0	23.1	15.4	10.0	23.0	62.5	14.6	17.8	17.9	13.3	27.8	24.5	21.1	24.0	17.5	14.7	19.7	12.3	26.8	18.5	24.3	48.5	18.3	17.1	20.0	16.8	18.7	15.5	21.3	15.7	26.6	52.6	29.5	23.6	19.6	19.9	6.3	8.8	7.7	4.4	3.2	4.9	2.4	22.8	56.3	21.5	22.1	26.8	32.8	11.9	15.3	22.6	31.7	28.3	24.8	21.3	23.3	13.6	33.6	13.3	10.0	23.8	31.8	20.4	22.3	27.1	15.3	35.7	15.5	16.8	17.5	18.4	30.2	19.1	21.5	20.4	25.1	6.9	25.7	19.6	24.5	17.6	19.0	27.8	8.5	11.6	25.4	15.1	18.5	11.7	16.8	24.7	37.4	29.6	18.1	15.7	26.8	12.7	23.0	21.2	22.6	6.8	19.4	19.2	17.3	23.9	22.8	19.5	19.1	18.9	20.8	15.8	7.6	4.4	3.6	4.5	2.0	4.5	3.9	3.6	3.0	3.0	6.3	3.5	4.9	7.7	3.2	2.6	8.8	2.7	2.4	15.4	15.2	46.3	18.2	15.4	10.0	17.9	13.3	14.7	15.7	14.9	12.8	36.4	20.9	21.2	67.1	26.8	28.1	12.0	10.3	57.6	39.3	25.4	18.3	18.1	2.9	17.0	18.8	0.0	26.0	20.6	22.1	24.5	13.9	74.6	19.3	57.2	18.5	12.9	19.7	7.4	39.7	13.5	21.9	19.8	19.0	52.5	20.4	19.2	25.1	18.3	109.8	19.4	23.3	11.6	16.2	24.0	32.4	17.1	20.1	24.4
AL035425.2		ENSG00000260548			X	108722070-108732687	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"				"Tissue enhanced"	"Detected in some"		"ovary: 13.0;pituitary gland: 7.4;thyroid gland: 8.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 19.0;NTERA-2: 2.7;RT4: 4.9;WM-115: 5.0"															NA	NA																							0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.6	2.9	0.0			0.0	3.9	0.9	0.0	0.5	0.0	0.0	0.1	5.1	0.0	0.0	0.0	0.0	0.5		13.0	0.9	0.0	7.4	0.0		0.1	0.0		0.0	0.7	0.0	1.1	0.0	1.5	0.1	0.0	0.4	0.0			8.9		0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	19.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.1	0.0	0.1	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ALK	CD246	ENSG00000171094	"ALK receptor tyrosine kinase"	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;pituitary gland: 17.9"	"Group enriched"	"Detected in some"	12	"Early spermatids: 36.6;Late spermatids: 30.9"	"Group enriched"	"Detected in some"	5	"glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"SH-SY5Y: 27.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010694	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA010694: AB_1078133"	"unprognostic (4.96e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.56e-7)"	"unprognostic (7.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (9.07e-3)"	"unprognostic (6.29e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-4)"	"unprognostic (3.70e-2)"	"unprognostic (2.06e-2)"	"unprognostic (7.15e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.61e-2)"	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2.0	0.0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0.0	1.6	0.0	0.3	0.6	1.2	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	3.6	0.0	0.0	0.1	0.3	27.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	3.2	0.0	4.1	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9	0.0	0.0	0.0	0.0	0.0	1.5	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	30.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0
AMER1	"FAM123B, FLJ39827, RP11-403E24.2, WTX"	ENSG00000184675	"APC membrane recruitment protein 1"	Q5JTC6	X	64185117-64205744	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Bipolar cells: 4.5;Cholangiocytes: 5.1;Sertoli cells: 6.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 15.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065214, HPA065265"	Approved		Supported	"Nuclear bodies,Vesicles,Plasma membrane"		NA	NA			"Nuclear bodies"	"Vesicles, Plasma membrane"	"HPA065214: AB_2685435, HPA065265: AB_2685450"	"unprognostic (1.56e-2)"	"unprognostic (8.85e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.74e-1)"	"unprognostic (2.12e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.48e-1)"	"unprognostic (8.02e-2)"	"unprognostic (1.75e-1)"	"unprognostic (6.31e-2)"	"unprognostic (3.43e-1)"	"unprognostic (4.69e-4)"	"unprognostic (1.26e-1)"	"unprognostic (1.13e-1)"	"unprognostic (6.19e-2)"	"unprognostic (2.89e-1)"	3.0	3.4	3.0	2.8	5.6	2.3	3.0	8.8	4.9	6.8	4.7	3.1	7.8	3.3	9.8	11.3	6.9	5.2	2.4	3.5	3.0	3.4	4.2	7.1	2.8	2.6	4.5	1.6	15.5	8.1	5.1	3.9	2.0	6.3	4.5	3.2	6.8	7.0	5.3	9.0	4.8	3.7	6.6	2.9	3.7	5.1	1.4	4.3	2.4	3.4	6.5	3.4	4.3	5.7	0.4	0.2	0.0	0.3	2.0	1.0	0.1	3.0	2.2	5.8	4.6	2.2	2.2	4.6	1.4	1.2	2.1	1.3	7.2	1.0	5.7	1.9	2.9	1.6	4.2	12.2	4.0	2.0	2.6	2.4	3.5	4.5	4.6	1.6	7.4	0.9	3.0	5.3	1.6	3.2	1.7	1.2	4.5	5.3	5.8	1.1	3.5	4.8	4.0	15.4	3.8	4.3	11.5	9.4	4.1	1.0	0.9	2.6	3.9	3.6	4.9	1.9	5.0	1.6	2.1	0.8	2.6	5.9	6.6	1.9	3.0	2.0	4.4	1.2	8.4	0.0	0.0	0.3	0.0	0.4	0.1	0.0	0.4	0.0	0.4	0.0	0.3	1.0	0.0	0.0	2.0	0.0	0.2	0.9	0.1	3.0	5.6	8.8	4.9	3.0	3.4	4.5	1.6	6.3	4.3	0.0	0.0	0.0	0.6	1.9	4.5	2.3	5.1	0.0	0.0	0.0	2.0	0.8	0.0	1.0	0.0	1.0	0.5	0.0	1.4	0.6	0.8	0.4	0.0	1.9	0.3	0.0	1.2	2.5	1.5	0.0	2.3	0.1	1.7	0.0	0.9	0.2	0.5	0.0	3.9	0.6	0.7	6.5	1.2	0.0	0.2	2.3	0.6	0.5	1.3	0.7
APC	"DP2, DP2.5, DP3, PPP1R46"	ENSG00000134982	"APC, WNT signaling pathway regulator"	P25054	5	112707498-112846239	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 40.9"	"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 169.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013349, HPA013362"	Supported		Approved	"Nucleoplasm,Golgi apparatus,Plasma membrane"		NA	NA			"Plasma membrane"	"Nucleoplasm, Golgi apparatus"	"HPA013349: AB_1844913, HPA013362: "	"unprognostic (4.80e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.72e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.10e-1)"	"unprognostic (7.09e-3)"	"unprognostic (1.62e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.35e-1)"	"unprognostic (4.85e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.35e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.96e-1)"	7.2	5.4	40.9	6.4	21.7	8.5	6.3	19.1	39.7	6.8	7.1	10.3	2.0	6.6	6.3	3.9	8.4	5.0	5.5	7.4	37.9	12.9	6.9	6.2	6.7	5.6	23.6	20.7	7.6	4.6	13.8	7.2	5.5	39.1	5.9	6.9	4.0	4.0	4.9	7.0	6.1	8.8	8.1	19.1	6.2	5.4	5.3	20.6	3.6	6.5	2.7	6.2	6.2	3.9	3.8	3.0	12.9	2.9	3.0	3.4	1.1	8.3	7.7	12.9	9.4	10.6	8.9	5.3	13.6	6.5	7.6	9.0	6.1	6.8	16.2	13.2	17.3	11.7	6.9	13.2	11.1	12.5	9.7	9.0	12.3	11.2	4.7	5.2	6.2	6.7	7.4	7.7	12.8	8.5	5.3	10.5	7.8	15.1	5.6	10.9	5.8	7.1	3.1	4.6	4.6	2.8	6.0	16.0	7.9	7.0	10.7	13.1	7.9	12.9	5.0	5.5	5.5	7.0	5.1	16.7	15.4	7.4	15.1	10.3	4.4	6.6	6.4	8.5	11.5	8.6	10.4	2.9	5.0	3.4	1.4	2.9	3.1	1.8	2.1	2.3	3.8	2.9	2.8	12.9	3.0	2.5	3.0	1.6	1.1	40.9	21.7	19.1	31.4	37.9	12.9	23.6	20.7	39.1	20.6	47.6	17.6	10.8	8.3	10.0	169.9	48.4	12.7	20.1	26.1	0.0	62.8	4.4	0.0	16.7	6.3	21.0	24.6	0.0	17.0	5.3	10.2	10.3	18.5	12.1	13.8	74.7	26.4	28.8	14.9	4.4	16.4	14.8	16.9	19.0	15.5	21.8	16.3	25.9	18.4	4.2	37.9	38.8	14.3	14.9	26.7	10.2	2.4	10.7	14.2	7.6
APOBEC3B	"FLJ21201, PHRBNL"	ENSG00000179750	"Apolipoprotein B mRNA editing enzyme catalytic subunit 3B"	Q9UH17	22	38982347-38992804	"Cancer-related genes, Predicted intracellular proteins"	"Antiviral defense, Immunity, Innate immunity"	"Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 20.1"	"Cell type enhanced"	"Detected in many"	8	"Basal keratinocytes: 4.7;Ductal cells: 7.3;Melanocytes: 6.8;Pancreatic endocrine cells: 5.7;Urothelial cells: 9.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 10.2"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A-431: 60.7;Karpas-707: 68.8"									"HPA056980, HPA066719"			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA056980: AB_2683298, HPA066719: AB_2685711"	"unprognostic (2.92e-2)"	"prognostic favorable (2.58e-5)"	"unprognostic (4.29e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.35e-1)"	"unprognostic (6.36e-2)"	"unprognostic (1.08e-2)"	"unprognostic (5.88e-2)"	"prognostic unfavorable (2.78e-4)"	"unprognostic (8.47e-2)"	"unprognostic (2.98e-2)"	"unprognostic (2.70e-1)"	"unprognostic (1.04e-1)"	1.6	2.3	0.3	4.4	2.2	20.1	1.4	0.3	1.2	2.3	9.9	0.7	0.3	5.8	2.0	2.4	4.6	1.2	2.2	1.6	0.6	0.2	3.6	0.9	2.5	4.3	0.3	0.3	1.7	5.7	0.4	0.3	6.4	0.8	2.1	10.0	1.3	4.8	0.3	4.1	1.9	8.8	1.0	0.7	10.4	3.8	2.0	0.3	5.9	3.3	0.3	12.0	2.0	2.4	10.2	0.8	1.7	5.8	2.2	3.8	5.9	60.7	6.8	2.6	16.4	0.3	1.5	4.5	5.6	4.9	10.8	14.2	13.0	11.1	0.6	5.1	5.6	15.9	26.1	0.3	1.1	10.9	21.9	0.6	17.5	1.5	3.4	0.1	14.5	10.6	0.6	0.1	11.2	0.5	2.2	4.1	0.0	9.8	68.8	16.6	1.6	0.0	8.1	0.0	5.8	6.1	0.4	26.3	21.8	2.2	10.2	0.4	0.0	0.0	0.0	3.7	0.4	8.1	4.2	2.5	11.9	20.8	1.8	0.1	15.3	4.2	0.0	8.5	16.2	24.1	0.5	1.3	0.0	0.3	5.8	0.0	10.2	0.8	0.5	0.8	3.2	0.0	0.4	1.7	2.2	1.8	0.1	3.8	5.9	0.3	2.2	0.3	1.2	0.6	0.2	0.3	0.3	0.8	0.3	0.0	1.7	0.8	2.2	4.7	0.0	0.2	0.0	1.4	2.3	0.0	0.0	0.3	0.0	7.3	0.0	0.0	0.5	0.0	1.6	1.9	0.4	1.2	0.0	0.0	1.8	0.0	0.0	0.0	1.6	0.0	0.0	1.6	6.8	1.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.9	0.7	0.0	0.6	9.5
AR	"AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1"	ENSG00000169083	"Androgen receptor"	P10275	X	67544032-67730619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 49.0"	"Cell type enhanced"	"Detected in many"	14	"Hepatocytes: 189.5;Leydig cells: 72.2;Peritubular cells: 81.3;Sertoli cells: 64.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"plasmacytoid DC: 5.4"	"Lineage enriched"	"Detected in single"	16	"dendritic cells: 5.4"	"Cell line enhanced"	"Detected in some"		"AF22: 11.3;BJ hTERT+: 9.8;HAP1: 14.4;LHCN-M2: 12.6;RH-30: 20.9;T-47d: 8.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000001, HPA004733, CAB065764"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: "	"unprognostic (1.34e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.49e-2)"	"unprognostic (5.95e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.35e-2)"	"prognostic favorable (8.77e-4)"	"unprognostic (4.99e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.29e-1)"	"prognostic favorable (1.03e-8)"	"unprognostic (8.23e-3)"	"unprognostic (8.90e-2)"	"unprognostic (4.23e-2)"	"unprognostic (7.97e-2)"	10.1	1.2	0.9	1.6	0.9	0.1	10.7	0.4	1.6	34.4	1.9	2.4	25.4	0.2	20.5	20.5	2.2	17.5	4.3	5.7	0.9	1.5	6.3	49.0	1.5	0.2	1.2	0.7	14.4	1.0	0.1	2.3	0.3	1.9	28.0	0.5	3.8	1.6	36.1	8.1	3.9	1.1	7.6	1.9	0.9	1.6	9.3	1.2	5.4	3.1	2.0	1.2	6.3	13.1	0.0	5.4	0.3	0.0	0.1	0.0	0.1	0.0	4.7	11.3	0.0	0.0	0.1	0.0	6.0	9.8	0.4	0.1	0.2	0.0	0.0	0.0	0.7	0.0	0.0	14.4	0.0	0.1	0.0	1.9	0.0	1.1	0.0	0.7	0.0	0.0	4.6	0.0	1.7	0.0	0.0	3.5	0.1	4.1	1.9	12.6	1.2	0.0	0.0	4.5	0.0	0.0	0.0	20.9	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	3.2	8.8	5.3	0.2	0.2	2.0	0.1	3.0	0.0	0.0	0.0	4.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	5.4	0.0	0.1	0.9	0.9	0.4	1.6	0.9	1.5	1.2	0.7	1.9	1.2	0.0	5.3	0.0	18.1	8.7	0.6	31.3	12.7	6.7	19.4	3.5	0.0	1.9	1.7	7.5	0.9	4.9	0.0	0.0	0.0	0.1	9.4	31.9	1.1	189.5	0.7	0.0	0.0	14.7	1.6	1.6	72.2	2.1	10.1	2.8	0.0	0.2	1.0	0.0	81.3	22.3	0.3	64.7	12.3	0.5	1.0	14.1	0.8	0.0	0.0	15.9
ARHGAP26	"GRAF, KIAA0621, OPHN1L, OPHN1L1"	ENSG00000145819	"Rho GTPase activating protein 26"	Q9UNA1	5	142770377-143229011	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Late spermatids: 105.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"neutrophil: 19.6;NK-cell: 5.8"	"Group enriched"	"Detected in many"	4	"granulocytes: 19.6;NK-cells: 5.8"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 39.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035106, HPA035107"	Enhanced		Approved	Cytosol		NA	NA			Cytosol		"HPA035106: AB_2674465, HPA035107: AB_10669855"	"prognostic favorable (2.05e-4)"	"prognostic favorable (1.36e-4)"	"prognostic favorable (6.95e-4)"	"prognostic favorable (5.93e-6)"	"unprognostic (1.19e-1)"	"unprognostic (1.93e-2)"	"unprognostic (4.19e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.22e-1)"	"unprognostic (9.43e-3)"	"unprognostic (7.19e-3)"	"unprognostic (8.65e-2)"	"unprognostic (3.21e-3)"	"unprognostic (5.67e-2)"	"unprognostic (2.70e-2)"	"unprognostic (2.95e-2)"	"prognostic favorable (2.88e-6)"	13.3	5.7	18.4	18.6	22.7	33.9	13.0	29.2	23.9	15.9	14.2	7.5	9.9	13.2	9.4	10.9	7.6	18.5	16.4	17.0	12.8	10.5	8.0	7.7	20.0	8.8	12.9	15.4	4.8	5.5	4.8	15.1	22.4	11.9	8.5	14.8	8.8	14.6	11.2	14.0	8.5	12.6	11.1	12.6	18.9	17.0	16.1	12.2	10.3	10.0	5.4	13.6	9.4	10.6	0.3	2.0	19.6	2.8	5.8	3.0	1.0	6.9	14.0	3.9	3.6	5.8	6.4	6.0	0.8	1.2	3.4	5.9	19.1	15.8	1.0	6.9	2.2	10.3	3.3	1.9	6.6	4.2	14.3	2.2	0.0	1.8	12.1	3.7	10.2	1.4	2.3	11.6	6.2	14.3	2.7	5.0	4.8	0.2	39.7	1.0	1.1	5.8	4.2	1.8	10.3	3.6	2.2	5.8	16.6	9.9	10.7	1.5	2.4	1.8	1.9	3.2	3.1	1.0	3.1	9.6	1.8	2.6	0.2	3.6	1.8	5.7	0.2	4.8	9.7	2.5	2.9	2.8	1.6	3.0	1.7	1.3	0.2	0.6	1.8	2.0	0.3	0.2	0.8	19.6	5.8	1.0	0.5	0.2	1.0	18.4	22.7	29.2	23.9	12.8	10.5	12.9	15.4	11.9	12.2	14.9	22.7	2.9	13.9	6.2	9.5	33.7	25.5	12.0	12.5	0.0	7.9	1.1	0.0	15.6	62.7	31.7	30.5	0.0	18.9	0.7	11.6	26.2	25.5	4.3	21.6	71.5	3.5	30.1	49.8	105.1	6.1	31.8	10.1	6.4	26.2	6.3	16.0	21.5	13.4	4.4	54.5	45.3	12.7	1.9	11.3	4.8	1.6	22.7	21.7	31.9
ARHGEF12	"KIAA0382, LARG"	ENSG00000196914	"Rho guanine nucleotide exchange factor 12"	Q9NZN5	11	120336914-120489936	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"GTPase activation, Guanine-nucleotide releasing factor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 2.2"	"Group enriched"	"Detected in many"	5	"granulocytes: 2.2;NK-cells: 1.5;T-cells: 1.0"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018911, CAB025581"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"	Nucleoplasm	"CAB025581: , HPA018911: AB_1845003"	"unprognostic (1.55e-1)"	"unprognostic (1.29e-1)"	"unprognostic (6.91e-3)"	"unprognostic (1.28e-1)"	"unprognostic (7.28e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.56e-1)"	"unprognostic (5.55e-2)"	"unprognostic (4.79e-2)"	"unprognostic (7.77e-2)"	"unprognostic (4.34e-3)"	"unprognostic (4.78e-2)"	"prognostic favorable (5.43e-6)"	"unprognostic (1.29e-1)"	"unprognostic (4.38e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.48e-1)"	17.6	19.2	27.6	8.3	32.5	5.9	19.6	40.4	41.5	21.7	16.4	12.4	15.7	14.9	17.5	15.9	17.8	18.6	17.3	23.4	21.8	17.7	41.2	38.8	24.1	6.5	15.8	26.3	16.3	16.9	55.8	17.2	25.4	21.1	16.8	17.8	20.7	16.7	20.0	24.1	29.0	14.8	18.6	10.8	12.4	19.0	6.7	13.0	3.0	31.3	15.0	10.9	19.4	22.9	0.3	0.3	2.2	0.1	1.5	1.0	0.4	13.2	11.1	14.9	14.3	20.2	20.2	6.2	15.6	17.7	9.5	12.1	13.0	9.7	1.1	19.2	27.8	16.8	9.9	19.1	19.7	18.6	10.9	9.4	21.5	12.0	9.9	18.1	0.0	16.0	19.3	14.3	20.8	23.2	21.0	28.7	11.7	18.1	44.1	23.9	9.2	0.0	0.0	4.1	17.1	9.6	4.7	17.1	4.2	23.3	23.0	11.0	13.6	21.8	18.3	5.7	9.3	15.6	1.7	28.4	21.1	9.0	13.7	11.3	13.0	5.2	7.3	8.7	2.8	15.9	2.2	0.0	0.0	1.0	0.1	0.2	0.3	0.6	0.6	0.0	0.3	0.0	0.5	0.0	1.5	0.1	0.3	0.7	0.4	27.6	32.5	40.4	41.5	21.8	17.7	15.8	26.3	21.1	13.0	68.5	79.7	12.3	48.8	80.4	124.2	79.1	58.6	52.2	67.1	92.5	174.7	13.7	29.9	34.0	5.0	74.1	47.9	23.3	43.8	8.3	45.2	80.8	10.5	105.8	6.1	85.8	36.4	81.0	27.2	11.5	27.6	17.4	49.0	10.8	44.1	42.4	44.6	49.0	31.5	60.7	84.8	25.8	70.9	13.5	11.9	74.4	24.0	17.5	34.8	95.3
ARID1A	"B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1"	ENSG00000117713	"AT-rich interaction domain 1A"	O14497	1	26693236-26782110	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Neurogenesis, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005456, CAB016334"	Supported		Enhanced	Nucleoplasm		NA	Yes			Nucleoplasm		"CAB016334: AB_673396, HPA005456: AB_1078205"	"unprognostic (2.83e-1)"	"unprognostic (1.81e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.41e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.89e-2)"	"prognostic unfavorable (4.18e-4)"	"unprognostic (3.02e-1)"	"unprognostic (3.66e-2)"	"unprognostic (1.34e-1)"	"unprognostic (9.69e-2)"	"unprognostic (7.76e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.62e-2)"	"unprognostic (6.05e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.54e-2)"	18.6	18.4	17.4	24.9	17.0	33.8	27.8	23.6	19.1	20.3	23.7	21.7	23.9	15.8	24.1	17.3	23.2	20.6	21.9	15.5	14.8	12.8	13.7	15.9	18.8	35.6	20.3	19.2	24.1	23.9	27.5	15.8	19.3	17.2	16.5	16.4	18.9	21.4	23.1	22.6	20.6	20.7	18.4	15.4	25.9	19.5	16.5	19.8	57.3	24.8	14.2	24.5	24.4	20.4	4.3	5.3	7.4	3.3	4.7	5.1	3.5	19.2	18.3	25.9	27.0	7.5	7.2	12.2	9.0	7.9	12.4	8.8	13.3	13.0	27.2	7.9	11.7	7.8	11.7	22.5	10.0	14.5	33.6	8.8	23.1	11.9	8.9	6.2	34.2	7.4	8.3	7.1	14.6	10.5	6.9	10.6	19.7	27.6	30.5	8.0	9.1	28.8	13.3	27.4	12.5	8.5	30.1	17.1	15.4	7.7	13.0	24.3	20.0	15.8	13.4	10.9	15.0	3.9	19.4	18.7	13.3	12.9	12.4	14.6	14.5	19.1	12.5	8.1	21.9	11.7	0.4	3.3	2.9	4.0	2.9	5.1	4.3	3.2	4.9	3.1	4.3	4.0	4.4	7.4	4.7	2.8	5.3	1.5	3.5	17.4	17.0	23.6	19.1	14.8	12.8	20.3	19.2	17.2	19.8	56.6	36.8	33.6	18.1	65.3	60.2	31.1	28.1	25.4	28.4	36.6	49.1	31.8	1.7	31.8	14.2	37.2	28.4	0.0	32.5	32.1	42.6	39.3	56.9	53.9	43.0	69.9	45.7	51.0	93.5	7.5	35.6	45.4	38.8	34.3	56.1	31.2	40.3	31.6	39.3	14.5	37.1	51.8	27.2	46.0	55.3	82.4	30.7	41.2	46.0	27.7
ARID1B	"6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R"	ENSG00000049618	"AT-rich interaction domain 1B"	Q8NFD5	6	156777374-157210779	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Neurogenesis, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016511, HPA075291"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA016511: AB_1845008, HPA075291: AB_2686743"	"prognostic unfavorable (1.04e-4)"	"unprognostic (9.82e-2)"	"unprognostic (1.73e-1)"	"unprognostic (5.42e-2)"	"unprognostic (7.47e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.73e-2)"	"unprognostic (2.89e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavorable (4.16e-4)"	"unprognostic (2.53e-1)"	"unprognostic (5.33e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.46e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.53e-1)"	"unprognostic (1.16e-1)"	18.3	15.0	20.2	18.8	20.9	25.8	19.3	42.1	32.8	20.0	17.4	26.3	21.7	15.3	23.0	14.2	18.6	20.7	15.9	16.8	20.4	11.3	14.2	10.6	17.0	18.3	19.4	16.7	30.2	18.5	47.4	29.2	12.2	17.7	17.7	13.3	24.0	20.0	20.2	30.6	27.3	17.8	21.7	14.9	21.1	15.0	10.7	24.6	24.0	23.8	13.3	26.3	23.5	21.0	9.5	11.9	5.6	3.0	2.7	5.6	1.6	7.2	11.1	16.4	22.3	13.5	12.4	11.2	7.7	10.1	10.0	10.0	9.8	10.5	22.8	4.8	13.0	12.3	9.2	14.0	12.5	9.9	22.9	9.8	16.5	11.2	11.6	9.5	13.7	12.1	14.0	10.1	15.2	13.6	10.9	13.8	14.9	19.4	17.8	7.1	8.5	15.9	15.5	8.3	9.6	5.9	36.3	7.0	12.3	6.9	13.4	15.0	19.2	15.4	16.2	9.0	9.0	10.9	21.6	14.2	12.6	13.4	11.6	15.0	12.3	11.0	29.2	11.0	16.5	16.9	5.6	3.0	2.5	5.4	2.4	5.0	6.8	4.7	3.8	2.3	9.5	4.0	5.6	5.5	2.7	2.6	11.9	4.6	1.6	20.2	20.9	42.1	32.8	20.4	11.3	19.4	16.7	17.7	24.6	44.7	46.7	59.6	18.3	42.2	35.6	27.8	28.1	28.1	36.4	120.4	27.5	10.8	6.6	33.6	12.1	27.8	19.2	0.0	29.8	6.4	27.7	23.2	38.1	23.3	12.3	44.5	39.2	37.4	29.2	13.0	52.6	28.8	28.7	72.1	38.0	23.8	39.9	21.0	59.1	12.2	30.1	45.3	28.2	6.3	14.9	48.7	14.6	23.2	34.9	20.2
ARID2	"BAF200, DKFZp686G052, FLJ30619, KIAA1557"	ENSG00000189079	"AT-rich interaction domain 2"	Q68CP9	12	45729665-45908040	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"Early spermatids: 522.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063044			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"HPA063044: AB_2684929"	"unprognostic (8.41e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.02e-2)"	"unprognostic (3.94e-2)"	"unprognostic (4.15e-2)"	"prognostic favorable (5.75e-4)"	"unprognostic (1.26e-2)"	"unprognostic (9.71e-2)"	"unprognostic (9.04e-2)"	"unprognostic (5.57e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.47e-1)"	"unprognostic (1.12e-2)"	"unprognostic (9.21e-2)"	"unprognostic (3.02e-1)"	"unprognostic (2.00e-1)"	"unprognostic (6.53e-2)"	9.0	7.9	7.1	14.6	7.2	14.0	11.8	15.7	8.8	10.2	11.4	8.2	17.9	6.4	12.2	10.7	11.5	8.8	10.6	8.2	7.4	5.8	8.7	6.9	10.2	13.0	9.6	3.8	12.2	10.7	18.4	15.1	10.3	7.5	9.9	8.1	10.1	9.7	20.6	8.6	13.5	12.6	12.5	7.3	10.2	9.0	30.9	11.0	33.3	11.5	8.2	11.2	10.0	10.0	2.1	5.3	10.5	4.9	3.1	4.4	1.3	5.4	7.8	14.0	6.1	6.0	4.2	7.6	3.8	5.4	5.3	5.0	11.1	5.6	10.5	7.1	5.2	3.9	6.6	11.3	6.5	7.7	4.6	5.4	13.9	8.6	5.4	4.1	10.9	6.4	3.4	4.9	6.7	10.8	7.5	5.4	15.9	11.7	10.9	4.7	7.1	15.6	7.8	8.4	0.0	4.2	12.1	10.0	10.1	5.1	9.1	7.6	9.7	6.2	7.2	6.0	8.4	11.0	21.9	6.4	5.7	6.9	3.8	4.9	7.3	6.1	29.4	4.4	28.8	4.0	10.5	1.7	4.2	4.1	2.2	4.3	1.7	3.7	4.4	2.4	2.1	3.6	3.3	2.4	3.1	4.9	5.3	3.1	1.3	7.1	7.2	15.7	8.8	7.4	5.8	9.6	3.8	7.5	11.0	26.8	27.9	10.2	11.5	30.0	49.0	12.6	5.1	9.4	12.5	27.9	64.8	11.9	6.6	11.2	522.0	21.5	15.0	0.0	8.7	8.9	17.5	17.9	20.9	13.1	9.9	30.2	20.2	16.5	27.5	122.6	23.0	20.0	13.5	12.6	19.9	19.7	15.6	24.6	21.2	6.9	67.9	25.8	22.7	61.7	16.5	36.1	19.6	24.5	16.0	16.5
ARNT	"bHLHe2, HIF-1beta"	ENSG00000143437	"Aryl hydrocarbon receptor nuclear translocator"	P27540	1	150809705-150876768	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in many"	7	"U-698: 97.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001759, CAB004318"	Supported		Supported	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nucleoplasm, Nuclear bodies"		"CAB004318: AB_626698, HPA001759: AB_1078213"	"unprognostic (1.81e-1)"	"unprognostic (8.14e-2)"	"unprognostic (6.87e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.10e-2)"	"unprognostic (9.43e-2)"	"unprognostic (5.27e-3)"	"unprognostic (5.05e-1)"	"unprognostic (3.42e-2)"	"unprognostic (1.22e-1)"	"unprognostic (9.52e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.68e-1)"	"unprognostic (4.67e-1)"	"unprognostic (6.45e-2)"	"unprognostic (6.92e-2)"	23.5	20.8	12.1	14.5	12.6	11.3	25.1	25.4	14.4	28.0	17.2	18.7	12.8	10.9	26.1	14.4	16.6	20.4	17.9	20.0	10.2	8.2	14.4	32.2	21.6	12.0	11.6	9.5	31.8	22.4	16.5	22.9	31.7	12.3	18.2	16.4	28.3	15.2	16.3	25.5	21.9	15.2	22.6	14.0	19.2	16.5	14.9	12.3	18.8	16.1	13.9	18.0	23.0	24.4	6.6	12.7	23.9	15.6	8.0	8.8	9.7	4.0	4.2	6.4	4.8	13.7	13.2	8.6	4.6	9.2	6.4	5.8	3.6	4.2	4.3	4.2	8.3	3.1	4.7	5.8	5.2	5.6	6.9	3.5	5.2	7.2	4.2	7.9	6.1	6.1	10.3	4.9	7.7	6.8	7.7	7.8	5.9	6.6	8.7	6.5	8.0	4.9	3.4	5.2	7.4	3.3	6.2	7.7	6.1	5.0	4.2	4.2	6.3	9.0	6.2	3.6	9.0	7.8	13.4	5.5	5.3	4.8	4.2	4.0	9.9	7.2	97.0	6.5	0.2	3.6	23.9	15.6	13.9	8.8	14.7	7.9	6.2	7.2	8.4	12.7	6.6	7.0	7.1	8.1	8.0	14.7	5.2	7.2	9.7	12.1	12.6	25.4	14.4	10.2	8.2	11.6	9.5	12.3	12.3	11.9	9.3	9.7	7.8	12.6	20.9	10.6	22.9	6.7	11.4	10.4	51.1	20.7	3.3	8.1	4.2	11.7	8.6	0.0	8.5	31.6	20.3	7.2	3.5	36.0	17.1	6.4	19.5	31.9	35.9	2.1	30.0	15.7	10.1	14.4	15.1	7.7	8.6	7.0	30.8	9.3	37.6	12.9	15.0	18.6	15.7	13.4	24.7	10.1	8.0	8.6
ASPSCR1	"ASPL, ASPS, TUG, UBXD9, UBXN9"	ENSG00000169696	"ASPSCR1, UBX domain containing tether for SLC2A4"	Q9BZE9	17	81976807-82017406	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Extravillous trophoblasts: 151.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	5	"Hep G2: 82.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA026749	Approved		Supported	"Nucleoplasm,Vesicles,Plasma membrane"		NA	NA			Nucleoplasm	"Vesicles, Plasma membrane"	"HPA026749: AB_1845114"	"unprognostic (5.01e-2)"	"unprognostic (1.19e-3)"	"unprognostic (7.61e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.36e-1)"	"prognostic favorable (8.55e-4)"	"unprognostic (2.02e-1)"	"unprognostic (2.07e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.71e-3)"	"prognostic favorable (2.67e-4)"	"unprognostic (1.13e-1)"	"prognostic unfavorable (1.26e-4)"	"unprognostic (3.16e-2)"	"unprognostic (1.13e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.01e-2)"	10.3	12.6	14.3	12.6	14.5	16.8	10.6	16.5	20.8	9.9	12.9	16.7	11.8	17.5	10.1	15.8	11.9	9.3	15.1	11.5	13.1	12.6	15.8	31.9	14.1	14.8	18.9	12.9	8.8	17.8	17.0	19.7	21.8	14.8	13.2	7.1	14.4	22.6	9.9	25.1	15.5	14.4	9.1	12.6	13.2	13.0	16.9	14.6	9.8	16.4	12.9	13.0	9.7	8.3	8.1	14.6	15.7	11.3	7.2	10.5	5.2	5.1	9.0	3.5	5.1	2.2	2.8	15.3	4.9	3.7	5.9	5.8	5.2	5.9	5.2	5.0	3.5	4.5	2.5	3.8	3.7	1.8	3.6	11.5	5.8	7.3	82.6	7.3	5.1	8.5	3.2	4.0	2.9	2.1	3.1	5.6	4.4	5.8	7.5	3.3	17.3	4.7	11.1	4.4	9.5	6.6	5.2	5.1	10.6	5.7	4.7	9.4	9.6	3.9	12.6	9.0	4.2	7.5	12.2	4.6	10.1	7.0	7.4	6.1	5.4	3.2	5.8	5.4	5.2	6.0	15.7	11.3	8.0	6.7	7.6	4.0	7.9	10.5	9.0	14.6	8.1	8.0	6.0	2.9	7.2	9.3	9.1	4.9	5.2	14.3	14.5	16.5	20.8	13.1	12.6	18.9	12.9	14.8	14.6	8.9	46.0	18.6	20.7	11.8	21.4	11.4	17.8	10.7	9.1	14.0	39.3	64.7	33.2	21.2	40.2	16.0	26.7	0.0	22.9	151.3	16.6	19.3	20.8	45.6	39.1	47.7	24.0	15.4	16.6	63.2	10.9	17.1	18.6	18.0	24.4	56.7	16.2	20.1	16.6	44.0	32.8	12.9	15.3	43.6	48.7	12.5	49.7	23.6	23.8	19.7
ASXL1	KIAA0978	ENSG00000171456	"Additional sex combs like 1, transcriptional regulator"	Q8IXJ9	20	32358330-32439319	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"Chromatin regulator, Repressor"	"Cancer-related genes, Craniosynostosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA064156			Approved	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA064156: AB_2685200"	"unprognostic (1.49e-1)"	"unprognostic (5.97e-2)"	"unprognostic (8.36e-2)"	"prognostic unfavorable (2.86e-4)"	"unprognostic (6.69e-2)"	"prognostic favorable (9.16e-4)"	"unprognostic (2.01e-3)"	"unprognostic (2.89e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.38e-1)"	"unprognostic (4.32e-2)"	"unprognostic (3.21e-2)"	"unprognostic (1.84e-3)"	"unprognostic (5.47e-2)"	"unprognostic (1.90e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.06e-1)"	24.3	19.6	19.0	35.0	18.2	39.0	24.7	28.3	23.8	32.4	22.7	17.7	16.9	15.6	32.4	22.2	14.3	20.5	21.6	17.9	19.7	10.7	21.2	25.2	27.3	26.7	20.3	14.7	28.1	27.1	21.2	16.3	19.8	18.2	20.6	16.4	16.6	17.4	23.3	25.5	18.2	21.8	21.8	12.2	28.2	19.7	32.1	23.0	47.4	26.8	15.8	29.0	23.2	35.3	9.8	3.1	1.3	0.8	1.7	14.6	1.9	22.9	13.3	20.9	11.6	9.6	12.0	18.2	15.4	13.2	26.9	19.9	39.6	14.8	21.7	9.9	19.0	25.6	16.0	17.6	14.8	22.0	32.5	9.6	34.6	21.1	21.6	8.6	14.4	14.4	13.3	9.9	18.7	14.1	13.3	14.8	17.9	16.7	11.8	12.5	7.0	19.7	11.6	5.0	10.7	15.4	11.5	25.1	9.4	11.0	11.1	9.6	15.1	27.9	9.3	12.2	11.6	13.3	10.2	15.3	28.6	25.0	13.2	17.1	13.8	14.7	16.0	14.5	38.4	10.9	0.0	0.8	1.3	4.4	0.7	3.5	9.8	5.2	5.6	0.7	5.8	5.8	5.9	0.9	1.7	0.7	3.1	14.6	1.9	19.0	18.2	28.3	23.8	19.7	10.7	20.3	14.7	18.2	23.0	47.6	38.1	41.7	41.8	35.5	18.7	18.5	15.3	21.4	25.0	26.2	49.1	16.2	21.6	12.4	73.4	61.8	21.2	0.0	10.8	12.8	37.0	40.7	17.4	29.3	18.3	17.5	6.9	34.4	16.8	61.5	23.6	23.6	74.2	10.0	12.1	12.6	14.1	11.5	13.8	22.1	30.4	6.5	44.0	25.6	13.5	26.7	4.9	41.5	15.5	32.6
ATF1	TREB36	ENSG00000123268	"Activating transcription factor 1"	P18846	12	50763710-50821122	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016222, HPA055069, HPA055406"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB016222: AB_2290030, HPA055069: AB_2682688, HPA055406: AB_2682807"	"unprognostic (1.71e-1)"	"unprognostic (1.50e-3)"	"unprognostic (1.50e-1)"	"unprognostic (9.05e-2)"	"unprognostic (6.68e-2)"	"unprognostic (1.58e-1)"	"prognostic unfavorable (1.53e-5)"	"unprognostic (3.65e-1)"	"unprognostic (8.17e-3)"	"unprognostic (5.94e-2)"	"unprognostic (4.31e-3)"	"unprognostic (5.52e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.74e-2)"	"unprognostic (2.46e-1)"	"unprognostic (2.27e-1)"	"unprognostic (8.75e-2)"	24.4	20.7	9.8	13.7	9.5	10.2	16.2	28.1	10.6	22.4	19.7	8.1	14.6	12.3	19.2	14.2	16.2	15.5	13.4	20.0	10.8	8.0	17.7	19.8	15.1	15.8	12.2	6.0	24.7	11.8	18.1	15.2	36.1	11.9	20.7	15.1	12.5	16.3	14.2	37.9	12.9	18.8	13.4	12.3	22.9	12.7	9.3	13.9	34.4	30.8	16.3	16.2	21.6	20.0	13.3	13.6	26.3	12.3	12.2	18.8	11.6	13.5	9.8	10.4	10.6	15.0	16.0	25.9	14.4	24.8	22.8	18.0	20.1	21.5	18.7	23.8	16.6	10.0	11.3	12.3	14.8	24.4	18.4	12.7	20.6	22.2	10.7	28.8	29.6	19.8	17.0	23.5	16.3	26.8	23.8	11.0	13.2	25.1	18.1	16.9	20.1	18.6	18.8	15.1	15.7	15.7	17.9	16.2	22.1	17.3	9.3	14.0	7.6	30.5	13.3	21.7	14.9	18.5	18.1	7.6	16.1	19.5	13.5	11.4	10.0	11.8	29.9	15.5	16.7	7.6	4.2	11.5	26.3	13.9	12.3	15.8	13.0	15.1	16.4	13.6	13.3	18.8	14.3	7.3	12.2	7.7	6.2	17.9	11.6	9.8	9.5	28.1	10.6	10.8	8.0	12.2	6.0	11.9	13.9	50.6	14.4	34.4	42.6	66.9	12.0	12.9	10.2	18.7	23.9	12.2	0.0	27.2	44.7	20.3	6.5	18.6	17.3	70.0	18.5	60.0	36.0	33.7	9.3	15.7	24.6	12.7	5.8	15.4	21.9	4.9	29.7	29.4	21.9	18.0	13.9	12.9	18.2	14.0	26.2	25.4	6.9	38.8	32.0	9.3	10.2	47.7	67.4	30.9	21.2	30.7
ATIC	"AICARFT, IMPCHASE, PURH"	ENSG00000138363	"5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase"	P31939	2	215311817-215349773	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Purine biosynthesis"	"Hydrolase, Multifunctional enzyme, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cytotrophoblasts: 144.4;Extravillous trophoblasts: 132.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013462, HPA021012"	Supported		Approved	"Plasma membrane,Cytosol"		NA	NA		3400000	Cytosol	"Plasma membrane"	"CAB013462: , HPA021012: AB_1845169"	"unprognostic (1.41e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.13e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.81e-2)"	"prognostic unfavorable (1.99e-7)"	"unprognostic (1.86e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.31e-3)"	"unprognostic (9.21e-2)"	"prognostic unfavorable (8.77e-4)"	"unprognostic (1.00e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.18e-2)"	"unprognostic (4.39e-3)"	19.4	27.4	21.1	23.0	28.4	16.9	24.8	12.1	32.3	20.6	26.7	29.1	18.1	23.4	27.9	15.6	19.1	21.9	19.1	18.2	20.3	21.1	23.1	35.6	17.3	36.1	29.7	19.9	23.4	32.9	25.1	21.1	31.1	24.4	21.9	35.9	19.5	14.4	29.4	35.5	17.0	20.6	26.7	21.7	29.0	20.4	15.0	28.0	46.3	16.1	13.5	35.3	27.6	18.0	21.7	13.4	2.9	8.9	19.6	22.8	10.0	20.5	31.1	17.4	29.5	23.4	23.7	8.7	21.0	18.3	24.0	27.6	60.0	32.2	29.9	26.0	21.9	33.8	21.6	38.2	31.7	34.5	22.3	36.9	36.4	26.7	53.7	30.3	45.6	18.7	20.0	24.3	32.1	38.8	16.6	16.0	29.0	47.0	25.0	33.0	30.3	39.7	22.2	66.8	32.9	17.5	36.9	25.0	26.8	25.5	33.2	27.3	18.9	16.9	20.8	23.7	40.4	34.1	16.2	14.1	20.4	21.1	26.3	13.2	31.6	41.2	62.1	17.7	25.4	29.4	2.9	6.0	0.1	13.2	8.9	22.8	21.7	18.6	20.0	13.4	13.2	18.9	17.5	0.7	19.6	7.4	11.7	17.7	10.0	21.1	28.4	12.1	32.3	20.3	21.1	29.7	19.9	24.4	28.0	11.9	17.1	19.3	23.5	13.4	9.6	18.5	25.5	26.8	19.4	22.7	3.9	144.4	23.2	32.2	0.8	6.3	13.5	0.0	42.8	132.7	23.3	16.1	24.3	18.7	46.4	9.5	18.5	4.3	15.0	0.0	22.2	18.7	28.7	32.5	29.9	20.6	30.0	21.0	32.2	44.0	12.8	25.8	19.8	3.2	40.3	7.4	79.8	21.5	52.7	17.4
ATM	"ATA, ATC, ATD, ATDC, TEL1, TELO1"	ENSG00000149311	"ATM serine/threonine kinase"	Q13315	11	108222484-108369102	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell cycle, DNA damage"	"DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Neurodegeneration, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cone photoreceptor cells: 198.3;Rod photoreceptor cells: 196.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 48.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000102, HPA067142"	Supported		Enhanced	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"CAB000102: , HPA067142: AB_2685789"	"unprognostic (9.77e-2)"	"unprognostic (1.47e-1)"	"unprognostic (3.04e-1)"	"unprognostic (2.36e-1)"	"unprognostic (5.70e-2)"	"unprognostic (2.86e-2)"	"unprognostic (6.32e-3)"	"unprognostic (1.05e-1)"	"unprognostic (8.19e-2)"	"unprognostic (1.63e-1)"	"unprognostic (7.68e-2)"	"unprognostic (6.16e-2)"	"unprognostic (2.17e-3)"	"unprognostic (3.10e-1)"	"unprognostic (7.87e-2)"	"unprognostic (1.21e-1)"	"unprognostic (2.81e-1)"	8.3	10.9	12.7	26.5	19.3	16.8	9.4	17.7	14.4	10.9	8.5	10.9	8.8	6.0	11.2	11.4	6.9	9.5	9.2	9.6	12.4	8.5	7.7	9.5	10.1	33.4	19.6	6.7	20.5	20.7	15.7	29.2	8.8	14.5	9.1	7.9	7.2	15.1	9.8	6.2	8.4	16.5	10.6	23.4	22.6	8.9	6.1	17.9	19.5	10.7	5.1	26.9	10.7	10.7	13.7	6.1	13.5	12.5	7.6	18.5	4.4	2.7	3.9	7.7	4.1	10.0	14.6	2.0	6.1	6.8	3.5	5.9	4.8	6.5	9.6	9.1	4.9	5.6	4.1	5.8	5.1	5.5	7.7	3.4	8.7	4.8	4.8	5.3	10.5	9.4	9.4	3.2	5.4	10.4	7.7	7.4	8.2	8.4	6.6	6.9	2.0	7.1	9.7	6.3	4.1	3.9	5.6	5.3	15.1	4.0	5.5	5.2	6.4	7.1	3.3	10.5	7.1	5.0	5.9	11.5	8.8	4.9	5.0	5.7	4.4	4.6	48.5	5.8	11.5	9.8	13.5	5.7	3.8	14.9	5.3	10.4	11.1	10.5	11.3	2.7	13.7	18.5	17.9	10.8	7.6	12.5	6.1	5.3	4.4	12.7	19.3	17.7	14.4	12.4	8.5	19.6	6.7	14.5	17.9	35.7	21.0	122.7	17.4	11.2	101.7	35.4	10.2	13.4	19.4	21.0	198.3	14.8	5.0	7.7	12.8	18.8	4.9	0.0	10.6	10.5	26.4	9.5	12.7	21.2	26.0	57.2	19.5	36.8	82.2	2.7	36.5	48.1	25.3	9.0	15.9	35.9	7.6	10.5	26.2	10.3	196.6	25.8	17.3	18.7	33.6	10.8	3.5	111.7	11.7	9.9
ATP1A1		ENSG00000163399	"ATPase Na+/K+ transporting subunit alpha 1"	P05023	1	116372668-116410261	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"	Translocase	"Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 195.4;parathyroid gland: 194.4"	"Cell type enhanced"	"Detected in all"	5	"Enterocytes: 917.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 254.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018702, CAB069993"	Enhanced					NA	NA		380000			"CAB018702: AB_626713, CAB069993: AB_2060979"	"unprognostic (6.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (6.91e-2)"	"unprognostic (1.42e-2)"	"unprognostic (6.80e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavorable (1.42e-4)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.65e-1)"	"prognostic favorable (8.98e-8)"	"unprognostic (4.75e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.11e-2)"	"prognostic unfavorable (4.01e-4)"	17.4	25.6	22.4	16.2	40.3	10.5	26.9	74.2	67.4	17.8	121.9	14.2	56.1	92.3	13.1	38.3	34.9	17.7	65.8	41.1	26.1	18.7	162.7	34.6	35.1	9.6	19.2	27.6	17.4	78.6	194.4	25.0	19.2	34.1	22.1	65.7	24.1	84.4	53.7	19.0	40.5	195.4	17.7	20.7	13.7	25.0	17.0	13.9	9.1	101.2	13.7	16.2	14.2	23.1	10.3	22.0	6.4	29.7	10.4	30.2	17.2	33.7	12.4	12.9	6.5	26.0	25.3	66.6	20.2	40.3	24.9	35.4	49.8	24.2	26.7	28.6	23.9	25.3	44.1	25.5	42.6	36.3	9.8	28.3	15.5	23.5	42.0	19.9	38.9	21.9	28.1	71.5	29.0	38.3	35.2	30.5	16.3	25.6	25.8	22.0	67.0	15.7	14.1	30.4	53.6	25.0	15.2	30.3	23.6	90.1	34.8	12.7	11.2	31.4	59.6	254.2	33.2	15.7	22.6	26.9	14.2	19.9	36.7	40.9	12.5	9.7	20.5	43.6	22.5	83.4	6.4	13.3	6.1	23.2	20.9	24.8	10.3	26.4	24.9	22.0	5.3	30.2	22.0	1.6	10.4	29.7	11.1	20.3	17.2	22.4	40.3	74.2	67.4	26.1	18.7	19.2	27.6	34.1	13.9	256.1	246.7	58.7	265.3	245.9	76.0	62.7	540.1	113.8	203.6	731.0	375.0	70.1	316.7	432.8	25.0	117.9	917.6	93.5	278.3	130.8	110.9	297.5	43.8	66.4	114.8	96.9	169.4	90.9	77.6	11.5	109.0	130.5	197.4	47.7	304.0	513.0	192.4	264.8	94.7	289.6	141.6	32.3	179.2	17.9	27.5	235.0	56.5	95.6	365.5	236.0
ATP2B3	"CFAP39, CLA2, PMCA3, SCAX1"	ENSG00000067842	"ATPase plasma membrane Ca2+ transporting 3"	Q16720	X	153517676-153582939	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"	"Calcium transport, Ion transport, Transport"	"Calmodulin-binding, Translocase"	"Cancer-related genes, Disease mutation, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 18.6;brain: 23.2"	"Group enriched"	"Detected in some"	4	"Bipolar cells: 5.0;Extravillous trophoblasts: 8.3;Rod photoreceptor cells: 2.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"SCLC-21H: 14.6;SH-SY5Y: 4.3;THP-1: 3.5;U-937: 3.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001583	Enhanced	Supported				NA	NA					"HPA001583: AB_1079641"	"unprognostic (1.35e-1)"	"unprognostic (3.07e-2)"	"unprognostic (3.28e-1)"	"unprognostic (6.82e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.32e-2)"	"unprognostic (2.67e-1)"	"unprognostic (6.34e-2)"	"unprognostic (2.68e-2)"	"unprognostic (8.58e-2)"	"unprognostic (1.38e-3)"	"unprognostic (3.44e-1)"	"unprognostic (2.71e-12)"	"unprognostic (1.44e-3)"	"unprognostic (2.04e-1)"		"unprognostic (2.42e-2)"	0.8	18.6	5.4	0.9	11.3	0.8	0.8	16.1	23.2	0.8	0.9	3.9	0.0	0.9	0.9	2.6	0.8	3.1	0.8	0.8	7.8	5.5	1.0	0.8	0.8	0.8	4.3	11.5	0.8	0.9	0.8	1.2	1.7	13.6	0.8	0.8	1.4	1.3	1.3	0.8	0.9	0.9	0.9	1.4	0.8	0.8	1.1	0.9	0.0	0.8	0.0	0.8	0.8	0.1	0.0	0.5	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.6	4.3	0.0	0.0	0.0	0.1	0.0	3.5	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.4	11.3	16.1	20.7	7.8	5.5	4.3	11.5	13.6	0.9	0.0	0.0	0.0	0.0	0.0	5.0	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0
ATR	"FRP1, MEC1, SCKL, SCKL1"	ENSG00000175054	"ATR serine/threonine kinase"	Q13535	3	142449235-142578826	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA repair"	"DNA-binding, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cone photoreceptor cells: 35.3;Spermatocytes: 42.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054320			Supported	"Nucleoplasm,Golgi apparatus"		No	No			Nucleoplasm	"Golgi apparatus"	"HPA054320: AB_2682448"	"unprognostic (1.47e-1)"	"unprognostic (8.90e-2)"	"unprognostic (2.90e-1)"	"unprognostic (4.23e-2)"	"unprognostic (2.25e-2)"	"unprognostic (6.42e-2)"	"prognostic unfavorable (8.39e-5)"	"unprognostic (3.44e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.02e-1)"	"prognostic unfavorable (1.23e-5)"	"unprognostic (1.94e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.55e-1)"	"unprognostic (1.69e-2)"	"unprognostic (1.43e-1)"	10.5	24.3	7.7	11.4	15.9	10.1	14.8	11.3	14.6	10.1	8.5	10.0	10.4	6.0	14.7	16.8	9.4	12.1	9.3	8.8	9.8	7.1	9.6	12.0	10.3	16.0	10.0	8.1	12.3	13.6	18.0	22.5	8.8	12.5	11.0	11.2	9.5	12.5	10.8	7.7	11.2	10.9	9.8	8.8	14.2	9.0	15.3	9.7	19.0	13.8	7.7	15.1	10.9	10.6	5.8	2.8	2.2	4.0	6.7	6.0	0.8	22.7	11.2	7.5	8.5	10.7	11.8	8.9	12.6	7.1	9.4	9.7	5.2	7.3	18.6	13.0	8.9	12.3	14.8	11.0	11.6	14.2	5.9	7.2	10.2	8.5	5.1	4.7	17.1	5.7	9.2	6.4	8.9	10.6	6.4	9.7	9.7	7.1	8.4	9.6	10.0	12.9	7.1	7.2	14.9	8.0	10.7	10.9	13.5	9.5	10.6	5.3	5.4	23.2	8.4	8.2	7.1	12.2	6.9	12.5	9.6	4.8	12.4	13.5	11.0	6.5	17.3	12.5	6.7	7.6	0.7	2.7	2.2	4.4	4.0	6.0	3.1	3.2	4.2	2.8	5.8	4.1	4.0	1.7	6.7	2.5	2.5	2.4	0.8	7.7	15.9	11.3	14.6	9.8	7.1	10.0	8.1	12.5	9.7	6.0	8.8	13.4	6.5	3.5	14.7	7.1	7.6	18.7	6.8	3.5	35.3	6.6	0.0	5.3	12.0	7.1	2.1	0.0	4.3	3.3	4.8	6.7	1.1	6.0	5.7	7.9	7.5	8.6	9.1	6.9	6.1	6.9	10.1	4.6	5.4	4.8	6.2	0.0	6.7	4.1	23.4	0.0	6.4	42.3	15.8	4.0	4.2	5.1	7.0	5.2
ATRX	"JMS, MRX52, RAD54, XH2, XNP"	ENSG00000085224	"ATRX, chromatin remodeler"	P46100	X	77504878-77786269	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"DNA damage, DNA repair, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001906, CAB009372, HPA064684, CAB068176"	Supported		Supported	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"CAB009372: AB_2061023, CAB068176: AB_2665665, HPA001906: AB_1078249, HPA064684: AB_2685321"	"unprognostic (1.77e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.65e-2)"	"unprognostic (4.37e-2)"	"unprognostic (1.67e-1)"	"unprognostic (9.69e-2)"	"unprognostic (8.11e-2)"	"unprognostic (1.15e-2)"	"unprognostic (6.04e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.80e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.50e-1)"	"unprognostic (6.19e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.24e-1)"	16.4	16.6	24.5	18.9	29.3	24.3	16.3	48.2	26.4	20.6	15.4	7.1	18.9	10.2	20.2	17.1	13.5	13.8	13.4	15.1	22.9	15.8	16.6	12.2	15.9	18.6	21.1	21.3	25.4	18.3	35.7	28.1	15.9	20.2	18.4	12.6	7.1	15.8	16.5	20.1	14.1	13.5	22.3	15.3	20.1	15.6	6.5	22.4	23.7	19.8	12.7	16.5	19.9	21.1	21.9	12.8	21.5	11.5	14.6	17.7	5.7	15.3	24.7	25.4	17.1	12.7	17.1	9.0	13.3	12.3	9.9	11.7	8.4	13.5	21.4	13.7	14.1	18.6	13.7	20.4	7.9	16.8	12.0	13.3	12.9	29.4	6.2	6.9	16.7	4.4	11.2	7.8	14.5	13.9	12.3	17.4	13.5	15.1	24.6	12.3	12.1	12.9	8.7	18.4	7.1	19.2	21.0	35.2	10.9	9.6	20.6	14.5	25.1	26.8	10.5	8.8	17.2	8.5	8.6	24.0	14.0	21.6	15.6	9.3	7.3	22.7	19.2	10.2	13.3	12.3	21.3	6.9	13.8	17.7	8.7	17.1	19.2	16.3	13.7	5.1	21.9	16.8	13.5	21.5	14.6	11.5	12.8	12.8	5.7	24.5	29.3	48.2	26.4	22.9	15.8	21.1	21.3	20.2	22.4	148.9	213.6	88.0	96.7	82.1	217.2	263.3	58.6	120.5	117.2	68.0	200.3	58.0	19.9	72.8	3.1	123.5	43.3	23.3	72.0	39.7	90.3	99.7	106.6	45.6	60.7	149.4	121.7	91.4	84.5	4.9	150.4	86.3	59.1	120.0	68.3	114.7	80.3	40.3	195.6	28.6	231.4	90.5	113.3	13.6	49.5	73.8	50.0	94.4	62.6	104.6
AXIN1	PPP1R49	ENSG00000103126	"Axin 1"	O15169	16	287440-352673	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB012987	Approved		Supported	Nucleoli,Vesicles		NA	NA			"Nucleoli, Vesicles"		"CAB012987: AB_2533178"	"unprognostic (3.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.90e-1)"	"unprognostic (7.64e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.06e-1)"	"prognostic unfavorable (3.38e-5)"	"unprognostic (1.23e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.56e-1)"	"unprognostic (4.58e-2)"	"unprognostic (2.02e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.03e-1)"	10.8	8.3	13.7	18.9	17.1	28.1	21.0	26.4	13.6	10.4	15.8	12.7	9.4	17.3	12.6	8.5	14.1	10.7	12.7	11.0	11.5	7.7	9.8	9.6	13.6	13.4	15.6	10.6	13.3	17.7	11.1	11.9	8.4	13.9	11.4	10.2	9.6	13.9	9.5	17.7	16.9	17.6	18.9	9.6	15.1	15.2	9.6	14.6	17.5	12.7	7.5	14.5	11.9	22.9	1.8	1.4	5.5	1.1	3.6	10.4	2.4	9.6	14.0	7.5	13.2	5.6	5.2	15.8	6.5	6.0	9.1	7.8	20.6	11.3	15.0	10.1	6.7	10.9	13.9	11.7	10.2	4.1	14.7	19.2	9.7	11.8	14.9	9.6	11.1	10.8	5.1	17.8	9.3	11.5	8.0	6.0	11.0	24.1	8.3	4.1	25.8	12.0	7.7	17.1	11.7	8.6	22.7	6.8	20.8	6.8	5.7	17.1	10.5	12.4	13.9	20.5	5.9	9.2	14.2	6.7	9.0	9.7	10.3	9.4	9.6	9.3	18.3	4.3	7.4	8.8	1.4	1.1	5.5	10.4	0.9	9.5	1.8	3.0	7.0	0.8	1.6	3.2	4.3	3.2	3.6	0.7	1.4	3.0	2.4	13.7	17.1	26.4	13.6	11.5	7.7	15.6	10.6	13.9	14.6	3.0	11.3	5.2	5.3	16.4	4.9	5.0	5.1	6.7	6.8	3.5	0.0	3.1	0.0	6.1	1.0	6.7	18.6	0.0	6.1	20.3	5.9	9.4	10.4	4.7	6.5	4.8	10.4	4.3	7.5	1.3	4.9	5.9	10.1	3.6	14.5	3.7	8.8	11.9	4.6	2.1	5.4	12.9	5.3	4.4	7.6	13.2	3.1	7.7	11.8	8.7
AXIN2	"DKFZp781B0869, MGC126582"	ENSG00000168646	"Axin 2"	Q9Y2T1	17	65528563-65561647	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	12	"Extravillous trophoblasts: 87.1"	"Cancer enhanced"	"Detected in all"		"colorectal cancer: 33.4"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 5.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 11.8;CACO-2: 22.1;Hep G2: 32.9;OE19: 36.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012283, CAB017783"	Approved		Uncertain	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Plasma membrane"	Cytosol	"CAB012283: AB_2290204, CAB017783: "	"unprognostic (1.31e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.45e-3)"	"unprognostic (4.48e-1)"	"unprognostic (9.81e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.82e-1)"	"unprognostic (4.57e-2)"	"unprognostic (8.84e-3)"	"prognostic favorable (6.58e-4)"	"unprognostic (1.98e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.45e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.25e-1)"	7.4	10.1	9.0	7.0	8.9	0.9	5.2	8.2	13.1	16.5	12.2	8.7	10.5	7.2	29.0	7.7	6.5	18.6	6.9	7.3	7.9	5.7	3.5	2.5	15.2	3.4	5.3	10.3	14.7	3.9	3.2	5.8	18.2	10.6	14.8	15.2	7.8	4.6	9.8	12.4	14.9	7.5	18.0	4.8	6.9	14.6	6.8	9.0	27.6	11.3	3.6	3.8	11.8	8.7	4.1	0.0	4.4	0.0	1.9	5.1	0.8	0.0	5.9	11.8	0.2	4.3	1.8	5.2	0.1	0.5	0.4	0.7	22.1	2.1	0.4	0.7	3.4	0.4	0.1	2.4	0.0	0.8	1.0	1.3	0.0	1.0	32.9	0.4	0.0	0.0	1.0	0.9	0.9	0.2	0.7	1.0	2.2	0.0	0.5	0.6	0.1	5.7	0.0	2.3	36.5	0.2	4.1	0.6	0.0	1.1	0.1	3.7	2.4	0.2	0.1	2.0	9.1	0.4	0.1	2.6	2.3	4.3	3.3	0.7	0.0	1.2	1.5	1.1	0.2	1.1	4.4	0.0	0.0	0.3	0.0	0.8	1.0	2.3	0.4	0.0	4.1	5.1	0.8	0.0	1.9	0.0	0.0	0.0	0.8	9.0	8.9	8.2	13.1	7.9	5.7	5.3	10.3	10.6	9.0	0.0	7.0	0.0	1.2	10.0	3.8	8.1	2.5	1.4	10.3	0.0	3.9	14.3	0.0	1.0	27.8	3.8	2.8	0.0	0.7	87.1	17.5	4.1	0.0	1.9	3.3	1.6	5.2	1.3	0.0	11.2	6.1	0.3	16.9	1.8	18.7	3.5	0.7	3.5	10.3	0.6	1.9	12.9	5.9	5.4	12.6	4.8	11.9	0.0	16.8	1.1
B2M		ENSG00000166710	Beta-2-microglobulin	P61769	15	44711477-44718877	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	Immunity		"Amyloidosis, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	9	"monocytes: 43079.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"THP-1: 178.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002572, HPA006361"	Enhanced		Enhanced	"Golgi apparatus,Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA	1790000000	3200000000	"Golgi apparatus, Plasma membrane"	Cytosol	"CAB002572: AB_563434, HPA006361: AB_1078278"	"unprognostic (9.45e-2)"	"unprognostic (5.63e-2)"	"unprognostic (3.02e-1)"	"unprognostic (8.14e-2)"	"unprognostic (1.18e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.44e-3)"	"unprognostic (2.02e-2)"	"unprognostic (4.77e-2)"	"unprognostic (2.39e-1)"	"unprognostic (5.25e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.17e-2)"	127.2	50.9	24.2	109.2	29.8	131.1	85.2	11.8	23.1	70.5	111.4	29.1	43.3	79.1	72.7	74.7	80.5	36.8	112.8	73.6	26.0	23.1	109.7	140.3	191.2	172.1	42.2	18.8	54.8	42.7	7.8	40.5	91.9	33.1	78.7	128.9	53.5	121.5	40.9	45.7	94.1	178.5	55.1	56.7	272.8	52.5	30.0	29.5	108.0	97.7	71.5	131.6	135.9	73.5	138.9	74.9	341.3	132.8	128.8	215.8	323.7	33.7	14.9	1.4	8.4	55.5	74.8	52.9	22.3	45.6	36.4	61.8	19.4	78.7	16.1	31.6	21.7	34.6	29.7	5.6	9.9	17.5	112.5	13.2	61.2	90.6	22.5	42.2	34.2	36.7	37.8	9.3	11.1	12.0	49.2	24.8	9.3	15.5	2.2	40.2	18.0	14.0	90.3	2.5	9.7	31.9	17.1	36.6	101.9	31.7	139.7	5.9	2.1	23.3	18.9	26.3	8.0	6.3	178.1	49.3	71.4	7.9	94.1	43.6	41.7	95.3	29.9	69.6	113.1	34.1	221.2	90.4	210.9	126.8	132.8	125.9	138.9	171.7	141.1	58.9	109.4	137.0	167.5	341.3	128.8	106.5	74.9	215.8	323.7	24.2	29.8	11.8	23.1	26.0	23.1	42.2	18.8	33.1	29.5	3147.5	4324.0	5959.3	2738.0	6967.5	30.8	1001.8	3658.6	2584.4	1819.9	1992.5	25.5	1178.5	880.3	10047.2	36.4	7847.2	5137.6	1074.6	7941.0	3388.9	4495.5	5043.9	2851.5	3441.9	11377.9	4.8	2180.6	6477.0	10376.7	71.4	2794.5	10340.1	6397.4	43079.4	4753.5	280.0	9393.5	5334.1	1587.5	2212.2	49.3	3951.7	5055.6	55.6	68.2	7534.8	673.0	11479.7	3001.5	5867.1
BAP1	"hucep-6, KIAA0272, UCHL2"	ENSG00000163930	"BRCA1 associated protein 1"	Q92560	3	52401013-52410350	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Chromatin regulator, Hydrolase, Protease, Thiol protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 81.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004322, HPA028814, HPA028815, HPA055560"	Approved		Enhanced	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB004322: AB_626723, HPA028814: AB_10602393, HPA028815: AB_2672785, HPA055560: AB_2682850"	"unprognostic (1.52e-1)"	"unprognostic (7.96e-2)"	"unprognostic (1.96e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.55e-2)"	"unprognostic (9.41e-3)"	"unprognostic (8.53e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.64e-3)"	"unprognostic (3.30e-3)"	"prognostic favorable (3.29e-7)"	"unprognostic (6.37e-2)"	"unprognostic (1.91e-1)"	"unprognostic (5.54e-2)"	"unprognostic (2.92e-1)"	13.8	17.6	35.6	14.7	33.3	37.3	13.5	21.8	50.4	12.5	17.0	16.3	11.5	12.4	14.7	14.6	21.2	12.1	15.7	16.4	41.5	15.5	16.6	19.0	14.9	15.2	19.4	27.6	16.9	16.3	30.0	11.1	14.8	19.6	14.4	14.9	15.6	17.9	14.6	24.8	40.5	13.9	14.5	10.0	16.1	13.3	37.3	14.7	18.6	15.3	12.9	16.0	14.1	11.7	5.5	8.4	11.3	5.0	3.0	8.5	3.9	14.8	16.9	20.6	17.4	19.9	12.8	23.2	14.7	19.1	24.0	18.6	20.5	13.9	21.4	7.4	20.5	27.1	12.1	21.6	23.8	15.3	21.1	20.5	26.4	35.8	21.2	18.5	24.8	23.5	19.1	31.9	26.5	14.2	13.2	19.1	41.2	22.6	18.9	18.0	12.9	29.4	34.0	23.2	11.8	20.6	12.7	16.7	21.1	14.8	24.1	7.8	25.3	18.1	5.3	21.5	12.1	14.8	34.3	20.4	21.7	20.0	26.0	27.3	28.7	37.7	30.6	23.7	26.2	25.6	3.4	5.0	7.4	8.5	3.9	4.0	5.0	6.8	6.9	3.3	5.5	4.9	6.4	11.3	3.0	3.1	8.4	6.0	3.9	35.6	33.3	21.8	50.4	41.5	15.5	19.4	27.6	19.6	14.7	0.0	13.6	15.0	8.8	28.0	15.3	19.3	10.2	5.3	9.1	24.4	0.0	12.2	10.0	12.0	81.1	12.4	17.6	0.0	14.3	13.1	11.8	9.7	20.7	25.8	11.0	9.5	10.4	15.4	19.3	32.6	9.5	10.2	11.8	11.8	12.9	9.9	12.6	15.3	11.0	14.6	11.3	19.4	13.2	30.9	12.4	20.6	10.1	11.3	16.4	8.5
BARD1		ENSG00000138376	"BRCA1 associated RING domain 1"	Q99728	2	214725646-214809711	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Basal glandular cells: 54.9;Basal keratinocytes: 60.9;Spermatogonia: 54.9;Suprabasal keratinocytes: 65.1;Urothelial cells: 57.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB034106, HPA035354, HPA044864"	Enhanced		Supported	"Nuclear speckles,Cytoplasmic bodies"		No	No			"Nuclear speckles"	"Cytoplasmic bodies"	"CAB034106: AB_2061237, HPA035354: AB_2674585, HPA044864: AB_2679119"	"unprognostic (4.85e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.74e-2)"	"unprognostic (8.37e-3)"	"unprognostic (2.57e-2)"	"unprognostic (1.03e-2)"	"unprognostic (6.25e-4)"	"unprognostic (1.99e-1)"	"unprognostic (2.16e-2)"	"unprognostic (3.92e-3)"	"unprognostic (2.80e-2)"	"unprognostic (7.41e-2)"	"unprognostic (1.94e-8)"	"unprognostic (3.94e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.08e-1)"	4.4	1.9	3.2	11.8	4.8	16.1	4.9	1.2	5.8	7.3	5.4	5.4	3.6	3.7	6.8	5.0	10.0	4.1	3.9	3.6	3.4	2.8	2.2	2.1	5.3	8.2	5.1	1.9	5.8	3.7	3.6	6.3	3.8	4.5	5.7	6.1	1.9	4.7	6.5	12.4	16.3	4.5	7.5	5.3	4.7	3.8	9.5	3.9	25.8	4.0	8.0	9.9	8.3	7.8	9.7	6.6	6.0	3.4	6.1	16.0	2.0	7.8	4.3	11.9	6.1	1.6	2.0	8.2	9.6	5.6	9.4	10.9	5.5	7.8	8.5	4.6	3.9	5.8	8.6	8.5	5.6	13.5	6.7	4.4	8.4	8.0	5.8	0.6	9.4	8.5	2.7	0.8	8.3	4.6	3.2	3.2	9.4	4.7	23.9	9.1	6.5	16.8	9.8	9.4	4.9	2.2	14.5	12.0	7.7	2.8	6.6	3.7	6.0	8.8	10.1	3.5	7.1	10.3	9.4	2.7	12.2	8.6	7.1	8.6	7.2	8.0	17.2	4.9	7.2	8.1	2.9	1.7	6.0	4.8	3.4	3.1	8.9	5.3	5.2	3.0	9.7	2.5	3.6	0.5	6.1	2.9	6.6	16.0	2.0	3.2	4.8	1.2	5.8	3.4	2.8	5.1	1.9	4.5	3.9	6.0	2.1	9.5	54.9	60.9	3.3	12.5	15.3	12.0	9.1	8.7	0.0	9.4	3.3	6.8	8.1	7.5	3.4	23.3	6.0	13.6	7.7	21.0	15.0	3.6	10.6	1.6	1.2	12.3	8.8	3.6	5.8	8.8	3.3	17.2	11.3	3.3	5.6	5.8	9.6	0.6	6.8	19.4	15.5	19.7	54.9	65.1	4.2	8.6	11.0	57.3
BAX	BCL2L4	ENSG00000087088	"BCL2 associated X, apoptosis regulator"	Q07812	19	48954815-48961798	"Cancer-related genes, Predicted intracellular proteins, Transporters"	"Apoptosis, Host-virus interaction"		"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"monocytes: 382.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004206, HPA027878"	Approved					NA	NA		1300000			"CAB004206: AB_626729, HPA027878: AB_10601687"	"unprognostic (4.11e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.50e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.82e-1)"	"prognostic unfavorable (1.63e-5)"	"unprognostic (4.92e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.66e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.19e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.47e-3)"	"unprognostic (6.22e-2)"	15.2	20.0	12.3	26.0	13.2	25.3	20.2	7.6	13.6	14.9	33.3	15.1	13.5	30.7	19.3	11.2	21.4	15.5	40.4	14.9	11.3	10.2	19.5	26.1	26.6	25.9	18.7	12.5	16.4	16.2	8.8	10.0	21.5	14.9	16.6	27.8	10.3	16.5	13.3	11.6	17.1	28.7	16.3	15.1	37.8	19.6	10.7	13.2	37.8	17.7	16.3	26.5	19.1	19.5	6.6	10.6	11.1	16.5	9.1	6.4	6.6	34.3	57.2	34.6	30.3	34.6	33.9	57.1	23.5	47.2	31.0	43.4	15.1	33.7	42.1	11.0	35.9	28.9	18.7	15.7	45.8	25.8	32.4	36.2	17.9	11.6	56.0	55.6	18.6	57.5	46.4	32.9	25.7	15.5	37.7	71.3	16.7	17.5	17.3	53.1	24.3	30.1	29.2	26.8	33.6	16.4	21.2	23.0	16.1	32.5	33.5	19.9	23.5	19.8	14.1	10.8	51.5	11.3	33.6	41.7	40.0	43.4	24.4	32.2	20.0	25.4	27.3	24.2	25.3	55.2	4.3	10.4	10.5	6.0	15.3	4.3	6.6	3.4	6.4	10.4	5.8	2.3	5.3	11.1	9.1	16.5	10.6	6.3	6.6	12.3	13.2	7.6	13.6	11.3	10.2	18.7	12.5	14.9	13.2	3.0	4.5	117.5	48.9	48.7	17.5	7.3	79.0	5.3	3.4	57.6	9.8	113.9	63.0	111.1	0.9	69.9	164.3	0.0	84.3	129.6	73.3	76.7	44.8	26.7	232.2	28.6	109.5	54.0	114.6	1.6	44.5	121.4	79.2	382.3	86.5	32.3	116.8	161.4	36.0	172.3	13.7	45.3	56.6	12.6	35.8	49.3	85.2	119.3	131.1	73.4
BCL10	"c-E10, CARMEN, CIPER, CLAP, mE10"	ENSG00000142867	"B cell CLL/lymphoma 10"	O95999	1	85266248-85277090	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Immunity"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Basal keratinocytes: 172.4;Urothelial cells: 313.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HUVEC TERT2: 40.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001944, HPA017925"	Approved					NA	NA					"CAB001944: , HPA017925: AB_1845312"	"unprognostic (3.78e-3)"	"unprognostic (2.53e-1)"	"prognostic favorable (2.51e-4)"	"unprognostic (1.61e-1)"	"unprognostic (3.47e-1)"	"unprognostic (2.61e-2)"	"prognostic unfavorable (7.21e-7)"	"unprognostic (7.06e-2)"	"unprognostic (2.36e-1)"	"unprognostic (9.46e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.73e-1)"	"unprognostic (4.92e-3)"	"unprognostic (3.18e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-1)"	17.2	10.7	5.8	16.4	6.0	19.6	20.7	5.8	8.6	14.7	21.5	7.5	9.5	12.2	14.8	10.0	29.0	8.5	16.7	7.5	5.9	5.4	11.9	11.4	20.4	21.5	6.5	5.2	11.6	9.1	5.4	6.3	11.8	5.9	11.6	20.4	6.4	11.8	12.4	5.0	14.6	27.6	9.9	6.1	18.5	13.0	8.5	5.1	18.3	11.3	12.7	22.1	14.3	17.6	22.4	14.2	37.5	18.2	10.4	13.3	9.0	16.0	3.4	4.6	5.0	6.7	10.0	7.9	12.3	11.2	8.9	12.4	4.0	6.5	7.2	8.7	9.6	16.9	8.7	5.3	13.1	13.0	6.1	4.0	7.6	3.3	5.6	10.5	7.4	7.1	7.9	14.5	13.3	11.9	10.8	40.6	4.2	5.3	6.5	14.9	3.0	7.1	6.1	8.2	9.0	11.3	5.1	10.7	4.6	31.0	12.4	3.1	4.2	3.7	12.7	11.7	6.7	4.3	5.0	20.2	9.2	6.5	11.2	12.2	5.3	2.9	7.0	4.6	6.5	6.3	25.2	15.1	20.1	10.0	18.2	11.1	22.4	13.1	11.3	14.2	20.3	12.4	11.4	37.5	10.4	13.5	12.0	13.3	9.0	5.8	6.0	5.8	8.6	5.9	5.4	6.5	5.2	5.9	5.1	20.8	18.6	32.1	121.5	172.4	5.3	3.6	15.3	24.1	36.4	22.7	0.0	13.1	14.9	59.3	42.4	34.3	75.1	0.0	39.3	23.1	20.1	72.2	39.2	15.3	19.5	9.5	47.0	20.9	28.8	8.6	10.3	35.3	15.1	19.0	59.4	9.9	56.0	60.3	10.6	16.3	5.4	0.0	22.0	7.6	12.4	149.7	19.8	24.9	40.5	313.8
BCL11A	"BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856"	ENSG00000119866	"B cell CLL/lymphoma 11A"	Q9H165	2	60450520-60555154	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 107.1"	"Cell type enhanced"	"Detected in many"	8	"B-cells: 89.5;Erythroid cells: 93.5;Horizontal cells: 49.3;Suprabasal keratinocytes: 61.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"memory B-cell: 39.6;naive B-cell: 53.7;plasmacytoid DC: 107.1"	"Group enriched"	"Detected in many"	16	"B-cells: 53.7;dendritic cells: 107.1"	"Cell line enhanced"	"Detected in many"		"Daudi: 20.7;MOLT-4: 19.1;REH: 19.5;U-698: 42.7;U-937: 13.7"	"Group enriched"	"Detected in all"	5	"amygdala: 42.3;basal ganglia: 57.1;cerebral cortex: 62.7;hippocampal formation: 65.3;olfactory region: 101.8"	"Group enriched"	"Detected in all"	4	"basal ganglia: 58.3;cerebral cortex: 93.2;hippocampal formation: 97.2;olfactory region: 128.9"	"CAB014891, HPA029003, HPA075941"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"		NA	NA			Nucleoplasm	"Nuclear bodies"	"CAB014891: , HPA029003: AB_2672863, HPA075941: "	"unprognostic (4.10e-3)"	"unprognostic (6.72e-2)"	"unprognostic (4.50e-2)"	"unprognostic (9.41e-3)"	"unprognostic (2.37e-1)"	"unprognostic (4.47e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.45e-1)"	"unprognostic (4.27e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.35e-2)"	"unprognostic (3.59e-2)"	"unprognostic (2.26e-1)"	"unprognostic (4.40e-2)"	"unprognostic (2.99e-2)"	1.5	2.4	6.6	13.9	14.6	17.0	5.5	1.8	34.5	3.9	8.6	0.2	0.1	7.6	1.8	1.4	13.6	4.8	2.2	4.7	14.5	3.4	1.7	1.5	3.0	21.2	3.5	14.4	1.6	11.3	1.2	3.9	0.9	9.6	4.8	5.1	0.0	11.4	2.0	1.4	24.9	11.4	2.9	2.0	13.5	3.3	2.0	2.6	20.9	2.4	4.0	30.4	3.6	7.8	53.7	107.1	1.3	5.1	1.0	0.1	1.2	0.2	0.0	1.7	0.0	0.3	0.3	0.1	0.6	0.0	0.0	0.0	0.0	0.0	20.7	0.1	0.0	0.0	4.2	6.4	3.0	0.0	0.3	6.2	0.0	0.2	0.1	0.0	7.4	0.0	0.7	1.7	0.0	1.0	1.7	1.0	7.0	0.3	0.1	0.0	0.0	19.1	7.6	11.8	3.0	0.1	19.5	0.5	7.9	0.0	0.3	8.4	2.0	0.1	0.1	0.1	3.5	0.1	3.6	0.5	0.1	4.9	0.1	0.0	0.3	0.0	42.7	0.0	13.7	0.6	0.4	2.9	0.5	0.0	5.1	0.1	39.6	0.0	0.0	10.7	53.7	0.1	0.1	1.3	1.0	3.7	107.1	0.1	1.2	6.6	14.6	1.8	34.5	14.5	3.4	3.5	14.4	9.6	2.6	0.0	9.0	89.5	14.8	41.1	0.5	12.2	5.1	5.3	7.9	1.8	0.0	0.5	5.0	7.7	9.4	1.2	8.4	93.5	5.6	0.7	5.1	4.2	9.3	0.0	32.9	49.3	19.0	0.6	8.2	3.6	0.3	17.9	15.1	6.4	11.7	0.1	5.4	13.6	0.0	0.3	0.1	0.0	1.3	1.6	5.9	61.1	0.7	0.0	24.2	4.1
BCL11B	"CTIP-2, CTIP2, hRIT1-alpha, ZNF856B"	ENSG00000127152	"B cell CLL/lymphoma 11B"	Q9C0K0	14	99169287-99271524	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes, Disease mutation, Mental retardation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 13.7;lymphoid tissue: 25.4;skin 1: 17.6"	"Group enriched"	"Detected in many"	8	"Basal keratinocytes: 55.8;Suprabasal keratinocytes: 62.4;T-cells: 48.4"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 13.7"	"Group enriched"	"Detected in many"	8	"gdT-cell: 3.3;MAIT T-cell: 3.0;memory CD4 T-cell: 4.5;memory CD8 T-cell: 3.7;naive CD4 T-cell: 7.4;naive CD8 T-cell: 4.9;T-reg: 3.0"	"Lineage enriched"	"Detected in single"	14	"T-cells: 7.4"	"Group enriched"	"Detected in some"	6	"JURKAT: 24.7;MOLT-4: 29.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA049117	Enhanced	Supported	Approved	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			Nucleoplasm	"Nucleoli fibrillar center"	"HPA049117: AB_2680639"	"unprognostic (1.64e-5)"	"unprognostic (4.66e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.87e-2)"	"unprognostic (9.37e-2)"	"unprognostic (5.97e-2)"	"unprognostic (4.75e-2)"	"unprognostic (6.07e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.60e-6)"	"unprognostic (1.07e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.31e-3)"	"prognostic favorable (7.48e-4)"	0.3	0.4	4.4	6.6	13.7	5.2	1.3	0.3	3.8	0.8	1.3	0.1	0.0	2.3	1.9	0.8	3.9	0.3	3.0	0.8	4.8	1.0	0.3	0.5	1.1	10.8	0.8	2.6	0.2	0.1	0.0	0.1	0.0	0.6	0.6	1.7	0.3	5.0	0.7	0.1	17.6	3.0	0.2	0.7	4.9	2.1	0.4	1.6	25.4	0.9	1.5	8.8	2.0	2.3	0.0	0.0	0.1	0.0	0.5	7.4	1.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	1.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.1	0.0	0.0	24.7	0.0	2.8	0.0	1.6	29.5	0.4	0.3	2.2	0.0	4.6	0.0	0.0	0.0	1.6	2.4	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.1	0.1	0.0	1.8	0.0	0.0	1.2	0.4	0.0	0.0	0.0	0.1	3.3	0.0	3.0	0.0	4.5	3.7	0.0	0.0	7.4	4.9	0.0	0.5	0.0	0.0	3.0	1.1	4.4	13.7	0.3	3.8	4.8	1.0	0.8	2.6	0.6	1.6	3.0	0.0	2.7	1.6	55.8	0.1	3.1	5.1	0.0	1.2	0.0	0.0	0.1	1.7	0.3	0.0	0.1	4.3	0.0	0.4	0.0	1.1	0.2	4.7	0.0	0.2	0.0	1.2	4.3	1.2	0.2	0.6	0.7	5.0	0.0	2.6	0.0	0.7	4.3	0.0	0.3	0.0	0.0	3.3	0.7	4.9	62.4	0.0	48.4	6.9	0.6
BCL2	"Bcl-2, PPP1R50"	ENSG00000171791	"BCL2, apoptosis regulator"	P10415	18	63123346-63320128	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis		"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7"	"Group enriched"	"Detected in many"	8	"B-cells: 5.2;T-cells: 7.6"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 22.8;U-266/70: 79.4"	"Low region specificity"	"Detected in all"							"CAB000003, HPA055295"	Enhanced		Supported	"Nucleoplasm,Nuclear membrane"		NA	NA			"Nuclear membrane"	Nucleoplasm	"CAB000003: AB_2064429, HPA055295: AB_2682776"	"unprognostic (1.11e-3)"	"prognostic favorable (5.13e-5)"	"unprognostic (5.49e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.05e-3)"	"unprognostic (2.88e-1)"	"unprognostic (1.93e-3)"	"unprognostic (4.78e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.23e-2)"	"unprognostic (8.51e-2)"	"prognostic favorable (1.29e-8)"	"unprognostic (6.67e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (2.47e-4)"	"unprognostic (2.63e-1)"	12.9	3.0	10.1	15.7	9.4	5.3	24.6	4.7	8.4	14.8	7.8	7.4	9.1	5.0	17.1	9.3	4.7	12.2	9.2	6.5	10.0	8.1	8.5	2.3	5.0	14.6	10.8	5.6	18.2	2.9	19.6	7.0	22.4	9.2	8.4	5.9	10.8	5.4	15.7	20.0	6.3	10.5	8.6	9.3	17.8	5.4	3.5	10.5	21.0	35.6	2.9	13.4	7.9	16.4	5.2	0.3	0.7	0.2	0.7	7.6	1.9	0.5	0.1	2.3	1.8	2.8	0.4	0.8	0.2	0.2	0.8	0.5	1.1	0.1	0.0	0.4	0.2	1.5	0.1	2.1	0.3	0.4	13.6	0.4	0.1	0.6	0.2	0.5	12.4	1.8	0.5	0.2	0.9	1.9	0.3	0.2	1.4	0.2	22.8	0.4	0.4	2.6	5.4	0.5	0.2	0.4	11.7	0.5	8.8	3.9	1.9	1.9	1.8	0.0	0.0	2.8	0.5	0.1	10.5	0.1	3.0	1.0	0.3	1.5	79.4	10.4	0.9	0.5	8.8	1.7	0.7	0.0	0.0	2.3	0.0	7.6	5.2	6.3	3.8	0.1	4.1	5.1	4.5	0.1	0.7	0.2	0.3	6.7	1.9	10.1	9.4	4.7	8.4	10.0	8.1	10.8	5.6	9.2	10.5	0.0	0.6	41.9	30.2	17.3	1.0	15.4	17.8	0.0	3.4	7.0	0.0	8.5	13.3	2.5	0.2	3.5	0.8	0.0	0.0	0.9	10.3	31.5	15.1	1.5	8.3	0.0	5.2	3.7	10.4	2.1	8.1	16.9	43.9	29.7	9.9	18.9	0.3	0.0	13.1	13.5	0.5	25.8	10.8	0.3	0.6	15.4	41.1	28.7	10.6	39.2
BCL3	"BCL4, D19S37"	ENSG00000069399	"B cell CLL/lymphoma 3"	P20749	19	44747705-44760044	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"neutrophil: 16.5"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 16.5"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 27.0;Karpas-707: 22.4;SiHa: 28.7;U-266/70: 21.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"CAB002051, HPA047514"	Approved		Supported	Nucleoplasm,Vesicles,Midbody		Yes	No			Nucleoplasm	"Vesicles, Midbody"	"CAB002051: AB_563428, HPA047514: AB_2680074"	"prognostic favorable (9.67e-4)"	"unprognostic (8.82e-2)"	"unprognostic (2.81e-1)"	"unprognostic (7.54e-2)"	"prognostic unfavorable (4.01e-4)"	"unprognostic (3.49e-2)"	"unprognostic (2.34e-3)"	"unprognostic (2.79e-1)"	"prognostic favorable (3.74e-4)"	"unprognostic (2.09e-2)"	"unprognostic (9.23e-2)"	"unprognostic (1.81e-1)"	"prognostic unfavorable (3.13e-14)"	"unprognostic (8.24e-2)"	"unprognostic (1.36e-1)"	"unprognostic (3.77e-2)"	"unprognostic (3.04e-2)"	17.7	13.0	4.0	21.1	5.6	35.2	18.7	1.4	4.7	11.7	14.9	2.4	5.9	24.5	10.4	9.7	27.1	12.5	22.7	20.1	3.9	2.0	17.8	52.1	36.4	20.5	4.3	0.5	26.5	13.2	2.4	9.2	9.5	5.6	16.0	8.0	8.8	13.7	13.7	20.2	9.0	35.5	11.5	6.5	41.6	15.0	8.3	4.0	6.5	13.9	22.9	37.0	18.7	11.9	1.3	2.6	16.5	2.4	1.8	1.5	0.7	3.9	13.6	0.3	7.2	2.6	5.5	0.7	2.4	2.6	1.5	2.2	2.8	7.2	3.9	5.6	4.8	8.0	4.4	0.9	4.1	1.0	27.0	0.2	0.5	7.1	3.6	6.3	0.3	11.6	9.6	3.2	3.4	4.3	7.1	4.1	0.0	0.5	22.4	0.9	3.3	0.0	3.0	0.3	6.0	5.7	1.8	2.7	1.4	6.9	8.2	0.0	0.4	28.7	14.7	0.7	0.5	5.1	3.0	6.9	4.9	5.1	7.6	0.9	21.3	8.3	4.0	9.1	0.5	3.7	0.2	2.4	4.2	0.7	1.6	1.0	1.3	0.9	1.1	2.1	1.1	0.5	0.6	16.5	1.8	0.9	2.6	1.5	0.7	4.0	5.6	1.4	4.7	3.9	2.0	4.3	0.5	5.6	4.0	17.9	53.0	18.6	32.7	41.4	1.7	2.4	25.5	18.7	31.8	12.2	0.0	0.3	8.3	26.4	9.3	39.0	55.4	0.0	58.8	5.9	33.8	37.5	36.9	31.7	13.9	7.9	20.6	35.6	31.1	1.3	12.4	45.8	38.8	36.9	31.6	2.3	42.1	35.1	4.2	17.7	0.5	6.5	57.5	0.5	1.2	53.3	1.1	14.6	22.9	44.4
BCL6	"BCL5, BCL6A, LAZ3, ZBTB27, ZNF51"	ENSG00000113916	"B cell CLL/lymphoma 6"	P41182	3	187721377-187745727	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Immunity, Inflammatory response, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 114.3"	"Cell type enhanced"	"Detected in many"	5	"Smooth muscle cells: 96.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"neutrophil: 63.4"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 63.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 27.3;Daudi: 42.9;HSkMC: 31.1;U-698: 59.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000307, HPA004899, HPA050645"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000307: AB_2063451, HPA004899: AB_1078273, HPA050645: AB_2681199"	"unprognostic (5.36e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.63e-3)"	"unprognostic (2.49e-1)"	"unprognostic (2.85e-1)"	"unprognostic (6.34e-3)"	"unprognostic (2.62e-2)"	"unprognostic (3.33e-3)"	"unprognostic (8.75e-2)"	"unprognostic (2.04e-2)"	"unprognostic (1.63e-3)"	"unprognostic (1.29e-1)"	"prognostic unfavorable (1.27e-9)"	"unprognostic (5.22e-2)"	"unprognostic (7.82e-2)"	"unprognostic (5.67e-2)"	"unprognostic (2.58e-2)"	47.1	14.3	21.8	23.2	25.9	50.6	48.0	58.7	23.7	21.2	21.2	19.2	11.5	4.1	17.7	8.8	20.9	28.3	22.3	18.6	21.5	8.0	10.1	20.1	26.3	24.5	31.6	9.3	20.2	15.6	9.1	23.3	7.5	28.5	17.3	5.8	15.9	19.1	11.8	114.3	36.4	8.1	24.4	50.1	27.2	16.1	10.2	26.6	18.9	14.8	10.4	22.4	24.9	20.0	3.9	5.6	63.4	15.4	0.9	1.3	5.2	1.2	3.6	3.6	0.8	27.3	21.8	3.9	4.3	10.5	5.0	5.3	2.6	2.0	42.9	3.1	5.4	3.1	2.1	1.2	2.8	4.3	9.0	1.4	0.0	1.8	6.1	14.2	0.5	0.2	31.1	18.2	6.1	9.4	16.3	2.8	1.1	0.4	7.4	4.8	1.4	1.4	0.3	0.3	0.7	2.7	11.9	1.8	0.2	3.5	6.3	0.8	0.0	5.0	2.1	2.8	8.3	9.4	1.5	5.6	12.1	1.9	4.4	2.0	5.5	1.8	59.6	6.6	1.6	8.5	1.6	6.9	4.1	1.3	8.7	1.3	1.4	0.8	1.2	5.6	3.9	0.5	0.6	63.4	0.9	15.4	0.9	0.6	5.2	21.8	25.9	58.7	23.7	21.5	8.0	31.6	9.3	28.5	26.6	17.9	76.9	6.5	13.3	42.0	11.0	60.5	17.8	25.4	22.7	15.7	19.6	1.1	0.0	9.2	12.3	27.7	1.6	0.0	10.6	2.0	36.2	28.7	10.5	44.4	11.2	0.0	4.6	9.8	56.3	6.2	26.7	26.7	33.7	3.6	1.1	40.1	8.7	0.0	17.7	1.1	9.6	32.3	96.4	0.4	0.7	53.8	3.4	10.7	1.9	21.9
BCL7A	BCL7	ENSG00000110987	"BCL tumor suppressor 7A"	Q4VC05	12	122019422-122062044	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Horizontal cells: 101.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 8.4;plasmacytoid DC: 9.7"	"Group enriched"	"Detected in many"	10	"B-cells: 8.4;dendritic cells: 9.7"	"Cell line enhanced"	"Detected in many"		"Daudi: 26.2;MOLT-4: 19.2;U-698: 30.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019762	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"HPA019762: AB_10962489"	"unprognostic (3.27e-1)"	"unprognostic (2.97e-2)"	"prognostic unfavorable (6.81e-4)"	"unprognostic (1.35e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.23e-1)"	"prognostic unfavorable (2.04e-4)"	"unprognostic (5.18e-1)"	"unprognostic (5.13e-2)"	"unprognostic (1.06e-2)"	"unprognostic (3.13e-1)"	"unprognostic (3.11e-1)"	"prognostic favorable (1.54e-6)"	"unprognostic (4.86e-2)"	"unprognostic (8.56e-2)"	"unprognostic (6.16e-3)"	"unprognostic (1.51e-2)"	3.8	3.7	13.0	9.8	14.5	9.9	6.5	19.8	18.2	6.7	4.2	6.8	3.3	3.6	6.0	7.4	3.3	10.3	4.3	9.4	9.5	7.5	10.7	5.3	5.1	19.4	6.6	15.9	4.9	11.7	8.3	6.1	2.8	6.8	6.3	3.8	3.8	8.2	7.2	12.8	8.2	3.4	4.1	5.1	6.5	4.4	3.1	7.9	26.4	11.1	3.5	15.8	6.9	5.4	8.4	9.7	0.1	0.1	0.5	0.9	0.6	1.7	2.4	8.0	5.6	0.5	0.3	1.7	1.0	1.1	1.7	1.5	1.0	0.7	26.2	2.9	0.8	1.0	2.3	5.8	5.5	1.5	0.0	9.5	1.3	0.2	1.4	1.7	4.0	2.3	1.3	5.3	1.2	7.2	2.0	2.1	12.3	5.9	0.0	1.0	3.6	19.2	0.3	2.9	2.4	4.1	10.6	2.8	0.3	3.2	4.5	8.0	9.0	1.3	0.3	3.3	2.0	5.4	3.3	1.9	0.3	1.7	3.0	1.7	2.7	1.8	30.3	0.5	2.6	1.8	0.1	0.0	0.0	0.1	0.0	0.0	2.9	0.2	0.2	2.2	8.4	0.9	0.6	0.1	0.5	0.1	9.7	0.0	0.6	13.0	14.5	19.8	18.0	9.5	7.5	6.6	15.9	6.8	7.9	20.8	8.6	37.2	47.6	31.9	38.8	25.8	38.2	14.7	22.7	36.6	17.7	1.0	49.7	25.7	6.1	3.1	1.7	0.0	9.5	0.8	8.7	26.5	10.4	16.8	3.2	101.7	20.6	4.3	3.5	9.8	13.0	8.5	11.8	5.4	8.0	5.6	10.5	7.0	7.4	18.9	13.5	6.5	15.6	0.5	4.3	26.3	0.5	0.0	11.4	26.0
BCL9		ENSG00000116128	"B cell CLL/lymphoma 9"	O00512	1	147541412-147626216	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Wnt signaling pathway"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Intestinal endocrine cells: 27.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 24.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020274	Approved		Approved	"Nucleoplasm,Nuclear bodies"		No	No			"Nucleoplasm, Nuclear bodies"		"HPA020274: AB_2670400"	"unprognostic (2.31e-1)"	"unprognostic (1.52e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (6.74e-4)"	"unprognostic (1.03e-1)"	"unprognostic (2.78e-1)"	"unprognostic (2.29e-1)"	"unprognostic (4.78e-3)"	"unprognostic (3.92e-2)"	"unprognostic (1.64e-3)"	"unprognostic (2.58e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.60e-2)"	4.5	7.8	10.2	5.9	9.2	3.1	4.8	22.3	12.6	18.2	9.4	8.1	10.9	5.3	23.9	15.9	6.8	18.9	5.2	8.3	8.0	7.4	9.6	4.3	5.0	4.0	5.9	8.7	17.0	6.1	14.6	10.6	4.5	6.8	10.5	7.9	11.8	8.1	13.2	7.9	7.8	5.5	15.7	5.4	3.8	7.6	6.1	6.5	22.4	7.8	8.0	6.0	9.6	8.0	0.4	0.0	0.6	0.3	0.1	2.6	1.0	2.9	2.9	20.6	15.3	2.3	2.8	4.0	2.4	3.9	2.7	2.6	3.8	4.5	2.8	5.5	2.3	4.5	2.4	13.0	4.4	2.5	6.7	3.6	1.3	3.1	2.5	2.0	0.8	4.1	2.7	3.8	3.2	2.3	4.8	4.1	9.4	2.6	4.6	2.3	6.7	7.0	0.6	24.3	6.0	6.4	7.5	5.2	5.5	10.4	3.3	5.6	12.2	2.7	5.1	4.7	19.8	6.4	1.3	3.0	1.9	9.0	5.3	3.8	20.9	5.3	5.4	4.8	0.8	9.1	0.0	0.3	0.6	1.0	0.0	0.9	0.2	1.2	1.2	0.0	0.4	2.6	1.6	0.2	0.1	0.1	0.0	0.9	1.0	10.2	9.2	22.3	12.6	8.0	7.4	5.9	8.7	6.8	6.5	0.0	2.1	0.0	5.2	2.7	7.9	4.7	7.6	2.7	2.3	12.2	2.0	1.8	10.0	3.4	9.0	2.8	1.8	0.0	4.0	2.0	4.6	7.6	8.1	2.6	1.1	6.4	27.2	6.2	2.8	4.2	8.9	0.4	0.0	1.0	10.9	4.3	3.8	0.0	7.4	4.9	2.8	0.0	3.8	3.2	6.8	3.1	1.7	0.5	6.9	2.7
BCL9L	DLNB11	ENSG00000186174	"B cell CLL/lymphoma 9 like"	Q86UU0	11	118893875-118925608	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049370, HPA053421"	Uncertain		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA049370: AB_2680732, HPA053421: AB_2682145"	"unprognostic (1.67e-2)"	"unprognostic (1.48e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.71e-1)"	"unprognostic (2.87e-1)"	"unprognostic (1.90e-1)"	"unprognostic (6.61e-3)"	"unprognostic (1.17e-3)"	"unprognostic (1.03e-1)"	"unprognostic (4.61e-2)"	"unprognostic (4.66e-3)"	"unprognostic (1.39e-1)"	"unprognostic (2.83e-3)"	"unprognostic (4.85e-3)"	"unprognostic (2.24e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.90e-3)"	18.4	18.9	10.2	17.2	10.0	13.3	23.8	31.7	9.9	27.4	16.4	6.7	15.8	13.2	22.3	12.8	18.9	22.2	21.2	15.6	9.0	4.1	10.9	9.0	17.1	13.8	9.5	7.7	22.2	16.4	9.0	6.5	31.9	9.1	16.1	4.1	14.5	21.5	14.7	19.1	19.9	14.6	22.8	7.9	13.9	14.0	9.0	8.6	13.0	12.2	11.9	16.7	21.9	25.6	0.6	0.6	1.1	0.5	0.7	2.2	0.8	12.3	22.5	3.2	5.9	10.5	10.2	20.7	17.1	13.2	5.4	3.2	23.9	24.7	3.4	22.9	17.9	22.2	24.0	1.5	31.4	1.4	4.1	0.8	3.3	12.6	8.2	11.9	1.1	3.2	12.9	19.6	6.5	13.1	10.5	4.8	2.0	4.3	3.9	3.7	20.8	2.5	0.9	3.8	7.4	13.0	5.3	1.4	2.3	5.7	8.6	1.7	2.6	24.1	36.6	3.4	6.0	28.8	1.4	16.0	17.5	13.3	5.2	14.5	0.8	0.0	1.0	9.4	3.9	9.9	0.0	0.5	0.0	2.2	0.0	1.5	0.3	1.2	1.3	0.1	0.6	1.9	1.5	1.1	0.7	0.0	0.6	0.2	0.8	10.2	10.0	31.7	9.9	9.0	4.1	9.5	7.7	9.1	8.6	14.9	11.5	2.4	8.8	34.5	18.4	2.0	15.3	4.0	11.4	7.0	3.9	9.8	0.0	11.8	0.1	10.1	8.0	0.0	12.7	7.0	11.6	18.2	2.3	10.0	3.8	12.7	5.2	11.1	5.2	0.0	13.6	2.6	6.8	19.8	5.0	6.9	20.3	7.0	13.4	2.2	2.8	25.8	14.7	0.5	1.0	39.5	29.6	11.8	6.3	9.1
BCOR	"FLJ20285, KIAA1575"	ENSG00000183337	"BCL6 corepressor"	Q6W2J9	X	40049815-40177329	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA056308, HPA073591"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA056308: AB_2683095, HPA073591: AB_2732227"	"unprognostic (2.75e-2)"	"unprognostic (2.83e-1)"	"unprognostic (2.45e-1)"	"unprognostic (9.26e-2)"	"unprognostic (1.55e-1)"	"unprognostic (9.80e-3)"	"prognostic unfavorable (1.30e-5)"	"unprognostic (3.82e-3)"	"unprognostic (6.86e-2)"	"unprognostic (1.86e-1)"	"unprognostic (4.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.91e-3)"	"unprognostic (6.83e-2)"	"unprognostic (9.57e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.55e-1)"	9.1	12.8	8.7	8.7	10.5	20.6	13.3	11.5	12.0	10.0	12.6	22.7	11.9	7.8	11.1	13.9	13.6	10.4	8.6	13.0	7.1	5.4	11.2	13.3	11.4	15.2	12.9	8.4	19.8	13.6	19.7	11.9	12.5	10.7	13.2	8.2	13.7	11.1	16.5	28.8	13.6	10.3	12.9	8.6	11.4	11.5	9.8	15.8	18.4	16.0	11.4	13.5	13.8	25.5	6.5	7.3	7.6	7.1	8.2	6.8	11.8	13.1	8.7	17.8	21.7	2.0	1.6	3.1	4.5	7.1	5.7	4.7	3.7	5.3	12.0	5.3	8.3	3.7	12.4	29.0	3.8	5.1	20.9	26.4	13.4	13.4	14.4	3.4	10.8	7.7	2.6	5.6	6.3	3.6	8.4	7.7	7.9	34.3	29.0	7.0	8.4	24.4	22.6	17.5	6.2	13.6	11.9	18.4	13.5	10.5	8.3	12.8	23.1	9.4	8.3	7.0	9.1	8.9	23.8	6.4	6.2	7.8	9.1	5.0	17.2	13.3	12.5	5.4	9.9	9.5	7.6	5.0	4.5	6.8	6.1	4.3	6.5	4.7	3.9	7.3	5.5	4.7	4.8	1.1	8.2	7.1	3.1	5.5	11.8	8.7	10.5	11.5	12.0	7.1	5.4	12.9	8.4	10.7	15.8	20.8	23.2	12.3	3.2	13.1	34.2	7.6	10.2	6.7	5.7	10.4	11.8	3.7	1.7	4.5	2.1	17.4	4.9	0.0	9.1	5.5	13.6	7.9	23.2	9.5	6.4	14.3	15.6	19.0	11.0	2.1	9.8	8.6	5.0	7.2	11.7	7.7	6.6	0.0	7.4	4.0	22.0	0.0	26.4	1.1	13.5	12.2	1.7	7.5	7.6	2.6
BCORL1	"CXorf10, FLJ11362"	ENSG00000085185	"BCL6 corepressor like 1"	Q5H9F3	X	129981107-130058083	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	7	"Syncytiotrophoblasts: 78.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 20.4;HAP1: 30.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031775, HPA031777, HPA068568"	Uncertain		Approved	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"HPA031775: AB_10602332, HPA031777: AB_10671578, HPA068568: AB_2686007"	"unprognostic (8.07e-2)"	"unprognostic (2.78e-2)"	"unprognostic (7.09e-2)"	"prognostic unfavorable (2.20e-5)"	"unprognostic (4.58e-1)"	"unprognostic (1.68e-3)"	"unprognostic (1.96e-3)"	"unprognostic (5.56e-3)"	"unprognostic (2.39e-1)"	"unprognostic (8.02e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.04e-1)"	"prognostic unfavorable (5.00e-4)"	"unprognostic (9.18e-2)"	"unprognostic (2.60e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.41e-2)"	7.5	7.9	7.7	5.2	9.1	9.8	9.1	19.8	10.5	8.7	8.3	10.7	8.1	5.4	9.2	5.4	5.8	9.3	4.2	6.9	8.4	4.5	7.5	4.7	6.7	5.3	7.6	5.9	11.4	8.9	13.4	15.0	28.9	7.5	8.1	4.5	6.0	6.5	8.4	6.0	6.5	6.0	8.8	5.3	7.7	6.6	26.1	8.1	6.8	10.3	2.2	5.1	6.7	8.5	1.2	1.6	3.5	1.3	0.8	1.3	0.7	2.2	5.5	12.9	20.4	7.6	5.5	3.6	3.0	3.5	3.9	4.5	6.6	1.4	1.0	6.7	6.0	3.7	1.3	30.8	1.2	3.7	2.2	4.5	10.6	2.7	2.2	3.8	2.6	3.1	3.4	2.5	7.7	0.4	5.8	4.7	3.5	5.1	10.8	2.5	1.3	3.9	8.0	3.5	1.8	3.9	8.3	5.2	1.4	2.2	0.3	2.1	7.3	1.6	0.4	2.0	7.2	4.5	4.0	3.9	3.2	4.1	3.8	2.9	3.5	6.3	1.6	2.1	5.4	1.5	0.1	1.3	2.8	1.3	0.2	1.0	1.2	0.9	0.8	1.6	1.0	0.6	0.7	3.5	0.8	0.5	0.7	0.2	0.7	7.7	9.1	19.8	10.5	8.4	4.5	7.6	5.9	7.5	8.1	0.0	3.2	0.0	2.3	10.5	1.8	6.4	5.1	2.7	1.2	7.0	0.0	10.7	0.0	3.2	0.4	7.1	2.7	0.0	0.9	4.2	5.8	2.9	6.9	3.0	2.8	7.9	11.5	3.1	2.6	1.0	4.4	1.8	6.8	1.0	1.7	3.1	2.3	0.0	3.5	2.2	1.0	6.5	4.5	3.5	5.3	10.0	78.1	1.5	2.8	2.5
BCR	"ALL, BCR1, CML, D22S11, D22S662, PHL"	ENSG00000186716	"BCR, RhoGEF and GTPase activating protein"	P11274	22	23179704-23318037	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Ito cells: 62.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"K-562: 44.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010421, CAB018545, HPA038337"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"	Nucleoplasm	"CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795"	"unprognostic (7.46e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.15e-3)"	"unprognostic (1.16e-1)"	"unprognostic (5.35e-2)"	"unprognostic (1.45e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.44e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.81e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.39e-2)"	"prognostic favorable (9.15e-10)"	"unprognostic (1.47e-1)"	"unprognostic (7.10e-2)"	"unprognostic (4.10e-2)"	"unprognostic (7.43e-2)"	14.5	8.4	24.0	9.1	41.2	26.7	10.5	14.2	26.5	13.6	9.7	10.3	10.6	8.7	9.2	13.9	19.3	10.8	8.3	7.8	20.9	13.0	16.3	8.3	11.3	10.9	16.0	15.6	8.8	12.9	14.5	14.9	15.7	14.2	7.0	6.8	8.3	15.5	9.7	3.4	12.8	8.7	9.0	9.5	9.1	14.0	9.6	15.4	11.8	16.6	5.5	9.2	9.2	8.8	1.5	0.8	1.2	1.0	2.8	6.6	2.5	19.0	8.2	12.7	13.0	7.6	5.2	19.2	6.9	6.5	6.4	5.2	14.4	7.7	13.3	12.9	5.9	6.2	19.6	1.3	19.2	1.8	25.4	13.2	11.6	11.3	11.4	9.9	10.7	6.1	4.4	13.0	9.5	8.4	11.4	22.3	9.6	44.4	6.3	2.9	12.5	10.0	8.4	10.7	15.1	8.1	13.2	5.1	8.7	9.9	12.1	11.7	11.1	12.6	10.9	5.2	8.5	6.9	8.8	25.1	3.8	0.4	6.2	5.7	1.4	5.8	4.7	9.9	8.1	5.9	0.0	1.0	0.0	6.6	0.4	2.3	1.4	3.3	3.3	0.8	1.5	2.6	3.6	1.2	2.8	1.0	0.8	1.6	2.5	24.0	41.2	14.2	24.9	20.9	13.0	16.0	15.6	14.2	15.4	8.9	11.5	3.0	9.5	13.7	24.0	7.3	20.4	2.7	19.4	17.4	21.6	10.5	8.3	12.4	3.9	22.4	11.1	0.0	14.1	5.9	7.3	10.2	10.4	18.4	6.0	22.3	19.1	62.0	10.8	7.7	8.1	5.4	5.0	6.4	12.0	13.4	21.8	5.8	5.3	14.3	8.0	0.0	8.6	1.6	6.8	13.8	9.0	9.2	11.2	11.5
BIRC3	"API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49"	ENSG00000023445	"Baculoviral IAP repeat containing 3"	Q13489	11	102317450-102339403	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 46.0;lymphoid tissue: 46.3"	"Cell type enhanced"	"Detected in many"	16	"granulocytes: 530.1;monocytes: 1925.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 32.9;naive B-cell: 32.9"	"Group enriched"	"Detected in many"	10	"B-cells: 32.9;T-cells: 17.1"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 38.4;Daudi: 33.7;HDLM-2: 31.9;hTERT-HME1: 33.6;U-266/70: 22.5;U-266/84: 19.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002317	Enhanced	Approved	Supported	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA002317: AB_1846748"	"prognostic favorable (3.60e-4)"	"unprognostic (2.89e-1)"	"prognostic favorable (9.35e-4)"	"unprognostic (3.28e-2)"	"prognostic unfavorable (7.28e-4)"	"unprognostic (5.83e-3)"	"unprognostic (2.23e-1)"	"unprognostic (3.88e-3)"	"unprognostic (9.62e-2)"	"unprognostic (1.29e-1)"	"prognostic unfavorable (3.03e-4)"	"unprognostic (3.21e-1)"	"prognostic unfavorable (6.66e-6)"	"unprognostic (6.42e-2)"	"unprognostic (6.23e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.85e-2)"	6.9	3.3	1.4	43.9	2.3	5.1	5.4	0.5	2.0	5.3	13.1	0.5	2.8	6.8	2.9	3.7	8.4	3.9	13.9	6.0	2.2	1.3	10.8	12.5	21.8	46.3	2.8	1.2	3.4	7.0	1.1	14.5	0.9	2.2	8.7	6.2	1.1	9.2	4.7	2.2	5.5	46.0	7.3	3.0	34.9	15.9	3.2	2.7	34.2	3.0	4.1	34.0	12.6	6.2	32.9	0.8	2.0	2.6	2.5	17.1	2.8	6.5	5.3	0.0	0.1	0.1	0.7	0.6	0.5	4.4	0.6	0.7	0.9	38.4	33.7	17.4	0.3	5.5	3.6	0.0	0.9	2.1	31.9	0.1	0.1	1.6	0.2	6.6	0.5	0.7	0.7	4.7	2.1	33.6	1.2	0.1	2.7	0.1	0.0	0.8	0.0	2.3	0.3	0.1	3.1	0.2	0.0	0.3	1.7	8.7	3.4	0.0	0.1	0.5	0.6	0.3	0.2	1.7	0.3	1.7	7.3	0.8	0.4	6.7	22.5	19.2	11.9	1.3	1.9	0.9	2.0	0.9	0.4	1.4	2.2	2.5	32.9	10.7	3.5	0.8	32.9	7.5	2.2	0.5	2.5	2.6	0.3	17.1	2.8	1.4	2.3	0.5	2.0	2.2	1.3	2.8	1.2	2.2	2.7	134.0	68.1	285.1	318.0	89.9	0.3	12.0	76.5	30.8	73.9	38.4	0.0	1.7	6.6	193.4	1.3	50.1	284.0	46.7	153.8	0.5	71.9	371.3	530.1	3.4	11.1	0.0	14.5	7.4	18.1	1.3	4.6	71.9	182.2	1925.2	27.1	0.1	190.8	361.2	2.1	8.8	0.0	0.0	133.5	0.5	0.4	73.9	0.5	89.3	29.9	164.7
BLM	"BS, RECQ2, RECQL3"	ENSG00000197299	"Bloom syndrome RecQ like helicase"	P54132	15	90717327-90816165	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 36.7"	"Cell type enhanced"	"Detected in many"	6	"B-cells: 18.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005689	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA005689: AB_1845372"	"unprognostic (2.77e-1)"	"unprognostic (3.82e-3)"	"unprognostic (4.03e-2)"	"unprognostic (2.98e-2)"	"unprognostic (4.75e-2)"	"unprognostic (9.89e-2)"	"unprognostic (6.12e-5)"	"unprognostic (2.82e-2)"	"unprognostic (4.55e-3)"	"unprognostic (5.24e-3)"	"unprognostic (1.80e-3)"	"unprognostic (9.12e-2)"	"unprognostic (1.55e-15)"	"unprognostic (6.53e-3)"	"unprognostic (6.55e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.83e-2)"	1.8	0.4	3.1	11.4	1.5	5.5	0.6	4.7	2.6	0.7	1.9	0.9	0.5	1.4	1.2	1.1	2.9	0.4	1.3	1.0	2.3	2.4	0.9	0.5	2.0	7.7	2.8	0.2	0.9	0.4	0.0	1.2	3.6	0.5	0.7	2.5	0.7	7.8	0.0	1.7	0.6	2.8	0.5	1.9	6.7	1.4	4.9	0.5	36.7	0.6	3.1	9.3	1.4	0.7	7.4	1.2	4.3	1.6	4.6	5.0	1.6	5.5	7.8	8.8	5.1	0.0	0.4	5.5	4.1	1.2	4.7	5.1	6.9	3.9	14.2	2.6	1.1	5.9	9.2	13.5	3.7	6.1	8.6	10.0	14.9	8.5	2.2	0.0	14.3	7.4	0.0	0.0	4.7	2.4	0.6	3.3	7.7	12.8	4.4	4.9	3.4	10.7	7.8	9.3	12.1	1.7	10.9	16.5	5.5	1.1	9.9	6.5	6.1	3.3	4.5	2.6	8.6	3.1	11.7	1.8	3.4	6.3	3.5	8.8	3.3	13.2	14.8	1.9	10.1	5.9	2.5	1.0	4.3	3.1	1.2	4.8	7.4	2.8	3.8	1.2	4.3	2.0	2.2	0.8	4.6	1.6	1.2	5.0	1.6	3.1	1.5	4.7	1.7	2.3	2.4	2.8	0.2	0.5	0.5	3.0	12.8	18.6	0.5	0.2	2.9	8.4	0.0	9.4	6.8	0.0	2.0	1.8	1.7	0.9	2.0	0.7	0.0	0.0	0.6	6.5	1.5	0.6	12.7	0.5	4.8	0.0	0.0	2.5	9.7	1.6	0.0	3.8	0.0	1.0	1.2	1.2	0.8	0.0	0.4	0.0	6.5	0.0	0.4	12.0	11.8	0.5	0.8	8.7	2.3	0.3
BMPR1A	"ACVRLK3, ALK3, CD292"	ENSG00000107779	"Bone morphogenetic protein receptor type 1A"	P36894	10	86756601-86932838	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB019398	Approved		Approved	Cytosol		NA	NA			Cytosol		"CAB019398: "	"unprognostic (1.36e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.34e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.05e-3)"	"unprognostic (9.34e-2)"	"prognostic unfavorable (8.93e-4)"	"unprognostic (3.64e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.24e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.07e-1)"	8.9	7.0	9.4	7.9	12.4	0.9	10.7	14.1	9.2	19.4	20.6	10.9	7.7	6.2	16.3	12.3	8.4	10.9	10.8	11.0	7.7	6.1	8.2	4.6	7.4	2.9	7.3	7.6	16.1	10.6	10.0	14.0	7.4	8.5	12.8	9.3	10.9	12.6	14.2	8.4	11.3	9.8	16.5	12.2	3.4	12.1	7.8	9.2	0.3	19.4	7.8	5.7	16.0	11.4	1.8	1.1	3.6	0.8	0.9	1.4	0.3	7.3	3.7	14.3	12.1	7.5	4.8	2.5	7.4	7.7	4.3	5.1	6.2	6.4	2.2	3.4	9.4	3.1	7.8	6.3	8.0	6.4	2.4	3.6	2.8	3.5	10.3	4.0	3.8	19.7	4.2	3.4	5.8	4.3	6.4	0.0	4.1	4.4	1.5	5.0	3.1	2.6	3.1	7.7	2.6	1.7	0.0	5.6	0.0	8.9	6.9	1.4	4.6	8.2	4.2	4.9	18.2	7.1	1.9	3.7	3.1	5.0	6.4	6.8	0.4	6.8	2.8	2.7	2.6	2.5	2.0	0.8	0.6	1.4	0.5	0.9	1.8	1.4	1.2	0.3	1.5	1.0	1.1	3.6	0.9	0.6	1.1	0.7	0.3	9.4	12.4	14.1	9.2	7.7	6.1	7.3	7.6	8.5	9.2	32.8	24.8	0.0	6.7	10.8	6.0	19.0	10.2	13.4	9.1	10.4	19.6	10.0	1.7	9.8	0.6	2.1	9.0	0.0	8.1	0.7	13.3	12.9	15.0	7.2	2.7	11.1	17.3	8.0	4.0	1.7	31.1	3.5	8.5	1.0	13.6	12.9	7.7	3.5	29.4	4.7	19.0	6.5	14.1	2.3	3.6	8.5	4.2	0.0	10.0	4.2
BRAF	BRAF1	ENSG00000157764	"B-Raf proto-oncogene, serine/threonine kinase"	P15056	7	140719327-140924928	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001328, CAB004552, HPA071048"	Approved		Approved	Vesicles,Cytosol		No	No			Vesicles	Cytosol	"CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: AB_2686336"	"unprognostic (2.98e-3)"	"unprognostic (5.66e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.66e-3)"	"unprognostic (2.44e-1)"	"unprognostic (1.48e-2)"	"unprognostic (2.07e-2)"	"unprognostic (4.23e-2)"	"unprognostic (4.07e-2)"	"unprognostic (1.58e-2)"	"unprognostic (6.53e-2)"	"unprognostic (1.91e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.08e-1)"	"unprognostic (1.76e-1)"	"unprognostic (8.01e-2)"	"unprognostic (5.46e-2)"	13.1	12.1	20.1	16.5	20.4	27.8	14.2	29.9	21.5	12.4	12.3	9.5	12.5	9.3	15.3	17.0	11.8	11.5	12.0	13.6	13.2	12.2	13.7	12.8	15.9	13.3	9.9	17.8	16.8	13.2	28.9	24.8	13.7	15.3	14.5	11.0	10.7	11.6	16.6	12.9	15.6	10.5	13.0	10.9	12.3	12.0	24.9	12.2	13.5	16.6	7.5	12.1	18.6	18.1	2.6	1.9	7.5	2.4	7.0	5.6	1.1	5.5	4.7	6.9	8.3	8.4	11.0	11.1	6.2	6.6	5.0	7.2	5.1	6.0	9.5	4.8	6.4	8.0	3.1	6.1	4.9	9.3	8.8	5.0	6.2	4.6	4.7	7.2	10.0	6.2	7.3	5.6	5.3	11.1	7.4	5.8	7.1	9.7	17.1	8.8	2.9	13.3	10.5	6.4	5.4	3.0	8.7	5.9	7.7	4.9	10.7	8.1	6.8	7.2	4.4	6.5	7.1	4.1	6.8	8.6	5.5	4.2	11.7	5.0	19.8	11.2	15.2	8.9	10.1	5.9	3.3	2.0	7.5	3.1	1.7	2.1	2.6	3.0	2.4	1.6	2.6	5.6	2.8	4.1	7.0	2.4	1.9	2.7	1.1	20.1	20.4	29.9	21.5	13.2	12.2	9.9	17.8	15.3	12.2	20.8	34.2	19.5	20.3	19.2	29.1	12.7	5.1	24.1	25.0	24.4	33.4	12.4	6.6	10.9	55.6	17.1	7.5	0.0	8.6	10.3	13.1	23.9	24.3	8.7	7.9	23.8	18.4	8.6	14.8	30.8	15.3	17.2	15.1	10.0	8.1	11.8	12.5	6.6	9.6	9.6	32.5	6.5	17.3	33.7	23.0	21.0	63.2	17.5	8.1	23.8
BRCA1	"BRCC1, FANCS, PPP1R53, RNF53"	ENSG00000012048	"BRCA1, DNA repair associated"	P38398	17	43044295-43170245	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA recombination, DNA repair, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transcription, Transcription regulation, Ubl conjugation pathway"	"Activator, DNA-binding, Transferase"	"Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Spermatocytes: 64.7;Spermatogonia: 61.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in all"	5	"dendritic cells: 9.1;granulocytes: 9.7;monocytes: 12.7"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001946, HPA004840, HPA034966, HPA057371"	Approved		Supported	"Nucleoplasm,Nuclear bodies"		NA	Yes			"Nucleoplasm, Nuclear bodies"		"CAB001946: , HPA004840: , HPA034966: AB_10795287, HPA057371: AB_2732611"	"unprognostic (7.87e-3)"	"unprognostic (6.97e-2)"	"unprognostic (3.53e-3)"	"unprognostic (2.39e-1)"	"unprognostic (5.42e-2)"	"unprognostic (7.07e-3)"	"unprognostic (1.56e-3)"	"unprognostic (4.14e-3)"	"unprognostic (9.62e-3)"	"unprognostic (2.47e-1)"	"unprognostic (5.53e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.08e-4)"	"unprognostic (1.08e-3)"	"unprognostic (1.48e-1)"	"unprognostic (2.12e-1)"	"unprognostic (8.31e-2)"	4.8	4.3	6.0	9.6	11.3	15.3	5.1	12.9	10.6	5.4	9.2	3.4	6.8	4.3	5.4	5.5	9.1	5.5	3.3	6.5	6.6	5.3	4.2	7.7	4.9	13.0	7.5	5.9	5.1	4.7	4.2	11.0	5.3	10.5	4.1	10.4	3.7	5.4	7.4	7.3	8.3	6.7	5.5	9.2	5.9	5.1	17.6	7.0	10.9	15.6	7.3	14.6	5.5	5.6	2.0	9.1	9.7	12.7	1.4	1.3	10.7	15.7	25.6	14.1	11.2	2.3	5.2	13.8	18.6	8.0	15.6	14.9	15.5	12.3	36.4	3.4	7.1	18.5	18.3	19.1	10.4	26.2	16.6	14.0	17.1	20.1	13.4	0.5	30.5	14.9	1.4	1.7	23.5	7.5	4.0	8.1	17.0	25.8	15.6	14.7	10.5	25.5	10.1	7.7	10.6	6.8	17.6	29.7	14.9	5.8	15.3	9.7	10.4	14.3	4.7	7.0	10.0	12.6	14.1	5.2	14.0	11.4	18.1	19.3	7.3	17.8	28.0	11.3	18.1	14.6	4.6	12.7	1.8	1.3	4.0	1.3	1.1	1.3	1.0	9.1	2.0	1.2	1.3	9.7	1.4	1.5	1.4	0.4	10.7	6.0	11.3	12.9	10.6	6.6	5.3	7.5	5.9	10.5	7.0	0.0	3.2	5.2	3.8	2.6	8.3	10.4	7.6	13.4	5.7	1.8	21.6	7.0	0.0	2.6	11.1	2.9	1.0	0.0	1.0	17.5	2.9	2.4	8.1	16.1	8.6	11.1	0.0	5.5	4.0	5.2	2.3	5.3	0.0	3.6	3.7	2.8	1.6	3.1	1.4	0.8	21.1	6.5	1.4	64.7	61.1	1.9	3.3	2.5	3.5	2.5
BRCA2	"BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11"	ENSG00000139618	"BRCA2, DNA repair associated"	P51587	13	32315474-32400266	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 23.2;testis: 16.9"	"Group enriched"	"Detected in many"	4	"Erythroid cells: 23.3;monocytes: 31.5;Spermatocytes: 75.1;Spermatogonia: 82.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA026815	Uncertain		Supported	Nucleoplasm,Cytosol		Yes	No			Nucleoplasm	Cytosol	"HPA026815: AB_10602692"	"unprognostic (9.36e-2)"	"unprognostic (2.50e-1)"	"unprognostic (4.50e-3)"	"unprognostic (1.06e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.60e-2)"	"unprognostic (2.01e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.06e-2)"	"unprognostic (3.07e-9)"	"unprognostic (2.36e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.32e-1)"	2.4	1.0	0.6	13.8	0.6	11.6	3.2	0.6	0.6	1.8	4.0	0.2	0.2	1.4	1.5	2.7	3.0	1.0	0.7	2.1	0.6	0.7	1.0	1.4	3.5	5.3	0.7	0.5	1.4	3.3	0.4	0.7	7.0	0.8	0.9	2.0	0.1	1.8	0.3	3.3	1.8	3.2	0.8	2.1	6.6	1.5	16.9	0.1	23.2	0.9	4.8	4.2	1.3	1.7	1.3	1.9	0.4	0.2	1.5	0.8	0.0	4.0	3.5	6.1	4.6	0.6	1.6	6.2	4.3	2.7	5.0	4.6	8.3	5.3	14.2	2.9	2.1	6.9	5.4	5.0	2.5	9.7	9.2	2.7	9.0	2.2	3.2	0.2	12.8	4.5	0.4	0.3	9.2	6.4	0.5	4.1	7.2	5.9	4.9	5.7	4.6	10.3	7.6	7.2	4.6	1.9	10.1	15.7	2.7	1.3	4.3	2.3	4.4	5.2	2.3	2.1	2.2	2.7	6.4	3.2	5.8	6.2	6.4	6.0	1.9	2.9	7.3	3.0	5.1	5.5	0.1	0.2	0.2	0.3	0.2	0.1	0.9	0.4	0.2	0.2	1.3	0.6	0.8	0.4	1.5	0.2	1.9	0.4	0.0	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.5	0.8	0.1	8.9	1.6	1.9	2.8	2.3	0.0	1.6	0.0	4.0	2.3	0.0	0.0	9.1	0.0	1.8	4.3	3.6	1.0	23.3	1.4	9.1	3.5	0.6	3.5	0.8	8.2	0.0	1.2	2.5	6.7	2.5	2.0	13.2	3.3	31.5	3.0	0.2	1.1	1.5	1.1	0.6	0.0	12.9	2.0	75.1	82.4	1.1	4.6	3.8	5.3	1.4
BRD3	"KIAA0043, ORFX, RING3L"	ENSG00000169925	"Bromodomain containing 3"	Q15059	9	134030305-134068535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051830	Approved		Approved	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"HPA051830: AB_2681627"	"unprognostic (3.53e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.90e-1)"	"unprognostic (6.20e-2)"	"unprognostic (2.60e-2)"	"unprognostic (2.98e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.11e-2)"	"unprognostic (6.75e-2)"	"unprognostic (2.79e-1)"	"unprognostic (1.98e-1)"	"prognostic favorable (2.71e-7)"	"unprognostic (1.00e-1)"	"unprognostic (4.71e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.42e-1)"	16.3	15.7	18.0	12.0	20.0	12.3	14.2	21.8	21.8	21.0	20.3	26.7	17.3	13.8	21.7	17.4	14.6	17.7	12.6	17.1	19.9	14.8	11.3	14.5	14.6	11.9	15.8	15.8	19.1	18.7	21.8	15.8	15.7	15.6	19.9	10.3	16.6	16.5	22.5	29.2	19.6	12.9	16.3	17.8	20.1	14.8	17.8	18.2	35.4	18.7	9.2	10.3	17.9	14.1	7.3	16.6	14.6	12.9	15.4	11.9	7.8	4.1	12.6	16.1	12.5	8.9	7.3	14.7	4.2	4.8	4.7	4.8	10.5	6.9	1.6	4.5	3.8	5.3	14.4	14.9	5.8	3.7	9.8	8.3	9.0	14.3	11.8	8.0	11.7	8.1	7.8	7.2	5.4	6.2	7.7	7.7	15.1	8.1	4.7	4.8	13.9	21.7	15.8	21.4	10.8	9.8	16.1	23.2	7.8	6.6	4.4	23.6	21.8	18.9	7.2	5.0	10.1	10.3	19.6	9.8	11.6	6.5	7.5	3.7	2.5	2.7	1.4	5.8	8.1	7.6	5.9	12.9	14.5	11.9	9.8	10.0	7.1	9.6	10.6	12.5	7.3	9.1	9.7	14.6	15.4	7.9	16.6	4.4	7.8	18.0	20.0	21.8	21.8	19.9	14.8	15.8	15.8	15.6	18.2	29.8	21.6	14.1	17.5	28.7	54.2	17.9	25.5	24.1	29.6	22.7	35.3	22.4	16.6	37.3	34.3	26.7	15.2	93.5	21.3	17.8	30.4	33.1	16.1	25.1	15.9	54.0	51.9	27.0	25.1	14.1	52.9	20.6	21.9	19.0	24.6	41.9	25.2	21.0	63.3	13.0	54.0	58.2	32.6	13.7	61.1	31.1	27.3	25.8	30.3	14.7
BRD4	"CAP, HUNK1, HUNKI, MCAP"	ENSG00000141867	"Bromodomain containing 4"	O60885	19	15235519-15332545	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015055, HPA061646, CAB068177, CAB068178"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB068177: AB_2665685, CAB068178: AB_2665686, HPA015055: AB_1845435, HPA061646: AB_2684575"	"unprognostic (2.83e-3)"	"unprognostic (2.39e-2)"	"unprognostic (6.37e-3)"	"unprognostic (3.38e-2)"	"unprognostic (2.15e-1)"	"unprognostic (9.53e-3)"	"unprognostic (3.03e-3)"	"unprognostic (6.13e-2)"	"unprognostic (7.63e-2)"	"unprognostic (2.72e-2)"	"unprognostic (3.98e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.83e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.22e-1)"	23.0	20.7	27.8	25.6	30.1	25.2	20.4	32.1	29.9	20.8	19.6	17.2	18.9	17.6	23.4	12.5	22.9	18.6	15.8	21.3	20.3	12.4	18.1	25.3	22.5	22.7	14.8	17.6	27.3	31.3	19.1	18.8	34.0	17.6	20.8	10.7	18.9	22.0	19.3	47.7	27.3	21.0	20.3	13.9	26.8	20.2	20.1	16.8	34.2	21.5	11.6	23.7	20.9	24.8	6.9	4.3	11.6	4.4	4.9	3.5	2.0	20.4	20.7	12.9	24.3	12.3	8.7	15.6	15.1	12.3	11.9	12.6	21.8	30.9	25.7	25.0	16.4	11.7	20.5	15.0	14.2	10.4	25.7	9.9	24.3	18.1	19.0	18.8	24.0	27.1	12.8	14.7	14.8	29.2	7.9	11.5	17.3	41.1	26.1	7.6	26.5	22.5	17.3	26.3	9.4	24.3	28.3	13.6	16.1	9.5	22.1	15.6	14.1	19.9	14.6	17.0	11.0	14.6	16.4	18.3	31.2	14.9	27.7	23.7	21.3	18.8	13.1	17.2	19.5	24.2	5.2	3.6	3.9	3.5	4.4	2.7	5.4	3.1	2.9	2.1	6.9	3.1	2.9	11.6	4.9	3.9	4.3	2.2	2.0	27.8	30.1	32.1	29.9	20.3	12.4	14.8	17.6	17.6	16.8	59.6	53.2	59.1	104.0	104.5	62.2	73.0	56.0	22.7	28.4	24.4	78.5	177.3	21.6	46.6	107.0	73.3	66.9	93.5	57.8	59.0	72.1	110.7	34.8	77.4	51.9	74.7	109.2	55.3	67.7	148.2	71.7	51.2	42.2	43.3	47.3	38.6	55.1	44.4	75.0	28.3	85.9	71.1	85.8	52.5	37.5	125.2	212.7	56.7	51.5	128.6
BRIP1	"BACH1, FANCJ, OF"	ENSG00000136492	"BRCA1 interacting protein C-terminal helicase 1"	Q9BX63	17	61681266-61863521	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 30.1"	"Group enriched"	"Detected in many"	11	"Early spermatids: 136.2;Late spermatids: 148.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"B-cells: 2.2;granulocytes: 2.1;T-cells: 3.7"	"Cell line enhanced"	"Detected in many"		"MCF7: 42.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005474	Approved		Supported	"Nucleoplasm,Nuclear membrane"		NA	Yes			"Nucleoplasm, Nuclear membrane"		"HPA005474: AB_2667333"	"unprognostic (1.88e-1)"	"unprognostic (1.55e-2)"	"prognostic favorable (3.45e-5)"	"unprognostic (6.85e-4)"	"unprognostic (3.09e-1)"	"prognostic favorable (3.62e-4)"	"unprognostic (2.60e-3)"	"unprognostic (5.60e-2)"	"unprognostic (5.66e-3)"	"unprognostic (6.71e-2)"	"unprognostic (1.50e-3)"	"unprognostic (2.75e-2)"	"unprognostic (3.41e-12)"	"unprognostic (1.19e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.96e-2)"	"unprognostic (3.62e-3)"	1.0	0.9	0.7	6.3	3.5	9.1	1.1	0.6	1.4	1.4	2.6	0.2	0.6	2.8	1.5	1.2	3.7	0.8	1.8	0.4	0.5	0.5	0.6	2.3	1.3	4.0	0.5	0.9	2.1	1.3	0.1	0.4	1.7	0.7	1.0	2.8	0.4	1.4	0.0	0.4	2.7	5.5	1.0	0.5	2.3	1.3	10.8	0.4	30.1	0.4	2.0	6.6	1.3	1.7	2.2	0.5	2.1	0.3	0.6	3.7	0.5	12.5	4.3	12.4	7.1	0.4	1.1	2.7	11.6	6.8	12.4	16.1	4.4	4.0	7.5	2.7	2.4	3.6	4.5	6.4	2.4	16.8	1.9	7.8	7.6	6.8	5.4	0.1	9.8	4.5	0.2	0.1	9.9	2.6	1.7	2.7	7.4	5.3	5.1	7.8	42.2	15.5	3.4	2.7	3.0	3.7	9.7	23.9	3.6	1.7	5.7	5.0	12.9	4.5	1.6	1.8	4.9	4.2	3.8	2.3	18.3	13.4	6.7	13.3	3.2	6.1	8.0	3.7	4.7	4.5	2.1	0.3	1.5	0.5	0.2	0.6	2.2	1.2	0.6	0.4	1.8	1.8	0.9	1.0	0.6	0.2	0.5	3.7	0.5	0.7	3.5	0.6	1.4	0.5	0.5	0.5	0.9	0.7	0.4	0.0	0.3	1.5	1.3	2.1	0.1	0.5	0.0	1.4	6.8	0.0	0.0	0.7	0.0	0.3	136.2	0.3	0.9	0.0	0.2	2.5	0.6	0.1	0.0	3.0	1.4	0.0	0.0	0.6	0.3	148.4	1.1	0.4	3.3	1.0	1.5	0.3	0.5	0.0	1.1	0.0	0.2	0.0	0.9	13.3	4.5	0.4	0.2	0.8	2.5	0.3
BTG1	APRO2	ENSG00000133639	"BTG anti-proliferation factor 1"	P62324	12	92140278-92145897	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 190.7"	"Cell type enhanced"	"Detected in all"	5	"Basal keratinocytes: 2444.1;Suprabasal keratinocytes: 2626.0"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	5	"cerebellum: 66.8"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC TERT1: 50.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005972			Approved	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA005972: AB_1078303"	"prognostic favorable (4.36e-5)"	"unprognostic (1.43e-1)"	"unprognostic (2.32e-1)"	"unprognostic (1.37e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-3)"	"unprognostic (1.10e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.34e-2)"	"unprognostic (2.50e-1)"	"unprognostic (4.94e-2)"	"prognostic unfavorable (1.95e-7)"	"unprognostic (1.14e-1)"	"unprognostic (1.56e-1)"	"unprognostic (5.79e-2)"	"unprognostic (9.81e-2)"	52.0	22.1	11.5	58.3	13.4	126.9	114.4	66.8	10.4	41.7	40.1	5.5	21.9	15.5	30.1	22.0	28.7	27.9	39.9	49.2	11.9	8.1	22.2	58.1	85.6	190.7	10.4	8.2	29.1	64.2	17.6	17.1	23.4	13.3	28.7	18.1	21.0	19.0	25.9	31.6	70.6	34.3	26.0	24.6	77.1	26.4	19.0	8.9	148.9	15.7	14.3	58.2	54.2	35.2	58.3	6.6	94.3	14.0	47.1	95.2	26.1	7.0	8.8	9.7	1.1	36.3	50.4	4.2	7.9	17.4	5.3	5.3	5.2	2.4	7.5	1.6	8.3	8.4	4.8	3.2	8.8	9.9	9.0	6.8	1.5	6.1	2.7	36.8	5.5	2.6	43.0	26.7	12.1	37.5	23.5	10.6	5.0	5.2	10.0	6.0	7.2	3.9	17.7	2.3	7.7	10.0	13.4	5.4	2.3	16.3	14.6	5.4	10.8	9.8	7.6	25.5	7.8	32.0	12.8	3.4	6.0	1.8	4.6	4.8	13.8	7.4	12.5	4.7	4.4	6.7	22.3	13.6	94.3	17.0	10.6	20.1	44.5	34.3	29.8	6.6	58.3	95.2	39.1	52.3	47.1	14.0	6.2	39.2	26.1	11.5	13.4	66.8	10.4	11.9	8.1	10.4	8.2	13.3	8.9	89.3	164.0	1133.8	898.4	2444.1	509.3	99.7	695.5	18.7	63.7	165.7	184.6	344.9	271.9	357.5	306.7	258.8	666.0	140.2	222.2	261.3	225.7	728.6	288.8	235.3	359.2	400.5	434.2	206.2	468.4	134.9	265.8	682.9	933.0	1485.2	192.1	767.8	308.3	596.2	227.4	96.3	342.5	530.3	1116.5	68.9	113.5	2626.0	1122.8	1563.2	226.0	1040.3
BTK	"AGMX1, ATK, IMD1, PSCTK1, XLA"	ENSG00000010671	"Bruton tyrosine kinase"	Q06187	X	101349447-101390796	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 77.5;lymphoid tissue: 37.0"	"Cell type enhanced"	"Detected in some"	19	"B-cells: 86.8;granulocytes: 203.6;Hofbauer cells: 50.3;Kupffer cells: 53.4;Macrophages: 53.0;monocytes: 52.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 77.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 29.5;HEL: 40.9;HMC-1: 147.5;U-937: 21.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001198, HPA002028, CAB016689"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA		610000	"Plasma membrane, Cytosol"		"CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306"	"unprognostic (3.19e-2)"	"unprognostic (2.51e-3)"	"unprognostic (1.06e-2)"	"unprognostic (3.66e-2)"	"unprognostic (5.69e-2)"	"unprognostic (3.76e-3)"	"unprognostic (6.55e-2)"	"unprognostic (3.58e-3)"	"unprognostic (6.02e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.08e-3)"	"unprognostic (7.80e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.14e-2)"	7.3	2.4	3.3	23.5	5.6	14.0	2.6	0.8	3.6	2.3	3.0	4.7	0.3	2.2	1.9	2.6	2.4	2.0	3.7	3.3	3.3	2.5	2.2	2.5	10.7	25.1	5.4	1.2	1.2	1.5	0.2	1.4	3.2	4.1	2.5	4.5	1.5	3.2	1.0	1.0	2.5	12.9	3.3	10.8	37.0	3.1	1.3	6.3	4.0	1.7	1.8	36.7	5.8	2.0	13.7	13.2	77.5	20.7	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.9	0.0	0.0	0.0	16.4	147.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6	0.3	0.0	0.0	0.0	11.5	0.2	0.0	0.0	12.3	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	9.8	0.0	0.0	0.0	0.0	0.0	0.3	0.2	14.0	0.0	21.4	0.0	77.5	11.3	19.3	0.0	18.1	0.0	13.7	0.0	0.0	13.2	13.7	0.0	0.0	4.5	0.0	20.7	6.0	0.0	6.1	3.3	5.6	0.8	3.6	3.3	2.5	5.4	1.2	4.1	6.3	3.0	12.8	86.8	0.1	0.9	0.0	0.4	0.0	0.0	1.2	0.0	0.0	1.1	0.0	0.0	0.2	0.6	0.0	23.3	0.0	0.4	0.5	0.0	203.6	0.0	50.3	0.0	0.0	1.3	53.4	0.0	0.3	53.0	3.3	52.3	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.3	0.4	1.6	0.3	1.6	0.8	0.0	0.1
BUB1B	"Bub1A, BUBR1, MAD3L, SSK1"	ENSG00000156970	"BUB1 mitotic checkpoint serine/threonine kinase B"	O60566	15	40161023-40221136	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Mitosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 49.5;testis: 25.6"	"Group enriched"	"Detected in many"	7	"Spermatocytes: 66.9;Spermatogonia: 28.8"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 2.8;plasmacytoid DC: 2.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA008419			Supported	Cytosol		Yes	Yes			Cytosol		"HPA008419: AB_1078308"	"unprognostic (4.40e-2)"	"unprognostic (2.23e-1)"	"unprognostic (4.65e-2)"	"unprognostic (2.44e-3)"	"unprognostic (9.66e-2)"	"unprognostic (3.52e-2)"	"prognostic unfavorable (7.43e-6)"	"prognostic unfavorable (3.56e-4)"	"unprognostic (3.69e-3)"	"unprognostic (2.32e-1)"	"prognostic unfavorable (1.79e-4)"	"unprognostic (1.76e-2)"	"unprognostic (0.00e+0)"	"unprognostic (3.75e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.20e-1)"	"unprognostic (3.94e-2)"	1.0	0.9	0.3	18.4	0.6	11.4	1.5	0.4	0.5	1.3	4.0	0.4	0.1	3.3	1.1	0.8	6.5	0.5	1.1	0.6	0.4	0.4	0.8	0.7	1.8	8.7	0.4	0.3	0.6	0.5	0.0	0.4	3.4	0.5	0.6	4.4	0.3	1.6	0.1	0.7	2.3	2.9	1.2	0.6	5.4	1.7	25.6	0.1	49.5	0.5	3.1	10.6	1.1	2.0	2.8	2.8	0.0	0.2	0.7	0.7	0.5	21.8	11.1	35.5	14.1	0.9	2.5	11.5	20.8	11.7	22.3	19.4	16.2	8.4	19.8	11.7	7.5	20.5	24.7	33.5	11.3	24.3	17.0	18.0	28.9	28.7	15.0	0.0	26.1	15.9	0.5	0.6	13.6	12.8	4.4	16.1	22.9	24.9	21.1	22.2	7.4	20.4	15.9	24.0	18.4	12.7	21.9	29.2	15.0	6.8	11.1	23.2	14.3	12.8	12.3	4.5	16.2	14.3	13.5	9.3	17.1	18.1	17.0	18.4	11.1	18.8	32.4	9.1	29.3	22.2	0.0	0.0	0.0	0.2	0.2	0.3	2.4	0.7	0.6	0.7	2.8	0.1	0.4	0.0	0.7	0.1	2.8	0.0	0.5	0.3	0.6	0.4	0.5	0.4	0.4	0.4	0.3	0.5	0.1	3.0	1.4	0.8	0.3	0.7	0.4	0.4	0.0	0.0	3.4	0.0	0.0	1.3	0.0	0.3	2.5	0.0	0.3	0.0	0.0	5.1	0.4	0.2	0.0	0.2	4.3	0.0	0.0	1.3	0.6	2.4	1.4	1.5	0.0	0.0	1.4	0.0	0.8	0.8	0.4	0.0	0.1	6.5	0.0	66.9	28.8	0.3	0.7	0.8	1.7	0.4
CACNA1D	"CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2"	ENSG00000157388	"Calcium voltage-gated channel subunit alpha1 D"	Q01668	3	53328963-53813733	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 2: 45.9;Cone photoreceptor cells: 33.4;Intestinal endocrine cells: 57.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	9	"basophil: 7.2"	"Lineage enriched"	"Detected in single"	20	"granulocytes: 7.2"	"Cell line enhanced"	"Detected in some"		"HMC-1: 14.4;RPMI-8226: 33.6;SK-BR-3: 6.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA020215	Uncertain		Approved	"Nuclear membrane"		NA	NA			"Nuclear membrane"		"HPA020215: AB_1845860"	"unprognostic (5.85e-2)"	"unprognostic (4.90e-3)"	"unprognostic (5.09e-2)"	"unprognostic (2.24e-2)"	"unprognostic (7.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.32e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.42e-2)"	"unprognostic (3.90e-3)"	"unprognostic (1.53e-1)"	"prognostic favorable (8.34e-8)"	"unprognostic (1.14e-1)"	"unprognostic (3.05e-2)"	"unprognostic (8.09e-3)"	"unprognostic (6.70e-3)"	0.6	13.4	10.0	0.8	12.6	1.4	3.6	12.2	16.5	11.2	2.8	3.7	0.1	3.3	6.8	13.2	1.2	14.9	6.2	1.8	5.3	3.5	4.2	3.0	9.0	0.5	2.5	9.6	1.2	5.3	3.0	13.6	1.4	8.7	5.7	3.1	10.1	1.1	3.5	0.6	1.5	4.2	1.7	2.2	4.4	1.8	3.0	1.6	0.0	5.2	0.0	0.6	2.3	0.6	0.1	0.3	7.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	1.6	1.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	14.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.2	0.5	0.0	0.0	0.1	33.6	0.3	2.2	3.1	1.3	0.2	6.3	0.7	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	7.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	10.0	12.6	12.2	16.5	5.3	3.5	2.5	9.6	8.7	1.6	3.0	45.9	0.0	0.6	0.8	23.0	1.2	12.7	14.7	14.8	1.8	33.4	0.6	0.0	5.5	3.6	0.5	3.3	0.0	2.0	0.1	1.0	2.6	11.6	2.4	0.2	7.9	57.1	0.0	1.0	4.9	4.0	0.3	5.0	0.0	2.7	2.5	2.6	3.5	25.5	1.6	13.0	0.0	2.8	1.1	2.5	0.9	0.2	1.3	4.5	0.6
CALR	"cC1qR, CRT, FLJ26680, RO, SSA"	ENSG00000179218	Calreticulin	P27797	19	12938578-12944489	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Extravillous trophoblasts: 1318.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001513, HPA002242, CAB019952, CAB079775"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA		450000000	"Endoplasmic reticulum"		"CAB001513: , CAB019952: AB_2069792, CAB079775: AB_303403, HPA002242: AB_1078384"	"unprognostic (1.49e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.46e-2)"	"unprognostic (4.25e-2)"	"unprognostic (9.44e-3)"	"unprognostic (6.93e-2)"	"unprognostic (2.47e-2)"	"unprognostic (4.60e-2)"	"unprognostic (2.61e-1)"	"prognostic favorable (1.10e-4)"	"unprognostic (2.07e-1)"	"unprognostic (3.76e-1)"	"prognostic unfavorable (1.11e-16)"	"unprognostic (2.37e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.37e-1)"	"unprognostic (5.27e-2)"	67.5	55.5	31.9	58.9	36.1	86.4	64.6	20.9	38.9	50.2	52.3	42.5	65.7	44.1	61.6	108.4	65.2	49.1	67.5	62.5	31.6	35.2	81.9	302.6	61.8	83.6	33.5	33.4	59.6	124.3	56.4	60.3	98.0	35.7	53.1	60.0	43.2	121.0	68.6	25.1	34.2	53.8	56.9	42.1	66.6	49.7	65.0	32.7	61.6	250.6	55.0	65.2	39.4	68.0	25.1	57.2	16.1	38.6	26.3	48.4	16.2	118.3	46.8	64.3	140.1	81.3	73.4	58.9	158.3	130.0	95.4	139.0	71.5	95.3	76.0	146.2	183.6	85.6	47.2	70.3	100.9	96.7	56.5	40.1	63.3	57.0	108.7	192.1	254.0	85.9	68.0	46.8	88.4	74.9	126.5	114.8	52.2	54.1	38.6	77.4	81.7	70.4	166.1	57.2	66.7	66.4	54.6	54.5	92.0	83.8	67.8	24.5	52.3	98.1	54.0	32.3	79.5	72.2	105.4	99.3	79.7	50.2	113.4	70.7	48.2	42.9	76.4	112.3	110.8	87.6	16.1	19.5	10.1	48.4	38.6	34.3	25.1	29.2	36.7	20.4	22.4	21.6	39.2	6.6	26.3	30.8	57.2	21.5	16.2	31.9	36.1	20.9	38.9	31.6	35.2	33.5	33.4	35.7	32.7	137.0	125.9	216.1	284.2	232.4	67.7	39.5	168.2	151.3	164.9	211.1	119.8	557.7	54.7	494.3	20.8	202.2	487.4	140.2	249.9	1318.6	319.8	346.7	204.2	513.5	724.5	33.4	339.2	328.4	165.0	18.8	295.1	261.1	202.4	256.1	263.3	298.5	397.7	287.1	292.4	139.9	115.0	200.5	213.6	255.0	394.6	186.7	806.5	193.7	294.0	285.1
CAMTA1	KIAA0833	ENSG00000171735	"Calmodulin binding transcription activator 1"	Q9Y6Y1	1	6785324-7769706	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036342, HPA036343"	Approved		Supported	Cytosol		NA	NA			Cytosol		"HPA036342: AB_2675072, HPA036343: AB_10671839"	"unprognostic (1.11e-1)"	"unprognostic (6.31e-2)"	"unprognostic (5.80e-2)"	"unprognostic (4.14e-3)"	"unprognostic (3.10e-2)"	"unprognostic (1.47e-2)"	"prognostic unfavorable (5.25e-4)"	"unprognostic (1.08e-2)"	"unprognostic (3.59e-1)"	"prognostic favorable (4.10e-4)"	"unprognostic (3.90e-3)"	"unprognostic (8.84e-2)"	"unprognostic (1.35e-3)"	"unprognostic (2.17e-2)"	"unprognostic (9.19e-3)"	"unprognostic (1.42e-1)"	"unprognostic (9.03e-3)"	18.4	24.3	31.6	12.2	30.7	12.1	21.7	24.4	37.1	16.5	30.2	19.9	13.2	28.3	20.0	46.7	22.7	16.8	17.7	58.1	26.4	27.6	36.7	37.2	16.5	13.3	31.2	26.5	17.1	18.6	22.0	17.6	14.3	47.5	22.2	27.1	25.0	27.1	29.6	48.0	12.9	30.4	38.4	23.9	15.7	21.5	23.0	19.4	14.7	30.8	20.5	17.5	31.3	18.7	19.8	32.3	28.3	32.4	10.3	18.1	18.9	22.0	12.4	34.6	17.5	17.9	27.4	9.7	23.9	18.4	25.8	21.9	15.0	28.0	18.3	18.8	25.0	17.3	13.7	18.0	24.7	36.9	13.7	19.6	20.6	29.4	29.2	29.1	15.6	15.0	18.3	17.2	18.6	28.7	22.3	28.7	26.1	14.4	24.9	29.7	21.3	20.7	42.9	23.9	28.1	14.6	13.9	30.8	40.5	34.8	12.9	35.8	28.9	16.9	25.2	36.8	26.0	13.6	19.6	16.7	18.4	15.6	18.9	14.8	19.0	23.5	49.2	27.5	35.2	10.3	27.5	32.4	28.3	11.5	19.4	12.5	19.8	18.0	14.2	30.6	16.2	14.7	12.8	6.6	10.3	14.7	32.3	18.1	18.9	31.6	30.7	24.4	37.1	26.4	27.6	31.2	26.5	47.5	19.4	50.6	45.6	87.6	306.4	275.2	103.9	495.7	107.0	68.3	46.6	181.5	237.6	60.6	354.8	147.0	138.1	160.0	190.4	46.7	180.4	116.8	142.3	320.6	54.3	215.1	94.9	149.4	125.6	81.6	94.6	111.6	70.8	142.3	226.0	196.6	153.7	60.0	175.4	166.1	120.9	611.1	144.7	135.8	271.7	133.0	213.0	247.2	73.7	58.9	164.9	354.7
CANT1	"SCAN-1, SHAPY"	ENSG00000171302	"Calcium activated nucleotidase 1"	Q8WVQ1	17	78991717-79009867	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Mucus-secreting cells: 134.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"OE19: 92.2;T-47d: 60.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019627, HPA019639, HPA022818"	Enhanced		Supported	"Golgi apparatus"		NA	NA		2300000	"Golgi apparatus"		"HPA019627: AB_1845969, HPA019639: AB_1845970, HPA022818: AB_1845971"	"unprognostic (1.98e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.50e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.13e-2)"	"unprognostic (2.21e-2)"	"prognostic unfavorable (1.41e-4)"	"prognostic unfavorable (2.90e-4)"	"unprognostic (1.76e-1)"	"unprognostic (9.00e-2)"	"unprognostic (3.30e-1)"	"unprognostic (2.49e-1)"	"prognostic unfavorable (6.21e-4)"	"unprognostic (7.04e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.23e-2)"	13.8	15.3	9.6	13.1	10.2	8.1	13.0	12.2	10.8	17.7	43.8	12.3	25.4	25.5	12.0	14.3	27.5	10.0	19.5	10.8	9.0	6.9	10.3	17.7	11.1	11.5	12.5	7.7	10.4	14.7	13.1	11.8	33.0	12.0	36.7	41.5	7.9	30.3	41.4	9.0	8.9	27.2	8.0	12.4	18.1	25.8	19.0	10.3	14.1	12.4	8.9	14.4	10.3	13.7	4.1	3.8	17.5	4.4	3.1	6.2	4.4	22.2	24.4	6.8	9.9	6.5	7.8	8.8	13.8	12.1	14.8	12.6	11.6	21.1	5.4	8.1	9.6	18.1	11.3	5.8	10.8	14.9	9.0	10.6	7.0	7.4	9.6	5.6	6.7	11.1	8.0	7.0	13.7	7.5	8.8	25.6	9.1	8.8	9.2	9.8	12.1	10.1	4.0	4.7	92.2	26.0	5.7	11.2	6.1	6.5	11.2	9.9	9.9	7.3	48.8	10.4	11.4	60.2	8.0	12.7	22.2	20.1	9.9	17.2	10.9	9.0	5.3	14.2	5.2	13.9	6.1	3.8	8.1	6.2	4.4	6.1	4.1	4.6	5.2	3.8	2.9	4.5	4.4	17.5	3.1	2.9	2.7	3.8	4.4	9.6	10.2	12.2	10.8	9.0	6.9	12.5	7.7	12.0	10.3	26.8	19.4	13.7	13.8	14.7	5.9	11.6	15.3	6.7	10.3	12.2	13.7	30.3	3.3	30.3	11.4	14.3	61.6	23.3	25.4	31.5	12.3	34.8	5.7	12.1	21.5	4.8	49.0	54.6	9.2	10.4	10.9	11.3	13.5	11.8	134.8	6.7	27.4	49.1	7.1	6.1	8.5	6.5	7.2	23.2	5.5	11.4	84.9	10.2	83.2	16.5
CARD11	"BIMP3, CARMA1"	ENSG00000198286	"Caspase recruitment domain family member 11"	Q9BXL7	7	2906141-3043945	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 21.4;lymphoid tissue: 44.7"	"Cell type enhanced"	"Detected in some"	13	"B-cells: 19.1;Pancreatic endocrine cells: 15.2;T-cells: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 21.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Daudi: 40.6;K-562: 16.2;RT4: 30.6;U-698: 36.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			HPA052984	Approved					NA	NA					"HPA052984: AB_2682005"	"unprognostic (3.12e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.17e-1)"	"unprognostic (8.46e-3)"	"unprognostic (4.81e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.71e-1)"	"unprognostic (2.31e-1)"	"unprognostic (5.65e-2)"	"unprognostic (5.11e-2)"	"unprognostic (2.09e-2)"	"unprognostic (3.09e-1)"	"prognostic unfavorable (6.68e-8)"	"unprognostic (3.74e-2)"	"unprognostic (4.75e-2)"	"unprognostic (1.31e-1)"	"prognostic favorable (1.10e-4)"	1.2	1.7	1.4	44.7	1.0	9.0	0.9	0.7	1.4	1.7	1.4	1.2	0.6	1.9	0.8	0.5	2.7	1.2	11.4	0.8	1.4	2.3	1.9	1.4	3.8	25.0	2.1	0.5	0.9	1.4	0.1	1.0	0.5	1.1	2.8	1.2	1.2	6.7	1.0	0.3	0.5	14.2	1.4	2.9	27.4	3.9	1.4	1.5	22.8	1.3	1.7	28.6	9.4	5.2	4.6	21.4	0.3	0.0	3.3	5.5	1.8	5.4	0.8	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.2	0.0	10.7	12.0	40.6	10.1	0.0	0.0	9.1	0.0	0.1	0.1	13.8	0.4	0.0	1.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	7.8	4.5	16.2	0.0	0.0	0.1	1.5	0.0	15.3	6.8	0.0	1.9	0.0	10.1	3.9	30.6	0.1	0.5	0.0	0.0	0.0	6.4	0.0	0.8	5.1	0.0	4.1	0.0	0.0	4.2	0.0	36.2	0.0	0.0	0.0	0.3	0.0	0.0	5.5	0.0	5.2	3.8	3.2	3.6	0.6	4.6	2.1	3.8	0.1	3.3	0.0	21.4	2.2	1.8	1.4	1.0	0.7	1.4	1.4	2.3	2.1	0.5	1.1	1.5	0.0	0.0	19.1	0.3	0.0	0.4	1.7	0.0	0.0	0.0	1.8	0.0	0.0	0.0	4.6	0.1	0.0	0.0	0.0	4.7	0.0	0.5	0.3	5.7	0.0	1.5	0.0	0.0	0.0	1.5	0.0	0.3	2.2	3.3	0.0	0.0	0.0	15.2	0.0	0.0	0.0	0.0	0.0	0.4	1.4	0.0	0.3	0.0	24.5	0.0	3.1
CARS	CARS1	ENSG00000110619	"Cysteinyl-tRNA synthetase"	P49589	11	3000922-3057613	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Protein biosynthesis"	"Aminoacyl-tRNA synthetase, Ligase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Ciliated cells: 92.3;Early spermatids: 93.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737"	Enhanced		Enhanced	Cytosol		NA	NA		110000	Cytosol		"CAB075734: AB_2665740, CAB075735: AB_2665741, CAB075736: AB_2665742, CAB075737: AB_2665743, HPA002383: AB_1078399, HPA002384: AB_1846033"	"unprognostic (9.10e-3)"	"unprognostic (1.83e-1)"	"unprognostic (4.16e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.00e-2)"	"unprognostic (7.97e-2)"	"prognostic unfavorable (5.16e-4)"	"unprognostic (1.41e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.00e-2)"	"unprognostic (5.51e-2)"	"unprognostic (2.45e-1)"	"prognostic unfavorable (0.00e+0)"	"unprognostic (5.37e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.48e-1)"	"unprognostic (3.46e-1)"	24.9	15.9	15.8	15.8	17.7	9.0	15.9	9.5	29.1	13.4	16.3	19.1	11.1	15.9	14.0	10.7	16.0	10.8	14.2	12.5	15.3	18.7	10.7	22.1	15.1	17.2	23.3	15.9	14.5	42.5	14.9	15.9	14.0	23.0	10.8	17.6	7.4	20.3	14.8	24.6	18.8	17.8	21.0	16.1	14.8	22.8	13.4	17.3	9.8	23.0	14.5	22.7	14.4	19.4	8.3	13.3	18.0	23.9	16.4	18.1	11.6	7.4	3.8	4.9	14.8	19.3	17.8	4.4	19.1	21.8	13.2	23.9	9.3	17.9	11.6	5.6	24.1	0.0	19.2	16.2	21.7	18.2	33.8	3.7	6.5	6.5	7.1	46.3	13.5	14.4	29.3	17.1	11.4	12.7	0.0	17.4	28.8	10.9	41.0	13.0	11.3	9.5	0.0	18.5	26.5	6.8	4.6	8.2	14.5	0.0	12.5	10.6	14.1	4.7	13.4	20.9	3.8	0.0	0.0	6.0	5.4	5.1	13.5	0.2	30.5	27.8	7.4	0.0	7.1	10.7	7.7	12.0	8.8	15.2	10.5	13.0	8.3	13.6	13.6	13.3	6.0	7.5	12.1	18.0	16.4	23.9	5.2	18.1	11.6	15.8	17.7	9.5	29.1	15.3	18.7	23.3	15.9	23.0	17.3	17.9	31.5	21.7	25.4	12.8	11.7	6.7	2.5	92.3	27.3	10.4	5.9	18.8	8.3	35.4	93.7	13.7	18.6	0.0	34.2	34.8	12.6	16.1	20.7	16.8	18.9	14.3	18.3	13.5	15.1	39.9	11.5	14.7	8.5	14.4	16.9	10.8	37.5	21.0	18.0	13.4	10.0	6.5	14.1	39.5	24.2	10.5	27.0	24.2	14.3	35.5
CASP8	"Casp-8, FLICE, MACH, MCH5"	ENSG00000064012	"Caspase 8"	Q14790	2	201233443-201287711	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 52.5"	"Cell type enhanced"	"Detected in many"	5	"T-cells: 55.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001302, CAB002047, HPA005688, HPA006191"	Approved		Supported	Nucleoplasm,Cytosol		No	No			Cytosol	Nucleoplasm	"CAB002047: AB_563465, HPA001302: AB_1846057, HPA005688: AB_1846056, HPA006191: AB_2667535"	"unprognostic (5.21e-3)"	"unprognostic (2.10e-1)"	"unprognostic (1.83e-2)"	"unprognostic (9.69e-3)"	"unprognostic (2.09e-1)"	"unprognostic (5.60e-2)"	"prognostic unfavorable (3.02e-4)"	"unprognostic (2.10e-1)"	"unprognostic (4.79e-2)"	"prognostic favorable (1.25e-4)"	"unprognostic (7.75e-2)"	"unprognostic (5.11e-2)"	"prognostic unfavorable (1.27e-6)"	"unprognostic (7.67e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.53e-1)"	"unprognostic (4.53e-3)"	14.1	10.6	2.0	31.6	2.6	27.1	10.2	1.4	1.8	7.9	18.5	3.9	7.0	9.6	9.6	12.0	11.7	9.1	12.1	4.4	2.1	2.3	16.4	14.8	17.1	28.3	3.9	1.1	8.2	7.6	1.8	5.9	12.3	3.2	9.8	8.7	4.4	9.6	8.4	2.7	7.4	34.7	5.1	5.0	37.7	7.4	3.8	2.7	43.7	6.7	10.7	43.4	9.6	7.3	13.8	13.7	52.5	17.0	22.2	26.4	12.0	14.5	12.4	3.6	10.1	10.1	14.8	5.6	6.4	6.3	7.6	12.6	16.6	25.4	1.6	14.1	4.9	13.7	7.4	7.9	7.6	15.1	9.4	7.2	14.2	10.1	15.8	8.2	11.0	15.4	12.8	18.8	14.4	11.3	6.4	7.2	12.3	12.7	31.6	6.9	6.0	14.3	11.6	5.9	8.0	11.1	10.8	7.5	25.9	14.3	16.2	1.1	0.5	8.3	13.8	8.2	3.5	3.6	8.6	9.0	8.2	8.6	4.3	5.0	28.7	12.8	9.9	12.3	14.8	7.7	20.7	13.0	24.9	25.0	17.0	23.1	13.8	20.5	26.4	13.7	7.8	13.3	16.9	52.5	22.2	15.6	6.1	24.0	12.0	2.0	2.6	1.4	1.8	2.1	2.3	3.9	1.1	3.2	2.7	23.8	26.1	34.1	10.1	6.6	1.5	1.6	7.6	16.0	18.2	5.2	9.8	7.5	13.3	9.0	5.6	7.1	19.8	0.0	7.3	10.3	3.8	8.1	23.2	10.4	11.2	0.0	4.1	5.5	25.6	0.7	2.3	21.7	6.8	19.8	13.0	0.1	9.6	12.7	0.7	20.0	0.4	0.0	1.4	0.7	0.4	6.8	2.9	55.4	12.1	12.7
CBFA2T3	"ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4"	ENSG00000129993	"CBFA2/RUNX1 translocation partner 3"	O75081	16	88874858-88977204	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 75.9"	"Cell type enhanced"	"Detected in many"	7	"B-cells: 11.5;Mucus-secreting cells: 13.5;Sertoli cells: 19.4;Smooth muscle cells: 11.2"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in all"		"cerebellum: 26.0"	"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 11.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HEL: 21.4;K-562: 37.4;MCF7: 17.3;MOLT-4: 19.0;NB-4: 23.1;REH: 37.6;T-47d: 17.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA059931, HPA062423, HPA065890"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA059931: AB_2684168, HPA062423: AB_2684758, HPA065890: AB_2685575"	"unprognostic (2.47e-1)"	"unprognostic (2.03e-2)"	"unprognostic (9.24e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.98e-1)"	"prognostic favorable (3.95e-4)"	"unprognostic (1.13e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.10e-1)"	"unprognostic (7.30e-3)"	"unprognostic (2.38e-1)"	"unprognostic (7.04e-5)"	"unprognostic (2.18e-1)"	"unprognostic (4.08e-2)"	"unprognostic (4.62e-2)"	"unprognostic (9.35e-3)"	10.0	1.7	3.6	11.3	7.4	8.2	6.1	26.0	5.4	2.3	3.9	1.3	1.4	3.9	3.2	2.1	2.1	1.9	2.5	6.2	3.0	3.0	0.7	2.0	6.4	9.5	2.0	3.8	0.9	24.9	0.7	2.7	3.8	2.3	3.7	1.5	3.1	4.5	2.9	14.2	2.6	5.5	1.5	1.2	14.7	3.5	3.2	2.2	75.9	2.4	2.0	10.3	3.6	4.8	3.7	11.6	3.6	4.9	0.1	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	21.4	0.0	0.0	0.0	5.6	10.6	0.0	0.0	0.0	0.0	0.0	0.0	10.3	37.4	0.2	0.0	17.3	19.0	23.1	0.4	0.0	0.0	37.6	0.3	3.7	0.0	0.0	7.4	1.6	0.8	0.1	0.1	0.1	17.1	6.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	12.4	0.0	6.5	0.0	1.1	2.7	2.7	0.0	3.2	0.0	3.7	0.0	0.0	7.1	2.1	0.0	0.0	3.6	0.1	4.9	11.6	0.0	1.7	3.6	7.4	26.0	5.4	3.0	3.0	2.0	3.8	2.3	2.2	0.0	1.4	11.5	5.1	2.3	7.7	1.6	0.0	0.0	2.3	0.0	0.0	0.1	0.0	0.2	0.0	3.6	0.9	0.0	2.4	0.1	1.6	2.5	5.8	5.7	2.4	0.0	3.5	2.5	2.8	0.0	2.0	6.4	0.0	1.0	13.5	0.1	1.4	0.0	0.7	0.5	1.2	19.4	11.2	0.2	4.5	1.9	0.2	1.0	0.8	3.8
CBFB	PEBP2B	ENSG00000067955	"Core-binding factor beta subunit"	Q13951	16	67029116-67101058	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 101.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038852	Uncertain		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA038852: AB_10795358"	"unprognostic (1.05e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.22e-2)"	"unprognostic (4.66e-2)"	"unprognostic (3.80e-3)"	"prognostic unfavorable (2.83e-4)"	"unprognostic (1.63e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.11e-1)"	"unprognostic (4.46e-3)"	"unprognostic (1.88e-2)"	"prognostic unfavorable (2.89e-8)"	"unprognostic (1.03e-1)"	"unprognostic (4.31e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.20e-1)"	15.9	10.9	15.9	26.4	25.1	20.5	15.0	9.5	14.3	15.4	10.6	23.3	11.8	8.8	15.3	10.2	20.5	14.3	16.3	21.5	16.2	13.2	12.1	14.4	16.1	32.6	23.6	12.4	17.3	13.6	40.4	18.8	13.2	17.5	14.6	11.1	13.7	19.6	10.3	33.3	14.8	12.2	11.7	22.4	18.2	17.1	7.3	24.2	42.2	17.0	14.8	31.0	15.9	18.8	6.5	9.1	20.5	9.2	14.8	7.0	5.1	15.6	10.5	9.2	14.9	6.7	8.6	14.7	18.2	10.9	17.2	15.2	21.0	18.0	34.7	17.4	15.5	7.2	15.6	16.4	10.2	23.2	11.9	9.4	24.1	9.0	16.7	9.6	31.4	51.9	8.7	7.0	19.2	14.8	9.1	13.9	17.2	25.6	12.4	17.8	11.9	32.3	16.8	9.0	8.3	14.8	65.6	39.7	29.5	12.1	14.0	13.5	12.1	46.7	7.1	18.6	11.3	6.4	22.6	19.3	26.7	18.3	15.1	24.4	17.0	30.2	101.5	20.3	21.6	24.0	20.5	7.4	7.4	6.7	9.2	7.0	6.5	6.6	7.0	9.1	6.4	6.3	5.3	4.6	14.8	6.1	3.3	7.0	5.1	15.9	25.1	9.5	14.3	16.2	13.2	23.6	12.4	17.5	24.2	8.9	19.8	29.2	37.0	49.9	4.5	15.4	15.3	13.4	17.0	38.4	11.8	12.1	23.2	14.4	4.4	17.4	7.3	0.0	24.0	26.0	32.1	38.3	26.6	14.0	33.8	9.5	18.2	27.0	43.0	5.7	22.2	46.5	49.0	10.8	12.4	12.3	47.8	5.8	19.8	9.8	14.2	12.9	24.7	13.4	16.3	55.2	14.2	54.9	11.5	52.5
CBL	"c-Cbl, CBL2, RNF55"	ENSG00000110395	"Cbl proto-oncogene"	P22681	11	119206276-119313926	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 40.9"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 11.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004350, HPA027956"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB004350: AB_2244054, HPA027956: AB_10601094"	"unprognostic (2.52e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.92e-1)"	"unprognostic (4.10e-3)"	"unprognostic (9.75e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.03e-2)"	"unprognostic (5.23e-2)"	"unprognostic (5.21e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.12e-1)"	"unprognostic (5.85e-2)"	9.9	5.5	9.1	17.0	11.1	11.1	8.8	10.7	12.0	6.2	7.5	8.7	3.0	5.7	9.9	5.3	7.5	7.4	6.3	5.9	8.0	9.6	5.5	4.0	10.3	16.3	8.1	6.9	6.3	5.6	16.6	4.1	9.1	9.3	5.3	7.5	6.4	5.4	7.1	3.9	7.4	8.6	10.6	8.9	13.3	7.3	32.3	5.1	40.9	6.0	5.5	15.6	7.6	7.7	1.8	3.3	11.8	3.7	0.6	1.9	1.0	6.3	4.8	16.9	10.6	5.1	6.0	10.0	6.9	7.2	6.7	6.6	10.3	7.9	15.1	6.2	8.7	13.8	9.3	11.6	5.9	14.7	8.6	2.7	15.5	3.7	3.1	6.2	18.0	17.7	5.3	6.5	17.0	18.4	7.1	16.5	14.8	12.5	6.3	12.0	6.9	9.6	10.1	8.8	5.7	5.4	10.4	8.5	2.8	5.9	5.1	2.3	7.1	12.8	5.6	4.6	12.1	5.8	15.2	13.7	10.4	7.4	7.2	9.0	2.1	3.1	12.3	4.2	15.6	7.4	0.8	3.2	2.4	1.3	3.7	1.1	1.8	1.6	1.3	3.3	1.8	1.8	1.9	11.8	0.6	3.1	1.8	1.4	1.0	9.1	11.1	10.7	12.0	8.0	9.6	8.1	6.9	9.3	5.1	8.9	8.8	18.8	4.9	16.0	12.4	5.9	7.6	1.4	4.5	10.4	43.2	5.2	1.7	5.8	22.7	17.8	6.3	0.0	5.8	8.0	8.0	6.2	3.5	2.6	15.0	12.7	8.1	19.0	52.9	32.8	7.2	29.9	15.1	5.4	4.3	17.5	8.7	8.6	12.0	3.1	33.8	25.8	17.6	38.1	26.2	19.2	5.8	20.0	4.5	9.5
CBLB	"Cbl-b, RNF56"	ENSG00000114423	"Cbl proto-oncogene B"	Q13191	3	105655461-105869552	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-138 MG: 23.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018327, HPA019880"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"HPA018327: AB_1846097, HPA019880: AB_1846099"	"unprognostic (2.65e-1)"	"unprognostic (9.42e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.38e-1)"	"unprognostic (5.89e-3)"	"unprognostic (2.80e-2)"	"unprognostic (8.18e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.05e-2)"	"unprognostic (1.66e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.43e-2)"	"unprognostic (8.21e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.09e-2)"	38.4	9.0	3.7	19.5	4.9	15.5	16.3	24.4	3.8	13.7	18.7	5.9	7.7	9.3	13.8	12.2	8.3	12.5	13.4	27.5	3.8	4.8	7.4	6.7	16.3	19.1	4.4	1.9	17.7	6.8	3.4	13.5	25.4	7.9	12.9	8.0	11.6	9.1	6.3	10.3	8.5	13.8	25.6	5.7	16.4	12.4	9.2	5.2	11.6	13.5	7.0	18.0	24.9	24.1	5.1	3.1	2.8	2.1	10.3	9.9	1.6	1.6	2.3	7.7	3.8	8.9	9.0	5.0	5.8	2.9	1.7	2.7	2.9	2.0	3.6	4.0	3.0	2.7	2.9	1.0	1.0	2.1	2.8	2.9	2.0	12.0	1.9	13.1	1.4	1.5	8.6	3.1	4.5	12.3	6.4	5.6	3.7	2.1	11.7	3.6	2.1	2.0	0.9	2.7	2.0	3.3	4.2	2.3	0.6	4.1	7.4	6.0	6.5	6.8	0.8	8.9	5.6	1.7	2.9	3.1	23.9	2.0	3.2	1.4	6.6	0.6	5.7	6.4	1.2	1.5	0.7	1.5	2.8	9.9	0.9	8.8	2.2	5.1	5.6	1.3	5.1	4.4	8.0	1.0	10.3	2.1	3.1	5.6	1.6	3.7	4.9	24.4	3.8	3.8	4.8	4.4	1.9	7.9	5.2	14.9	6.7	21.6	6.8	9.6	44.8	39.9	0.0	10.7	6.8	12.2	25.5	8.9	5.0	6.0	27.4	22.6	8.7	0.0	6.9	53.5	21.6	9.6	8.1	6.7	12.2	3.2	12.1	39.3	11.3	9.0	6.9	10.4	15.1	5.4	16.2	7.4	11.7	7.0	10.3	3.1	27.4	6.5	19.9	9.8	15.8	6.0	38.0	52.3	10.7	3.0
CBLC	"CBL-3, CBL-SL, RNF57"	ENSG00000142273	"Cbl proto-oncogene C"	Q9ULV8	19	44777869-44800634	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 66.8"	"Cell type enhanced"	"Detected in many"	8	"Enterocytes: 105.9;Pancreatic endocrine cells: 67.6;Paneth cells: 84.2;Undifferentiated cells: 54.6;Urothelial cells: 56.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 19.0;BEWO: 13.1;CACO-2: 12.9;CAPAN-2: 26.3;HaCaT: 18.4;HBEC3-KT: 16.0;hTCEpi: 12.3;OE19: 16.9;RT4: 16.0;SK-BR-3: 14.6;T-47d: 10.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB008087, HPA035266"	Approved		Approved	Nucleoplasm,Aggresome		NA	NA			Nucleoplasm	Aggresome	"CAB008087: AB_2228531, HPA035266: AB_2674542"	"unprognostic (1.58e-1)"	"unprognostic (2.25e-1)"	"unprognostic (8.21e-3)"	"unprognostic (1.55e-1)"	"unprognostic (3.04e-2)"	"unprognostic (3.91e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.82e-1)"	"unprognostic (7.39e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.85e-1)"	"prognostic favorable (3.11e-6)"	"unprognostic (3.50e-1)"	"unprognostic (8.25e-3)"	"unprognostic (2.90e-2)"	"unprognostic (2.21e-3)"	0.1	0.0	0.5	8.5	0.2	0.0	4.8	0.1	0.4	4.4	39.5	0.1	3.2	29.5	1.7	1.7	22.0	1.4	18.8	0.1	0.6	0.0	4.9	15.1	1.3	0.1	0.1	0.3	0.8	18.1	0.9	0.7	4.1	0.2	6.9	6.9	0.5	11.4	5.2	0.1	20.8	66.8	0.4	0.1	0.1	10.2	1.6	0.1	0.5	1.9	13.2	15.7	7.6	8.9	0.0	0.0	0.0	0.0	0.0	0.8	0.0	19.0	0.0	0.0	0.0	0.0	0.0	13.1	0.0	0.0	0.0	0.0	12.9	26.3	0.0	0.0	0.0	0.0	18.4	0.0	16.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	16.9	0.0	0.0	0.0	0.0	0.0	16.0	0.1	0.0	0.0	14.6	0.0	0.1	10.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.1	0.4	0.6	0.0	0.1	0.3	0.2	0.1	0.0	1.6	0.0	28.6	13.4	0.0	0.2	5.1	5.3	11.4	7.0	0.0	4.6	1.7	37.5	0.0	0.1	105.9	0.0	42.7	1.3	0.4	14.4	0.0	8.5	0.3	0.0	16.7	0.0	0.0	0.0	0.0	0.9	0.0	1.0	35.8	0.0	67.6	84.2	0.0	9.9	0.0	0.0	0.4	0.0	1.7	22.5	2.1	0.7	54.6	56.4
CCDC6	"D10S170, H4, PTC, TPC, TST1"	ENSG00000108091	"Coiled-coil domain containing 6"	Q16204	10	59788763-59906656	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019049, HPA019051"	Enhanced		Supported	Cytosol		No	No			Cytosol		"HPA019049: AB_1846163, HPA019051: AB_1846164"	"unprognostic (1.88e-2)"	"unprognostic (1.72e-2)"	"unprognostic (4.41e-2)"	"unprognostic (1.25e-3)"	"unprognostic (5.98e-3)"	"prognostic favorable (5.48e-4)"	"prognostic unfavorable (1.11e-4)"	"unprognostic (7.39e-2)"	"unprognostic (2.45e-1)"	"unprognostic (2.28e-1)"	"prognostic unfavorable (3.95e-4)"	"unprognostic (4.08e-1)"	"unprognostic (4.69e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.56e-1)"	"unprognostic (9.95e-2)"	"unprognostic (4.19e-2)"	13.7	13.3	22.8	11.7	41.8	12.8	20.7	13.8	27.1	23.0	23.9	11.3	10.7	20.4	28.4	16.6	33.2	23.6	16.2	11.2	17.0	18.1	19.4	10.9	15.5	18.7	13.8	17.6	19.8	22.5	16.8	13.7	13.3	14.5	18.7	18.4	9.6	25.5	14.0	18.2	26.0	20.4	28.1	11.8	14.5	16.6	12.6	12.3	10.6	19.1	14.8	20.7	21.7	23.8	7.1	7.3	0.2	3.4	1.2	2.3	1.4	16.0	14.5	7.3	16.3	11.1	16.8	14.9	7.9	10.5	7.9	9.4	28.2	31.6	13.8	12.0	13.2	4.6	23.9	14.6	14.4	11.9	20.7	7.3	11.2	11.8	17.1	13.5	12.8	10.6	12.1	19.1	13.2	32.5	11.2	11.7	7.9	8.4	8.9	10.3	21.6	5.3	7.4	11.7	15.2	9.9	7.2	12.0	8.7	13.3	13.8	7.5	6.5	10.0	42.1	8.8	9.9	26.7	6.9	11.9	7.4	13.6	11.4	13.2	4.7	5.4	6.3	11.7	24.5	4.6	0.0	2.9	0.0	1.5	3.4	1.8	6.7	2.3	2.1	7.3	7.1	2.2	1.6	0.2	1.2	1.9	1.9	2.1	1.4	22.8	41.8	13.8	27.1	17.0	18.1	13.8	17.6	14.5	12.3	92.3	20.4	12.6	42.6	84.3	14.0	14.2	28.1	20.1	47.8	24.4	39.3	32.1	24.9	42.8	25.1	15.7	40.4	0.0	56.0	14.6	20.6	38.1	27.8	19.1	20.3	15.9	25.9	19.6	29.9	60.3	22.7	22.5	15.1	11.8	37.1	11.8	47.6	17.5	18.4	30.5	42.9	19.4	21.8	2.6	20.8	70.0	22.5	13.4	39.3	38.3
CCNB1IP1	"C14orf18, HEI10"	ENSG00000100814	"Cyclin B1 interacting protein 1"	Q9NPC3	14	20311368-20333312	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Meiosis, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-HME1: 88.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.79e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.37e-2)"	"unprognostic (5.46e-3)"	"unprognostic (2.79e-2)"	"unprognostic (8.43e-2)"	"unprognostic (5.88e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.88e-2)"	"unprognostic (4.87e-2)"	"unprognostic (4.77e-2)"	"prognostic favorable (5.18e-6)"	"unprognostic (2.12e-1)"	"unprognostic (1.54e-2)"	"unprognostic (4.43e-1)"	"unprognostic (1.52e-1)"	12.6	9.7	10.9	9.8	13.7	14.2	27.2	14.5	16.4	20.3	13.4	13.2	17.2	9.9	20.4	24.2	17.4	18.8	12.4	33.8	11.1	11.2	31.2	34.4	15.4	11.2	13.4	11.1	49.1	20.6	14.5	12.1	14.4	15.9	18.0	14.5	15.8	14.0	12.3	20.6	14.6	10.0	27.6	15.8	11.3	13.0	9.7	13.9	11.2	35.8	15.3	16.1	33.6	17.7	9.3	13.7	3.5	3.1	4.4	10.7	3.0	6.7	5.5	31.5	30.2	16.1	22.2	25.4	8.2	16.6	12.7	16.9	18.7	7.5	23.4	5.5	6.0	12.9	12.1	21.8	15.6	17.3	6.7	18.5	13.8	5.2	17.6	47.5	25.4	13.0	30.2	26.4	9.1	88.5	15.5	9.6	28.4	16.8	18.6	8.3	10.7	14.7	17.3	18.9	14.7	10.6	18.2	15.6	9.8	13.3	9.9	25.1	26.1	5.7	13.3	37.0	18.2	4.2	18.7	4.0	7.3	9.3	8.7	10.7	8.7	10.9	16.0	2.4	21.5	8.3	3.5	3.1	0.0	6.7	1.1	9.1	9.3	7.4	8.3	13.7	8.4	7.7	10.7	0.5	4.4	1.1	13.7	9.9	3.0	10.9	13.7	14.5	16.4	11.1	11.2	13.4	11.1	15.9	13.9	26.8	25.6	34.4	63.5	51.6	3.2	25.0	56.0	4.0	18.2	22.7	19.6	34.7	87.9	23.7	47.1	18.0	13.1	0.0	33.0	56.8	32.0	34.6	34.6	30.1	15.8	1.6	39.6	16.5	17.5	58.8	47.8	23.1	49.0	8.2	37.0	24.9	27.7	14.0	41.4	71.2	15.5	45.3	24.0	49.1	59.6	35.0	28.5	27.7	41.7	43.6
CCND1	"BCL1, D11S287E, PRAD1, U21B31"	ENSG00000110092	"Cyclin D1"	P24385	11	69641087-69654474	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation"	"Cyclin, Repressor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Ductal cells: 534.1;Pancreatic endocrine cells: 367.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.0;myeloid DC: 3.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-266/70: 96.3;WM-115: 134.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000024, HPA027802"	Uncertain		Supported	Nucleoplasm		Yes	No			Nucleoplasm		"CAB000024: AB_563678, HPA027802: AB_2672390"	"unprognostic (4.90e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.62e-2)"	"unprognostic (1.39e-2)"	"unprognostic (2.18e-1)"	"prognostic unfavorable (5.51e-4)"	"unprognostic (1.38e-1)"	"unprognostic (2.53e-2)"	"unprognostic (9.46e-2)"	"unprognostic (4.84e-3)"	"prognostic unfavorable (1.96e-4)"	"unprognostic (4.39e-2)"	"unprognostic (2.61e-3)"	"unprognostic (4.38e-3)"	"unprognostic (1.16e-1)"	"unprognostic (6.40e-3)"	"unprognostic (2.57e-1)"	52.0	11.6	9.7	6.0	9.7	0.7	22.8	3.4	7.7	15.4	8.9	15.4	19.9	8.4	18.8	23.1	37.7	11.8	31.0	23.9	10.8	8.8	14.5	68.1	22.2	3.7	12.4	5.6	6.5	31.5	83.2	16.6	38.1	10.0	30.7	6.8	24.8	25.6	21.7	2.0	43.6	10.4	16.5	12.6	12.9	19.2	4.0	7.5	9.0	17.1	23.1	23.6	21.4	22.1	3.0	3.4	0.8	0.0	0.0	0.9	0.3	48.7	19.5	6.5	0.2	20.0	21.1	14.0	77.2	28.8	9.0	5.3	21.9	37.8	0.0	35.1	40.1	15.1	35.7	0.7	21.0	16.2	0.1	3.9	0.0	4.8	22.2	4.8	0.3	0.7	11.9	4.1	12.7	4.9	21.3	15.4	0.0	0.0	0.1	71.0	20.6	0.0	2.8	11.9	20.2	21.5	0.1	20.6	1.1	41.9	30.1	1.1	25.5	0.9	18.3	48.0	16.5	11.1	1.0	64.4	44.3	12.3	19.2	52.4	96.3	57.5	0.1	37.9	0.6	134.1	0.8	0.0	0.0	0.9	0.0	0.1	3.0	0.4	0.2	3.4	2.5	0.8	0.2	0.2	0.0	0.0	0.0	0.0	0.3	9.7	9.7	3.4	7.7	10.8	8.8	12.4	5.6	10.0	7.5	169.7	99.5	5.9	202.5	179.8	2.2	68.0	124.9	78.9	155.8	118.7	2.0	6.4	26.6	534.1	0.2	134.5	22.2	0.0	128.5	1.1	63.9	195.1	27.8	148.1	60.6	0.0	54.3	108.1	18.0	0.9	3.7	17.9	49.0	3.6	40.4	66.7	367.2	54.7	54.1	42.3	2.0	129.4	220.1	0.2	19.0	306.9	2.1	7.0	62.1	326.2
CCND2		ENSG00000118971	"Cyclin D2"	P30279	12	4273772-4305350	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cardiomyocytes: 305.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 32.3;HBEC3-KT: 29.5;HDLM-2: 49.7;Karpas-707: 71.8;RH-30: 47.0;SuSa: 37.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA049138, HPA054196"	Approved		Enhanced	Nucleoplasm		Yes	Yes			Nucleoplasm		"HPA049138: AB_2680650, HPA054196: AB_2682412"	"unprognostic (2.98e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.21e-2)"	"unprognostic (1.65e-2)"	"unprognostic (1.70e-2)"	"unprognostic (4.82e-2)"	"unprognostic (4.94e-2)"	"unprognostic (2.01e-3)"	"unprognostic (3.16e-2)"	"unprognostic (1.66e-2)"	"prognostic favorable (2.52e-4)"	"unprognostic (1.75e-1)"	"unprognostic (1.25e-1)"	"unprognostic (8.23e-2)"	"unprognostic (4.52e-1)"	"prognostic favorable (9.76e-5)"	"unprognostic (7.06e-2)"	13.7	39.3	20.8	12.0	15.9	23.6	10.4	6.1	22.3	14.4	28.3	8.1	24.3	18.5	21.9	41.9	12.2	16.5	9.1	36.9	17.5	7.3	6.0	5.7	12.8	24.5	7.9	17.0	11.6	18.4	8.3	19.2	23.5	9.3	16.4	24.2	14.1	8.3	22.4	2.0	9.2	19.6	45.5	14.0	16.5	11.1	5.2	8.6	6.2	18.5	6.9	13.6	22.3	16.3	3.9	2.1	4.6	1.0	9.1	14.8	5.4	0.0	0.0	32.3	0.0	5.6	0.8	0.0	0.0	0.0	0.0	0.0	13.9	0.0	0.0	0.2	0.0	0.0	4.1	0.9	29.5	0.0	49.7	0.8	0.3	0.0	0.2	0.1	12.6	2.7	10.8	4.9	0.0	22.3	0.2	0.0	0.9	3.4	71.8	6.3	0.0	0.0	16.6	13.3	0.2	0.0	0.0	47.0	23.4	0.0	2.8	0.0	0.0	0.0	0.0	0.0	37.8	0.0	0.1	2.3	0.0	9.4	0.0	0.0	1.2	12.2	0.0	0.1	9.1	0.0	4.1	1.0	4.6	9.1	0.2	13.7	3.9	13.0	11.0	2.1	1.5	8.2	9.8	1.5	9.1	0.1	1.0	14.8	5.4	20.8	15.9	6.1	22.3	17.5	7.3	7.9	17.0	9.3	8.6	56.6	49.3	25.1	24.4	94.8	6.8	305.9	0.0	9.4	43.3	12.2	0.0	2.6	0.0	2.5	0.7	38.4	26.9	46.7	59.7	1.7	135.6	5.7	54.3	0.8	12.0	3.2	62.3	17.8	13.3	0.9	48.6	38.9	37.1	6.4	146.6	155.3	32.6	35.1	116.7	1.0	3.7	25.8	50.5	0.7	3.6	34.6	5.3	61.2	109.0	7.0
CCND3		ENSG00000112576	"Cyclin D3"	P30281	6	41934933-42050357	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 129.2;lymphoid tissue: 142.5"	"Cell type enhanced"	"Detected in all"	5	"Syncytiotrophoblasts: 197.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MOLT-4: 94.2;REH: 89.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000116, HPA042871"	Approved		Supported	Nucleoplasm		NA	Yes			Nucleoplasm		"CAB000116: , HPA042871: "	"unprognostic (4.53e-2)"	"unprognostic (4.45e-2)"	"unprognostic (2.45e-1)"	"unprognostic (4.40e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.40e-2)"	"unprognostic (5.25e-2)"	"unprognostic (7.76e-2)"	"unprognostic (3.45e-1)"	"unprognostic (9.17e-2)"	"unprognostic (6.39e-2)"	"unprognostic (2.45e-3)"	"unprognostic (9.12e-2)"	"unprognostic (1.71e-1)"	"prognostic favorable (8.08e-6)"	"unprognostic (2.11e-1)"	20.2	39.8	16.1	28.9	17.5	74.7	36.0	13.3	19.8	13.3	17.3	11.3	14.1	16.0	10.8	10.4	13.5	13.4	19.0	16.3	15.4	14.5	13.7	8.0	32.1	83.8	14.1	15.5	11.1	10.9	5.0	10.1	21.9	9.3	14.2	11.4	10.2	18.1	14.4	6.5	14.6	22.0	11.7	11.5	51.2	18.0	7.4	10.0	142.5	26.8	9.3	32.8	13.0	16.6	24.1	42.4	129.2	45.8	39.0	52.8	66.2	9.2	33.7	3.5	7.8	6.4	13.2	40.9	10.8	6.2	11.2	8.2	6.3	4.2	39.7	18.4	7.2	10.0	5.7	9.4	13.2	5.8	6.7	6.1	62.9	15.0	5.1	14.1	10.2	55.6	12.5	8.7	10.8	4.1	3.4	13.7	26.7	31.7	3.9	16.0	12.5	94.2	49.4	1.5	28.4	7.2	89.5	13.7	4.4	25.9	6.2	12.0	3.1	9.2	11.8	5.3	4.7	7.3	40.2	22.9	12.5	6.9	10.7	12.1	2.5	2.0	62.1	7.3	21.7	7.5	129.2	30.5	87.7	52.8	35.1	37.0	16.4	36.4	42.5	42.4	24.1	42.8	45.0	42.8	39.0	45.8	27.8	23.2	66.2	16.1	17.5	13.3	19.8	15.4	14.5	14.1	15.5	9.3	10.0	56.6	64.8	78.2	82.2	24.0	9.3	21.8	56.0	16.0	18.2	19.2	5.9	150.0	24.9	17.1	12.1	47.0	34.6	93.5	21.5	66.5	22.6	44.0	25.5	3.9	39.8	11.1	9.2	55.9	111.4	7.4	38.3	68.6	35.4	7.2	16.9	35.9	21.6	28.8	48.8	13.2	14.6	45.3	26.8	1.7	5.7	19.7	197.8	130.7	19.5	56.2
CCNE1	CCNE	ENSG00000105173	"Cyclin E1"	P24864	19	29811898-29824308	"Cancer-related genes, Predicted intracellular proteins"	"Cell cycle, Cell division"	Cyclin	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 23.3;placenta: 46.7"	"Cell type enriched"	"Detected in many"	14	"Extravillous trophoblasts: 1526.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BEWO: 81.6"	"Low region specificity"	"Detected in all"							"CAB000308, CAB016682, HPA018169"	Approved		Enhanced	Nucleoplasm		Yes	Yes			Nucleoplasm		"CAB000308: , CAB016682: AB_1614564, HPA018169: AB_1847384"	"unprognostic (2.90e-3)"	"unprognostic (1.33e-2)"	"unprognostic (1.47e-3)"	"prognostic unfavorable (6.35e-6)"	"unprognostic (5.78e-2)"	"unprognostic (4.77e-2)"	"prognostic unfavorable (3.89e-5)"	"unprognostic (1.26e-3)"	"unprognostic (3.14e-3)"	"prognostic unfavorable (2.97e-4)"	"unprognostic (3.29e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.11e-16)"	"unprognostic (5.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (6.63e-2)"	"unprognostic (1.46e-1)"	1.6	6.8	2.4	4.5	2.9	23.3	0.6	6.3	3.3	0.8	3.0	1.7	1.1	2.3	1.2	0.6	4.7	0.7	2.2	4.4	2.3	2.8	1.2	0.7	1.1	4.6	1.9	1.9	0.9	1.4	1.7	1.0	46.7	2.8	1.1	3.8	1.5	3.2	1.2	2.2	4.4	2.5	3.0	1.7	4.6	2.0	12.3	1.6	4.1	1.6	2.1	5.9	2.7	2.5	2.7	1.6	1.6	1.9	0.0	1.4	0.5	4.1	8.6	6.6	9.4	1.4	1.6	81.6	6.6	1.4	2.9	3.6	8.7	8.4	3.5	15.7	2.9	3.8	1.3	7.8	3.4	4.2	11.1	4.8	2.9	8.4	9.1	1.1	11.5	7.9	1.7	1.9	4.0	0.5	0.9	3.5	3.5	11.8	1.6	4.4	6.2	6.3	3.3	11.0	9.4	2.0	9.5	7.7	2.6	2.2	6.6	5.6	4.7	9.5	11.7	1.0	10.1	2.6	8.6	2.0	6.9	25.9	4.1	4.4	6.6	4.6	23.9	3.9	1.4	3.7	0.0	0.1	0.0	0.6	1.9	1.1	2.7	0.5	0.4	1.6	0.2	0.1	0.9	1.6	0.0	1.9	0.0	1.4	0.5	2.4	2.9	6.3	3.3	2.3	2.8	1.9	1.9	2.8	1.6	0.0	1.1	0.8	1.0	4.2	2.4	2.8	0.0	0.0	2.3	0.0	0.0	112.5	0.0	0.4	7.1	1.1	1.7	0.0	0.6	1526.8	4.8	1.9	0.0	0.0	37.5	3.2	2.9	1.3	0.3	2.6	1.1	1.1	1.7	0.0	2.7	1.8	1.0	2.9	2.1	0.2	0.8	6.5	3.1	14.1	19.5	5.3	96.8	2.2	3.8	2.4
CD274	"B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1"	ENSG00000120217	"CD274 molecule"	Q9NZQ7	9	5450503-5470566	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lung: 23.9;placenta: 56.0"	"Cell type enhanced"	"Detected in many"	14	"granulocytes: 26.7;monocytes: 73.9;Syncytiotrophoblasts: 37.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 8.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 8.4;T-cells: 2.4"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 34.2;HHSteC: 22.8;U-251 MG: 37.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003528, CAB076385"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane, Actin filaments"	Nucleoplasm	"CAB076385: AB_2687655, HPA003528: "	"prognostic favorable (8.89e-4)"	"unprognostic (4.54e-2)"	"prognostic favorable (1.64e-5)"	"unprognostic (1.27e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.61e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.67e-4)"	"unprognostic (7.39e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.67e-1)"	"unprognostic (9.02e-2)"	3.4	2.1	1.7	10.8	3.2	1.4	2.2	2.5	3.3	2.0	2.3	2.5	2.8	2.6	1.7	2.4	3.0	1.9	4.3	9.5	1.4	3.7	3.0	3.6	23.9	6.4	2.3	0.7	1.7	2.7	3.8	7.4	56.0	3.2	2.9	2.2	3.3	1.7	1.6	4.3	1.3	2.7	2.3	2.4	12.8	1.9	1.2	1.0	11.6	3.7	2.1	5.8	3.1	1.9	0.9	0.0	8.4	0.1	0.4	2.4	0.7	5.9	0.1	0.0	0.2	0.0	0.0	0.0	11.9	10.1	3.0	4.2	0.0	1.9	0.0	0.2	0.3	1.5	0.2	0.0	5.2	9.9	34.2	0.0	3.4	0.1	0.0	22.8	0.0	0.0	0.2	0.0	6.3	9.3	3.1	5.9	0.3	0.0	1.1	9.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	1.7	0.3	0.6	0.1	0.0	0.1	0.1	0.9	0.7	0.9	0.0	0.1	10.9	6.5	2.0	0.2	37.9	0.2	0.1	0.1	2.1	0.1	0.0	8.4	0.1	0.3	1.2	0.1	2.1	0.9	2.4	1.8	0.0	0.2	1.3	0.7	5.7	0.4	0.0	0.0	1.1	0.7	1.7	3.2	2.5	3.3	1.4	3.7	2.3	0.7	3.2	1.0	11.9	10.7	0.5	1.2	4.0	1.4	6.5	0.0	4.0	3.4	0.0	0.0	4.9	0.0	6.4	0.2	6.3	0.8	0.0	3.7	20.2	1.9	0.9	26.7	1.0	4.9	0.0	0.0	10.4	1.9	0.0	0.3	7.7	3.3	73.9	0.1	0.6	12.0	0.0	0.4	0.4	0.1	0.0	0.9	0.5	0.7	2.3	37.2	1.3	0.2	2.2
CD74	DHLAG	ENSG00000019582	"CD74 molecule"	P04233	5	150401637-150412929	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 504.7"	"Cell type enhanced"	"Detected in many"	16	"Hofbauer cells: 4588.2;Macrophages: 7133.7;monocytes: 15196.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 191.6;intermediate monocyte: 303.5;memory B-cell: 467.7;myeloid DC: 437.9;naive B-cell: 504.7;non-classical monocyte: 140.0;plasmacytoid DC: 303.2"	"Group enriched"	"Detected in all"	5	"B-cells: 504.7;dendritic cells: 437.9;monocytes: 303.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 118.2;Daudi: 181.9;HDLM-2: 261.1;REH: 157.4;RPMI-8226: 107.2;U-266/70: 87.7;U-698: 100.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002506, HPA010592"	Enhanced		Supported	"Golgi apparatus"		NA	NA		90000	"Golgi apparatus"		"CAB002506: AB_563630, HPA010592: AB_1078482"	"prognostic favorable (1.06e-4)"	"unprognostic (1.48e-2)"	"unprognostic (4.80e-3)"	"prognostic favorable (6.53e-6)"	"unprognostic (1.41e-1)"	"unprognostic (4.53e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.69e-3)"	"unprognostic (1.54e-2)"	"unprognostic (3.48e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.64e-1)"	"unprognostic (5.44e-3)"	"unprognostic (1.73e-1)"	"unprognostic (4.95e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.24e-2)"	137.8	95.7	53.2	177.0	81.4	40.7	104.2	8.4	43.5	89.6	68.2	79.0	30.0	98.3	60.0	73.9	43.6	68.1	81.3	104.1	46.9	43.5	168.3	60.1	222.5	310.1	78.3	23.1	53.4	34.1	15.1	51.0	27.9	79.8	72.6	63.6	72.9	123.0	55.4	40.5	56.6	182.8	55.1	123.1	372.1	77.3	23.7	68.1	201.1	83.4	45.6	288.2	91.7	47.0	504.7	437.9	76.1	303.5	42.2	41.2	238.1	1.9	0.0	0.0	0.1	0.1	0.1	0.7	0.0	0.0	0.0	0.0	23.6	118.2	181.9	7.3	0.0	0.5	0.5	0.0	0.0	0.0	261.1	0.0	5.9	0.1	14.4	0.3	0.4	0.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	72.4	0.0	0.0	0.2	0.8	0.3	0.0	0.0	157.4	0.2	107.2	0.5	7.7	0.3	0.5	0.3	0.2	5.2	1.2	4.8	21.8	0.2	0.6	0.5	0.5	0.2	87.7	9.4	100.8	42.2	8.2	38.5	6.3	191.6	76.1	16.8	303.5	18.7	467.7	14.8	24.8	437.9	504.7	7.8	13.5	16.8	42.2	140.0	303.2	41.2	238.1	53.2	81.4	8.4	43.5	46.9	43.5	78.3	23.1	79.8	68.1	390.1	2012.6	3694.0	133.2	635.9	0.3	57.9	405.1	591.6	683.6	476.3	0.0	29.1	99.5	571.4	6.9	1116.8	170.9	23.3	476.1	19.5	234.4	182.3	395.1	56.2	4588.2	1.6	233.2	353.6	3259.2	11.0	108.4	7133.7	1135.4	15196.0	331.4	14.5	306.9	131.5	16.6	759.6	8.0	161.7	171.2	2.3	7.6	503.4	34.8	370.6	168.2	195.9
CD79A	"IGA, MB-1"	ENSG00000105369	"CD79a molecule"	P11912	19	41877120-41881372	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 125.3;intestine: 43.5;lymphoid tissue: 119.2"	"Cell type enriched"	"Detected in some"	6	"B-cells: 739.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	38	"memory B-cell: 106.4;naive B-cell: 125.3"	"Lineage enriched"	"Detected in many"	41	"B-cells: 125.3"	"Group enriched"	"Detected in some"	24	"Daudi: 159.2;REH: 49.5;U-698: 138.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB000019	Enhanced					NA	NA					"CAB000019: AB_2244527"	"prognostic favorable (8.45e-5)"	"unprognostic (1.63e-3)"	"unprognostic (4.13e-3)"	"unprognostic (1.31e-3)"	"unprognostic (2.02e-1)"	"prognostic favorable (1.18e-5)"	"unprognostic (1.23e-2)"	"unprognostic (8.11e-3)"	"unprognostic (9.41e-3)"	"unprognostic (1.12e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.32e-1)"	"prognostic unfavorable (2.15e-5)"	"unprognostic (6.08e-2)"	"unprognostic (3.39e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.46e-1)"	1.3	0.6	0.5	103.8	0.5	5.4	1.3	0.5	0.5	1.8	6.3	0.1	0.1	4.9	0.6	0.2	4.4	1.0	2.3	0.8	0.5	0.5	2.3	0.9	4.3	114.9	0.5	0.1	0.6	0.6	0.0	0.5	0.5	0.1	1.0	3.4	1.8	13.6	1.2	0.5	0.5	43.5	0.2	0.5	108.1	9.7	0.8	0.1	32.0	2.4	1.9	119.2	6.8	1.0	125.3	3.0	0.7	0.3	0.2	2.3	4.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	159.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.1	0.1	0.9	0.0	0.0	0.0	49.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.0	0.4	0.0	0.0	0.8	0.1	138.6	0.0	4.7	0.0	0.7	0.1	0.5	0.1	0.1	0.0	106.4	0.3	0.1	0.2	125.3	0.4	2.3	0.4	0.2	0.3	3.0	0.8	4.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.1	0.1	0.1	0.0	3.7	739.3	0.4	1.5	0.0	0.2	2.5	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.0	22.3	0.2	0.6	0.2	0.0	0.0	0.8	0.0	0.0	1.8	3.1	0.0	0.3	1.7	131.6	2.8	0.3	0.0	105.8	0.0	0.4	0.6	0.0	0.0	0.4	0.0	0.6	1.3	0.1	6.5	0.6	0.1
CD79B	"B29, IGB"	ENSG00000007312	"CD79b molecule"	P40259	17	63928740-63932354	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 138.8;lymphoid tissue: 56.6"	"Cell type enriched"	"Detected in many"	8	"B-cells: 486.9"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"memory B-cell: 100.6;naive B-cell: 138.8"	"Lineage enriched"	"Detected in many"	6	"B-cells: 138.8"	"Cell line enhanced"	"Detected in some"		"Daudi: 117.7;REH: 38.7;U-698: 161.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA009178, CAB009751, HPA044107"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"CAB009751: AB_2275844, HPA009178: AB_1078483, HPA044107: "	"unprognostic (3.90e-3)"	"unprognostic (1.61e-3)"	"unprognostic (5.21e-2)"	"unprognostic (3.45e-3)"	"unprognostic (4.22e-3)"	"prognostic favorable (2.35e-4)"	"unprognostic (1.82e-1)"	"unprognostic (9.25e-3)"	"unprognostic (3.89e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.87e-2)"	"unprognostic (2.50e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.44e-1)"	"unprognostic (4.28e-2)"	"unprognostic (2.75e-1)"	1.7	0.7	0.4	50.6	0.4	11.1	1.2	0.3	0.4	0.6	1.7	0.3	0.3	0.7	0.6	0.5	2.6	0.6	1.4	3.4	0.4	0.2	2.3	1.7	1.3	56.6	0.4	0.3	0.6	1.6	0.0	9.0	0.5	0.3	1.0	1.3	0.8	8.9	0.9	1.2	0.9	22.4	0.5	0.4	56.0	1.8	0.6	0.3	3.7	1.4	1.7	46.6	4.5	0.9	138.8	4.2	0.5	25.0	3.4	9.2	9.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	6.5	0.0	0.0	0.0	2.5	0.0	0.0	0.0	38.7	0.1	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	1.8	0.1	0.0	0.4	0.0	0.0	5.9	5.7	161.1	0.0	0.2	0.0	0.5	1.1	0.0	4.2	16.5	4.8	100.6	5.4	2.8	4.2	138.8	3.7	2.2	0.5	3.4	25.0	0.6	9.2	9.0	0.4	0.4	0.3	0.4	0.4	0.2	0.4	0.3	0.3	0.3	0.0	2.2	486.9	0.3	3.9	0.0	0.8	2.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	7.1	0.0	23.3	0.0	0.4	4.3	0.3	15.0	0.5	4.7	0.0	1.2	62.0	14.1	1.1	1.1	3.5	20.3	1.0	0.0	0.0	0.0	0.0	1.8	0.8	0.0	0.0	3.3	0.7	0.1	2.8	0.3	34.6	0.0	0.1
CDC73	"C1orf28, FIHP, HRPT1, HRPT2, parafibromin"	ENSG00000134371	"Cell division cycle 73"	Q6P1J9	1	193121997-193253901	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Transcription, Transcription regulation, Wnt signaling pathway"		"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002326, CAB016359, HPA069324"	Supported		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB016359: AB_628102, HPA002326: , HPA069324: "	"unprognostic (4.41e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.30e-2)"	"unprognostic (2.88e-3)"	"unprognostic (3.53e-2)"	"unprognostic (2.48e-3)"	"unprognostic (5.74e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.40e-1)"	"unprognostic (7.23e-3)"	"unprognostic (2.17e-1)"	"unprognostic (5.44e-3)"	"unprognostic (3.47e-1)"	"unprognostic (2.49e-1)"	"unprognostic (6.73e-3)"	"unprognostic (2.98e-3)"	23.4	20.0	18.1	16.8	22.9	21.0	20.1	25.6	22.6	20.4	20.1	14.5	16.3	12.0	26.8	15.2	20.6	14.9	16.4	21.4	18.4	15.0	18.8	17.1	17.2	16.6	19.7	15.9	23.3	14.5	27.1	24.8	17.3	19.4	26.9	16.2	13.6	17.3	19.0	44.5	15.0	14.5	25.6	23.9	16.0	15.7	16.3	22.1	20.6	27.1	14.1	15.8	26.8	35.0	6.6	6.7	10.2	7.0	9.0	12.5	5.2	13.4	12.1	16.0	10.3	15.0	14.6	12.3	14.5	14.1	17.6	15.4	8.3	16.0	17.5	10.3	17.8	9.7	13.2	14.5	13.7	21.5	11.1	6.9	12.7	10.9	8.0	14.1	17.2	12.7	11.9	13.3	16.5	15.8	15.6	14.9	10.0	19.2	14.2	23.5	12.4	14.1	8.5	15.4	19.8	4.5	12.6	9.7	16.7	20.6	9.4	4.8	13.2	18.1	22.4	20.7	18.6	19.2	12.5	16.6	17.1	4.0	14.5	14.8	13.3	9.9	14.4	10.3	10.6	29.9	6.6	7.0	10.2	9.3	6.8	12.5	6.6	9.2	9.2	6.7	5.4	8.4	8.7	7.4	9.0	5.7	4.9	9.3	5.2	18.1	22.9	25.6	22.6	18.4	15.0	19.7	15.9	19.4	22.1	32.8	20.1	34.3	31.1	33.1	31.2	36.4	20.4	20.1	19.4	31.4	33.4	21.8	28.2	29.4	11.9	30.1	16.2	23.3	28.5	34.0	29.2	33.5	39.4	14.3	28.0	20.6	10.9	22.1	25.9	6.1	31.1	38.8	27.0	47.7	15.3	33.5	28.2	13.1	33.9	26.4	36.3	25.8	57.1	56.5	32.0	30.6	31.8	29.8	16.1	23.2
CDH1	"CD324, UVO, uvomorulin"	ENSG00000039068	"Cadherin 1"	P12830	16	68737225-68835548	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 125.5"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"myeloid DC: 2.8;plasmacytoid DC: 8.5"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 8.5"	"Cell line enhanced"	"Detected in some"		"BEWO: 107.1;CACO-2: 36.0;CAPAN-2: 50.3;HaCaT: 48.6;hTCEpi: 34.3;MCF7: 29.7;OE19: 31.7;RT4: 37.0;T-47d: 32.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857"	Enhanced		Supported	"Golgi apparatus,Plasma membrane,Cell Junctions"		NA	NA		22000000	"Plasma membrane, Cell Junctions"	"Golgi apparatus"	"CAB000087: AB_2533003, CAB028364: AB_2076812, CAB072855: AB_2665698, CAB072856: AB_2665699, CAB072857: AB_2665700, HPA004812: AB_1078369"	"unprognostic (3.95e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.78e-1)"	"unprognostic (5.04e-3)"	"unprognostic (1.63e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.85e-1)"	"unprognostic (1.19e-2)"	"unprognostic (3.61e-1)"	"prognostic favorable (2.06e-4)"	"unprognostic (1.21e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.51e-1)"	"unprognostic (5.92e-2)"	1.1	0.7	1.3	14.8	1.5	0.5	15.3	0.8	1.1	14.4	63.8	1.8	42.4	25.5	4.7	18.6	48.5	9.7	48.9	0.8	1.5	1.0	24.2	64.9	24.4	0.5	1.8	0.9	5.6	71.5	62.2	13.2	55.2	2.8	28.9	25.9	11.8	66.6	43.7	0.8	30.5	125.5	1.5	1.1	3.5	21.6	2.1	1.8	11.7	83.0	26.2	32.6	16.8	21.7	0.0	8.5	0.0	0.0	0.3	0.4	0.1	21.6	2.2	0.0	0.0	0.0	0.0	107.1	0.0	0.0	0.0	0.0	36.0	50.3	0.0	0.4	0.0	0.0	48.6	0.0	24.1	0.0	4.2	0.6	0.0	0.1	7.7	0.0	0.0	0.2	0.0	34.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.7	0.0	0.1	0.8	31.7	0.1	0.0	0.0	0.3	8.8	37.0	1.3	0.1	0.2	0.0	9.1	15.2	32.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	2.8	0.0	0.0	0.0	0.0	0.3	0.0	8.5	0.1	0.1	1.3	1.5	0.8	1.1	1.5	1.0	1.8	0.9	2.8	1.8	122.1	58.7	0.9	101.9	83.6	0.0	0.8	152.8	73.6	64.8	155.3	0.0	97.3	1.7	107.7	0.0	1.2	202.1	0.0	98.3	22.3	4.1	170.0	1.1	44.7	10.1	0.0	83.2	0.6	1.5	0.0	0.3	6.3	50.6	5.4	180.9	0.0	193.9	160.9	0.4	3.3	0.0	0.0	4.7	0.0	0.1	114.9	42.2	0.0	125.1	204.2
CDH11	"CAD11, OB"	ENSG00000140937	"Cadherin 11"	P55287	16	64943753-65126112	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Deafness, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 71.0"	"Group enriched"	"Detected in many"	5	"Fibroblasts: 97.0;Ito cells: 32.5;Leydig cells: 48.6;Muller glia cells: 51.3;Peritubular cells: 72.9;Sertoli cells: 25.8;Smooth muscle cells: 24.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 48.0;BJ hTERT+: 27.9;fHDF/TERT166: 65.6;HSkMC: 45.2;PC-3: 56.5;U-2197: 38.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013072	Enhanced					NA	NA		70000			"CAB013072: AB_2533068"	"unprognostic (1.77e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.93e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.02e-1)"	"unprognostic (6.96e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.09e-1)"	"unprognostic (2.30e-2)"	"unprognostic (3.74e-2)"	"unprognostic (6.75e-2)"	"prognostic unfavorable (2.48e-9)"	"unprognostic (1.43e-3)"	"unprognostic (3.20e-2)"	"unprognostic (1.26e-1)"	"unprognostic (5.07e-3)"	8.1	3.6	5.5	9.2	12.1	0.3	6.1	5.5	8.8	24.1	4.3	7.5	2.4	2.7	25.9	5.9	3.0	6.8	22.4	4.6	7.3	5.1	4.8	1.0	20.8	5.9	7.8	8.5	71.0	1.7	1.2	6.0	44.2	8.3	8.0	4.9	22.2	7.3	9.7	2.5	5.7	3.4	20.5	10.6	35.1	5.1	4.0	5.4	0.1	4.8	1.9	4.9	18.4	11.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	10.4	0.0	7.4	16.3	0.0	48.0	27.9	12.4	7.1	0.9	0.0	0.0	0.0	65.6	0.0	0.0	0.0	0.3	8.9	0.0	0.4	0.0	0.2	0.0	6.2	0.0	2.9	45.2	0.0	15.1	3.0	0.0	3.5	0.0	0.0	0.0	6.6	0.0	0.0	0.0	3.8	7.2	56.5	0.1	7.5	0.0	0.0	0.0	0.1	7.2	0.0	0.0	0.0	13.7	0.0	0.0	0.0	25.6	3.5	38.6	13.6	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	12.1	5.5	8.8	7.3	5.1	7.8	8.5	8.3	5.4	3.0	0.0	0.0	1.1	3.4	11.0	2.8	2.5	0.0	4.5	0.0	0.0	1.8	0.0	0.0	2.4	9.0	0.0	0.0	0.0	1.4	97.0	0.8	0.0	0.0	4.2	0.0	0.0	32.5	0.0	3.1	48.6	1.1	5.0	0.0	0.0	51.3	0.6	0.0	72.9	1.0	1.1	25.8	24.7	0.6	1.1	2.8	4.7	0.0	0.0	0.4
CDK12	"CRK7, CRKR, CRKRS, KIAA0904"	ENSG00000167258	"Cyclin dependent kinase 12"	Q9NYV4	17	39461511-39564907	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 87.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008038, HPA073305"	Supported		Enhanced	"Nucleoplasm,Nuclear speckles"		NA	NA			"Nucleoplasm, Nuclear speckles"		"HPA008038: AB_1078570, HPA073305: "	"unprognostic (2.02e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.19e-1)"	"unprognostic (2.56e-3)"	"unprognostic (2.37e-2)"	"unprognostic (3.86e-2)"	"unprognostic (3.00e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.86e-1)"	"unprognostic (3.06e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.22e-2)"	"unprognostic (5.32e-1)"	16.0	13.1	12.4	17.4	9.2	32.4	14.0	23.4	17.8	18.2	17.6	9.6	15.7	11.1	15.7	12.0	16.9	12.2	12.5	11.0	10.1	6.7	10.2	18.5	13.5	15.2	10.9	14.3	17.4	11.3	19.0	12.2	18.4	9.5	12.7	11.7	10.4	15.6	11.1	11.1	17.0	16.5	11.0	10.6	16.3	11.8	18.9	8.3	29.0	15.0	5.4	17.3	16.3	20.5	5.1	4.0	10.4	2.9	6.6	4.0	0.9	8.9	11.1	6.7	6.2	4.9	5.5	6.2	8.1	6.9	11.1	8.3	13.6	5.5	12.7	7.1	8.5	11.3	14.6	13.3	10.2	10.8	8.3	11.4	13.7	7.5	10.5	4.8	18.7	9.6	5.9	7.1	13.5	10.7	4.6	6.7	7.7	23.2	8.4	6.3	4.2	15.3	4.8	7.0	4.4	5.0	10.1	14.4	7.2	4.2	10.7	7.2	4.6	10.3	87.5	7.0	10.1	11.2	8.1	7.2	10.1	8.1	7.0	10.4	6.9	4.9	17.9	7.2	7.9	6.6	10.4	2.9	4.1	4.0	2.2	3.0	2.9	2.5	2.7	1.8	5.1	2.9	2.7	9.7	6.6	1.8	4.0	2.0	0.9	12.4	9.2	23.4	17.8	10.1	6.7	10.9	14.3	9.5	8.3	23.8	26.1	37.7	45.0	57.5	45.4	12.1	35.7	29.4	40.9	36.6	60.9	27.7	11.6	24.4	15.9	29.6	32.0	23.3	23.8	24.7	35.7	62.9	27.8	38.9	23.9	33.4	29.9	27.6	37.0	14.0	34.5	34.5	25.3	27.9	26.9	31.5	36.1	31.6	31.8	12.9	67.7	32.3	33.0	113.1	90.5	60.3	48.7	42.9	28.8	77.9
CDK4	PSK-J3	ENSG00000135446	"Cyclin dependent kinase 4"	P11802	12	57747727-57756013	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in all"	10	"HBEC3-KT: 128.1;LHCN-M2: 141.4;RH-30: 445.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006024, CAB013116, CAB069405"	Supported		Supported	"Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Nuclear membrane, Nucleoli"	"CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: AB_2667497"	"unprognostic (8.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (5.27e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (2.09e-7)"	"unprognostic (7.39e-2)"	"unprognostic (3.23e-3)"	"unprognostic (2.93e-2)"	"unprognostic (3.19e-2)"	"unprognostic (9.10e-2)"	"prognostic unfavorable (3.15e-5)"	"unprognostic (3.32e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.57e-2)"	32.2	43.1	13.8	22.2	15.7	24.0	45.0	13.1	17.9	36.3	28.2	20.1	22.8	15.2	51.4	28.1	29.9	31.0	32.3	27.4	14.5	12.1	24.0	36.9	26.8	26.4	18.3	13.7	61.4	54.4	18.9	34.2	25.0	16.0	37.2	26.9	26.2	29.3	24.1	27.8	25.6	20.7	34.1	13.5	27.2	23.9	24.6	17.5	29.2	54.3	32.1	27.5	33.6	30.9	29.6	25.5	2.6	19.9	15.8	32.1	22.2	9.5	11.1	14.6	13.0	13.4	11.8	9.8	5.5	18.0	24.4	20.2	15.8	9.1	13.9	10.0	8.6	14.4	7.4	20.2	128.1	18.5	6.8	9.3	13.0	7.5	11.1	15.7	14.7	9.0	11.6	9.4	14.9	17.2	16.6	15.6	13.3	13.8	12.0	141.4	13.9	14.1	12.0	17.2	10.0	11.2	12.6	445.0	12.9	7.6	15.1	13.3	12.4	9.8	7.4	14.7	10.5	9.8	17.9	7.1	11.4	10.8	12.9	11.1	6.0	9.7	21.4	10.5	13.7	13.7	1.7	14.3	2.6	26.2	19.9	27.0	29.6	23.1	23.7	21.0	28.1	32.1	28.5	1.2	15.8	12.0	25.5	16.6	22.2	13.8	15.7	13.1	17.9	14.5	12.1	18.3	13.7	16.0	17.5	20.8	25.0	32.0	62.9	79.7	15.3	0.5	48.4	4.0	23.9	45.4	9.8	64.6	59.7	71.7	10.1	44.2	11.3	23.3	53.6	108.9	77.4	41.8	68.1	32.1	111.7	17.5	43.8	34.4	23.2	6.8	59.2	34.0	50.6	54.1	33.5	51.3	55.4	7.0	59.4	66.3	15.3	32.3	54.2	25.9	40.3	75.3	39.1	34.1	78.3	32.5
CDK6	PLSTIRE	ENSG00000105810	"Cyclin dependent kinase 6"	Q00534	7	92604921-92836594	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 74.6"	"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 219.8;Late spermatids: 186.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"MOLT-4: 93.5;REH: 45.7"					"Low region specificity"	"Detected in all"			"HPA002637, CAB004363"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB004363: AB_627242, HPA002637: AB_1846432"	"unprognostic (1.29e-1)"	"unprognostic (5.98e-3)"	"unprognostic (9.07e-2)"	"unprognostic (2.78e-3)"	"unprognostic (2.56e-2)"	"unprognostic (3.24e-2)"	"unprognostic (3.39e-1)"	"unprognostic (2.42e-3)"	"unprognostic (7.19e-2)"	"unprognostic (7.78e-3)"	"prognostic unfavorable (3.86e-6)"	"unprognostic (4.06e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.09e-1)"	"unprognostic (7.88e-2)"	"unprognostic (1.93e-1)"	"prognostic unfavorable (2.33e-5)"	6.6	11.3	6.0	9.1	7.5	22.5	5.9	2.4	6.0	7.8	10.0	9.6	5.7	7.5	6.0	5.9	8.5	4.6	7.8	6.6	6.9	4.2	6.5	7.5	7.3	7.4	7.0	5.2	5.0	10.0	25.7	4.2	20.5	7.5	6.1	9.2	4.4	10.9	6.1	2.0	11.6	9.4	9.8	7.5	6.3	10.8	5.4	8.0	74.6	4.3	9.2	10.3	6.7	9.0	3.6	5.6	6.5	4.8	3.9	7.1	2.3	6.2	2.9	8.0	5.1	2.3	2.6	1.7	6.4	4.0	3.2	3.0	7.8	4.8	4.8	3.7	4.3	2.0	3.8	4.4	9.2	7.6	10.5	3.1	12.0	5.5	7.5	1.4	7.4	0.6	2.6	5.0	4.3	20.4	3.0	1.2	19.6	11.5	13.3	5.7	1.2	93.5	0.8	2.5	7.9	2.6	45.7	28.1	8.1	4.4	0.1	4.2	27.3	0.7	2.2	3.7	6.1	0.1	12.3	4.7	10.5	16.5	4.1	12.9	7.1	0.1	6.4	1.5	25.5	13.9	4.9	1.9	6.5	5.2	3.9	5.9	2.0	5.5	5.6	4.0	3.6	7.1	4.0	1.1	3.9	4.8	5.6	2.8	2.3	6.0	7.5	2.4	6.0	6.9	4.2	7.0	5.2	7.5	8.0	23.8	3.0	11.9	19.5	53.5	0.2	14.8	25.5	4.0	27.3	21.0	0.0	42.7	8.3	31.7	219.8	24.1	11.0	0.0	20.1	3.4	21.6	18.1	24.3	18.4	15.0	0.0	16.1	7.4	23.4	186.0	4.6	21.9	18.6	20.8	46.7	0.5	63.1	14.0	3.2	5.1	0.0	6.5	22.1	2.6	46.4	44.2	14.8	20.3	68.3	23.3
CDKN1B	"KIP1, P27KIP1"	ENSG00000111276	"Cyclin dependent kinase inhibitor 1B"	P46527	12	12715058-12722371	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle"	"Protein kinase inhibitor"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Muller glia cells: 157.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003691, CAB021888, HPA059086"	Approved		Supported	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"CAB003691: AB_425362, CAB021888: , HPA059086: AB_2683900"	"unprognostic (5.67e-2)"	"unprognostic (9.76e-2)"	"prognostic favorable (5.15e-4)"	"unprognostic (6.90e-3)"	"unprognostic (5.84e-3)"	"unprognostic (1.03e-2)"	"prognostic unfavorable (3.25e-4)"	"unprognostic (4.04e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.85e-3)"	"unprognostic (9.23e-3)"	"unprognostic (2.96e-1)"	"prognostic unfavorable (8.39e-4)"	"unprognostic (1.23e-1)"	"unprognostic (8.68e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.15e-1)"	29.8	30.9	30.2	25.0	30.0	40.2	45.3	64.5	50.6	31.6	34.4	35.6	19.9	29.2	33.1	19.8	26.0	24.3	24.3	21.2	33.0	29.5	20.8	23.3	29.2	38.5	42.9	25.1	46.2	15.1	22.2	15.9	26.8	26.3	25.1	22.2	31.4	23.5	24.2	48.8	26.1	26.4	19.4	46.0	34.3	19.4	19.2	39.0	43.0	29.4	21.4	25.5	34.1	29.1	6.2	3.3	19.2	4.5	6.2	10.6	2.9	12.4	6.2	33.2	5.8	11.4	6.5	16.3	11.7	18.6	16.2	20.0	17.7	14.1	0.1	4.4	6.6	5.8	11.9	15.5	5.7	14.5	21.1	11.0	9.7	17.1	17.8	15.3	8.2	6.9	7.1	12.4	5.3	15.6	38.1	9.6	18.8	10.4	35.5	5.7	15.9	11.5	11.8	13.3	10.8	5.8	8.5	10.8	20.9	7.8	13.5	12.6	20.7	16.8	12.1	21.9	12.4	6.4	18.5	6.5	8.0	12.8	7.2	11.3	30.8	20.3	11.2	10.0	12.4	7.7	4.5	3.1	6.8	5.4	3.1	5.6	6.2	6.9	6.5	3.2	4.8	7.4	5.2	19.2	6.2	4.5	3.3	10.6	2.9	30.2	30.0	64.5	50.6	33.0	29.5	42.9	25.1	26.3	39.0	41.7	24.0	37.6	14.6	46.8	43.1	37.8	20.4	48.2	27.3	8.7	25.5	36.5	13.3	8.0	57.9	56.5	24.9	23.3	8.0	38.1	31.0	32.5	30.1	26.7	22.7	9.5	43.9	46.6	57.3	37.2	51.8	41.9	70.9	14.4	35.8	157.6	10.4	17.5	25.1	12.1	25.0	90.5	40.9	7.7	4.9	45.9	32.6	76.1	40.2	13.6
CDKN2A	"ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf"	ENSG00000147889	"Cyclin dependent kinase inhibitor 2A"	"P42771, Q8N726"	9	21967753-21995301	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway"	DNA-binding	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 22.6;pituitary gland: 39.3"	"Cell type enhanced"	"Detected in many"	13	"Early spermatids: 178.1;Late spermatids: 275.2;Pancreatic endocrine cells: 259.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 22.6"	"Group enriched"	"Detected in many"	8	"B-cells: 7.2;T-cells: 22.6"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 50.2;HEK 293: 56.9;HeLa: 53.2;SK-MEL-30: 53.1"					"Low region specificity"	"Detected in some"			"CAB000093, CAB000445, CAB018232, HPA047838"	Enhanced		Supported	Nucleoli		NA	NA			Nucleoli		"CAB000093: AB_442119, CAB000445: , CAB018232: AB_785018, HPA047838: AB_2680174"	"unprognostic (3.41e-2)"	"unprognostic (4.51e-2)"	"unprognostic (3.00e-3)"	"prognostic unfavorable (1.82e-7)"	"unprognostic (5.22e-2)"	"prognostic favorable (5.19e-4)"	"prognostic unfavorable (2.17e-4)"	"unprognostic (1.25e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.56e-2)"	"prognostic unfavorable (5.76e-7)"	"unprognostic (9.41e-2)"	"unprognostic (1.22e-2)"	"unprognostic (3.05e-2)"	"unprognostic (3.55e-1)"	5.4	8.6	2.9	4.5	3.9	1.8	5.3	1.7	3.1	1.2	2.5	4.4	0.1	1.2	1.2	1.9	6.3	3.0	2.6	0.7	1.7	1.0	0.9	1.2	3.0	3.0	3.6	1.6	1.5	1.5	8.5	39.3	6.7	5.0	1.9	1.1	1.2	2.4	2.9	0.9	1.3	3.7	1.0	3.0	8.9	6.0	13.0	1.9	3.9	1.4	3.0	14.0	2.7	1.5	7.2	0.2	0.8	1.8	0.4	22.6	2.2	2.1	0.0	0.3	14.1	0.1	0.1	6.1	2.3	0.0	19.7	35.1	3.5	50.2	7.2	32.3	1.6	0.0	6.0	5.9	36.5	15.9	31.0	56.9	0.0	53.2	2.3	1.5	3.6	3.0	3.8	0.0	19.8	11.0	42.3	2.0	0.0	0.0	33.0	18.0	0.1	0.3	0.0	0.4	4.0	29.3	0.0	13.4	26.5	4.0	0.0	33.1	2.3	38.2	6.3	53.1	1.7	7.5	0.1	6.6	0.1	0.4	0.0	0.1	14.7	8.3	29.5	0.0	9.5	0.1	0.8	1.3	0.2	6.2	0.6	9.7	7.2	8.0	11.0	0.2	7.0	0.5	4.7	0.4	0.4	1.8	0.0	22.6	2.2	2.9	3.9	1.7	3.1	1.7	1.0	3.6	1.6	5.0	1.9	0.0	0.0	1.5	0.7	1.5	0.2	4.0	0.0	14.7	1.2	10.4	0.0	20.9	0.0	32.4	178.1	2.2	6.9	0.0	22.9	52.3	3.6	10.0	4.6	0.0	6.6	0.0	68.2	0.6	8.2	275.2	2.8	1.8	8.5	26.2	6.2	0.8	259.8	10.5	1.8	0.0	0.0	0.0	1.0	5.7	4.1	0.4	7.7	12.5	2.3	34.0
CDKN2C	"INK4C, p18"	ENSG00000123080	"Cyclin dependent kinase inhibitor 2C"	P42773	1	50960745-50974633	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Erythroid cells: 70.0;Sertoli cells: 84.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-937: 53.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB005303, CAB018398, HPA019057, HPA019764"	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB005303: AB_2078729, CAB018398: AB_2078731, HPA019057: AB_1854865, HPA019764: AB_1854866"	"unprognostic (4.07e-2)"	"unprognostic (1.47e-3)"	"unprognostic (2.89e-1)"	"unprognostic (4.86e-2)"	"unprognostic (6.70e-2)"	"unprognostic (4.76e-3)"	"prognostic unfavorable (1.58e-4)"	"unprognostic (1.59e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.28e-1)"	"unprognostic (2.38e-1)"	"prognostic unfavorable (1.70e-10)"	"unprognostic (2.55e-2)"	"unprognostic (2.12e-1)"	"unprognostic (6.45e-2)"	"unprognostic (1.24e-1)"	42.1	12.6	5.9	10.7	7.9	14.9	31.7	4.3	5.7	13.1	13.0	8.7	7.7	6.6	17.1	13.9	11.5	8.4	13.7	20.1	5.7	3.1	7.4	3.3	7.9	11.0	13.7	5.3	22.5	9.4	23.1	5.7	3.1	3.9	10.3	5.7	6.0	5.4	12.2	9.2	8.5	7.9	15.1	7.5	8.5	5.3	5.3	8.9	54.2	8.0	4.9	9.8	17.4	21.7	3.4	7.4	12.2	2.5	6.0	14.1	3.8	14.0	5.8	1.1	19.4	20.0	2.9	0.2	13.4	13.6	22.5	19.8	0.3	4.8	27.6	12.1	11.4	8.2	1.7	13.0	1.7	11.1	16.7	17.5	20.9	44.3	3.5	1.0	14.5	9.6	1.0	0.3	6.1	2.6	8.5	5.9	22.9	9.4	0.0	13.0	3.5	18.7	7.0	0.0	5.3	14.2	22.3	18.3	0.0	7.1	5.9	9.8	23.0	18.3	12.8	4.3	0.1	6.3	49.3	4.7	25.8	10.0	15.6	0.2	28.3	26.9	22.7	0.0	53.0	22.8	12.2	2.5	11.0	5.2	1.4	6.0	3.4	7.7	6.8	6.1	1.9	4.3	4.1	0.2	6.0	0.6	7.4	14.1	3.8	5.9	7.9	4.3	5.7	5.7	3.1	13.7	5.3	3.9	8.9	0.0	4.6	5.3	2.5	9.0	4.2	12.5	2.5	2.7	2.3	3.5	15.7	1.1	14.9	3.3	3.6	5.3	3.9	70.0	3.1	11.0	20.6	2.5	16.1	6.0	22.5	4.8	8.1	17.2	19.7	5.3	36.5	11.2	6.8	24.4	4.8	27.8	4.0	4.0	44.9	26.6	9.7	84.1	18.6	5.1	6.8	9.8	1.6	33.8	3.9	1.0
CDX2	CDX3	ENSG00000165556	"Caudal type homeobox 2"	Q99626	13	27962137-27971139	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"intestine: 21.2"	"Group enriched"	"Detected in some"	7	"Enterocytes: 190.4;Intestinal endocrine cells: 60.0;Mucus-secreting cells: 200.2;Paneth cells: 129.8;Undifferentiated cells: 183.4"	"Cancer enriched"	"Detected in many"	6	"colorectal cancer: 63.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"CACO-2: 14.7;CAPAN-2: 4.9;HEK 293: 8.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB002221, HPA045669, HPA049580"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB002221: AB_563649, HPA045669: AB_2679413, HPA049580: AB_2680823"		"unprognostic (1.42e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.92e-1)"		"unprognostic (8.11e-3)"	"unprognostic (4.19e-6)"	"unprognostic (1.73e-4)"		"unprognostic (1.71e-1)"	"unprognostic (1.58e-1)"	"unprognostic (5.51e-2)"		"unprognostic (6.07e-3)"	"unprognostic (1.13e-1)"		"unprognostic (1.09e-1)"	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	21.2			13.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	1.6	0.0	0.0	0.0		0.1	14.3		0.0	0.0	0.0	0.0	16.3	0.3	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	14.7	4.9	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	8.1	0.0	0.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	2.3	0.0	20.8	0.0	0.0	190.4	0.0	0.6	0.3	0.0	0.2	0.0	0.0	0.4	0.0	60.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	200.2	0.0	1.1	129.8	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	183.4	0.1
CEBPA	"C/EBP-alpha, CEBP"	ENSG00000245848	"CCAAT/enhancer binding protein alpha"	P49715	19	33299934-33302564	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 52.3;liver: 44.3"	"Cell type enhanced"	"Detected in many"	10	"Hepatocytes: 84.7;Hofbauer cells: 76.1;Suprabasal keratinocytes: 150.2;Syncytiotrophoblasts: 177.5"	"Cancer enhanced"	"Detected in all"		"liver cancer: 70.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 11.0;non-classical monocyte: 11.8"	"Group enriched"	"Detected in many"	13	"dendritic cells: 4.1;granulocytes: 11.0;monocytes: 11.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 43.5;Hep G2: 23.3;NB-4: 24.0;THP-1: 86.8;U-937: 27.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA052734, HPA065037, HPA067937"	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA052734: AB_2681931, HPA065037: AB_2685410, HPA067937: AB_2685927"	"unprognostic (1.80e-1)"	"unprognostic (7.62e-3)"	"unprognostic (2.09e-3)"	"unprognostic (2.21e-2)"	"unprognostic (3.38e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.43e-3)"	"unprognostic (5.95e-2)"	"unprognostic (3.96e-2)"	"unprognostic (3.09e-1)"	"unprognostic (9.45e-2)"	"unprognostic (8.02e-3)"	"unprognostic (2.19e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.49e-2)"	"unprognostic (2.72e-2)"	40.7	1.5	2.3	7.6	4.6	8.4	52.3	2.1	4.0	3.5	9.0	5.2	1.1	9.0	2.2	2.1	6.1	2.4	6.4	6.6	3.9	2.4	2.0	44.3	39.9	10.3	4.1	3.1	1.3	9.0	4.5	1.7	17.4	2.7	3.8	5.1	1.9	5.6	1.6	15.4	23.7	12.7	2.9	6.6	3.0	3.5	1.2	2.6	2.2	2.5	10.7	3.5	5.4	7.9	0.1	4.1	11.0	11.8	0.0	0.6	1.5	0.5	1.1	0.0	1.5	12.5	0.0	43.5	0.0	0.3	0.0	0.0	5.3	0.0	0.0	0.6	0.0	0.2	2.0	1.2	0.1	0.0	7.5	1.5	0.0	0.0	23.3	0.2	7.6	9.3	0.5	5.6	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	2.6	0.0	24.0	1.1	13.1	0.6	0.0	0.0	0.2	0.0	3.8	0.0	0.3	0.1	0.1	0.1	1.4	3.0	86.8	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	27.8	0.0	11.0	6.0	0.0	0.6	9.4	0.6	0.0	0.1	0.4	4.1	0.1	0.2	0.4	2.1	0.0	11.8	0.2	0.0	1.5	2.3	4.6	2.1	4.0	3.9	2.4	4.1	3.1	2.7	2.6	14.9	27.8	1.4	20.5	33.2	0.7	0.4	25.5	6.7	5.7	0.0	0.0	27.5	3.3	0.6	0.0	0.6	62.2	0.0	5.0	35.2	6.1	11.7	1.1	84.7	76.1	0.0	4.1	1.3	21.4	0.0	2.8	23.2	5.0	1.0	22.1	8.0	2.1	31.3	1.4	3.7	0.3	0.0	4.1	0.2	0.7	150.2	177.5	1.0	26.9	9.5
CHCHD7	"COX23, MGC2217"	ENSG00000170791	"Coiled-coil-helix-coiled-coil-helix domain containing 7"	Q9BUK0	8	56211686-56218798	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA050783	Approved		Approved	"Cell Junctions,Aggresome"		NA	NA			"Cell Junctions"	Aggresome	"HPA050783: AB_2681236"	"unprognostic (1.64e-2)"	"unprognostic (3.23e-2)"	"unprognostic (3.18e-2)"	"prognostic unfavorable (1.39e-6)"	"unprognostic (4.46e-2)"	"unprognostic (2.43e-1)"	"unprognostic (5.04e-2)"	"unprognostic (8.38e-3)"	"unprognostic (1.62e-1)"	"unprognostic (9.03e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.15e-1)"	"prognostic favorable (9.47e-5)"	"unprognostic (1.94e-1)"	"unprognostic (5.07e-1)"	"unprognostic (1.77e-2)"	"unprognostic (2.50e-1)"	16.6	14.8	24.1	19.6	29.4	17.6	18.9	27.1	23.3	17.6	20.7	18.3	22.8	22.5	13.1	34.3	15.7	17.6	12.3	27.0	21.0	19.5	23.4	18.0	19.4	24.4	27.0	16.0	36.3	20.0	22.5	48.3	13.3	26.7	19.2	21.3	19.2	34.5	18.0	23.2	14.6	26.2	14.8	32.0	33.0	17.7	7.6	24.8	27.4	19.8	18.3	24.9	15.5	16.4	31.0	33.6	26.2	20.6	24.2	31.1	17.3	18.7	6.0	13.5	4.4	35.9	25.5	13.9	13.4	12.7	10.7	8.0	15.4	23.0	17.8	11.9	7.9	14.8	10.6	13.9	20.7	13.3	7.7	26.8	27.1	14.3	21.2	18.2	23.1	17.4	30.4	19.1	7.6	34.1	15.2	11.1	33.4	13.2	11.7	25.3	9.4	23.1	34.3	11.8	30.0	8.7	26.5	4.1	14.8	19.8	20.3	3.5	2.3	7.0	11.0	9.9	16.9	11.5	13.0	16.1	5.7	12.1	18.3	12.6	12.3	12.6	29.6	15.9	34.4	9.7	21.5	20.6	26.2	23.2	19.0	22.5	31.0	26.0	23.6	22.8	26.4	31.1	27.8	7.9	24.2	16.6	33.6	29.7	17.3	24.1	29.4	27.1	23.3	21.0	19.5	27.0	16.0	26.7	24.8	17.9	68.8	75.2	36.1	18.4	31.3	84.5	48.4	44.2	40.9	47.1	13.7	38.6	106.1	35.3	16.9	29.6	88.5	23.3	65.0	72.3	25.3	33.7	52.0	63.7	129.2	12.7	38.1	46.6	72.1	9.6	34.2	55.9	50.6	69.5	53.7	38.5	58.7	54.7	29.0	49.6	34.8	12.9	36.3	52.6	37.9	20.8	35.2	57.5	63.2	39.1
CHD4	"Mi-2b, Mi2-BETA"	ENSG00000111642	"Chromodomain helicase DNA binding protein 4"	Q14839	12	6570082-6614524	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA012008	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA012008: AB_1846633"	"unprognostic (6.11e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.40e-3)"	"unprognostic (8.99e-2)"	"unprognostic (3.36e-3)"	"prognostic unfavorable (6.03e-6)"	"unprognostic (2.66e-2)"	"unprognostic (1.05e-1)"	"unprognostic (6.85e-2)"	"unprognostic (3.15e-1)"	"unprognostic (3.94e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.33e-1)"	"unprognostic (1.82e-1)"	"unprognostic (9.84e-2)"	"unprognostic (1.66e-1)"	23.5	34.9	21.9	50.0	33.5	27.2	25.9	29.4	25.1	28.1	29.5	29.3	38.5	18.6	37.2	35.4	29.1	28.0	40.3	52.8	23.5	19.2	29.5	25.0	25.5	30.9	33.6	19.4	34.6	27.4	58.4	25.3	29.5	27.2	21.5	26.0	26.5	24.8	46.2	33.7	31.1	24.4	36.6	30.3	29.4	27.2	29.7	28.9	75.7	38.4	33.7	38.4	34.7	24.3	12.6	16.8	12.8	9.1	13.5	16.7	5.8	20.4	18.7	46.4	17.4	19.0	21.4	27.3	22.7	22.2	25.1	23.2	31.2	15.9	44.1	9.0	25.7	16.4	18.3	43.5	25.0	33.9	33.0	22.4	61.6	29.1	19.4	16.5	48.3	29.6	20.7	12.4	24.3	17.0	31.7	29.3	24.7	48.4	22.0	23.8	25.6	45.8	15.8	44.4	19.0	17.7	39.3	28.5	24.1	15.9	24.2	22.0	28.3	29.2	32.6	22.6	53.2	14.9	27.5	27.2	25.7	54.7	18.8	26.5	35.7	21.2	56.3	17.0	29.5	18.7	9.0	7.7	9.2	12.2	9.1	12.0	10.5	10.3	11.1	7.9	12.6	13.0	12.3	12.8	13.5	8.1	16.8	16.7	5.8	21.9	33.5	29.4	25.1	23.5	19.2	33.6	19.4	27.2	28.9	56.6	102.0	59.1	45.6	60.9	103.2	110.8	66.2	96.4	79.6	83.7	66.8	38.6	11.6	71.4	71.8	70.5	43.4	23.3	62.1	41.7	66.9	40.2	81.1	60.6	61.2	131.9	93.2	49.7	44.2	45.3	60.9	57.6	45.5	56.9	59.2	71.6	76.6	24.6	70.0	30.3	60.2	51.8	73.5	97.0	107.1	59.1	56.9	61.8	61.8	37.3
CHEK2	"bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53"	ENSG00000183765	"Checkpoint kinase 2"	O96017	22	28687743-28742422	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Apoptosis, Cell cycle, Cell division, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Erythroid cells: 23.3;Spermatogonia: 20.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001878, CAB002030"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus"		NA	NA			Nucleoplasm	"Golgi apparatus"	"CAB002030: AB_563660, HPA001878: AB_1078514"	"unprognostic (1.54e-1)"	"unprognostic (2.20e-1)"	"unprognostic (5.83e-2)"	"unprognostic (2.93e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.83e-2)"	"unprognostic (1.49e-3)"	"unprognostic (5.08e-3)"	"unprognostic (3.33e-3)"	"unprognostic (9.62e-3)"	"unprognostic (1.28e-2)"	"unprognostic (3.13e-1)"	"prognostic unfavorable (7.80e-9)"	"unprognostic (2.38e-2)"	"unprognostic (1.78e-1)"	"unprognostic (7.27e-2)"	"unprognostic (6.79e-3)"	5.6	8.3	2.5	13.0	7.0	13.7	5.6	0.7	5.6	6.6	9.8	2.5	4.8	6.8	4.8	10.9	10.0	4.3	6.0	6.0	4.1	2.3	5.3	6.5	7.9	10.1	6.7	1.6	12.9	6.7	1.2	4.2	10.1	5.1	8.3	10.6	8.7	7.0	5.8	2.2	6.3	8.5	5.4	5.0	9.8	5.8	9.7	3.6	13.1	7.5	4.8	13.7	6.2	6.7	11.8	8.7	6.5	8.4	2.9	4.4	3.7	14.9	4.8	13.7	17.0	3.9	19.5	8.8	7.4	8.7	9.8	14.4	12.1	10.2	17.7	6.3	5.2	10.6	14.4	20.8	13.6	11.5	12.6	16.0	23.3	9.2	20.2	3.8	14.7	17.1	8.2	6.3	12.6	11.2	6.0	10.8	14.2	14.0	15.5	9.2	21.0	11.8	23.7	19.3	18.5	12.2	25.6	9.4	20.6	6.1	6.2	8.1	4.6	8.3	14.7	8.2	10.6	10.1	13.6	3.7	7.9	9.5	6.9	3.9	9.4	16.5	34.6	7.5	15.5	10.0	6.5	3.7	1.2	1.1	8.4	2.3	11.8	2.2	2.1	8.7	8.4	4.4	2.8	0.3	2.9	4.1	7.0	2.8	3.7	2.5	7.0	0.7	5.6	4.1	2.3	6.7	1.6	5.1	3.6	8.9	4.5	7.5	4.5	5.7	1.0	1.0	0.0	2.7	4.5	1.8	0.0	10.5	0.0	1.7	4.7	2.2	2.0	23.3	1.2	11.7	8.9	2.3	3.5	0.9	8.4	0.0	1.2	3.1	2.1	0.5	5.8	6.6	1.7	2.8	4.7	0.6	1.3	3.5	4.2	3.2	1.2	0.0	2.8	2.5	20.2	1.9	2.9	4.3	7.9	3.4
CIC	KIAA0306	ENSG00000079432	"Capicua transcriptional repressor"	Q96RK0	19	42268537-42295797	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB026388, HPA044341, HPA064725"	Approved		Supported	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"CAB026388: , HPA044341: AB_2678901, HPA064725: AB_2685335"	"unprognostic (2.02e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.41e-2)"	"unprognostic (3.54e-3)"	"unprognostic (3.67e-1)"	"unprognostic (4.17e-3)"	"unprognostic (1.49e-1)"	"unprognostic (2.06e-1)"	"unprognostic (4.87e-1)"	"unprognostic (1.85e-2)"	"unprognostic (1.72e-3)"	"unprognostic (3.10e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.00e-1)"	"unprognostic (2.38e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.56e-1)"	18.6	15.7	30.5	22.8	29.9	28.1	20.3	46.8	31.6	17.5	14.7	24.7	13.0	16.5	28.6	12.3	12.3	22.1	17.4	12.1	25.5	15.2	14.9	15.1	15.8	21.5	25.2	20.1	31.5	22.6	16.6	22.6	13.2	20.4	14.4	6.2	19.0	23.8	20.8	21.0	34.1	16.1	16.3	16.5	24.7	14.5	31.5	25.6	13.6	16.8	10.6	13.4	13.6	17.4	2.3	2.0	5.0	2.6	0.6	2.5	1.6	17.7	32.1	12.4	17.0	8.0	15.2	6.1	13.6	11.3	11.5	10.6	9.1	11.0	12.3	12.9	10.7	9.5	8.7	6.9	20.5	3.7	29.9	9.3	10.4	20.3	10.8	10.1	5.8	29.5	18.0	12.1	13.0	7.6	12.1	10.5	7.8	10.1	26.0	6.4	16.9	11.5	11.2	7.7	5.7	18.3	9.9	10.5	7.4	9.6	16.7	16.0	13.1	12.8	8.1	10.1	4.1	9.5	12.5	20.0	27.5	22.3	9.4	16.5	21.6	14.8	8.4	21.3	9.2	16.2	3.4	1.8	1.0	2.5	2.6	1.9	1.7	1.3	1.6	1.7	2.3	0.9	1.5	5.0	0.6	1.9	2.0	0.5	1.6	30.5	29.9	46.8	31.6	25.5	15.2	25.2	20.1	20.4	25.6	0.0	4.0	8.0	14.4	23.0	32.4	5.6	22.9	2.7	1.2	8.7	19.6	5.9	3.3	11.2	3.5	17.5	10.7	0.0	13.1	4.3	11.3	8.6	11.5	17.4	10.3	39.7	14.3	12.3	18.4	2.5	20.1	10.7	23.6	10.8	9.4	17.4	13.4	10.5	17.0	5.0	18.3	25.8	13.7	10.2	22.9	16.9	10.9	11.7	8.4	9.8
CIITA	"C2TA, MHC2TA, NLRA"	ENSG00000179583	"Class II major histocompatibility complex transactivator"	P33076	16	10866222-10943021	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Kinase, Transferase"	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 67.2"	"Cell type enhanced"	"Detected in many"	14	"Alveolar cells type 2: 17.9;Macrophages: 36.9;monocytes: 58.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 23.3;REH: 40.9;U-266/70: 8.6;U-698: 12.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB016084, HPA054757"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB016084: AB_627261, HPA054757: "	"unprognostic (1.45e-3)"	"unprognostic (1.38e-2)"	"unprognostic (8.22e-3)"	"unprognostic (1.12e-2)"	"unprognostic (5.66e-2)"	"unprognostic (2.88e-3)"	"unprognostic (2.92e-2)"	"unprognostic (1.55e-2)"	"unprognostic (1.15e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.23e-1)"	"unprognostic (3.72e-1)"	"unprognostic (1.64e-2)"	"unprognostic (2.72e-2)"	"unprognostic (6.33e-3)"	"unprognostic (2.74e-1)"	"unprognostic (1.05e-2)"	8.0	5.9	4.6	47.7	7.1	4.3	6.8	1.5	5.5	6.3	3.7	10.6	4.2	10.4	8.1	10.4	4.8	5.2	8.1	4.9	4.7	3.5	8.8	2.9	15.0	27.0	9.4	1.1	2.5	3.5	1.9	4.0	1.2	6.6	5.5	4.3	5.5	13.3	4.3	2.9	4.4	17.4	3.7	15.6	25.9	6.2	1.5	7.4	12.6	6.1	5.2	67.2	6.3	6.8	27.3	19.0	6.5	11.9	0.7	0.5	1.7	0.1	0.2	0.3	0.3	0.1	0.0	0.2	0.1	0.0	0.1	0.1	0.3	5.6	5.1	0.8	0.0	0.9	0.9	0.0	0.0	0.1	23.3	0.3	2.9	1.1	0.6	0.0	0.5	0.4	1.0	0.0	0.1	0.0	0.9	0.0	0.3	0.3	2.0	0.1	0.3	0.2	0.4	0.1	0.2	0.1	40.9	0.3	3.6	0.0	1.7	0.9	0.1	0.9	0.3	0.9	0.3	0.5	1.7	0.3	2.1	0.3	0.6	0.2	8.6	0.6	12.1	7.7	0.5	6.9	0.2	11.9	6.5	0.3	9.5	0.1	17.9	0.1	0.5	17.7	27.3	0.1	0.2	2.8	0.7	10.0	19.0	0.4	1.7	4.6	7.1	1.5	5.5	4.7	3.5	9.4	1.1	6.6	7.4	6.0	17.9	12.3	0.3	2.1	0.6	2.8	2.5	2.7	1.2	3.5	0.0	0.1	0.0	2.5	0.6	4.2	3.4	0.0	1.7	0.2	1.0	0.3	10.4	1.0	9.1	0.0	2.4	2.5	15.6	0.0	0.6	36.9	6.8	58.7	0.7	0.4	1.7	0.0	0.0	3.3	0.9	0.0	0.9	0.0	0.0	2.5	0.1	1.0	0.4	0.3
CLIP1	"CLIP, CLIP-170, CLIP170, CYLN1, RSN"	ENSG00000130779	"CAP-Gly domain containing linker protein 1"	P30622	12	122271432-122422632	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 96.5"	"Cell type enhanced"	"Detected in many"	6	"Syncytiotrophoblasts: 400.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004399, HPA026678"	Approved		Supported	"Microtubule ends,Cytosol"		NA	NA		7700	"Microtubule ends, Cytosol"		"CAB004399: AB_671001, HPA026678: AB_1846954"	"unprognostic (1.18e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.72e-1)"	"unprognostic (4.91e-2)"	"unprognostic (6.28e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.20e-1)"	"unprognostic (4.73e-2)"	"unprognostic (2.51e-1)"	"unprognostic (7.62e-2)"	"unprognostic (2.31e-2)"	"unprognostic (8.97e-2)"	"unprognostic (3.26e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.63e-1)"	"unprognostic (3.37e-1)"	"unprognostic (2.52e-3)"	14.4	12.6	9.8	9.1	10.9	6.4	11.7	44.5	11.5	11.6	19.5	4.3	13.9	5.7	14.3	10.1	24.8	7.5	7.7	11.8	9.3	7.5	10.0	15.2	10.0	5.8	6.5	9.5	6.3	9.1	37.8	10.9	36.5	8.7	13.2	7.1	6.7	11.8	15.1	96.5	16.8	9.1	31.1	7.2	5.9	9.6	6.1	6.9	3.7	24.1	25.9	10.1	22.2	16.6	5.3	5.4	18.2	10.6	3.9	7.2	3.7	15.5	19.7	12.2	12.3	10.4	16.1	21.3	22.3	21.2	15.1	9.5	9.1	7.7	7.0	15.0	28.8	19.4	20.0	7.7	9.1	17.1	29.3	5.6	2.3	13.1	9.6	20.8	8.1	12.9	10.6	31.5	17.4	26.3	20.2	15.1	6.2	8.7	4.8	15.1	9.0	5.0	2.8	4.6	6.7	17.5	4.6	9.4	3.5	13.6	17.9	4.7	3.0	47.7	11.7	19.5	11.0	10.1	4.8	29.2	11.5	12.4	26.9	14.5	5.3	4.2	4.2	19.7	4.1	7.9	3.6	6.5	5.2	7.2	10.6	5.4	5.3	6.7	6.5	5.4	3.6	5.0	3.7	18.2	3.9	8.6	3.5	5.8	3.7	9.8	10.9	44.5	11.5	9.3	7.5	6.5	9.5	8.7	6.9	125.0	126.6	21.9	132.8	59.6	59.4	113.6	43.3	131.2	134.2	41.8	41.2	101.8	6.6	54.0	137.2	49.6	24.3	0.0	56.4	29.4	46.1	121.3	69.5	39.3	33.9	125.5	13.4	48.5	34.8	68.2	33.1	51.6	52.3	30.7	18.9	36.4	75.0	24.6	58.4	10.5	41.9	71.1	40.1	21.2	29.5	125.3	400.9	27.1	21.5	189.8
CLTC	"CLTCL2, Hc"	ENSG00000141367	"Clathrin heavy chain"	Q00610	17	59619689-59696956	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Autophagy, Cell cycle, Cell division, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB010389, CAB011571, CAB017155, HPA059143"	Approved		Enhanced	"Vesicles,Endosomes,Lysosomes,Mitotic spindle,Cytosol"		Yes	No		51000000	"Vesicles, Endosomes, Lysosomes"	"Mitotic spindle, Cytosol"	"CAB010389: AB_2083184, CAB011571: AB_2083165, CAB017155: , HPA059143: AB_2683924"	"unprognostic (1.56e-1)"	"prognostic unfavorable (7.35e-4)"	"prognostic favorable (7.65e-4)"	"unprognostic (1.03e-1)"	"unprognostic (2.62e-1)"	"unprognostic (5.23e-3)"	"prognostic unfavorable (5.54e-4)"	"unprognostic (1.11e-1)"	"unprognostic (6.43e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.22e-2)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (2.02e-4)"	39.5	45.7	47.4	35.1	57.6	30.7	57.9	59.1	83.6	38.1	45.0	25.1	47.7	27.9	38.7	52.3	32.1	30.9	34.1	39.9	47.1	53.7	48.6	46.0	46.5	60.7	53.9	59.3	29.8	23.3	96.1	30.0	51.5	57.0	38.9	48.9	22.7	28.6	54.4	44.2	30.5	27.7	45.8	47.8	28.0	34.2	29.4	28.8	28.0	43.7	26.6	31.2	37.1	40.6	10.0	24.6	13.9	24.6	12.3	15.6	13.1	47.4	71.8	35.4	35.0	59.8	48.8	40.5	51.0	53.8	45.7	47.8	44.0	29.2	33.0	58.6	72.4	50.6	31.3	52.8	42.4	61.1	35.5	28.4	54.1	45.4	68.2	45.7	37.0	31.3	46.1	26.0	69.5	44.8	36.0	50.5	16.9	53.9	46.8	71.2	84.6	21.9	11.0	30.5	43.4	41.9	19.5	59.3	40.0	51.2	67.3	31.8	37.8	31.6	20.7	30.2	47.8	49.2	23.3	64.5	83.9	50.1	40.0	52.2	36.8	51.7	30.5	61.5	25.1	51.2	10.5	20.9	13.9	12.7	24.6	15.6	10.0	11.7	13.7	24.6	9.1	10.0	11.0	13.4	12.3	20.7	16.1	14.5	13.1	47.4	57.6	59.1	83.6	47.1	53.7	53.9	59.3	57.0	28.8	92.3	94.7	38.0	37.2	56.7	86.7	68.8	86.6	72.3	81.9	73.3	56.9	86.9	23.2	67.8	20.6	66.0	118.0	93.5	84.2	40.6	77.3	84.0	65.9	162.9	151.0	81.0	115.9	156.5	173.7	53.1	68.4	90.2	50.6	62.3	109.9	47.7	89.2	73.7	88.1	105.0	55.3	77.6	61.2	51.7	37.2	69.4	90.3	33.1	108.8	72.3
CLTCL1	"CHC22, CLH22, CLTCL, CLTD"	ENSG00000070371	"Clathrin heavy chain like 1"	P53675	22	19179473-19291716	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 53.0"	"Cell type enhanced"	"Detected in many"	7	"Cardiomyocytes: 11.2;Cone photoreceptor cells: 13.7;Early spermatids: 15.7;Late spermatids: 12.9;Spermatocytes: 13.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	8	"classical monocyte: 3.3;neutrophil: 8.4"	"Group enriched"	"Detected in many"	15	"granulocytes: 8.4;monocytes: 3.3"	"Cell line enhanced"	"Detected in many"		"HMC-1: 34.9;K-562: 16.3"									"HPA075327, HPA075795"	Enhanced		Approved	Vesicles		NA	NA			Vesicles		"HPA075327: , HPA075795: AB_2686764"	"unprognostic (1.29e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.93e-2)"	"unprognostic (3.16e-3)"	"unprognostic (8.20e-2)"	"unprognostic (6.93e-3)"	"unprognostic (1.60e-1)"	"unprognostic (3.28e-1)"	"unprognostic (4.42e-2)"	"unprognostic (2.93e-3)"	"unprognostic (3.14e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.20e-1)"	"unprognostic (8.71e-4)"	"unprognostic (1.61e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.06e-1)"	2.9	3.3	1.1	0.9	2.0	9.7	1.6	3.4	1.8	1.3	1.0	3.7	1.2	0.4	2.3	3.1	2.2	1.4	0.9	5.6	1.3	1.7	1.0	1.7	1.2	0.6	2.7	1.4	1.4	0.9	2.1	14.9	1.1	4.1	1.8	0.8	4.2	1.5	1.1	53.0	2.1	0.9	2.4	3.6	0.9	1.0	17.2	1.2	1.3	2.7	10.4	0.7	1.2	1.3	0.2	0.3	8.4	3.3	0.0	0.3	0.6	2.3	2.4	1.6	2.6	5.9	3.2	0.7	1.6	1.7	2.3	3.4	0.8	0.7	0.9	0.2	3.6	1.7	0.8	2.5	4.6	1.9	0.1	2.4	0.1	2.2	2.7	3.0	3.3	34.9	13.9	3.7	4.2	5.9	6.7	1.4	1.3	16.3	0.9	5.3	1.8	0.4	11.6	2.0	9.4	2.0	1.2	13.3	0.0	1.8	0.9	3.8	0.6	3.5	2.2	0.2	2.0	4.7	14.1	0.4	4.1	8.7	2.3	2.7	1.8	4.2	0.4	2.4	9.0	0.8	0.0	3.3	0.3	0.1	0.7	0.0	0.0	0.1	0.3	0.3	0.2	0.3	0.0	8.4	0.0	0.0	0.1	0.0	0.6	1.1	2.0	3.4	1.8	1.3	1.7	2.7	1.4	4.1	1.2	3.0	0.3	0.0	0.5	0.6	1.6	11.2	2.5	0.0	2.3	0.0	13.7	0.3	0.0	0.7	15.7	0.4	0.0	0.0	0.0	0.1	0.9	1.4	0.0	1.5	0.3	0.0	0.0	1.3	1.5	12.9	2.3	0.0	0.0	0.0	1.2	1.7	1.0	0.0	3.9	0.6	2.1	0.0	2.1	13.4	5.3	0.6	0.9	0.0	0.9	0.0
CNBP	"CNBP1, DM2, RNF163, ZCCHC22, ZNF9"	ENSG00000169714	"CCHC-type zinc finger nucleic acid binding protein"	P62633	3	129169484-129183922	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063097			Approved	Nucleoplasm,Cytosol		NA	NA		43000	Nucleoplasm	Cytosol	"HPA063097: AB_2684939"	"unprognostic (1.74e-1)"	"unprognostic (3.11e-2)"	"unprognostic (4.84e-1)"	"unprognostic (3.35e-2)"	"unprognostic (6.28e-2)"	"unprognostic (7.38e-2)"	"unprognostic (7.02e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.06e-3)"	"unprognostic (6.39e-2)"	"prognostic unfavorable (3.51e-4)"	"unprognostic (4.72e-3)"	"unprognostic (4.62e-3)"	"unprognostic (1.89e-1)"	"unprognostic (2.03e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.58e-1)"	54.2	52.8	36.4	33.6	33.7	35.9	46.6	43.5	35.6	58.1	47.1	34.5	40.5	32.4	54.5	49.4	55.6	40.9	48.5	78.2	33.0	32.0	38.0	71.6	47.5	40.6	39.7	30.3	67.4	65.4	39.3	33.5	41.5	33.3	62.3	37.1	41.3	48.9	50.9	182.1	46.7	40.6	71.9	38.0	43.2	43.1	32.1	33.1	39.0	67.3	81.1	41.2	76.1	63.5	74.3	60.3	120.1	84.1	61.7	83.4	172.9	61.7	36.6	53.4	42.3	53.4	45.8	42.2	48.6	77.1	53.0	60.9	53.6	43.5	82.2	41.7	45.2	38.9	46.5	69.8	56.3	71.9	55.1	50.8	79.4	37.8	57.7	53.2	85.1	45.7	44.3	66.2	37.1	134.1	36.1	46.7	46.4	59.4	56.6	55.5	73.9	78.8	62.6	65.1	55.1	61.9	69.3	49.6	97.9	54.9	59.5	72.8	58.3	38.3	37.9	103.0	32.6	43.6	58.6	49.2	39.3	38.7	53.9	49.1	53.2	48.4	129.3	40.5	58.4	51.8	93.4	84.1	96.8	64.1	63.8	80.6	74.3	77.4	68.9	60.3	62.7	83.4	72.0	120.1	61.7	48.9	35.1	73.9	172.9	36.4	33.7	43.5	35.6	33.0	32.0	39.7	30.3	33.3	33.1	241.2	236.8	168.8	346.4	466.2	151.2	559.4	112.1	211.5	257.0	75.0	31.4	228.5	316.7	172.7	25.7	265.4	148.7	46.7	254.5	331.1	308.6	248.1	302.0	134.8	219.0	87.4	164.4	125.8	185.1	30.7	292.6	305.9	301.9	415.6	158.2	306.6	196.4	147.3	300.5	191.8	122.5	258.7	447.2	255.1	271.9	512.9	243.9	251.4	182.3	305.2
CNOT3	"KIAA0691, LENG2, NOT3, NOT3H"	ENSG00000088038	"CCR4-NOT transcription complex subunit 3"	O75175	19	54137717-54155708	"Cancer-related genes, Predicted intracellular proteins"	"RNA-mediated gene silencing, Transcription, Transcription regulation, Translation regulation"	"Developmental protein, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEK 293: 72.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006408	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA006408: AB_1078543"	"unprognostic (1.23e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.86e-2)"	"unprognostic (1.90e-1)"	"prognostic unfavorable (2.22e-4)"	"unprognostic (9.06e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.65e-2)"	"unprognostic (9.30e-3)"	"unprognostic (4.08e-3)"	"prognostic unfavorable (2.77e-4)"	"unprognostic (2.18e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.66e-2)"	18.1	25.2	25.5	23.6	26.4	21.4	20.2	46.8	27.9	22.1	20.7	24.5	27.7	21.3	25.0	26.5	22.1	23.6	19.7	16.2	21.9	15.6	21.3	20.2	17.9	23.9	25.5	20.8	28.0	22.7	27.6	30.2	24.2	20.3	23.3	17.5	20.7	22.4	31.4	20.2	25.2	21.4	22.0	16.7	26.3	21.9	34.4	26.9	33.6	26.3	14.3	23.3	23.8	29.9	3.2	6.7	8.4	3.1	1.6	3.6	2.9	13.8	22.3	23.2	13.3	8.6	8.8	16.2	13.0	22.5	17.4	15.6	14.3	12.0	17.1	8.3	15.0	14.3	14.6	25.7	12.6	18.1	17.6	72.5	26.5	14.5	12.7	15.0	15.1	18.6	11.0	12.2	15.5	26.3	12.6	13.8	13.0	19.5	16.0	12.8	17.1	18.7	8.9	14.1	28.5	17.9	18.7	17.8	11.1	11.7	28.1	15.0	12.6	25.1	18.1	8.2	18.0	10.3	16.2	12.3	14.8	17.1	7.9	17.6	15.1	16.4	23.6	12.9	11.6	15.6	1.4	3.1	5.2	3.6	2.2	2.5	2.9	2.4	3.2	2.8	3.2	2.7	2.6	8.4	1.6	2.6	6.7	2.5	2.9	25.5	26.4	46.8	27.9	21.9	15.6	25.5	20.8	20.3	26.9	11.9	9.0	17.1	14.7	8.9	17.3	1.7	12.7	12.0	11.4	7.0	15.7	23.7	8.3	12.8	7.4	10.5	14.4	0.0	12.6	22.9	13.5	16.1	3.5	7.6	14.1	15.9	13.8	12.9	7.9	5.4	15.8	7.2	5.0	16.2	15.2	11.3	13.1	20.1	8.9	8.1	17.8	6.5	11.2	44.2	39.9	8.7	41.9	12.5	11.9	14.8
CNTRL	"CEP1, CEP110"	ENSG00000119397	Centriolin	Q7Z7A1	9	121074863-121177610	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	13	"Ciliated cells: 156.6;Spermatocytes: 334.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HL-60: 35.4"	"Low region specificity"	"Detected in all"							"HPA020468, HPA020480, HPA051583"	Approved		Supported	Centrosome,Cytosol		NA	NA			Centrosome	Cytosol	"HPA020468: AB_2670455, HPA020480: AB_2670457, HPA051583: AB_2681542"	"unprognostic (4.33e-3)"	"unprognostic (2.89e-3)"	"unprognostic (2.09e-2)"	"unprognostic (7.97e-2)"	"unprognostic (1.17e-2)"	"prognostic favorable (9.21e-5)"	"unprognostic (1.05e-2)"	"unprognostic (3.22e-3)"	"unprognostic (3.74e-3)"	"unprognostic (2.02e-1)"	"unprognostic (1.78e-2)"	"unprognostic (5.47e-2)"	"unprognostic (3.60e-3)"	"unprognostic (9.83e-3)"	"unprognostic (2.43e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.13e-2)"	7.7	4.7	5.5	22.2	11.7	24.0	6.8	10.9	8.7	8.4	5.5	4.9	5.9	3.8	7.3	6.4	5.6	8.4	5.1	4.4	6.6	4.3	4.0	3.8	9.3	20.3	8.1	4.1	10.6	5.2	4.0	17.3	5.8	7.0	7.2	5.5	4.4	6.3	8.6	2.8	5.2	8.8	5.7	9.7	14.8	7.1	30.2	9.8	26.7	6.2	4.2	19.2	8.6	7.1	12.7	10.5	15.0	6.9	4.8	10.4	2.5	5.4	3.6	10.2	7.3	1.5	2.3	1.8	3.8	2.8	3.0	2.6	2.1	6.0	25.1	1.5	2.7	5.4	11.5	3.4	2.3	4.9	15.1	2.6	13.1	6.7	2.5	2.1	35.4	15.9	1.4	1.7	3.1	7.6	1.3	6.5	10.4	8.4	14.3	2.9	3.5	13.9	12.1	3.5	7.0	3.0	13.1	15.4	7.2	1.4	2.5	3.8	5.8	12.9	2.3	2.9	1.8	4.9	17.0	4.8	3.2	5.5	4.9	7.0	10.0	10.9	17.0	2.6	14.6	7.2	12.2	6.9	15.0	7.5	4.5	5.7	10.8	7.7	5.5	3.4	12.7	9.3	6.6	2.7	4.8	5.8	10.5	10.4	2.5	5.5	11.7	10.9	8.7	6.6	4.3	8.1	4.1	7.0	9.8	26.8	26.2	35.1	12.7	3.0	28.2	7.0	5.1	156.6	48.9	3.5	35.3	1.5	3.3	3.8	56.2	14.4	2.1	0.0	5.2	2.1	5.9	3.8	49.9	2.0	22.5	28.6	8.1	12.3	34.6	27.0	12.7	37.9	8.5	22.6	7.3	7.0	5.3	3.5	11.3	1.1	64.1	38.8	5.1	334.4	72.6	5.0	0.7	29.8	5.2	4.7
COL1A1	OI4	ENSG00000108821	"Collagen type I alpha 1 chain"	P02452	17	50183289-50201632	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 415.7"	"Cell type enhanced"	"Detected in many"	22	"Fibroblasts: 2038.6;Ito cells: 615.0;Leydig cells: 514.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 91.8;BJ: 176.2;fHDF/TERT166: 266.1;HHSteC: 71.8;HSkMC: 134.8;U-138 MG: 143.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA011795, HPA012111"	Approved		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"	NA	NA		58000000	"Endoplasmic reticulum, Vesicles"		"HPA011795: AB_1847088, HPA012111: "	"unprognostic (1.61e-1)"	"unprognostic (3.60e-3)"	"unprognostic (8.29e-2)"	"unprognostic (5.52e-2)"	"unprognostic (7.74e-2)"	"unprognostic (2.22e-1)"	"unprognostic (6.01e-2)"	"prognostic unfavorable (4.43e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.55e-2)"	"unprognostic (8.53e-2)"	"unprognostic (9.90e-2)"	"prognostic unfavorable (7.19e-12)"	"unprognostic (2.74e-2)"	"unprognostic (4.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.87e-3)"	30.2	5.7	0.7	28.2	4.0	0.1	31.7	0.6	0.9	415.7	25.7	1.6	23.9	3.0	121.8	70.9	17.4	33.0	110.3	43.9	0.7	0.1	7.5	4.6	18.8	38.5	0.7	1.2	73.6	10.5	1.0	10.7	89.1	2.2	31.5	4.0	9.2	9.1	21.0	11.0	35.5	10.6	88.0	1.3	13.7	15.0	44.6	0.7	7.7	6.7	15.5	8.7	67.3	49.7	0.2	0.0	0.0	0.0	0.0	1.1	0.0	0.3	0.2	0.9	0.1	37.7	91.8	1.6	176.2	47.9	43.9	27.6	3.5	0.8	0.0	0.4	266.1	0.3	0.5	0.4	0.1	7.9	0.2	0.3	0.0	4.4	0.2	71.8	0.0	0.0	134.8	2.6	53.7	0.2	7.3	0.0	0.2	0.1	0.0	22.1	0.4	0.0	0.0	0.9	0.6	0.5	0.3	0.1	0.1	0.2	0.0	0.1	0.5	0.3	0.2	0.0	13.7	2.2	0.0	0.0	143.2	31.3	21.4	0.8	0.1	0.3	0.0	10.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.0	0.6	0.9	0.7	0.1	0.7	1.2	2.2	0.7	8.9	14.4	0.5	11.0	166.9	0.0	4.8	0.0	5.3	12.5	7.0	0.0	29.5	0.0	11.2	0.9	5.1	0.0	0.0	3.7	26.1	2038.6	12.1	2.3	1.9	59.9	0.0	2.9	615.0	0.8	4.5	514.8	7.7	178.8	0.0	2.2	2.8	25.7	0.0	252.1	0.5	0.1	77.6	273.4	4.2	1.7	142.9	93.5	0.5	1.3	7.5
COL2A1	"AOM, SEDC, STL1"	ENSG00000139219	"Collagen type II alpha 1 chain"	P02458	12	47972965-48004554	"Cancer-related genes, Disease related genes, Predicted secreted proteins"			"Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Stickler syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"epididymis: 22.7;pituitary gland: 11.0;retina: 8.1;stomach 1: 11.3"	"Cell type enhanced"	"Detected in some"	24	"Early spermatids: 12.7;Intestinal endocrine cells: 42.2;Muller glia cells: 19.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 55.2;HAP1: 34.6;HEK 293: 12.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB002214, HPA055753"	Approved		Approved	Nucleoplasm	"Secreted to extracellular matrix"	No	NA			Nucleoplasm		"CAB002214: AB_563666, HPA055753: AB_2682908"	"unprognostic (7.25e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.58e-1)"	"unprognostic (3.44e-1)"	"unprognostic (2.88e-2)"	"unprognostic (3.08e-2)"	"unprognostic (8.63e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.12e-2)"	"unprognostic (1.31e-4)"	"unprognostic (2.64e-1)"	"unprognostic (3.44e-3)"	"unprognostic (1.89e-1)"	"unprognostic (2.93e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.02e-1)"	0.0	0.0	0.1	2.2	0.3	0.0	0.7	0.9	0.9	0.0	0.2	0.3	0.0	0.0	0.3	22.7	0.0	0.0	0.0	0.0	0.5	1.3	0.0	0.0	1.4	0.0	0.0	0.7	1.3	0.0	0.0	11.0	0.4	1.9	2.6	0.4	8.1	0.0	0.0	0.0	0.0	0.2	0.0	0.6	0.0	11.3	2.8	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	55.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.2	0.0	0.0	0.0	34.6	0.0	0.0	0.0	12.8	0.0	0.0	1.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	4.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.9	0.9	0.5	1.3	0.0	0.7	1.9	0.0	0.0	0.0	0.0	0.2	0.1	0.6	0.8	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	12.7	0.0	0.0	0.0	0.0	0.2	0.4	0.1	0.0	0.0	0.2	0.0	42.2	0.0	0.0	7.1	0.9	0.0	0.0	0.0	0.3	19.5	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.5	0.7	0.0	0.7	0.0	0.9	0.1
CREB1		ENSG00000118260	"CAMP responsive element binding protein 1"	P16220	2	207529737-207603431	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Differentiation, Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"Early spermatids: 355.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003803, HPA019150"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB003803: AB_562092, HPA019150: AB_1847220"	"unprognostic (1.20e-1)"	"unprognostic (3.15e-1)"	"unprognostic (3.30e-2)"	"unprognostic (2.69e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.03e-1)"	"prognostic unfavorable (2.77e-5)"	"unprognostic (8.41e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.53e-1)"	"unprognostic (9.58e-2)"	"unprognostic (1.74e-2)"	"unprognostic (4.82e-3)"	"unprognostic (5.53e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.77e-1)"	"unprognostic (8.45e-2)"	21.2	12.9	19.4	24.8	17.0	22.9	16.7	25.5	18.7	17.6	15.7	14.3	14.7	12.6	19.3	14.9	17.9	15.4	15.5	14.4	15.4	14.5	14.6	13.1	17.7	21.7	15.8	17.7	20.5	12.9	19.8	20.0	19.8	16.1	16.3	16.2	11.2	16.2	14.9	11.6	14.3	15.2	19.5	19.8	19.0	13.3	39.2	18.5	38.4	19.7	13.3	27.7	16.1	23.6	22.1	20.7	34.8	19.1	28.4	22.5	14.5	15.3	13.8	25.5	9.8	15.0	15.4	14.6	9.9	14.8	17.2	18.1	13.9	15.6	10.0	13.3	14.5	20.2	13.4	23.1	13.5	25.3	15.9	8.3	18.3	12.3	14.2	12.6	17.3	13.5	11.1	10.0	14.2	21.1	17.2	24.1	18.7	12.8	14.6	21.2	10.6	26.2	10.2	18.2	15.4	8.4	20.5	13.9	13.1	15.4	15.9	17.6	15.3	13.7	10.1	11.9	25.5	11.3	18.9	11.5	14.1	15.1	14.7	12.6	13.2	16.7	23.0	17.3	15.9	14.7	16.9	17.0	16.8	17.3	18.0	15.4	22.1	16.6	16.7	20.7	20.2	19.9	13.5	34.8	28.4	19.1	11.3	22.5	14.5	19.4	17.0	25.5	18.7	15.4	14.5	15.8	17.7	16.1	18.5	17.9	12.8	45.4	39.6	63.0	36.1	22.1	12.7	9.4	25.0	12.2	31.4	24.5	19.9	20.2	355.9	44.6	20.0	0.0	17.9	21.7	32.3	41.9	42.7	14.3	25.7	38.1	31.2	31.3	43.4	27.4	24.2	38.0	42.2	36.9	24.2	40.0	21.9	23.5	27.6	15.6	36.9	38.8	34.1	24.7	27.5	50.6	15.6	31.9	23.0	54.8
CREB3L1	OASIS	ENSG00000157613	"CAMP responsive element binding protein 3 like 1"	Q96BA8	11	46277661-46321422	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 60.7"	"Cell type enhanced"	"Detected in many"	14	"Mucus-secreting cells: 277.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 30.1;BJ hTERT+: 29.5;BJ hTERT+ SV40 Large T+: 27.6;fHDF/TERT166: 71.5;OE19: 28.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA024069, CAB026151"	Enhanced					NA	NA					"CAB026151: , HPA024069: AB_1854750"	"unprognostic (2.46e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.34e-1)"	"prognostic favorable (3.92e-4)"	"unprognostic (1.66e-3)"	"unprognostic (2.93e-1)"	"unprognostic (5.41e-2)"	"unprognostic (2.75e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-1)"	"prognostic unfavorable (2.97e-4)"	"unprognostic (2.62e-1)"	"unprognostic (1.93e-1)"	"prognostic unfavorable (8.59e-4)"	"unprognostic (1.12e-2)"	2.5	3.6	3.7	3.1	2.3	0.0	3.0	1.6	2.9	17.2	13.1	0.9	9.5	8.6	9.7	9.2	2.2	1.7	37.6	4.8	3.3	3.5	1.4	1.5	10.4	0.5	3.4	1.7	9.7	60.7	0.0	3.3	8.2	0.6	17.6	14.1	1.8	28.3	14.3	1.6	2.3	12.9	12.8	1.8	2.2	22.1	3.8	0.2	0.4	1.8	2.2	13.0	15.1	3.4	0.0	0.1	0.0	0.4	0.1	0.0	0.0	0.2	0.1	0.3	5.9	19.1	18.3	0.1	30.1	29.5	27.6	19.2	3.0	0.0	0.0	0.1	71.5	1.9	0.0	0.3	0.0	15.4	0.0	0.3	0.4	0.1	0.0	26.6	0.0	0.4	17.6	0.0	15.6	0.5	25.1	0.2	0.1	2.4	0.0	23.1	0.0	0.0	0.0	3.8	28.4	3.1	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	5.6	0.0	1.0	0.0	14.5	4.3	11.1	18.3	0.0	0.0	0.0	17.3	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	3.7	2.3	1.6	2.9	3.3	3.5	3.4	1.7	0.6	0.2	0.0	39.0	0.0	35.2	1.3	0.0	14.6	15.3	5.3	4.5	27.9	0.0	0.7	3.3	38.7	1.0	1.3	18.0	0.0	79.2	1.7	61.0	50.4	4.6	0.0	1.7	0.0	8.7	5.5	0.0	3.9	77.3	1.8	10.1	3.6	277.8	0.0	45.1	42.1	41.8	0.5	0.0	0.0	3.6	0.9	1.1	1.9	2.9	0.0	48.7	36.7
CREB3L2	"BBF2H7, TCAG_1951439"	ENSG00000182158	"CAMP responsive element binding protein 3 like 2"	Q70SY1	7	137874979-138002067	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation, Unfolded protein response"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 81.6"	"Cell type enhanced"	"Detected in many"	5	"Syncytiotrophoblasts: 120.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA015068, HPA015534"	Enhanced		Supported	"Nucleoplasm,Endoplasmic reticulum"		NA	NA			"Nucleoplasm, Endoplasmic reticulum"		"HPA015068: AB_1847224, HPA015534: AB_2669210"	"unprognostic (8.50e-2)"	"unprognostic (3.70e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.50e-3)"	"unprognostic (9.88e-2)"	"unprognostic (9.09e-2)"	"unprognostic (5.17e-2)"	"unprognostic (4.50e-1)"	"unprognostic (4.77e-1)"	"unprognostic (8.93e-2)"	"unprognostic (9.48e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.42e-1)"	"unprognostic (3.08e-3)"	"unprognostic (7.65e-2)"	"unprognostic (2.59e-2)"	"unprognostic (1.32e-2)"	14.9	19.8	4.7	17.1	9.8	10.8	15.7	1.9	6.0	25.4	16.7	11.4	18.7	11.6	28.2	25.5	12.8	16.2	16.2	20.4	5.6	4.3	17.0	11.7	14.6	15.2	11.8	3.7	25.9	16.0	38.4	28.8	81.6	9.8	15.9	9.5	24.9	26.5	23.3	5.0	6.9	17.5	17.7	6.2	12.1	14.1	9.8	9.1	7.0	35.8	10.9	18.1	21.3	15.7	4.6	12.4	7.4	5.6	6.5	11.8	3.2	4.0	6.3	12.0	0.2	20.5	20.4	9.0	20.4	33.0	14.3	14.5	8.6	3.7	0.8	5.5	22.1	7.8	2.2	7.0	14.9	28.0	5.9	3.5	25.7	8.6	20.5	13.6	7.7	36.9	8.4	9.5	18.0	21.1	14.7	18.8	2.1	13.2	12.0	16.7	7.3	2.4	9.5	4.3	5.6	4.5	5.4	6.5	6.8	11.2	4.2	3.1	7.2	6.6	17.1	9.1	7.3	2.5	5.8	20.0	19.2	2.9	23.1	7.4	14.2	4.9	5.3	23.0	21.8	42.5	7.4	5.6	5.9	8.2	2.9	10.6	4.0	6.0	8.6	5.8	4.6	2.2	3.8	2.1	6.5	1.5	12.4	11.8	3.2	4.7	9.8	1.9	6.0	5.6	4.3	11.8	3.7	9.8	9.1	6.0	20.4	20.6	8.1	10.9	7.2	14.1	20.4	10.7	18.2	22.7	9.8	50.6	11.6	9.3	48.0	20.2	32.0	0.0	15.3	76.5	40.4	27.0	48.5	24.5	49.4	14.3	15.1	30.1	33.2	14.1	57.2	25.1	25.3	10.0	17.0	6.7	15.1	17.3	96.9	9.1	12.4	38.8	42.4	1.1	4.3	6.1	120.8	27.3	14.9	17.2
CREBBP	"CBP, KAT3A, RSTS, RTS"	ENSG00000005339	"CREB binding protein"	Q92793	16	3725054-3880726	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004212, HPA055861"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"		No	No			Nucleoplasm	"Nuclear bodies"	"CAB004212: AB_626817, HPA055861: AB_2682948"	"unprognostic (1.17e-1)"	"unprognostic (8.51e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.49e-1)"	"unprognostic (5.09e-2)"	"unprognostic (9.59e-3)"	"unprognostic (6.98e-2)"	"unprognostic (8.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.84e-1)"	"prognostic favorable (6.24e-5)"	"unprognostic (1.47e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.97e-2)"	"unprognostic (8.23e-2)"	18.5	10.9	17.2	22.8	17.5	37.0	17.4	42.6	18.8	20.1	17.2	16.8	17.1	9.9	25.1	15.2	14.1	18.9	21.3	14.5	17.1	8.7	11.1	12.3	16.9	14.4	20.5	12.0	31.6	23.4	24.3	13.0	13.3	15.8	18.4	11.6	14.6	14.9	16.7	28.2	20.4	16.4	17.0	13.6	17.4	14.7	29.1	20.2	29.6	19.5	13.8	16.1	19.0	29.9	4.7	2.3	10.6	3.8	2.0	2.7	1.1	5.6	14.5	18.8	8.3	11.5	11.4	9.8	8.1	13.7	14.0	13.7	13.1	10.6	15.6	9.7	15.5	9.0	10.9	21.6	6.7	16.0	26.3	8.7	12.2	13.4	8.3	12.8	12.2	17.6	10.1	6.8	15.6	18.9	8.7	10.5	8.0	13.9	21.4	7.6	19.3	8.1	5.9	15.4	5.4	6.0	38.3	14.9	11.9	5.4	7.6	15.7	10.3	13.9	13.7	8.2	12.7	12.2	12.0	16.3	17.2	17.2	8.8	7.4	10.0	10.8	30.3	3.5	7.3	12.1	2.9	1.7	1.3	2.7	2.2	1.4	4.7	1.3	2.0	1.0	3.3	1.4	1.7	10.6	2.0	3.8	2.3	1.3	1.1	17.2	17.5	42.6	18.8	17.1	8.7	20.5	12.0	15.8	20.2	41.7	45.9	13.8	25.5	49.9	31.9	37.0	43.3	32.1	33.0	10.4	23.6	14.6	5.0	17.4	38.0	35.3	24.0	0.0	17.7	9.4	24.3	32.2	30.0	25.1	17.8	27.0	14.5	32.5	38.7	57.1	52.3	33.5	16.9	27.9	22.4	31.4	22.7	17.3	48.1	10.7	15.8	45.3	36.0	33.1	46.0	51.4	25.7	35.9	23.8	31.6
CRLF2	"CRL2, TSLPR"	ENSG00000205755	"Cytokine receptor like factor 2"	Q9HC73	X	1187549-1212750	"Cancer-related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"endometrium 1: 7.8"	"Cell type enriched"	"Detected in some"	9	"monocytes: 174.9"	"Cancer enhanced"	"Detected in single"		"thyroid cancer: 1.0"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	43	"plasmacytoid DC: 4.3"	"Lineage enriched"	"Detected in single"	43	"dendritic cells: 4.3"	"Cell line enhanced"	"Detected in some"		"GAMG: 2.4;HMC-1: 18.5;RPMI-8226: 4.7;U-698: 4.0"														"Intracellular and membrane"	NA	NA						"unprognostic (7.84e-2)"	"unprognostic (7.99e-4)"	"unprognostic (6.02e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.15e-3)"	"unprognostic (2.31e-6)"	"unprognostic (1.72e-1)"	"unprognostic (5.10e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.46e-2)"	"unprognostic (9.72e-3)"	"unprognostic (6.88e-5)"	"unprognostic (7.09e-3)"	"unprognostic (4.81e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.62e-1)"	0.8	0.0	0.2	4.1	0.2	4.1	0.6	0.2	0.2	3.0	0.7	0.2	0.2	0.2	7.8	0.2	0.9	0.2	3.7	0.2	0.2	0.1	0.9	0.2	1.9	0.2	0.2	0.2	0.2	0.2	0.0	0.2	1.0	0.2	0.6	0.9	0.2	0.8	0.2	0.2	0.7	1.5	0.3	0.2	0.6	1.0	0.2	0.2	0.2	0.2	0.2	1.4	1.3	0.6	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.5	0.0	0.6	1.0	0.2	0.3	2.4	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.1	0.0	0.0	0.0	18.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.5	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.7	1.0	4.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	3.0	3.4	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	19.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	174.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CRTC1	"FLJ14027, KIAA0616, MECT1, TORC1"	ENSG00000105662	"CREB regulated transcription coactivator 1"	Q6UUV9	19	18683677-18782333	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 40.7"	"Cell type enhanced"	"Detected in many"	6	"Horizontal cells: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA022035, HPA063619"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Nuclear bodies"	"Plasma membrane, Cytosol"	"HPA022035: AB_1847255, HPA063619: "	"unprognostic (5.95e-3)"	"unprognostic (2.57e-1)"	"unprognostic (9.94e-2)"	"unprognostic (8.62e-3)"	"unprognostic (9.07e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.04e-1)"	"unprognostic (5.57e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.68e-2)"	"prognostic favorable (1.80e-5)"	"unprognostic (3.37e-2)"	"prognostic favorable (3.83e-5)"	"unprognostic (6.83e-3)"	"unprognostic (1.02e-1)"	"unprognostic (2.51e-2)"	"unprognostic (2.03e-2)"	8.6	7.7	26.0	7.4	38.8	3.2	3.8	40.7	30.1	5.0	4.4	6.5	4.3	6.5	6.8	5.6	3.1	10.5	5.5	5.6	17.7	7.8	6.6	4.5	5.7	6.3	6.4	18.1	6.7	10.0	8.4	11.3	6.4	6.0	7.0	2.6	5.1	8.8	9.4	12.4	5.5	6.2	4.3	4.8	8.1	8.0	7.5	10.2	1.9	7.4	1.1	3.7	4.6	3.5	4.1	3.8	1.8	3.4	1.1	3.0	1.3	4.4	8.1	5.9	9.4	5.5	4.6	16.7	4.9	3.3	4.7	4.5	5.4	5.8	6.2	10.4	4.6	3.3	4.8	1.8	3.0	1.1	2.7	14.1	5.2	7.2	8.9	5.3	7.1	14.6	7.5	2.9	4.0	1.2	6.2	2.6	6.4	4.1	5.7	2.6	16.1	4.6	8.1	7.6	2.3	11.9	7.3	2.6	6.8	2.9	7.9	10.8	9.7	5.5	5.2	5.8	2.0	5.8	4.3	4.7	5.3	8.2	9.7	5.6	3.8	3.0	4.1	6.2	7.7	4.0	1.5	3.4	1.8	1.7	1.3	1.8	2.3	2.7	3.0	3.0	4.1	2.3	1.8	1.7	1.1	1.9	3.8	1.8	1.3	26.0	38.8	40.7	30.1	17.7	7.8	6.4	18.1	6.0	10.2	0.0	4.0	4.2	9.5	2.4	24.9	14.0	5.1	2.7	2.3	17.4	25.5	8.5	10.0	3.6	0.7	4.5	5.1	0.0	5.3	2.1	5.4	3.0	2.3	3.4	7.8	41.3	18.4	1.3	5.4	1.7	8.6	3.7	3.3	1.8	6.9	8.9	2.6	8.6	4.6	4.3	14.1	0.0	8.2	2.9	7.2	1.8	8.7	5.1	4.8	2.5
CRTC3	FLJ21868	ENSG00000140577	"CREB regulated transcription coactivator 3"	Q6UUV7	15	90529925-90645345	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 16.0"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HeLa: 40.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043735, HPA063691"	Uncertain		Enhanced	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA043735: AB_10794286, HPA063691: AB_2685092"	"unprognostic (7.60e-2)"	"unprognostic (6.13e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.31e-2)"	"unprognostic (5.12e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.69e-1)"	"unprognostic (6.48e-2)"	"unprognostic (3.60e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.23e-1)"	"unprognostic (5.22e-3)"	"unprognostic (4.67e-2)"	"unprognostic (9.32e-2)"	"unprognostic (9.51e-2)"	"unprognostic (2.30e-1)"	22.3	14.0	13.7	17.0	20.9	11.4	26.6	15.0	16.2	21.2	22.2	27.5	15.3	8.9	23.9	14.5	15.1	19.4	21.5	17.2	14.0	9.7	10.7	11.7	19.2	21.7	24.1	10.9	45.9	13.9	17.1	9.6	20.2	15.7	18.2	11.7	17.4	19.9	22.0	16.1	15.8	13.7	31.8	20.3	13.1	14.2	15.3	23.6	12.8	22.7	9.2	18.1	24.0	29.6	5.3	2.1	16.0	2.5	3.3	6.6	3.0	4.8	8.0	5.5	8.9	11.9	8.8	25.1	6.2	9.0	9.8	9.3	6.6	4.9	0.1	4.5	12.8	8.1	8.2	8.8	5.4	7.7	8.4	10.2	12.3	40.0	3.0	13.5	3.2	21.1	9.9	8.7	8.1	10.9	7.2	7.0	5.5	6.5	2.8	7.2	5.6	1.3	4.6	2.0	1.4	3.7	4.2	8.8	0.2	3.5	10.3	10.1	8.9	18.1	6.0	10.1	6.0	6.0	6.0	8.6	10.9	8.0	10.0	7.1	3.8	5.1	3.7	4.5	6.4	5.2	16.0	2.5	1.4	3.7	0.8	4.2	3.1	4.5	4.0	1.6	5.3	6.6	4.1	0.5	3.3	0.3	2.1	4.2	3.0	13.7	20.9	15.0	16.2	14.0	9.7	24.1	10.9	15.7	23.6	6.0	8.6	37.4	23.2	20.9	21.6	13.4	17.8	0.0	4.5	12.2	25.5	12.1	1.7	12.0	22.9	18.0	6.4	0.0	9.4	36.5	23.1	23.5	23.1	13.5	13.5	54.0	15.0	20.9	19.7	14.7	24.7	21.3	16.9	8.2	10.0	20.4	9.0	10.5	41.1	8.4	55.7	45.3	38.4	7.7	16.5	21.0	14.9	30.5	11.3	31.1
CSF3R	"CD114, GCSFR"	ENSG00000119535	"Colony stimulating factor 3 receptor"	Q99062	1	36466043-36483278	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7"	"Cell type enhanced"	"Detected in many"	27	"Alveolar cells type 2: 228.0;Cytotrophoblasts: 271.6;Syncytiotrophoblasts: 999.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 167.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 167.3"	"Group enriched"	"Detected in some"	18	"BEWO: 34.9;NB-4: 9.4;THP-1: 22.9;U-937: 22.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB017116, HPA048086"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB017116: , HPA048086: AB_2680257"	"unprognostic (5.57e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.88e-1)"	"unprognostic (2.92e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.83e-1)"	"unprognostic (5.65e-2)"	"unprognostic (2.47e-1)"	"unprognostic (3.44e-1)"	"prognostic unfavorable (5.72e-4)"	"unprognostic (6.33e-2)"	"prognostic unfavorable (3.79e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.31e-2)"	8.5	1.5	2.9	39.5	3.2	88.9	2.4	0.7	2.9	1.1	1.1	4.2	0.4	0.6	0.7	1.1	1.2	6.9	4.3	5.6	2.6	2.0	1.7	4.5	26.9	27.5	7.2	1.1	1.1	1.3	0.3	1.1	152.7	3.8	1.3	0.5	2.1	1.6	0.5	0.6	0.3	1.6	3.1	7.1	71.4	2.2	1.4	3.3	1.1	1.0	0.4	0.9	4.6	3.9	0.0	8.2	167.3	22.1	0.2	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	34.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	9.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.0	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.1	0.0	0.0	22.1	0.6	0.0	4.8	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	167.3	0.2	1.8	0.2	0.0	10.3	2.9	3.2	0.7	2.9	2.6	2.0	7.2	1.1	3.8	3.3	23.8	228.0	2.4	0.6	0.9	0.0	1.4	0.0	12.0	18.2	0.0	0.0	271.6	0.0	0.0	0.4	1.9	0.0	0.0	0.0	49.1	3.0	0.2	17.4	0.8	60.8	0.0	0.0	3.7	146.3	0.4	0.3	62.6	0.0	3.6	0.0	0.2	0.1	0.0	0.0	0.4	0.2	0.0	0.3	0.0	0.2	0.1	999.2	0.5	0.0	2.2
CTCF		ENSG00000102974	"CCCTC-binding factor"	P49711	16	67562407-67639185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Chromosome partition, Transcription, Transcription regulation"	"Activator, Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004122, CAB062550, CAB068181, CAB068182"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB062550: AB_2665624, CAB068181: AB_2665625, CAB068182: AB_2665626, HPA004122: AB_2667139"	"unprognostic (2.70e-1)"	"unprognostic (4.21e-2)"	"unprognostic (3.41e-2)"	"unprognostic (4.70e-2)"	"unprognostic (4.41e-2)"	"unprognostic (2.70e-1)"	"prognostic unfavorable (4.21e-4)"	"unprognostic (1.71e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.36e-2)"	"unprognostic (1.99e-2)"	"prognostic favorable (4.06e-4)"	"unprognostic (3.47e-1)"	"unprognostic (5.99e-2)"	"unprognostic (4.58e-2)"	"unprognostic (1.11e-2)"	19.1	17.5	22.3	35.0	24.3	32.2	20.2	31.6	26.6	23.0	19.4	20.5	21.0	16.5	24.2	15.4	23.1	21.7	20.3	17.6	21.8	16.7	19.5	19.5	17.2	27.9	22.3	21.0	24.6	21.2	42.4	21.8	23.5	17.9	19.4	23.2	14.3	19.9	24.9	29.4	25.2	21.4	22.0	20.2	26.1	18.5	14.8	22.9	68.8	20.7	16.2	35.5	22.6	26.7	10.1	7.9	9.6	6.2	4.9	7.2	1.9	11.0	17.1	22.8	9.0	10.4	8.9	18.5	10.6	11.3	15.7	15.0	14.0	11.5	34.7	8.6	9.2	8.9	14.4	21.9	11.9	17.7	12.3	14.4	21.1	9.7	16.0	7.1	23.8	20.2	7.2	14.5	11.7	13.1	9.4	11.9	27.9	18.4	14.5	13.0	21.7	50.0	9.1	19.8	12.7	11.5	36.6	18.7	19.1	9.6	16.1	19.5	13.5	19.2	11.2	9.3	12.5	13.8	14.8	11.3	13.6	14.1	10.3	11.6	12.7	15.9	50.6	7.8	14.3	14.5	9.4	3.4	4.9	6.7	3.4	6.3	7.9	7.2	5.4	3.1	10.1	5.9	6.7	9.6	4.9	6.2	7.9	5.4	1.9	22.3	24.3	31.6	26.6	21.8	16.7	22.3	21.0	17.9	22.9	20.8	28.0	26.8	21.6	19.8	33.6	32.3	38.2	17.4	38.7	22.7	7.9	20.9	16.6	25.5	0.9	30.1	18.7	46.7	29.1	27.5	18.8	26.1	18.5	21.3	20.8	42.9	30.0	20.3	23.2	2.0	23.0	23.7	11.8	24.4	25.6	30.4	26.6	14.0	26.9	19.5	27.1	19.4	21.7	15.8	25.6	21.7	24.7	32.3	21.2	29.4
CTNNB1	"armadillo, beta-catenin, CTNNB"	ENSG00000168036	"Catenin beta 1"	P35222	3	41194741-41260096	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation, Wnt signaling pathway"	Activator	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Syncytiotrophoblasts: 451.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000108, CAB001950, HPA029159, HPA029160"	Supported		Enhanced	"Plasma membrane"		NA	NA		1000000	"Plasma membrane"		"CAB000108: , CAB001950: , HPA029159: AB_10599619, HPA029160: AB_10600996"	"unprognostic (2.47e-1)"	"unprognostic (3.48e-2)"	"prognostic favorable (7.54e-4)"	"unprognostic (1.61e-1)"	"unprognostic (9.55e-2)"	"unprognostic (1.05e-2)"	"unprognostic (3.20e-3)"	"unprognostic (2.79e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.80e-2)"	"unprognostic (1.88e-2)"	"unprognostic (9.05e-2)"	"unprognostic (1.97e-3)"	"unprognostic (1.82e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.61e-1)"	"unprognostic (9.79e-2)"	52.9	54.5	38.8	33.5	45.9	46.3	70.5	78.8	59.3	71.7	49.6	57.3	34.2	48.7	79.2	42.5	46.3	49.8	45.0	42.1	38.6	41.5	46.9	53.2	53.6	31.6	37.0	47.0	84.2	38.6	59.2	44.0	82.6	41.5	50.8	50.1	75.9	53.9	49.7	31.2	44.7	70.4	66.5	39.4	41.0	37.3	29.0	39.3	40.1	62.3	44.5	36.6	46.9	54.2	10.1	13.5	7.5	14.5	11.1	13.5	4.8	22.5	30.0	63.3	35.4	34.1	28.0	48.6	25.4	36.1	42.5	42.3	20.7	32.2	18.5	23.2	44.9	19.1	16.9	45.8	73.4	45.6	17.1	31.2	29.8	39.9	73.8	25.5	16.9	14.4	40.8	33.3	50.8	30.9	34.8	37.3	8.9	21.1	11.5	47.1	22.8	11.8	9.1	57.6	30.1	23.3	8.9	41.2	12.3	26.3	70.4	15.1	25.6	42.1	21.5	113.0	78.5	35.2	35.2	48.1	32.0	24.5	20.5	37.2	7.2	11.1	19.7	32.8	21.3	53.4	4.3	8.1	6.9	11.2	14.5	13.5	9.6	10.5	12.1	13.5	10.1	10.7	10.8	7.5	11.1	13.7	11.7	12.6	4.8	38.8	45.9	78.8	59.3	38.6	41.5	37.0	47.0	41.5	39.3	128.1	177.9	34.4	112.8	189.7	38.8	66.6	99.3	119.1	161.5	59.3	31.4	274.7	29.9	114.0	5.5	164.1	147.7	46.7	68.4	90.6	121.0	101.1	113.2	146.9	108.7	12.7	90.0	114.2	130.0	5.0	55.3	139.8	192.3	115.4	132.0	103.7	102.3	182.4	81.7	57.4	56.6	45.3	106.2	71.5	40.7	152.9	451.2	62.8	118.4	109.3
CUX1	"CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6"	ENSG00000257923	"Cut like homeobox 1"	"P39880, Q13948"	7	101815904-102283958	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation, Transport"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"non-classical monocyte: 21.0"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003277, HPA003317"	Approved		Supported	"Nucleoplasm,Golgi apparatus"		NA	NA			"Nucleoplasm, Golgi apparatus"		"HPA003277: AB_10601804, HPA003317: AB_2666891"	"unprognostic (5.86e-2)"	"unprognostic (5.39e-3)"	"unprognostic (9.62e-3)"	"unprognostic (1.73e-1)"	"prognostic unfavorable (7.51e-4)"	"unprognostic (5.85e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.89e-3)"	"unprognostic (2.20e-1)"	"unprognostic (2.50e-1)"	"prognostic favorable (5.72e-7)"	"unprognostic (1.12e-1)"	"unprognostic (8.85e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.97e-1)"	19.3	12.7	22.9	19.2	24.4	19.5	12.3	48.6	29.9	31.6	26.4	23.1	17.3	22.2	52.1	17.4	23.9	24.5	23.2	53.8	18.8	18.3	27.4	16.0	22.0	11.8	20.4	11.7	33.0	41.4	34.4	30.2	24.4	16.9	22.8	17.2	26.8	26.3	16.9	31.0	15.9	25.3	27.5	31.6	15.0	23.4	8.3	17.1	44.0	33.5	23.2	24.1	31.8	21.9	2.0	12.1	4.7	21.0	3.0	2.2	4.5	14.5	15.6	11.0	13.7	9.0	18.6	6.9	14.7	15.6	6.2	4.1	9.3	9.4	18.9	23.6	14.5	11.5	12.0	7.0	11.8	3.7	9.0	7.8	6.6	11.6	7.7	23.9	8.5	3.6	12.9	24.1	4.8	10.9	17.9	8.0	12.2	15.3	16.0	5.8	30.0	27.8	10.5	4.5	22.5	16.4	18.4	9.2	22.3	10.2	16.7	10.2	30.3	12.8	32.2	12.5	9.6	6.3	10.3	11.9	26.3	17.8	19.8	8.3	10.5	4.9	40.8	24.3	7.9	18.3	2.1	8.6	1.5	2.1	8.8	2.2	2.0	1.6	2.2	7.0	1.7	1.6	2.2	4.7	3.0	21.0	12.1	1.5	4.5	22.9	24.4	48.6	29.9	18.8	18.3	20.4	11.7	16.9	17.1	92.3	45.5	28.3	27.6	23.4	53.5	101.2	28.1	46.8	45.5	38.4	64.8	44.1	8.3	29.7	7.2	31.1	49.5	0.0	20.8	48.4	40.9	44.0	11.5	30.9	29.9	50.9	40.8	32.5	70.3	7.4	38.3	36.4	16.9	25.2	44.2	49.6	28.5	54.3	57.3	53.1	57.1	25.8	24.5	12.0	13.8	37.9	73.6	20.8	37.2	42.8
CXCR4	"CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R"	ENSG00000121966	"C-X-C motif chemokine receptor 4"	P61073	2	136114349-136118165	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 149.9;lymphoid tissue: 186.3"	"Cell type enhanced"	"Detected in many"	14	"B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.19e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.69e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.12e-2)"	"unprognostic (4.99e-2)"	"unprognostic (9.25e-2)"	"unprognostic (6.06e-2)"	"prognostic favorable (2.05e-4)"	"unprognostic (1.23e-1)"	"unprognostic (2.66e-1)"	"prognostic unfavorable (1.41e-7)"	"prognostic unfavorable (5.67e-4)"	"unprognostic (1.57e-1)"	"unprognostic (3.47e-2)"	"unprognostic (9.33e-2)"	15.4	26.5	3.0	39.1	3.4	149.9	9.7	0.8	2.1	7.7	8.7	6.8	1.5	1.6	8.3	3.8	16.4	9.1	12.0	5.4	4.1	4.7	8.2	7.1	29.3	94.5	6.5	1.3	6.3	3.1	0.7	8.1	7.8	6.1	6.8	7.0	10.0	10.6	2.2	3.2	2.3	57.8	3.8	22.9	82.4	8.0	7.2	3.4	186.3	9.2	4.6	97.5	50.0	6.6	47.3	16.8	37.8	7.2	4.0	32.0	11.9	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	76.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	3.8	0.9	4.6	12.1	0.0	0.0	10.5	8.3	0.0	0.0	0.0	0.0	0.0	7.3	43.5	0.1	41.0	0.0	0.2	69.2	9.4	1.2	5.9	0.4	36.7	8.5	13.3	0.6	0.0	4.2	3.5	0.0	0.2	0.0	0.4	0.0	20.7	1.0	0.0	0.2	0.0	0.0	88.9	15.0	89.4	0.0	17.4	0.0	17.9	7.2	29.6	22.9	3.8	18.7	30.1	21.1	21.7	6.6	47.3	32.0	30.1	37.8	4.0	2.1	16.8	18.9	11.9	3.0	3.4	0.8	2.1	4.1	4.7	6.5	1.3	6.1	3.4	14.9	64.2	772.9	4.0	36.5	4.4	3.6	2.5	4.0	6.8	3.5	0.0	1.4	11.6	3.6	0.9	19.0	0.0	46.7	0.8	2.2	30.2	4.8	11.6	5.5	168.4	0.0	1.7	22.7	175.5	1.7	1.4	299.5	108.0	255.1	0.1	1.0	1.6	0.0	2.5	2.1	0.6	45.3	16.3	0.5	5.5	31.1	5.3	588.4	0.4	3.2
CYLD	"CYLD1, KIAA0849, USPL2"	ENSG00000083799	"CYLD lysine 63 deubiquitinase"	Q9NQC7	16	50742050-50801935	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Immunity, Innate immunity, Ubl conjugation pathway, Wnt signaling pathway"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 47.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011713, HPA050095"	Approved		Supported	"Nucleoplasm,Centriolar satellite"		Yes	No			"Centriolar satellite"	Nucleoplasm	"CAB011713: AB_731794, HPA050095: AB_2681013"	"unprognostic (9.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (5.01e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.84e-1)"	"unprognostic (5.06e-2)"	"unprognostic (3.87e-2)"	"unprognostic (3.24e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.18e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.43e-2)"	"unprognostic (6.83e-2)"	"unprognostic (8.42e-2)"	9.3	16.2	13.9	22.9	26.4	51.1	9.1	14.2	20.9	9.2	10.3	18.8	12.8	10.2	16.1	8.1	15.3	8.5	13.3	12.7	15.7	17.0	9.4	13.2	15.6	30.7	16.3	14.3	11.5	12.2	20.3	27.8	9.8	20.0	11.0	12.7	13.3	12.6	10.9	31.7	12.4	14.2	12.5	16.3	23.4	12.4	22.6	13.7	16.9	16.2	8.0	29.3	14.1	12.6	9.2	10.2	31.4	9.8	13.6	19.1	10.2	9.3	2.9	3.4	3.8	5.4	7.8	3.1	13.8	20.2	14.4	8.5	2.4	4.4	10.7	5.0	13.5	15.7	3.6	4.0	8.4	21.5	47.2	6.1	5.3	5.2	2.0	10.7	5.3	25.3	8.5	6.8	17.4	18.2	13.7	5.8	7.6	2.2	9.4	20.1	1.4	5.2	7.7	3.6	2.9	4.9	4.7	6.9	10.3	4.7	3.2	4.4	3.3	11.7	4.0	3.4	5.4	4.0	6.7	6.5	24.7	5.6	8.6	5.6	24.8	23.5	12.0	18.1	6.0	5.2	31.4	8.6	20.8	10.7	9.8	12.9	9.2	15.8	14.4	10.2	6.2	14.7	11.4	19.4	13.6	9.5	6.2	19.1	10.2	13.9	26.4	14.2	20.9	15.7	17.0	16.3	14.3	20.0	13.7	41.7	25.6	39.6	48.8	106.7	75.4	32.7	25.5	12.0	19.4	17.4	88.4	5.4	5.0	18.3	32.8	37.9	13.4	46.7	16.5	3.8	37.2	52.3	78.5	22.1	19.0	63.5	29.9	21.5	32.3	24.7	23.6	47.1	70.9	34.3	10.3	22.6	15.2	18.7	19.8	10.3	49.3	6.5	34.4	52.6	13.8	135.9	3.4	73.4	12.0	56.3
DAXX	DAP6	ENSG00000204209	"Death domain associated protein"	Q9UER7	6	33318558-33323016	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Host-virus interaction, Transcription, Transcription regulation"	"Chaperone, Chromatin regulator, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002224, HPA008736, HPA008797, CAB025546, HPA065779"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nucleoplasm, Nuclear bodies"		"CAB002224: AB_563688, CAB025546: , HPA008736: AB_1078625, HPA008797: AB_2797218, HPA065779: AB_2685558"	"prognostic favorable (6.05e-4)"	"unprognostic (2.90e-1)"	"unprognostic (9.66e-2)"	"unprognostic (4.04e-2)"	"unprognostic (8.55e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.46e-3)"	"unprognostic (3.48e-1)"	"unprognostic (1.92e-1)"	"unprognostic (8.58e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.01e-2)"	"prognostic unfavorable (6.32e-7)"	"unprognostic (2.43e-1)"	"unprognostic (5.37e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.04e-1)"	10.4	14.3	10.7	13.5	11.9	8.8	10.8	11.3	14.8	11.8	12.2	9.4	7.3	11.2	13.2	43.7	13.5	12.6	12.1	9.1	9.7	7.3	9.2	12.0	10.3	18.3	10.2	8.5	13.8	18.6	24.4	10.4	11.6	11.6	13.0	14.1	7.3	10.7	15.2	14.8	11.6	12.7	15.5	8.1	20.4	10.5	20.2	11.5	25.0	16.1	6.8	30.9	11.5	10.9	17.0	5.9	12.6	11.2	15.3	18.2	21.8	2.1	0.0	7.1	2.8	1.2	2.3	4.7	7.0	22.9	17.9	13.2	0.8	2.4	6.9	2.5	5.4	20.5	1.3	0.1	5.7	16.6	8.2	15.6	9.0	12.4	11.1	3.9	9.6	2.6	6.0	8.5	2.0	5.3	5.3	0.5	4.5	5.0	4.5	5.5	5.2	3.8	21.3	0.4	0.1	3.3	5.9	0.1	7.7	1.4	0.7	8.5	2.2	0.0	0.4	3.7	3.5	2.2	0.2	5.9	4.4	5.6	0.2	0.1	7.8	16.2	14.9	3.3	4.4	4.7	7.8	7.5	12.6	16.3	8.0	18.2	16.6	15.4	15.8	5.9	17.0	13.9	14.1	7.4	15.3	11.2	5.9	17.1	21.8	10.7	11.9	11.3	14.8	9.7	7.3	10.2	8.5	11.6	11.5	6.0	21.4	27.0	17.6	52.0	17.3	7.5	15.3	14.7	25.0	12.2	17.7	21.7	19.9	29.4	9.8	20.6	18.0	0.0	33.3	29.5	26.3	21.9	35.9	13.5	21.9	14.3	20.2	11.6	13.7	4.7	16.4	20.8	23.6	60.5	19.5	17.7	46.9	21.0	21.9	11.9	73.3	12.9	23.7	48.8	34.9	53.2	20.7	51.7	20.9	30.2
DCTN1		ENSG00000204843	"Dynactin subunit 1"	Q14203	2	74361154-74392087	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Mitosis, Transport"		"Amyotrophic lateral sclerosis, Cancer-related genes, Neurodegeneration, Neuropathy, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009108, HPA034635, HPA071875"	Approved		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		Yes	No		220000	Microtubules	"Cytokinetic bridge, Mitotic spindle"	"CAB009108: AB_2090601, HPA034635: AB_2674256, HPA071875: "	"unprognostic (1.14e-1)"	"unprognostic (7.19e-2)"	"unprognostic (1.33e-3)"	"unprognostic (4.08e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.67e-1)"	"unprognostic (4.61e-3)"	"unprognostic (2.11e-2)"	"unprognostic (2.79e-1)"	"unprognostic (3.73e-3)"	"unprognostic (1.87e-1)"	"unprognostic (2.26e-1)"	"prognostic favorable (2.34e-7)"	"unprognostic (5.41e-2)"	"unprognostic (3.11e-1)"	"unprognostic (7.86e-3)"	"unprognostic (1.12e-3)"	20.7	21.1	36.0	13.7	54.6	11.1	14.0	45.9	70.9	23.5	17.1	37.8	8.9	11.8	18.5	9.8	22.9	19.7	15.1	37.7	39.5	35.8	13.5	10.0	18.9	10.9	37.7	40.3	21.9	15.2	70.2	21.6	17.2	54.6	16.5	14.0	13.2	23.5	21.7	39.5	19.9	13.7	26.5	32.2	12.4	16.0	25.5	26.7	9.4	17.0	9.5	12.8	17.2	18.0	11.6	12.1	12.9	15.8	9.8	16.7	15.5	19.1	22.5	21.1	22.0	38.8	29.0	17.1	30.9	32.3	39.5	28.2	29.9	14.8	26.4	12.7	64.2	21.8	19.2	25.8	39.3	30.2	32.9	26.0	27.4	18.1	25.1	30.0	14.9	34.0	34.7	19.2	42.9	25.6	27.1	33.7	24.2	11.8	18.9	29.7	16.4	27.1	15.5	22.8	23.5	24.0	24.4	37.2	18.9	21.9	11.9	26.1	23.1	17.3	20.8	18.6	19.2	13.4	10.9	25.5	36.0	26.1	15.4	23.0	11.7	9.3	24.0	33.7	24.4	25.2	7.3	11.4	12.9	16.7	14.2	13.5	11.6	9.5	12.4	12.1	8.6	6.8	7.5	9.8	9.8	15.8	9.6	8.1	15.5	36.0	54.6	45.9	70.9	39.5	35.8	37.7	40.3	54.6	26.7	29.8	20.1	9.7	8.2	9.0	26.0	50.1	12.7	12.0	15.9	27.9	23.6	24.7	16.6	19.4	5.8	25.5	38.3	23.3	17.1	23.3	20.8	9.2	28.8	17.0	24.6	85.8	16.0	25.8	15.9	3.9	41.4	16.7	15.1	27.9	26.4	15.6	21.6	24.6	48.8	16.1	43.6	19.4	27.1	28.4	35.7	10.3	21.1	13.8	20.7	9.5
DDB2	"DDBB, FLJ34321, UV-DDB2, XPE"	ENSG00000134574	"Damage specific DNA binding protein 2"	Q92466	11	47214465-47239240	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair, Ubl conjugation pathway"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"monocytes: 221.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025912, HPA058406"	Enhanced		Supported	"Nucleoplasm,Cell Junctions"		NA	NA			"Nucleoplasm, Cell Junctions"		"CAB025912: , HPA058406: AB_2683708"	"prognostic favorable (7.29e-4)"	"prognostic favorable (1.58e-4)"	"unprognostic (1.49e-1)"	"prognostic favorable (1.20e-4)"	"unprognostic (4.29e-2)"	"unprognostic (2.04e-2)"	"unprognostic (2.96e-2)"	"unprognostic (6.18e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.58e-3)"	"unprognostic (3.53e-1)"	"unprognostic (1.94e-1)"	"unprognostic (4.57e-3)"	"unprognostic (1.21e-2)"	"unprognostic (4.25e-2)"	"unprognostic (9.82e-3)"	"unprognostic (1.07e-1)"	12.2	22.2	5.3	13.3	8.6	8.1	11.3	11.0	8.2	16.8	13.5	7.3	13.4	6.0	18.2	14.1	25.4	14.3	13.0	6.1	4.7	2.9	6.6	20.8	11.3	16.1	15.0	5.0	9.8	15.6	6.1	8.6	5.5	6.3	20.9	12.3	8.1	17.6	14.8	6.3	36.9	11.0	19.0	17.6	15.1	9.1	7.6	7.6	23.3	6.6	16.7	26.0	17.3	15.2	11.4	6.1	11.5	11.0	7.4	27.0	9.0	8.4	22.7	9.5	7.1	6.1	12.4	11.2	9.2	21.7	11.9	14.0	3.7	4.9	20.3	1.9	8.4	8.9	14.8	5.4	18.8	5.9	5.0	10.2	4.7	21.7	16.8	6.0	5.5	12.7	16.6	21.4	5.9	13.2	3.8	34.6	5.3	1.2	9.9	19.4	15.9	21.1	2.6	3.0	11.1	8.2	10.6	2.4	10.9	5.0	8.3	5.0	6.2	11.3	3.3	3.0	11.9	20.8	1.8	14.9	36.4	16.6	7.9	4.3	10.4	7.9	4.5	13.7	7.0	13.0	5.9	8.1	11.5	12.1	11.0	11.7	11.4	12.7	11.7	6.1	7.4	9.4	10.1	2.2	7.4	9.2	0.1	27.0	9.0	5.3	8.6	11.0	8.2	4.7	2.9	15.0	5.0	6.3	7.6	14.9	20.3	19.2	35.4	34.6	4.6	7.2	12.7	10.7	13.6	5.2	9.8	2.1	8.3	9.6	1.1	17.8	7.9	0.0	12.0	7.7	14.1	9.5	22.0	12.4	15.9	1.6	7.5	14.1	16.5	1.6	17.5	16.5	18.6	221.8	13.6	14.2	15.3	7.0	9.9	6.2	11.6	0.0	15.5	0.7	9.9	26.5	1.3	38.8	14.0	21.3
DDIT3	"CHOP, CHOP10, GADD153"	ENSG00000175197	"DNA damage inducible transcript 3"	P35638	12	57516588-57521737	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Cell cycle, Growth arrest, Stress response, Transcription, Transcription regulation, Unfolded protein response, Wnt signaling pathway"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 50.8"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HHSteC: 125.3;hTERT-HME1: 63.0;SK-MEL-30: 58.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058416, HPA068416"	Uncertain		Supported	Nucleoplasm		No	No			Nucleoplasm		"HPA058416: AB_2683712, HPA068416: AB_2685985"	"unprognostic (1.12e-1)"	"unprognostic (5.33e-2)"	"unprognostic (2.20e-3)"	"unprognostic (4.92e-2)"	"unprognostic (7.86e-3)"	"unprognostic (2.28e-1)"	"prognostic unfavorable (6.55e-4)"	"unprognostic (8.55e-2)"	"unprognostic (1.26e-3)"	"unprognostic (9.40e-3)"	"unprognostic (4.92e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.52e-2)"	"unprognostic (3.70e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.56e-1)"	"unprognostic (6.76e-2)"	19.1	25.5	15.9	8.3	29.9	82.2	21.4	16.7	25.2	14.8	13.5	20.1	15.7	10.6	19.5	55.8	13.0	13.1	16.0	25.8	18.6	19.8	28.8	26.1	17.1	8.8	34.4	15.5	27.3	13.0	13.5	26.8	18.0	32.1	22.8	13.9	27.3	20.7	13.9	18.0	16.3	10.9	15.4	21.8	11.2	14.7	14.3	35.3	2.9	88.9	12.6	9.4	30.2	17.0	13.8	4.6	50.8	5.4	9.2	10.9	5.1	2.6	2.4	1.5	5.3	14.4	9.8	8.4	7.3	16.3	10.9	10.3	8.6	7.0	3.8	7.4	2.1	29.4	3.2	5.9	1.1	11.3	3.1	2.4	2.9	2.7	6.2	125.3	4.6	4.6	27.9	23.7	18.4	63.0	12.8	2.6	4.0	12.6	14.5	4.8	1.6	3.1	6.1	3.0	5.6	5.8	1.7	34.4	3.2	3.8	3.4	3.2	2.4	2.1	2.5	58.5	6.1	5.3	12.5	1.5	7.5	3.2	7.0	6.3	25.7	8.6	4.0	9.0	4.4	13.1	27.5	5.4	13.5	8.0	4.6	7.0	13.8	5.7	7.3	3.7	13.1	10.9	9.9	50.8	9.2	5.1	4.6	6.5	5.1	15.9	29.9	16.7	25.2	18.6	19.8	34.4	15.5	32.1	35.3	17.9	66.4	36.9	73.0	50.0	111.0	146.3	38.2	24.1	25.0	21.0	86.4	37.7	97.8	32.3	4.8	25.9	67.5	0.0	13.8	18.0	63.8	157.0	198.7	17.9	39.8	52.4	221.2	23.4	24.7	5.5	25.9	50.7	84.4	8.2	36.5	118.8	35.9	70.2	35.7	34.7	135.4	12.9	94.3	83.5	13.4	40.0	90.2	46.8	32.1	42.1
DDR2	"NTRKR3, TKT, TYRO10"	ENSG00000162733	"Discoidin domain receptor tyrosine kinase 2"	Q16832	1	162631373-162787400	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Osteogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Fibroblasts: 84.7;Leydig cells: 58.4;Peritubular cells: 83.1;Smooth muscle cells: 68.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;MAIT T-cell: 1.3"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 61.7;ASC TERT1: 61.0;BJ hTERT+: 45.1;fHDF/TERT166: 32.3;HSkMC: 43.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070112			Supported	"Plasma membrane,Actin filaments"		Yes	No		850000	"Plasma membrane, Actin filaments"		"HPA070112: AB_2686229"	"unprognostic (4.12e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.62e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (1.73e-7)"	"unprognostic (1.56e-3)"	"unprognostic (8.26e-3)"	"unprognostic (7.57e-2)"	"unprognostic (4.10e-3)"	42.1	43.5	4.7	10.9	6.9	0.2	15.6	7.9	7.1	30.3	30.4	9.0	18.6	3.3	24.2	17.7	25.0	13.4	16.6	15.4	7.9	4.7	4.0	3.3	8.9	5.1	12.9	3.4	26.4	2.2	2.1	4.0	6.6	12.7	21.8	9.1	30.7	6.4	19.3	5.2	6.1	10.1	34.3	19.7	3.4	14.1	8.3	7.5	0.0	8.6	12.8	4.1	29.0	18.3	0.1	0.2	0.0	0.0	0.2	1.3	0.0	0.1	0.0	0.0	16.3	61.7	61.0	0.2	24.0	45.1	10.5	15.1	0.0	0.0	0.0	0.0	32.3	2.1	0.0	0.0	0.1	14.4	12.9	0.1	0.0	0.1	0.0	26.8	0.0	0.0	43.3	0.1	18.5	0.5	17.0	12.1	0.1	0.1	5.1	9.6	0.0	0.0	0.0	0.1	0.0	0.1	0.0	6.9	0.1	0.0	0.0	0.0	9.9	0.0	0.0	0.8	0.9	0.0	0.0	0.6	16.8	3.7	8.5	3.3	0.7	1.3	0.0	15.2	0.0	17.0	0.0	0.0	0.0	1.1	0.0	1.3	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	4.7	6.9	7.9	7.1	7.9	4.7	12.9	3.4	12.7	7.5	3.0	2.9	0.0	2.4	11.2	3.1	23.3	2.5	4.0	1.2	0.0	0.0	0.5	0.0	0.5	6.9	21.3	2.0	0.0	1.5	0.4	84.7	4.1	1.1	3.0	1.1	0.0	1.2	24.5	2.1	4.0	58.4	1.5	21.9	0.0	0.7	19.0	1.5	1.7	83.1	0.9	2.9	38.8	68.4	0.9	0.9	7.5	0.8	1.3	0.6	3.3
DDX10	"Dbp4, HRH-J8"	ENSG00000178105	"DEAD-box helicase 10"	Q13206	11	108665025-108940930	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cone photoreceptor cells: 90.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 58.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004691	Approved		Approved	Nucleoli		NA	NA			Nucleoli		"HPA004691: AB_1078629"	"unprognostic (9.49e-2)"	"unprognostic (9.32e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.58e-1)"	"unprognostic (7.97e-2)"	"unprognostic (1.48e-2)"	"prognostic unfavorable (2.52e-5)"	"unprognostic (2.86e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavorable (5.75e-4)"	"unprognostic (1.00e-1)"	"prognostic favorable (2.14e-5)"	"unprognostic (5.20e-2)"	"unprognostic (1.98e-1)"	"unprognostic (4.64e-1)"	"unprognostic (2.43e-3)"	14.0	11.9	17.3	15.0	20.3	10.4	15.5	20.5	18.3	14.3	12.2	8.1	11.7	8.8	18.4	12.8	12.6	16.8	8.8	12.1	13.5	11.5	19.6	12.5	10.6	13.1	12.2	16.3	18.6	18.0	16.7	22.2	12.9	13.1	12.4	13.3	7.9	10.6	14.7	13.6	14.8	9.1	16.8	13.3	15.0	11.3	25.1	12.6	13.8	13.4	8.8	14.2	14.3	18.8	11.6	8.4	1.4	6.7	9.4	11.3	4.3	7.4	7.3	6.9	9.7	6.9	5.6	7.2	8.0	4.3	9.7	9.6	20.8	10.9	25.3	15.1	6.1	10.5	8.3	19.8	9.7	14.0	9.6	8.9	17.1	4.3	7.7	12.3	17.4	8.2	5.0	7.6	11.0	13.8	5.8	8.8	6.6	24.0	2.8	9.5	4.8	14.6	14.7	9.0	14.0	11.1	12.5	11.3	23.6	6.0	6.4	12.9	6.8	11.2	9.9	4.2	9.7	12.0	6.1	9.2	10.2	10.4	9.7	10.8	4.3	7.5	58.4	3.5	21.1	10.3	1.4	5.0	1.0	8.6	6.7	11.3	10.4	7.5	10.1	8.4	11.6	8.1	7.8	0.7	9.4	6.4	8.2	6.3	4.3	17.3	20.3	20.5	18.3	13.5	11.5	12.2	16.3	13.1	12.6	14.9	30.3	22.6	17.3	25.2	21.1	18.2	7.6	18.7	22.7	3.5	90.3	21.4	16.6	13.2	28.6	19.8	2.9	0.0	18.3	17.8	17.6	12.7	13.9	10.2	13.1	17.5	14.5	9.2	9.2	5.9	27.3	18.2	6.8	18.0	7.8	8.9	15.1	3.5	20.1	46.2	25.2	12.9	15.6	64.4	44.6	25.3	21.6	14.4	13.6	12.2
DDX3X	"DBX, DDX14, DDX3, HLP2"	ENSG00000215301	"DEAD-box helicase 3, X-linked"	O00571	X	41333284-41364472	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Chromosome partition, Host-virus interaction, Immunity, Innate immunity, Ribosome biogenesis, Transcription, Transcription regulation, Translation regulation"	"DNA-binding, Helicase, Hydrolase, RNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Late spermatids: 631.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001648, HPA005631, HPA059585"	Supported	Supported	Approved	Nucleoplasm,Cytosol		NA	NA		110000	Cytosol	Nucleoplasm	"HPA001648: AB_1078635, HPA005631: AB_1078633, HPA059585: AB_2684073"	"unprognostic (2.42e-2)"	"unprognostic (1.11e-1)"	"unprognostic (8.01e-3)"	"unprognostic (1.66e-1)"	"unprognostic (8.12e-2)"	"unprognostic (6.43e-2)"	"unprognostic (1.17e-3)"	"unprognostic (1.88e-1)"	"unprognostic (9.80e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.25e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.95e-1)"	"unprognostic (4.77e-1)"	"unprognostic (9.44e-2)"	"unprognostic (2.93e-2)"	80.9	49.3	26.1	40.0	34.5	49.3	46.5	31.1	36.2	52.4	43.3	35.1	21.3	29.5	56.4	25.9	53.5	56.3	42.6	47.6	30.8	24.5	55.6	77.9	45.3	40.4	41.4	29.0	60.1	30.9	68.7	60.2	79.9	37.9	30.0	29.2	30.8	37.4	26.5	63.4	42.2	54.0	57.2	53.9	46.1	43.0	27.0	39.0	49.2	45.6	44.0	42.6	55.8	50.2	13.1	20.5	32.0	21.6	17.3	21.5	17.9	45.8	51.1	47.7	26.2	56.2	47.7	29.1	33.5	47.1	34.4	27.6	52.5	30.9	0.5	23.9	37.4	41.4	31.0	58.3	47.1	57.3	27.2	45.4	29.2	50.8	31.5	29.2	54.7	52.5	34.5	33.4	57.9	56.0	38.5	53.9	25.7	53.6	28.9	31.9	34.7	34.4	17.1	45.9	24.4	20.6	40.4	50.8	37.4	32.4	61.9	32.6	49.4	75.8	38.9	40.1	50.2	35.0	37.2	48.6	35.5	37.9	37.9	39.7	33.7	40.0	45.3	35.7	33.2	33.6	22.5	20.2	17.5	14.8	21.1	21.5	13.1	14.5	16.3	20.5	9.0	16.3	15.1	32.0	17.3	21.6	6.9	14.3	17.9	26.1	34.5	31.1	36.2	30.8	24.5	41.4	29.0	37.9	39.0	80.4	161.8	98.4	138.2	234.8	74.1	130.3	81.5	65.6	85.3	55.8	123.7	79.4	36.5	59.8	317.8	170.8	178.1	116.8	73.8	80.3	155.2	122.4	162.7	142.1	107.7	57.2	176.3	120.3	200.6	631.6	61.5	160.4	121.4	72.1	136.1	88.8	86.2	143.8	59.1	71.7	117.4	71.1	155.5	15.7	55.7	291.5	144.6	132.3	100.9	182.7
DDX5	"G17P1, HLR1, p68"	ENSG00000108654	"DEAD-box helicase 5"	P17844	17	64499616-64508199	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005868, HPA020043, HPA071154"	Supported		Supported	Nucleoplasm,Nucleoli		No	No		150000	"Nucleoplasm, Nucleoli"		"CAB005868: AB_446484, HPA020043: AB_1847572, HPA071154: "	"unprognostic (6.64e-2)"	"unprognostic (6.98e-2)"	"prognostic favorable (2.12e-4)"	"unprognostic (8.94e-2)"	"unprognostic (5.08e-2)"	"unprognostic (9.85e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.17e-2)"	"unprognostic (4.71e-2)"	"unprognostic (3.03e-3)"	"unprognostic (1.44e-1)"	"unprognostic (4.00e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.17e-1)"	"unprognostic (9.28e-3)"	91.6	61.4	46.9	80.0	68.0	108.3	94.7	61.6	58.9	81.6	81.1	53.3	104.2	27.4	106.7	94.5	64.5	96.9	101.4	53.9	48.5	30.6	53.1	68.0	84.8	70.9	62.8	44.1	74.0	49.3	88.9	110.5	56.6	73.1	59.5	55.4	50.9	62.2	103.6	77.6	59.7	54.7	113.1	71.0	67.6	69.0	39.7	57.8	82.1	81.1	77.7	69.3	91.0	63.9	46.9	59.6	66.4	66.2	40.3	60.8	109.8	55.1	20.8	63.0	39.9	58.4	55.0	40.1	54.7	70.6	67.1	67.2	22.5	33.8	80.9	31.4	71.8	47.8	32.9	67.8	62.9	75.9	28.7	48.7	52.6	15.9	17.2	42.8	66.9	56.1	61.9	54.3	61.3	47.8	37.4	71.6	69.9	41.7	69.1	51.7	32.8	139.9	19.5	36.7	50.9	64.3	87.6	66.6	56.9	41.1	26.5	44.3	74.3	53.1	51.5	66.6	56.7	48.2	37.7	50.3	40.8	45.6	43.9	56.6	38.6	76.1	142.8	43.2	32.9	48.1	66.4	62.5	66.4	53.7	56.9	60.8	46.9	42.9	51.7	59.6	46.8	44.5	43.1	37.8	40.3	66.2	37.0	50.2	109.8	46.9	68.0	61.6	58.9	48.5	30.6	62.8	44.1	73.1	57.8	497.3	661.1	481.3	1231.3	781.2	369.6	221.7	262.4	725.4	624.4	350.7	316.1	372.7	283.5	416.6	432.3	643.3	503.6	116.8	366.6	307.8	528.8	417.0	836.7	222.3	399.0	397.3	638.0	483.1	539.2	80.3	384.6	631.0	410.0	779.1	366.4	576.1	376.0	445.4	411.5	208.8	514.0	485.0	599.5	374.0	341.8	652.0	741.9	719.3	310.9	1106.4
DDX6	"HLR2, RCK"	ENSG00000110367	"DEAD-box helicase 6"	P26196	11	118747766-118791149	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"		"Helicase, Hydrolase, RNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004668, HPA024201, HPA026644"	Approved		Supported	"Cytosol,Cytoplasmic bodies"		NA	NA			"Cytoplasmic bodies"	Cytosol	"CAB004668: AB_436960, HPA024201: AB_10603562, HPA026644: AB_1847582"	"unprognostic (1.26e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.40e-2)"	"unprognostic (4.12e-2)"	"unprognostic (5.82e-2)"	"prognostic unfavorable (6.56e-4)"	"unprognostic (3.43e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.00e-1)"	"unprognostic (7.76e-2)"	"unprognostic (1.98e-1)"	"unprognostic (4.91e-3)"	"unprognostic (1.88e-1)"	"unprognostic (9.58e-2)"	"unprognostic (4.55e-2)"	29.8	23.0	25.0	24.1	41.0	43.3	25.1	41.9	39.2	26.9	23.2	29.4	14.5	17.1	30.1	22.9	31.8	23.4	17.5	26.8	25.5	25.1	22.8	24.6	23.4	32.2	21.9	27.1	38.2	27.9	30.9	43.2	26.1	29.6	24.9	20.8	25.4	26.8	22.9	43.8	23.9	24.1	27.8	30.4	30.6	21.2	19.9	24.0	46.0	27.9	19.4	42.8	33.0	25.7	12.2	6.5	17.8	10.3	7.2	12.6	5.7	11.9	16.3	26.3	25.9	23.1	23.7	17.2	16.2	21.3	15.1	14.4	23.7	18.4	27.4	17.1	26.5	15.1	19.1	30.6	23.7	24.4	20.6	6.1	52.9	10.5	19.3	15.3	37.9	20.4	25.0	17.5	22.4	36.4	19.9	24.0	18.5	24.3	39.8	21.3	32.6	27.5	17.6	18.7	16.9	12.0	30.3	21.3	21.9	17.7	31.0	17.4	24.0	30.6	24.6	9.7	20.6	28.7	14.9	27.4	25.1	13.8	14.3	16.3	12.4	16.1	32.7	10.0	18.2	21.4	10.5	4.1	11.6	10.1	5.7	12.6	11.4	9.9	10.4	4.7	12.2	12.4	10.8	17.8	7.2	10.3	6.5	8.9	5.7	25.0	41.0	41.9	39.2	25.5	25.1	21.9	27.1	29.6	24.0	56.6	60.1	71.3	62.3	26.9	78.4	105.7	35.7	40.2	43.3	41.8	47.1	31.3	26.6	28.5	3.7	65.3	48.0	46.7	30.5	30.1	37.5	44.5	49.8	37.6	33.8	58.8	82.4	58.9	51.1	8.2	50.0	42.0	32.1	73.1	55.4	81.3	38.8	65.4	42.5	35.6	75.0	38.8	41.9	66.1	72.8	26.7	64.0	103.8	45.4	65.9
DEK	D6S231E	ENSG00000124795	"DEK proto-oncogene"	P35659	6	18223868-18264823	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Chromatin regulator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB015226, HPA054505, HPA057799"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB015226: , HPA054505: AB_2682508, HPA057799: AB_2683530"	"unprognostic (6.35e-2)"	"unprognostic (6.11e-2)"	"unprognostic (5.04e-3)"	"unprognostic (1.40e-2)"	"unprognostic (3.66e-1)"	"unprognostic (5.02e-3)"	"prognostic unfavorable (9.65e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.61e-3)"	"unprognostic (6.49e-3)"	"unprognostic (1.12e-2)"	"prognostic unfavorable (3.45e-4)"	"unprognostic (1.59e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.78e-1)"	30.9	20.0	22.9	41.8	29.5	50.8	28.9	41.5	30.2	31.0	35.8	11.4	24.0	28.2	32.9	19.7	31.0	23.8	19.2	33.5	26.8	14.1	19.3	23.8	29.2	42.7	30.7	17.6	28.3	19.3	20.5	27.8	24.3	27.7	33.9	29.9	11.0	26.8	21.4	40.2	23.2	35.9	51.3	28.1	29.8	24.2	12.6	32.9	58.8	44.9	33.9	38.4	45.1	43.3	40.0	40.2	57.7	49.3	34.0	46.3	35.0	60.9	18.0	47.6	39.7	9.6	16.7	27.7	56.2	31.0	50.7	68.8	29.4	22.9	69.4	59.6	25.3	40.8	36.6	35.2	27.9	85.4	46.7	33.6	42.9	32.3	34.2	9.3	65.3	34.9	8.2	13.9	35.0	27.7	24.0	24.2	25.6	52.1	0.0	32.3	21.9	47.1	29.3	29.2	24.3	20.1	62.8	63.2	40.7	24.4	35.3	29.2	26.8	50.7	44.1	30.6	32.6	39.6	26.9	24.6	59.5	33.0	33.1	69.9	4.2	10.2	73.2	14.2	33.3	55.1	51.1	49.3	21.9	41.4	39.3	46.3	40.0	42.1	42.5	40.2	33.2	33.5	32.0	57.7	34.0	43.9	31.0	40.6	35.0	22.9	29.5	41.5	30.2	26.8	14.1	30.7	17.6	27.7	32.9	113.2	133.1	112.0	157.1	241.0	64.8	174.2	152.8	109.7	146.7	75.0	76.6	208.5	69.6	136.5	15.9	140.0	115.1	443.9	150.2	201.0	139.1	206.8	105.4	107.1	166.8	25.4	84.9	75.5	163.3	15.6	175.4	212.2	96.2	259.7	117.1	119.5	110.8	110.4	180.0	82.7	127.2	207.0	187.2	63.1	177.2	204.1	90.8	150.3	203.5	166.1
DICER1	"Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1"	ENSG00000100697	"Dicer 1, ribonuclease III"	Q9UPY3	14	95086228-95158010	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"RNA-mediated gene silencing"	"Endonuclease, Helicase, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000694, CAB068185"	Approved		Supported	Cytosol		NA	NA			Cytosol		"CAB068185: AB_2665650, HPA000694: AB_1078661"	"unprognostic (2.97e-1)"	"unprognostic (2.70e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.72e-1)"	"unprognostic (6.75e-2)"	"unprognostic (9.62e-2)"	"unprognostic (1.96e-2)"	"unprognostic (7.73e-2)"	"unprognostic (1.21e-1)"	"unprognostic (8.52e-3)"	"unprognostic (5.73e-2)"	"unprognostic (9.22e-2)"	"unprognostic (4.22e-2)"	"unprognostic (9.07e-2)"	"unprognostic (2.58e-1)"	"unprognostic (6.04e-3)"	"unprognostic (3.74e-2)"	23.2	12.5	18.4	22.4	33.3	20.5	23.2	28.5	29.9	19.0	18.1	31.4	22.4	13.0	20.8	20.6	23.4	18.5	16.2	15.3	22.0	14.1	19.5	23.6	22.4	20.3	29.7	19.6	23.8	19.8	26.9	30.9	29.9	23.2	20.3	19.7	14.5	19.5	18.9	28.0	20.7	17.3	19.0	26.8	20.7	17.1	20.6	32.0	17.0	23.8	14.7	20.3	20.7	24.1	2.5	1.8	10.7	7.2	1.2	3.3	1.0	12.9	13.6	25.4	9.4	6.6	9.9	20.1	10.7	6.5	6.8	8.3	17.2	10.0	14.7	11.6	10.0	7.1	15.3	20.1	10.1	14.4	22.7	9.0	22.2	7.4	12.4	6.6	13.6	13.6	9.2	8.3	9.2	14.1	5.9	10.2	11.6	9.3	13.1	11.5	18.2	15.2	9.0	7.2	9.1	6.7	12.1	20.8	8.1	9.1	20.7	21.1	11.9	10.8	11.1	12.2	14.1	12.6	10.0	10.1	5.3	10.5	10.2	12.0	14.9	21.3	20.8	5.5	11.0	9.4	3.1	3.0	1.2	1.6	3.1	3.3	1.9	1.5	1.2	1.8	2.5	1.5	1.3	10.7	1.2	7.2	1.6	1.6	1.0	18.4	33.3	28.5	29.9	22.0	14.1	29.7	19.6	23.2	32.0	50.6	47.2	32.6	39.2	24.4	99.7	34.3	38.2	32.1	51.2	43.6	53.0	39.4	5.0	30.3	19.8	39.1	29.6	23.3	19.9	20.7	34.6	55.9	11.5	50.5	41.7	101.7	44.3	41.1	94.2	12.0	50.3	46.8	21.9	19.0	30.6	35.0	28.4	23.0	49.5	22.6	68.5	32.3	35.0	34.9	52.5	24.1	21.5	23.0	31.6	49.7
DNAJB1	"Hsp40, HSPF1, RSPH16B, Sis1"	ENSG00000132002	"DnaJ heat shock protein family (Hsp40) member B1"	P25685	19	14514770-14529770	"Cancer-related genes, Predicted intracellular proteins"	"Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 291.1"	"Cell type enhanced"	"Detected in many"	4	"Smooth muscle cells: 802.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 110.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017450, HPA063247"	Enhanced		Supported	Nucleoplasm		NA	Yes		9600	Nucleoplasm		"CAB017450: AB_10631418, HPA063247: AB_2684971"	"unprognostic (3.75e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.74e-2)"	"unprognostic (3.83e-1)"	"unprognostic (1.85e-1)"	"unprognostic (7.91e-3)"	"unprognostic (2.17e-1)"	"prognostic favorable (5.96e-4)"	"unprognostic (2.20e-2)"	"unprognostic (4.44e-2)"	"unprognostic (2.00e-2)"	"unprognostic (6.77e-2)"	29.2	76.9	28.5	13.2	30.0	36.2	67.0	41.4	29.4	19.3	15.5	21.5	14.5	10.5	20.4	11.8	72.3	21.7	56.4	23.5	28.2	31.6	23.4	37.7	35.7	10.7	53.4	12.0	32.3	22.6	18.3	25.0	33.5	45.8	29.6	13.1	12.2	18.4	40.8	16.1	25.3	9.5	24.0	40.2	9.4	19.1	37.5	37.9	15.0	28.9	18.0	31.1	19.2	291.1	19.7	15.2	28.2	31.6	23.0	61.6	56.7	36.9	39.3	14.2	15.1	26.2	21.1	8.9	24.6	18.3	39.0	29.5	23.2	20.9	10.2	28.2	20.9	25.5	28.1	29.1	17.7	27.7	10.7	14.4	16.3	26.0	48.6	17.9	11.5	15.5	11.7	42.4	15.1	13.2	20.4	12.8	6.9	24.1	110.7	21.4	23.4	18.5	10.7	15.1	48.9	42.4	14.2	20.0	23.0	17.7	12.7	13.1	9.7	22.3	44.2	24.2	16.6	12.1	11.2	13.3	31.7	19.1	36.5	51.6	49.3	30.2	13.4	22.6	19.9	28.2	11.5	18.9	22.3	36.6	31.1	38.9	19.4	52.5	45.4	15.2	19.7	61.6	47.6	28.2	23.0	31.6	9.1	51.8	56.7	28.5	30.0	41.4	29.4	28.2	31.6	53.4	12.0	45.8	37.9	145.9	105.3	114.6	695.7	378.2	47.1	335.7	48.4	87.0	71.7	22.7	111.9	123.3	34.9	105.0	377.6	275.7	133.0	0.0	143.2	142.5	617.3	678.1	342.8	50.4	134.5	49.3	390.0	73.1	71.9	368.9	58.7	232.5	477.5	35.1	126.4	109.5	97.8	108.7	34.6	43.9	149.2	25.8	802.9	139.1	31.8	418.7	229.9	251.4	123.6	238.8
DNM2	"CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII"	ENSG00000079805	"Dynamin 2"	P50570	19	10718079-10833488	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Endocytosis, Phagocytosis"	"Hydrolase, Motor protein"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054246	Supported		Approved	"Golgi apparatus,Cytosol"		NA	NA		500000	"Golgi apparatus, Cytosol"		"HPA054246: AB_2682427"	"unprognostic (2.30e-1)"	"unprognostic (5.23e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.76e-1)"	"prognostic favorable (8.91e-4)"	"prognostic unfavorable (3.63e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.79e-1)"	"unprognostic (1.89e-1)"	"unprognostic (4.75e-2)"	"unprognostic (5.35e-2)"	"unprognostic (5.47e-2)"	"unprognostic (5.40e-3)"	"unprognostic (2.68e-1)"	"unprognostic (1.61e-1)"	"unprognostic (1.99e-3)"	23.8	32.6	18.5	29.3	31.2	53.4	20.4	25.7	29.7	20.1	51.4	57.5	46.0	32.1	20.4	16.8	29.9	19.7	27.0	35.0	20.8	18.0	38.5	25.1	39.2	28.2	48.3	18.0	17.9	32.2	19.5	20.0	32.3	32.2	24.0	42.5	24.5	24.7	37.7	46.6	40.6	50.8	18.6	43.1	37.6	48.2	23.3	36.4	39.1	23.5	21.1	41.5	35.7	31.5	3.4	11.1	8.6	9.8	10.1	5.8	4.6	35.0	29.0	21.3	16.9	22.0	21.5	27.3	23.5	22.3	34.8	29.6	28.9	23.2	25.5	42.3	25.3	16.6	30.8	29.0	25.5	29.2	31.2	23.0	48.9	25.9	32.3	27.1	26.8	46.4	22.1	19.7	26.6	25.1	21.2	33.8	26.3	39.3	43.9	21.4	42.5	37.3	25.6	24.2	41.6	35.2	37.9	23.1	28.7	22.9	52.9	30.7	20.1	26.8	23.0	16.8	24.8	18.4	32.0	30.6	38.3	13.0	53.7	31.0	36.4	37.1	23.5	28.6	41.1	18.9	3.0	4.5	8.6	5.6	8.2	5.1	3.4	4.2	5.8	5.3	3.1	2.4	4.1	8.5	10.1	9.8	11.1	4.8	4.6	18.5	31.2	25.7	29.7	20.8	18.0	48.3	18.0	32.2	36.4	29.8	21.1	33.5	15.2	20.6	26.5	23.8	15.3	5.3	18.2	48.8	21.6	21.9	43.1	30.7	37.5	27.5	130.4	0.0	27.6	96.1	18.2	17.4	18.5	18.7	42.3	41.3	20.7	20.3	22.9	75.8	15.5	40.5	18.6	50.5	92.3	16.0	35.8	87.7	26.2	31.5	27.7	25.8	19.8	8.0	13.3	27.6	26.5	39.9	56.9	19.7
DNMT3A		ENSG00000119772	"DNA methyltransferase 3 alpha"	Q9Y6K1	2	25227855-25342590	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors"		"Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cone photoreceptor cells: 119.8;Horizontal cells: 90.6;Rod photoreceptor cells: 144.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 25.7;REH: 25.4;SH-SY5Y: 31.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009469, HPA026588"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB009469: AB_2093990, HPA026588: AB_1847812"	"unprognostic (2.38e-1)"	"unprognostic (2.94e-1)"	"unprognostic (5.65e-2)"	"prognostic unfavorable (1.55e-4)"	"unprognostic (8.38e-2)"	"unprognostic (7.27e-2)"	"prognostic unfavorable (1.58e-4)"	"unprognostic (2.24e-1)"	"unprognostic (7.25e-2)"	"unprognostic (2.72e-1)"	"prognostic favorable (1.18e-4)"	"unprognostic (2.35e-2)"	"prognostic unfavorable (2.49e-4)"	"unprognostic (1.43e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.70e-2)"	7.8	12.4	13.7	12.7	15.5	10.8	8.6	21.6	20.1	9.0	12.7	14.5	7.6	9.1	13.0	12.2	8.0	9.6	8.9	8.2	12.3	6.7	9.4	6.9	9.5	13.6	15.3	10.1	18.3	12.1	6.3	12.6	20.8	10.7	9.3	9.2	12.0	8.5	9.2	29.1	6.6	11.4	11.3	7.9	17.5	11.6	6.6	15.2	20.8	9.1	10.5	11.8	9.8	8.4	3.0	4.1	4.9	4.1	8.7	8.3	2.3	1.1	3.5	14.9	3.6	1.6	1.2	19.5	1.0	0.9	2.0	1.6	8.8	5.7	0.0	2.2	1.9	1.6	1.0	1.6	2.2	1.2	3.7	2.6	6.4	5.3	10.5	3.9	1.3	4.1	3.6	1.1	2.6	0.9	3.9	8.3	14.5	7.3	1.4	1.5	8.5	13.9	15.1	25.7	5.9	1.9	25.4	16.4	2.1	1.2	1.5	8.8	31.3	1.2	8.4	2.6	13.4	1.0	6.7	2.8	2.5	3.3	0.6	1.3	3.2	2.2	8.6	0.9	3.8	2.6	4.7	1.8	3.1	5.2	3.0	7.0	2.3	3.4	4.9	2.0	3.0	8.3	6.6	4.9	8.7	4.1	4.1	2.8	2.3	13.7	15.5	21.6	20.1	12.3	6.7	15.3	10.1	10.7	15.2	6.0	13.3	10.0	8.3	4.6	74.9	13.7	5.1	9.4	12.5	19.2	119.8	30.2	5.0	13.8	1.5	14.6	5.3	0.0	8.5	9.4	14.7	11.7	36.9	5.5	19.8	90.6	12.6	6.2	10.5	1.1	17.8	11.9	6.8	4.6	11.5	22.7	9.2	10.5	14.5	5.6	144.9	19.4	8.2	2.3	13.4	2.3	26.9	18.7	11.0	6.7
DROSHA	"Etohi2, HSA242976, RN3, RNASE3L, RNASEN"	ENSG00000113360	"Drosha ribonuclease III"	Q9NRR4	5	31400497-31532196	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Ribosome biogenesis, RNA-mediated gene silencing"	"Endonuclease, Hydrolase, Nuclease, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031150			Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA031150: AB_2673761"	"unprognostic (8.37e-3)"	"unprognostic (1.81e-1)"	"unprognostic (9.56e-2)"	"prognostic unfavorable (6.79e-4)"	"unprognostic (5.40e-2)"	"unprognostic (6.03e-2)"	"prognostic unfavorable (1.39e-4)"	"unprognostic (3.11e-1)"	"unprognostic (4.08e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.86e-1)"	"unprognostic (5.43e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.74e-1)"	"unprognostic (2.39e-1)"	"unprognostic (6.94e-2)"	"unprognostic (2.32e-2)"	15.7	16.8	18.4	17.7	32.1	12.2	16.1	33.7	33.7	17.4	16.3	19.1	12.2	15.9	22.3	25.8	16.0	18.2	14.1	15.2	16.6	15.1	15.3	11.7	13.9	17.8	13.6	16.4	26.7	17.8	23.9	38.9	17.0	18.9	17.2	19.2	23.7	17.5	19.2	23.6	16.0	17.5	16.9	19.4	16.8	16.0	12.8	16.4	25.6	21.9	13.4	19.8	18.2	16.2	4.7	6.4	3.3	4.8	4.8	6.4	3.1	12.4	15.7	17.4	23.6	9.3	11.4	25.1	16.5	8.1	15.4	11.5	16.5	16.2	14.0	19.0	12.1	17.9	10.9	21.4	12.5	17.2	13.1	15.1	17.2	51.6	11.9	8.4	19.2	51.4	8.9	8.8	17.2	8.3	11.8	13.1	15.0	21.8	6.6	13.4	12.4	18.5	14.4	16.4	10.1	12.6	16.8	33.3	10.1	8.7	14.2	9.1	12.0	41.9	17.2	10.1	16.2	15.8	11.1	11.4	14.9	17.3	13.3	15.6	12.1	19.8	15.4	10.3	21.7	14.2	1.8	2.4	3.3	5.2	2.6	5.5	4.2	5.4	6.0	5.2	4.7	6.4	4.4	0.8	4.8	4.8	6.4	5.1	3.1	18.4	32.1	33.7	33.7	16.6	15.1	13.6	16.4	18.9	16.4	11.9	14.7	3.0	4.6	3.2	18.2	21.0	7.6	20.1	15.9	5.2	0.0	6.6	3.3	7.2	2.5	6.2	7.3	0.0	7.0	6.4	7.4	5.0	9.2	5.1	6.7	6.4	10.9	9.2	7.8	4.3	10.0	3.2	1.7	9.0	10.1	10.5	7.8	8.6	12.4	4.2	16.8	6.5	4.7	5.8	8.4	3.0	4.1	5.7	10.0	5.1
EBF1	"EBF, OLF1"	ENSG00000164330	"Early B cell factor 1"	Q9UH73	5	158695916-159099761	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	16	"Leydig cells: 264.3;Peritubular cells: 114.2;Sertoli cells: 97.0;Smooth muscle cells: 110.4"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	5	"cerebellum: 23.6"	"Group enriched"	"Detected in some"	62	"memory B-cell: 11.8;naive B-cell: 10.4"	"Lineage enriched"	"Detected in single"	66	"B-cells: 11.8"	"Cell line enhanced"	"Detected in some"		"ASC diff: 19.4;HSkMC: 15.1;REH: 40.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA061169			Approved	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA061169: AB_2684441"	"unprognostic (7.86e-2)"	"unprognostic (3.08e-2)"	"unprognostic (7.29e-2)"	"unprognostic (4.70e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.39e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.60e-1)"	"unprognostic (5.75e-2)"	"unprognostic (1.60e-1)"	"unprognostic (4.58e-2)"	"unprognostic (1.02e-1)"	"prognostic unfavorable (9.62e-7)"	"prognostic unfavorable (7.80e-4)"	"unprognostic (5.75e-2)"	"unprognostic (5.81e-2)"	"unprognostic (4.37e-3)"	33.7	3.3	1.9	9.7	2.5	3.1	25.0	23.6	2.0	15.9	5.8	1.1	9.0	1.2	19.7	13.0	5.0	8.5	9.4	15.5	2.0	2.4	3.3	0.9	5.2	12.7	3.2	1.2	7.4	3.7	1.8	2.6	10.7	4.7	8.5	3.4	10.4	4.7	10.8	15.5	4.8	4.5	25.7	6.6	5.4	3.4	8.4	1.0	0.1	6.8	13.2	9.1	11.7	12.5	11.8	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.2	6.2	0.0	19.4	8.4	0.0	0.0	0.0	0.2	0.6	0.0	0.0	5.6	0.0	2.3	1.2	0.0	0.2	0.0	0.1	1.3	0.0	0.0	1.6	0.0	0.3	0.0	0.0	15.1	0.0	6.0	0.2	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.5	0.0	0.0	40.6	0.2	0.0	0.0	0.0	3.3	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.8	8.5	0.1	0.0	0.0	5.6	4.9	0.4	6.7	0.1	0.0	0.1	0.0	0.0	0.0	11.8	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.9	2.5	23.6	1.6	2.0	2.4	3.2	1.2	4.7	1.0	0.0	0.3	44.7	0.4	10.9	4.1	4.3	0.0	1.4	1.2	1.8	0.0	0.1	0.0	2.4	15.8	55.5	0.0	0.0	0.0	0.3	40.4	0.6	0.0	1.0	0.7	0.0	0.0	2.5	0.8	15.5	264.3	1.0	13.5	16.2	0.0	1.7	0.2	0.0	114.2	0.0	2.0	97.0	110.4	2.2	0.4	6.0	0.3	1.3	0.0	0.5
EGFR	"ERBB, ERBB1"	ENSG00000146648	"Epidermal growth factor receptor"	P00533	7	55019021-55211628	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Host-virus interaction"	"Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 102.3"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 207.2;Syncytiotrophoblasts: 315.1"	"Cancer enhanced"	"Detected in all"		"glioma: 136.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	12	"A-431: 345.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534"	Enhanced		Enhanced	"Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA	4740000	93000000	"Plasma membrane, Cell Junctions"		"CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044"	"unprognostic (2.62e-2)"	"unprognostic (9.56e-3)"	"unprognostic (1.59e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.27e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.88e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.30e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.98e-3)"	"unprognostic (1.72e-1)"	"unprognostic (6.62e-2)"	"prognostic unfavorable (2.04e-5)"	16.2	8.4	4.9	7.5	6.8	0.1	39.8	5.1	8.5	13.8	7.8	3.3	10.7	3.6	8.2	11.7	15.6	8.8	8.5	4.8	6.8	2.7	7.6	23.5	14.2	2.3	4.1	3.9	10.4	10.1	1.8	2.1	102.3	5.6	10.9	6.7	9.2	15.4	12.9	10.7	32.5	6.3	15.5	3.5	3.3	7.8	5.5	5.9	3.2	12.8	15.5	8.0	10.2	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	345.9	4.4	1.1	1.5	7.1	4.4	1.2	3.4	4.6	2.1	1.6	0.8	3.7	0.2	0.8	2.9	9.0	13.9	0.0	15.3	2.5	0.1	0.2	0.0	1.9	0.2	1.8	0.0	0.0	2.1	14.0	5.3	28.6	3.1	0.2	0.0	0.0	0.0	4.5	0.2	0.0	0.0	0.3	1.3	2.2	0.0	0.6	0.0	2.6	3.7	0.0	1.3	2.9	3.5	0.7	1.2	0.3	0.8	1.0	1.9	0.5	14.9	3.2	0.0	0.3	0.2	2.6	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	6.8	5.1	6.6	6.8	2.7	4.1	3.9	5.6	5.9	89.3	37.5	4.2	67.7	76.2	1.5	7.3	53.5	16.0	59.1	21.0	5.9	207.2	0.0	30.6	4.6	10.9	15.9	23.3	21.0	36.6	45.3	37.8	0.0	77.4	24.2	0.0	4.1	6.7	7.0	2.2	118.8	1.3	16.9	2.8	25.3	106.1	41.7	17.3	125.5	14.0	2.3	77.6	23.1	1.6	2.7	78.5	315.1	0.0	20.0	46.4
EIF3E	"eIF3-p48, eIF3e, EIF3S6, INT6"	ENSG00000104408	"Eukaryotic translation initiation factor 3 subunit E"	P60228	8	108201216-108435333	"Cancer-related genes, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023973	Approved		Supported	Cytosol		NA	NA			Cytosol		"HPA023973: AB_1848083"	"unprognostic (8.18e-2)"	"unprognostic (4.28e-2)"	"unprognostic (6.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.52e-3)"	"unprognostic (6.93e-3)"	"unprognostic (2.29e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.47e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.67e-3)"	"unprognostic (3.63e-1)"	"prognostic unfavorable (3.06e-7)"	"unprognostic (2.46e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.77e-2)"	88.2	44.0	27.6	49.2	38.2	57.8	75.1	41.5	25.2	101.6	73.6	14.6	47.2	34.4	55.5	47.6	111.2	45.4	41.0	39.5	23.9	22.4	51.8	63.6	60.3	75.3	33.0	19.5	127.6	90.2	29.2	72.5	54.6	28.9	100.1	40.3	22.8	56.9	45.5	100.4	46.7	56.3	73.7	38.4	63.9	49.7	52.7	31.5	100.5	93.8	70.8	50.7	121.7	69.2	49.0	51.7	14.0	39.5	38.7	78.1	59.4	61.5	30.3	40.7	50.3	69.5	146.9	27.8	32.2	50.3	47.9	50.1	38.0	62.1	106.1	42.3	36.2	25.9	38.4	53.7	63.1	63.8	41.7	54.6	84.7	32.2	54.3	55.6	50.4	39.8	110.9	93.4	36.1	100.3	95.8	72.8	68.0	71.3	44.1	53.9	60.9	65.4	95.7	40.6	101.8	48.5	60.8	50.4	82.6	62.5	37.1	46.1	42.0	18.1	15.3	71.7	49.3	65.1	73.2	46.2	28.0	48.4	29.0	40.4	33.3	24.9	60.8	34.6	88.2	31.2	14.0	39.5	7.4	26.6	36.2	52.0	49.0	52.6	37.7	51.7	40.4	78.1	56.1	3.7	38.7	33.6	27.3	45.2	59.4	27.6	38.2	41.5	25.2	23.9	22.4	33.0	19.5	28.9	31.5	125.0	164.2	521.1	900.1	920.2	60.0	77.3	196.1	124.5	205.9	150.1	51.1	533.6	514.0	289.5	296.8	388.9	107.5	70.0	306.5	673.2	507.3	554.3	369.5	167.4	375.7	55.6	285.6	304.5	609.8	52.5	420.5	585.5	490.9	376.1	360.5	84.2	309.4	241.9	308.0	535.0	54.4	187.5	536.7	231.2	100.5	976.5	518.8	456.1	516.4	811.5
EIF4A2	"BM-010, DDX2B, EIF4A, EIF4F"	ENSG00000156976	"Eukaryotic translation initiation factor 4A2"	Q14240	3	186783205-186789900	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Protein biosynthesis"	"Helicase, Hydrolase, Initiation factor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB011690, HPA068286"	Uncertain		Approved	Cytosol		NA	NA		1000000	Cytosol		"CAB011690: AB_732123, HPA068286: AB_2685968"	"unprognostic (1.49e-1)"	"unprognostic (9.62e-2)"	"unprognostic (3.78e-2)"	"unprognostic (9.50e-3)"	"unprognostic (2.82e-2)"	"unprognostic (1.10e-2)"	"unprognostic (4.46e-2)"	"unprognostic (6.27e-2)"	"unprognostic (4.32e-3)"	"unprognostic (1.00e-1)"	"unprognostic (6.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (6.36e-2)"	"unprognostic (3.22e-1)"	"unprognostic (3.03e-1)"	"unprognostic (4.67e-2)"	"unprognostic (2.62e-2)"	34.6	66.1	61.2	27.7	79.9	1.9	53.5	121.1	111.5	65.1	52.1	26.5	30.1	30.3	73.1	45.5	44.5	73.9	45.1	83.7	58.4	71.9	63.9	43.5	33.7	36.1	48.9	61.7	142.0	59.0	30.9	84.1	47.3	69.6	57.9	40.1	31.8	43.7	62.8	126.7	19.8	35.6	57.1	41.9	32.5	39.0	32.9	39.5	23.9	67.8	36.4	35.4	61.1	51.7	55.1	19.3	39.4	24.8	33.0	63.4	51.3	10.1	5.1	21.4	3.5	82.7	78.0	6.6	18.3	16.5	19.4	25.6	18.9	3.7	22.7	102.5	26.2	35.9	17.1	31.5	7.7	34.3	21.2	16.6	36.6	6.8	25.3	32.4	7.7	25.7	52.2	37.0	5.6	46.7	98.7	34.4	19.2	12.3	38.3	63.1	1.7	12.2	3.8	21.3	41.0	24.6	15.7	15.2	13.8	38.5	12.4	42.2	8.5	29.7	20.5	38.9	56.7	32.0	28.2	25.1	15.4	7.7	14.8	11.2	30.5	43.2	10.4	10.6	8.1	7.2	39.4	16.0	18.5	28.5	18.2	45.3	55.1	41.9	34.8	19.3	46.1	63.4	50.2	11.0	33.0	24.8	17.4	38.6	51.3	61.2	79.9	121.1	111.5	58.4	71.9	48.9	61.7	69.6	39.5	110.2	187.7	337.3	695.6	613.2	269.9	244.1	206.4	220.8	192.2	247.7	60.9	410.2	560.3	199.1	25.8	233.7	293.3	23.3	81.4	227.6	351.3	637.4	309.0	119.2	199.9	368.7	391.5	183.0	192.6	37.8	357.2	230.1	327.3	376.9	296.7	294.3	160.6	364.6	444.5	452.5	161.0	232.8	455.3	100.9	174.0	540.1	514.8	331.3	287.0	611.0
ELF4	"ELFR, MEF"	ENSG00000102034	"E74 like ETS transcription factor 4"	Q99607	X	130064874-130110716	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Extravillous trophoblasts: 31.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA058595, HPA060277"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nuclear bodies"	Nucleoplasm	"HPA058595: AB_2683768, HPA060277: AB_2684239"	"unprognostic (1.33e-1)"	"unprognostic (8.51e-2)"	"unprognostic (3.83e-1)"	"unprognostic (2.13e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.43e-3)"	"unprognostic (7.86e-3)"	"unprognostic (3.50e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.29e-2)"	"unprognostic (3.95e-1)"	"prognostic unfavorable (6.49e-6)"	"unprognostic (1.43e-1)"	"unprognostic (5.46e-2)"	"unprognostic (2.51e-1)"	"prognostic favorable (1.42e-4)"	16.9	3.6	2.0	18.1	2.5	27.6	16.9	0.5	3.0	7.7	10.8	3.1	7.0	8.4	10.5	8.1	10.5	9.5	11.0	7.3	3.1	1.2	5.9	2.5	21.9	33.3	3.8	0.9	12.7	4.5	3.8	4.2	23.5	3.0	6.6	10.9	3.6	5.4	7.9	5.7	9.1	16.3	6.4	4.2	18.9	12.3	3.5	2.9	18.1	3.9	7.4	11.5	11.7	14.4	3.9	6.1	9.4	10.3	8.4	10.3	5.1	22.8	8.5	1.5	0.1	3.9	8.5	22.3	10.7	13.6	13.0	14.4	11.8	16.3	11.7	21.4	14.4	18.0	14.9	8.5	12.5	12.7	12.5	7.0	23.0	11.4	5.4	8.8	20.0	29.5	8.8	14.1	20.8	20.6	8.1	12.5	2.6	8.8	3.2	7.0	13.2	3.2	11.4	1.0	11.6	8.4	7.1	2.7	5.0	7.9	26.4	5.9	2.5	9.5	9.3	2.9	8.4	4.6	19.3	11.6	9.1	7.2	16.9	19.6	1.8	0.7	9.4	10.7	18.5	2.1	1.6	5.4	7.8	10.3	10.3	8.3	3.9	6.2	8.8	6.1	3.5	6.2	7.2	9.4	8.4	7.0	3.7	6.3	5.1	2.0	2.5	0.5	3.0	3.1	1.2	3.8	0.9	3.0	2.9	8.9	4.1	0.5	8.0	12.0	0.0	0.6	0.0	6.7	5.7	0.0	0.0	9.1	0.0	2.2	0.1	4.5	15.6	0.0	3.6	31.1	5.6	5.4	1.1	0.4	8.7	0.0	8.6	6.7	10.2	0.4	1.7	8.9	3.3	7.2	6.6	0.0	5.7	14.0	1.1	0.3	0.0	6.5	3.8	0.0	3.8	9.2	9.4	5.3	5.9	15.5
ELK4	SAP1	ENSG00000158711	"ELK4, ETS transcription factor"	P28324	1	205597556-205631962	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Bipolar cells: 95.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 8.7"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028863	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA028863: AB_10602492"	"unprognostic (2.08e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.59e-1)"	"unprognostic (2.15e-1)"	"prognostic favorable (4.65e-4)"	"unprognostic (2.97e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.19e-1)"	"unprognostic (3.53e-1)"	"unprognostic (1.27e-2)"	"unprognostic (2.64e-1)"	"prognostic unfavorable (2.94e-6)"	"unprognostic (2.21e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.08e-1)"	"unprognostic (5.58e-3)"	14.1	7.1	10.0	14.7	12.7	12.0	13.8	16.2	10.4	10.1	8.9	10.4	8.6	7.3	11.3	9.2	11.7	9.5	11.4	10.8	10.6	5.0	15.2	15.6	13.8	19.1	10.0	6.9	13.1	12.4	13.6	16.8	9.5	9.5	32.6	8.7	12.2	12.4	8.2	14.7	17.6	13.5	10.5	8.2	18.3	9.4	8.4	11.0	24.4	10.8	8.3	19.6	15.1	13.2	2.2	1.5	8.7	1.1	1.2	3.1	0.6	8.2	7.5	2.9	7.7	7.1	9.1	7.5	5.6	5.8	4.4	5.2	3.2	8.4	17.6	5.3	6.9	3.3	10.4	6.2	6.8	7.7	20.0	4.4	7.6	12.2	6.8	9.7	14.2	30.3	8.0	8.5	7.0	14.4	8.6	18.6	8.4	6.9	14.8	6.2	11.2	11.7	5.3	4.9	1.9	4.5	8.7	18.3	14.3	5.9	18.2	3.5	4.1	14.4	7.9	9.5	5.4	7.3	4.8	13.4	9.0	10.6	8.0	10.5	11.1	10.1	11.9	7.8	5.8	10.5	8.7	0.8	1.2	1.6	1.1	2.1	1.4	1.8	2.1	1.1	2.2	2.2	3.1	0.4	1.2	0.6	1.5	1.8	0.6	10.0	12.7	16.2	10.4	10.6	5.0	10.0	6.9	9.5	11.0	8.9	11.5	21.4	29.2	34.9	95.4	18.7	28.1	17.4	15.9	29.6	11.8	11.3	3.3	12.9	11.6	35.7	9.8	0.0	15.6	5.2	25.6	62.3	27.7	28.9	8.9	23.8	12.6	25.8	20.0	14.0	23.6	18.5	28.7	5.4	15.8	10.6	12.9	3.5	14.5	13.9	26.7	25.8	23.4	20.0	9.8	42.4	15.3	37.4	17.3	61.0
ELL	"C19orf17, ELL1, Men, PPP1R68"	ENSG00000105656	"Elongation factor for RNA polymerase II"	P55199	19	18442663-18522127	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"Early spermatids: 301.9;Late spermatids: 183.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004202, HPA046076"	Uncertain		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"		NA	NA			Nucleoplasm	"Nuclear bodies, Cytosol"	"HPA004202: , HPA046076: AB_2679526"	"unprognostic (9.49e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.26e-3)"	"unprognostic (2.07e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.10e-1)"	"unprognostic (8.26e-2)"	"unprognostic (2.71e-1)"	"unprognostic (2.34e-1)"	"unprognostic (3.00e-2)"	"unprognostic (6.28e-3)"	"unprognostic (2.38e-2)"	"unprognostic (1.57e-1)"	"unprognostic (2.07e-1)"	"unprognostic (5.12e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.06e-1)"	19.9	7.7	5.1	13.4	9.9	38.4	10.8	17.0	9.7	11.9	13.5	7.7	8.6	10.4	12.6	9.5	9.3	9.1	10.9	9.5	5.8	4.4	9.8	11.6	14.2	10.7	6.2	3.5	12.7	14.6	6.2	10.5	27.0	6.3	10.4	4.4	9.1	10.6	9.0	20.3	13.3	10.9	10.0	5.1	15.9	9.3	31.7	7.7	11.0	7.8	7.2	13.6	18.5	13.2	3.1	8.6	17.2	5.6	2.1	7.9	3.3	8.9	4.4	2.3	4.9	2.5	3.2	17.0	7.1	6.3	5.4	5.2	5.0	7.1	11.3	8.8	4.7	3.7	6.3	3.4	7.8	2.7	9.2	8.0	6.8	4.4	4.3	3.8	7.4	8.7	6.5	6.7	7.0	5.5	4.2	3.8	6.2	9.4	15.6	2.8	7.6	8.7	8.1	7.7	5.4	12.6	7.5	3.7	11.9	3.8	6.3	4.2	4.6	5.2	9.0	7.7	3.1	4.5	9.3	6.3	6.3	4.9	8.6	6.6	25.5	16.0	8.4	8.3	12.6	8.9	0.3	5.6	3.8	4.7	4.1	7.9	3.1	2.9	4.2	4.7	2.3	1.9	2.9	17.2	2.1	2.1	8.6	3.0	3.3	5.1	9.9	17.0	9.7	5.8	4.4	6.2	3.5	6.3	7.7	6.0	6.7	6.0	22.3	24.8	4.1	4.0	10.2	6.7	3.4	3.5	3.9	37.4	10.0	7.0	301.9	11.7	10.5	0.0	7.0	14.6	16.0	13.8	10.5	13.4	16.6	1.6	18.9	8.6	11.5	183.8	6.1	13.8	6.8	11.8	9.0	4.2	8.8	2.9	2.8	5.7	3.5	19.4	28.8	19.0	21.8	26.6	57.4	11.4	6.4	18.6
EML4	"C2orf2, ELP120, ROPP120"	ENSG00000143924	"Echinoderm microtubule associated protein like 4"	Q9HC35	2	42169350-42332548	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 60.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036687, HPA036688, HPA065337"	Enhanced		Supported	"Intermediate filaments,Microtubules,Cytosol"		NA	NA		41000	Microtubules	"Intermediate filaments, Cytosol"	"HPA036687: AB_2675251, HPA036688: AB_10671968, HPA065337: AB_2685474"	"unprognostic (1.70e-1)"	"unprognostic (1.38e-1)"	"unprognostic (8.17e-2)"	"unprognostic (3.53e-3)"	"unprognostic (1.79e-2)"	"unprognostic (9.19e-2)"	"unprognostic (8.61e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.96e-3)"	"unprognostic (6.80e-2)"	"unprognostic (7.44e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.13e-2)"	11.3	17.3	5.8	29.3	6.8	19.2	10.5	4.6	5.2	9.4	21.6	6.7	6.8	20.3	13.6	11.6	10.7	8.7	20.3	6.5	5.1	3.9	11.7	26.4	19.3	27.7	4.6	4.0	12.5	37.8	10.8	11.6	26.9	6.5	8.5	12.8	12.1	17.7	8.9	4.3	17.9	33.5	9.2	5.0	30.9	11.7	14.2	5.3	17.4	13.2	6.9	30.0	14.0	9.0	11.5	4.2	10.0	11.0	9.4	17.5	5.9	14.6	25.5	14.9	11.8	5.4	8.9	16.3	9.1	7.2	10.1	9.8	26.6	18.5	13.4	6.3	8.9	15.6	7.6	12.7	8.8	17.7	26.2	10.7	12.3	7.9	60.9	6.9	9.3	12.7	9.7	3.3	13.4	9.1	4.9	7.0	4.6	12.1	13.6	10.9	8.6	8.7	2.5	15.2	18.9	7.4	9.0	23.6	7.9	8.3	21.3	14.7	29.6	9.0	9.4	6.9	14.1	4.9	3.7	8.2	10.4	13.9	8.3	8.2	15.3	10.6	11.6	9.0	8.9	7.2	4.4	3.9	7.7	7.8	10.9	16.3	11.5	13.0	12.7	3.3	7.9	11.4	8.3	10.0	9.4	11.0	4.2	17.5	5.9	5.8	6.8	4.6	5.2	5.1	3.9	4.6	4.0	6.5	5.3	56.6	103.1	87.1	59.5	59.8	36.4	5.7	40.8	32.1	69.4	38.4	45.2	112.3	14.9	30.5	25.2	34.6	46.7	0.0	65.3	37.0	71.8	58.2	46.2	54.6	62.4	15.9	98.2	48.5	34.8	23.1	22.2	58.2	15.1	24.4	56.5	34.1	37.0	58.3	21.5	31.5	48.1	6.5	46.2	40.3	39.2	69.6	99.4	95.6	60.7	86.1
EP300	"KAT3B, p300"	ENSG00000100393	"E1A binding protein p300"	Q09472	22	41091786-41180079	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000146, HPA003128, HPA004112"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000146: AB_2533138, HPA003128: AB_1078745, HPA004112: AB_1078746"	"unprognostic (7.67e-2)"	"unprognostic (5.56e-2)"	"unprognostic (2.29e-1)"	"unprognostic (2.52e-1)"	"unprognostic (6.10e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.21e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.54e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.74e-2)"	"unprognostic (8.54e-2)"	"prognostic favorable (7.45e-5)"	"unprognostic (7.97e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.01e-1)"	"unprognostic (8.66e-2)"	16.8	14.8	19.1	13.9	15.5	45.3	14.5	33.0	20.6	14.8	16.8	15.6	18.9	11.1	18.1	11.6	16.8	15.7	16.5	10.7	16.6	8.3	11.5	12.2	14.1	12.9	16.9	12.7	20.2	15.7	26.4	14.5	27.7	13.8	13.2	12.2	12.3	15.3	17.9	19.5	18.2	17.4	13.8	12.7	15.9	14.7	20.6	18.6	29.3	16.9	10.9	14.1	18.7	22.5	4.3	4.4	9.8	3.9	5.7	3.9	2.3	15.7	11.3	19.2	11.9	12.2	13.2	17.2	7.6	11.0	11.4	11.0	14.4	5.8	16.4	6.7	15.0	10.5	12.7	27.7	10.4	12.7	15.9	18.4	12.3	13.0	11.2	13.9	29.2	13.9	12.9	10.9	16.5	13.8	10.0	12.6	9.5	13.0	22.6	9.0	5.8	8.4	9.1	13.8	19.8	7.9	17.3	9.0	10.2	10.8	20.9	6.1	6.5	26.9	13.7	13.1	16.7	9.7	17.0	16.3	11.4	13.8	8.1	10.8	15.5	7.3	25.6	8.4	9.0	10.8	5.0	3.2	3.0	3.7	3.9	3.2	4.3	3.6	3.9	4.4	2.9	3.1	2.6	9.8	5.7	2.1	3.0	2.6	2.3	19.1	15.5	33.0	20.6	16.6	8.3	16.9	12.7	13.8	18.6	62.5	45.1	44.7	19.0	21.9	43.6	25.4	53.5	29.4	18.2	24.4	33.4	15.3	3.3	13.2	12.6	27.2	22.2	46.7	16.0	15.4	23.4	24.1	24.3	24.1	15.9	23.8	23.7	34.4	59.8	3.4	26.7	31.6	8.5	20.8	23.1	31.8	20.2	26.6	28.7	9.2	31.1	25.8	15.6	20.6	29.9	22.6	25.3	26.6	20.3	30.6
EPAS1	"bHLHe73, HIF2A, HLF, MOP2, PASD2"	ENSG00000116016	"Endothelial PAS domain protein 1"	Q99814	2	46293667-46386703	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Angiogenesis, Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Congenital erythrocytosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 200.8"	"Cell type enhanced"	"Detected in many"	6	"Endothelial cells: 341.0;Ito cells: 438.9;Smooth muscle cells: 281.4;Syncytiotrophoblasts: 292.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"basophil: 14.9;eosinophil: 7.1"	"Lineage enriched"	"Detected in single"	21	"granulocytes: 14.9"	"Cell line enhanced"	"Detected in many"		"BEWO: 46.9;BJ hTERT+: 46.2;HHSteC: 58.7;RT4: 58.1;TIME: 58.0;U-138 MG: 50.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA031200, HPA069697"			Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA031200: AB_2673785, HPA069697: AB_2732139"	"unprognostic (1.74e-1)"	"unprognostic (9.47e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.74e-1)"	"unprognostic (5.25e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.22e-2)"	"unprognostic (8.67e-2)"	"unprognostic (6.00e-2)"	"unprognostic (9.72e-2)"	"unprognostic (1.55e-2)"	"unprognostic (9.29e-2)"	"prognostic favorable (2.63e-4)"	"unprognostic (6.66e-3)"	"unprognostic (7.75e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.36e-1)"	71.2	14.2	12.5	17.1	15.7	0.8	101.7	5.3	13.9	24.9	20.9	8.9	11.3	12.0	28.8	13.0	21.6	24.8	35.2	40.0	12.8	11.0	35.2	31.2	200.8	27.2	14.3	11.1	20.2	15.5	18.1	9.4	119.6	18.4	20.7	11.5	41.2	13.3	18.7	25.2	13.0	15.6	19.2	12.5	20.5	12.8	13.8	8.0	1.1	43.8	15.2	10.3	32.2	39.3	0.0	0.0	14.9	0.1	0.7	0.1	0.1	5.3	5.7	0.3	0.4	27.6	17.8	46.9	16.9	46.2	9.7	10.6	1.0	0.9	0.0	4.2	32.2	9.7	2.6	0.1	13.5	7.3	0.1	0.2	0.0	1.8	12.0	58.7	0.0	3.4	26.0	18.7	19.0	13.4	7.2	33.4	0.1	0.5	0.0	5.9	4.6	0.1	0.1	0.2	3.7	3.2	0.1	0.6	1.7	6.0	58.1	0.2	12.0	13.3	30.6	3.6	12.5	2.0	2.3	58.0	50.4	1.4	6.7	1.4	0.0	0.0	0.0	36.7	0.9	1.2	14.9	0.1	7.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	0.0	0.1	0.1	12.5	15.7	5.3	12.6	12.8	11.0	14.3	11.1	18.4	8.0	71.5	137.9	8.1	61.5	42.7	3.5	58.5	50.9	30.8	96.7	3.5	9.8	93.6	1.7	15.5	12.6	341.0	66.4	0.0	45.9	256.0	104.5	46.7	40.4	77.4	47.9	0.0	4.1	438.9	58.4	41.8	11.5	23.9	27.0	0.0	13.6	89.1	25.9	40.4	6.0	24.0	57.7	278.1	281.4	1.2	1.7	29.1	292.5	9.6	11.6	58.0
EPS15	"AF-1P, MLLT5"	ENSG00000085832	"Epidermal growth factor receptor pathway substrate 15"	P42566	1	51354263-51519328	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Endocytosis, Host-virus interaction, Protein transport, Transport"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008451, CAB010164, HPA061431"	Approved		Enhanced	Vesicles,Cytosol	"Intracellular and membrane"	NA	NA		67000	"Vesicles, Cytosol"		"CAB010164: AB_631445, HPA008451: AB_1848221, HPA061431: AB_2732662"	"unprognostic (1.45e-2)"	"prognostic unfavorable (6.44e-4)"	"unprognostic (1.05e-2)"	"unprognostic (7.72e-3)"	"unprognostic (3.99e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.96e-3)"	"unprognostic (9.26e-2)"	"unprognostic (4.13e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.41e-1)"	"unprognostic (5.36e-2)"	"unprognostic (8.73e-3)"	"unprognostic (2.13e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.24e-1)"	39.0	26.9	35.5	25.3	27.8	13.2	19.3	22.2	41.0	25.7	16.7	35.7	16.2	11.4	21.8	21.3	19.6	14.1	19.3	18.9	40.7	26.0	21.0	19.1	24.4	30.7	36.2	11.2	22.4	10.9	17.0	14.6	22.8	20.3	22.5	15.5	25.7	24.3	16.4	30.9	18.1	19.3	18.2	36.8	33.8	15.2	32.4	33.1	25.0	20.3	23.4	32.1	25.3	17.0	16.1	10.8	14.9	12.2	10.7	18.7	8.0	14.8	4.4	9.6	9.0	22.3	22.3	24.0	10.4	16.4	8.5	12.6	6.1	8.3	30.3	10.7	16.2	17.4	14.1	12.4	9.9	12.9	34.2	7.8	26.9	7.6	7.2	21.0	15.3	24.9	18.1	9.2	14.9	20.3	14.8	15.8	10.8	16.7	13.8	12.9	7.3	12.3	8.3	13.2	10.4	7.2	10.1	14.6	6.6	11.2	18.4	6.6	9.2	12.3	22.0	17.9	27.7	8.9	10.9	21.9	7.9	8.6	15.9	8.6	16.5	16.7	20.4	11.8	17.4	7.0	14.9	10.1	11.6	10.1	10.7	15.3	16.1	12.2	15.6	10.8	10.0	7.3	10.5	7.8	10.7	12.2	7.1	18.7	8.0	35.5	27.8	22.2	41.0	40.7	26.0	36.2	11.2	20.3	33.1	32.8	43.7	52.2	25.1	38.1	16.1	53.7	20.4	26.8	21.6	41.8	29.5	17.7	16.6	12.4	21.7	42.7	20.1	0.0	16.4	15.6	33.6	48.2	23.2	33.7	65.6	27.0	27.6	74.9	76.1	45.1	60.9	39.3	97.8	33.3	31.1	41.6	19.4	24.1	45.3	22.7	26.0	38.8	31.5	70.5	36.4	44.5	23.8	47.5	19.5	42.3
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	"Erb-b2 receptor tyrosine kinase 2"	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Collecting duct cells: 129.1;Enterocytes: 93.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.8"	"Lineage enriched"	"Detected in many"	4	"T-cells: 8.8"	"Group enriched"	"Detected in many"	41	"OE19: 366.2;SK-BR-3: 179.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		430000	"Plasma membrane"	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500"	"unprognostic (1.97e-1)"	"unprognostic (6.60e-3)"	"unprognostic (6.21e-2)"	"prognostic unfavorable (8.99e-8)"	"unprognostic (2.96e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavorable (9.17e-4)"	"unprognostic (3.92e-1)"	"prognostic favorable (2.41e-14)"	"unprognostic (9.29e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.96e-1)"	5.8	2.4	5.2	10.4	7.0	0.1	20.1	4.2	7.0	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4.0	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	2.1	2.5	2.9	1.8	3.5	2.4	3.9	1.5	2.5	3.3	2.8	1.9	5.8	0.1	3.1	3.5	1.8	6.7	0.1	3.4	1.5	0.2	2.2	0.1	2.0	3.1	2.0	0.0	0.0	2.4	3.2	2.0	1.2	3.2	1.3	0.1	0.3	0.1	2.4	3.3	0.3	0.1	5.2	366.2	0.6	0.2	1.1	0.3	3.4	6.7	0.5	0.1	2.9	179.8	0.9	3.7	5.0	0.1	0.1	1.7	2.2	2.1	0.9	0.3	0.1	0.1	0.1	0.0	5.6	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1.0	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7.0	4.2	7.0	6.3	3.1	5.1	5.6	7.5	3.7	38.7	34.4	1.3	21.0	12.5	4.3	13.5	30.6	10.7	15.9	129.1	11.8	9.7	6.6	27.1	0.3	4.6	93.2	0.0	22.3	75.4	11.0	33.4	0.0	10.4	3.5	6.4	15.0	12.3	2.4	0.7	17.0	1.8	10.1	1.0	56.6	30.9	26.2	42.1	21.5	20.7	5.9	0.0	10.3	7.1	5.3	16.6	19.0	2.2	63.0	28.1
ERBB3	"HER3, LCCS2"	ENSG00000065361	"Erb-b2 receptor tyrosine kinase 3"	P21860	12	56076799-56103505	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Cholangiocytes: 180.9;Enterocytes: 163.1;Paneth cells: 165.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.3"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 5.3"	"Cell line enhanced"	"Detected in many"		"Hep G2: 30.9;MCF7: 20.2;OE19: 31.8;RT4: 24.2;SK-BR-3: 28.4;SK-MEL-30: 37.9;T-47d: 31.5;WM-115: 40.2"	"Low region specificity"	"Detected in many"							"CAB025331, HPA045396"	Uncertain		Supported	"Plasma membrane,Actin filaments"	"Secreted - unknown location"	NA	NA		420000	"Plasma membrane"	"Actin filaments"	"CAB025331: , HPA045396: AB_2679312"	"unprognostic (2.97e-1)"	"unprognostic (2.71e-2)"	"unprognostic (1.91e-1)"	"unprognostic (8.97e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.07e-3)"	"unprognostic (2.31e-3)"	"unprognostic (2.66e-2)"	"unprognostic (9.89e-2)"	"unprognostic (4.30e-2)"	"unprognostic (4.76e-3)"	"unprognostic (5.77e-2)"	"unprognostic (1.06e-2)"	"unprognostic (4.56e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.72e-3)"	"unprognostic (2.07e-2)"	1.1	1.4	11.6	12.6	16.5	0.6	26.8	2.0	16.7	6.8	40.5	40.3	12.0	37.7	2.8	7.5	29.4	5.7	22.9	3.4	18.6	9.0	16.5	33.9	13.4	0.5	23.5	9.3	0.9	21.5	11.4	1.0	15.4	14.9	16.8	29.7	5.5	36.8	22.3	1.1	30.7	41.3	3.2	27.4	0.5	32.9	1.2	23.8	0.0	4.5	7.4	8.5	11.8	14.4	0.9	0.7	5.3	0.6	1.2	1.2	0.2	10.0	0.6	0.8	0.3	0.0	0.0	16.4	0.8	1.9	1.1	1.1	5.5	18.2	0.0	0.2	0.2	0.1	8.6	1.2	1.9	0.6	0.2	0.8	0.0	0.3	30.9	0.0	0.0	0.1	0.4	2.5	0.2	0.0	0.2	0.0	0.1	0.7	0.3	0.1	20.2	0.1	0.3	2.8	31.8	0.4	0.1	1.9	0.5	2.1	24.2	0.9	0.3	0.7	28.4	37.9	2.7	31.5	0.1	0.0	0.1	1.1	0.6	0.1	0.2	0.1	0.1	0.1	0.0	40.2	5.3	0.4	0.8	0.9	0.4	0.4	0.4	0.7	0.3	0.3	0.9	0.6	1.2	3.3	1.2	0.6	0.7	0.8	0.2	11.6	16.5	2.0	16.7	18.6	9.0	23.5	9.3	14.9	23.8	110.2	61.2	1.3	13.0	16.3	1.5	1.4	180.9	21.4	61.4	33.2	2.0	44.4	1.7	41.9	0.9	2.2	163.1	0.0	77.1	73.6	2.7	83.4	1.1	83.9	5.5	0.0	89.5	6.7	1.9	0.0	1.4	1.7	52.3	2.8	134.3	11.3	75.9	165.5	0.0	31.8	1.1	6.5	1.7	2.4	2.3	32.2	84.1	1.5	124.3	62.5
ERBB4	"ALS19, HER4"	ENSG00000178568	"Erb-b2 receptor tyrosine kinase 4"	Q15303	2	211375717-212538841	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Lactation, Transcription, Transcription regulation"	"Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 24.5"	"Cell type enhanced"	"Detected in many"	10	"Bipolar cells: 11.2;Cardiomyocytes: 15.3;Ciliated cells: 26.8;Club cells: 17.0;Collecting duct cells: 12.2;Muller glia cells: 12.4"	"Cancer enhanced"	"Detected in many"		"breast cancer: 4.1"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 9.6;EFO-21: 7.2;HEK 293: 5.3;RPTEC TERT1: 7.8;SCLC-21H: 4.4;T-47d: 7.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000276, HPA012016, CAB025522"	Enhanced					NA	NA		140000			"CAB000276: , CAB025522: , HPA012016: AB_1846541"	"unprognostic (1.48e-1)"	"unprognostic (3.28e-1)"	"unprognostic (4.31e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.59e-1)"	"unprognostic (2.75e-1)"	"unprognostic (2.88e-1)"	"unprognostic (9.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.67e-3)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.49e-3)"	"unprognostic (1.41e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.11e-2)"	1.6	1.9	15.1	1.2	15.0	1.0	13.4	18.6	14.1	7.8	1.1	7.6	8.8	1.1	1.5	1.2	1.3	24.5	1.2	7.0	14.3	6.5	11.9	1.1	2.9	1.2	7.8	10.7	1.3	2.4	10.8	5.1	1.3	8.8	1.7	1.1	2.0	9.7	18.1	3.8	1.8	1.2	1.1	7.3	1.2	1.5	7.6	12.0	0.0	4.5	1.1	1.2	1.4	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	9.6	0.2	0.0	0.0	0.0	0.0	0.3	0.5	0.1	0.0	0.0	0.0	7.2	1.0	0.0	0.4	0.2	0.0	0.0	0.1	5.3	0.0	1.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.8	0.0	0.0	0.5	0.0	7.8	0.4	4.4	0.2	0.0	0.1	0.1	0.1	7.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.1	15.0	18.6	14.1	14.3	6.5	7.8	10.7	8.8	12.0	0.0	9.3	0.0	0.8	0.6	11.2	15.3	0.0	26.8	17.0	12.2	0.0	0.0	5.0	0.4	4.1	0.1	0.0	0.0	0.4	0.1	0.2	2.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.3	1.7	0.0	3.3	0.0	0.0	12.4	0.0	0.0	0.4	0.0	1.4	6.5	3.1	1.9	1.5	1.1	0.0	0.0	0.0	1.0
ERC1	"CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2"	ENSG00000082805	"ELKS/RAB6-interacting/CAST family member 1"	Q8IUD2	12	990509-1495933	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Horizontal cells: 174.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019513, HPA019523, HPA024130"	Approved		Supported	"Vesicles,Plasma membrane,Cytosol"		NA	NA			Cytosol	"Vesicles, Plasma membrane"	"HPA019513: AB_1856012, HPA019523: AB_1856013, HPA024130: AB_1856014"	"unprognostic (2.41e-1)"	"unprognostic (4.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (5.70e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.32e-1)"	"unprognostic (5.50e-2)"	"unprognostic (8.49e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.26e-2)"	"unprognostic (1.04e-1)"	"unprognostic (6.79e-2)"	"unprognostic (3.75e-3)"	"unprognostic (4.19e-2)"	"unprognostic (3.01e-1)"	"unprognostic (7.37e-2)"	"prognostic unfavorable (7.01e-4)"	12.6	11.4	10.3	12.5	14.7	7.4	15.1	41.7	10.4	11.2	11.9	8.5	9.2	4.3	17.1	11.0	13.7	9.8	9.9	14.7	10.0	11.2	11.2	8.0	8.8	5.4	9.0	6.4	12.5	8.6	24.3	19.4	13.2	10.7	11.4	7.5	10.1	9.3	14.4	9.2	9.9	6.4	22.1	8.5	7.3	8.6	11.0	9.9	9.8	15.3	7.2	8.6	15.7	15.3	8.6	2.9	2.1	3.8	1.1	3.5	0.5	2.9	7.3	3.9	2.6	10.4	8.8	5.4	9.2	7.4	6.3	5.8	6.4	3.6	4.5	1.3	11.9	6.3	4.9	8.3	7.1	8.8	9.5	4.2	11.1	7.3	3.2	7.9	5.7	2.6	7.1	6.2	11.1	20.8	7.6	8.1	2.9	3.3	8.9	4.7	3.2	1.8	1.2	6.2	2.8	3.5	3.6	14.8	1.4	6.2	5.3	2.3	4.6	14.4	3.3	5.2	14.7	3.4	2.4	15.0	10.9	11.1	8.0	8.6	2.4	4.5	6.7	7.1	3.4	4.8	1.4	2.8	2.1	1.6	1.0	2.2	8.6	2.4	2.4	2.4	5.6	3.5	2.6	2.1	1.1	3.8	2.9	2.2	0.5	10.3	14.7	41.7	10.4	10.0	11.2	9.0	6.4	10.7	9.9	23.8	21.4	15.2	22.2	18.7	34.0	51.9	15.3	14.7	23.9	19.2	45.2	25.8	1.7	17.5	29.4	26.3	7.0	0.0	11.7	14.8	17.3	21.4	13.9	15.3	10.8	174.8	28.8	24.5	10.7	24.2	23.0	11.3	13.5	16.2	8.4	47.3	15.2	9.0	29.0	3.3	34.7	19.4	16.5	15.6	28.4	24.0	65.8	7.4	7.6	29.2
ERCC2	"EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD"	ENSG00000104884	"ERCC excision repair 2, TFIIH core complex helicase subunit"	P18074	19	45349837-45370918	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Chromosome partition, DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Cataract, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Spermatocytes: 33.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005375, HPA038057, HPA069266"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB005375: AB_2100152, HPA038057: AB_2675810, HPA069266: AB_2686104"	"unprognostic (1.10e-1)"	"unprognostic (5.48e-1)"	"unprognostic (5.08e-2)"	"unprognostic (9.92e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.67e-3)"	"unprognostic (1.46e-1)"	"unprognostic (3.41e-1)"	"unprognostic (1.06e-1)"	"prognostic favorable (3.26e-4)"	"unprognostic (3.36e-2)"	"unprognostic (2.44e-3)"	"unprognostic (1.94e-1)"	"unprognostic (5.47e-1)"	"unprognostic (8.99e-2)"	"unprognostic (3.45e-2)"	7.4	15.6	11.4	10.6	17.7	6.7	7.1	9.5	23.8	9.4	8.1	11.7	7.8	7.9	11.7	6.0	6.7	10.0	10.1	7.9	9.4	9.1	8.7	13.2	6.5	9.9	8.2	10.5	9.5	13.1	12.9	10.9	7.2	14.0	8.2	6.4	12.5	9.5	11.8	15.9	10.7	7.1	11.2	5.3	9.7	8.3	17.2	7.8	10.8	10.2	5.1	8.3	9.3	6.6	7.8	17.2	5.0	13.9	11.3	9.8	8.7	12.6	6.2	12.9	18.1	7.7	9.1	6.8	18.0	12.4	23.3	17.9	14.3	8.7	4.5	10.3	17.5	8.5	6.5	9.0	15.1	8.9	10.9	14.8	7.7	11.7	15.1	16.3	12.2	13.6	10.5	2.4	26.6	15.1	13.0	13.5	13.0	18.6	5.1	16.0	6.1	7.1	8.1	5.9	11.6	10.9	13.8	9.2	3.8	6.7	11.2	7.5	8.2	16.0	11.3	6.4	10.2	10.7	16.2	17.5	22.3	12.2	9.4	40.0	11.9	6.8	6.5	6.6	7.4	9.8	0.0	13.3	5.0	7.7	13.9	9.8	7.8	7.4	7.4	17.2	5.8	7.1	7.4	0.4	11.3	10.9	8.3	7.4	8.7	11.4	17.7	9.5	23.8	9.4	9.1	8.2	10.5	14.0	7.8	6.0	4.3	3.6	3.9	5.6	0.0	6.0	10.2	6.7	5.7	5.2	0.0	9.4	11.6	7.6	4.1	3.8	2.9	0.0	7.0	10.0	6.8	3.5	0.0	11.5	9.8	0.0	6.9	9.2	7.3	2.2	6.1	4.6	3.3	1.8	7.8	0.0	6.2	3.5	7.4	11.3	0.0	0.0	5.2	33.8	11.0	5.0	4.0	2.9	7.7	3.3
ERCC3	"BTF2, GTF2H, RAD25, TFIIH, XPB"	ENSG00000163161	"ERCC excision repair 3, TFIIH core complex helicase subunit"	P19447	2	127257290-127294176	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Helicase, Hydrolase"	"Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Ichthyosis, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037153, HPA046077"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB037153: AB_796181, HPA046077: AB_2679527"	"unprognostic (2.31e-1)"	"unprognostic (1.15e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.07e-3)"	"unprognostic (1.05e-1)"	"unprognostic (8.85e-2)"	"prognostic unfavorable (1.62e-7)"	"unprognostic (2.74e-1)"	"unprognostic (9.13e-3)"	"unprognostic (9.25e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.46e-2)"	"prognostic unfavorable (4.30e-6)"	"unprognostic (3.71e-1)"	"unprognostic (8.50e-2)"	"unprognostic (5.73e-2)"	"unprognostic (3.92e-2)"	17.4	20.0	26.1	23.8	28.9	20.5	21.0	35.9	32.0	22.1	19.4	19.7	17.1	11.5	21.6	15.7	19.1	23.6	20.4	20.4	23.2	18.8	17.5	17.4	19.4	23.1	19.7	25.8	23.3	22.4	32.0	26.4	16.3	21.5	20.1	17.1	18.3	18.0	21.8	30.1	19.7	17.3	26.1	16.0	24.5	17.4	39.5	20.1	24.1	19.3	15.8	25.9	22.4	20.8	11.8	13.9	7.2	9.7	18.8	16.2	11.7	22.2	15.3	19.0	20.1	21.1	14.5	23.5	20.5	26.6	33.2	32.2	23.4	16.3	16.9	17.0	18.7	21.5	20.0	28.9	21.6	28.9	26.4	25.9	21.2	18.7	24.6	15.7	18.4	23.1	15.0	20.3	38.3	16.4	21.2	21.3	22.2	20.6	11.1	20.9	22.0	26.2	19.8	27.6	14.5	23.9	21.6	21.8	14.0	18.5	20.8	23.0	24.8	17.5	26.7	26.8	22.7	14.4	21.1	16.9	20.0	22.9	18.1	24.3	19.9	38.8	26.5	17.7	8.9	21.3	6.6	9.5	7.2	16.0	9.7	16.2	11.5	11.8	13.5	13.9	11.8	15.8	10.9	3.1	18.8	7.9	11.3	16.1	11.7	26.1	28.9	35.9	32.0	23.2	18.8	19.7	25.8	21.5	20.1	20.8	13.4	8.2	8.1	6.8	0.0	10.5	5.1	32.1	22.7	7.0	0.0	15.9	1.7	12.0	3.5	14.3	4.9	0.0	13.1	10.3	12.0	6.2	9.3	7.8	12.5	0.0	5.8	12.3	12.6	3.1	15.3	9.2	8.5	12.6	8.2	0.0	12.9	5.8	12.0	7.0	0.0	12.9	8.5	34.7	27.5	8.3	12.2	13.8	9.9	5.6
ERCC4	"FANCQ, RAD1, XPF"	ENSG00000175595	"ERCC excision repair 4, endonuclease catalytic subunit"	Q92889	16	13920157-13952345	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Cockayne syndrome, Disease mutation, Dwarfism, Fanconi anemia, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Early spermatids: 121.2;Late spermatids: 71.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000156, HPA045828"	Approved		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane"		NA	NA			"Nucleoplasm, Nuclear bodies"	"Plasma membrane"	"CAB000156: , HPA045828: AB_2679463"	"unprognostic (2.05e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.12e-3)"	"unprognostic (9.41e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.26e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.49e-2)"	"unprognostic (5.26e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.15e-1)"	"unprognostic (6.30e-2)"	"unprognostic (5.88e-4)"	8.4	12.7	8.6	7.0	11.3	5.3	6.4	8.9	9.7	8.1	6.7	9.9	6.0	4.1	8.5	6.8	6.7	8.5	6.8	7.8	7.2	7.1	6.9	7.2	6.9	6.8	10.5	8.8	9.9	7.6	13.3	13.0	5.9	9.6	8.3	5.4	7.1	6.4	7.0	31.3	6.9	5.7	8.5	10.3	7.7	6.6	14.2	8.9	13.7	9.7	5.6	6.4	9.1	7.8	8.4	7.9	8.3	6.8	8.9	7.4	2.6	5.4	7.0	6.4	9.2	10.7	10.1	5.0	7.2	7.7	6.5	8.3	2.4	5.4	9.1	10.4	6.3	5.7	6.9	9.5	4.9	10.1	12.3	5.6	4.5	7.8	6.0	9.8	6.1	5.1	7.6	6.9	8.6	7.3	6.3	8.6	5.5	7.0	10.7	9.1	4.5	8.0	4.1	4.7	2.8	3.7	9.2	13.0	11.2	4.0	3.7	5.3	6.3	8.8	7.2	6.7	5.4	9.1	4.6	9.7	9.6	7.1	8.6	6.3	9.5	11.2	6.3	9.2	7.3	9.8	8.3	6.2	5.4	6.8	6.8	7.4	6.2	6.4	5.1	5.5	8.4	6.4	6.9	7.2	8.9	5.7	7.9	5.8	2.6	8.6	11.3	8.9	9.7	7.2	7.1	10.5	8.8	9.6	8.9	17.9	15.7	9.7	6.8	4.2	0.0	7.9	12.7	18.7	5.7	5.2	0.0	13.6	8.3	10.4	121.2	9.5	2.8	0.0	7.3	5.9	9.9	7.6	1.1	15.7	10.5	0.0	9.2	16.0	11.3	71.5	13.8	10.6	10.1	11.8	5.3	0.0	8.2	0.0	19.8	9.3	0.0	25.8	5.9	46.6	16.7	4.8	10.3	16.0	6.1	4.0
ERCC5	"ERCM2, XPGC"	ENSG00000134899	"ERCC excision repair 5, endonuclease"	P28715	13	102807146-102876001	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Cockayne syndrome, Deafness, Disease mutation, Dwarfism, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 44.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045845, HPA050126, HPA050374"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA045845: AB_2679471, HPA050126: AB_2681027, HPA050374: AB_2681106"	"unprognostic (1.28e-3)"	"unprognostic (1.32e-3)"	"unprognostic (1.86e-2)"	"unprognostic (9.28e-3)"	"unprognostic (6.19e-2)"	"unprognostic (8.73e-2)"	"unprognostic (1.23e-1)"	"unprognostic (8.72e-2)"	"unprognostic (2.52e-1)"	"unprognostic (2.55e-1)"	"unprognostic (7.77e-3)"	"unprognostic (5.76e-3)"	"prognostic unfavorable (2.96e-6)"	"unprognostic (3.56e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.67e-1)"	"prognostic favorable (6.82e-4)"	22.3	19.1	15.9	16.1	17.8	23.7	20.1	26.4	20.8	19.7	27.0	17.9	27.0	25.0	22.1	25.7	21.0	15.1	21.1	15.4	14.6	13.1	18.7	28.1	19.9	26.4	17.1	16.2	22.9	22.3	15.7	25.6	17.9	19.0	20.1	23.1	15.9	20.5	24.7	14.6	25.8	31.1	17.0	19.4	30.6	21.9	14.0	17.8	40.8	21.8	16.6	26.0	22.4	19.6	10.1	10.8	23.4	17.4	17.7	17.5	12.0	14.8	5.4	10.8	6.8	21.7	20.4	6.6	15.1	20.0	8.7	11.4	8.3	20.8	9.3	7.6	15.2	6.1	15.5	9.6	13.8	9.1	14.1	5.4	13.9	15.7	7.2	10.6	28.3	18.2	19.4	13.3	10.1	15.7	13.8	15.2	19.7	6.5	8.5	15.3	4.0	15.2	19.6	4.7	17.9	7.6	8.3	8.1	9.4	18.0	8.3	7.3	10.8	7.9	13.3	8.0	8.7	11.9	26.4	15.3	6.8	3.4	5.7	9.4	12.5	3.8	4.7	26.4	11.5	8.4	23.4	9.8	18.3	16.7	12.3	15.5	9.6	15.5	17.5	10.8	10.1	16.6	16.1	7.2	17.7	17.4	7.7	16.6	12.0	15.9	17.8	26.4	20.8	14.6	13.1	17.1	16.2	19.0	17.8	3.0	7.4	14.6	5.7	6.4	0.0	25.5	7.6	6.7	13.6	0.0	0.0	7.7	0.0	1.0	44.4	9.0	18.4	0.0	1.1	6.6	8.2	3.7	18.5	17.1	9.3	0.0	4.7	10.4	14.3	23.3	20.4	9.9	6.8	1.0	19.0	0.0	1.4	16.4	14.9	1.2	0.0	19.4	6.1	10.6	6.4	6.0	4.8	25.4	16.6	4.3
ERG	"erg-3, p55"	ENSG00000157554	"ERG, ETS transcription factor"	P11308	21	38380027-38661780	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 84.3;granulocytes: 22.1;Ito cells: 63.3"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 18.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"myeloid DC: 1.7;NK-cell: 1.0"	"Group enriched"	"Detected in many"	5	"dendritic cells: 1.7;NK-cells: 1.0"	"Group enriched"	"Detected in some"	5	"HUVEC TERT2: 43.7;MOLT-4: 14.3;REH: 46.4;TIME: 35.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB018377, HPA046598"	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB018377: AB_675518, HPA046598: AB_2679715"	"unprognostic (2.14e-1)"	"prognostic unfavorable (6.18e-6)"	"unprognostic (6.44e-3)"	"unprognostic (8.64e-3)"	"unprognostic (5.65e-2)"	"unprognostic (1.91e-1)"	"unprognostic (9.03e-4)"	"unprognostic (4.30e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavorable (3.94e-4)"	"unprognostic (4.31e-3)"	"unprognostic (3.88e-2)"	"unprognostic (2.64e-2)"	"unprognostic (5.63e-3)"	39.1	4.2	5.7	6.5	8.5	6.6	20.5	3.6	7.0	17.9	5.2	2.3	5.6	3.3	16.9	9.0	6.2	9.2	11.6	10.1	6.2	3.6	10.8	6.0	19.9	7.4	8.0	1.8	7.7	4.8	2.3	3.9	23.2	8.0	8.1	3.6	7.8	4.2	5.6	13.5	5.3	6.2	11.8	4.7	32.5	5.0	4.8	5.0	2.4	10.8	9.1	3.6	9.6	15.8	0.0	1.7	0.0	0.2	1.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	7.1	0.0	0.0	0.3	0.0	0.0	43.7	0.0	0.0	0.0	0.0	0.3	14.3	0.0	0.1	0.0	0.0	46.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	35.4	0.2	0.7	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.4	5.7	8.5	3.6	7.0	6.2	3.6	8.0	1.8	8.0	5.0	0.0	4.6	1.9	1.5	3.1	0.0	2.5	7.6	0.0	2.3	0.0	0.0	0.0	0.0	0.1	0.5	84.3	0.0	0.0	0.0	0.0	2.1	0.4	22.1	0.8	0.2	0.0	0.0	63.3	9.8	1.5	0.9	1.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.2	0.9	3.0	0.0	0.0	0.0	0.6
ESR1	"ER-alpha, Era, ESR, NR3A1"	ENSG00000091831	"Estrogen receptor 1"	P03372	6	151656691-152129619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 64.5;endometrium 1: 68.9"	"Group enriched"	"Detected in many"	6	"Early spermatids: 36.0;Hepatocytes: 48.4;Horizontal cells: 58.8"	"Group enriched"	"Detected in many"	9	"breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.5"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"MCF7: 24.9;T-47d: 32.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB000037, HPA000449, HPA000450, CAB055099, CAB072858"	Enhanced		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: AB_2665701, HPA000449: AB_1078753, HPA000450: AB_1078754"	"unprognostic (8.28e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.43e-2)"	"prognostic favorable (5.47e-7)"	"unprognostic (4.79e-1)"	"unprognostic (2.43e-3)"	"unprognostic (4.10e-5)"	"unprognostic (9.92e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.17e-2)"	"unprognostic (7.35e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.20e-2)"	"unprognostic (7.91e-3)"	"unprognostic (6.45e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.52e-1)"	3.0	0.9	0.5	1.6	0.5	0.2	16.2	0.8	0.4	64.5	1.5	0.2	2.2	0.1	68.9	27.7	1.1	26.7	1.9	1.1	0.5	0.8	1.5	6.6	3.6	1.6	0.4	0.1	14.2	0.4	0.0	9.3	0.9	0.6	3.6	0.1	2.6	1.6	4.1	2.0	0.6	0.5	20.8	0.4	1.6	0.3	1.9	0.4	1.9	1.3	2.2	2.5	3.8	23.7	0.6	1.0	0.0	0.8	0.3	2.5	1.0	0.3	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1	0.4	0.0	0.0	0.0	0.6	0.0	24.9	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.1	32.2	0.0	0.0	0.1	0.1	0.3	0.0	3.0	0.5	0.0	0.1	0.3	0.0	0.0	0.8	0.0	0.3	0.2	1.0	0.6	1.3	0.4	1.0	0.4	2.5	0.9	0.0	0.3	0.0	0.0	0.3	1.0	0.5	0.5	0.8	0.4	0.5	0.8	0.4	0.1	0.6	0.4	0.0	0.6	0.0	1.4	0.9	3.8	4.5	0.0	1.4	1.2	0.0	7.9	0.1	1.7	0.0	36.0	0.6	0.0	0.0	0.2	0.1	4.7	0.6	2.3	48.4	0.9	58.8	1.7	6.7	4.7	6.9	3.7	2.4	1.7	0.0	0.0	2.7	0.2	0.0	2.1	3.3	4.0	0.0	1.4	1.6	1.2	1.5	0.1	0.0	0.0	8.4
ETNK1	"EKI, EKI1"	ENSG00000139163	"Ethanolamine kinase 1"	Q9HBU6	12	22625075-22690665	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid biosynthesis, Lipid metabolism, Phospholipid biosynthesis, Phospholipid metabolism"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Early spermatids: 201.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010712, HPA029407"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Plasma membrane, Cytosol"		"HPA010712: AB_2668349, HPA029407: AB_2673026"	"unprognostic (2.06e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.23e-3)"	"unprognostic (2.19e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.31e-2)"	"prognostic unfavorable (5.85e-4)"	"unprognostic (3.98e-3)"	"unprognostic (8.30e-2)"	"unprognostic (7.97e-3)"	"unprognostic (2.01e-1)"	"unprognostic (1.64e-2)"	"unprognostic (4.53e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.91e-1)"	"unprognostic (3.01e-1)"	"prognostic favorable (1.75e-4)"	15.7	17.7	15.2	41.1	19.4	13.7	16.9	19.7	22.2	12.9	33.2	16.4	14.6	27.2	16.6	24.1	14.7	13.1	27.3	10.4	15.6	23.9	22.0	30.2	19.6	18.5	17.2	15.8	17.2	14.9	15.8	30.6	13.4	18.9	13.8	19.5	15.9	16.7	14.7	8.2	17.8	24.5	10.0	17.1	18.3	53.7	22.3	17.5	33.4	17.6	8.2	16.5	14.2	18.6	16.2	10.7	28.1	17.6	14.0	15.7	13.4	6.7	14.0	15.6	14.4	11.3	11.4	11.6	8.0	6.0	8.3	8.6	10.8	17.1	20.1	7.2	5.2	8.7	5.1	13.7	3.8	15.0	16.7	11.1	16.6	6.2	9.3	10.8	15.9	15.3	7.4	3.7	11.2	9.5	13.3	10.3	7.9	19.9	8.5	11.0	4.6	17.3	32.4	30.2	8.7	9.2	15.6	13.8	16.1	13.8	9.2	5.0	8.8	8.7	7.6	12.5	22.4	11.8	15.4	8.8	6.6	10.6	8.9	12.0	6.2	7.7	21.6	8.4	10.4	11.0	28.1	11.7	12.1	12.9	17.5	12.7	16.2	14.1	11.9	10.7	13.0	15.7	15.5	11.5	14.0	17.6	9.7	15.3	13.4	15.2	19.4	19.7	22.2	15.6	23.9	17.2	15.8	18.9	17.5	44.7	25.1	40.9	63.3	128.1	40.4	11.0	53.5	72.3	35.2	41.8	47.1	27.9	23.2	26.3	201.9	28.7	55.0	0.0	39.6	20.3	28.6	70.5	33.5	38.4	37.5	25.4	103.9	27.6	78.9	26.1	22.5	44.7	64.1	22.6	52.6	21.4	29.0	46.1	20.1	26.4	35.5	38.8	44.3	47.7	15.1	148.8	63.0	39.2	36.0	60.2
ETV1	ER81	ENSG00000006468	"ETS variant 1"	P50549	7	13891228-13991425	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 90.0;salivary gland: 45.8"	"Cell type enhanced"	"Detected in many"	16	"Alveolar cells type 2: 112.4;Cardiomyocytes: 72.8;Intestinal endocrine cells: 190.4"	"Cancer enhanced"	"Detected in all"		"glioma: 22.5"	"Region enriched"	"Detected in all"	8	"cerebellum: 90.0"	"Cell type enriched"	"Detected in single"	5	"T-reg: 3.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 3.1"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 22.2;hTERT-RPE1: 25.6;SCLC-21H: 26.3;U-87 MG: 51.8;WM-115: 25.6"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 418.9"	"HPA068389, HPA077249"		Supported	Approved	Nucleoplasm		No	No			Nucleoplasm		"HPA068389: , HPA077249: AB_2686829"	"unprognostic (2.45e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.64e-7)"	"unprognostic (7.08e-3)"	"unprognostic (7.21e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.01e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.51e-3)"	"unprognostic (2.21e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.20e-2)"	2.5	12.4	8.1	1.1	11.7	0.2	4.4	90.0	35.2	1.4	2.4	3.1	0.1	1.2	2.4	1.3	1.5	1.1	9.2	18.0	7.0	4.5	2.1	2.0	14.9	0.7	4.5	6.9	1.0	1.6	11.4	7.4	1.9	8.3	3.1	2.4	0.9	45.8	7.1	0.9	1.5	1.9	2.0	3.5	4.5	1.7	4.5	2.9	0.3	6.5	0.9	4.7	1.8	1.3	0.0	0.0	0.0	0.6	0.0	3.1	0.2	0.0	1.6	11.6	22.2	4.1	12.2	0.0	1.0	3.9	0.6	2.6	0.0	5.3	0.0	1.2	1.8	3.2	0.1	0.4	1.2	1.4	0.3	0.5	0.6	1.0	0.0	2.4	3.8	1.5	3.6	0.0	7.6	0.6	25.6	5.0	0.3	3.4	0.1	4.7	0.0	0.0	0.0	17.5	0.6	11.8	0.0	7.1	0.9	7.9	0.1	26.3	5.1	0.0	0.4	6.3	4.2	0.4	0.1	2.7	2.3	0.7	4.5	4.3	4.0	1.2	0.0	51.8	0.2	25.6	0.0	0.2	0.0	0.1	0.6	0.3	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.2	8.1	11.7	90.0	10.9	7.0	4.5	4.5	6.9	8.3	2.9	17.9	112.4	0.0	2.5	0.9	4.2	72.8	38.2	1.4	1.2	3.5	0.0	0.4	5.0	2.7	18.7	5.2	0.0	0.0	0.8	0.3	4.2	0.2	2.3	11.0	2.6	4.8	190.4	1.8	6.0	6.6	1.4	0.8	11.8	0.0	0.7	12.2	0.9	0.0	32.5	2.7	0.4	19.4	8.2	0.5	1.0	1.1	0.2	0.7	1.1	0.3
ETV4	"E1A-F, E1AF, PEA3"	ENSG00000175832	"ETS variant 4"	P43268	17	43527844-43579620	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 38.4"	"Cell type enhanced"	"Detected in many"	6	"Cholangiocytes: 10.2;Distal tubular cells: 14.9;Extravillous trophoblasts: 11.2;Intestinal endocrine cells: 14.3;Syncytiotrophoblasts: 12.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 45.2;Hep G2: 42.4;SK-MEL-30: 48.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA005768	Approved		Supported	"Nucleoli rim,Mitotic chromosome"		Yes	No			"Nucleoli rim"	"Mitotic chromosome"	"HPA005768: AB_1848294"	"unprognostic (2.32e-1)"	"unprognostic (7.33e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.97e-2)"	"unprognostic (3.14e-3)"	"prognostic unfavorable (2.48e-4)"	"unprognostic (1.58e-2)"	"unprognostic (5.34e-2)"	"unprognostic (8.13e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.01e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.03e-1)"	"unprognostic (7.08e-2)"	"prognostic favorable (7.60e-4)"	"unprognostic (1.69e-1)"	0.6	2.4	1.4	0.9	1.4	0.0	6.8	1.6	8.3	3.6	3.3	0.4	1.3	5.7	3.4	2.2	9.9	2.4	38.4	2.6	1.8	1.3	7.8	1.4	2.5	0.4	2.3	1.1	1.2	23.8	19.3	19.7	11.6	2.7	4.7	1.6	1.7	4.9	4.5	1.3	6.7	3.8	1.2	1.8	0.5	3.6	1.3	0.5	0.3	6.6	15.0	12.1	3.1	5.3	0.2	0.0	1.3	0.2	0.0	0.6	0.1	5.9	16.8	20.6	45.2	0.8	5.3	4.6	1.9	5.3	3.8	3.9	9.4	8.6	0.0	1.1	1.0	9.4	10.9	0.7	10.1	3.4	0.2	0.1	0.5	2.7	42.4	1.1	11.4	5.4	0.9	0.3	14.6	9.1	4.3	8.1	0.0	11.8	0.0	7.8	2.4	0.0	20.3	29.8	30.4	28.2	24.5	2.5	14.4	8.5	4.3	0.0	18.4	0.5	1.1	48.9	11.8	0.2	3.4	3.7	2.7	13.5	4.0	5.4	1.8	11.3	0.0	4.9	2.2	15.9	0.0	0.0	0.0	0.0	0.2	0.5	0.2	0.1	0.0	0.0	0.0	0.2	0.6	1.3	0.0	0.0	0.0	0.0	0.1	1.4	1.4	1.6	3.6	1.8	1.3	2.3	1.1	2.7	0.5	0.0	0.0	0.0	2.1	1.6	1.1	0.6	10.2	1.4	3.4	0.0	0.0	2.2	14.9	6.8	2.8	0.6	0.9	0.0	0.9	11.2	1.7	0.4	0.0	0.0	0.7	0.0	14.3	0.6	0.0	3.9	0.3	0.0	3.3	0.0	0.8	7.7	2.7	2.3	0.4	0.0	0.3	0.0	0.8	0.0	0.0	1.0	12.5	0.0	2.5	3.1
ETV5	ERM	ENSG00000244405	"ETS variant 5"	P41161	3	186046308-186110318	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"parathyroid gland: 55.3"	"Cell type enhanced"	"Detected in many"	5	"Muller glia cells: 62.8;Syncytiotrophoblasts: 74.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 3.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"SK-MEL-30: 56.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009590, HPA063065, HPA073889"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB009590: AB_2101008, HPA063065: AB_2684936, HPA073889: "	"unprognostic (3.85e-1)"	"unprognostic (5.81e-2)"	"unprognostic (1.54e-2)"	"unprognostic (3.30e-1)"	"unprognostic (9.00e-2)"	"unprognostic (2.56e-3)"	"prognostic unfavorable (7.85e-9)"	"unprognostic (3.52e-3)"	"unprognostic (2.97e-1)"	"unprognostic (1.22e-2)"	"unprognostic (4.18e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.57e-3)"	"unprognostic (6.80e-2)"	"unprognostic (1.57e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.84e-3)"	5.8	30.3	13.2	5.5	21.7	1.6	11.3	12.1	35.2	4.7	3.0	15.7	1.3	5.1	6.8	6.2	3.8	4.6	4.8	8.8	13.6	9.4	7.1	6.2	21.9	8.9	9.9	11.0	2.5	25.4	55.3	28.1	24.3	11.5	6.3	3.1	7.4	5.5	5.1	9.8	5.3	2.8	6.1	9.6	10.0	11.9	7.2	6.1	2.0	16.6	1.7	3.6	3.6	3.6	0.6	1.8	0.9	3.1	0.1	0.3	0.5	13.0	9.0	11.6	25.3	7.2	7.4	0.8	11.2	12.6	8.9	9.6	9.9	8.0	0.3	15.1	10.8	13.4	2.2	0.2	8.5	13.2	2.8	0.3	3.8	0.3	11.1	11.9	9.5	7.1	6.5	1.4	14.2	17.4	10.6	13.0	1.3	3.5	4.7	15.1	6.0	1.2	14.5	17.3	3.7	10.2	26.7	11.6	8.7	7.3	3.1	0.5	14.9	2.7	0.1	56.7	4.8	0.0	5.3	12.6	4.9	8.0	12.3	21.9	3.6	14.7	0.1	14.9	7.6	29.1	0.0	0.3	0.1	0.3	3.1	0.0	0.6	0.0	0.0	1.8	0.1	0.0	0.0	0.9	0.1	1.5	1.6	0.0	0.5	13.2	21.7	12.1	31.7	13.6	9.4	9.9	11.0	11.5	6.1	3.0	55.6	4.2	10.8	14.0	15.6	4.7	20.4	1.4	2.3	0.0	11.8	53.9	3.3	8.2	19.2	8.3	1.0	0.0	8.0	16.2	11.4	2.6	8.1	8.5	45.7	4.8	10.3	14.7	47.8	37.8	8.3	13.5	15.1	2.8	0.3	62.8	9.4	0.0	14.5	11.8	15.8	0.0	15.7	17.4	9.3	4.5	74.3	0.9	0.4	1.6
ETV6	TEL	ENSG00000139083	"ETS variant 6"	P41212	12	11649854-11895402	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 39.7;NB-4: 21.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA000264	Enhanced		Approved	Nucleoli,Cytosol		NA	NA			Nucleoli	Cytosol	"HPA000264: AB_611466"	"unprognostic (4.03e-3)"	"unprognostic (3.08e-2)"	"unprognostic (7.54e-3)"	"unprognostic (2.60e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.35e-3)"	"unprognostic (2.74e-2)"	"unprognostic (4.02e-2)"	"unprognostic (3.16e-1)"	"unprognostic (9.46e-2)"	"prognostic unfavorable (9.38e-5)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (4.66e-8)"	"unprognostic (1.33e-2)"	"unprognostic (5.99e-2)"	"unprognostic (8.92e-2)"	"prognostic favorable (1.54e-5)"	17.2	8.9	5.1	20.0	7.6	32.8	20.4	1.6	9.1	10.5	14.5	6.0	9.8	7.2	10.8	14.2	11.3	8.9	15.3	6.7	5.6	3.8	9.2	9.6	16.0	13.4	6.0	3.1	10.5	10.4	8.4	8.7	7.7	7.4	14.9	11.0	8.0	41.9	12.4	6.9	23.9	14.6	25.0	9.4	17.8	9.7	4.7	5.7	30.6	10.0	10.0	19.9	19.0	15.8	2.9	6.2	11.4	7.1	2.4	2.2	1.3	2.6	3.5	3.2	5.6	2.5	2.3	3.9	1.9	3.3	2.5	3.0	0.2	12.4	2.2	1.9	3.3	3.0	3.4	1.4	5.9	3.1	39.7	0.7	14.0	1.9	1.3	3.1	14.7	15.3	4.6	3.7	2.5	5.2	4.9	7.6	10.2	1.0	7.4	2.3	1.7	8.3	21.1	5.3	2.7	0.9	2.3	3.1	5.7	5.8	16.5	0.6	3.3	3.8	3.7	3.6	5.4	1.2	9.3	8.6	5.7	4.9	1.9	4.1	3.3	2.5	1.2	3.7	0.1	6.5	5.6	5.7	6.6	1.5	6.6	2.0	2.9	2.2	1.4	4.1	2.3	1.3	0.8	11.4	2.4	7.1	6.2	1.4	1.3	5.1	7.6	1.6	9.1	5.6	3.8	6.0	3.1	7.4	5.7	6.0	8.1	21.4	28.1	13.3	1.9	7.5	17.8	28.1	22.7	14.0	5.9	11.8	1.7	15.2	4.5	23.5	22.5	0.0	30.8	3.6	10.8	33.7	10.4	9.3	17.1	0.0	31.2	38.6	48.1	3.6	7.2	48.8	27.0	40.5	26.8	4.8	31.2	24.9	10.3	7.9	4.0	19.4	28.8	0.6	7.0	19.6	7.2	14.6	20.4	60.6
EWSR1	EWS	ENSG00000182944	"EWS RNA binding protein 1"	Q01844	22	29268009-29300525	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Calmodulin-binding, Repressor, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004230, HPA051771, HPA062953"	Enhanced		Enhanced	"Nucleoplasm,Nucleoli rim"		No	No			Nucleoplasm	"Nucleoli rim"	"CAB004230: AB_675526, HPA051771: AB_2681602, HPA062953: AB_2684910"	"unprognostic (1.96e-1)"	"unprognostic (6.39e-3)"	"unprognostic (1.32e-1)"	"unprognostic (3.93e-2)"	"unprognostic (3.59e-1)"	"unprognostic (3.15e-2)"	"prognostic unfavorable (1.27e-6)"	"unprognostic (1.33e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.71e-2)"	"unprognostic (7.04e-2)"	"unprognostic (9.30e-2)"	"prognostic unfavorable (1.21e-5)"	"unprognostic (7.33e-3)"	"unprognostic (1.79e-1)"	"unprognostic (3.67e-2)"	"unprognostic (1.50e-3)"	35.3	43.2	45.3	41.3	51.3	67.5	32.1	58.2	48.6	32.4	39.8	43.2	31.3	41.0	45.1	38.5	40.8	37.6	25.9	40.7	40.1	32.8	33.0	48.5	33.4	50.5	32.7	49.9	38.4	32.0	47.2	44.3	34.0	41.7	35.0	39.9	41.5	32.3	38.2	52.8	34.8	36.6	40.5	33.8	44.1	34.5	85.6	32.5	39.9	32.5	30.9	55.4	36.4	34.5	52.0	65.8	50.6	81.1	58.4	67.8	76.1	57.2	44.6	61.4	47.7	31.3	26.0	42.2	34.9	55.8	57.9	49.7	50.8	29.8	78.3	22.1	53.5	44.0	45.0	87.4	71.4	59.7	53.3	62.3	59.1	39.5	48.6	46.9	90.9	42.3	39.7	30.1	48.3	78.4	27.8	44.8	37.5	44.2	35.4	42.8	57.5	91.2	34.8	43.1	47.4	34.0	64.1	59.1	47.3	53.2	60.9	50.3	48.1	43.4	50.9	37.6	42.2	32.7	49.5	45.7	35.4	39.3	22.2	50.6	46.0	36.9	72.6	33.7	40.5	43.0	48.4	57.9	50.6	60.2	81.1	60.7	50.4	56.6	59.6	65.8	52.0	55.8	53.6	43.3	58.4	78.6	35.3	67.8	76.1	45.3	51.3	58.2	48.6	40.1	32.8	32.7	49.9	41.7	32.5	95.3	103.6	96.6	120.0	61.7	71.3	60.0	89.2	124.5	102.4	61.1	70.7	120.3	56.3	106.1	87.5	78.6	71.5	70.0	93.8	108.0	78.0	80.7	117.8	64.2	85.5	77.9	77.7	82.3	69.0	21.4	57.0	89.6	77.6	112.8	73.3	66.1	95.4	94.7	58.4	59.1	77.8	51.8	86.8	180.0	109.0	51.2	127.5	88.0	89.6	101.6
EXT1	"LGCR, LGS, ttv"	ENSG00000182197	"Exostosin glycosyltransferase 1"	Q16394	8	117794490-118111853	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Hereditary multiple exostoses, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 66.4"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 55.5;fHDF/TERT166: 56.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044394	Uncertain					NA	Yes		9600000			"HPA044394: AB_10963838"	"unprognostic (1.29e-2)"	"prognostic unfavorable (7.04e-4)"	"unprognostic (2.73e-2)"	"unprognostic (2.02e-3)"	"unprognostic (2.19e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.99e-1)"	"prognostic unfavorable (1.20e-5)"	"unprognostic (1.70e-1)"	"unprognostic (3.01e-2)"	"unprognostic (1.31e-2)"	"unprognostic (6.58e-2)"	"unprognostic (1.27e-2)"	"unprognostic (9.84e-2)"	"unprognostic (9.49e-2)"	"prognostic unfavorable (4.64e-4)"	"unprognostic (1.85e-1)"	13.8	11.9	5.8	20.5	4.6	2.1	16.5	7.3	7.4	13.3	17.1	4.1	8.7	23.2	11.5	12.5	11.2	8.8	19.3	14.4	4.6	3.1	8.8	66.4	19.9	8.3	3.0	6.8	10.4	17.9	7.1	6.4	15.6	4.8	9.8	16.0	13.2	9.8	13.3	4.2	12.3	32.0	16.8	4.3	20.1	11.5	5.0	2.7	8.7	12.0	10.3	7.2	11.0	18.5	0.8	1.7	1.2	4.5	0.7	2.4	1.0	17.3	5.0	7.6	3.0	13.7	11.1	3.5	32.5	55.5	24.0	22.1	5.2	1.7	0.3	14.6	56.1	17.9	11.0	3.3	19.1	33.8	6.5	5.6	0.7	4.7	4.1	6.4	0.0	1.2	6.9	5.1	29.1	26.8	30.1	14.7	1.6	0.4	4.8	11.1	1.4	0.8	0.0	2.4	9.2	6.5	0.0	2.8	0.5	9.4	6.3	2.4	2.2	5.0	2.3	4.8	20.2	3.2	0.2	19.5	20.2	18.6	18.6	9.5	2.8	2.7	1.6	18.8	0.0	5.4	0.3	4.4	0.2	0.2	4.5	1.3	0.8	0.5	0.6	1.0	0.1	0.5	0.9	1.2	0.7	2.2	1.7	2.4	1.0	5.8	4.6	7.3	7.4	4.6	3.1	3.0	6.8	4.8	2.7	17.9	5.9	1.4	18.7	48.7	21.1	6.2	28.1	5.3	6.8	7.0	13.7	5.2	0.0	34.9	1.3	16.6	42.3	0.0	17.2	3.2	32.1	10.0	6.9	22.6	2.2	9.5	4.6	17.8	28.9	1.6	16.1	5.4	18.6	5.4	20.7	6.0	21.6	14.0	33.9	5.0	24.5	0.0	28.1	0.5	4.3	41.4	10.2	2.2	21.2	17.9
EXT2	SOTV	ENSG00000151348	"Exostosin glycosyltransferase 2"	Q93063	11	44095549-44245429	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"		"Glycosyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, Hereditary multiple exostoses, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA078409			Supported	"Golgi apparatus"		NA	NA		20000000	"Golgi apparatus"		"HPA078409: AB_2686884"	"unprognostic (5.87e-2)"	"unprognostic (3.05e-3)"	"unprognostic (3.48e-2)"	"unprognostic (3.94e-1)"	"unprognostic (1.42e-1)"	"prognostic unfavorable (2.50e-4)"	"unprognostic (1.77e-3)"	"unprognostic (2.22e-2)"	"unprognostic (1.97e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.70e-2)"	"prognostic unfavorable (5.36e-6)"	"unprognostic (7.07e-3)"	"unprognostic (2.97e-1)"	"unprognostic (3.85e-1)"	"unprognostic (1.36e-2)"	24.5	19.5	11.6	17.2	18.5	6.6	25.8	14.5	23.0	26.8	25.0	15.5	17.5	17.6	37.1	25.5	16.7	26.0	23.4	22.7	11.7	13.0	19.2	36.3	22.3	16.8	11.8	12.3	29.3	21.8	25.7	17.3	58.0	16.2	23.7	20.6	22.9	24.7	22.8	16.9	20.2	34.0	35.0	12.2	18.7	19.3	20.0	11.4	16.2	24.7	16.7	13.0	20.2	23.2	6.7	14.9	13.0	12.0	17.8	17.6	9.8	13.1	18.2	9.9	30.7	45.6	33.6	13.6	40.8	51.1	24.2	33.0	12.9	9.1	9.1	18.6	47.8	25.6	21.0	10.5	29.0	29.3	18.2	14.5	8.4	9.6	9.9	18.0	8.4	18.1	26.0	19.2	14.6	22.9	28.5	34.3	8.7	11.2	16.4	17.6	10.1	5.8	5.1	10.6	16.8	13.0	7.3	28.2	4.6	14.0	12.5	7.1	7.9	25.8	10.6	6.8	18.3	17.6	9.0	31.0	32.7	21.4	32.0	26.2	7.4	9.7	6.7	21.5	6.5	34.9	9.3	11.9	13.0	15.6	12.0	17.6	6.4	12.5	14.4	14.9	6.7	11.9	11.7	2.6	17.8	8.5	5.1	9.6	9.8	11.6	18.5	14.5	23.0	11.7	13.0	11.8	12.3	16.2	11.4	14.9	8.8	10.5	13.2	13.5	11.5	9.2	5.1	5.3	10.3	12.2	13.7	27.3	5.0	28.2	30.2	16.7	20.5	0.0	20.6	30.2	24.4	17.7	5.8	15.5	16.2	12.7	1.7	21.5	11.9	17.4	25.3	7.7	5.0	10.0	14.0	16.6	21.7	14.0	26.9	7.0	14.3	19.4	16.9	36.9	21.7	11.0	29.5	7.5	13.3	14.6
EZH2	"ENX-1, EZH1, KMT6, KMT6A"	ENSG00000106462	"Enhancer of zeste 2 polycomb repressive complex 2 subunit"	Q15910	7	148807383-148884321	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 25.5;lymphoid tissue: 44.1"	"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 72.2;Spermatocytes: 126.7;Spermatogonia: 62.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009589	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB009589: "	"unprognostic (2.42e-1)"	"unprognostic (3.95e-3)"	"unprognostic (1.57e-1)"	"unprognostic (3.30e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.85e-3)"	"prognostic unfavorable (2.11e-6)"	"unprognostic (2.21e-2)"	"prognostic unfavorable (1.96e-4)"	"unprognostic (2.32e-3)"	"unprognostic (1.58e-3)"	"unprognostic (1.69e-3)"	"prognostic unfavorable (8.18e-12)"	"prognostic favorable (6.97e-4)"	"unprognostic (1.83e-1)"	"unprognostic (2.12e-1)"	"unprognostic (6.67e-2)"	2.0	1.7	1.8	10.6	1.6	25.5	1.4	4.9	2.7	2.6	4.8	1.1	0.1	3.8	1.7	2.8	11.0	0.9	3.0	0.9	0.8	0.6	1.7	3.3	2.3	12.6	1.3	0.3	2.2	3.8	0.6	1.7	3.4	1.4	1.4	5.1	1.8	3.2	1.6	3.7	6.4	4.8	1.5	1.2	5.8	2.7	19.6	1.3	44.1	0.9	5.5	12.4	2.6	3.5	1.5	4.7	1.3	3.9	8.5	10.3	1.7	17.0	8.0	27.3	18.2	0.8	1.4	14.9	13.3	5.4	11.0	11.1	12.0	19.7	30.2	6.5	5.0	10.0	10.5	14.0	4.6	14.0	43.2	14.0	12.9	9.9	9.3	2.2	28.6	10.6	1.2	2.6	8.2	4.4	3.3	6.4	29.3	27.3	20.1	9.8	19.3	55.6	23.9	21.7	15.0	10.8	34.4	15.3	18.7	5.1	8.2	26.1	16.6	16.7	12.7	4.4	7.3	9.3	12.3	3.9	11.7	5.4	23.3	23.8	18.0	19.6	30.4	10.7	19.6	22.9	0.5	2.2	1.3	1.7	1.5	1.3	1.5	3.4	2.9	4.7	0.8	1.9	1.2	0.2	8.5	3.9	1.0	10.3	1.7	1.8	1.6	4.9	2.7	0.8	0.6	1.3	0.3	1.4	1.3	0.0	7.9	6.7	5.7	23.6	4.8	6.5	2.5	14.7	7.9	7.0	33.4	13.6	3.3	9.1	72.2	7.1	6.7	23.3	7.4	29.5	10.8	4.4	21.8	1.3	10.4	14.3	8.6	4.3	8.9	19.2	2.8	10.9	13.5	19.0	10.2	2.0	10.1	9.3	0.7	1.0	21.1	6.5	9.9	126.7	62.4	25.3	25.5	18.7	18.6	4.0
EZR	VIL2	ENSG00000092820	Ezrin	P15311	6	158765741-158819412	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell shape"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Ciliated cells: 1685.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004035, HPA021616, CAB047324, CAB075739"	Enhanced		Enhanced	"Plasma membrane"		NA	NA		75000000	"Plasma membrane"		"CAB004035: AB_2100309, CAB047324: , CAB075739: AB_2665745, HPA021616: AB_1848342"	"unprognostic (4.79e-3)"	"unprognostic (1.48e-1)"	"unprognostic (1.97e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.31e-3)"	"unprognostic (1.76e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.32e-1)"	"unprognostic (7.53e-2)"	"prognostic unfavorable (1.70e-4)"	"unprognostic (5.59e-2)"	"prognostic favorable (9.56e-8)"	"unprognostic (1.16e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.34e-2)"	"unprognostic (9.00e-2)"	22.8	56.4	30.9	31.2	31.4	24.7	13.3	4.0	21.5	18.0	45.5	28.2	35.2	33.8	9.8	25.8	71.8	25.1	30.2	34.3	37.6	13.9	53.5	16.2	44.3	36.7	14.8	19.0	20.7	33.0	77.1	14.6	125.1	23.5	21.7	22.8	37.0	27.4	32.0	13.6	47.5	87.9	22.8	12.8	26.0	55.4	21.4	22.2	41.6	37.1	34.4	75.6	38.2	25.3	81.7	30.0	24.3	31.2	20.7	61.7	41.1	88.1	48.2	11.9	17.1	1.3	1.4	69.7	27.7	9.1	31.3	26.4	56.4	48.9	88.8	27.5	31.6	15.0	67.6	23.5	30.9	36.4	31.0	15.2	1.8	29.2	24.9	31.8	21.9	13.7	2.3	24.0	29.4	28.6	26.8	20.5	12.3	17.5	43.5	18.1	23.2	31.1	26.5	19.9	24.1	16.1	23.4	5.6	20.2	64.3	26.8	21.7	17.7	48.5	69.9	5.2	57.0	17.0	29.0	26.4	10.1	32.5	13.9	42.6	30.0	27.3	76.1	6.3	11.3	12.0	24.3	14.0	16.4	34.8	31.2	41.0	81.7	36.7	42.9	30.0	67.5	19.9	26.5	6.1	20.7	30.6	14.0	61.7	41.1	30.9	31.4	4.0	21.5	37.6	13.9	14.8	19.0	23.5	22.2	884.4	543.1	187.4	615.4	546.1	5.3	247.6	119.8	1685.0	977.1	148.3	0.0	366.9	82.9	222.1	7.9	84.3	679.2	46.7	221.5	488.7	135.0	354.7	114.5	30.6	98.9	0.0	153.2	31.3	77.1	21.1	125.4	213.0	305.4	115.4	206.3	31.3	408.3	238.4	276.5	168.7	4.0	245.8	120.5	46.2	56.6	635.1	1039.8	112.2	143.1	1039.6
FAM46C	FLJ20202	ENSG00000183508	"Family with sequence similarity 46 member C"	Q5VWP2	1	117605934-117628372	"Cancer-related genes, Predicted intracellular proteins"	"Host-virus interaction"	"Nucleotidyltransferase, RNA-binding, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 114.0"	"Group enriched"	"Detected in many"	9	"Early spermatids: 418.3;Late spermatids: 1175.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 16.3"	"Group enriched"	"Detected in many"	17	"B-cells: 9.7;granulocytes: 16.3;T-cells: 9.2"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 74.8;RPMI-8226: 44.6;U-266/70: 20.8;U-266/84: 17.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA054049	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA054049: AB_2682356"	"unprognostic (3.76e-2)"	"unprognostic (3.85e-3)"	"unprognostic (3.24e-3)"	"prognostic favorable (3.75e-5)"	"unprognostic (1.17e-1)"	"unprognostic (1.55e-3)"	"unprognostic (3.29e-1)"	"unprognostic (2.88e-2)"	"unprognostic (5.75e-2)"	"unprognostic (1.36e-3)"	"unprognostic (9.41e-3)"	"unprognostic (3.91e-2)"	"prognostic favorable (2.77e-5)"	"unprognostic (6.26e-2)"	"unprognostic (3.16e-2)"	"unprognostic (3.08e-2)"	"unprognostic (1.10e-2)"	3.2	1.8	1.2	24.5	1.1	28.9	4.4	1.1	1.1	8.1	16.1	1.8	8.4	5.6	4.8	16.6	6.9	3.3	9.7	6.4	1.2	1.1	5.0	5.5	11.2	16.3	1.2	0.1	8.3	114.0	7.2	5.3	10.6	3.9	6.4	9.5	4.4	37.8	11.9	10.0	1.8	10.6	4.7	1.4	19.1	12.2	34.0	0.2	1.5	10.3	10.9	37.0	9.5	8.6	9.7	0.2	16.3	0.0	0.6	9.2	2.1	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.1	6.7	0.1	0.0	0.4	0.0	1.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	4.2	0.4	9.2	0.0	0.0	0.0	5.4	11.9	0.0	0.0	0.1	0.0	0.0	0.0	2.5	1.2	74.8	0.0	0.9	0.0	5.5	0.9	1.1	0.6	0.0	0.0	44.6	0.0	0.9	0.5	0.0	0.4	0.6	0.4	0.1	0.4	0.0	0.1	0.0	0.5	0.0	0.1	20.8	17.2	0.4	0.4	1.9	0.6	16.3	0.0	10.5	2.5	0.0	2.2	9.7	2.5	3.1	0.0	8.0	0.3	1.4	1.1	0.6	0.0	0.2	9.2	2.1	1.2	1.1	1.1	1.1	1.2	1.1	1.2	0.1	3.9	0.2	6.0	42.9	52.6	7.5	7.6	0.0	0.0	5.1	21.4	36.4	0.0	0.0	1.9	0.0	0.0	418.3	2.8	12.0	93.5	0.0	2.0	7.3	6.6	7.0	4.3	1.1	0.0	19.0	0.0	1.5	1175.9	13.3	2.0	45.5	0.0	35.3	1.1	0.0	8.6	8.5	0.0	0.0	6.5	9.2	12.5	8.5	5.6	1.8	32.0	26.4	7.9
FANCA	"FA-H, FAA, FACA, FAH, FANCH"	ENSG00000187741	"Fanconi anemia complementation group A"	O15360	16	89737549-89816657	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 20.6;testis: 28.8"	"Cell type enhanced"	"Detected in many"	6	"Erythroid cells: 23.3;Spermatocytes: 22.3;Spermatogonia: 33.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA063236			Supported	Nucleoplasm		NA	Yes			Nucleoplasm		"HPA063236: AB_2684966"	"unprognostic (5.99e-2)"	"unprognostic (5.68e-2)"	"unprognostic (2.36e-1)"	"unprognostic (5.12e-2)"	"unprognostic (1.87e-1)"	"unprognostic (7.11e-2)"	"unprognostic (1.45e-4)"	"unprognostic (9.21e-2)"	"unprognostic (1.58e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.82e-3)"	"unprognostic (8.48e-4)"	"unprognostic (7.82e-10)"	"unprognostic (3.67e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.62e-1)"	2.1	2.0	2.2	16.5	3.7	17.1	1.7	5.7	6.6	1.7	5.1	1.1	0.6	5.0	1.7	3.1	6.6	1.9	1.6	1.7	1.8	1.4	2.1	5.8	3.3	11.1	1.3	2.7	1.6	1.8	2.3	1.9	11.2	2.4	1.7	6.3	1.5	2.2	0.5	0.7	5.0	5.4	2.0	1.6	6.9	3.5	28.8	0.8	20.6	1.7	4.6	17.6	2.9	2.5	7.4	6.5	9.9	9.2	7.5	9.5	4.2	9.3	14.4	17.3	15.1	1.1	2.2	13.2	11.7	6.4	19.8	8.3	12.6	15.6	23.1	5.5	4.0	6.6	14.5	11.6	8.7	20.9	5.4	19.5	6.8	18.5	25.8	0.7	6.9	7.5	0.7	0.9	16.0	5.1	2.8	6.2	11.7	16.3	7.1	10.3	21.7	13.8	30.0	11.2	12.9	9.0	25.2	13.9	4.2	4.9	8.9	15.5	8.4	17.5	5.2	2.2	10.4	9.4	12.5	4.6	15.9	16.8	8.8	12.2	6.4	7.5	22.9	7.5	15.5	15.1	2.6	7.9	9.9	4.7	8.8	3.3	7.4	2.8	4.1	6.5	5.5	0.7	3.0	9.8	7.5	9.2	0.4	9.5	4.2	2.2	3.7	5.7	6.6	1.8	1.4	1.3	2.7	2.4	0.8	0.0	0.6	13.1	1.4	3.1	8.8	1.6	0.0	1.4	3.4	15.7	9.8	10.9	1.7	1.6	5.3	0.8	2.0	23.3	1.4	7.5	1.3	0.5	2.3	4.0	7.7	3.2	1.7	7.4	4.3	3.5	1.4	6.3	0.0	0.0	6.1	1.4	1.5	0.0	0.0	6.8	7.2	0.0	1.0	22.3	33.2	1.6	21.2	3.2	6.3	2.1
FANCC	"FA3, FAC, FACC"	ENSG00000158169	"Fanconi anemia complementation group C"	Q00597	9	95099054-95426796	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 29.7"	"Group enriched"	"Detected in many"	5	"Early spermatids: 190.4;Late spermatids: 63.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"basophil: 10.4"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 10.4"	"Cell line enhanced"	"Detected in all"		"RH-30: 31.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017793, HPA030771"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB017793: , HPA030771: AB_2673604"	"unprognostic (1.48e-2)"	"unprognostic (4.33e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.63e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.32e-2)"	"unprognostic (3.41e-3)"	"unprognostic (1.26e-2)"	"unprognostic (7.45e-3)"	"unprognostic (1.37e-1)"	"unprognostic (8.00e-3)"	"unprognostic (3.19e-2)"	"prognostic favorable (6.03e-6)"	"unprognostic (2.35e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.49e-1)"	"unprognostic (5.71e-2)"	4.9	2.7	4.3	8.6	7.0	3.6	4.6	29.7	7.7	4.6	6.4	4.9	5.1	7.1	6.3	4.1	4.5	3.6	5.2	3.2	4.0	2.7	10.0	25.7	6.7	3.7	7.3	1.6	3.3	5.4	2.9	12.1	4.3	6.7	4.4	6.1	4.0	4.0	4.2	4.5	7.7	8.1	2.9	6.4	3.4	4.4	19.6	7.3	7.9	4.3	3.2	6.0	3.5	4.0	1.0	1.3	10.4	1.7	0.3	1.5	0.7	13.6	9.2	12.2	10.6	1.2	3.2	7.7	5.9	3.9	9.5	8.8	10.5	5.8	7.8	4.2	4.3	7.3	16.7	12.3	5.2	5.2	7.4	5.8	6.1	10.4	5.4	2.0	6.1	6.8	2.7	2.2	7.6	3.4	2.6	5.2	7.6	9.1	3.4	6.8	9.6	5.7	3.5	5.8	14.5	5.2	12.2	31.5	3.6	3.9	3.5	17.7	9.4	11.3	4.0	3.4	6.4	4.2	5.1	2.5	8.3	12.2	9.1	8.4	3.6	6.6	4.1	4.5	5.6	9.8	10.4	0.4	0.0	1.3	0.8	1.3	1.0	0.7	1.5	0.4	1.0	1.2	1.0	0.1	0.3	1.7	1.3	1.3	0.7	4.3	7.0	29.7	7.7	4.0	2.7	7.3	1.6	6.7	7.3	3.0	2.1	0.0	2.3	2.3	5.4	1.6	5.1	1.4	3.4	0.0	3.9	2.3	1.7	4.1	190.4	4.3	3.3	0.0	3.6	4.0	2.0	2.5	5.7	25.1	1.8	9.5	0.0	4.3	2.7	63.3	6.1	1.3	1.7	3.6	4.5	2.6	3.4	0.0	2.1	7.7	4.2	0.0	1.6	13.0	10.6	2.4	1.9	1.0	3.8	2.5
FANCD2	"FA-D2, FACD, FAD, FANCD"	ENSG00000144554	"Fanconi anemia complementation group D2"	Q9BXW9	3	10026414-10101930	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 24.4;testis: 23.3"	"Cell type enhanced"	"Detected in many"	9	"Erythroid cells: 46.7;Spermatocytes: 55.1;Spermatogonia: 32.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 46.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB016117, HPA063742"	Approved		Supported	"Nucleoplasm,Nucleoli,Nuclear bodies,Cytosol"		No	No			Nucleoplasm	"Nucleoli, Nuclear bodies, Cytosol"	"CAB016117: AB_2278211, HPA063742: AB_2685110"	"unprognostic (3.25e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.21e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.92e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.08e-5)"	"unprognostic (2.96e-2)"	"unprognostic (1.59e-3)"	"prognostic unfavorable (5.00e-5)"	"unprognostic (1.23e-2)"	"unprognostic (9.14e-2)"	"unprognostic (4.41e-10)"	"unprognostic (9.11e-3)"	"unprognostic (3.99e-1)"	"unprognostic (7.76e-2)"	"unprognostic (2.89e-2)"	2.0	1.3	0.8	10.3	2.6	12.2	2.4	1.6	2.7	1.7	2.9	1.1	1.0	2.2	2.2	1.8	4.7	2.4	2.5	1.1	0.8	0.9	2.3	1.0	2.4	9.5	1.3	1.2	3.5	3.5	0.6	1.1	5.3	1.4	2.2	4.9	1.6	3.3	0.4	3.0	3.3	6.2	1.2	2.0	7.3	2.4	23.3	1.6	24.4	1.6	5.6	14.6	2.2	2.4	6.8	3.7	5.3	2.6	2.1	2.9	1.0	8.7	9.3	17.8	5.0	0.9	1.4	46.0	8.0	3.6	11.5	9.4	6.9	8.7	17.1	3.8	2.6	9.5	7.6	18.3	6.2	11.5	8.1	12.4	23.3	14.3	6.6	0.1	17.3	14.6	0.4	1.0	13.0	7.2	1.6	6.9	14.7	14.2	19.6	8.7	10.0	14.4	6.7	21.4	6.7	6.5	15.8	14.5	12.1	4.0	9.8	4.9	9.8	9.8	7.7	3.1	13.5	11.8	11.0	4.0	9.6	11.0	5.8	11.6	8.3	16.3	28.9	5.5	17.8	16.3	5.3	1.4	3.7	1.5	1.0	1.3	4.9	2.0	1.2	0.9	6.8	2.5	1.9	3.3	2.1	2.6	3.7	2.9	1.0	0.8	2.6	1.6	2.7	0.8	0.9	1.3	1.2	1.4	1.6	0.0	0.3	9.7	2.8	4.0	2.8	1.6	0.0	1.4	1.2	1.8	9.8	6.6	0.0	1.6	4.4	1.5	0.7	46.7	2.9	12.7	1.3	2.2	1.1	1.0	5.0	0.0	1.2	3.7	3.4	5.6	2.0	5.2	3.3	7.2	2.0	0.8	1.4	2.8	1.4	0.5	5.8	19.4	0.8	55.1	32.4	2.4	5.8	3.8	5.0	2.3
FANCE	"FACE, FAE"	ENSG00000112039	"Fanconi anemia complementation group E"	Q9HB96	6	35452361-35467103	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	18	"Extravillous trophoblasts: 82.2;Syncytiotrophoblasts: 39.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											CAB014893	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB014893: "	"unprognostic (2.66e-1)"	"unprognostic (8.01e-3)"	"unprognostic (7.73e-2)"	"prognostic unfavorable (6.25e-4)"	"unprognostic (1.99e-1)"	"unprognostic (2.80e-3)"	"prognostic unfavorable (2.08e-9)"	"unprognostic (8.90e-2)"	"unprognostic (5.70e-3)"	"unprognostic (8.41e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.70e-1)"	"unprognostic (3.05e-1)"	"unprognostic (2.44e-2)"	"unprognostic (5.14e-2)"	7.2	2.1	2.6	7.0	3.8	7.2	8.5	5.5	3.9	6.7	4.1	4.8	1.5	3.1	6.1	4.7	10.0	4.9	5.4	4.1	2.8	3.2	2.4	1.7	5.5	5.4	2.4	1.8	10.8	6.9	2.7	4.0	21.3	3.9	6.7	4.1	3.7	5.3	4.0	20.8	16.8	4.7	4.1	3.7	4.6	3.8	12.1	3.5	3.0	5.9	10.1	8.5	6.7	15.0	2.4	1.8	1.0	1.0	2.6	3.6	0.9	5.7	2.8	7.9	17.6	5.7	10.2	21.1	6.9	5.9	9.1	7.9	6.7	3.3	19.6	4.6	4.3	6.9	4.3	8.8	5.9	8.8	6.6	7.6	13.7	6.9	4.3	3.1	8.0	5.6	6.4	17.8	11.1	17.1	2.4	5.3	7.6	12.6	7.3	7.6	6.7	3.7	10.0	3.2	6.2	4.5	11.1	7.5	7.4	2.0	6.3	7.8	7.3	4.0	5.6	6.2	7.6	5.5	26.3	3.2	11.0	9.2	7.0	10.8	4.9	16.9	7.1	2.4	14.8	10.3	0.7	1.0	1.0	2.2	0.6	3.0	0.7	2.8	3.6	0.6	2.4	1.9	1.9	0.6	2.6	0.6	1.8	1.7	0.9	2.6	3.8	5.5	3.9	2.8	3.2	2.4	1.8	3.9	3.5	6.0	0.0	0.8	3.9	7.8	0.5	1.7	0.0	0.0	1.2	0.0	0.0	17.8	0.0	1.2	0.2	2.5	0.9	0.0	0.7	82.2	3.8	2.4	0.0	0.0	5.2	0.0	1.2	1.8	1.2	0.0	1.4	1.3	1.7	0.0	2.9	1.5	1.0	0.0	0.7	0.2	1.7	0.0	2.5	6.9	10.4	6.1	39.0	1.0	3.3	2.7
FANCF	FAF	ENSG00000183161	"Fanconi anemia complementation group F"	Q9NPI8	11	22622519-22626787	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 15.2"	"Cell type enhanced"	"Detected in many"	11	"Early spermatids: 123.7"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA008899			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA008899: "	"unprognostic (1.16e-2)"	"unprognostic (4.10e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.37e-2)"	"unprognostic (4.55e-2)"	"unprognostic (8.84e-2)"	"prognostic unfavorable (2.27e-4)"	"unprognostic (4.29e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.74e-3)"	"unprognostic (3.95e-1)"	"unprognostic (1.67e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.81e-1)"	"unprognostic (9.14e-2)"	"unprognostic (7.64e-3)"	1.2	4.1	2.9	3.1	2.8	1.1	3.2	1.0	2.7	3.1	3.4			5.3	3.0	6.0	3.0	6.1	1.7	1.9	2.9	3.9	3.2	4.2	1.8	4.9	3.3		4.2	9.0	3.4	4.5	1.5		2.9	3.7		3.8	3.1	0.4	3.1	4.9	1.1	3.5	5.4	4.6	4.3			3.6		4.8	2.6	2.0	15.2	9.7	11.5	5.7	10.0	15.1	7.3	1.4	4.3	5.6	6.1	2.9	3.5	2.3	2.8	3.3	3.2	3.5	2.8	2.2	7.1	0.7	2.8	5.8	6.1	4.5	4.6	1.6	11.6	2.1	2.7	1.7	4.9	3.4	4.9	2.9	3.3	8.9	1.1	4.9	5.5	5.0	10.3	6.8	9.3	2.0	4.5	12.5	4.6	6.4	12.0	5.4	10.8	2.6	8.0	6.0	5.6	20.9	9.8	1.5	4.9	4.8	6.2	9.9	4.5	3.6	3.3	3.5	5.9	3.9	5.4	6.9	2.1	5.4	2.0	7.6	5.7	5.4	11.5	11.5	5.5	13.5	11.8	10.8	10.8	6.4	15.2	15.1	12.4	0.8	10.0	5.7	9.7	7.3	7.3											3.0	2.1	10.5	5.3	3.0	15.7	4.4	10.2	22.7	2.3	3.5	9.8	9.4	38.1	15.4	123.7	4.7	9.6	0.0	16.2	7.1	3.8	3.9	2.3	8.1	6.0	15.9	3.4	1.8	5.9	13.7	8.9	5.3	5.0	9.0	16.2	11.8	10.5	10.5	9.2	15.4	17.2	6.5	3.1	21.0	15.8	1.9	1.9	11.4	15.5	2.3
FANCG	"FAG, XRCC9"	ENSG00000221829	"Fanconi anemia complementation group G"	O15287	9	35073835-35080016	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Fanconi anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Extravillous trophoblasts: 17.3;Spermatogonia: 23.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008105, HPA045335"	Approved		Approved	"Nucleoli,Plasma membrane,Cytosol"		NA	Yes			"Plasma membrane, Cytosol"	Nucleoli	"CAB008105: AB_2231542, HPA045335: AB_2679292"	"unprognostic (9.41e-2)"	"unprognostic (2.62e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.83e-3)"	"prognostic unfavorable (2.02e-4)"	"unprognostic (8.92e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.27e-3)"	"unprognostic (9.01e-2)"	"unprognostic (5.62e-2)"	"prognostic unfavorable (2.38e-7)"	"unprognostic (1.14e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.10e-1)"	5.8	5.0	4.4	7.1	6.5	14.9	7.5	13.9	8.5	6.2	5.9	5.3	8.4	6.7	6.8	3.2	9.2	8.6	4.7	5.9	7.6	4.0	5.2	4.5	5.1	9.9	8.7	4.4	9.2	17.0	6.7	4.8	7.6	6.6	7.0	5.5	3.5	8.7	9.7	2.9	8.9	6.5	6.4	4.2	8.6	5.8	8.9	7.6	25.6	9.3	4.8	9.2	6.8	6.9	6.8	4.8	8.9	2.5	8.8	9.2	3.4	15.7	19.6	14.4	13.3	3.2	5.1	12.1	11.1	8.0	21.8	21.0	9.3	9.9	15.6	7.7	3.5	15.6	9.7	11.9	10.2	8.4	18.3	7.2	11.2	21.0	5.7	0.9	11.3	12.9	4.2	2.0	19.0	8.6	3.8	11.1	19.2	7.3	21.0	11.0	14.0	19.1	15.6	14.9	11.8	15.1	19.9	16.9	11.0	5.1	6.7	7.0	12.7	7.3	10.4	4.1	6.5	13.5	8.2	6.7	10.4	20.7	13.3	14.9	5.7	10.8	9.4	9.2	8.4	14.2	8.9	0.8	7.7	7.4	2.5	6.5	6.8	6.1	5.7	2.2	6.5	4.8	5.0	1.3	8.8	2.3	4.8	9.2	3.4	4.4	6.5	13.9	8.5	7.6	4.0	8.7	4.4	6.6	7.6	3.0	5.8	5.2	3.6	3.9	4.3	1.0	0.0	0.0	2.3	3.5	3.9	8.2	3.3	3.7	0.3	2.8	1.6	0.0	2.0	17.3	3.8	3.5	13.9	1.0	6.5	4.8	1.7	3.7	0.3	0.4	3.1	2.0	3.3	3.6	3.9	3.5	2.3	3.2	3.9	1.7	3.0	0.0	2.7	10.9	23.7	2.3	5.5	5.3	5.0	3.3
FAS	"APO-1, APT1, CD95, FAS1, TNFRSF6"	ENSG00000026103	"Fas cell surface death receptor"	P25445	10	88990582-89015785	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins"	Apoptosis	"Calmodulin-binding, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Basal glandular cells: 100.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 40.1"	"Group enriched"	"Detected in all"	5	"granulocytes: 40.1;T-cells: 30.9"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 28.0;Karpas-707: 44.7"					"Low region specificity"	"Detected in all"			HPA027444	Uncertain		Supported	"Nuclear bodies,Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA	11900000	450000	"Plasma membrane"	"Nuclear bodies, Cytosol"	"HPA027444: AB_10601378"	"unprognostic (6.84e-2)"	"unprognostic (2.88e-3)"	"unprognostic (8.38e-3)"	"unprognostic (1.94e-1)"	"unprognostic (2.35e-2)"	"unprognostic (9.56e-2)"	"unprognostic (7.00e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.01e-1)"	"unprognostic (7.70e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.52e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.32e-2)"	"unprognostic (4.95e-3)"	"unprognostic (1.65e-1)"	13.5	26.3	6.1	17.3	7.7	12.4	10.6	2.1	7.2	15.6	14.2	6.1	7.0	5.9	15.7	16.6	14.1	14.2	14.5	8.9	8.2	2.7	11.7	21.9	28.6	15.6	6.0	3.9	24.7	4.1	4.5	4.6	9.0	7.5	22.3	21.3	4.4	7.1	8.5	4.3	9.6	16.3	12.5	10.2	15.3	5.0	7.3	5.1	12.5	10.0	15.8	14.4	14.8	21.4	3.0	4.0	40.1	6.8	1.2	30.9	3.9	8.7	3.4	1.8	5.6	14.5	21.4	0.0	19.2	19.5	0.7	3.8	0.0	9.5	1.7	7.4	18.0	3.2	1.4	0.3	16.2	1.3	28.0	2.8	0.1	1.8	5.7	13.9	0.9	0.4	26.5	14.5	12.0	26.0	9.4	1.7	6.4	0.0	44.7	19.6	0.8	2.8	1.4	0.2	0.0	0.9	0.2	0.1	1.8	27.1	2.8	0.1	0.1	2.8	0.0	0.3	2.8	6.1	0.3	4.2	6.2	3.4	5.7	4.4	17.5	1.8	0.1	5.1	3.5	1.8	11.3	3.2	9.4	3.3	3.9	4.8	3.0	10.4	7.2	4.0	0.7	1.2	3.4	40.1	1.2	6.8	0.0	30.9	3.9	6.1	7.7	2.1	7.2	8.2	2.7	6.0	3.9	7.5	5.1	53.6	14.4	3.7	100.3	40.8	0.0	1.2	15.3	21.4	21.6	8.7	0.0	0.4	0.0	6.7	5.4	8.4	12.0	0.0	3.8	0.2	34.9	22.7	3.5	15.3	5.0	1.6	8.1	2.5	6.9	3.5	17.5	12.7	11.8	20.8	15.0	17.1	4.3	0.0	13.1	11.5	0.7	6.5	33.4	4.8	1.3	38.3	0.3	37.9	23.2	22.7
FAT1	"CDHF7, CDHR8, FAT"	ENSG00000083857	"FAT atypical cadherin 1"	Q14517	4	186587783-186726722	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 76.4"	"Cell type enhanced"	"Detected in many"	4	"Basal keratinocytes: 75.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 64.9;LHCN-M2: 47.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001869, HPA023882"	Enhanced				"Intracellular and membrane"	NA	NA		120000			"HPA001869: AB_1078818, HPA023882: AB_1848429"	"unprognostic (1.98e-1)"	"unprognostic (4.91e-2)"	"unprognostic (2.50e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.53e-2)"	"unprognostic (5.82e-3)"	"unprognostic (2.31e-1)"	"prognostic unfavorable (4.22e-4)"	"unprognostic (6.10e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.15e-3)"	"unprognostic (6.80e-2)"	"unprognostic (3.57e-2)"	"unprognostic (8.03e-3)"	"unprognostic (9.41e-2)"	"unprognostic (6.25e-3)"	"unprognostic (4.27e-2)"	15.5	1.3	7.9	12.3	9.8	0.4	15.4	11.9	8.4	15.9	40.4	11.8	8.1	17.9	20.6	14.0	9.7	9.6	28.2	21.1	10.0	6.0	29.1	13.3	10.9	1.4	11.4	6.2	9.7	13.8	7.5	10.5	14.6	24.7	15.9	22.9	5.0	13.9	18.2	3.0	13.1	76.4	18.3	12.8	1.7	11.5	7.0	11.2	1.3	10.5	10.2	6.7	17.5	9.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	19.0	18.9	0.0	18.9	22.8	4.6	25.4	41.9	12.4	7.9	11.3	11.2	0.0	6.1	64.9	8.0	9.2	7.4	31.3	16.9	0.0	3.0	0.0	6.7	11.4	9.4	8.2	6.8	8.2	11.3	23.0	15.0	17.0	0.2	10.3	0.1	0.0	47.7	6.0	14.6	0.0	4.2	9.5	3.2	0.0	5.2	0.4	18.6	17.9	2.0	7.6	4.4	7.5	3.0	13.5	0.0	3.0	5.4	35.4	13.7	0.4	15.7	0.1	0.0	0.1	8.1	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.9	9.8	11.9	8.4	10.0	6.0	11.4	6.2	24.7	11.2	14.9	4.1	0.0	25.5	75.6	5.2	20.3	35.7	16.0	25.0	50.6	0.0	1.1	5.0	21.9	0.6	5.1	58.5	0.0	23.2	3.5	24.9	37.8	16.1	22.9	0.3	0.0	13.9	1.8	1.0	0.4	13.6	3.1	11.8	0.0	54.8	4.2	24.0	23.0	35.0	21.4	0.3	38.8	54.6	1.8	7.7	40.9	1.4	0.0	38.7	20.0
FAT4	"CDHF14, CDHR11, FAT-J"	ENSG00000196159	"FAT atypical cadherin 4"	Q6V0I7	4	125316399-125492932	"Cancer-related genes, Disease related genes, Predicted membrane proteins"	"Cell adhesion"		"Cancer-related genes, Deafness, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"	15	"Endothelial cells: 11.1;Fibroblasts: 9.3;Ito cells: 30.7"	"Low cancer specificity"	"Detected in many"							"Cell type enriched"	"Detected in single"	12	"NK-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"NK-cells: 1.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 12.3;ASC TERT1: 9.1;fHDF/TERT166: 8.9;HSkMC: 10.5;HUVEC TERT2: 11.1;TIME: 17.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA052819	Approved		Approved	Cytosol		NA	NA		7900000	Cytosol		"HPA052819: AB_2681963"	"unprognostic (1.18e-1)"	"unprognostic (1.77e-1)"	"unprognostic (7.99e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.31e-1)"	"unprognostic (2.81e-4)"	"unprognostic (6.17e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.77e-2)"	"unprognostic (2.78e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.39e-1)"	"prognostic favorable (1.89e-4)"	"unprognostic (2.38e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.49e-3)"	3.8	0.5	0.9	0.8	0.7	0.0	3.2	0.0	0.5	4.4	7.1			0.3	2.7	0.6	1.9	2.1	4.1	5.0	1.0	0.4	2.6	2.0	5.3	0.1	0.9		5.3	0.5	6.7	0.4	2.5		3.6	1.9		1.0	2.3	1.1	1.4	2.4	3.3	0.6	2.1	2.4	0.1			3.9		0.2	3.0	2.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.7	6.0	0.6	12.3	9.1	0.0	2.0	2.4	1.0	1.0	0.0	0.3	0.0	2.5	8.9	1.2	0.0	2.2	2.5	0.6	0.0	1.0	1.3	2.5	0.0	4.0	0.8	0.0	10.5	1.4	0.5	5.5	7.2	11.1	0.0	0.0	1.6	5.0	0.1	0.4	0.0	0.4	0.0	0.2	0.7	1.2	0.0	0.1	0.0	0.1	1.2	0.3	0.0	0.0	0.3	0.0	0.0	17.3	6.1	1.7	2.1	0.9	0.2	0.0	0.0	1.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0											6.0	0.0	0.0	0.1	1.4	1.3	5.3	0.0	0.0	0.0	5.2	0.0	0.1	0.0	0.7	0.8	11.1	0.0	0.0	0.2	0.0	9.3	0.1	0.0	6.8	0.2	0.0	0.0	30.7	2.4	0.0	5.5	0.0	3.3	0.0	0.0	1.2	0.2	0.0	4.6	0.6	0.1	0.0	3.9	0.0	0.6	0.5	0.0	0.0	0.0	0.0
FBXO11	"FBX11, UBR6"	ENSG00000138081	"F-box protein 11"	Q86XK2	2	47789316-47905793	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002690			Supported	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA002690: AB_1848448"	"unprognostic (1.18e-1)"	"unprognostic (8.65e-3)"	"unprognostic (3.93e-2)"	"unprognostic (2.05e-2)"	"unprognostic (7.92e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.85e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.55e-2)"	"unprognostic (9.82e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.33e-2)"	"unprognostic (3.21e-2)"	"unprognostic (1.55e-1)"	"unprognostic (3.71e-1)"	"unprognostic (2.19e-1)"	"unprognostic (3.20e-2)"	18.0	13.8	18.6	15.7	18.8	17.5	26.1	42.2	31.7	21.3	15.3	12.7	15.1	10.4	28.9	16.8	14.5	16.3	15.0	14.1	16.9	13.6	14.3	17.0	22.3	15.0	17.4	21.7	28.9	12.4	25.2	14.4	14.5	19.7	15.3	13.3	12.0	15.6	16.5	22.9	14.5	13.5	19.9	16.4	14.5	13.3	25.1	16.0	14.6	17.3	9.8	17.2	19.3	21.9	4.7	4.3	8.2	2.7	4.8	6.6	2.0	25.5	13.3	31.9	27.2	22.4	21.1	19.0	17.9	24.6	16.7	16.5	11.2	13.0	16.5	23.4	25.1	20.8	12.7	21.8	18.9	24.7	11.0	10.8	15.4	10.9	17.8	21.5	16.0	16.4	20.6	21.3	14.9	25.2	26.6	21.4	8.3	15.0	17.1	20.5	12.3	15.3	15.6	19.4	16.9	13.1	20.0	29.6	12.3	23.9	20.9	22.5	26.6	16.9	15.9	26.1	24.7	7.4	13.7	23.1	20.8	19.2	13.9	19.6	14.8	7.7	30.1	14.1	15.1	21.1	8.2	2.3	4.3	3.8	2.7	3.8	4.7	3.4	4.1	3.1	3.6	6.6	4.1	4.1	4.8	2.4	4.3	3.6	2.0	18.6	18.8	42.2	31.7	16.9	13.6	17.4	21.7	19.7	16.0	14.9	36.6	13.7	38.4	59.5	42.4	7.8	12.7	37.5	23.9	17.4	31.4	16.6	10.0	15.5	22.2	26.9	15.8	0.0	13.2	13.7	43.3	34.1	27.8	17.0	21.7	52.4	23.0	29.4	42.9	29.9	27.9	40.9	33.7	17.2	16.7	30.9	20.6	14.4	37.4	11.3	39.1	19.4	35.3	51.9	40.4	51.6	30.1	26.6	16.9	57.8
FBXW7	"AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10"	ENSG00000109670	"F-box and WD repeat domain containing 7"	Q969H0	4	152320544-152536063	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 60.1;skin 1: 45.0"	"Cell type enhanced"	"Detected in many"	7	"Basal keratinocytes: 179.3;Suprabasal keratinocytes: 152.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-266/70: 38.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013793, CAB029987"	Supported		Supported	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"CAB013793: AB_2533451, CAB029987: AB_2246842"	"unprognostic (3.32e-1)"	"unprognostic (9.02e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.08e-2)"	"unprognostic (3.87e-1)"	"unprognostic (1.36e-3)"	"unprognostic (4.37e-1)"	"unprognostic (1.94e-1)"	"unprognostic (8.28e-2)"	"unprognostic (3.29e-1)"	"unprognostic (5.32e-3)"	"unprognostic (3.19e-2)"	"prognostic unfavorable (1.52e-4)"	"unprognostic (3.38e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.49e-3)"	"unprognostic (2.17e-3)"	9.2	6.8	27.0	8.9	27.9	11.1	9.8	27.2	60.1	5.5	6.1	3.6	3.8	4.9	6.0	18.3	9.8	10.6	6.3	10.9	21.4	10.1	4.1	7.3	6.9	9.8	9.1	40.5	6.4	8.0	6.4	7.3	6.2	37.2	5.1	6.9	2.8	7.6	5.3	15.8	45.0	6.5	6.1	6.4	10.1	8.0	13.7	5.7	6.5	6.8	10.6	12.3	7.9	6.5	2.9	2.2	16.6	3.4	7.8	5.0	1.3	4.9	4.0	10.3	7.5	7.2	5.2	8.6	7.2	6.6	4.5	4.2	8.0	6.4	12.9	2.0	6.9	3.4	3.0	8.9	16.2	6.3	7.3	4.2	6.0	4.9	5.7	7.3	14.6	5.5	8.2	25.8	7.7	13.1	4.7	7.8	10.5	9.4	13.8	5.6	7.0	16.8	5.8	5.0	4.2	3.2	16.9	4.4	2.5	5.5	8.6	6.6	5.7	4.6	6.3	3.9	12.2	3.4	6.9	8.2	6.1	6.9	3.1	4.0	38.0	21.7	12.6	4.9	4.8	4.3	16.6	3.1	1.7	5.0	3.4	3.3	2.9	3.7	3.2	1.8	2.4	3.9	3.2	5.5	7.8	2.5	2.2	3.3	1.3	27.0	27.9	27.2	60.1	21.4	10.1	9.1	40.5	37.2	5.7	8.9	18.5	27.6	32.1	179.3	67.8	54.1	7.6	8.1	13.6	8.7	29.5	9.7	3.3	11.6	13.1	26.4	13.5	0.0	11.7	33.1	24.6	28.4	15.1	15.6	9.4	11.1	13.9	17.8	16.2	7.4	14.1	20.2	27.0	16.2	11.7	30.1	15.8	15.8	10.6	6.0	40.5	12.9	25.6	57.9	80.3	152.9	26.1	34.6	11.3	48.9
FCGR2B	"CD32, CD32B, FCG2, FCGR2"	ENSG00000072694	"Fc fragment of IgG receptor IIb"	P31994	1	161663147-161678654	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Host-virus interaction"	"IgG-binding protein, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 53.3;placenta: 83.2"	"Group enriched"	"Detected in many"	5	"Ito cells: 479.4;Macrophages: 138.2"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"basophil: 53.3;memory B-cell: 42.2"	"Group enriched"	"Detected in many"	18	"B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.7;HMC-1: 23.5;NB-4: 5.2;RPMI-8226: 8.4"									"CAB007796, HPA014730"	Enhanced					NA	NA					"CAB007796: AB_562288, HPA014730: AB_2669074"	"unprognostic (1.58e-1)"	"unprognostic (5.14e-2)"	"unprognostic (3.32e-3)"	"unprognostic (3.12e-2)"	"unprognostic (6.79e-3)"	"unprognostic (4.05e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.65e-3)"	"unprognostic (1.91e-1)"	"unprognostic (4.72e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavorable (8.82e-4)"	"unprognostic (3.51e-2)"	"unprognostic (6.36e-2)"	"unprognostic (4.31e-1)"	"unprognostic (3.37e-1)"	11.3	2.4	0.0	2.0	0.2	0.0	4.1	0.0	0.0	1.9	3.4			0.2	0.9	0.2	2.1	2.1	2.3	3.7	0.0	0.2	2.0	9.5	5.6	2.5	0.5		0.8	0.6	0.0	0.3	83.2		0.3	2.0		3.3	0.2	0.5	2.0	4.6	3.1	4.7	6.7	1.5	0.1			1.7		5.6	3.3	1.2	42.2	14.5	53.3	1.9	0.1	0.3	2.4	0.0	0.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	5.2	0.1	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.1	0.1	0.0	0.0	1.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	2.2	0.0	53.3	1.8	5.4	0.3	1.9	0.1	42.2	0.1	0.2	14.5	34.3	0.0	0.3	11.2	0.1	1.7	0.0	0.0	2.4											0.0	4.6	57.3	0.0	4.7	0.0	1.9	5.1	0.0	2.3	0.0	0.0	0.2	0.0	0.0	4.2	1.4	0.0	23.3	0.0	0.2	2.7	0.0	2.3	2.5	7.6	0.0	0.0	479.4	63.3	2.3	0.6	138.2	21.9	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.3	0.2	2.8	0.3	4.9	0.0	0.0
FCRL4	"CD307d, FCRH4, IGFP2, IRTA1"	ENSG00000163518	"Fc receptor like 4"	Q96PJ5	1	157573749-157598080	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"intestine: 5.4;lymphoid tissue: 15.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	12	"memory B-cell: 1.1"	"Lineage enriched"	"Detected in single"	12	"B-cells: 1.1"	"Cell line enriched"	"Detected in single"	104	"U-266/70: 10.4"					"Not detected"	"Not detected"			HPA054030	Approved					NA	NA					"HPA054030: "	"unprognostic (6.06e-2)"	"unprognostic (3.41e-3)"	"unprognostic (2.57e-1)"	"unprognostic (5.08e-2)"		"unprognostic (4.69e-4)"		"unprognostic (2.06e-2)"			"unprognostic (6.38e-2)"			"unprognostic (1.99e-1)"	"unprognostic (2.14e-1)"	"unprognostic (3.37e-1)"	"unprognostic (6.77e-2)"	0.1	0.1	0.1	15.6	0.1	0.0	0.1	0.1	0.2	0.1	0.3	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	5.1	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.4	0.0	2.5	0.0	0.1	0.1	5.4	0.0	0.1	2.2	0.3	0.1	0.0	1.1	0.1	1.9	14.9	0.4	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FES	FPS	ENSG00000182511	"FES proto-oncogene, tyrosine kinase"	P07332	15	90883695-90895776	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 60.8;lymphoid tissue: 49.7"	"Cell type enhanced"	"Detected in many"	11	"Hofbauer cells: 40.6;Kupffer cells: 93.1;Macrophages: 37.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 60.8"	"Group enriched"	"Detected in many"	4	"dendritic cells: 32.6;granulocytes: 60.8;monocytes: 30.5"	"Cell line enhanced"	"Detected in many"		"HEL: 21.3;HL-60: 19.0;HMC-1: 40.7;NB-4: 24.9;THP-1: 37.4;U-937: 16.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA001376	Approved		Approved	Nucleoplasm,Vesicles,Cytosol		NA	NA			"Nucleoplasm, Cytosol"	Vesicles	"HPA001376: AB_1078847"	"unprognostic (1.07e-2)"	"unprognostic (2.54e-2)"	"prognostic unfavorable (5.78e-4)"	"unprognostic (2.31e-2)"	"unprognostic (4.05e-3)"	"unprognostic (7.33e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.58e-3)"	"unprognostic (1.35e-1)"	"unprognostic (4.66e-2)"	"unprognostic (5.15e-3)"	"unprognostic (1.78e-3)"	"unprognostic (2.53e-3)"	"unprognostic (6.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.40e-1)"	14.9	3.4	4.8	9.7	4.1	38.3	12.7	2.4	5.7	6.8	5.4	3.2	4.7	3.0	7.4	5.6	4.9	7.6	7.3	7.9	4.2	2.2	5.2	11.8	12.7	23.3	3.7	0.9	6.4	3.7	1.8	2.7	8.1	7.2	7.7	2.4	5.3	33.8	6.3	3.4	3.5	5.2	5.4	6.9	49.7	4.3	3.2	4.7	3.1	7.2	4.1	4.5	7.2	9.4	1.1	32.6	60.8	30.5	9.3	0.1	13.8	0.1	0.2	0.3	3.6	1.0	3.1	6.1	0.9	0.0	1.8	1.0	0.9	0.0	2.3	0.1	2.0	0.0	0.5	0.6	0.1	0.5	1.2	0.3	21.3	0.0	3.8	2.1	19.0	40.7	3.1	0.0	2.6	0.0	0.0	10.8	3.2	0.6	0.0	0.0	6.9	0.6	24.9	1.0	0.8	0.0	2.8	0.0	0.0	0.0	0.1	0.1	0.0	0.0	1.0	0.9	1.1	0.0	37.4	8.4	0.0	3.7	0.1	0.0	0.0	2.7	0.8	0.1	16.1	0.8	10.4	30.5	60.8	0.1	17.6	0.0	1.1	0.0	0.0	32.6	0.9	0.0	0.0	20.0	9.3	7.3	12.9	0.0	13.8	4.8	4.1	2.4	5.7	4.2	2.2	3.7	0.9	7.2	4.7	3.0	8.0	6.4	4.7	3.4	0.0	2.5	5.1	0.0	0.0	1.8	0.0	4.5	3.3	4.8	1.1	24.5	0.4	0.0	3.9	3.8	6.2	4.0	28.8	8.2	40.6	0.0	2.9	22.7	93.1	4.7	8.3	37.3	6.8	27.1	2.1	2.3	2.0	0.0	9.6	1.3	1.9	12.9	7.2	3.5	9.1	2.5	3.8	10.2	2.6	5.2
FEV	Pet-1	ENSG00000163497	"FEV, ETS transcription factor"	Q99581	2	218981087-218985657	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 6.9;intestine: 7.0;pituitary gland: 5.4;stomach 1: 6.1"	"Cell type enriched"	"Detected in some"	123	"Intestinal endocrine cells: 716.0"	"Group enriched"	"Detected in some"	10	"pancreatic cancer: 3.0;prostate cancer: 9.9;stomach cancer: 2.4"	"Region enhanced"	"Detected in many"		"pons and medulla: 6.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"HMC-1: 19.1;SH-SY5Y: 24.5"	"Group enriched"	"Detected in some"	13	"midbrain: 2.3;pons and medulla: 0.9"	"Group enriched"	"Detected in some"	35	"midbrain: 7.3;pons and medulla: 3.9"	HPA067679		Supported	Supported	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA067679: AB_2685884"			"unprognostic (4.58e-1)"		"unprognostic (1.60e-1)"					"unprognostic (7.21e-2)"	"prognostic favorable (4.85e-4)"	"unprognostic (2.87e-1)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.15e-1)"			0.1	4.1	0.0	1.2	3.5	0.0	0.0	0.0	2.6	0.0	2.0	0.7	0.0	7.0	0.1	0.0	0.0	0.1	0.0	0.0	1.1	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	4.2	0.0	5.4	0.0	6.9	4.0	3.2	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.1	0.0	6.1	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	19.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	24.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	2.6	1.1	0.2	0.2	0.0	6.9	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	716.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.3	5.8	0.0	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.2	0.1
FGFR1	"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM"	ENSG00000077782	"Fibroblast growth factor receptor 1"	P11362	8	38411138-38468834	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Transcription, Transcription regulation"	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Leydig cells: 177.8;Muller glia cells: 106.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 111.2;BJ hTERT+: 50.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033614, HPA056402"	Approved					NA	NA		120000000			"CAB033614: AB_783377, HPA056402: AB_2683118"	"unprognostic (9.53e-2)"	"unprognostic (7.33e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.23e-3)"	"unprognostic (7.02e-2)"	"unprognostic (6.59e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.99e-2)"	"unprognostic (7.97e-3)"	"unprognostic (4.59e-2)"	"unprognostic (7.69e-2)"	"unprognostic (6.87e-3)"	"unprognostic (5.60e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.05e-3)"	41.1	8.6	12.5	14.5	12.2	7.2	39.5	45.0	10.5	36.0	31.5	10.1	11.6	5.5	29.3	20.6	22.9	29.4	32.4	31.7	12.8	10.1	11.8	5.4	18.6	9.7	11.4	14.3	42.0	51.2	11.5	22.3	28.4	20.0	28.2	10.8	35.8	14.0	31.6	12.0	12.9	14.4	52.4	15.6	4.5	16.4	16.4	8.5	11.3	12.6	13.0	9.8	39.6	41.2	1.6	0.7	1.8	1.1	0.8	5.7	0.7	2.4	9.4	41.1	111.2	25.5	18.2	27.1	25.3	50.7	17.6	18.4	6.1	1.4	0.3	7.0	24.2	22.6	0.0	19.4	1.2	20.4	6.6	4.3	0.0	1.6	6.0	14.4	5.9	0.1	16.5	0.1	14.3	2.9	9.5	16.9	1.4	2.3	0.1	8.3	2.9	17.4	2.0	28.9	0.3	3.9	16.0	4.3	0.0	8.5	0.0	1.6	3.6	4.5	0.2	1.0	21.5	2.3	1.1	10.6	11.5	6.4	31.8	6.0	0.4	0.8	0.0	13.6	0.3	6.0	1.4	1.1	0.4	5.7	0.3	3.9	0.7	2.7	3.7	0.1	1.6	1.5	4.1	1.8	0.8	0.5	0.7	2.2	0.7	12.5	12.2	45.0	10.5	12.8	10.1	11.4	14.3	20.0	8.5	3.0	12.0	0.0	68.4	27.9	1.3	48.2	17.8	1.4	9.1	8.7	3.9	6.5	0.0	23.4	14.2	57.3	0.0	0.0	56.3	69.1	85.6	80.3	8.1	0.9	19.7	20.6	24.0	47.3	3.2	9.3	177.8	7.5	32.1	2.8	0.0	106.2	29.8	0.0	93.7	8.0	2.4	12.9	68.0	1.4	11.3	17.2	8.7	6.4	0.4	8.4
FGFR1OP	FOP	ENSG00000213066	"FGFR1 oncogene partner"	O95684	6	166999182-167094789	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cilium biogenesis/degradation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 50.3"	"Cell type enhanced"	"Detected in all"	10	"Early spermatids: 225.5;Late spermatids: 194.1;Spermatocytes: 97.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA071876	Approved		Supported	Centrosome		NA	NA			Centrosome		"HPA071876: AB_2686467"	"unprognostic (9.14e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.98e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.69e-2)"	"unprognostic (9.59e-2)"	"unprognostic (1.00e-1)"	"unprognostic (6.95e-2)"	"unprognostic (8.83e-2)"	"unprognostic (1.08e-3)"	"unprognostic (4.06e-2)"	"prognostic unfavorable (7.32e-4)"	"unprognostic (1.29e-2)"	"unprognostic (2.49e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.09e-3)"	6.2	12.2	11.2	12.9	12.5	9.8	10.2	11.9	13.0	10.1	9.5	6.9	11.8	10.8	13.6	14.1	8.8	19.1	7.9	6.4	10.8	9.1	12.2	24.9	6.7	9.4	6.4	11.5	11.8	10.2	8.2	17.2	6.6	9.4	7.4	12.1	8.9	8.1	11.6	5.8	7.9	13.0	7.4	7.4	9.4	7.8	50.3	8.0	14.5	12.5	6.2	11.8	7.0	8.2	6.8	10.0	24.1	4.1	3.5	6.8	3.0	11.6	6.5	16.5	11.2	9.7	7.3	20.0	15.1	10.1	12.4	12.0	24.0	9.9	13.9	8.6	9.2	33.0	11.0	14.4	10.7	23.3	8.7	12.4	9.6	11.7	26.0	5.2	17.0	10.1	4.0	7.9	25.3	11.9	7.7	8.5	15.8	31.2	11.9	15.8	10.7	13.7	25.0	14.0	22.5	5.0	15.8	11.2	11.5	12.9	6.3	12.3	12.3	12.3	13.2	5.2	12.1	10.9	21.1	5.5	12.3	20.6	14.7	18.8	10.2	14.0	14.1	13.9	16.0	15.0	0.2	4.1	13.5	3.3	3.6	4.9	6.8	3.9	3.1	6.5	5.0	2.3	3.7	24.1	3.5	3.6	10.0	6.8	3.0	11.2	12.5	11.9	13.0	10.8	9.1	6.4	11.5	9.4	8.0	11.9	15.6	12.7	7.4	5.4	20.9	11.2	15.3	30.8	12.5	5.2	21.6	12.3	10.0	11.1	225.5	5.5	15.2	46.7	6.4	13.6	6.8	4.7	4.7	18.8	9.2	9.5	10.3	6.2	7.6	194.1	12.0	7.7	5.0	15.4	12.7	9.3	8.4	12.9	12.0	14.3	55.1	6.5	6.6	97.9	28.4	5.6	5.3	13.1	13.2	4.3
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	"Fibroblast growth factor receptor 2"	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.8"	"Cell type enhanced"	"Detected in many"	16	"Cholangiocytes: 191.1;Club cells: 52.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	15	"basophil: 10.8;eosinophil: 4.6"	"Lineage enriched"	"Detected in single"	35	"granulocytes: 10.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	"Secreted - unknown location"	NA	NA		500000	"Cell Junctions"	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	"unprognostic (5.53e-2)"	"prognostic favorable (8.79e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.73e-1)"	"prognostic favorable (9.32e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"unprognostic (2.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (2.25e-1)"	2.1	8.8	16.4	3.0	30.3	0.0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22.0	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1.0	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0.0	2.2	0.1	9.2	58.9	0.0	0.0	19.8	0.1	0.0	0.0	0.0	15.4	0.3	0.0	4.2	0.9	0.0	17.8	19.1	4.0	0.0	0.0	4.1	0.0	0.0	0.3	0.4	0.0	3.8	0.0	8.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	18.9	2.7	0.0	0.0	0.0	2.3	5.7	5.0	0.1	0.1	0.1	10.8	0.0	11.5	15.8	0.0	0.0	0.1	2.9	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	10.8	0.1	4.6	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.0	0.0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1	17.9	31.8	0.0	29.5	35.6	0.0	2.7	191.1	18.7	52.4	34.9	0.0	12.6	0.0	4.0	2.9	0.5	2.6	0.0	0.2	2.7	17.5	9.8	0.0	4.3	2.0	0.0	2.4	3.1	0.3	6.5	1.1	1.3	5.0	1.0	32.0	1.6	0.6	1.4	5.6	11.5	0.1	0.0	2.1	0.9	7.7	24.2	3.3	1.5	3.0	27.7
FGFR3	"ACH, CD333, CEK2, JTK4"	ENSG00000068078	"Fibroblast growth factor receptor 3"	P22607	4	1793293-1808872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Apoptosis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"skin 1: 131.7"	"Cell type enhanced"	"Detected in many"	9	"Basal keratinocytes: 92.2;Cholangiocytes: 94.3;Suprabasal keratinocytes: 77.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 19.3;HaCaT: 15.1;Hep G2: 32.5;NTERA-2: 15.8;RT4: 19.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004231, HPA067204"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA		670000	"Endoplasmic reticulum"		"CAB004231: AB_627596, HPA067204: AB_2685804"	"unprognostic (1.34e-1)"	"unprognostic (5.29e-3)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (3.77e-4)"	"unprognostic (5.90e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.22e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.30e-1)"	"unprognostic (9.11e-3)"	"unprognostic (1.98e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.97e-1)"	1.5	1.5	24.7	1.7	30.3	1.6	4.2	10.2	22.0	4.1	4.9	15.8	3.4	9.9	1.8	2.7	26.9	2.0	5.0	2.0	21.6	11.7	9.6	7.4	4.5	1.3	17.6	21.5	1.1	23.0	1.2	3.0	5.6	15.1	3.7	3.8	1.7	3.8	9.0	1.7	131.7	7.4	1.3	9.0	2.1	4.9	8.1	10.6	0.1	1.3	8.5	7.3	8.5	10.1	0.1	0.6	0.1	0.1	0.2	0.3	0.0	0.0	1.5	9.2	2.6	0.0	0.1	9.4	1.1	0.1	0.4	0.2	19.3	0.4	0.0	7.7	0.3	0.4	15.1	2.6	0.1	0.1	0.1	9.7	6.0	1.5	32.5	0.0	0.0	0.2	0.0	5.1	0.1	0.0	0.0	0.0	0.9	6.5	0.0	0.0	9.6	0.4	0.2	15.8	8.8	0.0	0.5	0.5	0.1	1.3	19.3	2.7	0.7	0.8	1.6	0.0	11.1	9.0	1.1	0.4	0.0	0.9	0.2	0.6	0.0	0.0	0.0	0.1	0.7	0.5	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.6	0.1	0.0	24.7	30.3	10.2	22.0	21.6	11.7	17.6	21.5	15.1	10.6	0.0	23.8	2.4	3.6	92.2	0.0	2.0	94.3	0.0	21.6	14.0	0.0	0.4	0.0	4.8	5.4	0.9	20.6	0.0	0.6	9.2	7.0	3.3	0.0	27.0	0.5	0.0	4.1	14.7	1.2	0.4	0.6	1.2	11.8	1.0	20.7	0.2	0.4	17.3	0.4	7.5	0.6	0.0	2.8	0.4	17.9	77.5	0.7	0.0	13.0	11.8
FGFR4	"CD334, JTK2"	ENSG00000160867	"Fibroblast growth factor receptor 4"	P22455	5	177086886-177098144	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 33.6;kidney: 37.7;liver: 45.3"	"Cell type enhanced"	"Detected in many"	11	"Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.0"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005196, HPA027273, HPA027369, HPA028251"	Approved				"Intracellular and membrane"	NA	NA		4300000			"CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221"	"unprognostic (1.96e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.95e-2)"	"unprognostic (7.85e-3)"	"unprognostic (9.19e-2)"	"unprognostic (4.25e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.48e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.41e-1)"	"unprognostic (5.75e-2)"	"unprognostic (4.68e-2)"	0.5	5.7	0.7	14.3	0.6	0.1	1.6	2.6	0.5	2.8	10.4	0.9	0.7	13.5	0.9	4.8	1.6	1.7	33.6	0.7	0.8	0.3	37.7	45.3	25.3	2.5	0.7	1.0	13.6	26.0	0.0	0.7	1.3	0.8	4.0	3.7	2.0	1.6	0.3	4.3	0.5	17.3	1.6	0.8	11.2	5.4	2.9	0.4	0.3	0.8	2.3	0.7	1.9	3.6	1.1	0.9	3.0	1.1	0.4	0.4	0.0	0.7	12.1	0.2	2.9	0.0	0.0	5.9	0.0	0.0	0.0	0.0	43.0	1.6	1.3	5.6	0.0	0.6	0.6	2.4	0.4	0.0	0.7	2.8	0.1	0.6	43.0	1.3	0.1	1.0	0.2	0.0	2.1	0.0	0.0	0.0	0.8	4.0	0.1	0.9	9.8	0.0	0.8	7.3	7.6	1.0	1.9	69.1	7.2	5.8	0.1	0.4	0.7	0.4	3.1	1.4	1.6	2.9	0.6	0.2	0.0	5.8	0.0	0.1	0.4	0.4	0.7	0.0	0.2	0.5	1.5	1.1	0.4	0.4	0.3	0.3	1.1	0.4	0.0	0.1	0.6	0.4	0.4	3.0	0.4	0.3	0.9	0.2	0.0	0.7	0.6	2.6	0.5	0.8	0.3	0.7	1.0	0.8	0.4	0.0	0.0	0.8	0.6	0.6	0.4	0.8	50.9	0.0	0.0	3.5	0.0	1.1	3.3	8.4	0.1	0.1	10.6	0.0	4.4	3.2	1.7	0.3	0.0	23.7	0.3	0.0	4.1	2.5	0.8	0.0	0.6	0.0	0.0	1.0	5.2	0.9	3.6	2.9	1.4	19.5	0.1	19.4	0.5	1.6	12.8	0.4	7.3	0.0	33.6	0.6
FH	fumarase	ENSG00000091483	"Fumarate hydratase"	P07954	1	241497603-241519761	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair, Tricarboxylic acid cycle"	Lyase	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 93.4"	"Cell type enhanced"	"Detected in all"	4	"Early spermatids: 161.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017785, HPA025770, HPA025948, HPA027341"	Enhanced	Supported	Enhanced	Mitochondria		NA	NA		2800000	Mitochondria		"CAB017785: , HPA025770: AB_10599603, HPA025948: AB_10602177, HPA027341: AB_10601222"	"unprognostic (1.03e-2)"	"unprognostic (3.82e-2)"	"unprognostic (9.46e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.55e-1)"	"unprognostic (5.14e-2)"	"unprognostic (1.85e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.09e-1)"	"prognostic favorable (2.76e-7)"	"unprognostic (1.05e-1)"	"unprognostic (1.05e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.24e-2)"	14.3	28.1	15.7	10.4	20.2	9.3	13.3	15.7	24.4	10.5	22.7	9.9	16.7	23.2	13.7	10.7	17.7	10.3	9.5	59.0	22.9	13.9	35.0	93.4	9.9	13.3	15.2	19.4	9.4	13.9	25.2	11.4	14.3	18.4	12.3	24.4	10.2	18.4	20.6	65.1	13.4	21.4	14.7	14.4	11.1	17.5	14.0	11.7	13.8	12.3	45.2	13.4	13.4	11.2	16.0	26.4	4.5	18.8	10.4	13.9	8.9	29.3	24.6	23.3	21.0	22.9	27.1	37.0	36.4	28.5	41.1	25.8	35.1	18.3	18.6	24.1	27.8	18.0	41.8	35.6	27.0	35.8	21.3	11.5	17.5	26.0	30.0	20.6	40.8	15.9	19.6	16.9	23.0	26.0	14.4	25.2	41.2	53.1	24.1	29.9	14.6	35.1	27.3	24.8	42.8	52.8	29.1	25.5	83.6	39.6	24.9	30.0	26.0	30.6	36.3	23.2	16.8	27.7	27.7	24.8	18.5	23.8	32.6	60.5	21.6	23.1	22.6	20.6	46.9	26.5	4.5	12.8	2.7	9.7	18.8	12.6	16.0	11.4	9.0	26.4	14.1	13.9	12.7	0.7	10.4	15.7	13.2	13.2	8.9	15.7	20.2	15.7	24.4	22.9	13.9	15.2	19.4	18.4	11.7	35.7	27.5	27.0	18.6	17.7	23.0	151.3	33.1	30.8	22.7	22.7	13.7	91.1	66.3	49.6	161.2	17.9	46.4	23.3	39.2	43.6	21.6	16.1	18.5	73.1	45.3	33.4	17.2	11.6	12.6	20.1	22.2	26.8	23.6	29.7	35.6	28.0	29.4	35.1	25.1	58.8	32.6	38.8	21.7	82.8	44.5	16.3	138.9	12.9	60.7	16.3
FHIT	"AP3Aase, FRA3B"	ENSG00000189283	"Fragile histidine triad"	P49789	3	59749310-61251459	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation"	Hydrolase	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Late spermatids: 138.8;Proximal tubular cells: 112.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"naive CD4 T-cell: 38.3"	"Lineage enriched"	"Detected in all"	14	"T-cells: 38.3"	"Cell line enhanced"	"Detected in many"		"RPMI-8226: 12.1;U-266/70: 24.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002684, HPA018840, HPA018909"	Enhanced		Approved	"Nucleoli fibrillar center,Plasma membrane"		NA	NA			"Nucleoli fibrillar center, Plasma membrane"		"CAB002684: , HPA018840: AB_1848538, HPA018909: AB_1848537"	"unprognostic (2.36e-3)"	"unprognostic (6.38e-2)"	"unprognostic (1.59e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.16e-2)"	"unprognostic (2.77e-2)"	"unprognostic (8.49e-2)"	"unprognostic (2.36e-1)"	"unprognostic (6.77e-2)"	"prognostic favorable (1.36e-4)"	"unprognostic (1.54e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.80e-2)"	6.4	24.0	13.7	8.0	17.5	9.0	12.1	4.7	13.3	7.9	8.0	21.0	12.4	8.2	6.2	9.5	5.1	9.2	13.0	14.9	15.3	13.8	30.9	10.7	5.2	9.3	19.5	9.3	8.9	11.8	16.3	15.2	4.1	14.4	5.8	7.8	14.0	11.4	9.9	11.6	7.0	7.6	9.1	17.1	6.0	8.1	10.5	18.2	3.7	15.6	5.7	6.9	7.3	6.1	1.6	2.4	1.8	1.8	2.6	38.3	4.7	0.0	0.0	1.0	0.0	0.6	0.0	1.7	0.1	0.1	0.0	0.0	1.8	3.1	2.6	0.5	0.1	1.9	0.0	10.1	2.1	0.0	1.4	3.5	2.2	1.3	4.2	2.7	5.7	0.1	6.9	4.2	0.1	5.1	0.2	0.0	2.8	1.7	8.4	0.1	2.5	10.2	4.6	0.8	8.7	0.6	7.6	0.0	12.1	11.3	1.4	2.1	2.9	1.0	7.0	6.6	4.1	0.4	0.1	0.0	1.2	0.4	0.1	1.6	24.7	7.5	0.0	2.7	0.0	1.5	1.8	1.8	0.2	0.9	1.2	0.5	1.6	6.9	0.7	2.2	1.4	38.3	6.7	0.3	2.6	0.4	2.4	7.4	4.7	13.7	17.5	4.7	13.3	15.3	13.8	19.5	9.3	14.4	18.2	6.0	8.8	14.1	16.1	6.8	12.4	9.2	33.1	2.7	3.4	26.2	55.0	33.8	66.3	17.3	41.1	6.2	12.3	0.0	4.1	6.5	4.3	10.2	5.7	20.8	17.6	28.6	7.5	11.6	6.7	138.8	17.8	9.6	11.8	6.4	11.4	17.8	11.6	14.0	9.2	112.3	19.5	0.0	3.1	18.1	6.4	9.8	27.3	7.5	17.2	19.0
FIP1L1	"DKFZp586K0717, FIP1"	ENSG00000145216	"Factor interacting with PAPOLA and CPSF1"	Q6UN15	4	53377643-53460861	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"mRNA processing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA037475, HPA058202"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA037475: AB_10696933, HPA058202: AB_2683636"	"unprognostic (3.80e-1)"	"unprognostic (5.46e-2)"	"unprognostic (5.60e-3)"	"unprognostic (1.40e-1)"	"unprognostic (7.18e-2)"	"unprognostic (4.71e-2)"	"prognostic unfavorable (1.51e-4)"	"unprognostic (1.87e-1)"	"unprognostic (9.00e-3)"	"unprognostic (1.14e-2)"	"unprognostic (5.48e-2)"	"unprognostic (1.42e-1)"	"unprognostic (4.07e-1)"	"unprognostic (1.10e-1)"	"unprognostic (8.66e-3)"	"unprognostic (3.10e-2)"	"unprognostic (1.39e-1)"	25.7	24.4	20.2	27.6	25.8	35.8	24.0	23.0	25.1	24.5	18.0	19.4	16.1	16.0	27.4	17.7	23.4	22.4	16.2	19.7	17.1	16.6	19.7	19.0	20.3	24.5	20.1	26.0	32.2	16.9	26.6	26.6	28.2	20.9	21.7	21.0	16.2	21.5	18.0	33.9	24.5	20.0	23.5	19.4	24.5	20.4	40.2	22.4	42.4	22.7	17.8	29.2	26.6	22.6	26.5	32.7	36.5	24.0	33.7	32.4	21.3	18.3	12.1	22.2	13.3	16.8	17.1	28.4	23.3	29.3	19.0	14.7	17.6	17.1	33.7	18.1	24.8	17.8	11.6	24.1	17.3	24.7	11.7	13.1	26.6	10.0	16.2	26.7	39.5	22.8	19.6	15.8	24.0	24.6	18.4	14.0	20.4	30.6	15.8	14.9	13.5	35.6	18.2	14.6	23.5	11.9	32.0	10.1	14.8	15.4	16.6	17.3	18.7	16.3	18.8	26.7	21.8	10.7	14.7	14.7	19.5	17.0	18.1	27.9	19.8	11.5	42.6	16.9	24.8	34.7	25.8	16.9	36.5	25.7	17.8	29.2	26.5	25.8	25.1	22.6	24.2	28.9	25.4	20.7	33.7	24.0	32.7	32.4	21.3	20.2	25.8	23.0	25.1	17.1	16.6	20.1	26.0	20.9	22.4	23.8	20.1	45.5	37.4	34.5	40.5	13.1	17.8	45.5	27.3	26.2	17.7	52.0	31.5	34.1	7.4	26.3	21.3	0.0	30.6	43.6	38.6	25.4	47.4	18.7	28.6	73.1	35.2	33.2	19.4	8.8	61.9	27.7	30.4	46.9	24.6	45.2	30.3	31.7	50.2	19.6	28.8	38.8	24.7	112.4	78.8	29.7	72.2	41.5	25.5	30.3
FLCN	"BHD, MGC17998, MGC23445"	ENSG00000154803	Folliculin	Q8NFG4	17	17212212-17237188	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cone photoreceptor cells: 74.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SuSa: 34.9"									"CAB015158, HPA028760"	Supported		Supported	"Plasma membrane,Cytosol"		NA	NA			Cytosol	"Plasma membrane"	"CAB015158: AB_2231645, HPA028760: AB_10601323"	"unprognostic (1.99e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.74e-1)"	"unprognostic (3.85e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.32e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.90e-1)"	"prognostic favorable (4.49e-4)"	"unprognostic (6.45e-3)"	"unprognostic (2.55e-3)"	"unprognostic (1.92e-1)"	"unprognostic (9.71e-2)"	"unprognostic (2.62e-2)"	"unprognostic (1.65e-1)"	11.9	15.3	23.6	10.8	41.6	15.6	13.9	49.4	26.9	18.0	21.3	18.5	10.4	25.0	22.1	15.8	11.0	14.5	17.6	17.2	17.2	8.6	9.6	15.5	15.6	11.6	24.2	13.5	25.2	13.7	6.1	20.3	13.3	18.1	15.4	10.7	14.8	10.5	14.8	22.7	12.6	20.2	15.4	14.8	16.5	15.3	12.5	29.1	6.6	15.8	3.9	8.0	15.0	14.8	6.0	2.4	10.5	6.8	4.5	5.0	3.1	5.9	14.5	5.3	6.9	17.4	9.9	7.9	5.3	8.9	8.5	11.8	11.0	4.9	2.9	7.4	6.4	19.6	6.9	6.5	3.3	4.4	5.6	5.5	6.0	4.3	6.3	16.1	2.2	16.8	14.6	11.4	13.3	9.9	7.7	6.9	4.3	8.2	7.7	8.1	7.7	3.9	3.7	5.4	8.2	3.6	8.0	24.7	3.4	5.1	6.6	6.5	4.1	5.6	3.4	9.3	34.9	5.1	4.2	8.1	20.0	8.7	27.6	7.0	3.8	3.6	2.8	12.7	5.1	7.9	3.6	4.7	2.8	2.9	6.8	4.1	5.3	3.5	2.5	2.4	6.0	3.9	3.4	10.5	4.5	2.2	2.4	5.0	3.1	23.6	41.6	49.4	26.9	17.2	8.6	24.2	13.5	18.1	29.1	23.8	13.0	15.9	10.7	16.4	17.0	17.3	7.6	4.0	4.5	7.0	74.6	8.1	1.7	10.3	10.9	10.1	26.4	46.7	7.2	5.4	15.2	11.3	1.1	20.2	14.4	44.5	24.6	23.4	23.7	13.4	25.9	13.7	10.1	5.4	9.4	18.9	9.6	12.2	19.1	4.3	16.8	19.4	11.4	5.2	10.2	15.8	28.3	11.3	10.6	11.6
FLI1	"EWSR2, SIC-1"	ENSG00000151702	"Fli-1 proto-oncogene, ETS transcription factor"	Q01543	11	128686535-128813267	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 40.2"	"Group enriched"	"Detected in many"	6	"B-cells: 32.3;Endothelial cells: 76.4;granulocytes: 22.0;Hofbauer cells: 36.1;Ito cells: 49.7;Kupffer cells: 85.1;Macrophages: 24.6;T-cells: 47.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 41.0;HUVEC TERT2: 22.8;REH: 19.2;TIME: 23.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA065030, HPA073099"	Approved		Supported	"Nucleoplasm,Nuclear bodies"		Yes	NA			"Nucleoplasm, Nuclear bodies"		"HPA065030: , HPA073099: AB_2686572"	"unprognostic (1.38e-2)"	"unprognostic (7.46e-2)"	"unprognostic (6.16e-2)"	"unprognostic (3.74e-2)"	"unprognostic (6.22e-2)"	"unprognostic (4.26e-3)"	"unprognostic (1.33e-1)"	"unprognostic (8.32e-3)"	"unprognostic (2.97e-1)"	"unprognostic (9.91e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.42e-1)"	"prognostic unfavorable (4.60e-4)"	"unprognostic (4.79e-2)"	"unprognostic (2.07e-2)"	"unprognostic (2.62e-1)"	"unprognostic (4.79e-2)"	14.7	2.5	3.5	15.8	4.4	10.6	9.9	1.4	3.2	6.7	5.1	3.8	2.1	3.3	7.8	6.5	4.8	5.3	6.0	7.5	3.8	3.1	4.2	3.6	17.4	24.4	6.2	1.6	4.0	3.2	2.5	2.0	11.4	3.8	4.3	3.1	4.8	4.2	3.3	5.2	3.2	6.9	5.7	6.6	40.2	4.1	2.7	4.6	26.8	5.7	2.8	17.9	6.2	6.7	4.5	13.1	20.1	12.0	7.8	8.8	11.6	0.0	0.0	2.1	0.0	0.2	0.4	0.0	1.2	3.4	1.4	1.2	0.0	0.0	7.0	12.5	4.1	0.4	0.0	0.3	5.1	1.6	3.2	0.1	41.0	0.2	0.0	2.4	4.9	5.8	0.3	0.4	3.0	6.9	4.3	22.8	9.8	0.0	9.0	0.3	0.0	4.9	2.8	0.6	0.0	1.2	19.2	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.0	0.0	7.9	23.6	0.2	0.0	0.1	1.3	2.9	6.0	6.0	0.0	11.9	1.9	20.1	9.5	16.1	7.2	10.3	8.8	4.5	6.2	5.8	13.1	3.6	2.6	5.6	7.8	7.8	12.0	2.2	7.4	11.6	3.5	4.4	1.4	3.2	3.8	3.1	6.2	1.6	3.8	4.6	6.0	7.7	32.3	0.2	4.5	0.0	5.0	5.1	1.4	0.0	1.8	0.0	0.3	0.0	0.0	0.5	76.4	0.0	0.0	0.0	0.2	5.6	0.3	22.0	1.0	36.1	0.0	0.0	49.7	85.1	0.0	1.7	24.6	6.8	6.4	0.0	0.1	0.0	0.0	0.7	0.3	0.0	6.5	2.8	0.3	0.1	3.6	0.2	47.8	0.0	0.4
FLT3	"CD135, FLK2, STK1"	ENSG00000122025	"Fms related tyrosine kinase 3"	P36888	13	28003274-28100592	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.9;brain: 19.3;lymphoid tissue: 15.0"	"Cell type enhanced"	"Detected in some"	25	"Kupffer cells: 29.6;Macrophages: 12.4;monocytes: 55.9"	"Cancer enhanced"	"Detected in some"		"breast cancer: 1.8"	"Region enhanced"	"Detected in many"		"cerebellum: 19.3"	"Group enriched"	"Detected in some"	11	"myeloid DC: 29.9;plasmacytoid DC: 12.1"	"Lineage enriched"	"Detected in many"	16	"dendritic cells: 29.9"	"Group enriched"	"Detected in some"	11	"REH: 28.5;THP-1: 17.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA047539			Approved	"Endoplasmic reticulum"		NA	NA		180000	"Endoplasmic reticulum"		"HPA047539: AB_2680080"	"unprognostic (2.19e-3)"	"unprognostic (3.16e-3)"	"unprognostic (6.54e-3)"	"unprognostic (9.96e-2)"	"unprognostic (3.88e-1)"	"unprognostic (3.96e-7)"	"unprognostic (7.99e-3)"	"unprognostic (1.65e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.56e-2)"	"unprognostic (3.65e-1)"	"unprognostic (3.91e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	0.9	0.6	0.6	7.2	1.1	7.5	2.6	19.3	3.5	0.9	1.2	0.1	0.1	0.4	0.8	0.8	1.0	1.2	4.6	0.5	0.9	1.7	2.8	0.7	2.7	15.0	1.8	1.1	0.5	5.7	0.0	0.4	0.0	7.4	0.6	1.4	0.1	2.3	0.6	0.4	1.2	3.0	1.3	4.4	8.8	0.9	1.2	0.0	8.2	0.6	0.0	5.8	2.4	0.7	0.1	29.9	1.4	1.8	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.1	0.5	0.0	0.0	28.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	17.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	1.4	0.0	0.3	0.0	0.1	0.0	0.0	29.9	0.0	0.0	0.0	0.0	0.8	0.0	12.1	0.0	1.2	0.6	1.1	19.3	3.5	0.9	1.7	1.8	1.1	7.4	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.3	2.5	0.0	0.0	0.0	0.0	0.0	0.0	2.2	3.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	1.3	29.6	1.6	0.0	12.4	1.7	55.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.5	0.0	0.0	0.0	0.0
FLT4	"PCL, VEGFR3"	ENSG00000037280	"Fms related tyrosine kinase 4"	P35916	5	180601506-180649624	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 56.3"	"Group enriched"	"Detected in some"	5	"Extravillous trophoblasts: 31.7;Ito cells: 65.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"MAIT T-cell: 7.7"	"Lineage enriched"	"Detected in single"	35	"T-cells: 7.7"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;BEWO: 10.1;HEK 293: 12.5;HUVEC TERT2: 8.1;JURKAT: 10.0;T-47d: 11.9;TIME: 12.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000099, HPA046519, HPA067906, HPA074389"	Approved		Supported	"Nuclear speckles,Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA		270000000	"Nuclear speckles, Plasma membrane"	"Cell Junctions"	"CAB000099: , HPA046519: AB_2732527, HPA067906: AB_2732775, HPA074389: "	"unprognostic (7.35e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.45e-3)"	"unprognostic (3.81e-1)"	"unprognostic (9.26e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.69e-1)"	"unprognostic (1.88e-2)"	"unprognostic (9.41e-3)"	"unprognostic (1.83e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.32e-1)"	14.8	7.1	1.6	4.9	6.0	0.7	28.5	1.3	2.7	6.3	7.3	1.9	2.1	3.1	7.3	6.2	5.7	9.2	5.3	6.4	1.7	0.9	11.7	10.2	14.1	23.6	2.0	0.8	5.8	2.3	2.3	6.2	56.3	2.1	4.9	1.4	6.7	3.3	4.4	4.8	2.8	4.7	4.7	1.5	14.5	2.4	3.5	2.0	0.3	19.4	4.4	2.3	6.1	14.7	0.0	0.1	0.2	0.0	0.0	7.7	0.2	0.1	2.0	2.7	8.3	0.0	0.0	10.1	0.2	0.1	0.0	0.0	0.3	0.3	0.2	0.8	0.1	0.5	0.3	2.8	0.1	0.2	0.1	12.5	1.0	0.4	0.4	0.1	7.4	0.2	0.2	0.0	0.1	0.3	0.3	8.1	10.0	0.3	0.3	1.7	4.5	0.1	0.4	5.8	0.2	0.5	6.5	0.0	0.1	0.1	0.2	0.2	0.9	0.1	0.2	0.0	2.7	11.9	0.2	12.6	0.1	5.9	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.9	0.0	7.7	0.0	0.4	1.6	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	1.6	6.0	1.3	2.7	1.7	0.9	2.0	0.8	2.1	2.0	0.0	1.7	0.9	0.2	0.8	0.0	4.5	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.2	9.2	0.0	0.0	0.0	31.7	0.6	0.2	2.3	0.4	1.1	0.0	0.0	65.1	5.7	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	4.3	1.0	0.8	0.7	0.0	0.1
FOXA1	HNF3A	ENSG00000129514	"Forkhead box A1"	P55317	14	37589984-37596059	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 47.0;prostate: 44.4"	"Cell type enhanced"	"Detected in many"	9	"Basal glandular cells: 103.5;Glandular cells: 100.2;Intestinal endocrine cells: 81.2;Urothelial cells: 133.4"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 127.0"	"Region enriched"	"Detected in single"	6	"midbrain: 2.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Hep G2: 16.6;MCF7: 36.1;PC-3: 25.2;RT4: 33.8;SK-BR-3: 34.2;T-47d: 48.4"	"Group enriched"	"Detected in some"	15	"hypothalamus: 1.0;midbrain: 1.3;thalamus: 1.1"	"Region enriched"	"Detected in single"	6	"midbrain: 6.1"	"CAB011595, HPA050505"	Enhanced		Supported	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			Nucleoplasm	"Nucleoli fibrillar center"	"CAB011595: AB_2104842, HPA050505: AB_2681148"	"unprognostic (1.61e-1)"	"unprognostic (8.80e-2)"	"unprognostic (1.12e-1)"	"unprognostic (4.65e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.54e-2)"	"unprognostic (6.30e-2)"	"unprognostic (0.00e+0)"	"unprognostic (3.67e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.69e-2)"	"prognostic favorable (1.00e-4)"	0.1	0.0	0.1	6.1	0.1	0.0	23.5	0.1	0.3	1.5	9.4	0.1	0.1	4.6	0.1	0.5	7.2	1.3	6.5	0.1	0.1	0.3	0.4	47.0	13.2	0.1	2.0	0.1	0.6	0.2	0.0	1.1	0.1	0.2	44.4	6.0	0.2	9.4	0.7	0.1	0.7	5.1	2.4	0.1	0.1	13.0	0.6	0.1	0.2	0.1	4.4	9.9	12.5	11.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.5	0.0	0.9	0.0	0.0	0.2	0.0	0.1	0.0	0.0	7.4	0.9	0.0	0.5	0.0	0.0	8.4	4.7	1.1	0.0	0.0	8.3	0.0	1.4	16.6	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.6	0.0	0.1	0.3	0.0	0.0	36.1	0.0	0.1	0.0	11.0	25.2	0.0	0.4	0.1	3.5	33.8	4.3	0.0	1.6	34.2	0.0	0.0	48.4	0.1	0.0	0.3	0.0	0.1	1.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.1	0.3	2.0	0.1	0.2	0.1	26.8	38.7	0.0	103.5	0.9	0.0	1.1	25.5	52.2	37.5	3.5	0.0	0.0	0.0	1.8	0.3	0.3	14.7	0.0	2.1	0.0	0.0	100.2	2.3	27.6	0.0	0.0	81.2	1.3	1.2	0.5	0.0	0.1	3.3	1.8	34.4	0.0	3.1	21.0	0.0	0.0	0.0	0.0	0.1	0.5	1.3	0.1	0.0	0.0	25.3	133.4
FOXL2	"BPES, BPES1"	ENSG00000183770	"Forkhead box L2"	P58012	3	138944224-138947140	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Premature ovarian failure"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 13.9;ovary: 55.5;parathyroid gland: 15.3"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 5.6;fHDF/TERT166: 6.5;HEL: 9.2;hTCEpi: 8.5;K-562: 9.4;SiHa: 6.5;THP-1: 6.7"	"Not detected"	"Not detected"							HPA069613	Enhanced		Supported	"Nucleoplasm,Midbody ring"		NA	NA			Nucleoplasm	"Midbody ring"	"HPA069613: AB_2686160"	"unprognostic (1.46e-1)"	"unprognostic (3.28e-2)"		"unprognostic (4.76e-3)"	"unprognostic (2.05e-1)"	"unprognostic (5.16e-4)"		"unprognostic (3.55e-2)"	"unprognostic (2.35e-3)"	"unprognostic (5.08e-2)"	"unprognostic (3.79e-2)"	"unprognostic (2.19e-1)"	"unprognostic (9.63e-8)"	"unprognostic (2.16e-2)"	"unprognostic (4.65e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.61e-2)"	0.0	1.5	0.3	0.0	1.2	0.0	0.0	0.3	1.0	13.9	0.0	0.6	0.0	0.0	10.0	0.4	0.1	6.4	0.0	0.1	0.4	0.2	0.0	0.0	0.0	0.0	0.3	0.4	55.5	0.6	15.3	13.1	1.4	0.8	0.2	0.0	1.7	0.0	0.4	0.0	0.2	0.0	0.9	0.3	0.0	0.0	0.8	0.2	0.0	0.2	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	2.2	0.3	4.0	0.1	0.0	1.7	0.2	0.0	0.4	0.1	0.0	0.4	0.0	2.7	6.5	0.2	1.3	0.0	0.0	0.1	0.0	0.0	9.2	1.1	0.0	0.0	0.1	0.0	0.0	8.5	0.0	0.0	1.4	0.0	0.0	9.4	0.0	3.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.0	0.0	6.5	0.0	0.0	0.3	0.0	6.7	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.3	1.0	0.4	0.2	0.3	0.4	0.8	0.2	0.0	0.0	0.0	0.1	0.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.9	0.0	0.0	0.0	0.0
FOXO1	"FKH1, FKHR, FOXO1A"	ENSG00000150907	"Forkhead box O1"	Q12778	13	40469953-40666597	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Autophagy, Differentiation, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 85.9"	"Cell type enhanced"	"Detected in many"	6	"Ito cells: 72.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 19.3;Daudi: 20.4;HSkMC: 25.7;U-698: 26.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001252, CAB022326"	Approved	Approved	Supported	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB022326: , HPA001252: AB_1078906"	"unprognostic (4.72e-2)"	"unprognostic (1.81e-1)"	"unprognostic (8.54e-2)"	"unprognostic (4.35e-1)"	"unprognostic (2.42e-1)"	"unprognostic (2.52e-1)"	"prognostic favorable (3.74e-4)"	"unprognostic (6.35e-2)"	"unprognostic (1.60e-1)"	"unprognostic (8.65e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.31e-1)"	"prognostic favorable (1.33e-5)"	"unprognostic (1.93e-1)"	"unprognostic (5.44e-1)"	"unprognostic (9.09e-2)"	"unprognostic (9.63e-2)"	41.6	6.9	7.0	18.4	11.2	8.0	35.5	2.3	5.0	21.4	13.4	8.4	7.7	3.5	27.4	9.8	9.5	17.2	13.3	9.9	7.8	3.9	8.3	25.6	15.3	22.4	8.3	3.9	46.0	12.2	3.8	6.2	9.5	6.5	7.9	6.8	5.7	7.5	9.3	85.9	12.3	7.6	18.6	9.7	10.8	7.4	12.3	9.0	9.4	13.1	9.0	15.6	14.4	16.2	6.1	0.5	2.8	1.6	1.1	7.1	1.0	0.3	0.6	5.7	0.1	19.3	3.8	5.5	0.8	1.1	0.2	0.1	1.5	1.3	20.4	3.8	0.5	0.9	4.9	4.5	2.4	0.3	9.2	4.6	0.0	0.6	4.5	9.2	0.1	0.5	25.7	16.7	0.1	3.2	1.1	14.5	1.5	0.3	6.5	1.4	0.7	0.0	0.2	8.3	2.8	1.4	14.5	6.7	1.6	10.7	2.6	1.2	0.3	0.7	3.9	0.8	6.9	0.6	0.5	8.5	0.1	1.1	0.0	0.5	3.7	1.4	26.4	0.5	0.9	2.6	0.9	0.8	0.5	1.5	1.0	2.3	3.2	3.9	2.2	0.5	6.1	7.1	5.3	2.8	1.1	1.6	0.0	5.5	1.0	7.0	11.2	2.3	5.0	7.8	3.9	8.3	3.9	6.5	9.0	0.0	4.1	9.5	18.7	26.1	3.0	9.8	7.6	9.4	9.1	8.7	11.8	0.2	0.0	9.5	5.5	37.9	19.3	0.0	15.3	1.7	28.8	9.2	1.1	39.4	5.7	4.8	50.2	72.4	15.5	2.0	17.3	11.0	11.8	18.0	18.4	5.0	15.9	13.6	12.4	6.3	8.3	6.5	9.3	4.8	14.9	23.3	0.7	12.9	9.8	9.1
FOXO3	"AF6q21, FKHRL1, FOXO2, FOXO3A"	ENSG00000118689	"Forkhead box O3"	O43524	6	108559835-108684774	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Erythroid cells: 210.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 15.7"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 40.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004074, HPA063104"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB004074: AB_2106672, HPA063104: AB_2684941"	"unprognostic (3.42e-2)"	"unprognostic (3.76e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.96e-2)"	"unprognostic (6.68e-2)"	"unprognostic (4.63e-2)"	"unprognostic (4.08e-3)"	"unprognostic (1.73e-1)"	"unprognostic (3.81e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.98e-2)"	"unprognostic (1.75e-1)"	"unprognostic (2.54e-2)"	"unprognostic (9.09e-2)"	"unprognostic (1.13e-1)"	"unprognostic (5.81e-2)"	"unprognostic (5.68e-2)"	29.6	7.7	11.5	12.2	12.6	36.7	35.4	28.0	18.1	19.9	16.1	12.6	9.8	7.8	17.4	16.1	22.3	16.5	18.0	12.9	9.7	7.7	10.7	14.0	21.1	16.8	12.4	14.0	28.8	52.3	14.3	8.8	13.1	10.3	13.8	11.0	14.3	21.2	10.5	54.7	20.3	11.3	13.9	7.9	14.2	14.8	13.1	13.2	11.6	13.1	12.7	10.2	17.1	20.3	1.8	2.7	15.7	4.6	3.4	4.0	1.0	9.1	3.3	6.0	9.7	18.6	22.3	7.5	7.6	8.0	6.7	9.2	5.9	8.3	5.9	6.5	8.9	9.8	6.7	6.2	9.3	10.0	5.3	9.0	14.7	2.9	4.4	21.7	3.5	10.8	25.4	18.8	13.7	18.8	9.3	5.0	5.4	9.8	40.1	12.1	5.2	4.9	5.4	3.9	4.4	5.0	5.7	17.1	19.7	13.3	7.0	10.6	27.6	6.5	5.3	7.6	11.0	5.8	11.7	8.0	11.4	6.4	7.0	9.8	0.7	6.9	5.6	6.2	7.1	7.8	6.7	2.9	5.7	3.6	1.5	4.0	1.0	1.9	3.0	1.7	1.8	1.7	2.3	15.7	3.4	4.6	2.7	1.8	1.0	11.5	12.6	28.0	18.1	9.7	7.7	12.4	14.0	10.3	13.2	41.7	39.5	22.4	61.6	60.1	55.0	28.2	73.9	44.2	46.6	24.4	66.8	19.2	14.9	43.0	12.5	63.2	36.2	210.2	26.5	31.0	67.9	115.8	15.0	60.6	39.1	49.3	64.2	66.9	66.3	12.1	98.7	35.8	54.0	43.3	49.3	89.6	53.0	33.6	94.4	15.9	67.1	32.3	89.8	7.2	18.1	40.7	34.4	35.5	29.9	108.9
FOXO4	"AFX1, MLLT7"	ENSG00000184481	"Forkhead box O4"	P98177	X	71096197-71103535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Cell cycle, Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 98.6"	"Group enriched"	"Detected in many"	10	"Cytotrophoblasts: 207.8;Syncytiotrophoblasts: 257.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in many"	5	"BEWO: 61.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039560, HPA040232"	Enhanced		Supported	"Nuclear speckles,Cytosol"		NA	NA			"Nuclear speckles"	Cytosol	"HPA039560: AB_2676572, HPA040232: AB_2676894"	"unprognostic (4.64e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.49e-1)"	"unprognostic (4.79e-2)"	"prognostic favorable (4.61e-4)"	"unprognostic (1.09e-1)"	"unprognostic (3.20e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.18e-2)"	"unprognostic (2.13e-2)"	"unprognostic (8.16e-2)"	"prognostic favorable (3.46e-4)"	"unprognostic (2.45e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.75e-3)"	8.5	13.2	21.7	3.8	21.5	9.9	5.1	9.1	15.6	4.8	8.4	9.1	11.9	6.3	6.8	10.2	7.3	7.7	5.8	9.7	21.4	14.5	5.2	3.6	5.5	3.6	22.8	8.4	13.4	6.8	8.7	3.0	98.6	9.2	7.0	4.7	4.9	8.5	11.3	33.8	5.5	6.6	9.4	17.3	6.0	5.2	13.9	13.1	4.4	5.9	7.5	4.2	7.5	11.0	0.9	0.2	3.4	0.6	1.0	1.8	0.9	1.8	0.5	1.4	1.8	3.4	2.4	61.2	1.4	1.6	0.7	1.7	1.2	2.4	2.4	1.8	1.8	0.8	0.8	3.7	1.6	0.9	2.4	5.6	3.4	11.4	2.0	1.9	2.0	2.7	2.0	3.9	0.7	0.4	3.3	1.9	3.5	7.0	4.7	0.3	0.4	3.1	3.2	6.6	4.6	2.2	2.1	3.6	3.6	1.2	1.0	1.0	3.0	2.9	0.4	3.2	10.9	0.7	1.2	1.7	0.4	0.9	3.2	0.3	3.1	1.6	0.4	1.6	5.3	0.5	0.2	0.6	3.2	0.9	0.6	0.3	0.8	0.5	0.9	0.2	0.9	0.4	1.8	3.4	1.0	0.3	0.0	1.3	0.9	21.7	21.5	9.1	15.6	21.4	14.5	22.8	8.4	9.2	13.1	0.0	2.4	1.4	4.1	4.7	1.2	6.5	5.1	0.0	1.2	8.7	3.9	207.8	1.7	2.0	0.2	3.8	12.7	23.3	2.6	8.6	4.4	3.4	2.3	2.4	19.4	1.6	5.8	4.3	3.1	0.4	6.4	3.2	3.3	1.0	11.4	2.8	2.6	8.6	14.5	3.3	0.8	6.5	2.5	0.3	0.4	3.0	257.4	5.0	6.0	3.1
FOXP1	"12CC4, hFKH1B, HSPC215, QRF1"	ENSG00000114861	"Forkhead box P1"	Q9H334	3	70952817-71583993	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 40.2"									"HPA003876, CAB011501"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB011501: AB_732428, HPA003876: AB_1078907"	"unprognostic (2.31e-1)"	"unprognostic (4.35e-3)"	"unprognostic (2.09e-2)"	"unprognostic (3.54e-2)"	"unprognostic (2.69e-1)"	"unprognostic (2.81e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.03e-1)"	"unprognostic (4.38e-3)"	"unprognostic (3.40e-1)"	"unprognostic (6.14e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.65e-2)"	"unprognostic (1.27e-1)"	"unprognostic (6.05e-2)"	24.6	5.1	7.0	30.2	19.2	32.7	21.9	7.2	13.1	16.3	29.3	8.7	10.3	10.1	19.8	9.9	19.6	13.1	19.3	15.5	8.4	5.9	7.6	12.9	26.1	34.0	7.6	10.2	30.3	14.7	7.2	25.7	11.4	7.4	21.6	21.6	11.3	24.6	11.2	12.7	12.2	16.7	34.3	7.9	18.6	20.4	11.7	10.1	38.1	19.8	13.1	27.0	28.5	31.8	29.9	8.4	14.4	9.9	9.2	29.6	11.2	3.8	2.9	7.1	4.8	3.3	9.6	3.4	11.4	13.1	10.0	7.3	21.3	4.5	10.3	1.7	5.1	7.2	2.6	13.1	9.8	16.9	3.1	5.4	5.3	7.1	20.0	8.3	9.9	13.1	9.8	4.0	40.2	17.8	7.0	14.9	6.1	5.3	15.1	4.5	16.8	4.9	3.9	8.7	2.7	18.6	14.9	12.3	1.8	8.2	12.1	6.0	10.9	11.9	3.3	0.7	7.1	2.3	7.3	18.8	13.9	6.0	19.3	15.7	3.8	2.8	14.6	8.8	12.7	2.9	14.4	5.7	6.0	8.3	5.7	9.3	25.8	18.3	10.3	5.3	29.9	29.6	18.9	8.3	9.2	9.9	8.4	15.9	11.2	7.0	19.2	7.2	13.1	8.4	5.9	7.6	10.2	7.4	10.1	68.5	106.7	181.2	154.9	162.6	27.9	38.3	114.7	87.0	93.3	31.4	17.7	37.3	26.6	65.8	141.2	159.5	75.9	70.0	81.8	13.6	54.0	219.0	213.7	53.9	43.0	6.4	260.7	120.9	97.8	57.5	38.9	86.3	35.4	111.0	226.3	20.3	98.8	101.7	23.3	15.6	38.0	90.5	74.6	10.8	6.4	88.7	43.8	126.3	146.7	116.8
FSTL3	"FLRG, FSRP"	ENSG00000070404	"Follistatin like 3"	O95633	19	676365-683399	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Osteogenesis, Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	6	"placenta: 201.0"	"Cell type enriched"	"Detected in many"	4	"Extravillous trophoblasts: 2939.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BEWO: 36.2;hTCEpi: 40.0;SiHa: 73.8;U-2197: 38.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB024899, HPA045378"	Approved		Supported	Nucleoplasm	"Secreted in other tissues"	NA	Yes		6800000	Nucleoplasm		"CAB024899: , HPA045378: AB_2679300"	"unprognostic (9.86e-3)"	"unprognostic (1.32e-3)"	"prognostic unfavorable (3.01e-4)"	"prognostic unfavorable (3.03e-4)"	"unprognostic (2.19e-3)"	"unprognostic (1.51e-3)"	"unprognostic (8.64e-3)"	"prognostic unfavorable (4.61e-7)"	"unprognostic (9.50e-2)"	"prognostic unfavorable (1.65e-4)"	"unprognostic (3.50e-2)"	"unprognostic (5.91e-2)"	"unprognostic (1.03e-3)"	"unprognostic (7.22e-3)"	"unprognostic (3.07e-1)"	"unprognostic (3.75e-1)"	"unprognostic (5.89e-3)"	19.9	29.1	4.0	10.7	6.2	5.6	24.7	1.3	4.2	13.1	14.9	3.8	8.1	3.8	12.8	15.6	12.7	14.1	13.1	27.0	5.0	2.0	13.7	5.1	26.9	8.7	7.3	4.5	16.8	11.7	1.4	5.3	201.0	6.0	14.3	3.1	12.0	4.5	11.0	4.1	6.2	6.5	20.6	10.4	3.9	9.1	34.5	4.9	0.7	7.2	5.5	1.4	16.7	18.3	0.9	2.2	0.1	4.4	0.6	2.6	2.0	1.9	15.9	1.1	0.8	5.0	12.8	36.2	27.0	4.0	6.8	2.5	5.8	3.1	0.8	10.9	18.2	3.9	13.9	0.9	23.0	2.2	1.6	1.9	0.7	22.2	4.7	21.6	1.4	2.6	16.0	40.0	7.5	31.3	17.6	1.2	0.8	1.7	1.1	10.2	7.0	0.5	0.8	1.3	13.1	5.5	1.5	0.7	1.8	9.4	0.3	0.7	1.2	73.8	1.5	0.8	1.4	1.3	0.7	16.2	6.8	23.5	38.1	9.9	1.8	0.8	0.4	1.0	4.2	3.1	0.0	4.4	0.0	1.0	4.4	0.2	0.3	1.4	1.1	2.2	0.9	2.6	1.6	0.1	0.6	3.2	0.9	0.2	2.0	4.0	6.2	1.3	4.2	5.0	2.0	7.3	4.5	6.0	4.9	17.9	3.4	2.2	19.6	12.9	1.6	12.8	30.6	2.7	1.2	8.7	0.0	22.7	6.6	69.7	5.6	4.5	0.9	0.0	56.0	2939.6	52.2	21.7	0.0	0.9	68.4	3.2	1.2	22.1	3.8	6.5	56.7	4.0	5.0	11.8	0.9	7.8	198.1	0.0	25.1	5.6	0.5	45.3	32.5	2.3	7.7	6.8	662.4	2.9	1.7	20.7
FUBP1	"FBP, FUBP"	ENSG00000162613	"Far upstream element binding protein 1"	Q96AE4	1	77944055-77979110	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006149	Supported		Enhanced	Nucleoplasm		NA	NA		200000	Nucleoplasm		"HPA006149: AB_1849172"	"unprognostic (4.17e-2)"	"unprognostic (2.83e-2)"	"unprognostic (3.35e-3)"	"unprognostic (3.89e-2)"	"unprognostic (3.77e-1)"	"unprognostic (5.65e-2)"	"prognostic unfavorable (9.83e-9)"	"unprognostic (2.32e-2)"	"unprognostic (2.16e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.31e-3)"	"unprognostic (9.80e-3)"	"unprognostic (9.02e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.67e-1)"	"unprognostic (6.24e-2)"	"unprognostic (9.46e-2)"	23.9	35.5	21.8	42.4	26.9	56.8	27.0	34.0	31.8	24.3	19.6	18.1	23.0	21.8	29.4	35.0	23.5	25.2	18.4	27.5	22.0	22.3	26.6	16.3	27.2	37.6	17.5	28.8	44.4	31.6	36.0	41.5	27.3	26.3	22.4	28.3	22.0	28.2	35.6	27.4	21.3	24.0	22.7	31.3	28.6	22.6	17.6	19.9	64.9	35.0	26.2	40.3	24.0	29.1	16.1	11.3	10.8	16.1	23.5	22.2	12.8	22.3	19.7	46.6	18.5	7.2	9.1	38.2	23.1	13.8	22.2	16.2	19.9	25.0	40.0	10.8	17.1	26.3	22.3	31.2	25.4	29.7	44.0	15.9	25.6	32.7	29.2	15.7	43.8	10.8	11.9	21.0	23.7	18.9	18.2	17.7	27.0	29.3	17.8	17.5	22.5	34.7	21.2	36.4	22.0	14.1	42.7	36.9	15.3	23.0	22.0	24.6	23.2	21.5	20.4	18.2	26.0	24.8	15.9	22.7	21.5	31.3	6.1	27.6	17.1	18.4	51.9	9.3	19.3	21.9	3.8	9.6	10.8	18.7	15.7	22.2	16.1	18.3	19.4	8.7	13.1	17.9	20.9	4.0	23.5	16.1	11.3	21.3	12.8	21.8	26.9	34.0	31.8	22.0	22.3	17.5	28.8	26.3	19.9	68.5	47.3	43.1	67.8	75.3	41.1	65.5	30.6	96.4	89.9	31.4	39.3	42.2	36.5	50.0	27.8	42.8	20.6	0.0	62.7	54.9	40.0	39.3	75.2	20.7	29.1	17.5	52.9	33.7	27.2	15.1	44.5	34.8	37.1	55.9	32.7	36.4	54.2	30.6	28.3	19.7	37.0	32.3	42.4	33.8	40.6	55.2	29.9	54.8	35.4	54.0
FUS	"ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS"	ENSG00000089280	"FUS RNA binding protein"	P35637	16	31180110-31194871	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"DNA-binding, RNA-binding"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, Neurodegeneration, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008784, CAB033036, CAB058691"	Supported		Enhanced	Nucleoplasm		NA	NA		190000	Nucleoplasm		"CAB033036: AB_2105208, CAB058691: AB_2665583, HPA008784: AB_1849181"	"unprognostic (3.06e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.86e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.44e-1)"	"unprognostic (8.03e-2)"	"prognostic unfavorable (4.38e-4)"	"unprognostic (2.15e-2)"	"unprognostic (1.00e-1)"	"unprognostic (5.22e-3)"	"unprognostic (1.01e-1)"	"unprognostic (1.01e-3)"	"unprognostic (1.12e-3)"	"unprognostic (1.87e-1)"	"unprognostic (5.27e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.49e-2)"	44.0	24.2	35.0	47.1	43.3	41.7	29.9	64.1	59.0	39.7	32.4	48.6	22.6	28.0	54.5	44.7	29.6	48.6	35.9	32.0	32.7	34.6	30.3	24.4	27.7	51.3	31.1	39.0	66.7	28.8	41.7	24.8	44.1	39.2	29.1	30.2	39.3	27.6	30.5	43.6	24.3	28.7	46.5	33.7	36.2	27.7	40.7	30.7	66.3	29.1	40.1	49.6	30.3	31.4	16.4	22.3	24.2	29.0	14.2	24.8	9.4	48.3	42.0	55.3	35.9	13.6	11.6	58.9	65.2	23.7	29.8	22.8	56.6	32.6	74.6	46.5	32.9	36.9	21.1	55.1	42.2	28.5	44.3	35.8	63.0	31.7	57.0	22.8	67.0	43.4	23.5	11.6	43.0	29.2	14.3	28.4	44.4	66.8	25.4	37.0	59.2	48.6	59.3	84.2	29.4	46.1	79.9	73.7	42.7	33.3	35.5	36.1	64.8	42.8	30.2	32.3	36.7	36.4	74.6	35.2	47.8	48.0	31.5	68.8	23.6	45.2	105.0	26.7	45.6	57.7	5.6	17.5	24.2	24.8	29.0	24.0	12.8	17.4	21.8	19.3	16.4	20.3	21.1	14.9	14.2	25.1	22.3	13.9	9.4	35.0	43.3	64.1	59.0	32.7	34.6	31.1	39.0	39.2	30.7	95.3	108.8	163.2	313.8	128.6	263.0	87.0	94.3	111.1	129.7	99.5	123.7	234.5	58.0	142.1	94.6	197.5	188.3	46.7	133.2	323.0	212.4	178.2	227.1	52.9	180.4	190.7	203.5	174.3	132.4	22.8	284.5	176.9	156.9	172.3	132.7	214.0	132.4	175.4	202.6	57.5	247.1	161.7	222.6	158.2	225.3	134.9	246.8	262.6	169.5	255.7
GAS7	"KIAA0394, MGC1348"	ENSG00000007237	"Growth arrest specific 7"	O60861	17	9910609-10198551	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 86.2"	"Cell type enhanced"	"Detected in many"	6	"Early spermatids: 49.9;Kupffer cells: 62.0;Late spermatids: 52.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 54.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 17.6"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	9	"WM-115: 110.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004838, HPA064678"	Enhanced		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Plasma membrane"	"Actin filaments, Focal adhesion sites"	"HPA004838: AB_2667263, HPA064678: AB_2685319"	"unprognostic (1.68e-2)"	"unprognostic (2.84e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.01e-2)"	"unprognostic (7.32e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.94e-3)"	"unprognostic (6.48e-2)"	"unprognostic (8.78e-2)"	"unprognostic (3.08e-2)"	"prognostic unfavorable (6.89e-4)"	19.1	6.5	22.1	15.4	40.3	18.7	10.8	86.2	64.7	22.6	9.3	33.4	1.7	5.2	9.7	4.4	17.0	12.6	11.5	23.1	25.8	15.0	1.5	2.1	9.9	5.9	28.1	25.0	5.9	2.8	1.4	1.7	11.0	14.2	3.7	8.7	7.7	4.0	8.2	3.9	21.2	7.4	16.3	33.8	10.0	4.2	11.8	22.2	2.7	2.5	2.7	7.2	11.7	7.8	0.4	3.6	11.0	17.6	2.8	2.1	4.4	0.0	0.1	0.1	0.2	3.4	4.9	0.0	0.1	0.0	0.5	0.2	0.0	0.0	1.3	0.4	1.3	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.3	0.1	1.1	0.3	10.1	0.9	0.0	1.0	0.0	0.0	0.0	8.7	0.0	0.1	0.0	0.0	10.7	3.2	0.5	0.4	0.0	2.8	0.0	9.8	0.0	0.0	0.0	0.6	0.0	0.0	12.7	4.7	0.5	5.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	7.1	110.2	0.4	17.6	10.8	2.1	4.7	0.7	0.3	0.2	1.0	3.6	0.4	0.2	1.0	11.0	2.8	3.1	0.6	0.0	4.4	22.1	40.3	86.2	38.8	25.8	15.0	28.1	25.0	14.2	22.2	0.0	6.2	3.2	3.8	7.3	34.5	11.3	0.0	26.8	1.2	5.2	25.5	1.1	0.0	0.6	49.9	7.0	0.0	0.0	0.0	1.1	43.4	1.6	17.3	0.5	34.5	0.0	0.0	7.4	62.0	52.5	9.5	29.6	32.1	1.0	0.0	8.0	0.3	0.0	1.8	0.0	30.3	0.0	5.2	1.1	6.1	14.4	1.6	7.5	0.0	4.3
GATA1	"ERYF1, GATA-1, GF1, NF-E1, NFE1"	ENSG00000102145	"GATA binding protein 1"	P15976	X	48786554-48794311	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"blood: 78.3;bone marrow: 37.0"	"Group enriched"	"Detected in some"	10	"Early spermatids: 11.8;Erythroid cells: 23.3;granulocytes: 35.9;Late spermatids: 20.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	6	"eosinophil: 78.3"	"Lineage enriched"	"Detected in single"	784	"granulocytes: 78.3"	"Group enriched"	"Detected in some"	9	"HEL: 50.8;HMC-1: 52.4;K-562: 54.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA000232, HPA000233, CAB009195"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB009195: AB_2232148, HPA000232: AB_1078949, HPA000233: AB_1078951"	"unprognostic (1.93e-1)"	"unprognostic (7.54e-2)"	"unprognostic (8.95e-3)"	"unprognostic (3.84e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.00e-4)"	"unprognostic (4.87e-2)"	"unprognostic (3.48e-2)"	"unprognostic (4.44e-2)"	"unprognostic (1.95e-2)"	"unprognostic (6.04e-2)"	"unprognostic (7.71e-3)"	"unprognostic (4.13e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.78e-1)"	"unprognostic (9.10e-2)"	"unprognostic (2.71e-2)"	0.7	0.2	0.1	2.4	0.7	37.0	0.3	0.0	0.3	0.7	0.3	0.0	0.0	0.6	4.9	2.4	0.4	0.3	0.6	2.3	0.1	0.3	0.4	0.8	5.6	0.2	0.6	0.0	0.1	0.1	0.1	0.5	2.8	0.3	1.4	0.4	1.6	0.3	0.2	0.1	0.6	0.8	2.4	0.3	4.9	0.5	3.1	0.0	1.5	0.6	1.1	0.6	0.9	0.6	0.0	0.0	78.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.8	0.0	0.0	0.0	0.0	52.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	54.0	0.1	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.2	0.0	78.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.7	0.1	0.7	0.0	0.3	0.1	0.3	0.6	0.0	0.3	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	0.0	0.0	23.3	0.0	0.7	0.0	0.0	35.9	0.0	0.5	0.0	0.0	0.0	0.0	20.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0
GATA2	NFE1B	ENSG00000179348	"GATA binding protein 2"	P23769	3	128479427-128493185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Phagocytosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 81.2;ductus deferens: 85.8;seminal vesicle: 209.1"	"Group enriched"	"Detected in many"	5	"Extravillous trophoblasts: 226.1;granulocytes: 616.3;Syncytiotrophoblasts: 268.8"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 36.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	339	"basophil: 81.2"	"Lineage enriched"	"Detected in single"	813	"granulocytes: 81.2"	"Cell line enhanced"	"Detected in many"		"BEWO: 57.0;HEL: 70.3;HMC-1: 38.1;SH-SY5Y: 66.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA005633, CAB024847"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB024847: , HPA005633: AB_1078954"	"unprognostic (1.71e-1)"	"unprognostic (8.90e-2)"	"unprognostic (1.12e-1)"	"unprognostic (8.61e-2)"	"unprognostic (8.67e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.96e-3)"	"unprognostic (7.30e-2)"	"unprognostic (3.98e-2)"	"unprognostic (4.12e-2)"	"unprognostic (3.58e-2)"	"unprognostic (3.04e-1)"	"prognostic favorable (2.04e-4)"	"unprognostic (2.50e-1)"	"unprognostic (8.07e-2)"	"unprognostic (2.08e-1)"	"prognostic favorable (5.22e-5)"	7.0	6.2	2.1	1.5	2.4	2.5	7.9	1.2	1.9	22.4	2.8	1.4	85.8	2.5	20.6	5.4	3.2	23.0	9.7	4.8	1.5	1.0	7.6	0.6	16.1	2.2	1.8	1.1	4.6	5.8	3.4	4.5	51.8	2.4	27.8	1.8	6.1	1.9	209.1	3.5	4.1	3.4	8.4	1.4	5.1	2.9	2.7	1.5	0.4	3.3	2.7	1.5	22.4	12.4	0.0	0.0	81.2	0.0	0.0	0.0	0.4	4.7	1.1	0.2	3.1	0.4	0.1	57.0	10.6	9.1	3.6	1.3	1.9	2.1	0.1	3.0	6.3	0.3	5.0	2.9	0.0	1.5	0.0	1.6	70.3	7.8	3.1	0.8	7.1	38.1	0.0	0.0	0.1	0.0	0.5	5.7	0.0	18.4	0.1	0.0	1.7	0.0	14.4	0.2	0.0	0.3	0.0	1.4	0.0	0.1	4.2	4.4	66.4	2.7	14.1	0.4	3.0	2.7	2.9	10.2	0.2	0.1	2.5	1.4	0.0	0.0	0.0	0.1	0.4	0.7	81.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.1	2.4	1.2	1.9	1.5	1.0	1.8	1.1	2.4	1.5	6.0	48.7	0.5	16.6	4.2	0.2	6.1	0.0	1.4	3.4	71.5	0.0	50.4	1.7	0.3	5.8	56.9	0.0	0.0	12.6	226.1	5.8	36.8	616.3	0.0	9.5	0.0	2.9	34.4	0.8	4.0	0.6	2.9	8.5	0.0	0.0	0.0	1.3	0.0	0.4	0.1	0.2	0.0	7.6	0.5	2.8	2.0	268.8	0.0	0.1	10.0
GATA3	HDR	ENSG00000107485	"GATA binding protein 3"	P23771	10	8045378-8075203	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 97.8;skin 1: 61.7"	"Cell type enhanced"	"Detected in many"	19	"Cytotrophoblasts: 243.8;Extravillous trophoblasts: 651.3;Syncytiotrophoblasts: 949.1"	"Group enriched"	"Detected in many"	24	"breast cancer: 190.0;urothelial cancer: 87.0"	"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	42	"gdT-cell: 9.7;MAIT T-cell: 13.3;memory CD4 T-cell: 18.2;memory CD8 T-cell: 14.1;naive CD4 T-cell: 10.0;naive CD8 T-cell: 9.0;NK-cell: 16.6;T-reg: 18.9"	"Group enriched"	"Detected in many"	54	"NK-cells: 16.6;T-cells: 18.9"	"Cell line enhanced"	"Detected in some"		"BEWO: 33.3;MCF7: 79.6;RT4: 32.6;SH-SY5Y: 28.0;T-47d: 103.7"	"Region enriched"	"Detected in single"	6	"midbrain: 7.3"	"Group enriched"	"Detected in some"	38	"midbrain: 25.5;pons and medulla: 17.5;thalamus: 20.0"	"CAB016217, HPA029730"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB016217: AB_2108591, HPA029730: AB_10601907"	"unprognostic (1.70e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.00e-1)"	"unprognostic (7.03e-3)"	"unprognostic (4.68e-3)"	"unprognostic (4.23e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-1)"	"unprognostic (3.83e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavorable (3.13e-4)"	"unprognostic (1.48e-1)"	"unprognostic (5.16e-2)"	"unprognostic (6.31e-2)"	"unprognostic (1.82e-3)"	2.0	2.0	0.3	3.4	0.3	0.9	17.8	0.3	0.3	1.8	0.5	0.1	44.4	0.1	0.4	13.5	0.8	0.4	0.4	0.9	0.3	0.4	12.9	0.7	1.6	2.7	0.8	0.0	0.3	0.4	55.0	3.8	53.4	1.4	8.1	0.0	1.8	8.9	97.8	0.8	61.7	1.2	3.4	0.4	2.7	0.5	0.8	0.1	42.4	3.3	0.6	3.4	26.9	16.4	0.2	0.0	0.3	0.0	16.6	18.9	3.0	5.5	1.3	0.0	0.0	0.0	0.0	33.3	0.1	0.0	0.0	0.0	2.0	5.0	0.0	0.0	0.0	0.0	4.9	0.5	0.1	0.0	16.0	1.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.1	0.0	0.3	0.1	2.6	7.8	0.0	0.0	0.0	79.6	8.7	0.0	0.6	1.0	0.7	0.4	0.4	0.1	0.0	32.6	1.6	28.0	0.0	4.5	0.0	6.1	103.7	0.0	0.0	0.4	1.0	0.2	0.7	0.1	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	9.7	0.0	13.3	0.2	18.2	14.1	0.0	0.0	10.0	9.0	0.3	16.6	0.0	0.0	18.9	3.0	0.3	0.3	0.3	0.3	0.3	0.4	0.8	0.0	1.4	0.1	0.0	8.9	0.5	60.9	84.1	0.0	1.2	0.0	0.0	1.2	169.3	0.0	243.8	0.0	0.2	0.0	4.9	0.0	0.0	0.3	651.3	6.9	27.0	2.3	0.5	27.7	0.0	0.0	9.8	4.0	0.0	0.0	2.2	8.5	1.0	0.0	0.0	2.6	0.0	0.0	0.3	0.0	0.0	1.4	0.0	0.2	173.9	949.1	56.1	0.0	68.0
GNA11	"FBH, FBH2, FHH2, HHC2"	ENSG00000088256	"G protein subunit alpha 11"	P29992	19	3094410-3124004	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 103.3"	"Cell type enhanced"	"Detected in many"	9	"Enterocytes: 264.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 9.1"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048886	Approved					NA	NA					"HPA048886: AB_2680544"	"unprognostic (4.64e-3)"	"unprognostic (2.21e-1)"	"unprognostic (3.12e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.53e-2)"	"prognostic unfavorable (4.86e-4)"	"unprognostic (2.56e-2)"	"unprognostic (1.40e-1)"	"unprognostic (6.26e-2)"	"unprognostic (7.85e-3)"	"unprognostic (2.43e-1)"	"prognostic favorable (1.48e-11)"	"unprognostic (1.05e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.47e-1)"	"unprognostic (3.02e-1)"	19.3	14.2	17.3	13.7	17.1	5.9	14.2	38.5	28.0	16.1	40.8	18.6	18.3	65.9	19.8	14.5	17.2	19.8	19.5	21.9	16.0	12.8	17.8	16.6	15.1	5.0	11.7	12.6	19.4	19.6	14.2	13.8	20.0	14.1	18.2	23.0	27.1	17.5	30.5	27.3	20.0	103.3	17.6	12.2	10.5	17.2	20.1	12.5	3.9	18.0	13.5	7.6	19.2	22.1	2.4	3.9	9.1	2.4	0.7	2.2	0.4	20.5	12.6	11.4	19.8	16.9	11.2	12.6	20.5	20.4	27.7	22.7	15.7	10.6	5.1	11.3	28.5	17.1	15.0	14.4	16.3	17.7	11.1	8.5	1.4	13.6	9.0	16.7	1.3	4.6	15.4	14.2	18.7	11.3	14.3	22.0	1.7	10.3	1.0	18.5	9.6	1.4	6.1	7.9	14.3	11.3	9.0	10.1	4.7	13.4	16.1	25.8	16.3	14.7	17.6	10.2	7.8	12.7	2.9	18.9	18.3	13.0	33.0	27.3	0.5	1.5	3.3	13.1	1.1	19.8	2.8	2.4	0.5	1.1	1.3	1.4	1.3	0.9	1.1	0.4	2.4	2.2	1.6	9.1	0.7	2.4	3.9	0.3	0.4	17.3	17.1	38.5	28.0	16.0	12.8	11.7	12.6	14.1	12.5	29.8	23.7	9.0	7.9	29.0	17.2	15.5	38.2	22.7	6.8	26.2	35.3	11.2	6.6	18.6	27.8	23.8	264.0	0.0	21.8	10.5	18.3	14.0	4.6	26.3	7.4	42.9	52.5	62.6	6.2	13.4	46.3	3.2	21.9	0.0	73.7	28.4	28.3	80.7	75.7	16.1	14.9	19.4	17.3	17.6	9.1	36.0	17.0	2.2	62.2	12.7
GNAQ	"G-ALPHA-q, GAQ"	ENSG00000156052	"G protein subunit alpha q"	P50148	9	77716087-78031458	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 18.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 18.4"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010036, HPA048886"	Uncertain		Approved	"Nuclear speckles,Plasma membrane,Cytosol"		NA	NA		28000000	"Nuclear speckles"	"Plasma membrane, Cytosol"	"CAB010036: AB_631536, HPA048886: AB_2680544"	"unprognostic (2.10e-1)"	"unprognostic (8.53e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.87e-1)"	"unprognostic (6.83e-3)"	"unprognostic (1.05e-1)"	"unprognostic (3.84e-2)"	"unprognostic (2.46e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.44e-1)"	"prognostic favorable (1.11e-7)"	"unprognostic (1.90e-1)"	"unprognostic (3.13e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.01e-1)"	12.7	12.6	24.3	9.9	20.8	21.8	11.6	12.5	29.6	13.1	16.6	17.1	9.1	7.9	13.7	11.2	13.1	10.0	11.6	5.6	24.2	18.3	12.1	12.3	23.1	11.8	19.1	14.6	13.5	8.5	12.7	7.6	12.1	14.3	13.0	16.0	10.4	9.8	15.9	5.9	5.1	9.0	18.2	23.9	5.8	15.5	6.0	14.8	18.6	13.3	4.0	4.8	14.5	13.1	0.8	2.8	18.4	3.5	3.3	2.0	1.2	12.0	13.7	12.2	13.4	15.5	15.9	17.6	16.4	12.4	7.2	8.7	4.2	9.9	0.0	13.3	15.0	10.1	19.8	9.1	9.9	9.0	0.4	5.3	33.0	12.0	8.4	14.0	20.1	12.4	10.8	12.2	13.9	14.2	15.0	17.7	29.8	5.8	0.1	12.6	15.3	23.2	12.8	9.9	19.4	1.9	8.6	15.0	0.1	16.4	25.8	13.7	20.9	11.8	10.0	12.3	12.0	9.1	7.5	22.1	12.7	0.8	17.2	9.5	0.1	0.0	0.1	8.8	11.9	13.1	18.4	2.2	4.6	0.8	1.9	1.6	0.8	1.8	1.0	2.4	0.8	2.0	1.6	7.7	3.3	3.5	2.8	1.9	1.2	24.3	20.8	12.5	24.0	24.2	18.3	19.1	14.6	14.3	14.8	163.8	71.4	6.4	33.6	42.0	29.9	5.9	43.3	42.8	35.2	73.3	15.7	39.3	6.6	28.1	13.1	85.4	69.5	46.7	34.7	42.2	42.9	51.3	49.7	51.3	47.8	77.9	88.6	107.4	139.4	6.8	36.5	92.7	45.5	72.1	90.6	37.0	44.3	48.9	49.1	35.4	4.2	25.8	40.1	4.7	6.6	18.9	24.3	21.8	67.3	50.3
GNAS	"GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI"	ENSG00000087460	"GNAS complex locus"	"O95467, P63092, P84996, Q5JWF2"	20	58839718-58911192	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters"		Transducer	"Cancer-related genes, Cushing syndrome, Disease mutation, Dwarfism, Obesity, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pituitary gland: 303.3;thyroid gland: 304.5"	"Cell type enhanced"	"Detected in all"	5	"Horizontal cells: 1781.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010337, HPA018122, HPA027478, HPA028386"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cytosol"	"Intracellular and membrane"	NA	NA			Nucleoplasm	"Plasma membrane, Cytosol"	"CAB010337: AB_631538, HPA018122: AB_1849236, HPA027478: AB_10599284, HPA028386: AB_10601983"	"unprognostic (7.48e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.90e-2)"	"unprognostic (4.77e-2)"	"unprognostic (8.37e-3)"	"unprognostic (2.82e-2)"	"unprognostic (4.53e-3)"	"unprognostic (8.01e-2)"	"unprognostic (4.29e-2)"	"prognostic favorable (8.76e-4)"	"unprognostic (2.07e-2)"	"unprognostic (1.58e-1)"	"prognostic unfavorable (3.49e-4)"	"unprognostic (5.24e-3)"	"unprognostic (1.61e-1)"	"unprognostic (8.25e-2)"	"unprognostic (1.36e-1)"	56.2	79.0	84.2	34.4	44.5	42.1	87.4	86.0	107.4	43.2	42.3	25.4	27.0	33.2	37.2	44.7	41.0	43.6	34.4	106.0	71.0	144.0	39.6	35.3	46.6	44.6	75.8	64.7	43.6	118.1	120.9	303.3	49.8	85.6	36.3	31.5	42.7	171.6	31.1	172.9	26.3	34.9	40.5	61.4	36.9	42.4	18.2	27.4	56.0	304.5	80.6	41.0	37.3	44.6	27.3	41.5	29.9	36.2	25.3	24.2	24.6	9.7	32.8	55.4	25.8	94.2	43.0	49.8	56.4	51.6	64.5	46.3	95.8	50.6	32.0	87.9	73.2	46.2	42.3	50.8	75.1	43.7	21.1	30.6	35.6	49.9	62.7	43.5	20.7	22.4	51.3	38.2	31.3	42.2	51.2	48.9	39.5	31.2	43.7	42.5	133.6	105.4	50.6	17.6	6.4	34.7	64.9	48.5	56.5	51.7	38.7	68.7	157.4	78.4	77.9	62.9	50.7	59.5	56.7	53.7	85.7	77.0	30.8	53.1	76.8	49.5	67.6	37.6	10.1	43.7	29.9	24.8	29.5	20.7	35.7	22.1	26.7	22.0	22.2	37.8	27.3	21.3	24.2	29.1	25.3	36.2	41.5	23.3	24.6	84.2	44.5	86.0	107.4	71.0	144.0	75.8	64.7	85.6	27.4	205.4	224.1	189.5	151.9	115.9	363.0	884.0	242.0	250.3	255.9	247.7	53.0	672.6	376.4	220.5	577.5	343.9	323.7	303.7	196.1	292.5	221.9	260.9	133.0	165.2	333.8	1781.3	444.7	335.7	327.9	1338.6	245.7	276.8	210.9	147.9	250.3	861.2	313.5	239.3	185.3	130.9	175.1	207.0	226.4	48.2	25.4	103.0	1013.3	142.4	268.2	212.5
GOLGA5	"golgin-84, GOLIM5, ret-II, rfg5"	ENSG00000066455	"Golgin A5"	Q8TBA6	14	92794231-92839963	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000992, HPA063876"	Enhanced	Supported	Supported	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA000992: AB_1079009, HPA063876: AB_2685140"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.77e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.78e-1)"	"unprognostic (5.02e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.83e-2)"	"unprognostic (7.67e-2)"	"unprognostic (6.44e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.06e-2)"	"unprognostic (2.49e-2)"	20.8	20.3	16.8	15.7	17.3	6.5	24.4	11.6	17.5	24.9	20.4	17.2	25.5	16.5	18.2	41.7	21.2	15.3	17.5	18.3	17.5	15.6	21.5	51.0	16.6	18.2	18.6	14.6	18.9	26.8	23.6	27.2	44.4	16.4	23.4	23.7	12.7	24.3	30.2	20.6	18.9	25.6	18.9	19.4	16.9	23.0	23.5	17.6	13.5	24.8	17.8	16.4	20.7	15.8	9.7	9.7	22.2	12.7	8.1	12.4	6.3	12.6	11.7	10.6	9.6	22.2	30.1	18.2	17.6	32.4	17.2	20.3	8.6	17.4	8.2	14.5	27.9	12.0	13.4	9.3	14.3	23.4	10.0	4.5	7.8	5.9	11.5	25.8	9.0	13.1	23.1	26.1	12.0	25.0	19.0	16.9	8.7	6.8	11.1	18.8	23.5	6.9	7.8	6.6	27.7	12.6	5.4	15.5	8.2	17.5	15.5	7.5	10.7	16.0	12.0	17.9	15.3	20.6	10.1	13.9	9.9	6.5	12.8	8.7	13.7	10.5	7.2	22.7	7.2	16.4	9.1	9.8	22.2	10.9	12.7	12.3	9.7	11.1	11.1	9.7	9.2	9.9	8.6	8.7	8.1	10.8	9.1	12.4	6.3	16.8	17.3	11.6	17.5	17.5	15.6	18.6	14.6	16.4	17.6	26.8	19.9	6.7	9.6	6.9	7.5	23.8	12.7	17.4	15.9	14.0	11.8	20.5	24.9	22.5	25.9	13.5	17.1	0.0	28.6	27.4	17.9	21.7	9.2	30.6	13.9	23.8	21.5	11.6	11.6	13.3	21.3	11.3	11.8	17.2	31.9	14.3	22.7	10.5	23.7	17.8	10.9	25.8	17.6	22.4	28.3	9.9	42.1	11.8	16.1	11.2
GOPC	"CAL, dJ94G16.2, FIG, GOPC1, PIST"	ENSG00000047932	"Golgi associated PDZ and coiled-coil motif containing"	Q9HD26	6	117560269-117602542	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"											"HPA019477, HPA024018"	Approved		Enhanced	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA019477: AB_1849890, HPA024018: AB_1849891"	"unprognostic (2.48e-2)"	"unprognostic (1.63e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.84e-2)"	"unprognostic (3.17e-2)"	"unprognostic (3.12e-2)"	"unprognostic (9.21e-2)"	"unprognostic (6.22e-2)"	"unprognostic (6.77e-2)"	"unprognostic (8.23e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.67e-2)"	"unprognostic (1.38e-1)"	"unprognostic (9.55e-2)"	"unprognostic (3.01e-2)"	18.4	15.6	17.2	21.1	22.2	6.5	21.5	30.0	27.8	26.9	19.3	17.0	25.7	12.7	25.3	20.1	15.1	20.3	17.3	22.8	18.9	17.8	15.6	19.2	14.1	19.0	18.6	21.8	28.3	16.9	32.6	34.2	21.2	21.2	18.0	21.8	10.7	17.5	24.6	17.6	19.5	17.3	20.7	18.7	18.5	15.5	17.6	18.3	32.1	25.3	13.2	17.4	18.7	26.4	9.9	11.0	9.8	5.5	10.6	11.9	4.9	5.7	6.3	8.2	10.9	18.0	21.4	13.0	24.1	17.8	13.2	13.7	9.6	6.5	17.5	10.5	13.5	26.2	13.1	15.8	11.6	18.6	8.7	8.8	16.0	16.4	15.4	18.8	21.3	10.7	25.3	32.5	9.8	28.7	26.7	11.2	12.3	14.9	7.2	26.6	5.3	8.8	16.6	7.1	9.9	6.8	13.6	15.9	12.6	10.1	5.4	11.7	9.1	24.2	8.4	6.4	16.4	6.1	20.7	13.3	0.9	12.1	12.2	25.9	12.9	11.6	14.9	16.5	18.1	10.1	9.8	5.0	3.8	8.4	4.5	11.9	9.7	9.1	8.9	6.6	9.9	10.7	10.8	3.7	10.6	5.5	11.0	8.9	4.9	17.2	22.2	30.0	27.8	18.9	17.8	18.6	21.8	21.2	18.3	20.8	17.7	13.7	21.2	41.4	55.8	35.1	33.1	33.5	22.7	19.2	21.6	65.0	23.2	23.3	25.7	32.0	27.1	0.0	22.3	50.4	51.1	21.8	31.1	35.0	32.7	69.9	32.2	39.3	19.9	10.2	39.1	21.9	27.0	17.2	57.0	39.5	17.6	37.4	39.6	20.7	34.1	32.3	30.3	106.6	43.2	52.2	43.7	28.7	34.0	22.1
GPC3	"DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1"	ENSG00000147257	"Glypican 3"	P51654	X	133535745-133985895	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Protease inhibitor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"placenta: 262.7"	"Cell type enhanced"	"Detected in many"	10	"Fibroblasts: 127.3;Muller glia cells: 96.7;Syncytiotrophoblasts: 124.3"	"Cancer enhanced"	"Detected in all"		"liver cancer: 269.0"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	4	"naive CD4 T-cell: 5.0;naive CD8 T-cell: 3.5;NK-cell: 1.7"	"Group enriched"	"Detected in many"	12	"NK-cells: 1.7;T-cells: 5.0"	"Group enriched"	"Detected in some"	5	"HAP1: 54.2;Hep G2: 214.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA006316			Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"HPA006316: AB_1078994"	"unprognostic (2.06e-1)"	"unprognostic (2.36e-1)"	"unprognostic (9.51e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.46e-1)"	"unprognostic (6.10e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.07e-2)"	"unprognostic (3.92e-3)"	"unprognostic (6.06e-2)"	"unprognostic (1.71e-1)"	"unprognostic (3.81e-3)"	"prognostic unfavorable (4.83e-4)"	"unprognostic (1.43e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.60e-1)"	30.1	5.9	0.4	3.6	0.7	0.0	50.2	0.6	0.4	3.3	4.5	0.5	2.2	0.5	2.5	11.7	2.0	3.4	9.2	8.0	0.4	1.1	21.2	1.1	37.0	1.9	1.6	0.4	6.0	4.6	0.3	16.9	262.7	1.6	3.6	1.0	6.3	3.8	2.3	4.1	5.5	1.8	3.3	2.1	0.9	4.0	2.1	0.3	2.3	7.2	11.2	3.0	7.6	8.0	0.0	0.2	0.0	0.0	1.7	5.0	0.6	0.0	0.0	2.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.8	0.0	0.0	0.0	0.0	0.0	0.0	54.2	0.0	0.0	0.0	2.5	0.0	0.1	214.3	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.5	0.0	0.0	0.0	0.0	0.0	14.8	0.7	1.8	4.4	0.0	0.0	0.0	26.0	0.0	2.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.5	0.2	0.0	5.0	3.5	0.0	1.7	0.0	0.0	0.0	0.6	0.4	0.7	0.6	0.4	0.4	1.1	1.6	0.4	1.6	0.3	0.0	1.7	0.0	5.4	9.3	0.2	0.3	0.0	44.2	35.2	5.2	0.0	43.0	16.6	0.3	0.9	0.5	0.3	0.0	1.3	32.7	127.3	0.9	0.0	0.0	24.0	0.0	1.7	2.5	0.0	1.3	9.8	1.4	3.3	0.0	1.5	96.7	2.2	0.2	2.8	26.9	1.9	0.0	5.0	1.6	6.1	3.4	124.3	0.0	2.1	0.5
GPHN	KIAA1385	ENSG00000171723	Gephyrin	Q9NQX3	14	66507407-67181803	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Molybdenum cofactor biosynthesis"	"Multifunctional enzyme, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cone photoreceptor cells: 49.1;Hepatocytes: 42.9;Horizontal cells: 41.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003116, CAB004419, HPA024694"	Enhanced		Uncertain	"Cytoplasmic bodies"		NA	NA			"Cytoplasmic bodies"		"CAB004419: AB_627670, HPA003116: AB_1078963, HPA024694: AB_1849616"	"unprognostic (8.37e-2)"	"unprognostic (2.53e-2)"	"unprognostic (2.42e-1)"	"unprognostic (1.20e-1)"	"unprognostic (5.14e-2)"	"unprognostic (4.89e-3)"	"unprognostic (8.29e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.23e-1)"	"unprognostic (2.49e-2)"	"unprognostic (8.54e-2)"	"prognostic favorable (5.25e-12)"	"unprognostic (9.81e-2)"	"unprognostic (2.27e-1)"	"unprognostic (7.50e-2)"	"prognostic unfavorable (4.61e-5)"	13.0	12.4	26.1	10.9	31.1	5.2	17.1	40.9	31.2	11.0	18.2	9.3	15.6	11.1	12.3	20.8	8.6	7.5	8.2	11.9	26.4	22.9	34.5	49.0	14.1	7.3	18.3	11.5	7.2	22.9	17.4	24.5	5.8	13.9	11.1	13.2	7.4	10.8	21.3	23.4	10.7	10.8	11.6	16.4	5.6	13.5	7.8	16.2	3.1	12.2	10.0	6.8	7.4	15.1	3.1	3.0	0.5	2.5	2.3	6.2	1.5	22.2	4.4	7.8	8.5	9.2	7.8	5.0	6.3	3.1	6.5	6.5	1.3	10.0	0.0	1.1	3.1	3.3	7.9	7.8	12.3	8.6	6.8	8.4	6.6	6.3	13.6	4.8	3.7	9.8	6.7	7.3	1.8	7.2	2.7	7.5	8.3	4.5	8.4	3.6	11.9	6.5	13.9	3.3	16.8	10.1	0.0	15.0	6.4	10.5	4.4	13.8	5.4	4.3	18.9	6.9	2.2	10.1	6.4	2.8	6.5	14.5	6.4	6.5	11.2	4.8	0.1	5.1	0.5	6.3	0.0	1.3	0.5	3.9	2.5	6.2	2.4	4.9	2.9	1.9	3.1	3.5	3.3	0.0	2.3	1.9	3.0	5.3	1.5	26.1	31.1	40.9	27.0	26.4	22.9	18.3	11.5	13.9	16.2	6.0	9.6	5.4	8.3	4.1	33.5	10.9	7.6	1.4	13.6	1.8	49.1	2.8	11.6	4.1	2.5	9.0	5.1	0.0	4.7	2.1	4.1	6.7	0.0	42.9	3.1	41.3	5.8	19.0	7.6	3.6	10.3	2.7	1.7	0.0	11.9	10.4	2.9	7.0	5.3	14.9	34.2	0.0	6.2	10.9	8.9	5.1	1.7	4.9	8.9	6.0
GRIN2A	"GluN2A, NMDAR2A"	ENSG00000183454	"Glutamate ionotropic receptor NMDA type subunit 2A"	Q12879	16	9753404-10182754	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 25.2"	"Cell type enhanced"	"Detected in some"	9	"Cardiomyocytes: 14.9;Early spermatids: 13.4;Late spermatids: 13.0;Muller glia cells: 17.7;Rod photoreceptor cells: 12.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 7.8;hTERT-RPE1: 3.4;RPMI-8226: 2.9;U-138 MG: 8.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB022725	Enhanced					NA	NA					"CAB022725: "	"unprognostic (6.43e-2)"	"unprognostic (2.47e-1)"	"unprognostic (5.97e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.08e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.75e-3)"	"unprognostic (4.79e-3)"	"unprognostic (2.05e-1)"	"unprognostic (3.92e-3)"	"unprognostic (3.33e-2)"	0.9	1.0	5.4	0.5	5.9	0.4	0.6	8.5	25.2	0.6	0.7	1.5	0.0	0.9	0.8	4.5	2.1	4.1	0.5	4.0	8.0	1.9	0.9	0.4	1.0	0.5	1.7	10.3	0.5	0.6	0.4	0.3	0.4	1.4	0.5	0.7	1.4	0.7	1.0	0.5	1.2	0.7	0.9	1.2	0.4	1.1	5.2	0.8	0.0	0.8	0.0	0.7	0.6	0.5	0.6	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	1.9	0.6	1.4	0.0	0.1	0.0	0.0	7.8	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.3	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	8.5	0.8	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	5.4	5.9	8.5	17.9	8.0	1.9	1.7	10.3	1.4	0.8	0.0	0.0	0.0	1.9	1.6	3.6	14.9	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.6	13.4	0.1	0.0	0.0	0.2	0.0	0.2	0.4	0.0	0.0	0.1	1.6	0.0	0.0	0.0	13.0	0.9	0.0	0.0	0.0	0.0	17.7	1.2	0.0	0.0	0.0	12.1	0.0	4.2	3.2	3.8	0.4	0.0	0.0	0.0	0.3
H3F3A	"H3.3A, H3F3"	ENSG00000163041	"H3 histone family member 3A"	P84243	1	226061851-226072001	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 258.7"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 258.7"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 258.7"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011481, CAB037178, HPA042570"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB011481: AB_880446, CAB037178: AB_532248, HPA042570: AB_2678056"	"unprognostic (1.82e-1)"	"unprognostic (1.95e-2)"	"unprognostic (1.00e-1)"	"unprognostic (2.19e-3)"	"unprognostic (2.83e-2)"	"unprognostic (3.74e-1)"	"unprognostic (9.83e-3)"	"unprognostic (4.71e-2)"	"unprognostic (1.77e-3)"	"unprognostic (3.69e-2)"	"unprognostic (1.29e-1)"	"unprognostic (1.29e-1)"	"prognostic unfavorable (1.21e-6)"	"unprognostic (3.66e-2)"	"unprognostic (8.03e-3)"	"unprognostic (2.21e-3)"	"unprognostic (6.03e-2)"	39.0	43.4	37.2	83.4	33.4	126.8	67.9	45.0	42.8	44.6	54.0	31.6	62.9	47.9	43.4	60.6	66.3	42.4	49.6	59.4	36.1	31.2	45.9	59.2	73.2	217.9	37.8	23.2	44.4	79.7	30.8	34.8	59.1	29.2	38.4	59.4	42.7	49.0	49.7	37.0	47.1	50.0	42.0	48.6	71.9	41.4	87.6	31.7	148.9	38.5	71.0	84.1	43.5	47.6	39.2	44.6	258.7	56.9	23.6	34.9	60.5	53.9	30.8	120.2	67.8	33.4	38.9	90.3	25.6	31.1	41.6	32.9	32.1	90.0	51.9	56.9	31.4	20.7	51.8	59.4	46.6	40.9	32.1	102.6	64.2	45.6	42.9	33.1	65.9	78.0	35.6	54.0	29.1	38.3	56.4	61.5	67.9	90.4	88.9	47.3	31.2	136.8	122.6	163.0	137.1	61.1	92.6	87.8	133.8	86.0	57.7	117.4	174.5	73.0	92.4	63.2	71.8	104.7	154.7	34.6	30.3	42.3	40.9	74.1	39.6	50.7	90.7	28.9	63.0	64.7	40.0	56.9	80.8	23.1	44.9	23.6	39.2	25.0	24.9	44.6	36.0	23.7	25.7	258.7	23.6	50.8	36.6	34.9	60.5	37.2	33.4	45.0	42.8	36.1	31.2	37.8	23.2	29.2	31.7	485.3	628.9	1112.7	1421.3	1190.0	539.7	34.4	1036.9	1187.2	831.4	919.5	155.1	1193.7	1374.4	1195.9	1414.0	1038.4	1355.7	2359.5	1184.4	1689.1	947.0	1270.6	649.3	699.9	1338.0	554.6	1437.2	842.8	2198.6	1327.8	1016.5	1622.8	1010.6	1191.2	1707.9	908.2	1197.9	2104.2	985.0	1310.8	429.3	976.6	889.6	588.0	858.5	1210.5	1352.2	961.6	1983.9	1893.1
H3F3B	H3.3B	ENSG00000132475	"H3 histone family member 3B"	P84243	17	75776434-75785893	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 570.8;bone marrow: 441.9"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 570.8"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 570.8"	"Low cell line specificity"	"Detected in all"											"CAB037166, CAB037187, CAB037221, HPA042570"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB037166: AB_2115285, CAB037187: AB_477069, CAB037221: AB_477076, HPA042570: AB_2678056"	"unprognostic (1.66e-1)"	"unprognostic (8.42e-3)"	"unprognostic (3.42e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.41e-1)"	"unprognostic (2.43e-3)"	"unprognostic (3.37e-2)"	"unprognostic (1.64e-1)"	"unprognostic (5.88e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.26e-3)"	"unprognostic (9.20e-2)"	"unprognostic (4.81e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.99e-1)"	57.2	41.2	38.1	58.9	48.6	441.9	71.4	60.2	47.0	86.6	44.6	65.9	42.7	37.9	60.5	77.7	93.2	70.2	75.8	35.1	38.5	33.9	42.8	48.1	64.2	62.3	50.4	41.2	141.0	90.9	33.0	41.5	58.5	42.7	60.5	26.6	65.8	58.4	55.4	71.1	114.0	58.0	63.7	51.8	65.9	45.1	66.9	46.2	78.6	58.9	69.1	55.7	78.5	71.9	78.9	88.1	570.8	98.4	80.0	77.2	203.5	117.9	104.8	43.8	43.2	25.0	39.2	60.6	55.9	49.5	68.7	55.2	112.2	84.0	59.1	53.4	32.5	48.6	46.5	34.6	77.3	39.1	32.2	78.0	52.7	55.9	94.9	56.5	87.5	67.9	42.8	47.9	70.4	90.8	30.6	51.6	38.6	74.6	106.3	35.3	173.6	125.6	73.5	35.1	38.2	117.1	93.6	80.2	64.4	54.2	70.1	88.9	98.7	56.7	83.2	120.0	24.4	65.2	94.6	48.1	123.3	109.1	53.2	148.0	128.6	76.0	71.0	65.2	83.5	67.2	182.8	98.4	259.3	74.4	86.9	70.2	78.9	71.8	70.5	86.7	65.3	77.2	64.5	570.8	80.0	78.9	88.1	76.0	203.5	38.1	48.6	60.2	47.0	38.5	33.9	50.4	41.2	42.7	46.2	851.6	868.5	887.7	3350.2	2457.1	1722.8	361.5	690.4	1184.5	958.9	922.9	382.9	1428.6	1080.9	1926.0	2467.5	1156.8	1059.1	327.1	1563.3	1285.8	1898.2	1719.4	1592.3	352.8	1655.2	575.2	1610.5	672.8	901.1	452.7	934.0	1810.8	1808.5	1233.6	1221.5	2460.8	1745.6	1627.3	545.9	699.9	1161.2	983.1	2751.1	2035.3	943.0	3026.0	2929.8	1269.9	852.2	2611.9
HERPUD1	"HERP, KIAA0025, Mif1, SUP"	ENSG00000051108	"Homocysteine inducible ER protein with ubiquitin like domain 1"	Q15011	16	56932048-56944863	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Unfolded protein response"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Melanocytes: 899.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RPMI-8226: 78.5;U-266/70: 89.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB037041, CAB037104, HPA040754, HPA041219"	Approved		Uncertain	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB037041: AB_1840910, CAB037104: AB_1840912, HPA040754: AB_10794068, HPA041219: AB_10794268"	"unprognostic (1.92e-1)"	"unprognostic (3.47e-1)"	"unprognostic (8.64e-2)"	"unprognostic (3.93e-3)"	"unprognostic (3.39e-1)"	"unprognostic (5.00e-3)"	"unprognostic (1.17e-1)"	"unprognostic (9.69e-3)"	"unprognostic (3.33e-1)"	"unprognostic (2.56e-1)"	"unprognostic (2.84e-1)"	"unprognostic (3.50e-1)"	"prognostic favorable (1.41e-9)"	"unprognostic (1.06e-1)"	"unprognostic (3.93e-2)"	"unprognostic (2.19e-2)"	"unprognostic (2.27e-3)"	22.7	38.8	16.2	35.6	20.7	21.6	39.4	17.7	20.0	30.1	32.1	20.0	48.8	21.4	21.6	51.6	15.0	20.2	32.5	28.8	15.8	15.5	42.9	57.7	30.4	40.0	25.6	12.5	44.8	148.6	37.6	26.7	26.2	25.6	49.5	32.3	35.3	108.6	76.1	34.6	18.3	24.7	17.6	24.2	38.3	37.2	10.6	20.8	9.6	64.2	20.4	53.8	24.4	25.9	50.8	121.9	29.0	39.5	22.4	33.4	46.5	4.5	5.0	4.9	10.2	11.4	15.0	17.6	10.8	17.2	14.0	11.0	6.9	10.4	18.5	13.9	10.5	14.3	7.9	8.3	3.8	13.9	10.7	5.0	1.6	8.3	25.0	62.5	3.3	8.3	18.1	36.5	6.3	20.2	16.9	10.6	20.7	2.5	26.5	39.0	3.8	6.2	6.8	3.1	26.5	11.4	4.3	12.5	78.5	30.0	5.1	5.4	6.3	9.4	46.4	47.9	7.3	5.2	12.5	6.5	5.8	5.8	5.1	4.3	89.5	29.1	28.9	8.3	4.6	7.6	23.9	39.5	18.0	16.1	31.0	17.4	50.8	17.5	21.1	30.6	37.8	11.4	17.4	29.0	22.4	21.5	121.9	33.4	46.5	16.2	20.7	17.7	20.0	15.8	15.5	25.6	12.5	25.6	20.8	65.5	113.2	400.7	628.3	323.4	125.0	136.3	71.4	44.2	47.8	68.0	265.1	118.1	144.2	165.3	52.0	119.9	168.3	70.0	173.1	150.4	186.1	478.3	152.0	140.9	178.2	44.5	416.3	118.4	182.3	185.2	96.4	276.3	899.3	227.2	208.8	76.2	141.3	182.4	89.8	157.6	103.7	97.0	210.0	43.1	8.9	223.2	580.2	183.3	123.2	295.1
HEY1	"bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1"	ENSG00000164683	"Hes related family bHLH transcription factor with YRPW motif 1"	Q9Y5J3	8	79764010-79767863	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Notch signaling pathway, Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 60.6"	"Cell type enhanced"	"Detected in many"	6	"Endothelial cells: 39.4;Extravillous trophoblasts: 39.7;Intestinal endocrine cells: 35.4;Melanocytes: 32.1"	"Cancer enhanced"	"Detected in all"		"glioma: 43.1"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	6	"neutrophil: 9.9"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 9.9"	"Cell line enhanced"	"Detected in many"		"HEK 293: 49.4;PC-3: 11.2;SK-MEL-30: 33.8;WM-115: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055599, HPA063472"	Enhanced		Supported	"Nucleoplasm,Nuclear membrane,Cytosol"		NA	NA			"Nucleoplasm, Nuclear membrane, Cytosol"		"HPA055599: AB_2682858, HPA063472: AB_2685018"	"unprognostic (1.15e-1)"	"unprognostic (5.06e-2)"	"unprognostic (5.13e-3)"	"unprognostic (2.12e-1)"	"unprognostic (1.86e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.21e-3)"	"unprognostic (9.56e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.22e-2)"	"unprognostic (1.25e-2)"	"unprognostic (6.71e-3)"	"unprognostic (5.92e-3)"	"unprognostic (5.77e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.74e-2)"	"unprognostic (1.00e-1)"	13.3	3.8	13.7	3.6	22.9	1.8	8.8	11.2	60.6	8.9	4.4	10.7	0.0	3.3	3.8	2.4	4.6	3.9	5.7	13.4	11.3	11.6	3.8	2.9	16.4	3.3	11.9	9.3	2.6	4.3	3.0	9.9	20.3	12.5	4.5	3.9	10.3	4.5	3.0	10.3	3.5	3.2	4.4	9.1	2.8	3.6	3.9	10.5	1.3	5.0	3.7	3.7	5.2	2.5	0.0	0.0	9.9	1.7	0.0	0.3	0.1	0.6	0.0	0.4	3.5	0.3	0.3	9.0	0.8	0.8	0.1	0.1	0.1	0.0	1.6	0.9	0.3	0.4	2.2	1.8	0.1	0.2	0.1	49.4	0.0	1.6	0.9	0.5	0.0	0.4	0.5	1.4	0.0	6.2	0.3	1.6	0.0	3.2	1.4	0.5	0.1	0.0	0.2	0.2	0.1	11.2	0.0	1.9	1.4	0.1	1.5	2.0	5.7	0.0	1.0	33.8	8.4	0.0	0.0	1.1	0.2	0.9	0.0	0.6	1.2	0.2	0.0	1.2	0.0	11.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	9.9	0.0	1.7	0.0	0.0	0.1	13.7	22.9	11.2	12.3	11.3	11.6	11.9	9.3	12.5	10.5	0.0	2.6	0.0	2.2	2.9	5.3	3.2	0.0	8.1	3.4	0.0	0.0	5.4	13.3	2.1	3.3	39.4	0.9	0.0	1.0	39.7	2.7	1.6	10.4	0.5	1.6	20.6	35.4	13.5	0.6	1.6	0.0	2.1	32.1	0.0	1.9	6.0	0.5	5.8	0.4	0.3	11.5	0.0	6.1	0.7	4.1	2.6	19.6	0.0	2.3	1.8
HIF1A	"bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8"	ENSG00000100644	"Hypoxia inducible factor 1 alpha subunit"	Q16665	14	61695513-61748259	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 47.8"	"Lineage enriched"	"Detected in all"	6	"granulocytes: 47.8"	"Cell line enhanced"	"Detected in many"		"LHCN-M2: 119.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000907, HPA001275, CAB017442"	Approved		Enhanced	"Nucleoplasm,Nuclear bodies,Plasma membrane"		NA	NA			"Nucleoplasm, Nuclear bodies"	"Plasma membrane"	"CAB017442: AB_10621732, HPA000907: AB_2666139, HPA001275: AB_1079057"	"unprognostic (1.07e-2)"	"unprognostic (1.13e-3)"	"unprognostic (9.41e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.51e-2)"	"unprognostic (1.90e-1)"	"unprognostic (2.94e-3)"	"unprognostic (3.40e-1)"	"unprognostic (4.05e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.77e-2)"	"unprognostic (8.39e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.23e-2)"	"unprognostic (3.58e-1)"	"unprognostic (7.35e-2)"	"unprognostic (3.88e-2)"	31.9	62.0	15.6	45.2	17.8	125.2	24.9	22.7	18.5	45.7	15.3	12.3	23.5	10.8	17.7	31.3	31.2	21.7	50.0	19.4	17.5	16.5	76.4	42.7	42.8	27.3	18.3	11.0	34.5	12.7	13.7	26.8	24.2	25.1	17.6	13.9	14.0	24.6	36.2	8.0	17.4	16.9	18.7	27.2	57.3	16.0	21.1	12.4	24.7	26.9	18.4	28.8	37.8	21.5	6.6	6.0	47.8	6.8	6.2	7.9	5.1	38.0	15.2	15.3	43.7	24.3	39.2	20.7	31.7	38.2	39.9	36.0	6.6	12.6	9.3	23.9	39.1	11.4	9.0	9.8	52.0	50.0	4.0	5.1	5.7	14.0	11.4	54.2	2.4	6.2	68.3	16.5	29.3	31.4	53.9	25.1	5.4	3.8	0.0	119.1	7.9	7.4	2.9	13.8	6.0	20.1	0.5	34.3	2.7	51.5	25.3	12.9	14.3	59.4	8.5	20.9	21.8	8.9	4.5	14.9	90.7	20.3	30.0	26.6	5.0	7.2	10.6	47.8	4.7	24.5	11.2	6.8	47.8	3.8	5.5	4.9	6.5	5.0	4.4	6.0	6.6	7.9	5.1	18.2	6.2	5.6	2.9	3.4	5.1	15.6	17.8	22.7	13.2	17.5	16.5	18.3	11.0	25.1	12.4	65.5	115.1	54.6	71.5	94.4	49.4	37.3	86.6	33.5	69.4	247.7	47.1	22.6	87.9	226.7	3.1	113.7	30.7	0.0	216.2	57.6	82.5	54.8	217.2	23.7	123.2	147.8	63.8	177.4	143.9	3.6	22.5	156.8	97.8	76.7	36.5	141.2	213.6	23.0	45.6	116.2	52.0	51.8	129.7	27.4	24.9	76.9	21.3	60.6	34.8	75.6
HIP1	ILWEQ	ENSG00000127946	"Huntingtin interacting protein 1"	O00291	7	75533300-75738962	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Differentiation, Endocytosis, Transcription, Transcription regulation"	"Actin-binding, Activator"	"Cancer-related genes, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"Late spermatids: 1171.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 27.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013606, CAB015334, CAB016402, HPA017964"	Enhanced		Supported	Vesicles		NA	NA			Vesicles		"CAB015334: AB_2117565, CAB016402: AB_627725, HPA013606: AB_1850717, HPA017964: AB_1850719"	"unprognostic (8.23e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.20e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.59e-1)"	"unprognostic (2.73e-3)"	"unprognostic (1.03e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.02e-2)"	"unprognostic (2.70e-2)"	"unprognostic (7.98e-2)"	"unprognostic (1.73e-3)"	"unprognostic (9.67e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.00e-2)"	"unprognostic (1.09e-1)"	16.5	8.7	14.6	7.2	25.9	5.1	13.5	13.2	20.8	13.2	5.3	34.4	4.9	2.9	13.4	10.1	5.7	13.8	8.7	9.2	17.5	11.9	14.6	9.6	17.7	4.6	27.2	11.8	8.1	4.0	4.9	3.6	20.0	16.1	6.8	4.5	9.9	4.0	12.4	3.9	10.8	4.6	12.6	24.8	10.8	4.6	18.5	29.7	1.6	15.8	5.7	4.6	9.7	8.8	0.5	4.0	8.8	1.1	3.3	1.5	0.3	2.5	27.3	18.6	17.5	7.9	10.7	5.6	4.8	3.1	3.1	2.3	1.5	2.4	1.8	5.6	11.8	10.9	3.1	18.8	3.9	4.2	1.5	3.5	1.4	3.2	2.5	7.8	0.4	7.4	8.2	2.4	10.2	2.1	5.8	13.0	2.0	1.9	1.8	5.0	10.4	1.2	10.6	20.2	0.2	3.3	2.1	7.8	0.1	2.4	9.7	0.9	8.2	4.4	2.8	6.3	17.3	17.2	6.7	4.6	9.2	7.1	3.1	6.6	2.0	0.2	4.4	9.2	3.9	6.2	8.8	1.1	7.6	1.1	1.1	1.0	0.4	0.2	0.9	1.6	0.5	0.1	0.7	7.7	3.3	0.8	4.0	1.5	0.3	14.6	25.9	13.2	16.9	17.5	11.9	27.2	11.8	16.1	29.7	56.6	35.7	6.0	6.3	15.7	7.1	12.5	5.1	0.0	17.0	26.2	11.8	1.3	11.6	10.2	240.8	40.7	0.7	0.0	5.3	7.5	15.4	4.0	13.9	20.2	11.7	22.3	4.6	30.1	15.1	1171.7	20.8	22.9	10.1	1.0	1.4	18.6	2.6	8.5	23.3	2.2	8.2	84.1	37.2	9.3	4.1	8.0	0.7	17.0	2.6	3.1
HIST1H3B	"H3/l, H3FL"	ENSG00000274267	"Histone cluster 1 H3 family member b"	P68431	6	26031650-26032060	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	13	"lymphoid tissue: 343.5"	"Cell type enriched"	"Detected in some"	5	"Spermatogonia: 5.1"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in some"		"T-reg: 1.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-266/84: 12.0"									HPA042570	Approved					NA	NA					"HPA042570: AB_2678056"	"unprognostic (2.82e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.59e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.34e-2)"	"unprognostic (2.31e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.08e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.31e-7)"	"unprognostic (8.52e-2)"	"unprognostic (2.78e-1)"		"unprognostic (1.90e-3)"	1.7	0.7	0.0	36.1	0.0	18.1	3.6	0.0	0.3	0.8	6.9	0.0	0.0	0.3	0.8	2.5	11.8	0.5	1.9	2.4	0.0		0.6	0.3	3.4	10.4	0.0	0.0	0.3	0.3	0.3	0.0	7.8	0.0	0.3	0.8	0.0	1.0	0.3	0.3	0.3	6.3	0.8	0.0	14.7	0.5	26.9	0.0	343.5	0.8	18.2	27.7	0.3	0.0	0.8	0.1	1.2	0.0	0.0	1.4	3.1	1.8	4.6	1.3	4.0	0.0	0.4	0.0	0.2	0.8	0.8	0.7	1.1	1.0	3.0	2.0	0.3	1.2	0.7	1.6	1.2	1.7	2.0	4.4	3.2	6.0	1.3	0.0	2.4	2.1	2.9	0.0	0.6	0.0	0.1	1.0	0.9	6.5	5.9	1.1	1.0	7.4	7.4	3.1	0.7	3.2	4.3	2.9	8.5	0.5	0.0	2.1	1.7	5.1	1.6	0.5	0.1	2.8	1.5	1.4	1.4	4.1	0.7	1.7	9.6	12.0	3.9	3.4	4.6	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.8	0.1	0.5	0.0	0.2	1.2	0.0	0.0	0.0	1.4	3.1											0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.1	0.1	0.2	0.0	0.6	0.1
HIST1H4I	"H4/m, H4FM"	ENSG00000276180	"Histone cluster 1 H4 family member i"	P62805	6	27138588-27139881	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 14.5"	"Cell type enhanced"	"Detected in some"	11	"Alveolar cells type 2: 1.1;Cardiomyocytes: 1.8;Early spermatids: 2.7;Enterocytes: 1.3"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"K-562: 29.8;SiHa: 17.9;U-2 OS: 30.7;U-266/84: 31.0"									HPA042201	Approved					NA	NA		30000000			"HPA042201: AB_2677898"	"unprognostic (2.49e-2)"	"prognostic favorable (9.70e-4)"	"unprognostic (1.97e-2)"	"unprognostic (2.51e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.16e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.29e-3)"	"unprognostic (1.86e-3)"	"unprognostic (1.95e-1)"	"prognostic unfavorable (1.32e-5)"	"unprognostic (6.28e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.80e-1)"	"unprognostic (2.02e-2)"	0.1	2.5		2.4		1.7	0.0		0.1	0.0	0.8			2.7	1.1	0.0	1.7	0.0	1.3	0.5			0.0	1.9	0.8	2.6			0.8	2.7	0.0		1.5		2.0	0.0		1.6	0.0	0.0	0.2	2.9	0.0		2.3	3.2	1.8			2.6		0.0	1.9		6.0	5.5	14.5	4.6	2.4	3.4	3.1	1.7	3.5	1.9	1.2	1.3	0.1	2.1	3.3	0.1	0.1	0.1	3.3	2.5	0.5	9.6	0.0	5.3	2.6	0.3	0.1	0.0	2.3	5.1	1.2	5.6	0.1	0.2	1.0	6.2	0.4	0.1	0.0	0.1	3.3	0.1	1.2	29.8	9.2	0.0	5.1	1.5	2.2	0.7	12.3	2.2	1.3	1.1	8.4	0.1	0.9	6.5	2.3	17.9	8.3	1.9	2.3	15.8	0.7	1.1	2.4	30.7	2.8	0.3	9.3	31.0	5.8	1.4	6.7	2.4	9.2	2.6	14.1	1.5	2.0	1.3	4.6	1.3	1.4	2.5	6.0	1.6	1.7	14.5	2.4	4.6	5.5	3.4	3.1											0.0	1.1	0.8	0.2	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.7	0.0	1.3	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.4	0.8	0.1	0.3	0.0	0.6	0.0
HLA-A		ENSG00000206503	"Major histocompatibility complex, class I, A"	"P04439, P13746, P16188"	6	29941260-29945884	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"monocytes: 4504.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"A-431: 158.0;fHDF/TERT166: 42.3;HBEC3-KT: 43.4;RPMI-8226: 41.2;U-266/70: 42.1"									CAB078470			Supported	"Golgi apparatus,Plasma membrane"		NA	NA			"Plasma membrane"	"Golgi apparatus"	"CAB078470: AB_10985125"	"unprognostic (1.56e-2)"	"unprognostic (9.14e-2)"	"unprognostic (1.34e-2)"	"prognostic favorable (9.59e-4)"	"unprognostic (3.49e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.12e-1)"	"unprognostic (7.28e-2)"	"unprognostic (3.42e-2)"	"prognostic favorable (6.47e-4)"	"unprognostic (2.96e-1)"	"unprognostic (3.24e-1)"	"unprognostic (1.84e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.32e-2)"	"unprognostic (1.20e-2)"	"unprognostic (1.54e-2)"	69.4	57.5	16.0	69.1	18.2	41.2	40.8	9.1	20.7	54.4	92.6	20.4	28.6	105.7	38.4	76.2	48.4	27.8	92.3	59.1	14.6	16.6	80.5	47.6	112.0	90.5	19.5	8.9	57.2	30.0	22.5	33.3	38.7	22.7	64.1	38.5	52.4	28.3	19.2	44.0	110.4	129.4	30.3	22.8	150.0	115.9	26.6	12.3	71.1	62.3	38.5	97.7	86.4	41.0	23.0	10.9	65.8	25.2	25.9	46.7	45.4	158.0	4.0	0.0	0.0	25.5	24.1	0.1	0.1	0.3	0.2	0.3	0.0	0.0	0.4	0.0	42.3	21.5	3.9	0.0	43.4	0.0	0.3	1.6	27.6	1.2	0.8	1.4	0.0	1.8	0.2	0.0	0.3	0.1	0.0	0.0	21.2	0.0	0.1	0.0	0.0	0.1	2.5	0.3	0.0	0.4	3.3	0.3	41.2	29.6	32.5	0.0	1.4	3.5	0.0	1.4	10.4	0.2	3.7	0.6	2.4	0.1	0.7	0.5	42.1	10.7	8.9	0.0	23.3	0.0	65.8	25.2	35.4	38.3	17.9	28.8	23.0	29.6	34.4	4.1	14.9	21.7	29.7	47.9	25.9	19.8	10.9	46.7	45.4	16.0	18.2	9.1	20.7	14.6	16.6	19.5	8.9	22.7	12.3	345.4	508.3	1064.2	718.5	760.7	31.3	128.4	937.6	317.2	366.3	478.1	5.9	16.7	74.6	2692.4	38.8	1227.5	2851.3	186.9	1168.0	15.8	685.4	823.3	585.8	217.5	1814.8	35.0	917.5	1170.5	1323.9	66.9	652.4	1239.0	602.3	4504.1	1496.2	150.9	1505.1	2283.0	455.0	258.2	20.0	549.7	859.0	132.4	24.5	828.4	26.5	2218.3	1070.6	1059.3
HLF	MGC33822	ENSG00000108924	"HLF, PAR bZIP transcription factor"	Q16534	17	55265012-55325065	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in all"		"liver: 78.8"	"Cell type enhanced"	"Detected in many"	10	"Bipolar cells: 122.6;Hepatocytes: 152.5;Horizontal cells: 87.4"	"Cancer enhanced"	"Detected in many"		"liver cancer: 13.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	7	"memory CD4 T-cell: 2.4;T-reg: 2.1"	"Lineage enriched"	"Detected in single"	25	"T-cells: 2.4"	"Cell line enriched"	"Detected in some"	6	"Hep G2: 60.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA068156, HPA071210"			Enhanced	Nucleoplasm		Yes	NA			Nucleoplasm		"HPA068156: AB_2685963, HPA071210: AB_2686361"	"unprognostic (1.24e-1)"	"unprognostic (1.19e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.30e-1)"	"prognostic favorable (1.88e-4)"	"unprognostic (5.30e-3)"	"prognostic favorable (2.71e-7)"	"unprognostic (1.42e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.24e-3)"	"unprognostic (2.19e-1)"	"prognostic favorable (3.55e-6)"	"unprognostic (8.47e-2)"	"unprognostic (1.64e-1)"	"unprognostic (6.85e-2)"	"unprognostic (1.60e-2)"	9.5	15.2	13.3	2.0	26.2	1.0	10.8	15.2	38.0	10.5	10.6	6.4	2.4	1.7	10.3	8.5	18.1	9.3	6.1	15.9	12.6	6.9	9.2	78.8	9.5	2.1	6.6	24.5	34.6	2.7	2.8	8.0	1.5	12.3	9.9	3.1	23.7	15.9	9.5	5.3	11.6	3.0	14.3	5.5	5.7	4.7	3.4	6.3	0.0	23.4	7.1	5.6	9.2	5.2	0.0	0.0	0.0	0.0	0.0	2.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.2	0.0	0.0	0.0	0.1	0.0	0.0	10.0	0.2	0.0	0.0	60.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.5	0.0	0.2	0.0	0.2	0.4	0.0	0.0	0.0	0.9	0.0	0.1	0.1	5.0	0.0	4.2	0.2	0.0	2.7	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.2	0.1	1.9	1.7	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.1	0.1	13.3	26.2	15.2	38.0	12.6	6.9	6.6	24.5	12.3	6.3	3.0	36.8	0.0	4.7	19.8	122.6	31.9	15.3	1.4	11.4	7.0	9.8	0.1	10.0	1.5	0.9	8.6	0.0	0.0	0.8	0.0	6.0	1.2	0.0	152.5	0.1	87.4	2.9	4.9	4.1	2.7	26.2	1.0	10.1	0.0	0.1	54.5	0.3	0.0	36.7	18.9	13.0	12.9	6.2	0.3	2.7	24.1	1.0	2.2	0.0	0.5
HMGA1	HMGIY	ENSG00000137309	"High mobility group AT-hook 1"	P17096	6	34236873-34246231	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 107.3"	"Cell type enhanced"	"Detected in many"	6	"Cytotrophoblasts: 784.6;Pancreatic endocrine cells: 1097.2;Urothelial cells: 1250.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"											"CAB032200, HPA065612, HPA068442"	Enhanced		Approved	Nucleoplasm,Nucleoli		NA	NA		18000	Nucleoplasm	Nucleoli	"CAB032200: AB_2117771, HPA065612: , HPA068442: "	"unprognostic (1.81e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavorable (7.13e-4)"	"unprognostic (1.57e-1)"	"unprognostic (1.20e-3)"	"prognostic unfavorable (1.29e-6)"	"prognostic unfavorable (3.36e-4)"	"unprognostic (8.54e-2)"	"unprognostic (1.84e-2)"	"prognostic unfavorable (8.71e-4)"	"unprognostic (1.55e-1)"	"unprognostic (8.22e-2)"	"unprognostic (4.52e-3)"	"unprognostic (1.19e-1)"	"unprognostic (4.37e-1)"	"unprognostic (2.65e-2)"	15.8	3.5	14.8	35.7	13.5	55.4	13.0	13.8	19.0	26.1	22.0	5.9	7.7	42.3	8.6	7.2	79.4	15.1	17.8	13.0	11.7	12.6	14.6	6.9	16.0	46.1	10.7	8.7	3.9	13.0	4.1	5.1	31.8	12.5	8.7	21.2	9.9	22.0	6.9	33.7	38.3	36.0	3.8	8.4	31.6	24.2	32.6	7.2	107.3	12.5	39.6	72.7	13.0	29.6	26.6	33.4	12.8	10.1	7.3	22.4	11.0	121.6	48.2	24.7	17.2	11.5	85.4	108.0	49.2	56.3	38.2	21.3	31.5	85.4	57.4	24.8	20.1	24.0	26.1	29.1	87.7	30.4	12.5	19.5	17.6	16.2	42.1	24.4	62.8	20.3	36.6	9.8	69.1	36.1	98.7	115.2	32.8	70.8	2.9	53.1	12.3	54.4	77.4	120.4	60.7	81.6	80.9	0.5	63.3	25.8	11.2	43.2	18.3	5.2	25.0	45.4	40.8	10.0	67.4	99.8	19.9	62.8	28.9	46.0	23.6	36.5	74.1	42.1	26.2	99.3	6.2	10.1	12.8	10.2	10.1	13.3	26.6	18.7	16.0	30.7	16.4	22.4	17.7	2.6	7.3	9.4	33.4	21.0	11.0	14.8	13.5	13.8	19.0	11.7	12.6	10.7	8.7	12.5	7.2	26.8	23.7	124.5	686.8	384.1	27.4	24.5	38.2	10.7	36.4	38.4	3.9	784.6	39.7	243.5	6.1	27.0	148.7	46.7	242.2	663.0	71.9	750.7	66.8	10.6	337.7	11.1	112.2	16.0	59.4	17.5	5.2	107.5	86.0	66.7	165.5	27.9	1097.2	162.4	2.5	9.0	27.8	0.0	34.9	38.5	398.0	315.9	688.1	51.7	282.8	1250.0
HMGA2	"BABL, HMGIC, LIPO"	ENSG00000149948	"High mobility group AT-hook 2"	P52926	12	65824131-65966295	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Cell cycle, Cell division, DNA condensation, Growth regulation, Mitosis, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"testis: 25.3"	"Cell type enhanced"	"Detected in some"	10	"Early spermatids: 15.7;Hofbauer cells: 6.8;Late spermatids: 6.8;Pancreatic endocrine cells: 11.8;Undifferentiated cells: 8.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AF22: 63.0;hTERT-RPE1: 46.0;SuSa: 44.3"	"Not detected"	"Not detected"							"CAB017809, HPA039076"	Approved		Supported	"Nucleoplasm,Nucleoli,Nucleoli rim"		NA	NA			"Nucleoplasm, Nucleoli, Nucleoli rim"		"CAB017809: , HPA039076: AB_2676335"	"unprognostic (2.39e-1)"	"unprognostic (6.00e-2)"	"unprognostic (2.08e-1)"	"unprognostic (3.68e-3)"	"unprognostic (5.21e-3)"	"prognostic unfavorable (4.79e-4)"	"unprognostic (4.05e-3)"	"unprognostic (6.17e-3)"	"unprognostic (6.71e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.54e-6)"	"unprognostic (3.33e-2)"	"unprognostic (4.55e-5)"	"unprognostic (4.22e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.53e-2)"	"prognostic unfavorable (2.86e-4)"	6.5	0.3	0.5	3.8	0.8	8.1	2.1	0.2	0.6	2.5	7.6	0.4	0.0	2.4	2.7	0.1	1.1	2.4	3.3	0.5	0.3	0.4	1.0	0.4	0.5	0.1	0.3	1.3	2.1	1.7	0.0	1.7	0.3	0.6	0.5	4.6	0.4	0.5	1.8	2.0	0.7	5.1	0.7	1.7	0.8	2.1	25.3	0.0	0.8	1.1	3.0	0.1	0.8	2.8	0.7	0.3	3.8	2.1	1.3	0.7	0.1	9.1	4.0	63.0	9.0	3.0	16.5	0.0	29.1	13.3	5.1	5.1	5.2	3.9	0.0	18.9	1.3	24.0	4.0	10.4	25.1	24.5	0.0	10.9	0.0	0.1	31.5	1.7	0.8	0.1	12.5	1.5	11.0	19.8	46.0	20.1	0.0	0.0	0.1	29.1	0.0	0.0	5.1	36.9	0.8	18.1	2.4	3.1	0.0	13.6	0.0	0.0	0.0	0.0	0.0	16.0	44.3	0.1	0.1	23.5	18.5	5.5	14.1	8.7	0.0	0.0	0.0	22.4	0.0	4.2	3.8	1.0	0.7	0.5	0.6	0.3	0.3	0.4	0.5	0.2	0.7	0.4	0.7	2.5	1.3	2.1	0.3	0.3	0.1	0.5	0.8	0.2	0.6	0.3	0.4	0.3	1.3	0.6	0.0	0.0	1.4	0.0	2.2	0.0	0.0	1.2	0.0	4.0	0.0	0.0	0.0	0.8	0.0	3.0	15.7	0.1	3.3	0.0	0.7	0.3	0.9	0.4	0.0	0.0	6.8	0.0	0.0	0.6	0.0	6.8	0.3	0.0	0.0	0.0	4.7	0.0	11.8	3.5	0.0	0.0	0.0	0.0	0.8	0.5	0.2	0.1	0.7	0.0	8.5	0.9
HNF1A	"HNF1, LFB1, MODY3, TCF1"	ENSG00000135100	"HNF1 homeobox A"		12	120978543-121002512	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Tissue enhanced"	"Detected in some"		"intestine: 24.2;kidney: 17.2;liver: 15.6"	"Cell type enhanced"	"Detected in some"	8	"Enterocytes: 16.0;Hepatocytes: 13.9;Paneth cells: 14.4;Proximal tubular cells: 13.2;Undifferentiated cells: 8.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	6	"A549: 6.2;CACO-2: 20.5;Hep G2: 22.4;OE19: 10.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB010430, HPA035231"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB010430: AB_2116746, HPA035231: AB_2674528"	"unprognostic (5.92e-3)"	"unprognostic (8.47e-2)"	"unprognostic (4.12e-3)"	"unprognostic (6.18e-3)"	"unprognostic (3.72e-1)"	"unprognostic (1.27e-2)"	"unprognostic (9.18e-2)"	"unprognostic (9.18e-2)"	"unprognostic (2.99e-1)"	"unprognostic (2.01e-1)"	"unprognostic (9.77e-3)"	"unprognostic (5.21e-2)"	"unprognostic (6.25e-3)"	"unprognostic (5.55e-2)"	"unprognostic (2.48e-1)"		"unprognostic (6.93e-3)"	0.1	0.0	0.1	0.8	0.1	0.0	0.1	0.1	0.1	0.1	17.3	0.1	0.1	13.7	0.1	1.5	0.1	0.8	5.1	0.1	0.1	0.0	17.2	15.6	0.1	0.1	0.1	0.1	0.2	6.3	0.0	0.1	0.1	0.1	0.1	2.1	0.1	0.1	0.1	0.1	0.0	24.2	0.5	0.1	0.1	3.6	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.5	0.5	1.8	0.3	0.3	0.4	0.2	0.0	6.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	20.5	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.7	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.3	0.2	0.2	0.3	0.2	0.3	0.4	0.4	0.1	0.5	0.4	0.4	1.6	0.3	0.3	0.5	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.5	0.1	0.6	0.8	2.5	0.0	0.0	1.8	0.0	0.0	0.0	2.3	0.0	0.0	16.0	0.0	4.6	0.1	0.0	0.4	0.0	13.9	0.1	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	1.0	6.7	0.5	3.2	14.4	0.0	13.2	0.2	0.0	0.1	0.1	0.0	0.3	0.0	0.0	8.9	0.2
HNRNPA2B1	HNRPA2B1	ENSG00000122566	"Heterogeneous nuclear ribonucleoprotein A2/B1"	P22626	7	26189927-26201529	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, mRNA processing, mRNA splicing, mRNA transport, Transport"	"Ribonucleoprotein, RNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001666, HPA005812, CAB012403, HPA065537"	Supported		Enhanced	Nucleoplasm	"Intracellular and membrane"	NA	NA		11000000	Nucleoplasm		"CAB012403: , HPA001666: AB_1850836, HPA005812: AB_2667441, HPA065537: AB_2685507"	"unprognostic (1.19e-1)"	"unprognostic (4.45e-1)"	"unprognostic (2.33e-1)"	"unprognostic (6.39e-2)"	"unprognostic (5.64e-2)"	"unprognostic (8.04e-3)"	"prognostic unfavorable (1.03e-6)"	"unprognostic (1.25e-2)"	"unprognostic (9.12e-3)"	"unprognostic (4.35e-3)"	"unprognostic (1.31e-1)"	"prognostic unfavorable (5.12e-4)"	"prognostic unfavorable (8.01e-5)"	"unprognostic (6.74e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.56e-2)"	82.2	97.4	85.1	105.3	106.3	90.9	74.4	123.3	87.4	77.1	85.7	89.4	68.7	87.5	92.6	71.9	90.4	75.1	51.7	87.9	82.4	71.8	113.4	103.7	76.2	127.7	118.6	57.0	121.0	75.7	107.2	121.2	100.7	96.3	75.5	98.6	64.4	71.4	66.5	167.2	58.7	94.8	73.7	139.7	116.5	74.1	73.1	135.4	180.3	81.9	104.4	140.7	74.2	128.8	33.7	46.5	35.1	52.4	32.1	42.5	36.0	124.0	105.9	154.2	115.6	39.7	36.3	71.4	79.6	62.1	88.0	79.7	97.8	90.4	226.9	76.1	73.8	105.0	86.6	164.9	104.0	124.0	70.5	100.5	137.5	127.8	116.9	33.3	148.0	94.2	34.3	54.5	83.7	76.4	46.4	90.8	104.9	161.7	74.2	88.8	100.4	158.3	173.1	136.6	95.1	81.7	147.2	125.3	95.0	101.6	108.6	90.1	110.5	95.7	94.3	58.1	98.3	105.7	128.9	78.4	49.5	102.5	67.0	135.8	98.6	195.4	215.9	63.8	168.7	93.2	17.4	38.7	35.1	42.5	52.4	38.6	33.7	35.5	36.6	46.5	29.2	35.6	35.6	13.0	32.1	48.4	43.6	36.1	36.0	85.1	106.3	123.3	87.4	82.4	71.8	118.6	57.0	96.3	135.4	452.6	512.0	456.4	620.8	656.0	459.5	635.5	267.5	721.4	702.9	326.2	280.8	790.3	391.3	484.7	96.5	561.1	396.4	280.4	392.8	789.3	528.7	417.7	617.9	353.4	530.6	295.6	471.8	332.7	355.7	124.0	380.5	569.8	372.8	501.4	392.2	570.4	369.1	357.7	366.7	366.6	518.1	433.4	564.3	596.8	448.9	524.9	905.5	489.7	465.4	566.2
HOOK3	HK3	ENSG00000168172	"Hook microtubule tethering protein 3"	Q86VS8	8	42896932-43030539	"Cancer-related genes, Predicted intracellular proteins"	"Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA024756	Approved		Supported	"Golgi apparatus,Centriolar satellite,Cytosol"		NA	NA			"Centriolar satellite"	"Golgi apparatus, Cytosol"	"HPA024756: AB_1850913"	"unprognostic (1.84e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.73e-1)"	"unprognostic (8.61e-3)"	"unprognostic (6.05e-2)"	"unprognostic (1.77e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.78e-1)"	"unprognostic (3.97e-2)"	"unprognostic (1.13e-1)"	"unprognostic (4.13e-1)"	"prognostic unfavorable (1.32e-4)"	"unprognostic (1.63e-1)"	"unprognostic (3.78e-1)"	"unprognostic (2.55e-1)"	"unprognostic (7.12e-2)"	15.5	9.3	11.3	10.1	15.1	13.1	16.3	16.0	19.2	13.5	11.3	10.3	14.1	10.2	13.7	12.0	14.8	11.7	20.0	9.5	11.2	11.3	9.9	10.7	14.6	10.3	14.7	11.7	13.4	13.9	13.4	14.4	12.0	13.1	17.7	10.9	6.8	17.1	15.2	24.1	11.0	11.9	19.3	17.5	11.6	12.8	14.5	14.3	7.4	37.5	8.9	10.1	19.2	17.6	1.8	3.8	10.2	3.2	2.0	2.0	1.8	7.4	7.4	18.1	9.8	13.5	12.0	6.9	9.5	8.0	8.0	7.5	9.8	8.7	9.3	9.7	12.7	7.6	4.2	15.0	6.4	13.0	6.3	4.3	17.5	6.1	6.8	7.5	1.8	10.3	9.7	4.7	10.7	9.2	11.1	11.4	6.6	9.6	11.0	9.6	1.8	14.2	3.4	6.5	5.9	2.2	8.3	18.9	2.3	5.9	11.1	4.6	7.4	10.8	4.6	5.0	8.3	8.4	6.3	20.4	12.0	9.3	14.4	6.0	10.8	11.8	12.3	10.1	6.7	17.6	10.2	3.2	3.1	2.0	3.2	0.8	1.6	1.9	1.5	3.8	1.8	1.1	1.5	3.8	2.0	3.1	2.4	1.4	1.8	11.3	15.1	16.0	13.1	11.2	11.3	14.7	11.7	13.1	14.3	86.4	55.8	23.3	27.0	60.8	36.4	44.2	38.2	33.5	45.5	24.4	31.4	32.3	23.2	37.4	88.6	54.3	28.4	23.3	28.8	21.7	50.3	38.0	52.0	28.4	34.2	71.5	62.8	57.7	83.3	26.1	41.4	65.4	52.3	104.6	20.1	29.9	47.3	25.9	50.5	18.0	31.0	64.7	55.1	30.2	18.9	65.4	95.1	27.4	13.5	63.4
HOXA11	"HOX1, HOX1I"	ENSG00000005073	"Homeobox A11"	P31270	7	27181510-27185223	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 35.7;endometrium 1: 60.9;smooth muscle: 27.3"	"Cell type enhanced"	"Detected in some"	10	"Distal tubular cells: 5.0;Fibroblasts: 4.3;Intestinal endocrine cells: 5.1;Smooth muscle cells: 2.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 14.7;BJ hTERT+: 17.8;HEK 293: 25.0;THP-1: 17.9;U-937: 23.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA006770, HPA035623"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA006770: AB_2667672, HPA035623: AB_10601576"	"unprognostic (5.95e-2)"	"unprognostic (9.23e-2)"	"unprognostic (3.07e-2)"	"unprognostic (2.70e-2)"	"unprognostic (6.29e-2)"	"unprognostic (9.78e-2)"	"unprognostic (2.82e-3)"	"unprognostic (4.36e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.05e-2)"	"unprognostic (2.08e-3)"	"unprognostic (1.73e-2)"	"prognostic unfavorable (2.57e-5)"	"unprognostic (2.17e-2)"	"unprognostic (6.90e-2)"	"unprognostic (2.03e-2)"	"unprognostic (2.56e-1)"	1.5	0.4	0.0	1.7	0.0	0.0	2.0	0.0	0.0	35.7	9.3	0.0	5.7	0.0	60.9	8.8	0.0	0.7	0.0	0.2	0.0	0.0	3.6	0.1	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	9.0	0.0	16.5	2.4	0.0	0.1	6.3	4.9	0.7	0.2	27.3	0.0	0.0	0.1	3.1	0.0	0.0	0.0	0.0	0.0	20.1	6.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.3	0.1	0.0	6.8	8.4	5.9	0.0	14.7	17.8	10.5	7.5	0.1	0.8	0.0	3.4	12.5	0.0	1.6	8.7	0.0	7.7	0.8	25.0	3.1	6.1	0.3	0.5	6.2	0.9	3.7	0.3	0.0	0.0	0.0	7.6	0.6	0.2	0.0	1.1	0.1	0.0	4.8	0.0	2.1	7.4	0.4	0.0	0.1	5.0	4.3	3.2	0.0	3.6	0.0	1.0	2.1	0.6	17.9	0.0	0.1	7.2	1.6	0.7	0.0	0.0	0.0	0.1	23.4	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.2	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	5.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	4.3	2.0	0.0	0.0	0.3	0.0	5.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.0	1.4	0.0	0.0	0.0	0.0	2.3	0.0	0.1	0.0	0.0	0.0	0.6	0.7
HOXA13	"HOX1, HOX1J"	ENSG00000106031	"Homeobox A13"	P31271	7	27193503-27200106	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 48.5;prostate: 25.1"	"Group enriched"	"Detected in some"	15	"Basal glandular cells: 2.9;Enterocytes: 7.7;Fibroblasts: 3.5;Glandular cells: 4.8;Intestinal endocrine cells: 8.1;Mucus-secreting cells: 9.8;Paneth cells: 5.8;Undifferentiated cells: 9.7;Urothelial cells: 2.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 10.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HAP1: 15.5;HEK 293: 21.6;PC-3: 10.7;RT4: 23.9;THP-1: 10.2;U-937: 11.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA046098, HPA069061"			Supported	"Nucleoplasm,Mitotic chromosome,Intermediate filaments"		NA	NA			Nucleoplasm	"Mitotic chromosome, Intermediate filaments"	"HPA046098: AB_2679536, HPA069061: "	"unprognostic (7.20e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.02e-1)"	"unprognostic (8.04e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.40e-2)"	"unprognostic (9.22e-3)"	"unprognostic (7.30e-3)"	"unprognostic (8.39e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.42e-11)"	"unprognostic (2.58e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.36e-2)"	0.6	0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.1	48.5	6.9	0.0	7.1	0.0	5.5	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	16.5	0.0	25.1	8.6	0.0	0.1	17.9	1.2	0.4	0.1	15.7	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.0	0.0	12.1	12.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.9	0.0	1.4	0.1	0.0	0.0	7.6	8.3	3.0	1.9	1.5	0.1	0.0	0.9	3.5	0.4	0.0	15.5	0.0	2.5	0.0	21.6	1.0	4.1	0.1	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	4.9	0.0	6.6	10.7	1.5	0.4	0.0	0.0	23.9	0.4	0.0	1.9	0.0	0.1	1.2	0.0	10.2	0.0	0.3	2.7	0.1	0.1	0.0	0.0	0.0	0.0	11.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	7.7	0.0	0.0	0.1	3.5	4.8	0.0	0.0	0.1	0.0	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	0.0	0.0	5.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.0	9.7	2.8
HOXA9	"HOX1, HOX1G"	ENSG00000078399	"Homeobox A9"	P31269	7	27162435-27175180	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 35.1"	"Cell type enhanced"	"Detected in many"	9	"Distal tubular cells: 46.4;Intestinal endocrine cells: 37.7;Proximal tubular cells: 60.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"basophil: 5.4;myeloid DC: 6.0;NK-cell: 11.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.0;granulocytes: 5.4;NK-cells: 11.7"	"Cell line enhanced"	"Detected in some"		"HEK 293: 43.6;PC-3: 15.2;RPTEC TERT1: 15.0;SCLC-21H: 40.5;U-937: 14.5"									"HPA061982, HPA076200"	Uncertain		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA061982: AB_2684651, HPA076200: "	"unprognostic (4.72e-1)"	"unprognostic (1.23e-2)"	"unprognostic (2.86e-1)"	"unprognostic (5.24e-3)"	"unprognostic (2.36e-1)"	"unprognostic (2.02e-1)"	"unprognostic (8.35e-2)"	"unprognostic (8.44e-3)"	"unprognostic (5.50e-2)"	"unprognostic (5.71e-2)"	"unprognostic (9.87e-3)"	"unprognostic (4.42e-2)"	"unprognostic (2.80e-3)"	"unprognostic (6.45e-2)"	"unprognostic (7.58e-2)"	"unprognostic (1.92e-2)"	"unprognostic (1.35e-1)"	3.2	3.4	0.2	8.8	0.1	2.4	8.7	0.1	0.2	15.5	12.8	0.2	4.1	0.0	10.4	16.8	1.4	12.2	0.3	0.1	0.1	0.0	35.1	0.1	0.8	0.7	0.1	0.1	2.0	0.1	0.0	0.1	1.4	0.4	16.6	4.5	0.2	0.5	5.6	21.0	13.3	8.2	13.1	0.7	1.0	0.0	2.4	0.1	2.6	0.3	0.3	0.3	16.2	11.4	0.5	6.0	5.4	1.0	11.7	1.5	0.5	12.7	0.0	0.0	6.4	2.1	1.6	0.0	5.1	4.1	0.4	0.4	0.8	0.5	0.1	0.5	2.7	0.0	11.9	8.2	0.0	0.4	0.0	43.6	0.1	0.3	0.0	0.2	0.0	0.1	2.2	0.0	0.0	0.0	0.0	10.8	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	15.2	2.7	0.0	0.0	15.0	0.2	40.5	0.0	5.4	0.0	0.1	0.2	0.0	10.7	0.4	0.0	4.0	4.9	0.0	0.0	0.0	0.0	0.0	14.5	0.0	5.4	1.0	0.0	1.5	0.2	0.2	0.2	0.0	0.1	6.0	0.5	0.3	0.1	0.9	11.7	0.4	1.9	0.2	0.5	0.2	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.4	0.1	0.0	0.0	0.8	10.6	22.2	0.0	0.6	0.0	0.0	0.0	17.4	0.0	0.3	46.4	0.0	0.0	0.2	7.9	0.0	0.0	0.3	10.8	14.2	0.0	0.0	0.3	0.0	37.7	0.0	4.8	0.0	0.0	1.6	5.0	0.0	19.1	0.0	0.0	18.4	0.0	60.8	0.0	0.0	3.6	0.0	0.6	24.1	0.2	4.4	19.4	11.5
HOXC11	HOX3H	ENSG00000123388	"Homeobox C11"	O43248	12	53973126-53977643	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 7.0;skin 1: 9.2"	"Group enriched"	"Detected in some"	5	"Basal keratinocytes: 6.6;Distal tubular cells: 1.7;Fibroblasts: 2.3;Melanocytes: 3.3;Spermatocytes: 3.8;Suprabasal keratinocytes: 3.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 23.3;BJ hTERT+: 11.7;HaCaT: 10.3;T-47d: 18.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA038291	Uncertain		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA038291: AB_10674552"	"unprognostic (1.50e-3)"	"unprognostic (1.93e-2)"	"unprognostic (1.14e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.93e-3)"	"unprognostic (1.17e-2)"		"unprognostic (6.90e-3)"	"unprognostic (1.32e-2)"	"unprognostic (7.41e-3)"	"unprognostic (4.46e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.26e-3)"	"unprognostic (3.99e-2)"	"unprognostic (1.06e-1)"		"unprognostic (1.82e-1)"	4.8	0.0	0.1	0.1	0.1	0.0	1.2	0.1	0.1	2.5	0.1	0.1	0.1	0.8	2.0	1.0	0.1	0.7	0.1	0.1	0.1	0.0	2.0	0.1	0.1	0.7	0.1	0.1	0.5	0.1	0.0	0.1	0.6	0.3	0.5	0.0	0.1	0.1	2.0	7.0	9.2	2.7	0.4	0.1	0.1	0.0	1.6	0.1	0.5	0.1	0.1	0.1	1.2	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.7	0.0	23.3	2.2	3.4	0.0	3.4	11.7	5.0	3.7	0.2	0.9	0.0	0.2	3.2	0.0	10.3	4.4	0.0	2.3	0.6	0.1	0.1	7.6	0.0	0.0	0.1	0.1	0.6	0.9	0.0	0.3	0.0	0.0	0.2	1.0	0.0	3.2	1.4	0.0	0.0	0.0	6.6	0.0	0.0	0.4	0.0	0.4	0.8	0.0	0.1	2.1	5.3	2.0	0.2	18.4	0.0	0.0	0.0	4.0	0.3	0.2	0.0	0.0	0.0	0.0	0.4	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.0	6.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.5	3.8	0.2	3.3	0.0	0.0	0.0	0.0
HOXC13	"HOX3, HOX3G"	ENSG00000123364	"Homeobox C13"	P31276	12	53938765-53946544	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"breast: 4.4;skin 1: 13.5;tongue: 4.1"	"Group enriched"	"Detected in some"	6	"Basal keratinocytes: 1.4;Spermatogonia: 1.5;Suprabasal keratinocytes: 2.0"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 15.7;HaCaT: 33.1;SK-BR-3: 18.3;T-47d: 14.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA051634	Enhanced					NA	NA					"HPA051634: AB_2616459"	"unprognostic (5.16e-3)"	"unprognostic (1.46e-1)"		"unprognostic (1.29e-1)"	"unprognostic (2.27e-3)"	"unprognostic (2.78e-2)"		"unprognostic (1.20e-1)"	"unprognostic (2.20e-1)"	"unprognostic (4.04e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.77e-2)"	"unprognostic (9.74e-9)"	"unprognostic (2.41e-1)"	"unprognostic (1.41e-1)"		"unprognostic (1.68e-1)"	2.6	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.3	0.4	0.5	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.0	0.0	2.5	0.0	0.6	13.5	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	4.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6	5.2	0.0	15.7	0.2	0.0	9.4	1.0	2.2	1.4	0.8	1.3	0.2	0.0	0.2	0.0	1.0	33.1	4.0	1.0	0.8	0.0	3.2	0.0	4.3	0.0	0.0	0.0	3.3	0.0	7.8	0.0	3.1	0.0	0.0	0.0	5.6	0.0	5.8	9.7	0.0	0.0	0.1	3.2	1.3	0.0	0.2	0.0	0.0	2.9	0.0	0.0	5.2	18.3	2.4	3.9	14.1	0.0	0.0	0.0	6.8	0.1	2.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.0	0.1	0.0	0.0	0.0
HOXD11	"HOX4, HOX4F"	ENSG00000128713	"Homeobox D11"	P31277	2	176104216-176109754	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"endometrium 1: 15.8"	"Group enriched"	"Detected in some"	4	"Basal glandular cells: 21.0;Collecting duct cells: 21.0;Distal tubular cells: 8.3;Glandular cells: 6.3;Intestinal endocrine cells: 19.9;Mucus-secreting cells: 8.7;Undifferentiated cells: 6.0;Urothelial cells: 11.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 20.8;RPTEC TERT1: 2.6;SCLC-21H: 6.3;SiHa: 2.5;U-251 MG: 4.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA055155			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA055155: AB_2682719"	"unprognostic (1.99e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.32e-2)"	"unprognostic (9.05e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.48e-1)"		"unprognostic (1.93e-2)"	"unprognostic (2.13e-2)"	"unprognostic (6.73e-2)"		"unprognostic (5.00e-2)"	"unprognostic (2.11e-8)"	"unprognostic (2.09e-3)"	"unprognostic (2.49e-2)"		"unprognostic (2.27e-3)"	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	5.4	4.2	0.0	0.0	0.0	15.8	0.4	0.3	0.1	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	1.6	0.3	5.7	0.9	0.0	0.0	2.9	0.0	0.2	0.0	1.7	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	1.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.4	1.3	0.0	0.0	0.1	0.0	20.8	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.3	6.3	0.3	2.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	21.0	0.3	0.0	0.2	0.0	0.0	0.0	21.0	0.0	0.0	8.3	0.0	0.0	0.2	1.0	0.0	0.0	0.1	0.9	6.3	0.0	0.0	0.3	0.0	19.9	0.0	0.0	0.0	0.9	0.0	1.7	0.0	8.7	0.0	0.1	2.9	1.1	0.2	0.0	0.0	0.1	0.0	0.3	0.6	0.0	0.0	6.0	11.2
HOXD13	"HOX4I, SPD"	ENSG00000128714	"Homeobox D13"	P35453	2	176092891-176095938	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"cervix, uterine: 14.0;intestine: 13.1;prostate: 13.8;seminal vesicle: 19.0;vagina: 15.0"	"Cell type enhanced"	"Detected in some"	20	"Basal glandular cells: 10.8;Intestinal endocrine cells: 28.0;Mucus-secreting cells: 11.6;Undifferentiated cells: 8.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 9.8;HEK 293: 28.1;HL-60: 31.2;JURKAT: 8.8;NB-4: 18.6;SCLC-21H: 8.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA064064			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA064064: AB_2685186"	"unprognostic (2.04e-1)"	"unprognostic (1.13e-1)"	"prognostic unfavorable (6.95e-5)"	"unprognostic (2.52e-3)"	"unprognostic (7.25e-2)"	"unprognostic (2.08e-2)"		"unprognostic (4.62e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.66e-1)"		"unprognostic (1.01e-2)"	"unprognostic (2.82e-4)"	"unprognostic (4.95e-2)"	"unprognostic (3.70e-2)"		"unprognostic (9.98e-3)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	14.0	13.1	0.1	0.1	0.0	0.3	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.0	0.1	0.1	0.1	13.8	8.8	0.1	0.1	19.0	0.6	0.0	0.1	3.7	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	3.8	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	1.2	2.6	0.0	0.0	0.0	0.0	0.0	2.7	0.0	9.8	0.0	1.5	0.0	28.1	4.2	0.0	0.0	0.0	31.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.8	2.0	0.0	0.0	0.0	0.0	18.6	1.0	0.0	1.5	0.0	0.1	0.0	0.0	0.2	8.2	2.0	1.9	0.0	4.5	0.1	0.0	0.0	0.0	1.0	0.0	0.4	2.6	0.0	0.0	0.0	1.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	10.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	28.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	11.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	8.3	5.5
HRAS	HRAS1	ENSG00000174775	"HRas proto-oncogene, GTPase"	P01112	11	532242-537287	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002015, HPA049830, HPA070222"	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB002015: , HPA049830: AB_2680903, HPA070222: "	"unprognostic (3.06e-2)"	"unprognostic (2.98e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.08e-3)"	"unprognostic (3.49e-3)"	"unprognostic (3.87e-1)"	"prognostic unfavorable (2.32e-4)"	"unprognostic (1.07e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.88e-3)"	"unprognostic (9.85e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.38e-1)"	12.3	11.4	25.2	9.1	34.5	5.0	16.2	16.1	25.3	7.9	9.5	8.1	10.8	8.9	6.2	9.2	22.3	8.3	10.9	28.7	22.2	22.4	8.2	6.5	8.9	8.0	23.2	12.9	7.7	9.7	11.7	10.3	10.1	15.0	10.0	6.2	8.2	10.1	12.7	51.8	32.0	8.2	8.4	17.0	6.5	7.2	6.1	11.0	5.9	8.1	24.5	9.3	9.9	19.8	2.1	1.1	0.7	4.6	0.1	2.0	0.3	22.1	19.7	9.4	8.4	5.8	4.1	12.2	11.0	5.9	17.4	14.8	9.9	8.8	8.6	3.4	15.0	12.3	17.6	10.0	26.8	4.9	7.0	22.4	4.4	7.9	8.6	8.9	3.5	3.4	6.3	30.0	9.4	10.2	3.6	8.6	7.2	8.9	12.5	9.7	18.2	12.9	12.2	9.6	7.7	19.5	10.3	11.9	7.6	9.7	5.5	36.7	14.6	10.3	18.3	7.9	5.9	15.0	6.8	13.7	15.5	12.2	5.7	14.2	4.6	6.2	6.5	14.6	6.4	14.5	0.0	0.6	0.7	1.4	1.2	1.6	0.8	1.4	1.3	0.7	2.1	2.0	0.6	0.0	0.1	4.6	1.1	2.0	0.3	25.2	34.5	16.1	21.1	22.2	22.4	23.2	12.9	15.0	11.0	11.9	12.5	12.6	82.5	116.5	44.6	21.9	15.3	17.4	4.5	33.2	17.7	72.6	63.0	32.7	1.1	22.2	44.1	0.0	32.3	45.3	34.0	46.2	2.3	13.4	33.9	46.1	28.2	19.0	7.6	5.2	15.8	17.6	60.8	16.2	22.1	28.3	35.8	21.0	21.5	42.9	29.1	32.3	38.7	4.7	23.4	127.5	65.3	12.2	21.3	96.6
HSP90AA1	"FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA"	ENSG00000080824	"Heat shock protein 90 alpha family class A member 1"	P07900	14	102080738-102139699	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"vagina: 519.3"	"Cell type enhanced"	"Detected in all"	5	"Basal glandular cells: 6915.7;Urothelial cells: 5558.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002058	Approved		Supported	Cytosol		NA	NA		94000000	Cytosol		"CAB002058: "	"prognostic unfavorable (5.59e-4)"	"unprognostic (3.77e-2)"	"unprognostic (1.78e-2)"	"unprognostic (9.25e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.05e-3)"	"prognostic unfavorable (3.09e-5)"	"unprognostic (7.79e-3)"	"unprognostic (5.71e-2)"	"unprognostic (7.81e-3)"	"unprognostic (3.68e-2)"	"unprognostic (1.65e-2)"	"prognostic favorable (1.18e-5)"	"unprognostic (1.04e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.12e-1)"	50.8	75.3	96.1	46.7	106.8	64.1	118.6	81.3	113.4	51.0	47.3	50.7	43.0	31.0	40.7	55.5	40.9	94.7	61.0	70.9	99.6	113.3	75.6	62.5	51.7	48.1	134.4	58.6	53.4	40.1	94.9	121.6	67.2	143.6	63.2	53.3	23.4	57.0	57.0	65.2	35.6	38.9	51.0	139.7	35.7	41.3	84.6	132.7	53.5	91.5	34.3	59.5	54.2	519.3	30.7	46.9	31.8	29.9	57.7	63.1	21.9	86.8	118.8	75.9	52.3	46.1	39.0	100.8	96.7	46.5	118.6	66.9	72.1	81.6	106.8	91.1	62.1	77.8	96.5	217.7	94.5	216.3	80.8	71.7	82.4	67.9	92.0	22.8	122.7	63.6	36.6	40.2	75.8	27.9	74.2	65.4	115.4	113.8	54.9	107.3	117.4	131.1	56.4	78.8	160.2	112.4	126.5	103.1	46.1	68.8	112.3	100.0	72.2	122.2	92.0	53.9	132.9	118.3	49.0	46.2	83.0	53.7	123.3	183.5	52.0	162.1	158.0	78.5	75.9	99.9	31.8	19.9	24.0	47.8	29.9	63.1	29.6	40.5	49.0	23.9	30.7	30.1	43.5	13.5	57.7	27.5	46.9	39.2	21.9	96.1	106.8	81.3	102.7	99.6	113.3	134.4	58.6	143.6	132.7	1057.1	642.7	718.4	6915.7	1191.0	1040.4	2043.0	677.7	2973.9	1019.1	486.8	1981.1	1152.8	290.1	998.3	319.6	818.5	645.6	934.5	749.7	1610.0	1217.1	2796.5	903.1	527.2	1188.6	683.3	908.6	338.8	568.8	289.5	677.7	1578.9	1233.2	998.3	507.2	1211.6	739.1	659.3	679.6	610.3	3287.9	608.0	1393.6	3574.3	1881.8	973.5	1714.6	761.4	693.9	5558.4
HSP90AB1	"HSPC2, HSPCB"	ENSG00000096384	"Heat shock protein 90 alpha family class B member 1"	P08238	6	44246166-44253888	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Stress response"	Chaperone	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Basal glandular cells: 3438.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005230, HPA055729, HPA072606, HPA074351"	Enhanced		Supported	Cytosol	"Intracellular and membrane"	NA	Yes		62000000	Cytosol		"CAB005230: AB_2121392, HPA055729: AB_2682899, HPA072606: AB_2732203, HPA074351: AB_2732252"	"unprognostic (6.12e-3)"	"unprognostic (2.96e-3)"	"unprognostic (4.72e-2)"	"unprognostic (9.24e-2)"	"unprognostic (4.20e-1)"	"unprognostic (1.15e-3)"	"unprognostic (1.76e-3)"	"unprognostic (2.74e-1)"	"unprognostic (7.97e-2)"	"prognostic favorable (4.03e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.60e-1)"	"prognostic unfavorable (9.94e-4)"	"unprognostic (3.02e-1)"	"unprognostic (9.53e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.06e-1)"	79.9	116.1	88.0	65.9	105.0	74.6	107.8	92.1	118.2	92.3	60.4	61.7	80.9	40.6	113.3	107.6	71.6	138.4	63.8	115.0	89.0	110.5	72.0	70.7	76.2	73.8	109.7	94.4	238.4	113.9	151.6	95.3	83.6	133.7	93.5	76.4	52.7	64.8	100.3	197.1	67.9	49.0	102.1	93.9	57.5	77.3	45.9	100.2	58.3	133.8	89.8	102.5	86.2	223.4	75.9	50.5	7.2	45.7	55.7	82.5	74.9	135.6	87.0	77.3	95.0	53.1	55.6	81.0	61.3	60.1	113.6	80.0	130.1	41.6	173.8	66.5	63.8	115.6	79.1	188.1	91.3	140.6	57.5	76.1	135.2	49.3	170.0	38.5	135.0	93.7	51.4	61.8	89.2	77.1	99.7	108.6	89.9	180.5	64.9	77.2	137.0	112.4	81.4	90.2	251.8	66.7	108.5	79.1	95.4	76.8	82.5	113.3	69.2	47.6	69.1	86.0	109.7	89.8	67.6	68.1	67.8	113.5	55.4	140.0	75.2	117.8	313.9	73.7	99.3	77.2	7.2	30.2	6.8	49.3	45.7	82.5	75.9	55.2	56.4	50.5	63.2	75.2	71.3	3.7	55.7	43.3	31.4	42.6	74.9	88.0	105.0	92.1	118.2	89.0	110.5	109.7	94.4	133.7	100.2	833.7	606.4	539.1	3438.1	940.9	289.3	1217.7	456.0	1493.6	1074.9	347.2	214.0	960.1	618.4	836.0	145.7	761.3	375.2	163.5	596.7	897.4	930.6	1319.6	967.8	307.7	711.8	321.0	544.1	275.6	256.9	156.5	635.1	727.9	698.5	738.6	374.5	296.6	721.4	313.4	574.6	560.9	223.5	342.8	894.3	197.9	740.6	807.2	939.3	460.3	567.6	2341.3
IDH1		ENSG00000138413	"Isocitrate dehydrogenase (NADP(+)) 1, cytosolic"	O75874	2	208236227-208266074	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Glyoxylate bypass, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cytotrophoblasts: 277.8;Hepatocytes: 306.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Hep G2: 107.6;RT4: 75.1"	"Low region specificity"	"Detected in all"							"CAB033218, HPA035248, HPA057936, CAB062556"	Enhanced		Approved	"Nuclear bodies,Cytosol"		NA	NA		16000000	"Nuclear bodies, Cytosol"		"CAB033218: AB_2123166, CAB062556: AB_2665593, HPA035248: AB_10600714, HPA057936: AB_2683559"	"unprognostic (2.79e-1)"	"unprognostic (1.00e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.47e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.39e-2)"	"prognostic unfavorable (6.93e-5)"	"unprognostic (3.32e-1)"	"unprognostic (2.20e-3)"	"unprognostic (8.03e-2)"	"unprognostic (5.54e-2)"	"unprognostic (4.18e-3)"	"prognostic unfavorable (2.45e-5)"	"unprognostic (2.09e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.69e-2)"	41.3	82.3	6.2	8.8	7.0	1.3	20.9	6.5	8.3	12.6	35.2	8.7	38.0	30.6	8.0	29.9	30.3	8.8	18.7	10.8	6.3	6.2	20.5	91.0	19.8	14.3	8.1	4.7	19.4	21.5	4.8	6.2	24.1	8.7	38.5	23.1	15.4	18.7	39.0	4.7	7.4	54.1	10.1	9.3	21.3	20.4	15.6	8.4	3.5	7.9	11.0	11.9	43.4	12.1	4.9	22.8	6.4	31.6	7.4	6.6	12.0	9.5	16.1	23.0	9.3	41.8	29.9	13.1	4.0	18.3	6.7	16.4	25.4	23.4	1.9	25.4	12.4	28.6	14.8	16.5	19.3	6.5	1.3	6.2	8.2	13.2	107.6	55.7	5.3	8.2	25.7	41.0	15.4	11.2	10.7	18.5	5.6	8.2	6.6	10.3	6.1	3.8	9.2	42.0	68.5	6.6	3.6	8.4	5.4	30.4	75.1	3.9	6.9	15.2	14.7	49.7	25.4	5.6	15.7	12.2	6.9	6.9	9.7	4.3	3.2	5.0	2.5	22.2	32.5	5.5	5.7	31.6	4.8	4.5	14.5	5.1	4.9	4.0	5.3	22.8	4.9	3.3	3.9	6.4	7.4	6.5	8.4	6.6	12.0	6.2	7.0	6.5	8.3	6.3	6.2	8.1	4.7	8.7	8.4	11.9	38.0	25.9	15.5	11.0	19.3	16.8	58.6	14.7	27.3	27.9	23.6	277.8	18.3	23.8	6.9	15.5	112.0	0.0	76.5	152.3	23.7	78.5	13.9	306.5	146.5	11.1	56.1	41.1	109.5	7.7	22.7	46.5	25.3	53.3	85.9	26.7	42.8	52.6	27.6	74.2	45.5	12.9	12.2	7.7	30.8	13.0	80.0	16.0	106.9	38.2
IDH2		ENSG00000182054	"Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial"	P48735	15	90083045-90102504	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Glyoxylate bypass, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 126.2;skeletal muscle: 190.7"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 682.3;Distal tubular cells: 989.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MOLT-4: 69.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007831	Enhanced		Supported	Mitochondria		NA	NA		53000000	Mitochondria		"HPA007831: AB_1851397"	"unprognostic (2.45e-2)"	"prognostic favorable (5.15e-5)"	"unprognostic (2.92e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.53e-1)"	"unprognostic (8.46e-2)"	"unprognostic (3.83e-2)"	"unprognostic (2.55e-3)"	"unprognostic (1.86e-2)"	"unprognostic (1.89e-2)"	"unprognostic (2.76e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.19e-3)"	"unprognostic (3.92e-3)"	"unprognostic (4.46e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.58e-2)"	5.4	2.0	14.9	10.1	16.6	22.6	8.8	4.9	19.1	6.4	16.2	13.8	12.4	16.1	5.9	15.3	23.7	6.0	9.4	126.2	10.2	9.3	25.0	93.2	6.9	15.8	14.4	12.0	3.0	25.1	8.4	3.3	15.1	11.9	13.3	14.5	6.0	28.0	21.9	190.7	11.0	13.9	15.8	11.0	7.5	27.9	1.2	7.6	28.2	3.4	69.0	13.6	11.0	8.6	16.8	32.8	17.2	56.3	22.2	29.5	31.2	10.3	5.9	30.6	30.3	4.3	5.2	26.0	13.0	19.8	12.3	13.2	2.8	9.0	12.3	3.7	10.7	11.7	3.6	4.4	3.9	5.8	24.2	2.9	21.0	2.2	20.6	5.2	14.4	21.3	11.0	2.2	2.9	2.3	14.9	25.1	43.6	3.1	10.6	9.4	30.2	69.1	22.4	9.1	14.2	2.4	58.6	21.9	36.7	18.9	12.5	44.1	22.4	16.1	64.4	5.2	17.8	51.9	44.5	6.0	21.9	3.2	2.8	6.0	17.5	3.2	1.4	7.0	30.3	12.6	9.0	26.4	17.2	26.1	48.0	12.4	16.8	18.7	29.5	32.8	9.8	10.2	18.2	5.1	22.2	56.3	17.8	15.9	31.2	14.9	16.6	4.9	19.1	10.2	9.3	14.4	12.0	11.9	7.6	6.0	21.8	67.0	66.5	35.4	5.3	402.1	104.4	56.2	21.6	71.5	9.8	682.3	989.8	188.2	4.7	25.3	53.5	23.3	255.6	386.0	36.6	189.5	30.1	240.4	229.9	9.5	59.3	41.1	60.4	2.5	13.0	70.5	55.6	96.4	122.1	17.5	127.7	132.1	33.2	128.5	5.1	12.9	38.3	0.5	4.5	58.6	479.2	123.2	268.2	90.1
IKBKB	"IKK-beta, IKK2, IKKB, NFKBIKB"	ENSG00000104365	"Inhibitor of nuclear factor kappa B kinase subunit beta"	O14920	8	42271302-42332653	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cone photoreceptor cells: 127.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001249, CAB004447"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB004447: AB_627785, HPA001249: AB_1079126"	"unprognostic (1.04e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.73e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.27e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.89e-2)"	"unprognostic (9.20e-2)"	"unprognostic (3.02e-1)"	"prognostic favorable (1.46e-6)"	9.1	10.8	10.9	17.0	16.7	9.3	10.0	26.1	16.9	10.3	10.3	12.4	11.4	4.7	15.3	13.2	17.9	16.4	14.9	7.9	13.1	6.9	12.4	9.9	14.9	12.2	20.3	7.9	9.6	13.3	18.0	13.6	11.2	11.9	14.0	10.9	10.5	11.4	9.7	17.6	22.2	9.8	16.4	10.5	18.7	10.8	8.3	18.6	12.9	14.3	8.4	17.1	18.1	12.8	12.6	14.8	14.1	9.6	11.9	11.2	5.8	3.6	12.9	3.7	6.3	14.3	12.4	4.7	3.2	11.3	9.5	8.4	2.9	6.7	7.1	5.5	8.8	9.0	4.1	5.0	12.7	12.3	6.9	5.7	9.9	6.0	2.3	10.9	1.9	10.4	8.2	9.7	9.1	14.2	18.7	14.0	4.7	8.4	3.5	20.8	4.1	6.9	3.1	3.6	11.8	4.1	7.1	6.3	4.1	10.7	3.3	1.1	2.1	2.0	3.6	5.2	6.9	4.8	8.3	7.2	6.7	3.5	5.2	2.3	2.1	2.1	5.0	7.9	4.7	7.6	14.1	9.6	10.4	10.1	7.6	10.3	9.4	10.5	11.2	8.9	12.6	10.2	10.4	11.4	11.9	9.0	14.8	9.9	5.8	10.9	16.7	26.1	16.9	13.1	6.9	20.3	7.9	11.9	18.6	11.9	24.0	17.7	29.3	21.6	11.3	4.5	15.3	14.7	13.6	15.7	127.6	8.6	1.7	11.4	2.0	27.7	11.8	0.0	11.8	4.6	9.8	23.2	36.9	10.2	15.8	17.5	10.9	15.4	26.9	3.0	15.3	17.7	18.6	13.6	15.1	11.6	13.3	14.4	12.0	4.8	52.3	6.5	6.4	2.6	6.4	25.5	12.7	20.3	13.6	25.7
IKZF1	"hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1"	ENSG00000185811	"IKAROS family zinc finger 1"	Q13422	7	50304068-50405101	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Cell cycle, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.7;bone marrow: 55.2;lymphoid tissue: 86.7"	"Cell type enhanced"	"Detected in many"	11	"B-cells: 46.7;Kupffer cells: 47.2;Macrophages: 43.8;monocytes: 70.3;T-cells: 103.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 26.9;HDLM-2: 45.8;HMC-1: 42.9;JURKAT: 26.3;MOLT-4: 33.5;REH: 36.3;U-698: 68.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB009247, HPA035221, HPA035222"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB009247: AB_2124699, HPA035221: AB_2674524, HPA035222: AB_2674525"	"prognostic favorable (4.28e-4)"	"prognostic favorable (2.02e-4)"	"unprognostic (2.49e-3)"	"unprognostic (2.41e-3)"	"unprognostic (5.59e-1)"	"prognostic favorable (8.63e-4)"	"unprognostic (1.45e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.43e-1)"	"unprognostic (6.63e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.69e-3)"	"unprognostic (1.71e-1)"	"unprognostic (2.84e-2)"	"unprognostic (6.77e-2)"	"unprognostic (4.67e-2)"	3.5	1.5	2.9	25.5	3.8	55.2	2.3	0.7	1.8	1.6	3.6	2.8	0.8	2.4	1.6	2.1	2.2	2.4	2.9	1.6	3.4	1.8	2.5	2.3	8.3	44.4	5.9	1.1	1.1	1.3	0.2	1.2	1.2	3.4	2.2	2.5	1.5	5.2	0.7	0.9	1.9	14.5	1.4	5.1	31.0	3.7	1.1	4.1	86.7	2.4	1.2	26.3	4.5	2.9	24.0	12.6	12.8	23.6	12.8	28.7	12.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	45.8	0.0	9.2	0.0	0.0	0.0	16.3	42.9	0.0	0.0	0.0	0.0	0.0	0.0	26.3	11.9	3.2	0.0	0.0	33.5	16.2	0.4	0.0	0.0	36.3	0.0	7.6	0.0	0.0	0.3	0.3	0.1	0.2	0.1	0.0	0.0	22.5	0.0	0.0	0.3	0.0	0.0	14.6	7.5	68.8	0.1	17.7	0.1	10.2	7.7	12.8	20.4	23.6	17.0	24.0	21.2	19.9	8.2	21.3	28.7	20.7	11.2	12.8	22.3	12.6	17.1	12.7	2.9	3.8	0.7	1.8	3.4	1.8	5.9	1.1	3.4	4.1	3.0	16.4	46.7	0.1	2.5	0.0	1.1	5.1	2.7	3.4	1.8	0.0	0.3	0.0	0.1	3.0	2.9	0.0	23.3	0.0	0.2	3.4	0.1	22.0	1.0	27.1	0.0	0.0	4.3	47.2	4.5	0.0	43.8	18.6	70.3	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	2.1	0.0	0.7	2.4	0.6	103.3	0.0	0.1
IL2	"IL-2, TCGF"	ENSG00000109471	"Interleukin 2"	P60568	4	122451470-122456725	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	"Cytokine, Growth factor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 1.9;intestine: 2.4;lymphoid tissue: 1.9"	"Group enriched"	"Detected in some"	6	"Melanocytes: 3.3;T-cells: 3.8"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"memory CD4 T-cell: 1.9"	"Lineage enriched"	"Detected in single"	19	"T-cells: 1.9"	"Group enriched"	"Detected in some"	19	"JURKAT: 1.7;MOLT-4: 2.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB010310	Uncertain				"Secreted to blood"	NA	NA	20300				"CAB010310: AB_649346"	"unprognostic (8.87e-5)"	"unprognostic (6.13e-3)"		"unprognostic (1.38e-3)"				"unprognostic (9.79e-3)"			"unprognostic (2.56e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.06e-5)"	"unprognostic (5.21e-3)"	"unprognostic (8.01e-2)"			0.6	0.0	0.0	0.6	0.0	0.4	0.5	0.0	0.0	0.9	0.3			0.5	0.1	0.0	0.8	0.6	0.5	0.0	0.0	0.0	0.2	0.3	0.7	1.1	0.0		0.1	0.0	0.0	0.0	0.0		0.4	1.9		0.1	0.0	0.0	0.4	2.4	0.0	0.2	0.8	0.3	0.0			0.4		1.9	0.8	0.4	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	3.8	0.0	0.0
IL21R	CD360	ENSG00000103522	"Interleukin 21 receptor"	Q9HBE5	16	27402162-27452042	"Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 17.9;lymphoid tissue: 47.8"	"Cell type enhanced"	"Detected in some"	10	"B-cells: 11.8;Early spermatids: 5.2;Hofbauer cells: 7.0;T-cells: 8.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 10.3;HDLM-2: 43.9;Karpas-707: 20.4;RH-30: 15.4;RPMI-8226: 24.5;U-266/70: 10.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA042296	Uncertain		Uncertain	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA042296: AB_10806236"	"unprognostic (2.91e-2)"	"unprognostic (2.65e-3)"	"unprognostic (6.64e-4)"	"unprognostic (1.58e-3)"	"unprognostic (2.14e-1)"	"prognostic favorable (7.29e-4)"	"unprognostic (8.33e-2)"	"unprognostic (2.06e-1)"	"unprognostic (8.50e-6)"	"unprognostic (2.26e-2)"	"unprognostic (1.13e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.34e-10)"	"unprognostic (8.79e-2)"	"unprognostic (4.42e-2)"	"unprognostic (1.50e-1)"	"unprognostic (9.58e-2)"	0.8	0.6	0.6	33.6	3.7	5.7	0.6	0.5	1.6	0.5	0.9	0.3	0.0	0.5	0.5	1.3	1.0	0.8	1.1	1.8	0.6	2.3	1.6	1.3	5.6	20.9	1.3	0.0	0.5	0.5	0.0	0.9	0.9	1.9	0.9	0.9	1.8	3.7	0.3	0.7	0.7	4.0	0.6	1.7	11.2	1.3	1.0	1.4	47.8	1.3	0.8	31.7	2.7	0.8	11.5	1.6	0.7	17.9	6.3	10.3	4.2	0.0	0.0	0.1	0.1	0.0	0.5	0.3	0.3	0.0	0.0	0.9	0.0	0.0	10.3	0.1	0.8	0.5	0.0	0.0	0.0	0.0	43.9	0.0	2.1	0.0	0.3	1.4	0.0	0.6	1.6	0.0	2.8	0.0	0.3	0.0	0.2	0.1	20.4	1.5	0.0	0.0	0.2	0.3	0.0	0.0	0.1	15.4	24.5	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.1	0.0	0.5	1.1	0.8	0.3	0.2	0.0	10.3	3.6	2.3	2.1	0.5	0.0	0.2	0.3	0.0	9.8	5.8	3.6	1.0	6.3	10.3	1.6	11.5	6.9	6.7	0.7	6.3	17.9	0.7	7.6	4.2	0.6	3.7	0.5	1.6	0.6	2.3	1.3	0.0	1.9	1.4	0.0	2.2	11.8	0.1	0.3	1.5	2.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	5.2	0.6	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	7.0	0.0	0.0	1.3	4.5	4.0	0.0	2.2	1.7	1.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.1	0.0	0.6	0.1	8.2	0.0	0.0
IL6ST	"CD130, GP130"	ENSG00000134352	"Interleukin 6 signal transducer"	P40189	5	55935095-55994993	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	10	"Ito cells: 851.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 21.0"	"Lineage enriched"	"Detected in many"	5	"T-cells: 21.0"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 57.7;BJ hTERT+: 58.7;HHSteC: 65.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010558, CAB025784"	Approved		Supported	"Golgi apparatus,Plasma membrane"	"Secreted to blood"	NA	NA		100000000	"Plasma membrane"	"Golgi apparatus"	"CAB025784: , HPA010558: AB_1078439"	"unprognostic (1.81e-2)"	"unprognostic (1.25e-1)"	"unprognostic (7.61e-2)"	"unprognostic (3.95e-2)"	"unprognostic (8.93e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.18e-2)"	"unprognostic (9.53e-3)"	"unprognostic (1.89e-2)"	"unprognostic (2.29e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavorable (5.05e-4)"	"unprognostic (3.69e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.25e-1)"	44.8	34.2	24.7	25.5	23.4	8.8	76.9	15.9	22.9	38.1	23.9	15.0	29.0	8.7	26.1	24.9	22.7	23.1	31.1	31.9	21.9	19.7	37.2	71.2	36.3	70.0	25.8	14.7	42.1	16.4	35.8	36.2	97.0	22.5	31.9	17.1	20.0	26.3	33.0	27.1	12.5	20.6	36.6	33.8	35.5	19.7	13.7	20.3	19.4	37.6	12.5	18.7	33.7	51.1	0.7	2.1	0.9	3.8	0.8	21.0	4.0	9.5	11.9	3.9	9.2	27.6	57.7	15.9	28.5	58.7	15.4	22.9	16.7	9.2	0.3	21.4	17.6	35.0	4.1	3.0	8.5	31.6	0.8	3.1	2.2	9.8	13.7	65.6	0.2	4.6	50.5	4.6	33.4	16.3	22.9	35.1	0.8	1.6	40.2	17.7	1.6	0.4	0.4	0.6	1.2	3.9	0.5	10.8	5.5	8.4	5.6	2.1	3.4	11.5	3.8	11.7	10.7	19.2	1.5	56.4	5.9	6.7	24.1	15.0	9.9	4.2	0.3	15.9	0.4	15.5	0.2	3.8	0.1	0.8	3.5	0.4	0.7	4.9	0.8	2.1	0.6	21.0	5.9	0.9	0.8	0.6	1.8	3.4	4.0	24.7	23.4	15.9	22.9	21.9	19.7	25.8	14.7	22.5	20.3	125.0	112.6	23.8	82.7	92.3	54.8	67.9	140.1	99.0	149.0	64.6	33.4	63.8	6.6	64.2	9.5	210.0	31.1	23.3	53.6	60.1	240.2	110.2	31.3	186.2	46.3	15.9	19.0	851.3	103.7	11.5	98.1	51.0	75.9	21.6	29.0	179.7	66.2	30.6	122.7	46.2	33.9	97.0	142.0	37.1	34.3	73.0	85.1	35.0	13.3	89.2
IL7R	CD127	ENSG00000168685	"Interleukin 7 receptor"	P16871	5	35852695-35879603	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 70.3;intestine: 34.0;lung: 52.6;lymphoid tissue: 133.1"	"Group enriched"	"Detected in many"	5	"monocytes: 441.0;T-cells: 326.6"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 19.2;MAIT T-cell: 70.3;memory CD4 T-cell: 39.9;memory CD8 T-cell: 28.0;naive CD4 T-cell: 34.5;naive CD8 T-cell: 22.5;NK-cell: 19.1"	"Group enriched"	"Detected in many"	33	"NK-cells: 19.1;T-cells: 70.3"	"Cell line enhanced"	"Detected in many"		"BJ: 22.2;BJ hTERT+ SV40 Large T+: 20.1;fHDF/TERT166: 41.6;HBF TERT88: 38.3;REH: 86.5"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB010215, HPA067550"			Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		180000	"Plasma membrane"		"CAB010215: AB_673727, HPA067550: "	"unprognostic (2.93e-3)"	"unprognostic (3.38e-2)"	"unprognostic (3.82e-3)"	"unprognostic (5.58e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.74e-1)"	"unprognostic (2.51e-3)"	"unprognostic (5.53e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.29e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.69e-1)"	"unprognostic (1.76e-2)"	"unprognostic (5.64e-2)"	"unprognostic (3.27e-3)"	"unprognostic (2.22e-1)"	"unprognostic (1.78e-1)"	6.7	3.6	0.7	34.0	0.7	3.1	4.8	0.5	0.6	4.8	20.6	0.3	0.9	3.5	1.8	2.9	6.6	3.7	8.5	1.9	0.7	0.7	7.0	2.7	52.6	133.1	0.8	0.1	2.5	1.7	0.0	1.5	1.2	0.8	3.3	5.4	1.7	13.2	1.8	0.9	1.8	34.0	1.2	1.5	32.3	7.8	3.0	0.4	130.9	5.1	5.3	42.9	12.6	4.6	0.4	0.3	1.3	0.2	19.1	70.3	12.7	0.1	0.0	0.1	0.1	0.1	0.1	0.2	22.2	11.2	20.1	11.9	0.1	0.1	2.1	0.0	41.6	3.7	3.5	0.0	1.3	38.3	1.8	0.2	0.6	2.4	0.0	0.3	0.2	1.6	0.3	0.0	4.3	0.9	0.5	0.5	0.1	0.1	0.3	15.7	0.0	0.5	0.2	0.1	0.0	1.0	86.5	1.2	0.1	0.0	1.2	0.0	0.0	3.7	0.3	0.0	0.1	0.1	0.0	1.5	7.9	13.4	3.4	2.9	0.2	0.0	2.5	4.0	2.1	6.1	0.5	0.2	0.1	19.2	0.2	70.3	0.2	39.9	28.0	0.1	0.4	34.5	22.5	1.3	19.1	0.2	0.3	6.7	12.7	0.7	0.7	0.5	0.6	0.7	0.7	0.8	0.1	0.8	0.4	14.9	19.4	10.9	1.9	10.3	0.0	3.2	0.0	10.7	4.5	0.0	0.0	0.1	0.0	0.9	0.1	3.6	0.0	23.3	1.6	0.1	7.1	1.1	18.5	4.5	10.4	0.0	0.0	17.8	12.7	0.0	0.0	79.7	20.3	441.0	0.0	0.0	0.2	0.9	0.0	0.6	0.0	0.0	9.0	0.0	0.0	9.2	0.2	326.6	0.0	3.8
IRF4	"LSIRF, MUM1"	ENSG00000137265	"Interferon regulatory factor 4"	Q15306	6	391739-411447	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 48.7"	"Group enriched"	"Detected in some"	6	"Melanocytes: 42.2;monocytes: 92.8"	"Cancer enriched"	"Detected in many"	9	"melanoma: 27.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"memory B-cell: 9.5;myeloid DC: 9.0;naive B-cell: 9.7;plasmacytoid DC: 10.4;T-reg: 4.8"	"Group enriched"	"Detected in many"	5	"B-cells: 9.7;dendritic cells: 10.4;T-cells: 4.8"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 50.2;Karpas-707: 46.7;RPMI-8226: 45.1;U-266/70: 42.2;U-266/84: 31.4;WM-115: 25.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA002038, HPA002698, CAB013508"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB013508: , HPA002038: AB_1079148, HPA002698: AB_1851893"	"prognostic favorable (6.44e-4)"	"unprognostic (1.88e-3)"	"unprognostic (1.00e-3)"	"unprognostic (1.72e-4)"	"unprognostic (2.74e-1)"	"prognostic favorable (1.64e-6)"	"unprognostic (4.72e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.89e-2)"	"unprognostic (5.74e-4)"	"unprognostic (8.51e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.18e-7)"	"unprognostic (2.38e-1)"	"unprognostic (6.24e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.65e-2)"	7.1	0.5	0.4	36.6	0.4	18.4	4.0	0.4	0.4	17.4	13.9	0.1	0.4	5.0	2.2	0.7	6.4	1.2	4.1	1.6	0.4	0.5	1.4	5.6	4.2	31.5	0.5	0.0	1.9	0.7	0.0	0.7	0.5	0.1	1.5	4.8	15.8	21.3	1.9	0.7	4.5	11.1	0.3	0.6	33.8	4.6	1.7	0.1	15.2	1.3	2.4	48.7	8.4	4.2	9.7	10.4	0.0	1.6	0.2	4.8	1.3	0.1	0.0	0.0	0.0	5.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	5.9	0.0	45.1	0.0	0.0	0.1	0.0	0.0	0.0	7.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	42.2	31.4	13.7	0.0	0.0	25.6	0.0	1.6	0.0	0.6	1.2	0.0	9.5	0.9	0.9	9.0	9.7	1.6	0.7	0.0	0.2	1.2	10.4	4.8	1.3	0.4	0.4	0.4	0.4	0.4	0.5	0.5	0.0	0.1	0.1	0.0	4.0	12.0	0.1	7.3	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.6	0.0	0.6	0.2	0.0	0.2	0.2	0.0	0.0	1.8	0.0	0.0	3.1	6.9	42.2	92.8	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.1	3.8	0.1	6.2	0.0	0.0
IRS4	"IRS-4, PY160"	ENSG00000133124	"Insulin receptor substrate 4"	O14654	X	108732482-108736409	"Cancer-related genes, Predicted intracellular proteins"		Transducer	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"pituitary gland: 56.0"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	7	"hypothalamus: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 14.0;NTERA-2: 1.7;RT4: 4.1;WM-115: 3.1"	"Group enriched"	"Detected in some"	5	"basal ganglia: 12.8;hypothalamus: 52.4"	"Group enriched"	"Detected in many"	6	"basal ganglia: 21.5;hypothalamus: 55.3"	HPA017372	Uncertain					NA	NA					"HPA017372: AB_2669600"	"unprognostic (3.74e-3)"				"unprognostic (3.27e-2)"			"unprognostic (1.32e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.89e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.65e-1)"		"unprognostic (1.05e-2)"	"unprognostic (1.77e-1)"	"unprognostic (9.28e-4)"	"unprognostic (8.71e-2)"	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.6	1.9	0.0	0.1	0.3	0.1	2.6	0.3	0.3	0.5	0.0	0.0	0.3	4.6	0.0	0.0	0.1	0.0	0.5	0.1	9.5	0.0	0.0	56.0	0.1	0.6	0.2	0.0	2.7	0.0	0.5	0.0	0.6	0.0	1.0	0.2	0.1	0.5	0.1	0.5	5.1	3.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	14.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.3	0.3	4.6	0.5	0.1	0.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ITK	"EMT, LYK, PSCTK2"	ENSG00000113263	"IL2 inducible T cell kinase"	Q08881	5	157142933-157255191	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Adaptive immunity, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 28.0;lymphoid tissue: 60.5"	"Cell type enhanced"	"Detected in some"	20	"Alveolar cells type 2: 10.4;granulocytes: 32.2;T-cells: 47.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	28	"gdT-cell: 13.8;MAIT T-cell: 9.1;memory CD4 T-cell: 19.5;memory CD8 T-cell: 18.9;naive CD4 T-cell: 28.0;naive CD8 T-cell: 22.8;NK-cell: 9.2;T-reg: 23.1"	"Group enriched"	"Detected in many"	29	"NK-cells: 9.2;T-cells: 28.0"	"Group enriched"	"Detected in some"	9	"JURKAT: 36.5;MOLT-4: 13.3"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			HPA043670			Uncertain	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA043670: "	"unprognostic (2.08e-3)"	"unprognostic (6.57e-4)"	"unprognostic (5.06e-3)"	"unprognostic (4.96e-5)"	"unprognostic (1.52e-2)"	"unprognostic (1.12e-4)"	"unprognostic (8.45e-4)"	"unprognostic (1.56e-2)"	"unprognostic (1.87e-2)"	"unprognostic (5.99e-3)"	"unprognostic (1.76e-1)"	"unprognostic (2.52e-1)"	"unprognostic (4.52e-6)"	"unprognostic (3.64e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.46e-1)"	"unprognostic (3.26e-2)"	2.3	0.7	0.5	12.2	0.6	2.5	1.3	1.9	0.5	1.4	3.3	0.0	0.0	0.5	1.2	1.1	1.8	1.4	4.3	0.9	0.5	0.5	1.4	1.2	6.6	60.5	0.9	0.0	0.7	0.7	0.0	0.9	0.1	0.3	1.1	1.3	1.5	3.5	1.1	0.5	1.0	8.9	0.4	1.2	10.7	2.3	1.4	0.0	60.3	1.6	2.7	24.3	4.1	1.3	0.0	0.0	0.4	0.6	9.2	28.0	13.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	2.2	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	36.5	0.0	0.0	0.0	0.0	13.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	13.8	0.0	9.1	0.0	19.5	18.9	0.0	0.0	28.0	22.8	0.4	9.2	0.6	0.0	23.1	13.6	0.5	0.6	1.9	0.5	0.5	0.5	0.9	0.0	0.3	0.0	0.0	10.4	0.0	0.6	2.4	0.0	0.8	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.0	5.7	0.0	0.0	0.0	0.0	0.0	0.5	0.2	32.2	0.6	0.0	0.0	0.0	1.8	0.6	5.5	0.0	1.5	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.1	0.0	0.0	3.0	0.1	47.3	0.0	0.4
JAK1	"JAK1A, JAK1B, JTK3"	ENSG00000162434	"Janus kinase 1"	P23458	1	64833229-64966504	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 70.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013088	Approved					NA	NA					"CAB013088: "	"prognostic favorable (9.63e-4)"	"unprognostic (1.24e-1)"	"prognostic favorable (2.81e-4)"	"unprognostic (5.10e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.21e-2)"	"unprognostic (1.53e-1)"	"unprognostic (7.00e-3)"	"unprognostic (8.40e-2)"	"unprognostic (7.88e-3)"	"unprognostic (1.66e-2)"	"unprognostic (8.84e-2)"	"prognostic favorable (2.67e-4)"	"unprognostic (2.35e-1)"	"unprognostic (2.04e-1)"	"unprognostic (7.30e-2)"	"unprognostic (3.51e-1)"	46.7	20.4	15.5	31.1	16.5	21.2	56.6	24.3	20.4	27.3	27.1	16.3	16.5	13.8	28.2	22.0	27.0	20.7	27.7	27.3	15.3	16.5	31.4	38.3	36.5	61.4	15.6	14.1	33.3	29.1	28.3	39.8	22.9	25.1	26.0	22.2	18.1	19.8	21.3	45.1	29.7	29.3	30.7	16.3	52.7	20.9	17.3	15.0	62.7	29.0	17.9	42.5	37.2	29.3	20.2	15.4	34.9	17.1	68.1	27.5	25.8	11.2	14.6	6.1	0.6	70.7	40.1	7.9	17.5	25.9	14.6	17.2	4.8	6.2	17.1	13.6	31.1	27.2	6.3	4.1	13.5	20.8	22.5	6.6	23.1	7.7	10.4	26.1	8.8	16.1	35.1	18.8	22.0	23.0	17.4	45.4	8.5	8.4	18.3	16.1	6.4	4.8	5.9	4.2	12.9	8.8	6.9	17.6	6.3	37.6	19.8	4.3	12.9	24.0	11.3	10.3	12.7	24.0	5.5	41.2	17.5	7.8	39.6	9.3	11.5	5.2	13.5	16.3	11.7	7.9	31.2	10.9	31.5	22.8	15.2	27.5	20.2	22.0	25.7	15.4	16.1	24.3	20.7	34.9	68.1	17.1	10.5	26.5	25.8	15.5	16.5	24.3	20.4	15.3	16.5	15.6	14.1	25.1	15.0	47.6	79.3	120.3	114.0	103.6	35.7	98.8	79.0	41.5	63.7	106.4	21.6	5.5	36.5	152.3	100.2	130.9	49.5	23.3	184.7	94.8	76.6	173.3	55.4	77.3	52.1	20.6	63.8	178.0	138.0	72.8	88.9	109.3	47.2	252.5	54.9	54.4	180.7	49.2	79.5	61.6	35.1	161.7	144.2	30.5	50.9	145.2	10.2	159.2	38.1	188.3
JAK2	JTK10	ENSG00000096968	"Janus kinase 2"	O60674	9	4984390-5128183	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 36.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 40.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 40.8"	"Group enriched"	"Detected in many"	5	"ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013089, HPA040820, HPA043870"	Approved		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		No	No			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708"	"unprognostic (2.24e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (5.50e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.72e-2)"	"unprognostic (3.85e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.37e-3)"	19.8	8.8	11.5	19.0	10.5	19.0	17.7	14.7	14.4	17.8	10.6	7.0	10.3	7.2	14.8	13.6	12.4	13.4	14.6	27.6	10.3	6.7	7.7	5.6	16.1	19.4	7.0	10.5	15.9	6.7	10.1	7.5	12.0	10.0	12.0	7.4	9.4	7.2	7.4	14.4	19.0	12.3	10.4	11.7	21.5	14.1	10.1	9.0	13.6	8.6	6.5	13.5	13.9	15.6	2.1	9.6	40.8	7.5	3.4	2.1	2.5	2.5	1.5	1.5	2.5	19.4	5.0	0.4	3.5	3.0	2.7	1.8	0.1	0.8	0.1	0.8	2.1	2.2	0.9	1.6	2.1	2.0	27.4	0.5	56.1	3.0	0.7	4.0	3.8	2.9	4.1	0.9	1.1	1.8	3.3	2.5	2.0	4.0	6.5	4.8	0.9	0.9	5.4	1.3	1.3	1.7	1.9	2.8	0.8	2.0	1.3	1.7	0.9	1.0	1.5	1.1	1.6	0.8	6.7	5.1	4.1	1.4	4.2	2.4	1.2	2.3	0.5	5.3	1.9	2.0	40.8	7.5	13.4	2.1	7.3	1.7	2.1	1.6	1.2	9.6	1.9	0.9	1.1	7.1	3.4	5.8	3.6	1.6	2.5	11.5	10.5	14.7	14.4	10.3	6.7	7.0	10.5	10.0	9.0	14.9	6.4	6.9	2.8	8.7	7.4	22.0	0.0	5.3	7.9	7.0	7.9	1.8	1.7	3.0	7.4	8.7	3.9	23.3	3.4	0.8	7.0	1.7	13.9	1.6	11.9	7.9	2.9	4.9	36.0	5.3	21.9	27.7	5.0	16.2	4.2	12.2	5.4	14.4	31.5	2.5	11.1	0.0	5.0	14.9	5.7	7.3	2.9	5.0	3.3	4.1
JAK3	"JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK"	ENSG00000105639	"Janus kinase 3"	P52333	19	17824780-17848071	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 68.3"	"Cell type enhanced"	"Detected in many"	7	"B-cells: 18.2;Ito cells: 14.1;Peritubular cells: 13.8;T-cells: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 20.6;HEL: 9.2;HMC-1: 9.4;Karpas-707: 24.0;U-266/70: 9.3;U-266/84: 13.8;U-937: 14.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA070314	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA070314: AB_2686251"	"unprognostic (5.59e-3)"	"prognostic favorable (6.42e-5)"	"unprognostic (5.71e-2)"	"unprognostic (2.34e-1)"	"unprognostic (6.13e-3)"	"unprognostic (1.11e-3)"	"unprognostic (4.21e-2)"	"unprognostic (2.60e-1)"	"unprognostic (2.38e-2)"	"unprognostic (2.36e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.94e-1)"	"prognostic unfavorable (2.89e-14)"	"unprognostic (2.28e-1)"	"unprognostic (2.21e-2)"	"unprognostic (4.43e-2)"	"unprognostic (7.61e-2)"	6.8	1.7	4.0	24.5	8.5	12.0	2.7	2.4	3.1	1.9	2.3	1.0	0.0	2.2	1.7	2.0	2.5	3.5	3.6	4.3	2.7	2.8	3.8	2.0	8.4	68.3	7.5	0.0	11.0	2.0	0.4	2.3	4.1	5.3	3.0	2.4	1.6	6.1	1.5	0.7	1.3	9.5	2.5	8.4	36.1	3.2	1.8	5.8	20.9	3.4	1.7	28.8	5.3	2.4	7.4	4.5	16.9	9.6	8.4	15.0	6.8	0.1	0.3	0.3	1.1	0.4	1.5	0.2	0.5	0.0	0.0	0.1	0.0	0.9	0.4	2.0	0.4	0.3	0.1	0.0	0.2	0.0	20.6	0.0	9.2	0.0	0.8	0.7	0.0	9.4	5.1	0.2	0.0	0.0	0.0	0.2	2.1	0.0	24.0	0.0	0.4	3.6	0.0	0.2	0.5	0.7	4.7	0.0	0.4	0.5	0.0	0.0	0.3	0.1	0.2	0.0	0.1	2.0	1.4	0.4	0.0	0.4	0.0	0.0	9.3	13.8	2.5	0.1	14.0	0.2	1.2	4.9	0.2	12.6	9.6	14.5	6.5	15.0	13.1	4.5	7.4	14.9	13.0	16.9	8.4	8.8	3.7	11.8	6.8	4.0	8.5	2.4	3.1	2.7	2.8	7.5	0.0	5.3	5.8	0.0	5.8	18.2	0.5	0.7	0.3	1.4	0.0	0.0	1.2	1.8	0.0	0.9	0.0	0.6	1.0	5.8	0.0	0.0	0.3	0.7	2.3	0.2	4.7	0.0	11.5	0.0	0.0	14.1	10.8	0.9	11.5	3.5	3.3	12.6	0.0	0.8	0.4	0.0	13.8	0.1	0.5	6.5	2.1	0.3	0.7	0.9	1.1	24.5	0.0	0.5
JUN	"AP-1, c-Jun"	ENSG00000177606	"Jun proto-oncogene, AP-1 transcription factor subunit"	P05412	1	58780788-58784327	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RH-30: 71.6"	"Low region specificity"	"Detected in all"							"CAB003801, CAB007780, HPA031174, HPA059474"	Enhanced		Enhanced	Nucleoplasm		Yes	No			Nucleoplasm		"CAB003801: AB_365485, CAB007780: AB_562268, HPA031174: , HPA059474: AB_2684030"	"unprognostic (2.06e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.85e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.11e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.82e-1)"	"unprognostic (5.15e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-3)"	64.5	29.4	26.7	33.7	17.2	68.4	61.7	19.5	20.6	60.0	32.7	30.8	28.4	13.3	40.5	21.8	34.1	72.6	48.5	31.3	20.2	12.4	21.2	39.3	55.1	14.3	15.3	12.0	49.8	48.7	15.0	16.7	21.6	24.1	48.6	16.7	40.5	59.4	39.3	32.2	51.3	28.6	40.7	17.6	22.9	47.0	18.2	18.1	9.0	61.0	35.2	23.3	41.5	33.1	7.4	1.3	4.0	5.1	3.2	2.5	1.2	16.1	2.3	5.2	1.0	8.3	9.5	0.1	20.6	7.5	14.6	8.9	4.2	1.2	0.6	9.9	12.8	31.6	5.6	0.4	6.7	9.3	12.8	37.5	0.2	0.9	4.7	6.9	1.1	3.7	10.2	17.3	18.8	7.9	6.6	10.9	0.7	5.7	9.4	5.6	3.0	1.0	9.0	4.2	7.8	14.7	0.4	71.6	3.2	13.7	1.5	14.5	4.2	14.3	15.0	6.0	5.9	5.3	0.6	19.1	33.3	15.1	12.0	25.8	20.9	3.3	1.2	34.8	2.1	9.5	1.2	5.1	2.0	2.4	1.1	1.3	4.1	1.2	2.5	1.3	7.4	0.3	1.7	4.0	3.2	0.4	0.2	0.9	1.2	26.7	17.2	19.5	20.6	20.2	12.4	15.3	12.0	24.1	18.1	500.2	627.8	505.0	717.3	1097.5	107.5	1349.5	494.3	76.3	282.1	99.5	247.4	529.1	43.1	569.2	40.2	960.8	1411.6	46.7	449.9	86.5	867.7	1920.0	529.9	118.4	560.4	82.6	1440.1	352.4	430.2	18.1	1136.5	481.3	718.7	237.2	1907.1	688.6	543.7	1520.1	243.3	25.0	400.6	1513.4	1714.3	15.6	13.8	843.0	347.6	518.9	938.7	449.9
KAT6A	"MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220"	ENSG00000083168	"Lysine acetyltransferase 6A"	Q92794	8	41929479-42051990	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase"	"Cancer-related genes, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017023, HPA063266, HPA065052"	Supported		Approved	"Nucleoli,Nuclear speckles,Cytosol"		NA	NA			"Nuclear speckles"	"Nucleoli, Cytosol"	"CAB017023: , HPA063266: AB_2684973, HPA065052: AB_2685414"	"unprognostic (3.51e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.04e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.28e-1)"	"unprognostic (9.27e-3)"	"unprognostic (3.61e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.95e-1)"	"unprognostic (2.45e-2)"	"unprognostic (1.50e-1)"	"unprognostic (4.45e-2)"	"unprognostic (4.20e-3)"	"unprognostic (1.18e-1)"	"unprognostic (2.24e-1)"	"unprognostic (8.58e-2)"	"unprognostic (2.95e-2)"	20.8	10.9	15.3	19.8	20.3	36.8	22.6	29.9	18.7	19.7	14.6	19.4	14.4	10.7	20.6	12.1	16.9	16.5	14.3	13.0	15.5	11.5	12.3	13.6	26.9	28.2	23.2	10.3	27.2	13.1	26.8	22.3	20.9	15.7	14.1	12.0	12.8	15.1	17.0	21.0	25.5	18.0	25.0	22.9	20.4	14.0	14.1	21.7	30.4	17.9	14.3	20.1	16.9	24.2	4.7	1.8	10.9	1.6	3.1	3.9	1.4	13.1	10.8	17.8	11.3	10.0	11.4	6.0	8.8	11.5	10.9	8.5	6.8	6.3	19.5	8.9	8.7	10.6	8.5	13.8	8.4	13.0	10.0	8.1	28.1	6.7	5.1	7.5	14.8	12.9	9.5	9.6	10.1	12.6	8.0	10.5	17.3	23.5	12.4	10.0	5.8	30.0	4.7	6.8	9.9	4.3	24.0	19.9	6.2	5.4	15.1	11.1	9.5	10.3	6.9	7.1	8.4	15.9	6.5	12.2	13.5	9.6	12.0	9.4	10.1	16.4	21.2	7.3	6.7	11.6	3.5	1.6	2.8	3.5	1.2	3.9	2.4	2.6	3.3	1.0	4.7	3.6	2.9	10.9	3.1	1.2	1.8	3.5	1.4	15.3	20.3	29.9	18.7	15.5	11.5	23.2	10.3	15.7	21.7	32.8	30.4	27.2	23.8	44.8	44.6	22.6	25.5	21.4	30.7	12.2	51.1	12.1	3.3	11.8	1.8	50.4	18.7	46.7	10.4	13.1	28.5	21.6	33.6	22.2	14.6	55.6	23.7	43.0	37.4	3.5	26.2	31.3	21.9	8.2	25.7	32.4	13.2	17.5	21.5	9.3	45.4	19.4	33.9	41.9	36.2	53.4	17.6	45.8	18.9	26.1
KAT6B	"Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B"	ENSG00000156650	"Lysine acetyltransferase 6B"	Q8WYB5	10	74825582-75032622	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"PC-3: 22.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006104	Supported		Approved	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nucleoplasm, Nuclear bodies"		"HPA006104: AB_1079445"	"unprognostic (4.17e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.32e-2)"	"unprognostic (7.83e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.56e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.09e-1)"	"unprognostic (9.47e-2)"	"unprognostic (8.78e-2)"	"prognostic favorable (4.82e-4)"	"unprognostic (2.52e-1)"	"unprognostic (3.70e-1)"	"unprognostic (2.59e-2)"	"unprognostic (3.15e-1)"	11.6	9.5	11.1	13.2	11.9	15.1	12.4	19.0	11.6	16.7	12.2	13.3	15.3	7.2	25.1	13.0	12.0	13.2	12.0	10.0	10.6	9.5	9.0	7.3	9.2	9.0	9.0	9.9	24.6	13.3	24.8	31.1	9.4	8.9	13.5	9.6	10.1	17.9	12.0	15.3	10.6	11.3	16.2	9.3	10.4	13.0	12.8	12.1	26.6	13.0	8.9	12.5	14.3	12.7	3.2	1.9	1.6	1.1	5.3	3.7	1.5	3.9	4.1	7.4	6.3	5.9	8.7	3.6	3.5	7.0	3.0	3.4	2.7	4.6	8.5	1.9	6.4	3.2	3.1	3.9	3.1	5.0	3.6	5.7	3.1	3.3	3.9	4.4	7.4	2.1	5.6	5.0	4.2	6.7	9.9	3.5	6.7	3.3	7.3	3.8	4.3	7.1	3.4	4.1	4.3	22.9	11.1	3.8	1.8	2.2	2.0	3.7	6.2	3.6	6.6	3.2	2.8	3.7	2.9	4.2	4.3	5.1	2.8	3.3	5.4	6.3	5.7	4.6	7.8	0.9	0.7	1.1	1.6	3.2	0.9	3.4	2.4	2.4	2.7	1.2	3.2	3.7	3.4	0.9	5.3	0.8	1.9	2.4	1.5	11.1	11.9	19.0	11.6	10.6	9.5	9.0	9.9	8.9	12.1	41.7	50.1	23.2	20.4	17.6	50.8	43.1	10.2	38.8	35.2	8.7	64.8	8.7	8.3	8.6	4.4	18.6	17.3	23.3	15.8	8.8	28.2	22.8	39.4	14.4	9.7	41.3	22.8	13.5	11.0	6.7	39.1	13.9	13.5	4.6	18.3	49.8	10.2	14.4	37.8	8.0	53.6	25.8	24.0	25.6	21.2	15.3	19.0	34.6	15.5	17.1
KCNJ5	"CIR, GIRK4, KATP1, Kir3.4, LQT13"	ENSG00000120457	"Potassium voltage-gated channel subfamily J member 5"	P48544	11	128891356-128921035	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"Cancer-related genes, Disease mutation, Long QT syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 40.7;ductus deferens: 54.6;pituitary gland: 23.4"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 2: 10.6;Hofbauer cells: 37.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.9"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	13	"HBEC3-KT: 17.5"	"Group enriched"	"Detected in many"	6	"basal ganglia: 3.1;hypothalamus: 8.0;midbrain: 2.2;thalamus: 4.0"	"Low region specificity"	"Detected in all"			"HPA014722, HPA017353, CAB022569"	Approved					NA	NA					"CAB022569: , HPA014722: AB_1852133, HPA017353: AB_1852135"	"unprognostic (2.01e-1)"	"unprognostic (2.43e-3)"	"unprognostic (2.56e-3)"	"unprognostic (5.81e-2)"	"unprognostic (4.24e-2)"	"unprognostic (3.60e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.54e-2)"	"unprognostic (6.83e-2)"	"unprognostic (1.96e-1)"	"unprognostic (3.17e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.81e-2)"	"unprognostic (6.82e-2)"	"unprognostic (9.49e-2)"	"unprognostic (1.88e-2)"	"unprognostic (2.23e-2)"	1.8	40.7	0.8	0.3	1.9	0.2	0.9	0.3	1.2	0.8	0.8	1.9	54.6	0.4	0.3	1.1	0.6	0.6	1.3	8.7	1.6	2.5	2.0	0.3	3.4	0.8	3.7	0.8	0.8	16.6	0.7	23.4	4.3	3.4	0.8	0.4	3.3	0.9	21.7	0.3	0.4	0.5	0.7	4.5	7.7	1.5	0.7	0.9	2.3	0.7	0.4	0.3	1.1	0.5	0.9	0.4	2.9	0.7	0.6	0.4	0.4	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.3	0.1	0.1	0.0	0.3	0.1	0.4	17.5	0.0	0.2	0.1	0.1	0.6	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.3	0.4	0.3	0.0	0.2	0.0	0.4	0.3	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.2	0.0	0.1	0.0	0.2	0.2	0.1	0.0	0.5	0.2	0.1	0.1	1.3	0.0	2.2	0.7	0.6	0.4	0.3	0.3	0.3	0.2	0.3	0.3	0.9	0.3	0.4	2.9	0.6	0.4	0.4	0.2	0.4	0.8	1.9	0.3	1.2	1.6	2.5	3.7	0.8	3.4	0.9	0.0	10.6	0.0	2.3	1.3	1.7	5.8	0.0	0.0	0.0	1.8	0.0	0.7	0.0	0.0	2.1	0.6	0.0	0.0	3.2	0.6	2.1	0.4	0.0	0.0	37.1	1.6	0.0	0.6	1.8	4.5	0.9	1.9	3.3	1.8	0.0	0.3	1.3	0.0	0.7	0.0	1.4	0.0	0.1	0.2	0.7	1.5	1.0	0.0	0.0	0.5
KDM5A	"JARID1A, RBBP2"	ENSG00000073614	"Lysine demethylase 5A"	P29375	12	280129-389454	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, Dioxygenase, Oxidoreductase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006201			Supported	"Nuclear bodies,Cytosol"		NA	NA			"Nuclear bodies"	Cytosol	"HPA006201: AB_1079160"	"unprognostic (2.75e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.12e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.60e-1)"	"unprognostic (3.53e-3)"	"unprognostic (1.81e-2)"	"unprognostic (5.81e-2)"	"unprognostic (3.19e-1)"	"unprognostic (1.77e-3)"	"unprognostic (6.11e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.52e-1)"	"unprognostic (2.60e-2)"	"unprognostic (7.69e-2)"	13.6	14.4	10.6	13.7	13.0	41.6	13.1	21.8	13.2	11.8	10.3	14.8	11.3	7.8	14.2	8.1	13.6	11.2	10.0	10.1	11.5	5.7	9.0	10.7	13.1	14.9	15.1	9.1	15.2	11.5	16.8	13.8	12.4	11.3	10.6	10.9	10.6	12.9	8.6	9.7	20.3	13.0	10.4	10.1	15.5	10.6	21.2	14.8	28.8	11.4	7.1	16.1	13.1	18.8	17.2	16.8	33.7	14.1	18.6	18.1	10.1	7.7	14.0	10.3	7.9	9.3	8.8	11.5	6.9	9.2	10.4	11.3	8.3	9.4	13.0	2.2	11.5	9.1	7.4	10.7	7.8	12.5	20.5	8.9	15.9	14.6	4.9	7.5	20.7	12.6	9.6	7.4	12.8	17.1	10.7	10.5	11.7	9.5	18.3	8.8	5.2	14.8	5.9	16.0	6.7	4.4	13.9	26.9	6.1	5.0	17.9	4.0	11.6	13.6	6.2	7.3	14.9	6.7	13.1	14.3	6.9	9.9	7.6	11.5	6.5	7.1	29.9	8.8	9.1	10.1	30.2	11.3	22.2	17.7	13.1	18.1	14.1	13.8	14.2	11.8	17.2	15.1	12.9	33.7	18.6	14.1	16.8	10.5	10.1	10.6	13.0	21.8	13.2	11.5	5.7	15.1	9.1	11.3	14.8	59.6	53.6	57.8	19.7	29.3	64.2	35.8	35.7	40.2	39.8	33.2	110.0	38.1	3.3	31.6	79.2	46.6	34.3	0.0	27.4	28.3	35.7	25.6	52.1	23.6	26.7	82.6	66.8	42.4	53.2	21.3	44.8	47.2	25.3	60.5	35.6	48.0	31.1	37.9	52.3	10.5	68.8	58.2	30.9	105.6	111.6	41.7	59.5	62.5	36.0	33.9
KDM5C	"DXS1272E, JARID1C, MRX13, SMCX, XE169"	ENSG00000126012	"Lysine demethylase 5C"	P41229	X	53191321-53225422	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Dioxygenase, Oxidoreductase, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038244, HPA046147"			Enhanced	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA038244: AB_2675911, HPA046147: AB_2679555"	"unprognostic (1.19e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.56e-2)"	"unprognostic (7.10e-2)"	"unprognostic (9.75e-2)"	"unprognostic (2.19e-1)"	"prognostic unfavorable (2.11e-4)"	"unprognostic (2.08e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.24e-1)"	"unprognostic (5.45e-2)"	"unprognostic (1.58e-2)"	"unprognostic (5.05e-3)"	"unprognostic (1.96e-2)"	"unprognostic (6.91e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.00e-1)"	19.5	22.9	22.4	22.6	24.7	26.3	17.9	43.0	31.7	25.9	19.5	23.4	16.7	22.2	29.2	13.3	26.9	24.8	15.2	17.6	21.6	15.3	17.0	18.8	20.6	25.8	24.6	21.8	33.1	22.5	37.7	31.8	34.0	22.8	18.7	13.5	17.0	25.6	17.1	36.6	28.4	22.2	23.6	16.0	25.0	19.4	10.6	26.2	29.0	22.2	11.3	24.5	21.5	26.4	4.5	4.3	4.8	4.0	2.8	6.1	3.8	16.9	23.1	24.8	19.0	17.2	15.7	17.6	10.6	12.4	14.4	13.4	15.6	11.1	15.8	13.8	13.9	40.6	15.2	28.0	22.7	11.0	11.8	41.4	15.3	24.7	11.0	21.2	18.1	30.6	12.4	16.7	28.1	34.7	20.6	21.2	13.2	29.7	10.5	10.5	21.7	13.2	20.4	21.0	8.8	21.7	15.0	14.8	17.1	9.1	16.3	18.7	24.1	32.2	29.9	12.1	23.8	20.9	16.0	14.5	16.1	13.9	14.4	10.3	15.3	12.4	12.0	20.9	21.5	11.9	3.0	3.8	2.7	6.1	3.6	5.1	4.5	3.7	5.7	3.1	3.2	4.5	2.9	4.8	2.8	4.0	4.3	4.3	3.8	22.4	24.7	43.0	31.7	21.6	15.3	24.6	21.8	22.8	26.2	11.9	12.2	11.9	9.7	10.8	25.0	7.7	17.8	12.0	12.5	7.0	23.6	10.6	3.3	13.4	0.6	14.3	21.7	0.0	18.7	11.4	11.3	12.4	12.7	19.8	12.4	23.8	30.0	18.4	14.6	1.7	13.6	9.4	13.5	10.0	27.8	10.9	20.8	24.6	14.9	4.2	16.1	0.0	10.3	7.0	14.6	13.9	17.4	10.2	15.6	15.9
KDM6A	UTX	ENSG00000147050	"Lysine demethylase 6A"	O15550	X	44873177-45112602	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Chromatin regulator, Dioxygenase, Oxidoreductase"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000568, HPA001165, HPA002111"	Enhanced		Approved	"Nucleoplasm,Nucleoli,Nucleoli rim"	"Intracellular and membrane"	NA	NA			"Nucleoli, Nucleoli rim"	Nucleoplasm	"HPA000568: AB_1858705, HPA001165: AB_1080541, HPA002111: AB_1858704"	"unprognostic (1.73e-3)"	"unprognostic (6.86e-3)"	"unprognostic (1.45e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.58e-3)"	"unprognostic (8.22e-3)"	"unprognostic (3.23e-1)"	"unprognostic (2.44e-1)"	"unprognostic (2.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.73e-1)"	"unprognostic (2.24e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.26e-1)"	"unprognostic (3.16e-2)"	12.3	12.1	16.5	17.6	24.5	47.9	21.4	26.1	22.0	16.9	11.8	16.7	12.0	13.1	22.6	11.3	15.4	16.9	15.2	9.1	18.2	6.5	11.6	13.5	19.7	15.1	28.8	11.3	23.8	14.9	21.3	20.2	13.3	18.3	10.3	11.3	10.3	16.1	12.6	15.1	21.3	17.6	13.5	14.9	18.1	15.0	17.7	26.1	19.1	14.5	6.9	13.6	14.9	22.8	5.5	7.1	15.7	7.5	6.2	7.9	3.5	8.7	7.6	11.3	11.4	8.1	8.4	24.2	6.8	4.8	8.2	8.6	17.9	7.5	5.7	3.7	6.3	17.0	18.8	14.5	12.0	7.6	8.3	15.5	7.1	9.6	6.7	5.7	3.8	20.2	4.5	9.9	13.5	14.1	8.8	6.3	7.0	9.8	14.2	5.1	5.7	7.8	11.2	9.4	6.7	8.8	8.7	10.9	1.0	4.7	16.3	9.7	5.2	21.7	10.9	9.2	24.8	10.6	0.1	5.3	7.8	6.0	7.8	3.5	9.0	10.8	8.6	5.4	4.0	4.5	15.7	3.8	3.5	5.3	7.5	6.0	5.5	7.2	7.9	7.1	3.8	7.0	6.3	7.3	6.2	7.2	3.8	5.6	3.5	16.5	24.5	26.1	22.0	18.2	6.5	28.8	11.3	18.3	26.1	6.0	8.8	5.2	11.3	23.2	6.5	11.4	10.2	5.3	7.9	7.0	13.7	3.8	0.0	6.5	1.0	9.4	18.8	0.0	6.6	4.9	8.9	11.4	2.3	13.9	6.1	23.8	12.6	6.2	8.9	1.1	6.1	9.7	10.1	7.2	14.2	7.4	7.7	14.4	6.7	3.3	8.4	6.5	10.3	5.6	11.7	23.1	9.2	10.1	11.0	16.3
KDR	"CD309, FLK1, VEGFR, VEGFR2"	ENSG00000128052	"Kinase insert domain receptor"	P35968	4	55078259-55125595	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 100.3;Ito cells: 200.7;Muller glia cells: 229.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"HUVEC TERT2: 32.5;TIME: 36.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB004028	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		7400000	"Plasma membrane"		"CAB004028: AB_2212507"	"unprognostic (1.61e-1)"	"unprognostic (2.03e-1)"	"unprognostic (9.65e-2)"	"unprognostic (1.97e-1)"	"unprognostic (9.63e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.78e-3)"	"unprognostic (2.59e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.34e-1)"	"prognostic unfavorable (7.26e-4)"	"unprognostic (4.00e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.22e-1)"	"unprognostic (1.86e-1)"	19.7	6.2	1.8	4.4	3.1	0.4	20.5	1.1	2.2	11.4	6.0	1.8	11.5	2.3	28.8	10.2	5.2	9.5	6.2	12.1	2.3	1.7	7.8	10.4	13.2	14.1	3.1	2.9	6.0	8.1	8.0	6.8	34.5	3.9	9.5	1.4	27.6	7.1	10.3	5.3	3.0	3.8	7.7	2.6	4.4	4.2	5.3	1.2	0.5	20.0	5.3	3.0	4.4	12.0	0.1	0.1	0.7	0.0	0.2	0.2	0.1	0.0	0.0	1.7	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.8	0.0	0.0	0.3	0.0	0.0	0.2	0.2	32.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.7	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.1	1.8	3.1	1.1	2.2	2.3	1.7	3.1	2.9	3.9	1.2	0.0	8.2	7.5	0.4	2.3	7.4	4.8	0.0	6.7	30.7	0.0	0.0	0.1	0.0	0.5	0.8	100.3	0.0	0.0	0.0	0.1	1.9	0.4	2.3	1.3	0.4	0.0	0.0	200.7	14.5	0.6	0.0	1.0	6.8	0.0	0.0	229.2	0.3	0.0	0.4	0.0	6.0	0.0	1.4	0.2	0.2	2.4	0.1	0.0	0.0	0.4
KDSR	"DHSR, FVT1, SDR35C1"	ENSG00000119537	"3-ketodihydrosphingosine reductase"	Q06136	18	63327726-63367510	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Sphingolipid metabolism"	Oxidoreductase	"Cancer-related genes, Disease mutation, Palmoplantar keratoderma, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"U-266/70: 38.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003673, HPA044884"	Approved					NA	NA					"CAB003673: AB_425440, HPA044884: AB_2679131"	"unprognostic (4.44e-2)"	"unprognostic (8.57e-2)"	"unprognostic (2.52e-2)"	"unprognostic (4.56e-2)"	"unprognostic (5.88e-3)"	"unprognostic (7.50e-3)"	"unprognostic (1.80e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.97e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.70e-2)"	"unprognostic (6.81e-2)"	"prognostic favorable (9.53e-6)"	"unprognostic (3.32e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.16e-3)"	21.1	19.4	19.0	11.1	22.4	6.4	29.7	12.5	17.2	18.2	17.3	23.9	14.2	10.0	19.4	30.0	17.8	14.3	17.7	15.8	19.7	16.9	21.3	52.6	15.3	11.5	32.1	14.6	29.1	14.3	19.6	10.5	24.9	19.5	18.0	11.0	15.9	16.1	17.4	12.4	28.8	13.1	18.9	39.0	9.1	11.8	10.4	23.3	8.8	21.2	12.3	9.9	19.9	22.8	4.0	5.6	0.9	5.6	9.8	19.5	3.7	5.9	2.7	2.8	3.1	22.4	16.8	5.5	19.8	12.2	4.4	5.9	1.1	4.1	6.1	8.5	7.7	7.3	26.5	3.5	11.1	5.4	11.4	5.9	4.7	3.6	1.3	17.1	8.5	3.3	16.0	21.2	7.0	20.1	8.1	4.3	4.1	3.7	8.7	11.6	2.4	9.4	3.9	3.3	1.5	10.0	6.4	8.3	8.6	12.1	3.9	3.6	6.9	9.6	4.7	8.5	3.8	2.5	4.9	10.1	18.6	4.5	6.2	8.6	38.2	17.4	3.5	14.0	5.3	5.5	0.0	3.7	0.3	4.8	5.6	19.5	4.0	10.2	7.6	5.6	3.6	7.3	4.6	0.9	9.8	2.6	2.8	12.9	3.7	19.0	22.4	12.5	15.9	19.7	16.9	32.1	14.6	19.5	23.3	32.8	41.4	40.4	112.3	140.9	36.2	21.8	68.8	46.8	48.9	36.6	25.5	53.1	13.3	45.0	0.7	35.9	29.0	0.0	32.1	57.8	53.6	62.1	25.4	77.0	31.7	38.1	19.7	44.8	25.0	3.6	65.9	36.3	54.0	30.7	30.6	57.7	41.5	46.0	66.4	36.6	40.8	32.3	42.2	0.9	5.3	125.1	76.4	20.3	40.8	94.6
KEAP1	"INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454"	ENSG00000079999	"Kelch like ECH associated protein 1"	Q14145	19	10486120-10503741	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005558, CAB025337"	Approved		Supported	"Nucleoplasm,Centriolar satellite,Cytosol"		NA	NA			"Nucleoplasm, Centriolar satellite"	Cytosol	"CAB025337: , HPA005558: AB_1079175"	"unprognostic (1.98e-1)"	"prognostic favorable (3.28e-4)"	"unprognostic (1.61e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.48e-1)"	"unprognostic (5.22e-3)"	"unprognostic (2.04e-1)"	"unprognostic (9.99e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.71e-3)"	"unprognostic (5.06e-1)"	"unprognostic (8.18e-2)"	"unprognostic (1.60e-2)"	16.0	13.7	13.5	10.4	14.3	9.1	12.4	13.2	15.1	13.1	15.7	15.4	13.8	13.6	11.0	12.7	26.3	15.1	12.7	19.7	13.9	13.7	13.2	22.0	10.8	15.5	16.7	7.4	11.8	14.3	11.1	10.2	11.5	14.3	13.9	8.8	11.8	11.3	13.9	63.9	16.8	13.8	11.6	16.5	11.3	10.6	12.2	13.8	13.1	14.5	29.1	16.1	14.5	11.2	14.6	23.7	21.3	19.8	21.0	30.8	19.6	17.3	31.8	8.8	11.7	18.2	15.5	9.4	14.8	11.0	15.2	13.6	22.6	17.5	24.7	39.0	16.4	11.3	15.6	17.5	11.5	7.5	23.9	19.2	37.3	9.5	26.7	17.6	19.5	20.3	16.0	15.6	17.1	8.0	12.7	14.4	7.4	22.8	45.8	13.2	24.0	14.1	53.6	25.7	16.6	26.8	25.7	11.0	28.9	9.8	20.8	24.3	12.7	20.6	13.8	12.8	8.1	11.9	26.1	17.7	24.5	13.2	27.4	17.9	26.7	33.4	24.2	18.9	23.3	17.9	16.1	19.8	21.3	30.8	17.0	29.3	14.6	21.5	28.3	23.7	5.7	13.5	19.1	10.9	21.0	16.6	16.3	25.4	19.6	13.5	14.3	13.2	12.8	13.9	13.7	16.7	7.4	14.3	13.8	26.8	17.3	19.6	22.6	19.5	21.5	20.3	20.4	13.4	17.0	10.4	7.9	22.5	11.6	29.0	22.3	24.1	31.5	0.0	31.3	21.0	19.7	21.7	11.5	28.8	25.7	25.4	25.8	27.0	14.8	34.6	27.0	14.9	10.1	57.7	20.6	39.6	26.7	21.0	24.4	19.1	11.1	12.9	15.6	19.5	17.3	19.3	22.4	22.4	27.9	21.7
KIF5B	"KNS, KNS1"	ENSG00000170759	"Kinesin family member 5B"	P33176	10	32009010-32056431	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Motor protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009846, HPA037589, HPA037590"	Approved		Enhanced	"Centriolar satellite,Cytosol"		NA	Yes		260000	"Centriolar satellite, Cytosol"		"CAB009846: AB_2280915, HPA037589: AB_2675563, HPA037590: AB_2675564"	"unprognostic (4.94e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.84e-1)"	"unprognostic (4.00e-2)"	"unprognostic (6.21e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.84e-1)"	"unprognostic (2.70e-1)"	"unprognostic (6.37e-3)"	"unprognostic (2.03e-1)"	"unprognostic (2.60e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.39e-1)"	"unprognostic (8.06e-2)"	"unprognostic (1.76e-1)"	26.3	19.9	55.7	20.2	55.5	34.1	23.0	22.2	42.4	23.8	34.2	21.7	20.9	23.5	25.7	17.8	28.0	20.3	28.0	48.4	51.5	39.3	21.1	15.3	23.8	16.5	62.9	26.1	18.2	18.9	56.8	22.4	27.7	38.3	31.8	30.0	8.9	20.1	25.6	34.3	17.6	28.6	37.2	80.4	21.1	23.1	27.7	43.7	25.0	23.5	21.5	16.1	33.8	28.1	13.8	27.6	30.0	18.9	13.4	16.5	9.2	30.0	25.6	34.6	24.3	24.8	27.5	14.8	41.5	19.7	32.1	27.5	28.1	33.3	20.6	18.0	49.2	18.3	25.0	31.6	26.5	43.1	17.7	17.2	26.2	23.9	27.3	28.6	18.2	28.9	22.2	37.7	37.0	25.9	25.6	41.0	18.3	31.5	21.8	44.3	18.1	18.9	10.3	5.6	28.9	11.7	24.9	64.6	8.5	24.7	21.1	33.7	24.6	32.1	12.8	30.9	25.2	15.5	26.1	34.1	32.7	30.7	37.8	30.7	6.6	7.5	24.3	31.1	37.7	30.7	20.8	15.2	24.2	11.8	18.9	11.4	13.6	14.9	12.5	14.2	13.8	13.3	13.0	30.0	13.4	18.9	27.6	16.5	9.2	55.7	55.5	22.2	42.4	51.5	39.3	62.9	26.1	38.3	43.7	169.7	163.3	57.7	133.6	189.3	172.7	357.9	96.8	192.7	126.3	99.5	94.2	100.8	38.1	183.2	92.5	169.2	111.4	46.7	153.7	110.6	139.0	208.1	87.9	41.0	117.4	143.0	127.0	87.2	110.1	28.3	54.7	125.3	96.2	194.8	188.9	82.6	173.1	143.2	123.1	50.5	125.5	84.1	199.1	513.7	177.6	206.9	277.6	86.3	159.0	207.4
KIT	"C-Kit, CD117, PBT, SCFR"	ENSG00000157404	"KIT proto-oncogene receptor tyrosine kinase"	P10721	4	54657918-54740715	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 65.5"	"Group enriched"	"Detected in many"	10	"granulocytes: 496.5;Melanocytes: 200.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7"	"Group enriched"	"Detected in many"	6	"granulocytes: 12.7;NK-cells: 9.7"	"Group enriched"	"Detected in some"	13	"HEL: 48.8;HMC-1: 102.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252"	Enhanced	Supported	Supported	"Plasma membrane"		NA	NA		48000000	"Plasma membrane"		"CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589"	"unprognostic (1.55e-2)"	"unprognostic (1.91e-1)"	"unprognostic (4.04e-2)"	"unprognostic (8.19e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.92e-2)"	"prognostic favorable (5.63e-4)"	"unprognostic (1.34e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.30e-1)"	8.1	1.6	9.5	6.6	11.8	3.7	65.5	18.3	12.0	12.1	10.3	6.5	10.2	5.8	8.9	4.2	9.9	2.5	15.5	2.4	36.0	4.4	9.4	1.1	13.8	3.8	3.6	6.0	28.5	2.1	1.3	2.3	6.2	5.7	9.6	10.4	20.7	12.9	6.9	1.3	14.6	8.9	10.2	3.9	3.2	12.8	4.0	4.5	0.4	28.9	4.3	4.9	9.8	12.5	0.0	1.8	12.7	0.9	9.7	1.9	0.1	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.6	0.9	2.6	3.2	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.5	0.0	2.2	0.0	1.2	48.8	0.0	0.0	0.0	0.0	102.6	0.0	0.0	0.0	0.0	0.0	5.7	0.8	0.6	0.1	0.0	0.0	0.2	0.4	1.4	0.0	0.0	0.1	0.0	0.0	0.0	4.8	1.2	0.4	0.0	0.0	0.0	3.0	0.0	0.5	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	12.7	0.0	10.0	0.1	0.0	1.9	0.0	0.3	0.7	1.8	0.0	0.0	0.0	0.8	9.7	0.9	0.0	0.0	0.1	9.5	11.8	18.3	12.0	36.0	4.4	3.6	6.0	5.7	4.5	6.0	34.8	1.4	1.1	12.7	0.0	0.4	5.1	0.0	5.7	3.5	0.0	0.0	3.3	0.8	0.0	2.4	0.0	0.0	0.0	0.1	1.3	0.5	496.5	0.0	0.3	0.0	5.2	1.8	0.3	0.0	1.1	3.1	200.8	0.0	0.3	2.4	0.0	0.0	0.0	0.6	0.3	0.0	0.5	0.0	8.2	3.3	0.2	2.2	0.3	0.3
KLF4	"EZF, GKLF"	ENSG00000136826	"Kruppel like factor 4"	O43474	9	107484852-107490482	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skin 1: 92.1"	"Cell type enhanced"	"Detected in many"	6	"Mucus-secreting cells: 685.3;Suprabasal keratinocytes: 589.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	10	"classical monocyte: 5.2;intermediate monocyte: 7.4;myeloid DC: 4.4;non-classical monocyte: 2.9"	"Group enriched"	"Detected in many"	12	"dendritic cells: 4.4;monocytes: 7.4"	"Cell line enhanced"	"Detected in many"		"hTCEpi: 32.8;hTERT-HME1: 20.3;OE19: 17.5;U-2197: 49.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA002926	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA002926: AB_1852541"	"unprognostic (2.06e-1)"	"unprognostic (1.42e-2)"	"unprognostic (1.14e-2)"	"unprognostic (2.45e-1)"	"unprognostic (1.55e-1)"	"unprognostic (6.58e-3)"	"unprognostic (3.44e-2)"	"unprognostic (6.49e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.29e-2)"	"unprognostic (1.18e-2)"	"unprognostic (1.08e-1)"	"prognostic favorable (3.93e-5)"	"unprognostic (2.55e-1)"	"unprognostic (1.67e-1)"	"unprognostic (8.13e-2)"	"unprognostic (8.32e-2)"	29.2	8.5	2.7	23.8	3.9	14.4	23.7	1.8	3.5	39.1	28.9	5.6	5.5	10.2	17.8	18.6	34.9	22.0	32.4	18.6	2.4	2.2	4.8	5.1	35.6	4.4	2.7	2.2	18.6	2.3	2.7	2.8	41.0	6.2	11.3	29.6	11.7	11.9	6.5	13.6	92.1	39.4	16.0	3.3	21.8	22.2	11.2	2.0	1.9	7.8	81.1	30.7	16.8	24.1	0.0	4.4	0.4	7.4	0.1	0.0	1.3	5.7	2.3	0.2	0.0	6.0	15.5	2.2	2.0	10.6	2.7	3.2	0.8	7.3	0.0	0.3	2.6	9.4	4.2	2.6	1.5	1.0	0.0	1.1	0.0	4.0	0.1	9.0	0.0	0.0	2.0	32.8	5.5	20.3	0.6	0.2	0.1	0.2	0.0	1.5	3.7	0.0	0.7	1.8	17.5	11.5	0.1	0.6	0.1	0.8	1.6	0.1	0.1	1.6	4.8	6.0	4.8	0.7	2.5	1.2	1.6	0.0	49.8	0.8	0.0	0.0	0.0	1.6	1.0	2.8	0.0	5.2	0.0	0.0	7.4	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.4	0.1	2.9	0.4	0.0	1.3	2.7	3.9	1.8	3.5	2.4	2.2	2.7	2.2	6.2	2.0	11.9	47.4	12.3	228.3	387.3	0.4	56.5	17.8	18.7	29.6	1.8	7.9	33.0	1.7	21.1	201.9	242.7	430.0	0.0	34.8	55.7	240.7	170.1	55.2	3.9	80.6	0.0	118.8	142.4	148.1	123.4	133.2	214.3	195.7	12.6	685.3	1.7	32.1	447.5	57.0	1.2	1.8	38.8	108.2	4.1	15.1	589.1	90.3	5.3	253.4	169.8
KLF6	"BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9"	ENSG00000067082	"Kruppel like factor 6"	Q99612	10	3775996-3785281	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Basal glandular cells: 1442.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013529, HPA069585"	Supported		Supported	Nucleoplasm,Nucleoli,Vesicles,Cytosol		No	No			Nucleoplasm	"Nucleoli, Vesicles, Cytosol"	"CAB013529: AB_2533431, HPA069585: AB_2686157"	"unprognostic (1.23e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.47e-3)"	"unprognostic (4.53e-2)"	"unprognostic (1.47e-1)"	"unprognostic (7.55e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.08e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.83e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.35e-2)"	"prognostic favorable (2.28e-4)"	"unprognostic (8.07e-3)"	"unprognostic (4.85e-2)"	"unprognostic (6.87e-2)"	"unprognostic (1.37e-2)"	69.8	10.0	8.4	26.3	10.6	80.6	101.1	7.4	10.1	28.6	31.7	10.3	9.7	11.0	24.9	28.8	38.6	28.0	38.6	18.6	7.8	5.1	32.2	32.5	46.0	35.8	13.8	4.2	20.2	23.8	7.5	4.7	26.1	11.2	20.1	21.0	13.2	26.9	16.5	57.8	60.2	44.8	42.8	17.0	20.3	26.7	14.3	10.0	12.5	41.0	28.8	21.5	44.7	30.7	15.6	29.8	77.8	18.7	13.0	30.8	23.2	13.2	3.6	6.9	2.2	40.3	40.4	4.3	22.8	11.7	24.4	16.6	9.3	17.9	3.8	5.3	24.7	19.0	8.1	4.2	21.1	20.5	18.6	2.5	0.5	4.1	8.7	17.3	2.5	13.1	13.3	40.3	17.4	33.2	8.7	24.9	2.5	4.1	29.7	31.0	0.9	4.6	3.8	2.6	7.1	6.5	3.0	7.1	13.4	24.0	13.2	3.0	2.9	5.6	16.3	34.2	19.6	8.0	2.1	32.4	33.1	4.6	19.5	10.4	5.7	18.5	7.0	8.9	3.3	10.2	50.9	17.0	43.7	27.1	14.2	23.9	15.6	30.8	26.8	13.1	12.5	9.6	14.8	77.8	13.0	18.7	29.8	22.2	23.2	8.4	10.6	7.4	10.1	7.8	5.1	13.8	4.2	11.2	10.0	1158.3	540.6	237.0	1442.7	520.2	42.2	53.1	293.0	254.3	251.4	130.9	31.4	113.5	18.3	616.6	54.4	455.0	961.8	70.0	474.3	369.8	410.0	832.0	597.5	234.2	510.8	35.0	381.0	212.4	420.1	42.4	120.8	593.9	458.9	839.6	556.8	32.1	706.5	466.4	125.9	61.9	78.0	135.8	372.0	6.2	13.6	549.2	163.8	409.2	300.8	382.6
KLK2		ENSG00000167751	"Kallikrein related peptidase 2"	P20151	19	50861568-50880567	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	29	"prostate: 163.5"	"Cell type enriched"	"Detected in some"	36	"Glandular cells: 729.8"	"Cancer enriched"	"Detected in some"	1666	"prostate cancer: 989.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 5.0;NB-4: 10.2"									HPA000764	Supported				"Secreted in male reproductive system"	NA	NA					"HPA000764: AB_1079700"	"unprognostic (3.05e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.69e-1)"	"unprognostic (8.53e-2)"		"unprognostic (1.15e-1)"		"unprognostic (8.97e-2)"	"unprognostic (3.22e-1)"	"unprognostic (6.44e-2)"	"unprognostic (8.06e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.11e-3)"	"unprognostic (7.56e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.04e-1)"	0.0	0.1	0.0	0.1	0.0	1.1	0.2	0.0	0.6	0.0	0.0	0.0	0.6	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	163.5	0.0	0.1	2.3	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.6	0.0	0.0	1.1	0.0	0.0	0.2	0.0	2.2	1.9	5.7	2.2	1.6	1.3	0.5	1.7	1.1	0.6	1.6	0.0	0.9	5.0	0.5	0.3	0.2	0.2	0.6	0.8	1.8	0.2	0.0	0.8	2.0	0.2	0.0	0.3	1.7	1.1	0.0	1.3	0.4	0.0	0.3	3.1	0.5	0.3	0.3	0.4	0.5	0.0	1.1	1.5	2.0	0.3	1.8	1.2	10.2	1.1	1.7	0.0	0.9	0.0	2.9	0.0	1.7	0.9	1.6	0.3	1.4	1.3	0.2	1.3	0.4	0.8	1.3	1.9	4.9	1.7	1.8	3.2	0.8	1.9	1.7	1.4	0.9	2.2	1.6	1.2	1.0	1.0	1.0	0.8	1.0	0.5	2.2	0.8	1.3	5.7	1.6	0.8	1.9	0.4	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	13.7	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.1	0.0	729.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.4	5.0	0.6	0.0	0.0	0.0	9.2
KMT2A	"ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1"	ENSG00000118058	"Lysine methyltransferase 2A"	Q03164	11	118436490-118526832	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017794, CAB024270, HPA044910"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB017794: , CAB024270: , HPA044910: AB_2679141"	"unprognostic (6.80e-2)"	"unprognostic (8.93e-2)"	"unprognostic (1.83e-1)"	"unprognostic (4.56e-1)"	"unprognostic (4.96e-2)"	"unprognostic (1.72e-3)"	"unprognostic (4.52e-3)"	"unprognostic (6.07e-2)"	"unprognostic (1.61e-1)"	"unprognostic (8.46e-2)"	"unprognostic (3.21e-1)"	"unprognostic (1.16e-1)"	"unprognostic (5.91e-3)"	"unprognostic (7.90e-2)"	"unprognostic (3.73e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.02e-1)"	14.4	11.3	17.7	17.0	19.2	28.6	16.8	43.8	21.2	17.3	14.6	19.8	18.1	8.5	21.8	17.1	10.6	15.7	14.1	10.2	17.3	13.4	13.1	9.3	15.3	19.6	16.6	18.7	35.6	16.8	28.9	21.8	10.2	15.4	15.6	12.4	14.4	14.2	19.2	11.1	16.8	14.2	15.2	12.1	15.7	12.3	7.9	23.4	16.6	16.6	7.8	19.4	18.8	24.6	6.7	3.5	8.3	2.0	6.5	5.3	0.8	12.1	5.6	15.2	11.4	9.3	11.1	4.5	5.5	8.0	5.8	6.7	11.3	8.8	15.0	11.3	8.0	10.3	10.6	16.1	6.1	11.6	16.5	6.2	29.4	5.2	6.1	5.2	17.5	5.7	5.3	6.2	12.7	17.0	7.3	9.0	9.8	19.1	12.8	7.3	9.5	11.6	10.3	9.2	5.0	8.4	8.8	14.6	5.0	8.5	9.2	12.5	8.1	13.8	4.5	2.9	8.3	7.8	5.9	13.2	9.9	9.0	7.2	9.8	3.7	2.9	10.1	3.7	12.9	5.9	8.3	2.0	4.6	5.3	1.3	4.3	6.2	4.8	4.6	0.8	6.7	4.9	4.8	1.3	6.5	1.4	3.5	3.9	0.8	17.7	19.2	43.8	21.2	17.3	13.4	16.6	18.7	15.4	23.4	65.5	59.8	31.5	64.8	77.2	147.8	34.4	38.2	53.5	35.2	36.6	143.3	12.2	3.3	26.8	6.6	70.1	19.7	0.0	22.3	8.1	43.5	71.4	26.7	23.1	14.2	184.3	63.8	45.4	32.6	4.7	61.9	26.1	40.5	33.3	29.3	117.0	23.2	14.4	73.9	6.9	144.6	64.7	59.7	11.1	14.9	70.4	5.0	50.7	27.3	49.9
KMT2C	"HALR, KIAA1506, MLL3"	ENSG00000055609	"Lysine methyltransferase 2C"	Q8NEZ4	7	152134922-152436005	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA074736			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA074736: AB_2686709"	"unprognostic (7.75e-2)"	"unprognostic (3.10e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.31e-1)"	"unprognostic (5.23e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.45e-1)"	"unprognostic (1.06e-1)"	"prognostic favorable (8.01e-6)"	"unprognostic (1.78e-1)"	"unprognostic (3.83e-1)"	"unprognostic (3.04e-2)"	"unprognostic (2.64e-1)"	13.9	12.6	11.7	16.7	18.6	29.7	14.5	24.8	14.1	18.4	12.6	15.5	21.4	9.7	20.2	20.6	14.4	12.8	12.7	10.8	13.4	9.5	10.3	11.4	13.0	12.1	17.7	9.4	18.8	18.4	18.8	18.9	38.0	12.6	14.0	11.8	12.6	15.8	22.9	30.3	25.2	13.1	13.6	16.0	14.6	14.9	13.6	19.6	22.6	16.9	9.3	16.8	17.8	31.6	5.6	3.5	16.1	3.9	5.5	2.9	0.6	9.7	4.9	9.1	9.7	16.5	10.0	10.7	5.1	3.9	4.1	5.0	9.3	5.9	15.5	7.4	9.2	5.6	5.6	9.8	7.4	6.9	9.8	5.0	9.2	7.4	6.4	8.0	15.5	11.3	8.4	10.3	5.8	7.8	6.6	5.8	8.1	14.8	13.4	8.9	13.6	11.2	14.1	5.5	7.6	4.9	7.6	8.3	8.1	7.0	10.0	13.3	10.5	8.4	15.0	5.5	9.9	4.9	12.8	7.3	6.8	3.6	7.3	7.2	14.1	6.9	16.7	8.9	12.8	7.0	8.8	3.5	4.3	2.1	2.2	2.9	5.6	1.7	1.7	1.7	3.8	2.7	1.8	16.1	5.5	3.9	3.5	1.3	0.6	11.7	18.6	24.8	14.1	13.4	9.5	17.7	9.4	12.6	19.6	71.5	66.6	54.7	36.1	79.1	82.8	58.2	45.9	44.2	92.1	43.6	163.0	29.7	5.0	30.2	18.6	49.2	41.0	23.3	28.7	45.7	47.0	48.1	62.5	36.6	29.6	76.3	65.1	41.7	48.8	11.0	62.5	61.0	40.5	25.2	44.5	62.2	33.0	43.8	56.6	15.7	75.2	25.8	50.1	33.5	31.5	84.2	106.4	50.4	30.3	55.0
KMT2D	"ALR, CAGL114, MLL2, MLL4, TNRC21"	ENSG00000167548	"Lysine methyltransferase 2D"	O14686	12	49018975-49059774	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cone photoreceptor cells: 49.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 5.9"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA035977	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		Yes	No			"Plasma membrane, Cytosol"	Nucleoplasm	"HPA035977: AB_10670673"	"unprognostic (8.33e-2)"	"unprognostic (1.49e-1)"	"unprognostic (9.14e-2)"	"unprognostic (2.52e-1)"	"unprognostic (8.07e-2)"	"unprognostic (6.91e-3)"	"unprognostic (7.35e-2)"	"unprognostic (2.29e-1)"	"unprognostic (3.57e-1)"	"unprognostic (5.14e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.68e-2)"	"unprognostic (7.10e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.20e-2)"	"unprognostic (7.60e-2)"	12.1	7.6	4.9	6.7	10.8	26.1	6.8	11.7	10.5	9.5	6.5	5.8	13.0	5.5	15.7	7.4	8.8	8.9	5.8	9.1	6.1	3.5	6.2	6.5	22.9	9.6	6.7	3.3	9.7	11.6	13.3	9.2	12.9	13.7	6.7	6.6	9.8	7.6	8.0	16.1	13.6	9.4	7.1	9.1	13.6	8.3	7.3	5.7	6.2	11.0	6.1	7.6	7.0	6.3	2.0	2.2	5.9	0.5	1.5	0.8	0.6	17.1	16.3	16.5	13.3	17.1	11.5	17.7	9.1	9.5	11.8	6.3	28.6	7.3	17.8	11.8	12.7	8.5	11.6	21.7	10.0	9.8	10.4	17.4	22.6	17.1	15.3	11.7	26.8	22.7	9.7	14.4	16.5	17.1	14.1	17.5	18.5	28.3	9.9	13.3	18.9	13.3	25.0	15.6	23.7	14.1	20.0	10.2	6.4	9.9	19.0	13.8	11.7	14.0	13.8	9.5	15.0	13.7	23.5	23.3	9.3	16.6	8.1	15.2	14.1	9.1	17.3	10.7	13.9	6.9	0.6	0.5	3.0	0.8	0.2	0.4	0.3	0.3	0.5	0.3	2.0	0.3	0.8	5.9	1.5	0.1	2.2	0.0	0.6	4.9	10.8	11.7	10.5	6.1	3.5	6.7	3.3	13.7	5.7	8.9	18.4	11.1	6.5	12.5	25.2	4.7	12.7	5.3	9.1	17.4	49.1	6.6	1.7	5.8	2.5	12.6	11.1	0.0	5.2	4.6	8.5	8.3	8.1	12.3	8.3	20.6	12.6	17.2	19.7	1.1	8.9	9.6	10.1	4.6	10.5	5.2	7.2	8.6	10.3	4.3	38.9	6.5	3.3	3.7	3.2	15.4	9.5	10.4	10.1	8.4
KNL1	"AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7"	ENSG00000137812	"Kinetochore scaffold 1"	Q8NG31	15	40594020-40664342	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Mitosis"		"Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"lymphoid tissue: 54.7;testis: 35.6"	"Cell type enhanced"	"Detected in some"	12	"Club cells: 3.4;Extravillous trophoblasts: 9.3;Hofbauer cells: 5.6;Proximal tubular cells: 8.4;Syncytiotrophoblasts: 3.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"							"HPA026624, HPA049647"	Enhanced		Enhanced	"Nucleoplasm,Nuclear bodies"		Yes	Yes			Nucleoplasm	"Nuclear bodies"	"HPA026624: AB_10601696, HPA049647: AB_2680840"	"unprognostic (5.35e-2)"	"unprognostic (1.01e-1)"	"unprognostic (5.59e-3)"	"unprognostic (4.22e-2)"	"unprognostic (1.59e-2)"	"unprognostic (5.66e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavorable (2.11e-4)"	"unprognostic (2.06e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.20e-4)"	"unprognostic (2.22e-2)"	"unprognostic (1.93e-12)"	"unprognostic (3.07e-2)"	"unprognostic (3.08e-1)"	"unprognostic (8.45e-2)"	"unprognostic (7.36e-2)"	0.7	0.5	0.3	7.1	0.4	5.4	0.7	0.3	0.3	0.6	4.0	0.1	0.0	1.5	0.4	0.8	3.9	0.4	0.9	0.5	0.4	0.4	0.9	1.0	1.3	4.7	0.3	0.0	0.5	0.5	0.0	0.4	2.8	0.1	0.5	1.5	0.0	0.8	0.0	0.4	0.8	3.9	0.5	0.4	3.3	0.8	35.6	0.0	54.7	0.5	4.1	3.7	0.7	0.9	2.9	1.2	0.7	0.5	0.7	2.5	0.0	10.9	5.6	11.5	8.3	0.3	1.7	5.1	12.8	5.2	10.0	8.5	6.9	4.4	7.3	4.1	5.5	7.6	13.7	10.8	6.0	10.6	12.6	3.0	21.4	9.6	2.0	0.0	16.3	10.8	0.3	0.2	6.7	4.2	1.3	8.5	13.0	13.7	12.2	11.7	3.7	13.9	3.3	5.6	6.6	6.0	12.7	16.5	3.6	1.5	9.7	9.9	4.6	11.1	6.3	1.3	3.8	6.8	5.0	7.9	11.7	10.4	13.4	7.1	4.7	15.9	14.2	4.7	11.1	11.1	0.4	0.2	0.1	0.1	0.1	0.0	2.9	1.1	0.1	1.2	2.2	0.0	0.7	0.7	0.7	0.5	0.1	2.5	0.0	0.3	0.4	0.3	0.3	0.4	0.4	0.3	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	3.4	1.8	0.0	2.4	1.7	0.2	0.0	0.0	0.0	0.0	0.5	9.3	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	8.4	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0
KRAS	"KRAS1, KRAS2"	ENSG00000133703	"KRAS proto-oncogene, GTPase"	P01116	12	25204789-25250936	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins"		Hydrolase	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049830	Approved					NA	NA		5800000			"HPA049830: AB_2680903"	"unprognostic (2.24e-2)"	"unprognostic (2.16e-2)"	"unprognostic (4.86e-3)"	"unprognostic (1.08e-2)"	"unprognostic (7.39e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.47e-2)"	"unprognostic (3.74e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.39e-1)"	"prognostic unfavorable (3.59e-4)"	"unprognostic (6.42e-2)"	"prognostic favorable (2.75e-5)"	"unprognostic (1.95e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-2)"	"unprognostic (9.97e-2)"	11.7	9.9	14.4	15.5	19.5	24.1	10.6	21.1	25.6	10.3	26.2	7.3	7.9	16.1	11.3	7.7	25.1	10.1	13.9	9.3	13.6	16.6	14.0	17.9	14.9	15.1	11.6	15.8	13.1	13.6	12.7	9.8	15.7	21.1	12.1	28.1	9.8	16.2	9.8	10.0	14.0	23.7	17.2	11.3	15.7	23.6	7.8	9.5	18.5	11.1	10.6	16.3	16.8	14.3	10.0	7.1	20.8	18.9	9.4	13.8	5.0	6.8	6.9	15.5	8.7	5.8	7.9	31.2	7.0	8.8	7.3	8.7	24.0	15.7	15.7	4.2	12.1	9.8	7.5	18.1	7.6	13.8	10.7	6.3	14.8	7.4	5.9	6.1	13.8	11.3	7.3	10.4	8.8	7.9	13.4	10.6	11.5	10.5	7.5	10.7	5.8	19.0	21.1	34.1	11.2	2.8	16.5	16.4	22.6	10.8	12.1	4.7	13.3	8.3	11.0	8.3	42.6	12.2	10.0	12.2	8.2	10.9	15.4	8.6	6.6	11.0	17.0	6.3	8.1	5.9	20.8	7.8	12.4	11.9	14.4	7.5	10.0	10.4	13.0	7.1	8.6	13.8	12.1	19.0	9.4	18.9	7.1	6.7	5.0	14.4	19.5	21.1	25.6	13.6	16.6	11.6	15.8	21.1	9.5	44.7	28.0	47.9	74.6	89.6	61.8	13.7	71.4	22.7	23.9	36.6	68.7	77.0	49.7	64.2	2.8	58.3	123.1	46.7	79.4	16.4	50.1	116.8	23.1	52.1	45.9	87.4	75.6	73.6	60.9	2.5	37.7	60.3	59.1	92.0	88.6	31.5	107.1	78.0	48.4	38.6	62.1	25.8	43.4	57.5	37.0	136.1	116.4	56.8	58.1	134.2
KTN1	"CG1, KIAA0004, KNT"	ENSG00000126777	"Kinectin 1"	Q86UP2	14	55559072-55701526	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003178, CAB015331, HPA017876"	Enhanced		Enhanced	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB015331: , HPA003178: AB_1079218, HPA017876: AB_1852652"	"unprognostic (7.00e-3)"	"unprognostic (2.99e-2)"	"unprognostic (8.60e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.49e-1)"	"prognostic unfavorable (6.83e-5)"	"prognostic unfavorable (3.76e-4)"	"unprognostic (1.75e-1)"	"unprognostic (1.21e-2)"	"unprognostic (1.01e-1)"	"unprognostic (9.08e-2)"	"unprognostic (8.72e-2)"	"prognostic favorable (1.01e-6)"	"unprognostic (1.27e-1)"	"unprognostic (2.75e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.04e-1)"	26.5	27.5	30.8	18.9	37.3	9.5	44.2	30.8	35.2	22.7	28.8	15.8	23.4	13.0	18.8	30.8	26.1	16.8	18.1	36.1	32.2	25.3	33.1	31.8	21.2	16.9	39.3	24.5	23.1	22.8	48.3	54.7	21.3	49.5	26.9	28.7	13.1	21.4	24.0	101.9	41.4	20.1	40.5	51.9	22.1	18.9	40.9	42.0	14.5	33.3	37.9	17.9	32.7	39.7	35.6	58.3	27.0	15.5	19.6	24.0	4.8	40.7	28.2	21.1	23.0	29.2	28.0	30.6	33.3	26.8	20.9	18.6	18.8	50.7	31.4	47.7	34.2	22.3	76.3	25.8	29.0	35.4	52.8	14.1	22.2	46.7	35.6	27.6	32.5	18.0	26.0	26.6	25.8	44.8	45.0	34.3	25.1	21.6	18.4	40.1	31.8	27.9	19.3	16.2	18.9	42.1	22.3	55.5	14.9	52.5	64.1	26.0	21.7	52.7	24.2	29.2	45.0	25.1	20.9	48.3	42.8	54.8	21.9	31.2	8.3	11.2	23.4	50.1	19.1	23.7	27.0	14.8	14.6	19.6	13.1	18.7	28.3	23.2	22.1	14.2	35.6	24.0	20.6	9.4	19.6	15.5	58.3	14.8	4.8	30.8	37.3	30.8	35.2	32.2	25.3	39.3	24.5	49.5	42.0	285.9	218.9	134.1	191.3	581.3	188.0	751.3	254.8	254.3	215.0	406.5	339.7	116.7	26.6	214.2	480.1	300.8	208.9	46.7	262.9	169.7	168.2	247.6	130.6	360.3	102.3	308.3	215.0	264.6	155.1	281.2	230.1	161.1	163.6	161.5	208.3	454.2	307.7	252.8	415.1	100.9	370.8	329.8	235.9	615.9	350.9	632.0	137.8	123.1	224.4	298.6
LASP1	"Lasp-1, MLN50"	ENSG00000002834	"LIM and SH3 protein 1"	Q14847	17	38869859-38921770	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Transport"	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 124.5"	"Cell type enhanced"	"Detected in many"	8	"Late spermatids: 467.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012072, CAB022049"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA		26000000	"Plasma membrane, Cytosol"	"Focal adhesion sites"	"CAB022049: , HPA012072: AB_1852714"	"unprognostic (1.23e-1)"	"unprognostic (2.09e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavorable (4.57e-4)"	"unprognostic (1.47e-1)"	"unprognostic (3.03e-2)"	"prognostic unfavorable (2.41e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-1)"	"unprognostic (9.60e-2)"	"unprognostic (9.87e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.65e-3)"	"unprognostic (1.29e-3)"	"unprognostic (3.95e-2)"	"unprognostic (1.60e-3)"	"unprognostic (4.53e-2)"	51.2	20.0	23.8	40.3	22.4	45.4	35.5	15.5	25.7	23.6	57.4	16.3	18.7	54.4	23.4	24.1	22.4	20.8	48.3	15.2	18.4	23.3	33.1	47.5	33.3	44.2	20.0	14.3	28.4	30.1	10.1	17.6	40.0	16.1	18.9	38.6	24.2	22.4	24.1	10.7	18.3	124.5	21.3	12.2	43.1	39.5	13.9	12.9	40.5	18.3	18.7	33.7	22.0	28.3	6.4	13.9	34.0	19.9	17.3	16.5	13.1	35.4	73.9	21.6	19.1	31.8	34.5	37.3	44.6	43.6	47.0	34.6	22.0	38.6	16.2	37.3	68.9	26.7	56.5	9.8	33.9	41.2	11.8	5.3	7.7	21.4	38.3	30.2	17.8	23.4	30.6	11.9	39.8	11.3	29.4	31.5	10.0	13.1	5.4	65.4	11.7	21.1	27.5	10.8	31.2	18.5	11.9	11.5	20.4	57.7	31.2	3.2	7.9	26.5	27.9	23.1	41.8	44.0	21.8	55.0	28.2	41.2	33.0	27.0	14.0	18.4	12.6	29.8	16.0	33.9	9.9	14.8	16.8	16.5	17.1	11.3	6.4	8.4	11.0	13.9	6.3	7.2	10.9	34.0	17.3	19.9	10.7	10.7	13.1	23.8	22.4	15.5	25.7	18.4	23.3	20.0	14.3	16.1	12.9	38.7	25.9	38.3	19.5	37.2	55.7	0.8	66.2	32.1	19.4	69.8	9.8	4.3	14.9	58.2	85.5	48.9	225.0	0.0	65.7	33.5	47.6	22.3	51.8	85.9	75.8	25.4	83.1	70.6	116.7	467.6	48.1	58.0	33.7	52.3	91.2	21.1	95.7	106.3	37.4	62.1	22.0	64.7	29.7	2.1	4.1	24.8	5.4	60.9	75.9	23.8
LCK		ENSG00000182866	"LCK proto-oncogene, Src family tyrosine kinase"	P06239	1	32251239-32286165	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 112.2;lymphoid tissue: 153.0"	"Cell type enriched"	"Detected in many"	10	"T-cells: 207.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	14	"gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2"	"Group enriched"	"Detected in many"	13	"NK-cells: 42.8;T-cells: 112.2"	"Group enriched"	"Detected in some"	6	"JURKAT: 66.9;MOLT-4: 93.9;U-698: 54.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003494, CAB003816"	Enhanced		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"CAB003816: AB_562158, HPA003494: AB_1852751"	"unprognostic (6.38e-3)"	"unprognostic (5.45e-3)"	"unprognostic (8.39e-2)"	"prognostic favorable (2.96e-6)"	"unprognostic (2.20e-2)"	"prognostic favorable (2.91e-4)"	"unprognostic (4.78e-3)"	"unprognostic (1.33e-2)"	"prognostic favorable (5.65e-5)"	"unprognostic (3.07e-2)"	"unprognostic (3.80e-2)"	"unprognostic (2.83e-1)"	"prognostic unfavorable (2.60e-5)"	"unprognostic (8.15e-2)"	"unprognostic (4.05e-2)"	"unprognostic (7.39e-2)"	"unprognostic (1.17e-2)"	2.6	0.7	0.4	28.2	0.5	3.8	1.3	0.3	0.5	1.7	3.9	0.5	0.9	2.2	1.1	4.5	2.3	1.6	3.8	1.0	0.4	0.4	3.0	2.3	6.6	34.9	0.9	0.5	1.2	0.8	0.0	0.8	0.7	0.6	2.2	1.9	1.3	8.4	1.3	0.9	1.0	16.5	0.7	1.0	28.9	3.5	0.7	0.5	153.0	2.9	1.5	27.1	5.8	2.1	6.1	0.5	2.5	0.3	42.8	112.2	109.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	11.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.9	0.0	0.0	0.0	0.0	93.9	0.0	1.0	0.8	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	54.1	0.0	0.0	0.0	0.6	0.3	0.4	83.4	0.3	77.5	4.0	86.1	90.2	0.3	6.1	97.0	91.3	2.5	42.8	0.3	0.5	112.2	109.3	0.4	0.5	0.3	0.5	0.4	0.4	0.9	0.5	0.6	0.5	0.0	16.0	20.4	0.9	4.0	0.0	1.1	2.5	2.7	2.3	3.5	0.0	0.2	0.0	0.3	0.1	1.6	0.0	0.0	0.4	0.1	2.0	0.8	4.7	1.0	0.3	0.0	2.4	3.7	4.9	0.0	0.0	0.6	3.3	0.0	0.0	0.0	2.7	0.0	0.4	1.1	0.0	0.0	0.9	3.7	1.9	2.8	0.3	207.5	0.4	1.0
LEF1	"TCF10, TCF1ALPHA, TCF7L3"	ENSG00000138795	"Lymphoid enhancer binding factor 1"	Q9UJU2	4	108047545-108168956	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 231.5"	"Cell type enhanced"	"Detected in many"	12	"Distal tubular cells: 11.6;Melanocytes: 32.1;Spermatocytes: 21.3;T-cells: 13.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 42.2"	"Lineage enriched"	"Detected in many"	5	"T-cells: 42.2"	"Group enriched"	"Detected in many"	5	"JURKAT: 98.3;MOLT-4: 93.3;REH: 72.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002087, CAB019405"	Enhanced		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"CAB019405: AB_823558, HPA002087: AB_1079245"	"unprognostic (1.03e-3)"	"unprognostic (7.36e-3)"	"unprognostic (2.97e-2)"	"prognostic favorable (1.37e-5)"	"unprognostic (9.08e-2)"	"unprognostic (5.24e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.10e-2)"	"unprognostic (1.77e-1)"	"unprognostic (5.21e-2)"	"unprognostic (9.99e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavorable (2.47e-6)"	"unprognostic (1.12e-1)"	"unprognostic (5.22e-2)"	"unprognostic (7.88e-2)"	"unprognostic (8.91e-2)"	0.9	13.5	3.5	9.3	5.4	7.6	2.0	1.6	3.4	3.6	1.0	2.9	0.8	0.4	6.0	3.5	3.4	5.0	2.8	0.5	4.7	5.2	2.7	0.3	2.4	25.3	4.9	1.9	1.8	0.8	0.0	1.1	7.8	3.1	2.8	1.0	1.6	3.1	0.7	0.5	2.4	3.9	2.9	4.4	7.0	0.9	8.2	2.3	231.5	2.7	1.3	20.6	4.8	3.2	0.3	0.1	0.5	0.0	8.9	42.2	9.5	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	1.2	0.3	0.7	4.1	0.0	0.0	0.0	0.0	0.4	0.0	1.2	0.0	0.5	0.0	2.9	1.0	0.0	0.0	0.0	3.6	0.5	0.0	0.1	0.0	0.1	0.6	0.0	98.3	2.1	0.0	0.4	0.1	93.3	0.0	0.2	1.0	0.2	72.0	1.4	0.0	0.3	0.2	0.4	0.8	0.0	0.0	13.8	1.1	0.3	0.0	0.0	1.9	1.6	0.0	2.4	6.0	2.5	16.5	1.2	0.0	7.9	0.0	0.0	0.0	2.6	0.0	0.5	0.1	19.7	8.8	0.0	0.3	42.2	29.2	0.5	8.9	0.0	0.1	25.7	9.5	3.5	5.4	1.6	3.4	4.7	5.2	4.9	1.9	3.1	2.3	3.0	3.4	0.0	1.1	3.0	0.0	1.2	0.0	4.0	1.2	0.0	0.0	0.1	11.6	0.0	3.1	3.6	0.0	0.0	0.0	0.1	1.8	1.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	6.9	0.6	0.8	32.1	0.0	0.0	0.4	0.2	0.0	0.0	0.3	0.0	0.0	5.9	21.3	9.6	1.1	0.3	13.1	0.1	0.3
LIFR	CD118	ENSG00000113594	"LIF receptor alpha"	P42702	5	38474963-38608354	"Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	6	"Ito cells: 765.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 40.6;HHSteC: 17.3;SCLC-21H: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA		74000				"unprognostic (6.00e-3)"	"unprognostic (2.53e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.81e-3)"	"unprognostic (8.80e-2)"	"unprognostic (7.13e-2)"	"unprognostic (1.11e-1)"	"prognostic favorable (1.92e-4)"	"unprognostic (1.78e-1)"	"unprognostic (9.80e-2)"	"unprognostic (2.73e-3)"	"unprognostic (1.06e-1)"	"prognostic favorable (1.40e-7)"	"unprognostic (3.69e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.65e-1)"	35.3	14.7	15.8	8.2	19.2	0.5	33.9	10.1	21.3	27.7	10.4	25.3	22.8	4.9	34.8	14.8	10.4	26.0	10.2	16.3	19.1	11.0	20.3	23.9	21.7	20.2	24.3	11.8	17.9	17.8	13.5	12.5	41.5	23.4	23.6	7.5	17.1	24.9	24.7	24.0	10.5	11.7	26.9	21.4	22.5	18.8	9.3	25.3	4.7	31.4	7.3	8.1	13.6	15.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.6	2.3	40.6	3.0	11.4	12.7	0.3	3.4	1.9	2.7	1.7	0.4	2.2	0.0	0.5	4.8	6.9	0.3	2.6	0.9	4.7	0.0	3.7	0.0	4.3	1.6	17.3	0.0	0.2	10.6	0.7	6.6	0.7	2.6	3.8	0.4	1.1	6.5	3.4	0.5	0.0	0.1	1.0	0.0	7.2	0.0	8.6	0.0	2.6	1.0	26.6	3.3	14.0	0.7	0.0	5.3	0.9	0.0	0.8	4.4	8.7	10.3	2.0	0.0	0.0	0.0	7.2	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.8	19.2	10.1	21.3	19.1	11.0	24.3	11.8	23.4	25.3	11.9	34.9	9.3	5.9	20.6	5.8	24.6	10.2	10.7	10.3	14.0	7.9	7.7	5.0	1.9	12.6	122.5	0.0	0.0	7.8	22.5	46.1	21.1	1.1	6.8	3.2	1.6	0.0	765.5	62.0	21.6	105.3	2.6	16.9	0.0	0.0	5.1	6.9	0.0	18.7	13.5	35.3	38.8	42.2	8.9	6.1	15.8	23.9	7.5	0.0	4.7
LMNA	"CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1"	ENSG00000160789	"Lamin A/C"	P02545	1	156082573-156140089	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Cardiomyopathy, Charcot-Marie-Tooth disease, Congenital muscular dystrophy, Disease mutation, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"granulocytes: 1139.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"basophil: 10.4;memory CD4 T-cell: 8.9;myeloid DC: 34.8;T-reg: 35.4"	"Group enriched"	"Detected in all"	8	"dendritic cells: 34.8;granulocytes: 10.4;T-cells: 35.4"	"Cell line enhanced"	"Detected in many"		"WM-115: 137.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004022, HPA006523, HPA006660, HPA012078"	Supported		Supported	"Nucleoplasm,Nuclear speckles"		NA	NA		3200000	"Nucleoplasm, Nuclear speckles"		"CAB004022: AB_2136278, HPA006523: , HPA006660: AB_1079231, HPA012078: "	"unprognostic (2.22e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.04e-2)"	"unprognostic (5.75e-2)"	"unprognostic (7.43e-3)"	"unprognostic (1.47e-1)"	"unprognostic (5.23e-3)"	"unprognostic (3.27e-2)"	"unprognostic (8.33e-2)"	"unprognostic (5.90e-2)"	"unprognostic (5.10e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.41e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.08e-2)"	"unprognostic (1.44e-2)"	64.0	37.3	7.4	51.4	11.8	21.3	88.6	9.0	10.8	62.8	32.6	21.9	27.2	28.6	69.1	52.3	62.2	40.1	77.7	62.5	8.8	7.5	25.9	26.6	51.8	39.6	15.7	11.2	60.3	30.9	15.2	17.4	73.3	18.1	34.0	15.2	32.7	37.5	26.4	36.3	68.7	29.9	63.0	10.3	22.4	36.7	30.2	12.9	9.4	31.5	140.0	35.6	46.4	51.2	1.1	34.8	10.4	3.5	1.7	35.4	6.4	59.1	58.7	6.5	17.4	32.9	57.1	20.0	64.0	81.5	48.3	33.4	14.8	58.6	0.5	38.0	98.4	24.9	69.3	9.5	49.6	12.6	20.1	5.6	18.7	47.2	34.3	29.7	3.2	55.2	34.1	21.6	39.2	27.0	25.0	43.1	0.0	10.0	4.5	52.9	46.7	0.1	10.3	4.8	68.6	74.8	0.2	22.7	17.3	47.8	28.4	6.6	13.3	43.2	46.9	59.4	10.0	39.6	15.4	76.8	46.1	29.3	56.9	51.6	4.4	1.2	1.2	75.3	3.1	137.4	10.4	3.5	0.1	1.2	0.8	1.0	1.1	8.9	3.4	34.8	0.0	0.1	0.3	0.8	1.7	0.1	0.3	35.4	6.4	7.4	11.8	9.0	10.8	8.8	7.5	15.7	11.2	18.1	12.9	244.2	393.4	23.4	924.2	542.3	8.1	85.2	119.8	93.7	315.1	153.5	45.2	422.7	92.9	335.7	28.0	269.0	358.5	46.7	313.5	336.4	599.3	268.8	1139.0	91.5	324.9	12.7	414.0	194.0	35.3	30.8	267.2	305.5	814.9	19.0	337.1	35.8	392.9	289.2	270.1	93.5	18.0	200.5	784.5	74.2	30.2	526.5	569.5	18.5	345.1	767.5
LMO1	"RBTN1, RHOM1, TTG1"	ENSG00000166407	"LIM domain only 1"	P25800	11	8224304-8268716	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	5	"retina: 29.4;skeletal muscle: 29.1"	"Group enriched"	"Detected in some"	6	"Basal keratinocytes: 16.5;Distal tubular cells: 23.2;Early spermatids: 35.8;Horizontal cells: 38.1"	"Cancer enriched"	"Detected in many"	6	"glioma: 6.4"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 21.7;SCLC-21H: 8.5;SH-SY5Y: 26.0;SiHa: 5.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.74e-3)"	"unprognostic (1.45e-1)"		"unprognostic (4.75e-6)"	"unprognostic (9.34e-2)"	"unprognostic (2.37e-1)"		"unprognostic (1.98e-1)"	"unprognostic (7.06e-3)"	"unprognostic (8.09e-2)"	"unprognostic (2.24e-1)"	"unprognostic (9.05e-2)"	"unprognostic (4.36e-12)"	"unprognostic (1.76e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.58e-2)"	"unprognostic (3.13e-2)"	0.3	1.7	2.5	0.3	2.1	0.2	0.6	0.4	3.0	0.2	0.2	1.5	0.1	0.4	0.3	2.1	0.6	0.3	0.2	0.5	2.3	5.9	1.0	0.2	0.2	0.2	3.5	0.6	0.2	1.6	0.2	2.1	0.3	2.1	0.3	0.2	29.4	0.2	0.2	29.1	6.4	0.3	0.5	1.2	0.6	0.6	1.6	2.0	0.1	0.2	0.1	0.2	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	0.1	0.3	0.0	0.0	0.0	0.9	0.0	21.7	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.2	0.0	3.1	0.0	0.0	0.0	0.4	0.9	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	8.5	26.0	5.2	2.9	0.1	1.1	0.0	0.0	0.0	0.0	0.6	0.0	0.2	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.1	0.4	3.0	2.3	5.9	3.5	0.6	2.1	2.0	0.0	0.0	0.0	0.0	16.5	1.1	1.0	0.0	4.0	0.0	0.0	0.0	0.1	23.2	0.2	35.8	0.1	0.0	0.0	1.1	4.9	0.2	0.0	1.1	0.0	0.2	38.1	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.5	3.1	0.0	0.4	0.0	3.7	0.0	0.0	0.5	1.2	3.0	0.2	0.0	0.0	0.0
LMO2	"RBTN2, RBTNL1, RHOM2, TTG2"	ENSG00000135363	"LIM domain only 2"	P25791	11	33858576-33892289	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	11	"Endothelial cells: 121.0;Erythroid cells: 46.7;Ito cells: 110.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"basophil: 1.5;classical monocyte: 1.1;eosinophil: 3.0;intermediate monocyte: 3.1;myeloid DC: 4.3;neutrophil: 1.6;non-classical monocyte: 3.6"	"Group enriched"	"Detected in many"	7	"dendritic cells: 4.3;granulocytes: 3.0;monocytes: 3.6"	"Cell line enhanced"	"Detected in some"		"HEL: 23.3;HL-60: 23.2;K-562: 23.6;NB-4: 9.9;THP-1: 30.8;U-937: 10.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016258, HPA029285, HPA070901, HPA070910"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB016258: AB_2136572, HPA029285: AB_2672978, HPA070901: , HPA070910: "	"unprognostic (1.60e-1)"	"unprognostic (1.47e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.71e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.14e-3)"	"prognostic favorable (3.12e-4)"	"unprognostic (1.73e-3)"	"unprognostic (8.95e-2)"	"unprognostic (5.76e-2)"	"unprognostic (7.86e-3)"	"unprognostic (3.69e-1)"	"unprognostic (7.10e-2)"	"unprognostic (9.65e-2)"	"unprognostic (3.90e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.46e-2)"	18.2	6.1	13.8	13.6	15.6	28.8	14.5	5.2	18.4	9.4	5.5	10.3	6.4	6.2	9.7	9.9	6.9	8.6	9.1	6.4	15.8	12.2	12.9	5.5	15.9	22.2	14.2	7.2	5.1	3.9	4.2	8.3	8.5	11.9	8.3	2.7	14.6	4.5	4.0	25.0	4.2	5.5	6.6	13.9	22.0	4.4	3.6	11.1	1.0	10.7	8.1	13.3	11.1	14.8	0.5	4.3	3.0	3.6	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.9	0.5	5.7	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	23.3	0.0	0.0	0.1	23.2	8.1	0.0	0.0	0.0	0.0	0.0	4.5	0.0	23.6	0.0	0.0	0.1	2.1	9.9	0.4	0.0	0.0	6.6	0.3	0.0	0.0	0.3	1.9	0.0	0.1	0.2	0.0	0.1	0.0	30.8	0.3	0.0	0.1	0.7	0.0	0.0	0.1	0.2	2.1	10.9	0.1	1.5	1.1	3.0	0.0	3.1	0.1	0.5	0.0	0.0	4.3	0.0	0.0	0.0	1.6	0.0	3.6	0.3	0.0	0.5	13.8	15.6	5.2	9.5	15.8	12.2	14.2	7.2	11.9	11.1	3.0	10.3	7.6	7.8	7.4	1.4	1.7	7.6	5.3	0.0	5.2	2.0	0.3	0.0	2.9	0.2	121.0	0.0	46.7	1.7	1.7	8.4	4.1	7.0	1.0	33.2	0.0	0.0	110.5	41.7	0.7	3.7	42.5	10.1	0.0	0.0	1.0	0.9	0.0	0.0	5.6	1.9	0.0	2.8	0.2	2.7	5.3	18.0	0.5	0.4	19.5
LPP		ENSG00000145012	"LIM domain containing preferred translocation partner in lipoma"	Q93052	3	188153284-188890671	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 127.8;urinary bladder: 105.1"	"Cell type enhanced"	"Detected in all"	11	"Early spermatids: 514.4;Late spermatids: 1329.9;Smooth muscle cells: 529.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 18.0"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 29.5;EFO-21: 36.6;U-698: 61.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011133, HPA017342"	Enhanced		Enhanced	"Focal adhesion sites,Cytosol"		NA	NA		520000	"Focal adhesion sites, Cytosol"		"HPA011133: AB_1853247, HPA017342: AB_1853249"	"unprognostic (1.50e-1)"	"unprognostic (4.97e-3)"	"unprognostic (1.41e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.05e-1)"	"unprognostic (2.43e-3)"	"unprognostic (7.97e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.56e-2)"	"unprognostic (3.44e-3)"	"unprognostic (2.10e-1)"	"unprognostic (2.57e-3)"	"unprognostic (2.25e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.82e-3)"	"unprognostic (1.48e-1)"	19.6	4.2	2.7	29.5	2.8	3.1	12.5	3.0	2.7	42.2	29.9	2.1	19.6	5.0	68.6	14.9	59.7	10.0	37.9	9.3	2.6	2.8	10.9	5.3	11.4	6.0	2.8	1.6	26.1	4.4	4.7	3.2	5.2	3.0	37.7	12.8	8.5	7.0	28.4	11.6	5.9	17.2	127.8	3.2	9.5	12.1	30.7	1.5	5.1	5.4	4.2	7.8	105.1	38.3	5.9	4.9	18.0	4.5	4.3	5.0	1.4	7.7	7.1	5.2	3.5	11.3	11.7	5.6	5.1	6.5	3.7	2.5	12.9	3.7	29.5	36.6	11.4	4.6	3.3	1.5	3.4	9.4	3.2	1.7	1.4	5.5	3.4	4.8	0.6	1.7	8.3	4.8	8.3	7.2	5.4	6.2	1.6	0.0	0.6	6.5	2.4	1.5	0.6	2.1	4.9	2.3	1.9	3.9	0.1	4.1	8.2	0.3	0.0	10.9	3.6	6.1	9.0	2.8	2.4	13.4	8.6	6.6	6.1	12.5	0.0	1.1	61.0	4.3	1.3	7.7	0.8	4.5	1.9	5.0	4.2	3.2	2.9	4.3	3.6	2.4	5.9	2.3	2.9	18.0	4.3	4.0	4.9	1.6	1.4	2.7	2.8	3.0	2.7	2.6	2.8	2.8	1.6	3.0	1.5	83.4	55.0	41.3	72.1	69.3	7.7	101.6	99.3	40.2	83.0	66.3	13.7	35.7	24.9	114.3	514.4	83.0	142.7	23.3	78.6	20.6	102.9	124.2	17.4	84.7	36.8	4.8	74.4	114.2	61.5	1329.9	208.5	76.2	75.9	36.1	86.3	27.1	104.6	158.4	448.3	61.0	7.4	329.8	529.6	8.1	6.6	59.6	15.6	39.5	123.5	109.3
LRIG3	"FLJ90440, KIAA3016"	ENSG00000139263	"Leucine rich repeats and immunoglobulin like domains 3"	Q6UXM1	12	58872149-58920522	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"		"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	4	"Cholangiocytes: 33.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 27.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010773	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA010773: AB_1853275"	"unprognostic (1.79e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.01e-2)"	"unprognostic (3.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.46e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.34e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.92e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.25e-2)"	"unprognostic (2.74e-3)"	"unprognostic (2.47e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.28e-2)"	"unprognostic (1.46e-2)"	15.8	1.7	3.6	11.8	4.1	0.0	16.4	1.0	3.7	18.7	14.8	7.8	12.1	8.4	14.2	13.8	17.1	9.9	17.8	4.7	4.6	1.8	6.5	6.1	9.6	5.0	3.6	2.6	14.7	15.3	4.8	10.3	6.8	5.8	15.5	16.0	13.5	24.9	11.6	5.0	25.9	10.0	21.6	3.0	7.2	13.5	6.4	6.6	5.4	37.6	15.0	12.8	15.7	20.7	0.0	0.0	0.0	0.0	0.0	0.4	0.1	2.0	1.9	7.4	0.5	13.6	15.9	1.7	4.9	14.3	4.8	5.1	5.8	2.7	1.9	10.0	5.4	5.8	9.6	2.7	12.6	3.5	14.6	9.6	0.5	3.3	2.8	2.6	0.8	0.2	15.7	27.4	5.1	11.0	9.4	13.1	2.2	0.1	2.4	3.2	0.9	2.3	0.0	7.9	2.4	2.9	0.0	6.3	4.8	3.7	10.6	7.5	0.0	4.3	2.7	4.5	11.0	5.0	0.1	5.6	6.5	4.5	3.9	6.4	1.0	0.0	0.0	1.3	0.0	3.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.6	4.1	1.0	3.7	4.6	1.8	3.6	2.6	5.8	6.6	14.9	17.4	0.0	7.5	19.9	2.6	4.1	33.1	13.4	23.9	1.8	0.0	0.7	0.0	9.0	0.3	11.4	10.7	0.0	15.8	0.4	8.2	2.6	0.0	6.8	1.9	3.2	11.1	4.3	0.3	0.0	25.0	0.2	3.3	0.0	11.8	2.8	7.5	14.0	27.3	4.2	0.1	6.5	11.3	0.4	1.5	19.6	0.2	0.0	25.9	2.7
LRP1B	"LRP-DIT, LRPDIT"	ENSG00000168702	"LDL receptor related protein 1B"	Q9NZR2	2	140231423-142131701	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.7;thyroid gland: 14.9"	"Group enriched"	"Detected in some"	5	"Bipolar cells: 15.8;Early spermatids: 4.6;Late spermatids: 4.3"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"myeloid DC: 1.4;plasmacytoid DC: 1.2"	"Lineage enriched"	"Detected in single"	14	"dendritic cells: 1.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 4.2;HEK 293: 4.5;HeLa: 2.3;HSkMC: 2.2;U-138 MG: 4.9;U-87 MG: 2.6"	"Low region specificity"	"Detected in all"							"HPA069094, HPA074788"	Approved		Approved	Vesicles		NA	NA		63000	Vesicles		"HPA069094: AB_2686082, HPA074788: AB_2797273"	"unprognostic (5.31e-4)"	"unprognostic (3.68e-2)"	"unprognostic (2.61e-1)"	"unprognostic (7.36e-4)"	"unprognostic (5.19e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.00e-2)"	"unprognostic (3.49e-1)"	"unprognostic (3.75e-1)"	"unprognostic (7.02e-3)"	"unprognostic (1.64e-3)"	"unprognostic (1.05e-1)"	"unprognostic (2.94e-3)"	"unprognostic (4.85e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.36e-1)"	4.8	4.5	17.6	1.3	14.1	1.2	2.6	23.2	25.7	1.4	1.3	6.5	0.0	1.2	1.3	6.8	1.3	1.9	1.4	1.6	18.3	9.3	2.2	1.6	1.4	1.2	10.8	16.7	3.0	1.2	1.1	12.7	1.2	12.8	3.5	1.3	0.1	2.5	3.8	10.5	1.7	1.3	1.3	8.2	1.2	1.5	1.9	10.6	0.0	14.9	0.0	1.3	1.2	1.4	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	4.2	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	1.0	0.2	0.2	0.6	4.5	0.0	2.3	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.4	1.7	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.9	0.2	0.0	0.0	0.4	0.0	0.0	0.0	4.9	0.1	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	17.6	14.1	23.2	21.3	18.3	9.3	10.8	16.7	12.8	10.6	0.0	0.0	0.0	0.3	0.2	15.8	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	1.1	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.7	0.0	0.8	0.0	0.3	0.1	0.1	0.3	0.0	0.0	0.0	0.6
LYL1	bHLHa18	ENSG00000104903	"LYL1, basic helix-loop-helix family member"	P12980	19	13099033-13103161	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 37.4;lymphoid tissue: 25.4"	"Group enriched"	"Detected in many"	4	"Early spermatids: 274.5;Late spermatids: 496.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 8.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HEL: 33.0;HL-60: 23.1;HMC-1: 55.7;K-562: 25.9;NB-4: 33.8;REH: 24.8;THP-1: 22.4;U-937: 22.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA075004			Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA075004: AB_2686728"	"unprognostic (8.62e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.27e-2)"	"unprognostic (3.29e-3)"	"unprognostic (2.76e-1)"	"unprognostic (3.64e-3)"	"unprognostic (2.46e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.87e-2)"	"unprognostic (1.78e-3)"	"unprognostic (1.36e-1)"	"prognostic unfavorable (3.89e-4)"	"unprognostic (1.18e-1)"	"unprognostic (6.54e-2)"	"unprognostic (1.33e-1)"	"unprognostic (4.28e-1)"	6.3	3.0	3.4	19.9	5.8	37.4	8.0	1.1	3.8	4.0	3.7	5.5	1.3	3.0	5.3	3.9	5.9	3.8	3.5	4.9	4.5	2.9	3.9	2.0	8.1	24.0	7.1	1.6	3.2	1.6	0.8	1.7	8.0	5.1	6.2	1.4	4.4	6.4	2.4	3.5	2.0	8.8	3.3	6.0	25.4	4.2	11.9	4.1	3.6	3.5	1.4	18.9	3.3	7.0	4.6	1.4	8.8	3.6	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.0	6.4	2.2	0.0	0.0	0.0	0.1	0.0	0.0	3.7	0.0	33.0	0.0	0.3	0.3	23.1	55.7	0.1	0.0	0.0	0.0	0.0	8.5	0.0	25.9	1.1	0.0	0.0	0.1	33.8	0.0	0.1	0.8	24.8	0.0	2.8	0.0	0.0	0.0	2.4	0.7	0.0	1.5	0.0	0.0	22.4	13.6	0.0	0.0	0.9	0.0	0.0	0.0	5.2	0.0	22.3	0.0	2.5	2.3	8.8	0.1	2.9	0.2	2.8	0.3	0.2	1.4	4.6	0.2	0.2	3.6	0.0	3.6	0.4	0.5	0.6	3.4	5.8	1.1	3.7	4.5	2.9	7.1	1.6	5.1	4.1	0.0	0.3	46.4	0.5	2.3	0.0	2.0	2.5	1.4	0.0	1.8	0.0	0.6	0.0	0.2	274.5	27.4	1.1	70.0	0.0	0.8	4.7	0.2	44.9	0.8	92.6	0.0	1.7	20.9	52.2	496.4	7.5	33.5	6.8	2.8	1.1	1.4	1.2	1.5	11.3	0.2	0.1	12.9	1.8	39.2	5.5	1.6	1.3	2.2	0.8	0.4
LZTR1	"BTBD29, LZTR-1"	ENSG00000099949	"Leucine zipper like transcription regulator 1"	Q8N653	22	20982013-20999038	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA067852, HPA068772, HPA071248"	Approved		Approved	Nucleoplasm,Centrosome,Cytosol		No	No			Nucleoplasm	"Centrosome, Cytosol"	"HPA067852: , HPA068772: AB_2686031, HPA071248: AB_2686372"	"unprognostic (1.88e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.44e-2)"	"prognostic unfavorable (5.15e-4)"	"unprognostic (9.81e-2)"	"unprognostic (3.55e-1)"	"unprognostic (3.78e-2)"	"unprognostic (1.01e-2)"	"unprognostic (2.64e-1)"	"unprognostic (1.16e-3)"	"unprognostic (4.29e-2)"	"unprognostic (1.65e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.25e-2)"	21.2	16.9	17.3	15.6	17.4	10.3	17.9	20.7	24.7	18.5	18.3	25.3	20.6	18.9	24.9	14.0	16.5	18.3	21.2	15.8	15.4	10.9	17.2	13.1	16.2	12.8	19.6	16.5	21.7	16.2	24.9	26.0	18.8	19.0	16.9	12.9	18.9	17.5	18.0	17.2	15.0	15.7	21.9	14.0	19.3	14.5	10.8	19.2	10.8	19.6	12.6	12.5	18.5	16.4	1.6	2.2	0.2	3.4	1.8	3.0	1.5	6.3	5.2	7.8	9.4	17.9	12.4	6.3	13.0	9.1	7.4	10.2	3.0	2.6	6.7	4.8	14.5	6.9	8.6	5.8	10.6	3.0	12.5	13.6	7.2	6.8	4.5	9.6	3.9	9.6	11.4	5.4	9.4	6.8	11.8	14.4	6.3	30.0	11.7	8.4	3.8	6.9	3.7	2.4	7.7	5.7	8.2	11.3	2.6	5.9	8.6	7.7	11.4	7.1	12.3	7.6	4.9	5.7	7.2	12.8	17.4	8.9	7.8	7.0	5.1	4.4	2.0	7.8	3.8	8.4	0.0	2.5	0.2	3.0	3.1	1.6	1.6	1.5	2.8	2.2	1.0	2.1	1.5	0.1	1.8	3.4	1.2	0.5	1.5	17.3	17.4	20.7	24.7	15.4	10.9	19.6	16.5	19.0	19.2	11.9	10.4	9.7	1.4	1.9	8.1	11.2	2.5	6.7	5.7	8.7	5.9	3.6	1.7	6.6	0.8	9.5	7.8	0.0	4.3	3.2	5.4	2.0	5.7	6.2	6.9	3.2	8.7	12.3	11.6	1.3	8.1	4.9	6.8	4.6	9.1	6.6	5.7	5.9	9.2	6.1	9.3	0.0	7.2	2.6	1.7	3.1	3.0	6.9	5.8	0.9
MAF	c-MAF	ENSG00000178573	"MAF bZIP transcription factor"	O75444	16	79585843-79600714	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Cataract, Deafness, Disease mutation, Dwarfism, Mental retardation, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Hofbauer cells: 210.4;Ito cells: 532.8;Kupffer cells: 333.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"basophil: 20.7;MAIT T-cell: 6.3"	"Group enriched"	"Detected in many"	16	"granulocytes: 20.7;T-cells: 6.3"	"Group enriched"	"Detected in some"	12	"Karpas-707: 50.3;RPMI-8226: 81.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010296, HPA028289"	Approved					NA	NA					"CAB010296: AB_638562, HPA028289: AB_10602024"	"unprognostic (6.76e-2)"	"unprognostic (1.74e-2)"	"unprognostic (6.45e-2)"	"unprognostic (7.65e-2)"	"unprognostic (7.89e-3)"	"unprognostic (1.07e-2)"	"unprognostic (1.63e-2)"	"unprognostic (2.33e-1)"	"unprognostic (8.76e-2)"	"unprognostic (3.16e-2)"	"unprognostic (9.46e-2)"	"unprognostic (1.28e-1)"	"prognostic unfavorable (3.74e-4)"	"unprognostic (4.54e-2)"	"unprognostic (7.83e-2)"	"unprognostic (1.09e-2)"	"unprognostic (4.56e-3)"	19.0	10.2	15.4	17.3	13.5	2.5	28.5	9.3	11.2	25.6	31.8	10.7	9.1	41.7	18.8	15.6	16.7	15.1	12.4	19.0	14.3	5.8	28.7	18.0	16.8	38.1	20.5	9.9	31.4	3.1	59.1	4.8	21.7	13.9	15.8	7.2	14.1	9.7	10.4	26.3	37.2	57.7	15.8	18.7	19.8	9.5	12.4	14.0	10.2	18.4	16.7	14.3	14.6	23.4	0.0	0.0	20.7	0.8	0.6	6.3	0.4	0.0	0.0	5.3	0.0	0.2	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.0	1.6	2.0	0.0	0.0	0.0	0.2	0.0	3.5	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.5	50.3	0.3	0.0	0.0	0.1	3.3	0.0	0.0	0.0	1.5	81.9	0.0	0.4	0.1	0.0	0.2	0.0	0.1	2.2	0.0	0.0	1.0	0.0	1.7	0.1	0.2	0.0	0.0	0.0	0.2	0.0	0.3	20.7	0.2	0.0	0.8	0.8	6.3	0.0	2.4	1.9	0.0	0.0	0.2	0.3	0.0	0.6	0.2	0.0	3.1	0.4	15.4	13.5	9.3	11.2	14.3	5.8	20.5	9.9	13.9	14.0	8.9	20.0	10.0	3.4	78.5	3.6	6.5	50.9	0.0	5.7	3.5	0.0	1.5	10.0	1.5	0.9	17.7	9.3	0.0	0.7	2.2	63.5	45.2	20.9	52.3	210.4	0.0	2.9	532.8	333.1	4.8	138.7	42.5	42.2	0.0	2.8	71.1	2.6	3.6	108.2	90.5	2.3	12.9	23.7	0.3	0.9	123.3	3.5	69.2	1.2	4.8
MAFB	KRML	ENSG00000204103	"MAF bZIP transcription factor B"	Q9Y5Q3	20	40685848-40689240	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 87.6;parathyroid gland: 154.1"	"Cell type enhanced"	"Detected in many"	12	"Hofbauer cells: 322.7;Kupffer cells: 488.8;Macrophages: 252.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"intermediate monocyte: 27.4;non-classical monocyte: 36.7"	"Lineage enriched"	"Detected in many"	14	"monocytes: 36.7"	"Cell line enhanced"	"Detected in some"		"HSkMC: 16.2;hTCEpi: 34.0;SCLC-21H: 9.3;SiHa: 8.4;U-138 MG: 9.2;U-2197: 13.4;U-87 MG: 8.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA005653	Approved		Approved	"Nucleoplasm,Nucleoli,Golgi apparatus,Cytosol"		Yes	NA			Nucleoplasm	"Nucleoli, Golgi apparatus, Cytosol"	"HPA005653: AB_1079293"	"unprognostic (1.55e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.16e-3)"	"prognostic unfavorable (5.64e-4)"	"unprognostic (9.16e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.57e-2)"	"unprognostic (6.09e-2)"	"unprognostic (5.45e-3)"	"unprognostic (9.92e-2)"	"unprognostic (3.95e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.21e-3)"	"unprognostic (3.49e-2)"	"unprognostic (2.30e-2)"	38.3	7.9	3.2	13.0	4.0	17.0	19.5	1.0	9.7	10.6	6.9	3.0	1.2	3.3	5.6	8.9	16.8	7.0	9.2	12.4	3.6	2.3	10.9	14.0	21.9	28.9	4.7	3.4	7.0	6.1	154.1	2.3	9.4	5.0	7.6	3.3	5.6	10.4	2.7	11.0	41.6	7.6	5.5	7.7	87.6	4.7	7.5	3.8	6.9	18.2	20.5	11.4	8.2	10.9	0.0	2.5	0.7	36.7	0.0	0.0	2.5	0.0	0.0	0.0	1.4	0.8	0.1	0.2	0.2	0.0	0.1	0.0	0.2	0.1	0.0	1.1	0.2	0.0	2.0	0.0	0.0	0.0	0.0	0.7	0.0	0.6	0.1	0.5	0.0	0.1	16.2	34.0	0.1	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.1	3.9	1.4	3.3	0.0	0.0	0.0	0.0	0.3	0.2	9.3	0.7	8.4	0.8	2.0	3.1	0.8	0.1	0.2	9.2	0.1	13.4	0.0	0.0	0.0	0.0	8.9	0.3	0.0	0.1	7.3	0.0	0.0	27.4	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.7	0.0	36.7	0.0	0.0	2.5	3.2	4.0	1.0	9.7	3.6	2.3	4.7	3.4	5.0	3.8	20.8	32.3	6.7	25.3	60.9	14.6	153.6	7.6	0.0	13.6	48.8	23.6	7.5	1.7	2.0	0.6	19.9	50.9	0.0	3.0	2.1	61.9	37.1	10.4	32.6	322.7	3.2	55.5	34.4	488.8	0.7	27.3	252.1	20.3	0.0	13.7	25.8	5.4	24.6	23.0	0.8	8.2	12.9	44.3	0.5	0.9	77.0	10.4	4.4	8.1	17.7
MALT1	"MLT, PCASP1"	ENSG00000172175	"MALT1 paracaspase"	Q9UDY8	18	58671386-58754477	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Hydrolase, Protease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cone photoreceptor cells: 80.5;monocytes: 107.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RPTEC TERT1: 51.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB004494, HPA048432"	Enhanced		Approved	"Nucleoli fibrillar center,Cytosol"		No	No			"Nucleoli fibrillar center"	Cytosol	"CAB004494: AB_627909, HPA048432: AB_2680389"	"unprognostic (3.25e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.64e-2)"	"unprognostic (3.25e-2)"	"unprognostic (1.65e-3)"	"unprognostic (4.67e-2)"	"unprognostic (6.46e-2)"	"unprognostic (4.50e-2)"	"unprognostic (3.33e-2)"	"unprognostic (4.16e-3)"	"unprognostic (3.74e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.97e-1)"	"unprognostic (1.03e-1)"	"unprognostic (6.00e-2)"	11.2	3.9	4.1	21.7	5.6	10.2	10.6	9.1	6.8	11.0	10.7	3.9	10.9	5.5	8.1	10.5	16.4	6.6	8.1	8.7	4.0	4.3	14.9	10.5	14.3	29.0	4.1	1.8	8.1	6.2	10.0	9.3	8.8	4.9	18.1	7.9	7.5	10.7	8.4	10.7	12.6	12.2	6.6	6.2	19.9	6.2	11.8	4.8	22.4	7.9	12.4	24.0	9.6	12.3	6.3	3.6	1.2	1.7	1.6	4.8	1.1	7.5	10.8	13.2	3.3	2.6	5.9	6.0	13.6	9.6	11.8	10.1	8.8	9.8	12.0	6.1	16.8	8.5	7.4	5.7	5.6	14.6	8.1	3.1	4.2	7.7	14.1	4.3	8.6	5.8	3.7	11.9	9.3	9.4	6.2	2.5	3.4	7.0	21.0	6.4	2.4	1.9	3.7	3.3	3.1	3.7	6.5	7.8	8.5	51.8	3.1	1.4	3.0	7.5	3.8	5.1	9.8	3.8	5.0	3.5	15.3	6.7	4.5	12.5	18.8	22.2	10.5	6.1	6.5	6.0	0.8	1.5	1.0	2.7	1.7	2.1	3.6	4.8	2.9	2.2	6.3	4.3	2.8	1.2	1.6	1.6	3.6	2.9	1.1	4.1	5.6	9.1	6.8	4.0	4.3	4.1	1.8	4.9	4.8	20.8	19.2	15.7	28.7	29.3	12.4	13.1	10.2	6.7	7.9	10.4	80.5	5.2	3.3	14.7	9.8	21.6	6.8	0.0	7.2	5.0	8.0	52.3	31.1	8.9	10.4	52.4	6.4	9.8	16.4	5.3	9.5	23.0	11.8	107.4	8.2	29.6	11.9	20.1	6.7	17.3	17.2	19.4	12.0	33.4	32.5	21.7	7.6	22.4	9.1	29.1
MAML2	"KIAA1819, MAM3"	ENSG00000184384	"Mastermind like transcriptional coactivator 2"	Q8IZL2	11	95976598-96343180	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Notch signaling pathway, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cone photoreceptor cells: 86.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 27.9"					"Low region specificity"	"Detected in all"			HPA035223	Approved		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"		No	No			"Nuclear bodies"	"Nucleoplasm, Cytosol"	"HPA035223: AB_10671101"	"unprognostic (8.11e-2)"	"unprognostic (2.51e-1)"	"unprognostic (7.08e-2)"	"unprognostic (9.07e-2)"	"unprognostic (3.57e-3)"	"unprognostic (3.32e-2)"	"unprognostic (3.66e-2)"	"unprognostic (2.33e-1)"	"unprognostic (3.99e-2)"	"unprognostic (8.05e-2)"	"prognostic unfavorable (3.89e-4)"	"unprognostic (9.11e-2)"	"prognostic favorable (1.90e-4)"	"unprognostic (9.76e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.99e-1)"	"unprognostic (7.19e-2)"	26.3	5.5	10.2	16.1	8.1	4.2	19.7	27.8	13.4	15.8	9.2	10.4	8.4	4.3	11.2	8.5	9.3	11.7	10.8	8.9	10.5	6.9	13.8	3.5	15.0	10.9	6.9	3.4	11.7	8.2	13.3	15.2	18.8	9.3	12.3	8.9	10.8	16.6	12.3	4.4	14.2	8.9	10.2	14.4	16.8	6.5	4.3	10.6	21.2	11.8	4.8	13.6	16.0	15.3	2.1	1.2	4.7	1.1	4.2	6.4	2.0	5.6	1.1	9.8	2.6	10.2	11.8	2.1	6.5	9.8	4.3	4.5	0.7	12.0	1.2	15.5	15.1	2.3	5.2	2.0	6.3	6.0	27.9	0.7	0.7	2.0	2.1	6.0	0.0	0.0	17.2	0.6	7.7	4.5	8.0	2.4	0.1	3.1	1.8	7.6	0.4	0.1	1.5	1.0	2.9	1.8	1.9	1.8	6.5	6.4	8.0	0.1	0.9	2.4	1.0	2.7	3.3	0.9	0.3	10.6	7.6	1.8	2.6	4.1	1.2	0.2	1.8	3.6	1.1	13.9	0.1	1.1	0.0	1.5	0.6	2.6	1.9	3.2	4.1	1.2	2.1	6.4	4.3	4.7	4.2	0.7	0.9	1.2	2.0	10.2	8.1	27.8	7.0	10.5	6.9	6.9	3.4	9.3	10.6	14.9	7.5	12.1	17.3	17.3	40.8	4.1	12.7	18.7	19.4	12.2	86.4	10.3	10.0	14.8	1.1	20.5	18.4	0.0	0.4	20.6	19.5	17.4	1.1	0.2	16.3	0.0	6.4	6.7	12.6	1.4	8.1	15.7	11.8	16.2	6.2	24.7	9.5	14.4	8.1	11.8	21.9	32.3	17.3	0.5	0.6	11.8	10.9	16.0	11.8	13.1
MAP2K1	"MAPKK1, MEK1, PRKMK1"	ENSG00000169032	"Mitogen-activated protein kinase kinase 1"	Q02750	15	66386817-66492312	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003834, HPA026430"	Approved		Enhanced	"Plasma membrane,Cytosol"		NA	NA		62000	"Plasma membrane, Cytosol"		"CAB003834: AB_562310, HPA026430: AB_1853742"	"unprognostic (4.05e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.92e-2)"	"prognostic unfavorable (1.95e-4)"	"unprognostic (1.81e-3)"	"unprognostic (5.78e-2)"	"unprognostic (9.91e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.45e-1)"	"unprognostic (7.62e-3)"	"unprognostic (1.20e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.15e-1)"	"unprognostic (9.40e-3)"	28.6	16.9	33.9	19.1	54.1	29.0	23.6	32.5	48.4	12.5	12.1	8.4	10.2	10.0	11.8	16.5	22.0	10.6	14.4	19.1	49.2	26.4	15.3	53.1	16.4	23.3	17.6	31.2	13.5	11.7	23.4	12.0	15.4	17.2	14.4	12.9	9.1	13.2	12.4	39.5	12.3	10.9	16.9	17.4	14.5	10.8	7.8	12.6	12.6	12.3	9.7	27.9	13.6	18.7	4.6	16.2	5.5	8.2	8.4	7.9	2.7	33.6	15.9	31.9	13.3	19.3	14.5	18.5	24.4	20.9	26.5	23.7	23.8	27.7	30.9	30.3	20.1	20.2	30.0	29.8	35.7	31.3	24.9	17.8	9.9	16.6	12.9	15.6	13.0	14.8	11.2	22.1	19.2	28.5	28.3	20.7	15.8	17.5	39.6	38.7	13.0	10.5	17.1	16.3	31.2	13.9	11.9	19.7	27.5	25.7	14.5	19.7	11.0	19.8	15.5	20.5	26.9	14.0	11.2	28.5	34.6	21.2	24.4	36.2	24.5	43.6	19.7	36.5	23.1	16.1	3.2	8.2	5.5	7.4	8.2	6.7	3.0	6.6	6.9	8.3	4.6	7.9	4.9	3.9	8.4	7.3	16.2	4.9	2.7	33.9	54.1	32.5	46.9	49.2	26.4	17.6	31.2	17.2	12.6	26.8	21.9	30.2	40.5	73.6	8.5	16.9	38.2	6.7	13.6	24.4	13.7	40.9	39.7	65.3	10.2	19.0	20.0	46.7	20.4	39.4	31.3	59.4	9.2	116.5	44.9	9.5	20.8	17.2	91.3	18.3	20.8	67.7	50.6	88.4	17.0	33.9	70.1	21.0	20.5	28.5	5.6	6.5	53.6	16.3	44.5	58.8	43.3	40.5	16.8	65.5
MAP2K2	"MEK2, PRKMK2"	ENSG00000126934	"Mitogen-activated protein kinase kinase 2"	P36507	19	4090321-4124129	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Late spermatids: 596.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB003835, HPA051993"	Supported		Supported	Cytosol		NA	NA			Cytosol		"CAB003835: AB_562312, HPA051993: AB_2681685"	"unprognostic (4.39e-1)"	"prognostic favorable (3.72e-4)"	"unprognostic (4.24e-1)"	"unprognostic (1.26e-3)"	"unprognostic (2.58e-1)"	"prognostic favorable (7.98e-4)"	"unprognostic (2.08e-3)"	"unprognostic (2.11e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.06e-1)"	"unprognostic (7.45e-3)"	"unprognostic (4.95e-2)"	"unprognostic (1.32e-1)"	"prognostic favorable (5.43e-5)"	"unprognostic (2.91e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.90e-2)"	23.9	33.0	35.6	27.6	36.1	46.7	30.2	31.2	43.4	22.6	38.8	24.6	27.0	70.9	21.8	23.2	32.8	21.7	27.9	41.4	33.1	31.0	22.7	42.0	24.1	44.5	34.4	29.2	30.8	46.0	18.9	29.7	21.3	26.1	25.7	24.3	21.7	41.5	24.0	134.9	27.4	56.7	19.0	25.2	25.9	28.3	42.0	20.9	44.1	26.2	42.2	29.1	20.0	26.9	11.4	10.7	28.3	10.6	11.3	12.1	4.5	36.8	40.7	22.3	31.3	30.9	37.3	22.3	24.3	32.6	33.3	30.2	35.2	20.0	31.6	23.0	27.7	26.8	26.6	17.4	26.0	25.8	26.8	21.2	11.5	22.2	38.9	47.3	21.1	24.3	41.1	25.3	23.4	31.2	44.6	29.4	28.8	22.0	62.4	28.0	46.3	41.8	29.7	25.5	27.2	29.6	32.0	14.7	36.1	29.1	23.7	30.3	30.2	22.3	30.9	75.8	26.9	23.8	36.4	25.9	27.3	23.8	69.8	37.4	62.8	38.0	22.1	42.4	38.2	46.8	15.2	9.1	28.3	11.9	10.6	9.7	8.9	9.7	12.1	10.7	11.4	8.9	11.6	14.4	11.3	8.7	6.0	9.2	4.5	35.6	36.1	31.2	43.4	33.1	31.0	34.4	29.2	26.1	20.9	8.9	38.8	57.0	73.8	31.5	79.0	54.9	17.8	10.7	19.4	38.4	39.3	23.7	124.3	17.7	223.1	33.7	242.0	0.0	38.5	28.5	33.0	88.2	19.6	43.1	46.2	114.4	60.6	34.4	35.6	596.7	33.1	29.7	40.5	12.6	77.6	82.3	41.7	90.9	21.5	75.0	82.4	25.8	32.5	25.9	14.5	55.8	29.7	45.4	69.4	97.8
MAP2K4	"JNKK1, MEK4, MKK4, PRKMK4, SERK1"	ENSG00000065559	"Mitogen-activated protein kinase kinase 4"	P45985	17	12020824-12143830	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Stress response"	"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 13.2"	"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in all"	5	"SuSa: 67.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB007751, HPA060074"	Enhanced		Approved	"Nucleoplasm,Cell Junctions"		NA	NA			Nucleoplasm	"Cell Junctions"	"CAB007751: , HPA060074: AB_2684197"	"unprognostic (1.55e-1)"	"unprognostic (1.85e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.02e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.89e-1)"	"unprognostic (2.16e-1)"	"unprognostic (1.93e-3)"	"unprognostic (2.53e-1)"	"unprognostic (2.76e-3)"	"unprognostic (4.82e-2)"	"unprognostic (5.32e-3)"	"unprognostic (3.13e-1)"	"unprognostic (2.30e-1)"	"unprognostic (7.00e-2)"	"unprognostic (1.79e-1)"	10.7	13.2	23.7	9.4	21.0	3.1	14.4	25.0	42.7	12.5	11.5	7.9	8.5	9.6	12.1	17.8	18.5	11.5	10.7	14.9	31.7	29.3	15.8	20.6	11.4	14.6	24.5	27.1	13.0	11.1	19.6	16.7	15.1	23.4	14.5	13.1	6.5	9.8	13.2	20.6	14.4	9.9	13.5	16.3	10.7	10.7	10.3	9.8	10.3	16.5	11.6	13.4	11.1	11.2	2.8	1.8	13.2	4.3	3.5	3.3	2.3	10.6	9.2	12.1	6.2	6.7	8.7	7.7	7.3	9.6	8.3	8.0	5.4	3.7	4.4	5.9	11.3	5.4	7.1	10.5	10.1	12.5	7.8	12.3	4.9	5.4	10.2	7.9	4.7	7.4	7.2	10.0	9.7	10.2	8.6	7.5	6.3	5.2	2.6	10.4	3.9	5.6	4.4	7.0	11.5	4.5	7.0	13.6	3.0	11.4	6.9	2.4	7.2	8.4	4.5	7.0	67.1	5.7	3.4	6.8	4.1	6.3	5.6	8.6	5.1	5.7	3.5	7.7	3.7	5.9	0.6	2.7	2.0	3.0	1.5	2.7	2.8	2.4	2.4	1.8	2.7	2.0	3.3	13.2	3.5	4.3	1.8	2.6	2.3	23.7	21.0	25.0	42.7	31.7	29.3	24.5	27.1	23.4	9.8	8.9	14.2	10.8	26.3	36.9	14.2	21.2	10.2	2.7	21.6	14.0	7.9	10.7	21.6	11.2	6.3	8.7	11.8	0.0	12.4	8.6	12.9	32.3	1.1	16.3	10.2	17.5	11.5	10.4	17.7	5.8	10.9	11.7	11.8	19.0	13.8	10.3	14.7	11.5	12.0	17.7	9.7	12.9	12.0	7.9	8.1	34.4	21.2	9.5	10.6	40.3
MAP3K1	"MAPKKK1, MEKK, MEKK1"	ENSG00000095015	"Mitogen-activated protein kinase kinase kinase 1"	Q13233	5	56815574-56896152	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Kupffer cells: 81.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SH-SY5Y: 27.5;THP-1: 25.7"	"Region enriched"	"Detected in many"	6	"olfactory region: 22.5"	"Low region specificity"	"Detected in all"			"CAB004500, HPA046509"	Approved		Approved	Cytosol		NA	NA			Cytosol		"CAB004500: AB_627926, HPA046509: AB_2679678"	"unprognostic (1.77e-1)"	"unprognostic (1.71e-2)"	"unprognostic (4.09e-1)"	"unprognostic (2.18e-1)"	"unprognostic (3.48e-2)"	"unprognostic (5.39e-3)"	"unprognostic (5.20e-3)"	"unprognostic (2.52e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.18e-2)"	"unprognostic (1.58e-1)"	"unprognostic (9.92e-3)"	"unprognostic (1.11e-1)"	6.7	4.9	5.4	14.6	4.8	15.2	14.9	8.0	4.5	7.6	6.7	5.4	7.3	4.3	7.1	9.4	12.7	7.2	5.9	4.3	3.7	3.2	9.5	4.4	8.8	21.4	6.4	3.1	8.4	9.2	6.3	7.9	8.1	4.5	8.3	4.5	12.6	15.4	9.7	3.5	21.8	11.2	4.0	3.8	21.3	5.5	8.5	5.1	11.7	19.2	6.6	18.2	6.0	11.7	6.6	2.8	6.7	7.2	2.7	5.8	2.3	6.6	4.0	6.3	4.2	1.0	0.8	10.6	1.3	1.7	4.0	5.6	18.7	5.0	5.9	0.4	1.5	3.4	3.4	5.2	2.3	5.6	2.0	2.3	3.3	1.8	8.8	2.5	5.2	9.2	1.0	2.5	1.2	2.0	1.1	1.7	2.0	2.8	10.7	1.0	2.9	3.6	7.1	2.9	3.4	0.5	5.7	4.4	20.3	7.0	6.9	2.6	27.5	3.9	4.9	11.2	5.8	13.4	25.7	5.0	0.4	3.4	1.5	2.4	7.8	4.0	11.3	0.6	3.1	6.8	6.7	4.5	1.0	1.2	6.8	1.2	6.6	3.8	1.8	2.8	5.1	2.5	0.9	2.6	2.7	7.2	1.5	5.8	2.3	5.4	4.8	8.0	4.5	3.7	3.2	6.4	3.1	4.5	5.1	6.0	9.8	47.7	14.5	46.5	15.2	2.7	50.9	4.0	12.5	34.9	45.2	12.9	6.6	14.2	1.6	13.5	6.6	0.0	12.8	7.7	11.3	11.9	7.0	12.1	26.3	27.0	9.8	17.2	81.7	1.9	4.9	40.3	35.4	45.9	10.1	10.6	13.0	7.0	1.8	20.1	34.7	6.5	5.2	10.0	15.0	47.8	5.6	16.6	8.9	10.0
MAP3K13	"LZK, MEKK13"	ENSG00000073803	"Mitogen-activated protein kinase kinase kinase 13"	O43283	3	185282941-185489097	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"monocytes: 456.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016497, HPA036691, HPA036692"	Uncertain		Approved	"Nucleoplasm,Centriolar satellite,Cytosol"		NA	NA			"Centriolar satellite"	"Nucleoplasm, Cytosol"	"HPA016497: AB_10670027, HPA036691: AB_10673661, HPA036692: AB_10670845"	"unprognostic (8.95e-2)"	"unprognostic (6.72e-3)"	"unprognostic (9.46e-2)"	"prognostic unfavorable (1.28e-5)"	"unprognostic (5.16e-2)"	"unprognostic (2.81e-1)"	"unprognostic (2.61e-1)"	"unprognostic (1.23e-2)"	"unprognostic (9.04e-2)"	"prognostic favorable (1.11e-4)"	"prognostic unfavorable (7.27e-5)"	"unprognostic (2.70e-3)"	"unprognostic (1.54e-2)"	"unprognostic (2.94e-2)"	"unprognostic (2.82e-1)"	"unprognostic (6.64e-2)"	"unprognostic (9.31e-3)"	9.8	24.8	21.7	8.7	22.2	9.5	15.1	16.4	26.1	12.9	16.9	18.4	10.5	16.8	12.9	42.1	15.2	14.6	13.1	8.1	19.2	18.6	21.9	20.7	15.2	7.4	23.2	17.1	16.5	24.9	20.9	24.5	9.1	21.8	14.5	18.9	18.6	26.2	11.4	3.3	9.8	23.4	12.1	26.4	8.7	16.4	12.9	15.8	4.4	18.6	8.3	10.3	12.5	11.5	23.7	21.5	21.1	13.2	11.5	17.4	7.8	29.1	5.8	11.3	0.3	10.3	12.7	6.7	6.7	4.6	10.9	13.2	11.2	11.0	0.2	23.0	12.2	18.2	16.7	0.3	15.5	19.4	32.5	15.0	0.1	7.9	9.2	11.2	15.3	8.4	11.5	13.6	9.3	11.7	11.3	12.1	0.3	0.3	23.7	9.7	9.1	1.8	7.2	13.0	22.5	13.7	0.2	13.5	16.0	19.2	7.6	18.6	12.4	11.3	17.1	23.2	12.9	25.8	8.6	8.0	9.0	11.7	16.2	14.5	12.1	15.6	9.6	13.2	7.8	14.7	6.4	13.2	5.1	10.3	12.2	15.8	23.7	12.4	12.8	21.5	19.0	17.4	16.8	21.1	11.5	8.6	9.4	4.8	7.8	21.7	22.2	16.4	26.1	19.2	18.6	23.2	17.1	21.8	15.8	50.6	76.2	44.7	172.9	125.7	111.5	22.1	104.4	64.3	84.2	75.0	86.4	120.9	243.7	92.5	109.7	52.6	82.0	0.0	111.2	29.4	48.3	249.1	28.9	83.1	55.4	42.9	102.2	83.4	50.4	168.4	40.0	59.4	81.0	456.3	109.9	93.7	112.0	96.2	50.9	224.8	81.3	45.3	74.0	119.3	28.8	127.2	170.1	31.2	98.7	249.0
MAPK1	"ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2"	ENSG00000100030	"Mitogen-activated protein kinase 1"	P28482	22	21754500-21867680	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 80.3"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"K-562: 81.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003995, CAB004229, HPA005700, HPA030069"	Approved					NA	NA		250000			"CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035"	"unprognostic (9.41e-3)"	"unprognostic (2.68e-1)"	"unprognostic (2.50e-3)"	"unprognostic (4.17e-1)"	"unprognostic (4.44e-3)"	"unprognostic (1.72e-1)"	"prognostic unfavorable (4.95e-4)"	"unprognostic (2.29e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.58e-1)"	"unprognostic (8.43e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.35e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.41e-1)"	"unprognostic (6.49e-2)"	16.1	21.1	32.9	18.3	80.3	20.2	13.6	31.0	54.5	18.6	18.5	23.2	9.6	13.7	17.4	10.6	25.7	16.9	14.9	22.8	32.4	23.4	21.7	16.4	19.9	16.6	18.4	23.6	16.0	19.8	27.4	10.9	17.2	27.6	16.4	19.9	14.2	15.8	17.8	28.2	17.5	15.1	22.8	20.4	19.8	17.2	24.2	21.5	19.5	23.0	11.1	21.4	17.7	15.3	2.5	3.2	13.5	4.9	7.0	13.7	2.5	19.7	12.5	16.1	9.2	19.1	19.2	6.1	21.8	20.4	19.6	19.0	9.9	10.5	10.9	10.9	29.2	18.0	18.8	18.9	17.4	25.6	44.0	17.7	19.8	11.7	11.6	15.7	27.8	20.6	14.3	14.0	23.7	21.9	15.4	26.7	11.9	81.1	12.5	23.9	8.1	18.0	6.1	6.1	26.8	12.3	19.8	39.7	2.9	11.2	16.2	13.1	7.3	23.6	14.2	12.7	16.7	10.7	9.4	23.3	16.4	21.4	18.8	13.8	12.0	14.6	17.0	15.5	13.6	17.7	1.0	4.0	5.8	13.7	4.6	3.9	2.0	2.9	4.9	3.2	2.5	2.8	5.1	13.5	7.0	4.9	3.2	2.7	2.5	32.9	80.3	31.0	54.5	32.4	23.4	18.4	23.6	27.6	21.5	44.7	30.2	28.0	22.1	53.3	23.8	34.6	63.7	21.4	33.0	48.8	51.1	18.0	16.6	24.0	33.2	31.2	46.6	23.3	33.6	18.2	31.5	37.5	93.2	59.4	47.7	27.0	57.3	57.7	88.6	9.9	30.2	59.7	38.8	15.4	44.2	32.3	39.5	28.8	41.8	37.6	21.0	32.3	32.2	70.0	47.7	54.1	16.0	95.8	30.7	34.8
MAX	"bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8"	ENSG00000125952	"MYC associated factor X"	P61244	14	65006174-65102695	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 94.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000328, HPA003474"	Supported		Supported	"Nucleoplasm,Golgi apparatus,Vesicles"		NA	NA			Nucleoplasm	"Golgi apparatus, Vesicles"	"CAB000328: AB_2281783, HPA003474: AB_1079317"	"unprognostic (4.50e-3)"	"unprognostic (1.51e-3)"	"unprognostic (4.08e-2)"	"unprognostic (2.87e-1)"	"unprognostic (8.37e-2)"	"unprognostic (2.42e-2)"	"unprognostic (1.13e-3)"	"unprognostic (1.30e-3)"	"unprognostic (1.53e-2)"	"unprognostic (7.36e-3)"	"unprognostic (7.19e-2)"	"unprognostic (1.66e-2)"	"prognostic unfavorable (5.57e-4)"	"unprognostic (2.99e-1)"	"unprognostic (4.68e-2)"	"prognostic favorable (2.12e-4)"	"unprognostic (6.03e-2)"	33.4	25.5	31.3	31.5	38.6	68.7	25.8	59.0	38.2	34.6	29.4	37.2	26.3	31.5	34.3	24.0	47.6	38.2	27.9	30.1	29.9	28.4	26.3	21.8	31.4	43.4	37.1	21.6	39.7	20.0	17.4	23.7	30.2	32.7	31.9	25.0	26.8	33.6	37.7	27.8	32.1	40.2	30.7	34.8	42.9	24.8	15.7	40.9	41.3	30.2	22.5	40.7	35.1	40.7	18.7	19.1	87.5	23.6	19.2	30.0	44.8	28.9	11.3	7.0	11.3	18.4	14.4	9.1	10.2	15.6	12.7	15.7	7.2	20.4	24.1	8.6	12.2	11.3	14.5	17.5	14.2	9.6	24.3	10.6	37.5	7.5	7.9	21.6	14.1	94.4	17.2	10.1	11.7	13.0	16.6	14.1	16.3	17.6	9.8	12.9	16.0	32.6	48.6	9.3	17.1	18.6	18.5	11.0	10.8	11.8	9.7	15.1	9.8	13.4	14.3	13.1	6.5	14.0	18.0	17.6	11.7	14.2	10.8	8.1	12.1	10.2	15.3	14.6	13.6	11.7	87.5	23.6	80.6	21.7	20.1	23.7	18.7	25.4	22.1	19.1	17.6	26.6	22.3	49.5	19.2	17.4	18.3	30.0	44.8	31.3	38.6	59.0	38.2	29.9	28.4	37.1	21.6	32.7	40.9	26.8	27.2	50.6	55.5	151.2	22.4	25.5	22.9	21.4	27.3	17.4	19.6	34.8	44.7	33.9	34.8	46.7	63.2	0.0	27.8	36.5	43.0	52.7	62.2	19.1	53.4	44.5	42.5	68.2	78.5	71.7	72.2	46.3	54.0	34.3	40.5	43.3	45.6	87.7	56.6	49.1	15.0	135.8	55.6	40.5	26.6	157.8	45.2	59.0	24.2	65.0
MDM2	"HDM2, MGC5370"	ENSG00000135679	"MDM2 proto-oncogene"	Q00987	12	68808176-68850686	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 95.6;U-698: 91.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000086, CAB016303"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000086: AB_563872, CAB016303: AB_627920"	"unprognostic (1.16e-1)"	"prognostic favorable (3.23e-4)"	"unprognostic (6.16e-2)"	"prognostic favorable (4.51e-7)"	"unprognostic (7.25e-2)"	"unprognostic (6.91e-2)"	"unprognostic (3.77e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.45e-2)"	"unprognostic (3.23e-1)"	"unprognostic (1.80e-3)"	"unprognostic (2.36e-1)"	"unprognostic (4.22e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.68e-1)"	"unprognostic (8.95e-2)"	16.6	15.3	11.1	12.5	10.8	23.1	12.5	12.0	11.3	13.1	16.6	13.6	11.9	5.2	8.8	9.4	14.2	12.6	12.3	9.0	8.8	8.6	11.2	25.7	15.9	13.3	14.2	7.1	11.0	21.4	11.4	10.4	24.5	11.9	12.6	21.5	7.8	10.5	11.1	19.5	9.8	7.2	10.8	10.8	15.3	9.8	6.5	11.5	29.5	13.6	10.8	14.1	13.5	12.6	4.9	4.0	19.3	6.4	3.6	4.4	3.0	3.1	7.5	7.9	3.9	10.2	9.5	40.2	8.9	8.9	4.7	7.6	4.5	1.4	33.3	2.5	5.8	1.3	1.9	5.4	95.6	7.6	8.8	3.7	6.1	6.3	20.2	10.0	5.4	5.6	14.6	8.2	18.7	12.8	4.7	13.2	5.8	6.2	8.1	9.0	5.1	7.1	1.8	6.6	1.6	1.4	25.3	5.4	2.7	2.9	26.6	6.0	3.5	5.6	4.4	1.9	16.7	10.4	3.6	14.1	3.6	6.8	2.9	3.1	12.3	7.8	91.9	5.5	2.1	14.7	5.3	5.4	4.8	4.4	4.0	3.9	4.7	3.7	4.1	2.8	4.9	4.0	3.7	19.3	3.6	6.4	4.0	3.8	3.0	11.1	10.8	12.0	11.3	8.8	8.6	14.2	7.1	11.9	11.5	29.8	48.8	22.9	24.5	13.9	27.9	17.8	25.5	97.7	62.6	24.4	31.4	43.9	11.6	18.1	1.1	20.2	16.6	0.0	20.8	23.6	22.4	34.7	31.3	38.4	16.5	28.6	24.1	22.1	44.9	1.8	17.8	21.8	11.8	31.5	23.5	26.4	19.8	20.1	14.2	15.3	34.5	19.4	21.7	13.9	20.6	19.3	78.8	25.4	19.7	74.5
MDM4	"HDMX, MDMX"	ENSG00000198625	"MDM4, p53 regulator"	O15151	1	204516379-204558120	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"BEWO: 34.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018919, HPA048821"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA018919: AB_1853694, HPA048821: AB_2680531"	"unprognostic (4.63e-2)"	"unprognostic (3.73e-1)"	"unprognostic (6.38e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.84e-2)"	"unprognostic (1.68e-3)"	"unprognostic (2.33e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.17e-2)"	"prognostic unfavorable (9.87e-4)"	"prognostic unfavorable (7.06e-6)"	"unprognostic (1.20e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.49e-2)"	"prognostic favorable (2.49e-4)"	12.7	8.8	14.4	21.1	18.0	59.1	14.6	19.7	16.4	12.2	10.6	20.4	15.8	7.6	12.5	23.6	10.4	12.3	10.3	11.3	13.7	8.0	11.1	12.3	15.4	21.0	20.5	9.5	19.0	16.7	11.1	19.0	12.4	13.4	13.1	12.4	14.2	11.3	15.4	12.0	23.7	15.2	18.5	13.5	19.9	11.9	19.6	19.4	55.8	15.1	9.5	21.0	13.9	12.7	15.1	9.0	8.1	4.8	4.9	7.8	2.4	3.6	7.1	7.2	9.9	5.0	5.6	34.0	2.7	2.8	3.5	5.2	3.7	4.9	12.4	2.6	3.8	2.9	3.9	4.8	4.0	4.7	3.7	3.4	9.8	15.8	4.3	3.8	7.7	9.8	5.7	2.6	5.7	10.2	3.7	3.4	8.0	5.6	18.1	3.0	12.0	4.7	6.8	9.9	1.3	3.0	5.6	5.9	4.1	3.4	17.5	3.2	7.2	2.7	5.4	5.1	7.5	10.2	4.5	3.4	4.0	7.1	2.6	4.4	9.1	3.2	10.3	2.8	3.3	5.7	8.1	4.7	6.2	7.2	4.8	6.0	9.0	5.4	5.0	4.1	15.1	7.8	6.5	7.8	4.9	4.3	9.0	3.0	2.4	14.4	18.0	19.7	16.4	13.7	8.0	20.5	9.5	13.4	19.4	26.8	49.9	72.9	46.9	54.7	91.7	33.5	40.8	20.1	61.4	66.3	159.0	39.1	11.6	25.4	65.9	50.6	37.1	93.5	23.0	23.0	48.1	52.9	63.6	48.4	30.6	39.7	62.4	94.5	85.6	124.4	74.2	75.3	40.5	23.4	44.0	44.1	23.4	40.8	50.9	12.8	196.4	51.8	36.2	60.6	71.3	59.7	50.9	73.9	39.6	40.0
MECOM	"EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3"	ENSG00000085276	"MDS1 and EVI1 complex locus"	Q03112	3	169083499-169663618	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 2: 169.5;Club cells: 93.3;Collecting duct cells: 118.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 1.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"EFO-21: 15.6;HUVEC TERT2: 22.0;RPTEC TERT1: 28.2;RT4: 44.4;TIME: 20.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA046537	Supported		Supported	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA046537: AB_2679689"	"unprognostic (4.09e-2)"	"unprognostic (1.96e-1)"	"unprognostic (3.24e-3)"	"unprognostic (7.29e-2)"	"unprognostic (2.87e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.77e-3)"	"unprognostic (1.53e-2)"	"unprognostic (3.27e-3)"	"prognostic unfavorable (2.59e-4)"	"unprognostic (1.87e-1)"	"unprognostic (2.60e-3)"	"unprognostic (6.54e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.81e-2)"	"unprognostic (3.37e-3)"	25.9	0.7	3.3	5.7	5.6	0.3	9.1	3.4	5.3	13.5	13.9	1.6	22.1	11.2	15.4	5.7	10.4	14.3	8.1	8.2	3.3	2.9	32.2	2.6	30.0	1.5	4.6	1.4	6.2	27.8	1.1	5.3	10.0	4.7	9.3	17.5	4.2	5.9	25.3	16.0	2.3	5.9	5.6	5.8	6.4	39.4	2.7	3.5	0.2	4.7	3.3	3.5	18.1	18.5	0.3	0.0	0.6	1.5	1.8	1.0	0.0	9.8	0.1	0.2	0.0	1.3	1.0	0.1	1.3	1.6	0.5	0.9	3.9	10.1	0.0	15.6	0.2	2.2	5.2	4.1	6.1	1.1	0.5	6.4	6.2	1.7	0.1	0.1	0.0	1.9	2.1	0.8	0.3	4.6	4.8	22.0	0.5	4.7	0.7	3.9	1.0	0.0	0.0	0.2	5.1	2.5	3.7	5.1	0.2	28.2	44.4	0.3	1.2	0.4	2.6	0.1	0.3	3.0	0.0	20.9	3.9	2.5	1.0	6.5	0.5	0.1	0.3	1.9	0.0	0.6	0.3	0.0	0.6	0.4	0.2	1.0	0.1	0.1	0.0	0.0	0.3	0.2	0.0	0.3	1.8	1.5	0.0	0.1	0.0	3.3	5.6	3.4	5.3	3.3	2.9	4.6	1.4	4.7	3.5	56.6	169.5	0.0	27.4	1.9	0.0	6.7	5.1	64.3	93.3	118.7	0.0	0.9	44.7	0.8	4.6	40.2	10.5	0.0	65.4	0.1	1.5	9.9	9.2	0.0	0.0	0.0	19.1	34.4	0.6	1.7	0.3	1.0	1.7	1.8	23.3	0.0	42.3	3.5	0.0	0.3	0.0	0.0	0.7	2.1	0.4	1.3	0.3	0.5	49.4	38.8
MED12	"CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230"	ENSG00000184634	"Mediator complex subunit 12"	Q93074	X	71118556-71142454	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003184, HPA003185"	Enhanced		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA003184: AB_1079349, HPA003185: AB_1079350"	"unprognostic (1.39e-1)"	"unprognostic (2.23e-1)"	"unprognostic (5.42e-2)"	"unprognostic (2.07e-1)"	"unprognostic (6.89e-3)"	"unprognostic (7.14e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.45e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.22e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.02e-1)"	"unprognostic (3.67e-1)"	"unprognostic (5.16e-2)"	18.2	31.3	12.3	15.3	14.7	16.6	18.1	18.0	15.1	16.8	12.8	19.8	21.3	10.2	21.7	16.5	13.1	17.7	14.2	12.9	12.9	8.5	13.3	9.8	14.0	15.3	15.7	10.7	28.8	14.2	20.1	17.9	23.0	11.6	16.5	11.8	18.6	14.6	20.3	14.9	17.6	14.8	16.4	11.2	27.3	14.2	15.3	12.9	33.1	17.8	12.6	15.9	15.4	16.4	4.0	5.1	9.7	3.7	5.0	7.4	3.6	8.7	10.3	16.3	9.7	12.0	10.7	24.1	6.2	8.9	9.9	7.1	12.4	8.3	11.5	8.2	10.7	6.8	8.7	19.0	7.8	7.9	12.1	14.7	19.1	23.2	16.7	9.4	17.5	16.9	12.4	8.5	12.9	15.0	12.7	15.2	14.7	17.7	20.2	9.7	14.7	18.4	10.0	9.3	11.2	13.5	17.3	18.2	8.7	7.5	17.4	9.1	11.0	14.3	7.3	8.1	17.5	8.8	8.7	13.2	10.8	12.8	9.9	4.3	10.0	5.5	8.4	6.3	9.8	7.2	9.7	3.7	7.2	5.9	3.6	5.0	4.0	4.1	5.4	3.9	4.0	4.6	3.9	7.7	5.0	2.4	5.1	7.4	3.6	12.3	14.7	18.0	15.1	12.9	8.5	15.7	10.7	11.6	12.9	8.9	3.4	5.2	5.2	5.4	7.1	8.1	15.3	2.7	6.8	8.7	5.9	17.0	1.7	5.4	0.2	8.7	6.8	0.0	5.4	6.2	7.8	5.7	9.2	3.4	8.0	12.7	7.5	14.1	6.7	0.9	13.0	9.2	5.0	6.4	7.8	5.8	8.6	8.4	12.7	2.2	4.5	0.0	5.0	6.4	7.4	5.0	22.8	6.4	6.4	6.8
MEN1		ENSG00000133895	"Menin 1"	O00255	11	64803510-64811294	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030342	Uncertain		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA030342: AB_10610138"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-1)"	"unprognostic (3.78e-2)"	"unprognostic (2.31e-2)"	"unprognostic (1.05e-1)"	"unprognostic (8.41e-2)"	"prognostic unfavorable (1.08e-4)"	"unprognostic (2.66e-1)"	"unprognostic (2.59e-1)"	"unprognostic (1.42e-2)"	"unprognostic (4.96e-2)"	"unprognostic (1.36e-1)"	"unprognostic (7.39e-2)"	"prognostic favorable (6.31e-5)"	"unprognostic (1.40e-1)"	"unprognostic (3.03e-1)"	"unprognostic (3.76e-1)"	12.1	20.6	13.2	15.6	17.7	11.8	12.5	25.8	26.9	15.5	14.9	16.4	22.2	16.9	14.8	18.4	18.9	17.6	14.7	9.0	12.4	11.5	15.9	23.0	12.8	22.1	12.5	15.6	19.7	25.9	16.8	18.0	16.1	16.0	15.9	11.6	16.6	23.3	19.9	8.4	21.6	15.8	11.0	9.8	20.6	15.3	21.2	12.3	33.2	23.9	6.2	20.3	13.7	15.5	5.2	2.9	3.4	1.5	1.8	4.8	1.0	16.3	22.0	14.1	22.1	15.8	10.2	16.6	11.8	11.7	18.4	12.4	12.7	16.2	23.3	19.3	9.1	15.4	23.4	19.1	16.3	11.1	19.9	28.2	19.3	17.7	16.9	14.0	12.4	13.1	11.7	12.3	15.5	12.8	11.1	17.0	30.0	28.0	8.9	10.2	30.6	31.3	25.1	18.4	13.8	33.1	24.3	16.0	22.3	11.9	15.2	19.9	17.5	13.9	19.7	14.3	10.5	29.3	13.8	10.7	17.4	16.7	20.8	9.9	14.0	16.2	11.8	13.8	9.7	11.0	0.9	1.3	3.4	3.7	1.5	4.8	3.7	2.6	4.6	1.3	5.2	4.5	2.6	0.2	1.8	0.5	2.9	1.9	1.0	13.2	17.7	25.8	26.9	12.4	11.5	12.5	15.6	16.0	12.3	3.0	4.8	19.3	3.8	5.0	8.3	3.7	2.5	1.4	1.2	3.5	5.9	15.7	3.3	7.3	0.9	4.4	8.4	0.0	6.2	18.5	4.6	4.9	1.1	9.4	7.9	3.2	4.1	8.0	0.3	0.6	11.2	2.6	8.5	6.4	8.7	8.4	7.1	10.1	3.5	6.2	5.7	12.9	2.7	16.6	15.5	6.0	13.6	6.7	9.5	3.0
MET	"DFNB97, HGFR, RCCP2"	ENSG00000105976	"MET proto-oncogene, receptor tyrosine kinase"	P08581	7	116672390-116798386	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 2: 78.1;Club cells: 116.0;Urothelial cells: 88.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 45.3;CAPAN-2: 49.5"	"Group enriched"	"Detected in many"	5	"amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1"	"Low region specificity"	"Detected in many"			"CAB005282, CAB018577, HPA055607"	Approved		Approved	"Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA	179000000	70000000	"Plasma membrane, Cytosol"		"CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860"	"unprognostic (1.60e-2)"	"unprognostic (7.71e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.57e-3)"	"prognostic unfavorable (6.75e-4)"	"unprognostic (1.68e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (2.52e-2)"	"prognostic unfavorable (1.21e-7)"	"unprognostic (1.86e-1)"	"unprognostic (1.25e-1)"	"unprognostic (5.53e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.01e-2)"	"unprognostic (2.20e-1)"	16.2	1.1	1.8	4.5	2.3	4.3	11.2	0.9	15.2	9.9	6.5	2.4	2.4	4.4	7.5	5.2	5.1	4.6	12.3	5.4	5.7	1.8	20.1	30.2	15.6	1.4	3.6	2.1	2.0	9.3	0.7	8.1	24.4	2.6	8.0	6.6	34.1	12.2	8.4	12.8	7.2	8.6	4.0	2.3	5.7	10.6	2.7	2.4	0.5	21.4	7.0	2.1	10.1	15.0	0.2	0.3	1.2	0.2	0.3	0.4	0.0	45.3	26.1	0.0	0.1	2.0	2.0	1.8	25.9	10.5	14.0	11.8	5.4	49.5	2.0	43.2	16.2	37.7	12.0	4.4	24.7	28.6	0.1	5.6	0.0	27.1	4.7	0.3	0.0	0.0	2.6	9.8	9.1	30.0	25.3	9.6	0.0	0.9	0.2	25.9	1.0	0.0	0.0	3.9	7.2	26.6	0.0	22.0	0.0	24.5	5.2	3.8	0.0	10.6	3.4	10.1	4.7	0.0	0.2	17.6	20.9	7.4	11.0	20.0	0.5	4.0	0.2	22.9	0.0	2.9	1.1	0.2	0.4	0.4	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	1.2	0.3	0.1	0.3	0.1	0.0	1.8	2.3	0.9	15.2	5.7	1.8	3.6	2.1	2.6	2.4	26.8	78.1	2.4	56.1	34.7	0.9	10.0	15.3	22.7	116.0	29.6	0.0	57.9	0.0	28.0	0.0	11.7	11.2	0.0	39.8	5.0	4.0	55.8	0.0	26.0	6.1	0.0	6.9	1.3	1.0	0.0	0.6	2.0	3.3	1.8	19.7	7.4	69.4	7.0	0.0	13.5	0.3	0.0	2.3	0.0	0.6	15.6	18.2	0.0	12.7	88.5
MITF	"bHLHe32, MI, WS2, WS2A"	ENSG00000187098	"Melanogenesis associated transcription factor"	O75030	3	69739435-69968337	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Albinism, Cancer-related genes, Deafness, Disease mutation, Microphthalmia, Osteopetrosis, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"Melanocytes: 555.0"	"Group enriched"	"Detected in all"	8	"melanoma: 39.2;renal cancer: 9.1"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"basophil: 4.5;classical monocyte: 10.9;intermediate monocyte: 3.6;myeloid DC: 6.8;non-classical monocyte: 5.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 6.8;granulocytes: 4.5;monocytes: 10.9"	"Cell line enhanced"	"Detected in many"		"HMC-1: 27.1;SK-MEL-30: 72.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002578, HPA003259"	Enhanced					NA	NA					"CAB002578: AB_564111, HPA003259: AB_1079381"	"unprognostic (3.29e-1)"	"unprognostic (4.26e-2)"	"unprognostic (2.98e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.75e-1)"	"unprognostic (5.31e-3)"	"unprognostic (3.87e-3)"	"unprognostic (1.94e-1)"	"prognostic favorable (8.35e-10)"	"unprognostic (6.37e-2)"	"unprognostic (1.08e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.73e-1)"	12.8	3.8	2.6	2.6	3.9	0.8	17.8	1.7	3.0	30.6	10.1	5.9	6.4	1.5	37.9	6.2	8.3	6.4	9.9	23.4	3.1	2.4	12.8	1.8	7.1	1.7	4.2	1.1	11.1	2.4	9.7	6.2	1.8	4.0	9.0	2.5	40.1	4.0	8.2	39.1	5.8	4.1	26.2	5.0	1.8	5.1	4.7	5.1	0.1	4.4	8.1	1.0	12.1	10.3	0.0	6.8	4.5	10.9	1.4	0.1	3.4	4.9	3.4	0.4	1.5	5.7	0.1	0.6	5.0	2.9	2.3	1.4	1.8	0.2	0.0	1.2	0.0	6.4	2.7	1.0	2.7	2.6	0.0	0.6	10.9	7.3	0.1	1.4	0.2	27.1	4.7	1.1	0.6	2.6	8.7	0.7	0.0	3.6	1.5	1.6	0.2	0.2	0.3	0.2	0.2	2.4	0.0	0.5	2.3	13.7	2.5	0.2	0.6	2.6	0.9	72.8	0.6	0.2	0.6	0.0	1.1	4.1	1.6	1.0	0.1	0.3	0.0	2.3	0.8	2.9	4.5	10.9	0.0	0.0	3.6	0.0	0.0	0.0	0.1	6.8	0.0	0.0	0.0	0.7	1.4	5.7	0.5	0.0	3.4	2.6	3.9	1.7	3.0	3.1	2.4	4.2	1.1	4.0	5.1	26.8	5.0	0.0	3.1	38.0	0.2	101.2	5.1	12.0	9.1	14.0	0.0	1.2	43.1	11.4	1.1	6.8	0.0	0.0	7.7	1.0	21.0	4.4	100.8	2.4	40.1	6.4	1.2	4.3	23.9	0.6	41.1	24.0	555.0	10.8	0.0	0.8	7.4	0.0	47.4	18.3	0.2	12.9	20.3	3.3	7.3	16.6	0.9	2.5	0.6	4.7
MKL1	"BSAC, KIAA1438, MAL, MKL, MRTF-A"	ENSG00000196588	"Megakaryoblastic leukemia (translocation) 1"	Q969V6	22	40410281-40636702	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Actin-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 87.5;Late spermatids: 76.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 50.9"	"Group enriched"	"Detected in all"	5	"dendritic cells: 26.4;granulocytes: 50.9;monocytes: 15.0"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA030782	Approved		Supported	Nucleoplasm,Cytosol		No	No			Nucleoplasm	Cytosol	"HPA030782: AB_10600930"	"unprognostic (7.90e-3)"	"unprognostic (4.51e-2)"	"unprognostic (2.99e-1)"	"unprognostic (1.29e-1)"	"unprognostic (9.04e-2)"	"unprognostic (9.37e-2)"	"unprognostic (4.38e-3)"	"unprognostic (1.02e-3)"	"unprognostic (1.30e-1)"	"unprognostic (1.35e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.74e-2)"	"prognostic unfavorable (1.58e-7)"	"unprognostic (9.05e-2)"	"unprognostic (8.15e-2)"	"unprognostic (1.30e-2)"	"unprognostic (3.98e-1)"	18.1	11.1	15.4	25.4	19.1	69.2	15.8	16.2	26.1	17.6	14.2	13.5	10.1	11.3	27.6	12.9	12.3	17.5	13.2	16.3	14.2	11.1	11.3	8.9	17.4	25.6	11.8	16.6	16.9	14.5	10.2	10.5	18.9	12.6	14.2	9.4	13.3	16.9	15.7	14.3	18.0	13.6	15.7	11.0	23.9	14.3	25.4	10.8	28.2	17.3	9.0	25.5	15.5	14.6	4.9	26.4	50.9	15.0	3.8	5.6	7.5	10.9	14.8	6.5	7.7	8.2	6.2	12.7	10.7	7.0	9.9	9.6	7.0	3.3	11.7	4.4	11.3	8.5	14.4	5.4	13.2	6.4	13.0	9.5	19.4	16.6	10.3	8.1	22.4	38.2	6.7	15.9	9.5	6.6	7.3	7.2	6.9	5.4	5.3	4.6	10.7	8.7	25.2	5.1	5.6	5.2	14.2	7.2	5.9	7.8	8.2	3.6	3.8	17.5	8.9	6.5	8.7	6.0	25.4	11.8	6.7	18.1	8.9	9.2	7.1	6.3	16.9	5.5	11.4	13.0	12.0	15.0	50.9	4.4	11.6	4.1	3.2	4.0	3.4	17.8	4.9	5.6	4.7	14.5	3.8	15.0	26.4	5.2	7.5	15.4	19.1	16.2	26.1	14.2	11.1	11.8	16.6	12.6	10.8	6.0	8.3	7.8	6.0	13.9	11.5	7.3	2.5	8.1	2.3	8.7	21.6	7.0	3.3	9.5	87.5	7.1	7.4	0.0	12.0	6.9	9.1	8.9	16.1	3.9	10.9	3.2	6.4	6.7	17.0	76.0	10.3	13.9	6.8	16.2	6.5	3.7	14.1	2.9	7.4	2.6	12.0	25.8	12.1	9.2	9.5	11.2	6.5	10.1	3.7	8.0
MLF1		ENSG00000178053	"Myeloid leukemia factor 1"	P58340	3	158571163-158607252	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, Differentiation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 41.4;skeletal muscle: 53.6;testis: 101.1"	"Group enriched"	"Detected in many"	15	"Early spermatids: 4250.8;Late spermatids: 9284.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.4"	"Lineage enriched"	"Detected in single"	12	"T-cells: 10.4"	"Cell line enhanced"	"Detected in many"		"A-431: 33.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA069479, HPA079339"	Enhanced		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA069479: AB_2686140, HPA079339: "	"unprognostic (6.49e-2)"	"unprognostic (1.98e-3)"	"unprognostic (1.98e-1)"	"prognostic unfavorable (2.15e-5)"	"unprognostic (1.72e-2)"	"unprognostic (2.65e-2)"	"unprognostic (8.55e-2)"	"unprognostic (4.11e-2)"	"unprognostic (2.01e-1)"	"unprognostic (2.07e-1)"	"unprognostic (7.21e-2)"	"unprognostic (1.07e-1)"	"unprognostic (7.82e-2)"	"prognostic unfavorable (5.54e-4)"	"unprognostic (9.34e-3)"	"unprognostic (2.47e-3)"	"unprognostic (3.36e-2)"	3.5	2.6	6.0	1.8	11.9	0.9	5.3	3.4	7.1	3.1	2.7	6.5	0.5	0.8	4.9	5.6	3.5	18.3	4.9	41.4	6.3	6.3	5.7	1.2	5.2	1.0	4.9	6.3	6.2	3.1	5.2	10.4	1.0	20.1	2.0	1.7	2.8	2.2	1.6	53.6	1.8	1.3	4.5	4.7	1.2	1.9	101.1	5.7	0.0	5.3	18.9	1.4	4.2	1.5	0.6	0.3	0.4	0.3	0.8	10.4	2.3	33.7	4.4	11.4	0.0	6.0	7.1	3.4	3.5	3.3	12.8	11.7	0.0	19.2	0.0	13.4	6.0	18.7	6.6	0.1	5.9	17.1	0.0	7.4	2.0	3.3	0.3	4.1	0.0	2.5	4.4	8.7	6.1	3.4	13.4	3.0	0.0	2.5	0.0	8.4	4.9	0.0	0.1	2.7	18.0	9.9	0.0	6.4	0.4	9.8	2.4	14.7	8.7	15.9	5.6	16.7	11.7	16.2	3.4	1.1	12.0	12.2	14.1	13.6	6.1	3.8	0.0	8.7	0.0	8.6	0.0	0.0	0.0	3.6	0.0	1.6	0.6	8.3	8.7	0.3	0.3	2.1	4.4	0.4	0.8	0.3	0.2	10.4	2.3	6.0	11.9	3.4	7.1	6.3	6.3	4.9	6.3	20.1	5.7	23.8	26.2	2.2	109.9	39.8	12.6	168.2	0.0	238.3	60.3	19.2	31.4	0.6	61.3	22.4	4250.8	23.3	4.2	0.0	6.9	3.5	36.8	26.1	43.8	0.0	6.4	9.5	32.5	8.0	2.7	9284.2	64.7	13.2	21.9	1.8	14.3	25.9	7.6	14.4	47.4	27.5	58.5	19.4	36.9	440.7	150.0	29.9	1.4	8.9	10.3	65.9
MLH1	"COCA2, FCC2, HNPCC, HNPCC2"	ENSG00000076242	"MutL homolog 1"	P40692	3	36993332-37050918	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair"		"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013294, HPA052707, HPA060714, CAB070868"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB013294: AB_2533406, CAB070868: , HPA052707: AB_2681923, HPA060714: AB_2684348"	"unprognostic (1.26e-2)"	"unprognostic (3.88e-3)"	"unprognostic (2.36e-2)"	"unprognostic (1.82e-1)"	"unprognostic (3.33e-2)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (8.24e-5)"	"unprognostic (3.36e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.32e-1)"	"unprognostic (8.54e-2)"	"unprognostic (8.63e-3)"	"unprognostic (2.10e-3)"	"unprognostic (4.37e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (8.86e-2)"	16.3	20.7	18.2	19.4	21.4	24.4	18.7	19.7	19.6	15.3	17.3	28.8	19.6	12.4	18.7	23.6	15.1	16.2	14.4	32.0	17.3	17.7	18.8	20.5	17.8	22.8	19.9	16.0	17.6	18.1	26.0	29.4	17.3	19.2	18.5	17.7	16.7	15.6	18.1	46.4	14.2	14.1	21.1	21.6	20.7	16.5	27.6	21.5	29.0	22.2	19.5	24.5	16.9	21.4	12.0	12.9	13.2	23.2	6.7	13.4	9.0	14.2	22.5	28.1	0.0	12.5	15.7	12.6	21.3	17.0	24.8	26.4	17.0	15.9	35.3	10.6	17.3	14.0	9.8	24.2	18.0	26.6	16.0	12.5	24.7	20.8	23.8	13.9	30.3	17.2	11.7	12.7	23.1	28.8	9.8	15.3	23.9	31.6	16.9	25.1	11.5	31.6	12.4	20.6	14.5	12.4	3.1	34.4	14.9	15.7	15.5	6.0	14.2	21.6	23.0	14.2	16.4	33.2	21.6	12.1	19.5	21.0	19.1	25.0	13.4	36.6	33.1	15.1	28.7	17.5	10.9	11.7	13.2	13.4	19.5	9.7	12.0	8.4	10.7	12.9	10.3	9.6	9.7	3.4	6.7	23.2	6.1	12.5	9.0	18.2	21.4	19.7	19.6	17.3	17.7	19.9	16.0	19.2	21.5	23.8	12.0	16.0	10.7	6.4	19.2	37.1	15.3	16.0	13.6	10.4	9.8	27.1	16.6	12.5	20.3	11.2	5.3	0.0	13.0	23.0	13.4	8.0	7.0	14.5	17.5	3.2	5.2	12.3	14.3	9.5	10.3	11.4	8.5	19.8	7.2	14.3	8.6	7.0	13.1	9.2	17.9	12.9	9.5	37.0	25.4	4.8	16.7	13.1	7.6	3.4
MLLT1	"ENL, LTG19, YEATS1"	ENSG00000130382	"MLLT1, super elongation complex subunit"	Q03111	19	6210379-6279948	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	13	"Cytotrophoblasts: 494.9;Syncytiotrophoblasts: 951.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031166	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA031166: AB_10601874"	"unprognostic (3.21e-1)"	"unprognostic (2.75e-3)"	"unprognostic (4.84e-2)"	"unprognostic (3.36e-2)"	"unprognostic (2.47e-1)"	"prognostic favorable (6.03e-5)"	"unprognostic (1.30e-3)"	"unprognostic (1.44e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.98e-1)"	"unprognostic (3.93e-3)"	"unprognostic (4.76e-2)"	"unprognostic (3.65e-3)"	"unprognostic (1.14e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.66e-2)"	"unprognostic (7.99e-3)"	20.1	13.7	21.8	17.1	23.4	8.8	12.9	32.7	28.6	17.7	16.8	16.8	17.7	13.4	22.1	15.5	13.1	25.5	19.3	18.2	16.9	14.3	10.7	12.8	16.7	10.9	13.0	18.5	29.8	22.4	26.2	10.7	45.2	14.6	17.2	6.8	18.7	21.7	18.8	23.5	18.8	13.1	15.0	10.6	13.9	15.1	10.7	13.7	10.8	18.9	12.1	10.2	20.6	23.6	1.5	5.2	4.9	3.5	1.9	2.5	1.6	24.6	12.1	15.0	17.7	11.7	10.2	17.5	15.3	10.0	12.9	13.3	20.0	8.3	17.9	20.1	20.1	14.5	15.4	11.9	15.0	7.8	15.1	18.6	22.3	32.9	15.0	22.7	14.4	20.5	16.5	13.2	12.3	10.1	14.3	14.6	16.2	21.5	21.0	8.5	13.6	24.6	13.9	18.2	12.4	25.6	21.2	11.2	14.3	7.0	15.3	26.1	23.7	15.8	17.6	19.0	7.8	15.8	17.1	15.2	18.1	14.1	28.0	21.1	25.8	19.9	14.1	21.0	24.8	25.7	0.2	1.9	0.4	1.8	3.0	2.5	1.5	1.3	1.7	1.4	1.4	1.1	1.5	4.9	1.9	3.5	5.2	0.5	1.6	21.8	23.4	32.7	28.6	16.9	14.3	13.0	18.5	14.6	13.7	20.8	37.8	0.0	10.7	0.1	27.3	17.8	5.1	8.1	15.9	12.2	17.7	494.9	6.6	11.4	24.3	22.4	5.5	0.0	14.2	17.8	8.9	15.8	9.3	16.8	52.2	55.6	4.7	18.4	16.7	43.4	17.5	7.0	0.0	5.4	11.7	31.9	12.0	0.0	17.3	5.6	14.4	25.8	7.3	8.2	5.5	0.1	951.9	4.3	11.7	11.9
MLLT10	AF10	ENSG00000078403	"MLLT10, histone lysine methyltransferase DOT1L cofactor"	P55197	10	21524675-21743630	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 71.2"	"Cell type enhanced"	"Detected in many"	5	"Spermatocytes: 158.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005747	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA005747: AB_1079393"	"unprognostic (6.58e-2)"	"unprognostic (1.57e-1)"	"unprognostic (7.32e-2)"	"unprognostic (1.47e-2)"	"unprognostic (1.31e-2)"	"prognostic favorable (8.75e-4)"	"unprognostic (1.03e-3)"	"unprognostic (9.56e-3)"	"unprognostic (9.29e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.69e-2)"	"unprognostic (7.85e-2)"	"unprognostic (6.57e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.67e-1)"	16.3	12.1	11.7	18.4	14.3	21.9	12.8	25.4	13.6	19.0	17.0	12.0	13.6	8.5	26.3	12.8	14.7	14.5	13.7	15.8	10.2	8.5	12.3	13.5	12.3	11.6	10.5	9.9	21.4	12.3	16.6	23.2	20.3	11.8	12.6	11.3	14.6	13.2	16.3	13.4	18.7	12.1	18.7	11.2	10.6	11.4	71.2	14.3	14.6	18.1	9.7	15.2	18.5	19.6	5.5	6.9	12.0	6.8	5.3	7.2	2.8	14.5	12.4	19.1	13.2	12.1	15.3	21.0	9.2	5.8	11.6	11.3	13.1	15.5	17.4	5.1	10.2	10.0	13.7	21.0	12.4	11.6	12.0	12.2	27.0	10.8	18.9	15.0	0.6	17.4	11.4	14.8	9.6	11.1	11.8	15.3	18.3	28.8	13.6	9.1	11.3	20.9	12.6	7.8	8.1	3.9	18.3	10.2	14.6	11.1	6.9	6.7	18.6	12.2	14.7	20.7	17.7	6.9	18.7	13.8	7.3	12.7	14.5	9.1	11.8	13.6	19.5	8.4	10.4	5.6	10.6	6.8	12.0	5.3	4.6	5.2	5.0	6.2	5.7	5.6	5.5	7.2	6.7	5.8	5.3	5.2	6.9	4.6	2.8	11.7	14.3	25.4	13.6	10.2	8.5	10.5	9.9	11.8	14.3	26.8	36.0	13.7	13.7	33.5	31.4	23.5	20.4	17.4	20.5	17.4	41.2	28.7	11.6	12.4	52.7	20.3	15.5	0.0	11.2	48.3	23.9	18.2	23.3	17.8	25.1	28.6	3.4	27.0	30.5	78.0	36.5	23.5	45.5	20.8	15.6	19.7	11.6	14.0	45.3	17.5	50.9	38.8	19.4	158.1	57.1	38.3	42.0	23.5	18.3	10.1
MLLT11	AF1Q	ENSG00000213190	"MLLT11, transcription factor 7 cofactor"	Q13015	1	151057758-151068497	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 42.1"	"Cell type enhanced"	"Detected in many"	14	"Early spermatids: 72.1;Late spermatids: 161.6;monocytes: 56.9"	"Cancer enhanced"	"Detected in all"		"glioma: 29.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 38.6;EFO-21: 29.3;SH-SY5Y: 42.4;U-698: 36.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000540	Uncertain		Supported	Nucleoplasm,Cytosol		No	No			"Nucleoplasm, Cytosol"		"HPA000540: AB_2666024"	"unprognostic (2.96e-2)"	"unprognostic (1.98e-2)"	"unprognostic (1.08e-2)"	"prognostic unfavorable (4.26e-5)"	"unprognostic (1.69e-1)"	"unprognostic (1.96e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.17e-1)"	"unprognostic (1.01e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.01e-1)"	"prognostic unfavorable (4.25e-12)"	"unprognostic (5.66e-3)"	"unprognostic (1.42e-1)"	"unprognostic (1.29e-1)"	"unprognostic (3.94e-3)"	1.9	7.5	13.6	3.4	9.1	1.1	1.2	16.3	42.1	1.9	2.1	5.1	1.2	0.8	3.7	1.2	1.3	0.8	11.1	11.8	11.3	16.4	1.2	1.2	5.3	2.3	10.3	1.2	4.2	1.3	8.4	1.8	1.2	3.2	1.3	1.1	1.2	1.5	1.2	2.6	1.0	2.0	4.2	5.8	2.1	0.9	1.2	1.2	2.0	1.2	1.2	2.6	3.2	1.2	2.4	1.0	6.5	1.0	4.2	9.2	2.8	1.2	5.3	38.6	6.1	0.6	1.0	0.6	2.4	2.6	2.3	4.2	0.5	2.5	1.9	29.3	1.8	6.5	1.5	9.3	2.2	1.3	11.3	2.6	5.0	3.8	0.1	1.2	0.3	0.8	1.7	0.3	12.7	0.5	8.0	17.0	7.6	5.3	0.9	7.4	0.4	17.7	3.3	16.8	0.1	0.8	16.9	5.1	0.1	4.4	1.1	23.3	42.4	0.2	0.4	1.2	26.5	1.4	0.6	11.8	5.0	5.5	1.8	4.4	0.9	0.8	36.0	12.5	0.3	9.4	1.6	0.6	1.6	5.9	0.7	2.7	2.4	3.9	6.0	0.8	2.1	5.3	9.2	6.5	4.2	1.0	1.0	3.6	2.8	13.6	9.1	16.3	21.0	11.3	16.4	10.3	1.2	3.2	1.2	0.0	0.6	1.5	4.0	3.2	38.5	10.1	0.0	0.0	0.0	3.5	7.9	2.0	14.9	2.6	72.1	3.6	0.0	0.0	1.1	2.1	12.7	1.7	4.6	0.0	5.6	35.0	10.3	5.5	4.8	161.6	2.0	7.6	5.0	56.9	0.0	12.4	2.9	0.0	3.5	1.1	18.5	0.0	35.9	4.7	8.8	3.0	6.2	7.5	0.1	4.1
MLLT3	"AF-9, AF9, YEATS3"	ENSG00000171843	"MLLT3, super elongation complex subunit"	P42568	9	20341665-20622543	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Mucus-secreting cells: 101.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 14.4"	"Group enriched"	"Detected in many"	5	"NK-cells: 3.8;T-cells: 14.4"	"Cell line enhanced"	"Detected in many"		"HEL: 73.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001824	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA001824: AB_1079394"	"unprognostic (3.31e-1)"	"unprognostic (2.22e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.27e-2)"	"unprognostic (1.99e-1)"	"unprognostic (7.57e-2)"	"unprognostic (3.83e-2)"	"unprognostic (1.01e-3)"	"unprognostic (2.12e-1)"	"unprognostic (3.92e-3)"	"unprognostic (1.05e-1)"	"unprognostic (2.03e-2)"	"prognostic favorable (1.84e-4)"	"unprognostic (1.85e-1)"	"unprognostic (4.81e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.68e-1)"	8.6	17.3	18.0	10.4	25.8	19.7	11.4	34.6	20.3	12.3	20.9	7.2	10.6	7.2	13.6	7.9	10.2	11.5	12.7	8.6	18.0	12.8	10.1	2.1	10.7	9.1	14.8	13.8	10.5	4.6	18.3	24.7	10.3	13.2	11.7	22.8	7.4	21.3	12.1	9.1	7.9	12.3	13.5	12.0	5.9	15.3	3.6	21.4	22.1	22.5	6.1	6.5	12.9	10.4	1.4	0.7	1.6	0.3	3.8	14.4	2.8	2.6	7.2	2.6	2.9	6.0	3.7	1.6	6.8	11.5	3.1	3.5	7.0	2.5	10.0	3.7	3.2	0.9	1.3	2.4	11.8	2.8	20.6	6.3	73.6	22.3	3.3	4.3	1.3	6.2	2.8	4.5	1.1	7.4	10.4	3.0	4.2	0.0	12.9	6.4	2.0	7.2	4.3	1.6	14.4	2.1	0.0	4.7	2.7	14.1	3.9	8.3	2.9	5.5	2.8	3.0	2.6	2.9	1.9	2.0	0.0	1.7	1.7	2.4	5.8	5.3	4.1	0.0	3.2	1.4	1.6	0.3	0.5	3.9	0.2	3.6	0.5	7.0	5.3	0.7	1.4	14.4	8.3	0.1	3.8	0.3	0.4	7.3	2.8	18.0	25.8	34.6	20.3	18.0	12.8	14.8	13.8	13.2	21.4	26.8	23.0	7.3	15.3	7.3	5.5	12.1	7.6	9.4	38.7	21.0	31.4	0.9	11.6	23.0	2.7	8.6	13.6	0.0	7.3	5.3	16.7	15.6	11.5	1.7	2.0	4.8	31.7	6.7	2.6	4.2	12.7	3.2	21.9	1.0	101.9	37.2	18.7	17.3	8.9	7.0	1.0	0.0	16.5	0.1	5.6	7.3	1.4	25.4	28.6	13.2
MLLT6	"AF17, FLJ23480"	ENSG00000275023	"MLLT6, PHD finger containing"		17	38705542-38729803	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at transcript level"	"Evidence at transcript level"				"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Bipolar cells: 244.7;Cone photoreceptor cells: 192.4;Rod photoreceptor cells: 215.1"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004021	Approved		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA004021: AB_1853995"	"prognostic favorable (4.18e-4)"	"unprognostic (1.50e-1)"	"unprognostic (2.53e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.29e-1)"	"prognostic favorable (3.98e-4)"	"unprognostic (4.98e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.77e-1)"	"unprognostic (7.12e-3)"	"prognostic favorable (7.41e-4)"	"unprognostic (1.78e-1)"	"unprognostic (1.84e-2)"	"unprognostic (9.12e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.05e-1)"	"unprognostic (2.46e-3)"	6.5	7.6	10.0	10.3	10.6	7.3	6.3	14.1	16.9	6.2	6.8	7.2	11.1	7.2	9.2	8.6	5.5	10.3	9.2	7.5	9.7		5.8	1.2	8.5	11.8	8.5	9.6	13.0	9.0	12.8	10.1	4.8	7.2	7.3	5.7	10.0	10.3	12.5	22.3	8.5	8.9	8.2	8.1	11.7	6.7	4.1	9.2	6.3	7.2	4.8	10.1	5.5	11.5	1.4	0.9	2.0	0.8	2.8	6.0	1.7	5.8	6.5	6.6	14.4	7.3	6.6	3.4	3.6	6.7	4.5	5.4	2.4	11.5	16.6	5.3	4.3	6.4	15.2	4.2	7.5	4.0	17.7	11.5	6.1	10.8	10.6	3.5	9.3	8.3	6.7	7.7	3.9	8.9	10.9	7.3	12.6	10.1	14.0	3.8	4.9	18.2	9.0	0.8	5.0	3.4	10.8	9.0	15.3	5.2	13.5	14.8	16.4	3.8	12.6	10.7	4.3	12.4	6.8	9.6	5.2	7.8	7.3	6.6	23.9	7.8	11.2	7.7	8.6	5.5	1.7	0.8	0.4	6.0	0.5	4.6	1.4	3.2	4.2	0.4	1.4	3.1	4.1	2.0	2.8	0.3	0.9	1.7	1.7											44.7	51.0	32.0	22.5	27.1	244.7	23.4	30.6	14.7	36.4	31.4	192.4	15.0	10.0	20.0	2.7	38.7	26.1	0.0	35.9	4.1	20.2	29.7	35.9	9.4	12.0	112.8	47.7	31.9	18.3	3.1	43.4	18.1	18.6	23.4	30.0	32.6	28.3	21.0	39.6	13.5	215.1	32.3	25.4	16.1	23.5	25.5	32.0	48.9	37.7	23.0
MN1	"MGCR, MGCR1, MGCR1-PEN"	ENSG00000169184	"MN1 proto-oncogene, transcriptional regulator"	Q10571	22	27748277-27801498	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Developmental protein"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 62.7"	"Cell type enhanced"	"Detected in many"	11	"Bipolar cells: 9.8;Early spermatids: 22.6;Fibroblasts: 10.0;Late spermatids: 12.6;Peritubular cells: 9.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	6	"non-classical monocyte: 1.7"	"Lineage enriched"	"Detected in single"	8	"monocytes: 1.7"	"Cell line enhanced"	"Detected in some"		"AF22: 22.1;HeLa: 8.9;hTERT-RPE1: 9.9;RH-30: 8.9;TIME: 14.0;U-2 OS: 12.1;U-2197: 12.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA003072	Approved		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA003072: AB_1079399"	"unprognostic (5.64e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.88e-2)"	"unprognostic (2.52e-2)"	"unprognostic (7.01e-2)"	"unprognostic (3.03e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.64e-1)"	"unprognostic (4.00e-2)"	"unprognostic (7.33e-2)"	"unprognostic (5.13e-7)"	"unprognostic (3.84e-2)"	"unprognostic (2.00e-1)"	"unprognostic (5.28e-3)"	"unprognostic (2.21e-4)"	3.7	2.0	3.4	4.2	17.3	2.4	1.9	1.3	5.6	5.9	4.2	2.6	2.5	2.1	3.0	9.0	7.0	3.4	11.1	5.1	2.5	2.7	1.6	1.4	4.3	1.3	3.3	3.5	12.4	1.5	1.3	2.3	2.6	4.5	3.1	2.2	10.8	2.1	2.7	62.7	2.9	2.1	5.8	1.0	1.5	3.5	2.0	5.4	0.0	1.8	14.8	2.1	5.0	4.7	0.0	0.2	0.0	1.7	0.0	0.1	0.0	0.0	1.0	22.1	0.6	0.4	0.9	0.0	0.5	0.8	0.0	0.0	0.0	0.0	0.0	2.2	3.9	0.9	1.8	1.1	1.3	0.0	0.0	0.6	0.0	8.9	0.0	0.5	0.0	0.2	0.0	2.5	0.5	2.2	9.9	0.2	0.0	0.0	0.1	0.7	0.0	0.0	0.2	2.9	0.0	2.0	3.6	8.9	0.0	0.3	0.0	0.0	0.3	1.9	0.0	0.0	5.6	0.2	0.0	14.0	0.7	12.1	12.7	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.2	0.0	0.0	3.4	17.3	1.3	4.2	2.5	2.7	3.3	3.5	4.5	5.4	3.0	2.9	0.5	0.1	3.8	9.8	3.9	2.5	0.0	0.0	0.0	0.0	0.0	0.0	1.1	22.6	4.1	0.0	0.0	0.9	0.1	10.0	0.1	0.0	0.4	0.2	0.0	0.0	0.6	0.3	12.6	4.6	0.7	0.0	0.0	0.0	4.3	1.7	0.0	9.6	0.0	0.6	0.0	2.1	0.5	0.9	2.4	0.0	0.0	0.0	0.1
MPL	"CD110, TPOR"	ENSG00000117400	"MPL proto-oncogene, thrombopoietin receptor"	P40238	1	43337849-43352772	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 8.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.6"	"Cell line enriched"	"Detected in single"	78	"HEL: 41.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.4"	"Low region specificity"	"Detected in all"			HPA007619			Supported	"Nuclear membrane,Plasma membrane"		NA	NA			"Plasma membrane"	"Nuclear membrane"	"HPA007619: AB_1854080"	"unprognostic (2.74e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.95e-1)"	"unprognostic (8.71e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.22e-2)"	"unprognostic (5.83e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.94e-4)"	"unprognostic (1.51e-1)"	"unprognostic (1.19e-4)"	"unprognostic (2.39e-1)"	"unprognostic (3.26e-1)"	"unprognostic (1.03e-4)"	"unprognostic (1.42e-1)"	1.1	0.3	0.9	0.5	0.8	2.0	0.9	0.5	2.2	0.6	0.6	0.5	0.5	0.3	0.9	1.7	0.9	2.1	0.5	3.9	0.8	0.6	0.5	0.5	2.0	0.5	0.9	0.5	6.6	1.1	0.6	0.6	2.2	0.5	1.5	0.7	0.5	0.5	0.7	0.6	0.4	1.2	2.1	2.5	8.6	0.5	2.1	0.5	0.5	2.2	2.4	0.5	0.9	0.5	0.0	0.0	1.6	0.3	0.0	0.0	4.0	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	41.7	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.4	0.2	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	4.0	0.9	0.8	0.5	2.2	0.8	0.6	0.9	0.5	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MSH2	"COCA1, HNPCC, HNPCC1"	ENSG00000095002	"MutS homolog 2"	P43246	2	47402969-47663146	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Spermatogonia: 59.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009572, HPA066845, CAB070867"	Approved		Supported	Nucleoplasm,Vesicles		NA	Yes			Nucleoplasm	Vesicles	"CAB009572: AB_2144828, CAB070867: , HPA066845: AB_2732752"	"unprognostic (2.35e-1)"	"unprognostic (1.54e-2)"	"unprognostic (2.89e-3)"	"prognostic unfavorable (4.44e-4)"	"unprognostic (2.23e-1)"	"unprognostic (6.31e-3)"	"prognostic unfavorable (1.72e-9)"	"unprognostic (1.77e-1)"	"unprognostic (7.09e-3)"	"unprognostic (8.57e-2)"	"prognostic unfavorable (4.63e-4)"	"unprognostic (5.38e-2)"	"unprognostic (3.29e-3)"	"unprognostic (1.20e-3)"	"unprognostic (5.74e-1)"	"unprognostic (8.46e-2)"	"unprognostic (1.48e-1)"	7.3	9.8	14.2	12.2	25.5	11.4	14.1	22.6	18.1	9.4	11.6	7.6	5.6	6.5	10.5	13.3	10.8	11.1	4.9	8.4	13.0	14.0	7.3	5.5	7.1	19.7	12.5	17.0	7.9	8.4	15.3	9.1	9.9	18.5	7.9	13.8	12.3	9.4	7.3	6.7	10.3	8.0	7.8	13.8	9.4	6.7	13.4	13.5	37.0	13.9	6.6	21.4	8.5	7.6	7.4	2.9	3.9	4.2	12.2	12.6	6.2	28.3	9.7	26.5	14.3	2.0	5.6	16.1	16.9	8.4	21.0	20.3	18.2	12.3	34.9	22.8	5.9	14.8	12.1	19.8	9.6	31.7	18.0	14.8	25.1	11.2	16.5	2.0	24.5	8.8	3.1	2.8	17.8	4.8	4.7	11.5	0.8	41.8	8.1	16.0	11.3	28.4	18.5	49.9	17.2	11.5	38.1	47.4	20.4	9.1	15.0	22.0	23.9	14.9	11.6	11.9	22.3	11.6	9.6	4.6	13.9	18.3	14.4	18.8	5.2	18.5	48.9	8.5	18.1	8.6	2.8	1.0	3.9	7.9	4.2	8.6	6.3	7.4	9.5	2.3	7.4	12.6	11.9	0.7	12.2	3.2	2.9	10.1	6.2	14.2	25.5	22.6	18.1	13.0	14.0	12.5	17.0	18.5	13.5	8.9	11.5	13.7	5.7	7.3	16.8	13.8	5.1	25.4	13.6	8.7	43.2	14.2	3.3	9.6	13.1	11.7	4.6	23.3	7.3	16.3	8.7	3.4	11.5	1.0	9.6	11.1	3.4	3.7	4.0	17.6	4.9	4.0	8.5	6.4	9.1	20.0	6.0	5.8	6.0	3.5	38.3	0.0	5.5	34.2	59.5	5.6	4.2	8.7	9.8	2.7
MSH6	GTBP	ENSG00000116062	"MutS homolog 6"	P52701	2	47695530-47810101	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction"	DNA-binding	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009091, HPA028376, HPA028446, CAB070870"	Enhanced		Supported	"Nucleoplasm,Golgi apparatus,Vesicles"		NA	Yes			Nucleoplasm	"Golgi apparatus, Vesicles"	"CAB009091: AB_670083, CAB070870: AB_2144959, HPA028376: AB_10598909, HPA028446: AB_10602182"	"unprognostic (5.10e-2)"	"unprognostic (5.87e-3)"	"unprognostic (3.29e-2)"	"prognostic unfavorable (1.34e-4)"	"unprognostic (1.98e-1)"	"unprognostic (3.09e-2)"	"prognostic unfavorable (7.86e-4)"	"unprognostic (1.79e-1)"	"unprognostic (2.35e-3)"	"unprognostic (1.01e-1)"	"unprognostic (1.74e-3)"	"unprognostic (8.99e-2)"	"prognostic unfavorable (1.06e-7)"	"unprognostic (1.22e-1)"	"unprognostic (2.31e-1)"	"unprognostic (9.68e-2)"	"unprognostic (3.48e-2)"	13.0	20.5	9.7	13.1	18.8	13.6	13.0	20.5	13.1	17.9	13.3	17.6	10.7	6.1	28.2	11.0	12.4	18.3	8.4	8.6	11.4	8.8	9.5	14.6	11.0	21.7	23.9	9.6	43.2	27.6	16.2	17.3	14.9	15.0	14.6	10.3	8.7	12.0	13.2	10.4	10.3	10.5	22.1	14.9	11.6	11.1	25.1	22.0	40.4	13.4	10.4	25.8	14.2	16.4	8.4	8.4	7.6	9.8	9.7	15.1	5.7	27.5	20.6	38.3	9.1	11.6	12.2	17.3	15.3	13.5	15.9	16.7	15.1	9.6	45.5	23.0	16.6	21.9	11.6	34.5	19.5	20.8	19.8	17.2	29.1	16.3	15.3	7.1	29.2	10.7	9.9	6.2	16.2	10.8	14.9	9.9	1.1	25.3	16.7	15.5	19.9	31.1	13.8	33.6	18.6	9.5	73.8	50.2	20.5	9.7	17.9	21.5	23.3	21.3	10.2	9.3	35.1	12.2	10.3	6.0	18.5	22.6	14.0	19.8	15.7	21.2	76.2	15.6	18.7	11.3	7.6	5.8	4.9	8.4	9.8	10.4	8.4	9.5	8.3	8.4	8.1	15.1	7.6	3.9	9.7	9.3	4.2	9.5	5.7	9.7	18.8	20.5	13.1	11.4	8.8	23.9	9.6	15.0	22.0	26.8	18.4	9.7	20.1	22.3	26.4	6.9	0.0	28.1	31.8	7.0	33.4	24.9	3.3	12.8	25.7	15.3	2.6	0.0	8.4	16.9	17.4	11.4	17.3	8.5	11.1	14.3	4.6	12.3	5.1	11.5	23.6	12.1	3.3	7.2	7.9	27.0	8.8	3.5	21.2	5.3	29.7	6.5	17.2	40.0	40.2	15.3	8.0	13.3	9.3	10.7
MSI2		ENSG00000153944	"Musashi RNA binding protein 2"	Q96DH6	17	57255851-57684685	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	10	"Cone photoreceptor cells: 710.8;Rod photoreceptor cells: 517.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"REH: 48.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022300, HPA068990"	Approved		Supported	Cytosol		NA	NA			Cytosol		"CAB022300: , HPA068990: "	"unprognostic (4.73e-2)"	"unprognostic (2.28e-1)"	"unprognostic (3.42e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.08e-1)"	"unprognostic (4.20e-2)"	"unprognostic (2.20e-2)"	"unprognostic (4.89e-2)"	"unprognostic (2.96e-1)"	"unprognostic (4.17e-2)"	"unprognostic (1.18e-1)"	"prognostic favorable (9.22e-8)"	"prognostic favorable (2.00e-4)"	"unprognostic (4.87e-2)"	"unprognostic (1.57e-1)"	"unprognostic (2.72e-3)"	3.4	34.7	20.0	22.4	21.5	8.4	8.8	18.0	25.3	9.7	14.4	7.7	14.2	5.0	6.7	36.3	4.6	11.1	23.5	28.5	13.9	16.9	18.0	3.6	6.9	9.6	21.0	6.4	22.8	6.1	41.4	23.1	10.7	19.7	10.5	7.4	14.6	9.8	48.5	25.6	3.6	5.4	4.6	14.8	8.7	7.7	7.5	9.5	23.7	12.4	8.4	8.6	11.6	5.0	1.9	3.0	4.8	1.5	1.9	4.1	0.5	3.4	5.9	20.4	7.9	2.3	2.2	16.1	3.9	4.5	5.1	3.1	7.0	5.9	16.1	13.7	2.4	4.1	3.4	13.0	5.2	9.5	22.4	9.1	7.0	13.1	16.1	5.1	7.7	7.2	2.8	6.8	0.6	8.3	6.4	5.2	12.9	15.3	12.1	17.9	8.1	34.8	2.1	7.4	17.5	9.5	48.9	30.6	12.7	12.4	22.6	22.7	42.3	6.3	6.0	18.1	9.8	10.8	6.0	6.6	3.2	8.5	2.8	6.6	16.9	14.2	19.6	8.5	4.7	19.6	4.4	0.4	4.8	2.0	0.3	1.5	1.9	1.9	1.8	0.6	1.1	1.8	1.7	0.4	1.9	1.5	3.0	4.1	0.5	20.0	21.5	18.0	25.3	13.9	16.9	21.0	6.4	19.7	9.5	6.0	26.6	60.1	59.4	21.3	190.2	86.4	56.0	93.7	29.6	71.5	710.8	98.4	104.5	41.8	12.8	24.4	15.3	23.3	12.7	17.2	28.6	73.1	40.5	25.1	17.3	278.1	94.3	28.8	11.1	19.3	59.8	13.2	37.1	1.8	48.0	265.7	11.1	17.5	72.9	43.4	517.0	12.9	27.8	3.9	4.5	14.1	124.8	44.8	33.3	79.0
MSN		ENSG00000147065	Moesin	P26038	X	65588377-65741931	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047337, CAB047338"	Enhanced		Enhanced	"Plasma membrane"		NA	NA		340000000	"Plasma membrane"		"CAB010898: AB_260635, CAB047336: , CAB047337: , CAB047338: , HPA000263: AB_1856043, HPA011135: AB_1854053, HPA011227: AB_1854054"	"unprognostic (1.03e-1)"	"unprognostic (7.89e-2)"	"unprognostic (7.64e-2)"	"unprognostic (5.38e-2)"	"unprognostic (4.08e-3)"	"unprognostic (3.51e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.44e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.04e-3)"	"unprognostic (1.32e-1)"	"prognostic unfavorable (1.60e-5)"	"unprognostic (5.68e-3)"	"unprognostic (7.75e-2)"	"unprognostic (7.21e-2)"	"unprognostic (6.81e-2)"	36.3	17.6	10.2	40.7	14.4	38.5	98.2	8.6	18.6	25.1	21.3	19.2	7.6	6.5	33.4	14.2	15.7	21.8	20.2	53.8	11.5	10.4	25.6	29.5	102.8	85.0	17.5	5.4	28.8	19.4	5.7	10.2	24.2	30.0	23.1	13.0	16.6	16.3	21.9	13.6	19.5	18.3	41.4	21.8	31.6	17.3	9.0	12.9	18.7	26.2	17.6	38.1	22.7	28.9	16.0	36.4	54.1	69.0	28.0	37.1	81.8	28.3	21.7	21.3	17.6	25.6	33.9	0.1	71.8	46.5	39.8	30.9	0.0	5.0	23.7	64.2	63.5	21.1	19.5	22.5	51.2	52.0	44.0	6.2	65.9	37.7	0.0	24.2	80.0	106.7	25.3	11.0	73.2	64.8	38.6	87.9	33.2	31.9	74.1	63.0	0.0	47.3	60.0	26.4	0.0	41.4	24.8	38.3	18.1	42.6	0.0	0.1	0.0	57.7	0.4	22.8	25.1	0.2	43.6	139.1	45.4	28.8	61.0	47.5	26.9	40.7	25.8	33.2	101.6	50.5	30.8	44.4	30.0	37.1	58.9	27.9	16.0	20.4	29.1	36.4	13.9	14.0	21.3	54.1	28.0	69.0	5.2	15.5	81.8	10.2	14.4	8.6	18.6	11.5	10.4	17.5	5.4	30.0	12.9	166.7	148.6	101.2	51.9	182.5	0.5	23.6	10.2	32.1	70.5	64.6	3.9	5.0	24.9	169.4	1.1	154.5	2.6	23.3	146.5	11.7	88.8	25.9	158.4	46.9	150.1	4.8	0.0	91.4	236.8	3.0	68.1	215.1	65.8	158.7	2.3	38.6	229.7	3.1	102.9	81.2	1.8	71.1	127.7	1.9	3.6	130.7	3.5	174.0	1.8	47.2
MTCP1	"P13MTCP1, p8MTCP1"	ENSG00000214827	"Mature T cell proliferation 1"	P56278	X	155061622-155147937	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"	9	"Ciliated cells: 4.0;Club cells: 2.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HeLa: 14.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA032040			Approved	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"HPA032040: AB_2674122"	"unprognostic (2.42e-2)"	"unprognostic (2.07e-2)"	"unprognostic (1.14e-1)"	"unprognostic (6.29e-3)"	"unprognostic (8.30e-2)"	"unprognostic (4.10e-1)"	"unprognostic (2.40e-5)"	"unprognostic (9.30e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.94e-2)"	"unprognostic (5.72e-2)"	"unprognostic (1.15e-2)"	"prognostic unfavorable (4.52e-8)"	"unprognostic (1.55e-3)"	"unprognostic (1.06e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.75e-2)"	6.4	7.1	4.1	5.3	5.3	7.2	15.8	4.4	4.8	6.0	6.2	3.4	7.7	5.7	6.0	8.2	7.0	6.1	4.4	30.1	4.7	2.9	6.7	12.8	8.5	15.5	4.5	2.7	9.1	20.7	3.9	6.5	3.5	6.4	5.8	6.1	3.9	7.3	7.0	11.4	12.0	6.7	8.7	7.2	6.7	6.2	16.1	3.8	2.5	8.2	5.4	7.2	6.9	4.0	0.2	0.0	0.8	0.7	0.5	2.0	0.1	1.4	4.9	2.4	3.9	1.6	1.3	2.7	3.0	1.5	1.9	4.8	4.3	7.5	2.7	3.1	0.6	3.0	4.8	3.2	3.5	2.4	1.8	3.2	1.2	14.3	2.3	1.4	2.9	3.3	2.4	1.7	3.2	3.0	2.3	1.8	4.7	1.1	4.9	1.3	2.0	3.7	6.1	1.1	1.8	0.8	4.0	2.6	6.1	2.4	2.1	1.2	1.8	2.2	1.2	2.1	1.7	2.2	1.3	1.8	2.2	3.9	2.1	2.2	10.7	4.6	5.2	4.3	3.5	3.1	0.0	0.6	0.8	1.1	0.0	2.0	0.2	1.2	0.4	0.0	0.1	0.2	1.4	0.0	0.5	0.7	0.0	0.0	0.1	4.1	5.3	4.4	4.8	4.7	2.9	4.5	2.7	6.4	3.8	0.0	1.0	0.0	0.2	0.2	0.0	0.6	0.0	4.0	2.3	0.0	0.0	0.1	0.0	0.5	0.0	0.3	0.0	0.0	1.1	0.2	0.3	0.3	0.0	1.0	0.4	0.0	1.7	0.0	1.0	0.2	1.1	0.5	1.7	1.0	0.0	0.0	1.1	0.0	0.4	0.2	0.0	0.0	0.3	0.5	0.2	0.6	0.2	0.0	0.5	0.0
MTOR	"FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1"	ENSG00000198793	"Mechanistic target of rapamycin kinase"	P42345	1	11106535-11262507	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Sertoli cells: 38.8;Spermatocytes: 48.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB069425, HPA071227"	Approved		Approved	Vesicles,Cytosol		NA	NA			"Vesicles, Cytosol"		"CAB069425: , HPA071227: AB_2686367"	"unprognostic (3.18e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.45e-3)"	"unprognostic (5.50e-2)"	"unprognostic (2.55e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.24e-3)"	"unprognostic (3.48e-2)"	"unprognostic (1.88e-1)"	"prognostic favorable (1.49e-5)"	"unprognostic (1.27e-1)"	"unprognostic (2.45e-1)"	"unprognostic (6.60e-2)"	"unprognostic (7.55e-2)"	11.3	13.9	18.7	13.0	22.5	12.3	14.9	25.2	25.2	11.3	14.5	18.2	10.4	11.2	13.8	23.6	13.1	10.5	15.7	14.2	14.5	13.6	15.8	19.4	10.8	14.3	14.0	14.4	10.7	16.6	26.5	16.0	12.5	15.5	15.2	17.1	14.4	14.2	15.2	24.6	16.5	13.6	15.2	10.4	15.4	13.1	38.6	13.1	16.6	13.2	9.9	15.7	11.7	10.2	3.9	4.0	3.0	6.4	2.6	5.6	2.3	15.2	13.9	18.7	14.2	22.7	10.8	9.4	12.9	12.4	17.3	17.0	14.2	14.1	17.0	11.1	15.2	10.7	18.2	25.3	19.8	22.4	13.5	18.5	22.6	28.7	17.9	14.2	21.9	16.8	13.8	15.1	24.7	25.1	8.2	21.8	16.4	25.2	14.6	12.0	17.4	15.1	16.8	14.2	16.0	13.1	15.2	22.1	11.4	15.3	13.9	18.9	13.9	27.6	15.0	16.9	21.5	12.2	13.0	23.3	15.1	13.7	11.5	17.3	14.4	13.4	33.4	10.9	23.8	15.9	0.7	2.9	3.0	5.2	6.4	4.3	3.9	3.0	2.7	4.0	3.4	3.6	3.1	2.0	2.6	3.3	3.1	5.6	2.3	18.7	22.5	25.2	25.2	14.5	13.6	14.0	14.4	15.5	13.1	14.9	10.2	5.2	4.5	3.1	0.0	25.7	2.5	2.7	10.3	8.7	0.0	6.5	1.7	6.3	31.2	7.8	7.9	0.0	5.4	5.9	5.1	7.5	12.7	13.0	6.1	0.0	9.9	5.5	7.3	29.3	7.2	6.0	8.5	5.4	6.8	0.0	8.6	3.5	7.8	4.3	0.0	38.8	6.9	48.4	31.3	5.0	8.2	6.5	9.5	5.5
MUC1	"ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM"	ENSG00000185499	"Mucin 1, cell surface associated"	P15941	1	155185824-155192916	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"			"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 168.1;kidney: 158.5;lung: 143.5"	"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 2: 1308.2;Collecting duct cells: 465.9;Exocrine glandular cells: 994.6;Pancreatic endocrine cells: 807.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.0"	"Group enriched"	"Detected in many"	10	"granulocytes: 1.3;T-cells: 4.0"	"Group enriched"	"Detected in many"	6	"CAPAN-2: 139.4;OE19: 65.3;RPTEC TERT1: 107.0;T-47d: 47.0"									"CAB000036, CAB001986, HPA004179, HPA007235, HPA008855"	Enhanced		Supported	"Plasma membrane"	"Secreted in other tissues"	NA	NA		4900000	"Plasma membrane"		"CAB000036: AB_2148557, CAB001986: , HPA004179: AB_1846282, HPA007235: AB_1846281, HPA008855: AB_1846283"	"unprognostic (4.74e-2)"	"unprognostic (2.84e-2)"	"unprognostic (2.19e-1)"	"unprognostic (8.01e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.70e-1)"	"unprognostic (2.61e-3)"	"unprognostic (6.34e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.23e-1)"	"prognostic unfavorable (4.60e-4)"	"unprognostic (4.75e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.13e-1)"	"unprognostic (8.12e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.21e-1)"	1.5	0.7	0.8	12.6	1.2	0.9	12.6	0.4	0.7	31.6	15.9	1.2	2.4	2.9	10.5	9.8	51.8	18.7	168.1	0.8	0.5	0.3	158.5	2.0	143.5	0.3	0.5	0.3	14.9	74.2	0.0	4.7	15.5	2.1	6.1	16.1	0.8	17.0	5.9	0.8	1.8	3.6	2.8	0.7	0.6	105.0	4.3	0.5	0.7	15.7	10.5	47.8	12.3	5.2	0.0	0.2	1.3	0.1	0.0	4.0	0.2	1.8	0.9	0.6	0.5	0.4	0.5	0.2	0.6	1.4	0.7	1.9	0.0	139.4	0.0	10.1	1.1	0.3	2.8	0.1	0.0	0.2	1.2	0.1	0.2	11.8	0.0	0.3	0.0	4.4	1.2	0.2	0.3	0.2	1.5	0.2	0.2	1.0	1.9	0.5	14.2	0.1	0.1	0.4	65.3	0.2	0.2	0.0	3.4	107.0	0.1	0.6	0.2	3.3	5.9	0.1	0.5	47.0	0.6	0.2	0.4	0.8	1.3	0.1	2.1	1.1	0.0	0.7	0.1	0.1	1.3	0.1	0.0	0.0	0.0	0.8	0.0	2.3	0.4	0.2	0.0	0.3	0.7	0.0	0.0	0.0	0.0	4.0	0.2	0.8	1.2	0.4	0.7	0.5	0.3	0.5	0.3	2.1	0.5	402.0	1308.2	0.9	16.1	0.6	1.0	0.4	384.7	92.3	252.5	465.9	3.9	0.1	29.9	144.7	27.3	3.5	49.2	0.0	994.6	1.2	3.1	11.6	45.2	0.5	0.2	1.6	29.4	1.3	3.4	68.9	2.3	2.6	5.0	42.3	249.7	1.1	807.2	66.2	1.4	0.9	0.2	0.0	1.9	6.2	0.8	1.0	0.2	0.0	132.5	164.3
MUTYH	MYH	ENSG00000132781	"MutY DNA glycosylase"	Q9UIF7	1	45329163-45340470	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Glycosidase, Hydrolase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cytotrophoblasts: 33.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA008732	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA008732: AB_1854219"	"unprognostic (6.30e-3)"	"unprognostic (7.12e-2)"	"unprognostic (6.29e-2)"	"unprognostic (8.80e-2)"	"unprognostic (3.43e-1)"	"unprognostic (5.16e-3)"	"prognostic unfavorable (4.76e-8)"	"unprognostic (2.80e-2)"	"unprognostic (7.12e-3)"	"unprognostic (3.05e-2)"	"unprognostic (7.80e-2)"	"unprognostic (1.14e-1)"	"prognostic unfavorable (7.25e-5)"	"unprognostic (3.50e-3)"	"unprognostic (1.62e-1)"	"unprognostic (5.57e-2)"	"unprognostic (5.49e-3)"	7.7	8.4	10.3	12.7	14.8	11.1	8.3	31.6	12.4	10.5	10.1	15.1	11.0	11.1	11.5	9.8	8.3	11.0	10.0	6.1	10.9	7.3	9.7	9.0	7.2	14.0	13.6	10.1	12.9	8.4	7.5	12.5	12.5	11.6	9.1	11.0	12.6	9.5	11.7	8.5	11.1	9.8	7.5	12.6	12.8	11.8	4.9	16.6	14.1	11.9	7.4	12.0	9.3	9.2	7.2	6.5	1.9	8.9	6.6	15.4	6.3	4.9	4.3	10.1	6.9	7.2	5.4	17.6	3.4	4.7	7.4	6.1	9.1	7.0	13.9	6.1	2.3	5.9	7.6	5.3	6.3	3.4	11.5	4.0	6.8	6.9	6.5	6.7	5.8	5.0	3.6	6.5	9.9	16.6	1.9	5.3	18.3	10.5	5.4	3.1	8.0	15.9	5.5	25.5	11.7	5.3	21.6	7.8	7.5	3.8	9.3	9.2	7.2	7.4	5.8	11.5	13.6	4.6	6.7	3.3	6.5	4.0	5.0	5.4	8.2	9.4	8.5	5.6	8.8	4.9	1.5	5.6	1.9	9.8	8.9	15.4	7.2	10.2	9.9	6.5	7.2	11.3	11.0	0.9	6.6	6.8	5.5	10.3	6.3	10.3	14.8	31.6	12.4	10.9	7.3	13.6	10.1	11.6	16.6	0.0	6.4	7.0	10.7	6.2	14.7	3.1	0.0	9.4	6.8	7.0	2.0	33.3	3.3	5.7	0.8	5.2	13.7	0.0	4.6	11.1	7.0	7.0	10.4	3.9	8.7	4.8	7.5	6.7	6.4	0.6	10.0	6.9	6.8	9.0	12.3	11.8	3.3	14.0	11.3	7.0	18.5	12.9	7.1	7.1	11.1	4.6	18.5	12.9	12.5	6.4
MYB	c-myb	ENSG00000118513	"MYB proto-oncogene, transcription factor"	P10242	6	135181315-135219173	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lymphoid tissue: 104.9"	"Cell type enhanced"	"Detected in many"	11	"Ciliated cells: 44.2;granulocytes: 25.4;Intestinal endocrine cells: 16.9;Mucus-secreting cells: 26.5;Undifferentiated cells: 37.5"	"Cancer enhanced"	"Detected in many"		"breast cancer: 17.7"	"Region enhanced"	"Detected in some"		"basal ganglia: 4.7"	"Group enriched"	"Detected in some"	4	"basophil: 5.6;eosinophil: 10.0"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 10.0"	"Cell line enhanced"	"Detected in many"		"HL-60: 39.5;MOLT-4: 72.0;NB-4: 37.5;REH: 44.5;THP-1: 62.8;U-937: 34.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB017704, HPA071605"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB017704: , HPA071605: "	"unprognostic (1.69e-1)"	"unprognostic (5.82e-2)"	"unprognostic (1.82e-3)"	"unprognostic (1.37e-2)"	"unprognostic (4.06e-1)"	"unprognostic (8.35e-3)"	"unprognostic (1.13e-3)"	"unprognostic (2.48e-2)"	"unprognostic (6.44e-2)"	"unprognostic (1.00e-1)"	"unprognostic (3.71e-2)"	"prognostic favorable (9.65e-4)"	"unprognostic (2.41e-11)"	"prognostic favorable (9.87e-4)"	"unprognostic (8.35e-2)"	"unprognostic (3.04e-2)"	"unprognostic (9.40e-2)"	0.5	0.7	1.3	9.1	4.7	18.9	13.2	0.3	0.6	1.4	15.4	0.5	0.3	6.5	0.9	1.0	3.7	5.0	1.7	0.6	0.7	0.7	0.4	0.5	1.8	3.3	0.3	0.5	1.0	0.3	0.4	0.3	0.6	0.5	1.6	16.7	0.5	0.8	1.5	1.0	3.5	5.9	0.7	0.4	1.4	0.9	2.0	0.6	104.9	0.4	2.0	4.7	0.7	1.5	0.1	1.7	10.0	0.8	0.0	0.5	0.1	0.3	0.0	0.3	0.5	0.0	0.0	0.0	0.1	0.0	0.2	0.2	0.0	0.2	1.8	0.0	0.0	0.0	0.1	1.0	0.0	0.1	3.1	0.4	25.2	0.1	0.0	0.0	39.5	20.0	0.0	0.0	0.1	0.0	0.0	0.0	24.8	20.4	3.8	0.2	2.0	72.0	37.5	0.2	3.5	0.3	44.5	1.0	6.1	0.0	0.2	1.9	1.2	0.0	2.0	0.0	0.1	1.5	62.8	0.0	0.0	0.3	1.5	0.4	4.8	1.2	12.2	0.0	34.2	0.4	5.6	0.8	10.0	0.0	0.1	0.2	0.0	0.0	0.0	0.2	0.1	0.1	0.2	0.0	0.0	0.0	1.7	0.5	0.1	1.3	4.7	0.3	0.6	0.7	0.7	0.3	0.5	0.5	0.6	0.0	2.2	2.9	1.1	2.4	0.6	0.4	2.5	44.2	10.3	0.0	0.0	0.7	0.0	0.0	0.1	0.0	2.9	0.0	0.7	0.6	0.4	2.7	25.4	0.0	0.9	0.0	16.9	0.0	1.2	0.0	0.0	1.5	8.5	0.0	26.5	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.5	6.0	0.2	1.9	37.5	2.0
MYC	"bHLHe39, c-Myc, MYCC"	ENSG00000136997	"MYC proto-oncogene, bHLH transcription factor"	P01106	8	127735434-127741434	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Basal glandular cells: 812.6;Basal keratinocytes: 900.0;Smooth muscle cells: 529.5;Suprabasal keratinocytes: 935.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 132.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000084, CAB010307, HPA055893, HPA066556"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000084: , CAB010307: AB_631274, HPA055893: AB_2682960, HPA066556: AB_2685691"	"unprognostic (1.45e-2)"	"unprognostic (4.00e-3)"	"unprognostic (3.94e-3)"	"unprognostic (2.41e-3)"	"unprognostic (8.14e-2)"	"unprognostic (3.36e-3)"	"unprognostic (5.80e-2)"	"unprognostic (4.94e-3)"	"unprognostic (1.59e-1)"	"prognostic unfavorable (7.52e-4)"	"unprognostic (5.19e-3)"	"unprognostic (9.86e-3)"	"prognostic unfavorable (5.49e-8)"	"unprognostic (7.85e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.48e-1)"	"prognostic unfavorable (4.96e-5)"	67.4	20.8	3.2	46.6	7.1	16.3	36.0	1.2	5.0	23.9	23.3	3.8	11.8	11.1	23.8	14.4	47.6	59.5	32.4	23.7	5.8	2.2	11.2	36.6	16.0	40.5	5.8	1.2	38.7	64.6	2.1	7.4	14.9	9.8	20.6	11.3	6.1	14.4	21.8	69.6	78.5	17.2	21.3	12.0	38.3	24.7	16.3	3.8	40.2	9.0	48.4	27.1	28.9	37.3	25.5	8.8	1.0	10.3	20.9	55.2	22.0	7.2	14.0	1.2	12.5	20.4	24.1	3.7	8.7	3.8	10.9	9.1	19.2	19.1	74.3	12.3	5.2	10.7	15.8	65.1	28.3	7.2	17.5	22.7	44.7	23.8	25.0	18.8	31.2	7.2	16.8	62.6	7.3	58.0	8.8	12.5	26.2	66.0	39.3	5.4	20.8	51.0	68.1	3.5	31.3	28.1	28.4	5.3	132.1	9.1	7.5	86.4	8.2	4.0	34.1	22.6	2.1	13.9	20.5	15.2	8.2	9.8	6.3	10.9	0.7	1.2	35.9	7.2	35.0	4.1	0.7	10.3	0.1	8.6	9.1	43.4	25.5	31.1	18.6	8.8	20.6	55.2	34.8	1.0	20.9	6.1	0.3	24.8	22.0	3.2	7.1	1.2	3.6	5.8	2.2	5.8	1.2	9.8	3.8	53.6	68.5	50.1	812.6	900.0	0.0	10.2	28.1	18.7	83.0	12.2	0.0	20.0	1.7	71.3	0.9	89.5	6.3	0.0	37.0	51.5	149.4	176.0	54.4	27.1	25.9	0.0	12.0	96.3	42.9	1.1	91.5	19.1	160.3	3.6	66.1	1.0	60.5	11.5	63.3	5.3	0.2	45.3	529.5	0.5	0.7	935.3	4.9	39.5	82.4	301.8
MYCL	"bHLHe38, LMYC, MYCL1"	ENSG00000116990	"MYCL proto-oncogene, bHLH transcription factor"	P12524	1	39895426-39902256	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"pancreas: 46.4;skin 1: 26.0"	"Cell type enhanced"	"Detected in many"	5	"Cytotrophoblasts: 21.7;Hepatocytes: 21.9;Mucus-secreting cells: 22.7;Urothelial cells: 22.1"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 28.9"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"classical monocyte: 11.5;intermediate monocyte: 5.5;myeloid DC: 12.9;plasmacytoid DC: 15.4"	"Group enriched"	"Detected in many"	75	"dendritic cells: 15.4;monocytes: 11.5"	"Group enriched"	"Detected in some"	7	"U-266/70: 96.4;U-266/84: 70.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA063132, HPA074515"			Enhanced	"Nucleoplasm,Mitotic chromosome"		NA	NA			Nucleoplasm	"Mitotic chromosome"	"HPA063132: AB_2684946, HPA074515: "	"unprognostic (7.45e-2)"	"unprognostic (6.91e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.83e-3)"	"unprognostic (1.61e-2)"	"unprognostic (2.92e-3)"	"unprognostic (6.72e-3)"	"prognostic favorable (4.49e-4)"	"unprognostic (1.24e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.12e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.75e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.53e-2)"	"unprognostic (5.80e-2)"	0.3	0.3	1.2	4.4	2.1	0.1	1.7	0.8	1.7	3.6	7.5	1.8	8.5	2.6	1.0	4.0	17.8	1.6	2.3	0.7	1.1	0.9	0.8	6.4	1.9	2.9	0.6	1.4	0.5	46.4	0.0	2.1	11.2	1.8	5.3	3.6	1.8	4.6	16.6	0.6	26.0	7.3	1.2	1.1	4.0	3.3	1.5	0.6	6.4	4.2	3.1	6.0	18.4	7.3	0.0	15.4	0.1	11.5	0.0	0.1	3.8	0.2	0.0	2.9	0.7	0.0	0.0	7.1	0.1	0.0	0.2	0.1	0.1	0.1	0.4	0.3	0.0	0.0	0.7	2.0	0.5	0.1	0.4	1.1	0.1	0.0	0.1	0.0	0.0	1.7	0.2	2.4	0.0	0.2	0.0	0.2	1.1	0.7	0.0	0.1	0.2	0.0	0.0	2.8	0.4	0.1	0.2	3.4	0.6	0.2	11.6	0.5	0.7	0.2	0.4	0.1	1.1	0.7	3.7	0.0	0.0	1.1	1.3	0.1	96.4	70.7	0.2	0.0	0.4	0.0	0.0	11.5	0.0	0.0	5.5	0.0	0.0	0.0	0.1	12.9	0.0	0.0	0.0	0.1	0.0	2.3	15.4	0.0	3.8	1.2	2.1	0.8	1.7	1.1	0.9	0.6	1.4	1.8	0.6	0.0	0.6	0.0	9.0	6.0	0.2	3.3	0.0	1.4	4.5	8.7	0.0	21.7	0.0	1.1	0.1	0.5	9.5	0.0	5.1	11.3	0.7	4.8	0.0	21.9	4.9	0.0	16.6	2.5	6.9	0.2	0.0	9.6	1.7	0.0	22.7	1.1	2.4	8.5	0.0	0.0	0.0	0.0	0.3	0.0	0.7	10.3	14.6	0.0	10.5	22.1
MYCN	"bHLHe37, MYCNOT, N-myc, NMYC"	ENSG00000134323	"MYCN proto-oncogene, bHLH transcription factor"	P04198	2	15940564-15947007	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 16.8"	"Cell type enriched"	"Detected in some"	8	"Extravillous trophoblasts: 75.4"	"Cancer enhanced"	"Detected in many"		"testis cancer: 45.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 12.9;BEWO: 70.2;HMC-1: 16.9;NTERA-2: 26.6;RH-30: 18.6;SuSa: 12.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA057420			Approved	Nucleoplasm,Nucleoli		NA	NA			Nucleoli	Nucleoplasm	"HPA057420: AB_2683434"	"unprognostic (8.04e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.07e-2)"	"unprognostic (4.11e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.23e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.35e-3)"	"unprognostic (3.09e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.12e-3)"	"unprognostic (8.89e-2)"	"unprognostic (2.47e-1)"	"unprognostic (4.90e-2)"	"unprognostic (1.23e-1)"	0.9	1.9	5.1	1.8	5.5	1.6	1.2	1.4	8.4	3.1	1.2	12.1	0.0	3.0	1.9	0.8	1.3	1.4	2.6	2.3	7.0	4.7	6.0	1.5	1.6	2.9	6.0	2.2	10.3	0.7	0.4	0.7	16.8	6.8	0.6	1.3	1.1	6.6	0.7	1.0	2.4	1.7	0.9	8.9	0.9	8.5	6.5	4.0	5.7	5.1	2.3	3.5	2.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	0.0	0.0	0.0	70.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	16.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.1	0.0	26.6	0.6	0.0	0.0	18.6	3.5	0.0	0.9	0.2	4.7	0.0	0.0	0.0	12.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	5.5	1.4	7.0	7.0	4.7	6.0	2.2	6.8	4.0	0.0	0.0	0.0	0.1	0.5	2.6	0.7	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	1.2	0.2	0.0	0.0	0.0	75.4	0.6	0.0	0.0	0.5	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.2	0.0	0.4	2.1	0.1	0.0	0.0	0.5	3.6	0.0	9.6	0.0	0.2	0.0
MYD88		ENSG00000172936	"Myeloid differentiation primary response 88"	Q99836	3	38138478-38143022	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Immunity, Inflammatory response, Innate immunity"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 68.0"	"Cell type enhanced"	"Detected in many"	5	"Kupffer cells: 75.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SK-BR-3: 55.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009104	Approved		Supported	Vesicles,Mitochondria,Cytosol		NA	NA			Cytosol	"Vesicles, Mitochondria"	"CAB009104: AB_2146724"	"prognostic favorable (8.45e-4)"	"unprognostic (1.19e-1)"	"unprognostic (4.31e-2)"	"unprognostic (2.51e-2)"	"unprognostic (4.77e-2)"	"unprognostic (4.38e-3)"	"unprognostic (4.37e-2)"	"unprognostic (3.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (7.28e-2)"	"unprognostic (1.01e-2)"	"unprognostic (7.30e-2)"	"unprognostic (2.11e-2)"	"unprognostic (4.41e-1)"	"unprognostic (4.17e-2)"	"unprognostic (1.65e-1)"	"unprognostic (2.08e-2)"	25.0	11.3	5.9	19.5	6.9	18.1	14.7	5.2	4.6	10.0	13.4	5.8	5.0	15.1	9.5	12.3	25.5	9.8	12.4	10.4	5.3	3.2	15.1	47.9	25.6	40.1	6.2	3.5	13.3	10.3	5.4	10.4	17.8	6.7	11.3	14.3	8.8	13.9	5.4	3.9	12.5	30.4	10.7	7.0	39.0	12.5	5.8	5.1	28.5	10.4	17.5	30.8	13.9	13.7	7.8	34.7	49.0	68.0	8.3	14.3	34.6	8.1	12.2	1.8	10.8	8.6	11.2	3.8	8.1	13.2	22.8	24.3	7.6	10.0	17.6	4.8	14.5	5.2	10.3	14.4	8.1	7.6	13.6	3.0	9.5	6.2	11.5	7.1	12.1	24.8	12.9	8.6	12.9	4.8	4.3	13.0	13.5	4.1	7.2	12.0	8.3	19.8	3.9	7.7	17.2	12.1	8.5	2.3	7.5	11.7	19.3	0.8	4.0	11.5	55.1	7.1	1.5	8.6	13.7	12.0	4.5	2.7	20.7	7.7	10.7	11.8	13.1	8.7	21.1	9.7	38.3	37.6	48.1	12.2	56.5	10.4	7.8	11.0	12.2	34.7	6.7	7.7	10.9	49.0	8.3	68.0	16.6	14.3	34.6	5.9	6.9	5.2	4.6	5.3	3.2	6.2	3.5	6.7	5.1	6.0	14.6	17.4	10.4	12.8	0.9	1.5	7.6	10.7	11.4	5.2	0.0	12.2	6.6	22.7	0.7	10.5	25.9	0.0	24.0	20.1	9.1	11.9	24.2	27.6	30.3	0.0	9.2	9.8	75.0	0.6	12.7	48.3	3.3	18.0	16.3	3.5	43.6	34.5	9.9	9.2	0.0	12.9	7.0	2.1	0.4	15.1	10.1	20.3	13.1	37.7
MYH11	"SMHC, SMMHC"	ENSG00000133392	"Myosin heavy chain 11"	P35749	16	15703172-15857033	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Calmodulin-binding, Motor protein, Muscle protein, Myosin"	"Aortic aneurysm, Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 507.4;urinary bladder: 394.5"	"Group enriched"	"Detected in many"	29	"Peritubular cells: 1569.5;Sertoli cells: 614.4;Smooth muscle cells: 1327.8"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 173.2"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BEWO: 3.6;NB-4: 3.9;U-698: 9.9"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"midbrain: 54.5"	"CAB002302, HPA014539, HPA015310"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		130000000	"Plasma membrane, Cytosol"		"CAB002302: AB_563902, HPA014539: AB_1234906, HPA015310: AB_1854261"	"unprognostic (7.99e-2)"	"unprognostic (3.07e-2)"	"unprognostic (4.18e-2)"	"unprognostic (9.21e-3)"	"unprognostic (6.70e-2)"	"unprognostic (2.75e-2)"	"prognostic favorable (1.10e-5)"	"unprognostic (1.41e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.19e-3)"	"unprognostic (4.06e-2)"	"unprognostic (9.53e-2)"	"unprognostic (5.00e-2)"	"unprognostic (5.45e-3)"	13.2	3.0	0.6	31.5	1.2	0.0	5.9	0.5	1.7	90.3	227.5	1.3	100.0	11.6	102.0	38.4	233.0	43.8	94.3	6.2	0.6	0.7	4.7	0.7	8.5	1.5	1.4	2.6	45.5	1.3	0.0	1.0	5.3	3.6	164.7	22.2	37.0	8.8	127.2	6.4	5.0	50.6	507.4	1.4	3.7	77.7	22.3	0.2	0.1	3.7	6.2	3.0	394.5	57.5	1.5	0.9	6.0	0.9	1.1	1.5	0.4	0.1	0.4	0.2	0.1	0.0	0.0	3.6	0.1	0.0	0.0	0.0	0.0	0.4	0.1	0.2	0.0	0.2	0.6	0.0	0.0	0.0	0.4	0.4	0.2	0.1	0.0	0.0	0.1	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.1	1.5	0.0	0.3	0.3	3.9	0.4	0.1	0.1	0.4	0.2	1.9	0.0	0.2	0.7	1.4	0.2	0.5	1.2	0.2	0.5	0.0	0.3	0.1	0.3	2.0	0.1	0.5	0.4	9.9	0.4	0.4	0.4	3.1	0.9	2.7	1.2	0.6	1.2	1.5	1.5	1.4	0.5	1.2	1.4	1.4	6.0	1.1	0.6	0.9	1.4	0.4	0.6	1.2	0.5	1.7	0.6	0.7	1.4	2.6	3.6	0.2	0.0	2.6	4.5	1.6	11.7	1.5	38.7	0.0	1.4	2.3	0.0	7.9	0.2	0.0	0.0	36.6	5.7	0.0	0.0	0.3	0.2	8.0	5.1	0.0	0.0	1.1	0.0	1.2	4.3	0.0	30.8	39.7	3.8	11.8	2.8	0.3	0.3	0.2	0.0	1569.5	0.0	1.6	614.4	1327.8	3.2	7.5	16.3	0.0	4.9	0.4	2.5
MYH9	"DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA"	ENSG00000100345	"Myosin heavy chain 9"	P35579	22	36281277-36388067	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Cell shape"	"Actin-binding, Calmodulin-binding, Motor protein, Myosin"	"Alport syndrome, Cancer-related genes, Cataract, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001644, CAB015386, HPA064783"	Enhanced		Supported	"Plasma membrane,Actin filaments,Cytosol"		No	No		3100000000	"Plasma membrane, Actin filaments"	Cytosol	"CAB015386: AB_784698, HPA001644: AB_1079439, HPA064783: AB_2732721"	"unprognostic (1.38e-1)"	"unprognostic (9.12e-2)"	"unprognostic (4.21e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.49e-1)"	"unprognostic (3.90e-2)"	"unprognostic (9.56e-2)"	"unprognostic (8.28e-2)"	"unprognostic (5.50e-2)"	"unprognostic (6.38e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.61e-1)"	"unprognostic (7.98e-2)"	"unprognostic (9.48e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.59e-2)"	115.5	26.1	11.9	43.7	12.9	55.6	59.0	9.3	16.8	67.1	44.6	18.0	26.4	26.9	120.8	39.7	48.3	45.6	66.9	39.2	11.0	8.1	45.0	42.8	74.4	57.7	15.1	9.2	56.4	43.9	19.0	15.4	65.7	17.9	47.6	23.6	32.4	66.2	27.2	36.9	40.3	49.8	46.7	13.5	91.5	37.1	25.8	11.9	76.0	42.5	38.4	65.0	56.0	53.7	6.9	8.2	28.5	11.5	4.2	16.6	19.3	61.6	28.6	9.1	7.8	17.0	21.4	46.4	41.4	53.6	59.1	44.4	30.9	17.7	16.0	24.6	69.2	28.2	42.8	13.3	80.9	60.9	36.0	12.6	30.8	30.7	26.3	52.3	34.9	49.4	25.3	24.9	79.9	67.9	58.0	48.7	11.8	6.7	21.7	47.2	16.4	12.4	20.6	5.4	17.4	17.7	23.6	28.3	14.8	33.4	60.0	13.8	5.6	58.1	22.9	26.7	24.6	17.0	18.1	139.1	131.2	39.8	25.1	74.7	14.3	11.3	13.5	49.6	17.7	38.0	26.8	10.4	28.5	16.6	9.6	14.7	6.9	12.0	13.2	8.2	6.4	9.6	10.1	19.7	4.2	11.5	3.8	12.6	19.3	11.9	12.9	9.3	16.8	11.0	8.1	15.1	9.2	17.9	11.9	110.2	86.9	60.5	130.0	128.0	2.3	53.2	81.5	28.1	77.3	87.2	2.0	72.9	6.6	289.4	34.4	187.8	163.7	0.0	209.5	151.1	61.7	129.5	90.2	89.4	89.7	77.9	70.9	122.8	115.2	27.9	63.0	105.6	81.0	160.5	123.0	11.0	299.7	150.8	198.7	19.2	4.7	200.5	251.3	3.0	6.8	118.2	38.8	112.2	120.6	111.1
MYO5A	"GS1, MYH12, MYO5, MYR12"	ENSG00000197535	"Myosin VA"	Q9Y4I1	15	52307283-52529050	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Protein transport, Transport"	"Actin-binding, Calmodulin-binding, Motor protein, Myosin"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 34.5;parathyroid gland: 47.6"	"Cell type enhanced"	"Detected in many"	7	"Bipolar cells: 82.8;Melanocytes: 92.8"	"Cancer enhanced"	"Detected in all"		"melanoma: 25.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 60.0;RPMI-8226: 40.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001356	Enhanced		Approved	"Focal adhesion sites,Centriolar satellite"		NA	NA			"Focal adhesion sites, Centriolar satellite"		"HPA001356: AB_1079441"	"unprognostic (1.54e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.95e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.30e-2)"	"unprognostic (6.65e-2)"	"unprognostic (7.89e-2)"	"unprognostic (4.74e-2)"	"unprognostic (9.36e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.63e-3)"	"unprognostic (3.79e-3)"	"unprognostic (1.24e-1)"	"unprognostic (7.16e-2)"	"prognostic unfavorable (4.22e-4)"	8.4	7.1	16.6	9.5	27.5	15.7	5.5	27.4	34.5	6.2	4.4	7.8	0.4	3.3	4.2	3.2	5.0	3.6	7.3	4.6	15.9	15.4	4.6	2.7	7.3	11.2	15.6	17.6	5.4	4.3	47.6	10.5	5.2	29.3	4.5	5.2	9.9	4.0	3.4	4.1	10.4	3.9	7.7	10.1	7.3	4.1	4.6	7.1	3.1	6.8	2.7	10.3	7.3	4.2	2.3	5.2	6.3	4.4	0.7	4.5	1.9	5.5	9.8	5.2	6.3	5.3	6.5	5.6	10.1	9.1	5.4	4.2	0.9	2.2	5.3	2.6	12.0	7.9	4.6	12.0	10.4	6.7	30.0	2.8	4.9	2.5	1.2	2.7	2.6	4.8	4.3	6.5	7.9	15.8	5.3	31.4	3.5	0.1	60.0	10.4	9.8	2.3	0.3	2.4	0.1	7.8	4.2	8.4	40.7	4.4	4.0	3.8	2.3	9.4	7.8	18.3	4.0	4.1	2.9	15.0	10.9	4.7	5.1	9.8	6.2	13.8	6.4	11.9	7.5	15.7	0.9	4.4	5.4	2.9	3.6	4.5	2.3	2.9	1.9	5.2	1.6	0.5	1.0	6.3	0.7	2.6	3.1	4.1	1.9	16.6	27.5	27.4	34.5	15.9	15.4	15.6	17.6	29.3	7.1	11.9	10.7	12.3	8.4	18.4	82.8	8.7	5.1	9.4	29.6	14.0	37.3	0.5	0.0	4.8	16.0	9.0	0.0	0.0	5.4	0.4	6.0	6.8	22.0	1.0	21.3	25.4	1.2	1.8	24.4	6.4	3.4	39.4	92.8	27.9	0.0	4.5	5.0	0.8	1.8	2.2	27.1	6.5	4.7	8.7	7.0	10.2	0.9	12.9	0.0	7.4
MYOD1	"bHLHc1, MYF3, MYOD, PUM"	ENSG00000129152	"Myogenic differentiation 1"	P15172	11	17719568-17722131	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Myogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	7	"skeletal muscle: 31.8"	"Cell type enriched"	"Detected in single"	7	"Spermatogonia: 3.0"	"Cancer enhanced"	"Detected in single"		"ovarian cancer: 0.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	15	"RH-30: 103.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA055436, HPA078647"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA055436: , HPA078647: "						"unprognostic (1.07e-3)"				"unprognostic (2.10e-1)"					"unprognostic (1.01e-1)"			1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.5	0.0	31.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	4.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	103.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.0	0.0	0.0	0.0	0.0	0.0
NAB2	MADER	ENSG00000166886	"NGFI-A binding protein 2"	Q15742	12	57088894-57095476	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Repressor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Syncytiotrophoblasts: 47.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004510, HPA027464"	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB004510: AB_627982, HPA027464: AB_10601138"	"prognostic favorable (7.41e-4)"	"unprognostic (4.04e-2)"	"unprognostic (2.20e-3)"	"unprognostic (2.43e-2)"	"unprognostic (4.74e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.88e-3)"	"unprognostic (1.80e-1)"	"unprognostic (5.85e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.13e-1)"	"unprognostic (6.98e-2)"	"prognostic unfavorable (9.38e-6)"	"unprognostic (1.95e-1)"	"unprognostic (9.76e-2)"	"unprognostic (5.67e-3)"	"unprognostic (6.19e-3)"	9.5	12.6	11.7	9.9	14.2	4.8	7.9	33.3	20.4	18.7	13.7	5.3	9.6	8.2	22.8	18.9	10.5	15.6	14.5	9.6	8.6	6.8	8.4	18.7	12.8	9.1	4.4	14.6	29.2	8.5	14.5	17.0	13.4	6.8	15.0	4.4	8.5	5.6	14.5	7.1	18.6	7.1	14.5	4.1	8.0	8.2	11.8	7.0	12.4	9.8	7.7	8.6	14.5	26.5	4.2	1.2	0.9	5.4	0.9	2.5	1.2	5.5	3.6	18.9	17.3	17.0	22.3	2.0	16.8	15.2	10.6	8.9	5.8	3.3	3.5	6.9	16.5	3.2	10.1	6.5	12.4	5.7	1.5	1.7	4.2	2.8	5.9	12.9	3.4	10.1	24.7	13.7	12.6	4.3	16.9	2.8	2.6	9.5	3.7	12.3	26.0	5.1	16.3	3.8	4.8	6.3	3.8	24.9	1.8	4.5	2.2	2.1	5.0	8.1	4.7	35.2	5.1	10.6	7.4	3.2	15.7	13.1	11.1	4.9	8.7	2.1	1.8	15.3	2.2	9.4	0.0	2.3	0.3	1.2	5.3	1.4	2.1	2.0	1.5	1.2	4.2	2.5	2.5	0.9	0.9	5.4	0.0	1.9	1.2	11.7	14.2	33.3	20.4	8.6	6.8	4.4	14.6	6.8	7.0	11.9	15.4	9.0	20.1	26.3	18.7	2.4	0.0	1.4	13.6	8.7	2.0	2.7	6.6	7.2	0.4	10.5	2.6	0.0	1.2	8.8	23.4	12.6	16.2	13.0	10.6	9.5	6.3	16.5	13.7	2.1	18.1	18.0	20.3	0.0	0.5	7.5	3.3	0.0	17.7	4.4	3.8	19.4	16.0	1.6	15.0	28.4	47.0	5.1	1.3	8.4
NBN	"AT-V1, AT-V2, ATV, NBS, NBS1"	ENSG00000104320	Nibrin	O60934	8	89933336-90003228	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cell cycle, DNA damage, DNA repair, Host-virus interaction, Meiosis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-BR-3: 78.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001429, CAB003836"	Supported		Approved	"Nucleoplasm,Golgi apparatus"		NA	NA			"Golgi apparatus"	Nucleoplasm	"CAB003836: AB_562172, HPA001429: AB_1854460"	"unprognostic (1.52e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.32e-3)"	"unprognostic (7.46e-2)"	"unprognostic (2.49e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.05e-2)"	"prognostic unfavorable (5.46e-5)"	"unprognostic (5.05e-2)"	"unprognostic (4.61e-2)"	"prognostic unfavorable (4.20e-4)"	"unprognostic (1.15e-1)"	"unprognostic (6.68e-2)"	"unprognostic (3.14e-2)"	"unprognostic (3.28e-1)"	"unprognostic (2.84e-2)"	"unprognostic (1.03e-1)"	19.2	16.1	17.9	23.6	29.5	41.3	23.0	17.4	21.0	19.3	22.6	12.2	16.9	13.3	33.2	16.6	19.7	17.5	20.2	14.2	19.4	16.7	25.9	19.3	17.9	26.7	16.9	18.1	19.3	17.1	21.0	29.4	13.2	18.4	17.6	20.9	7.1	18.4	17.6	15.7	11.2	18.0	22.2	18.1	26.5	14.7	13.9	18.9	23.4	20.8	14.7	22.8	17.5	16.0	10.1	12.0	21.8	18.5	9.7	8.6	7.6	15.4	8.7	8.8	4.6	4.8	12.0	5.6	11.0	14.6	14.0	15.3	5.0	11.8	23.4	12.9	10.0	5.7	5.2	10.6	10.3	18.0	10.9	6.1	19.8	5.4	7.0	9.4	11.8	10.5	9.0	5.5	7.9	17.5	6.9	11.3	9.5	14.5	13.6	15.9	13.7	18.0	7.5	2.5	11.5	9.5	12.1	7.6	13.8	18.1	21.3	2.5	8.1	6.9	78.3	6.5	5.1	14.7	8.8	8.4	12.2	8.7	7.4	10.8	6.3	7.2	13.0	12.3	11.2	11.3	14.1	11.1	20.3	8.1	12.5	8.6	10.1	5.9	5.9	12.0	6.1	5.7	6.2	21.8	9.7	18.5	6.6	3.7	7.6	17.9	29.5	17.4	21.0	19.4	16.7	16.9	18.1	18.4	18.9	44.7	13.9	32.5	12.1	10.5	23.3	25.0	17.8	42.8	42.1	26.2	2.0	18.9	36.5	30.4	10.9	17.9	8.9	0.0	27.9	17.4	18.4	8.7	76.4	27.6	22.9	12.7	11.6	17.2	22.4	5.9	17.5	30.7	11.8	52.3	15.1	27.1	19.1	5.8	24.8	31.1	10.3	6.5	20.6	11.2	43.3	11.8	9.0	23.2	17.4	8.6
NCOA1	"bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1"	ENSG00000084676	"Nuclear receptor coactivator 1"	Q15788	2	24491914-24770702	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Acyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"RH-30: 41.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019402, HPA070213, HPA070520"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"		No	No			Nucleoplasm	"Plasma membrane, Cytosol"	"CAB019402: AB_2196189, HPA070213: AB_2686235, HPA070520: AB_2686276"	"unprognostic (2.73e-1)"	"unprognostic (5.82e-2)"	"unprognostic (2.46e-2)"	"unprognostic (9.89e-3)"	"unprognostic (7.60e-2)"	"unprognostic (2.36e-2)"	"unprognostic (7.06e-3)"	"unprognostic (1.45e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.93e-3)"	"unprognostic (1.16e-1)"	"unprognostic (2.10e-2)"	"unprognostic (7.15e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.29e-1)"	"unprognostic (2.92e-2)"	9.8	10.0	15.3	7.3	18.0	8.9	10.5	15.9	17.1	13.7	8.9	13.5	4.9	12.5	13.0	11.5	10.8	10.0	8.3	8.8	20.8	12.2	11.9	8.8	9.4	8.2	10.8	9.9	17.2	10.3	23.9	16.0	10.1	14.2	9.6	10.1	19.9	10.6	13.0	42.5	9.3	10.9	11.6	9.7	9.6	7.6	11.4	10.7	8.5	7.0	12.2	9.3	9.7	10.8	2.5	5.5	14.2	3.5	3.4	4.1	1.8	6.7	5.0	8.9	4.6	9.8	9.0	13.6	3.6	7.3	4.6	4.1	4.7	2.9	4.9	1.5	6.6	8.8	1.6	5.3	3.1	5.0	23.3	7.7	17.6	2.0	1.9	6.2	8.0	14.7	14.3	4.7	4.4	3.6	5.7	4.6	6.4	10.7	8.2	6.9	4.5	7.1	2.9	4.2	4.0	3.4	5.7	41.0	2.5	5.0	9.2	8.1	6.4	8.4	5.1	3.7	4.9	6.1	4.1	5.0	7.7	6.1	5.2	3.6	9.5	8.2	8.6	4.4	5.1	3.8	11.0	3.5	6.9	3.8	2.7	4.1	1.8	3.4	4.1	2.6	2.5	3.3	4.0	14.2	3.4	2.8	5.5	3.7	1.8	15.3	18.0	15.9	17.1	20.8	12.2	10.8	9.9	14.2	10.7	35.7	29.8	13.6	10.7	27.1	97.2	33.1	15.3	20.1	31.8	14.0	49.1	11.2	6.6	12.0	13.1	29.2	24.6	23.3	23.0	14.9	31.2	14.1	18.6	20.3	15.3	58.8	24.2	33.2	25.2	3.8	43.7	26.2	18.6	10.0	22.7	63.8	17.7	35.1	40.7	11.4	67.4	38.8	35.4	32.1	36.8	27.0	4.5	25.4	23.0	14.6
NCOA2	"bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2"	ENSG00000140396	"Nuclear receptor coactivator 2"	Q15596	8	70109762-70403805	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	Activator	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA060243			Supported	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nucleoplasm, Nuclear bodies"		"HPA060243: AB_2684229"	"unprognostic (9.79e-3)"	"unprognostic (1.40e-1)"	"unprognostic (2.72e-1)"	"unprognostic (4.94e-3)"	"unprognostic (1.91e-2)"	"unprognostic (2.18e-3)"	"unprognostic (1.30e-1)"	"unprognostic (6.77e-2)"	"unprognostic (2.06e-1)"	"unprognostic (7.00e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.63e-2)"	"prognostic favorable (5.08e-4)"	"unprognostic (2.52e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.76e-1)"	13.6	13.2	16.9	13.1	14.0	22.5	14.9	19.2	14.0	13.9	17.3	10.1	49.7	12.4	16.6	33.6	20.0	12.5	12.6	15.8	13.9	13.0	16.4	25.5	15.5	16.9	10.8	11.4	18.5	9.7	23.4	17.1	16.2	10.0	14.8	11.8	15.3	14.8	21.7	13.2	14.9	28.8	19.2	9.6	14.5	11.7	15.5	12.9	15.3	13.4	10.3	13.8	18.9	17.2	3.8	2.5	9.4	7.8	2.1	3.8	1.6	8.8	11.0	12.2	6.9	11.1	11.4	12.5	5.1	5.1	3.9	3.8	5.6	10.3	10.5	2.1	9.3	6.5	5.2	14.9	7.0	4.4	24.8	11.8	18.3	5.6	8.9	5.8	3.7	4.9	9.9	7.9	5.3	7.6	6.2	2.7	7.7	5.8	16.0	4.5	8.8	9.1	3.7	6.4	10.1	5.2	9.0	5.1	6.5	6.3	14.7	9.3	6.8	8.8	4.7	7.2	8.9	11.1	6.8	3.5	5.7	7.3	7.2	2.7	21.1	10.8	10.2	5.8	4.9	8.3	4.5	2.5	3.5	3.8	3.9	2.8	2.2	2.3	3.3	2.5	3.8	2.8	2.7	9.4	2.1	7.8	1.1	3.2	1.6	16.9	14.0	19.2	13.5	13.9	13.0	10.8	11.4	10.0	12.9	11.9	24.3	16.7	7.9	14.3	23.6	31.3	33.1	9.4	34.2	24.4	49.1	16.2	10.0	6.0	4.0	14.5	20.6	23.3	10.7	10.2	16.2	17.2	21.9	57.7	14.7	69.9	24.2	22.7	43.2	5.7	18.4	19.9	20.3	4.6	17.5	14.7	10.9	11.5	20.8	15.7	29.6	25.8	15.6	11.2	15.4	18.7	26.5	25.4	16.0	12.2
NCOA4	"ARA70, DKFZp762E1112, ELE1, PTC3, RFG"	ENSG00000266412	"Nuclear receptor coactivator 4"	Q13772	10	46005088-46030714	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 100.1"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"dendritic cells: 30.2;granulocytes: 100.1;monocytes: 40.4"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA051260, HPA065208"	Uncertain		Approved	"Nucleoli,Golgi apparatus,Cytosol"		NA	NA			Nucleoli	"Golgi apparatus, Cytosol"	"HPA051260: AB_2681412, HPA065208: AB_2685432"	"unprognostic (4.23e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.44e-2)"	"unprognostic (1.82e-1)"	"prognostic favorable (3.26e-4)"	"unprognostic (1.34e-1)"	"unprognostic (1.80e-1)"	"unprognostic (9.34e-2)"	"unprognostic (4.67e-2)"	"unprognostic (5.22e-2)"	"unprognostic (9.16e-2)"	"unprognostic (2.04e-2)"	"prognostic favorable (8.04e-6)"	"unprognostic (1.35e-1)"	"unprognostic (4.71e-3)"	"unprognostic (1.14e-1)"	"unprognostic (2.78e-1)"	18.5	6.9	5.5	9.5	10.0	17.4	10.0	5.5	11.3	10.8	22.5	13.6	5.9	27.0	9.9	9.4	17.0	6.3	9.0	16.6	5.7		20.8	40.9	11.6	11.6	8.7	7.1	11.0	9.1	9.3	9.6	28.4	13.5	14.7	12.4	9.9	12.6	8.5	15.5	6.8	36.4	11.2	9.7	23.8	8.9	6.4	8.1	26.8	13.2	13.9	16.3	13.0	6.4	7.3	30.2	100.1	40.4	13.4	10.9	53.9	31.8	13.5	15.9	16.3	42.1	38.2	39.8	29.3	47.4	28.9	28.4	20.8	23.6	36.0	35.3	47.8	16.2	32.6	16.6	32.3	32.3	25.4	17.1	24.3	18.6	59.4	29.5	61.8	54.3	37.1	32.4	24.6	41.4	30.9	42.5	18.2	26.4	21.7	39.4	14.2	30.0	23.2	9.6	24.6	8.0	17.8	23.1	21.5	34.6	27.1	16.0	10.8	29.6	33.8	29.3	32.9	24.4	30.4	39.1	17.9	21.5	18.9	19.7	16.2	17.3	35.8	22.4	52.1	9.5	69.1	40.4	70.7	10.0	26.8	10.9	7.3	9.4	9.5	30.2	6.6	10.2	8.6	100.1	13.4	30.4	9.3	10.8	53.9											47.6	78.0	32.8	33.2	44.0	13.3	136.0	38.2	50.9	59.1	41.8	27.5	85.3	68.0	41.7	72.4	47.2	113.4	186.9	45.2	92.9	44.2	51.5	191.6	148.1	148.2	19.1	25.8	53.4	209.6	51.8	34.5	96.2	49.0	73.1	41.3	37.9	41.1	57.5	44.6	100.4	11.3	12.9	47.2	22.7	15.1	49.4	132.3	41.5	50.4	45.0
NCOR1	"hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1"	ENSG00000141027	"Nuclear receptor corepressor 1"	O75376	17	16029157-16218185	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043246, HPA050288, HPA051168, CAB072830"	Supported		Enhanced	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB072830: , HPA043246: AB_2678386, HPA050288: AB_2681073, HPA051168: AB_2681370"	"unprognostic (1.83e-1)"	"unprognostic (3.05e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.38e-2)"	"unprognostic (3.59e-2)"	"unprognostic (2.55e-2)"	"unprognostic (4.27e-2)"	"unprognostic (4.87e-2)"	"unprognostic (4.06e-2)"	"unprognostic (7.07e-2)"	"unprognostic (1.52e-2)"	"prognostic favorable (7.92e-5)"	"unprognostic (4.40e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.33e-1)"	"unprognostic (5.42e-2)"	19.6	21.2	25.4	24.0	30.8	27.0	25.0	41.8	31.5	24.0	30.6	19.6	18.6	33.2	29.0	19.5	25.0	20.5	21.9	17.8	22.4	17.8	25.6	33.8	20.1	19.5	25.1	19.1	25.9	24.3	39.9	39.8	19.8	21.6	20.8	29.7	17.1	20.9	29.1	43.0	23.8	36.9	29.7	26.4	23.7	29.8	22.1	26.4	38.8	25.3	15.7	23.8	29.6	27.0	43.4	29.9	78.2	24.8	30.4	35.5	19.7	20.4	34.2	24.4	20.3	20.1	15.3	12.2	15.1	17.1	16.6	15.1	18.3	9.4	21.5	10.7	26.3	12.4	15.6	30.0	18.3	24.7	28.6	22.2	21.4	29.6	21.4	19.7	13.4	25.6	15.7	19.2	25.7	30.1	14.2	23.0	30.4	18.6	8.9	16.3	13.3	23.6	8.6	12.1	36.0	9.3	23.6	24.8	10.0	17.2	23.2	8.3	13.9	24.9	10.9	11.8	65.5	10.5	15.3	20.0	17.1	10.1	12.5	20.8	6.1	7.1	12.5	16.3	16.0	14.6	78.2	24.8	52.2	31.3	19.5	25.9	40.7	35.5	34.1	17.5	43.4	34.7	34.8	48.5	30.4	24.0	29.9	31.7	19.7	25.4	30.8	41.8	31.5	22.4	17.8	25.1	19.1	21.6	26.4	74.5	98.7	86.4	91.4	60.2	144.1	78.9	66.2	61.6	72.8	50.6	149.2	79.2	29.9	80.2	53.7	68.9	164.0	93.5	85.1	85.7	74.0	70.9	83.3	105.0	67.5	122.3	84.4	59.5	70.8	35.4	94.0	84.8	35.4	184.0	101.0	81.4	89.5	133.5	114.2	37.3	152.7	90.5	89.5	82.3	75.1	59.6	73.2	110.7	125.6	110.0
NCOR2	"CTG26, SMRT, SMRTE, TNRC14, TRAC-1"	ENSG00000196498	"Nuclear receptor corepressor 2"	Q9Y618	12	124324415-124567589	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Horizontal cells: 114.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 8.1"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001928	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA001928: AB_1079454"	"unprognostic (9.51e-3)"	"unprognostic (7.37e-3)"	"unprognostic (4.66e-2)"	"unprognostic (2.55e-3)"	"unprognostic (2.14e-1)"	"unprognostic (7.37e-2)"	"unprognostic (3.19e-2)"	"unprognostic (8.86e-2)"	"unprognostic (2.21e-2)"	"unprognostic (2.90e-3)"	"unprognostic (6.42e-3)"	"unprognostic (1.96e-1)"	"unprognostic (9.86e-2)"	"unprognostic (6.26e-2)"	"unprognostic (1.59e-1)"	"unprognostic (7.56e-2)"	"unprognostic (8.90e-2)"	24.0	22.0	21.3	21.3	19.0	16.8	18.3	33.8	33.5	24.5	17.2	24.3	17.7	16.4	21.3	19.0	15.7	16.3	21.5	18.2	22.0	14.8	16.0	11.2	23.4	11.9	19.0	15.6	28.6	30.0	13.8	39.5	13.2	28.3	21.3	7.6	32.7	29.2	24.5	62.4	22.8	22.2	17.4	12.2	17.4	24.0	10.8	22.0	9.3	16.7	25.0	7.6	16.3	14.7	0.6	1.7	8.1	4.0	0.2	1.9	0.4	19.7	37.2	10.6	10.1	6.2	8.4	31.8	20.5	10.2	12.0	5.3	19.7	14.6	20.0	15.2	16.7	10.7	18.8	4.2	21.8	4.9	21.1	8.2	16.1	35.1	12.0	12.4	12.1	20.5	13.5	8.2	14.9	8.9	18.4	11.4	9.2	20.6	6.0	10.7	17.0	43.4	14.0	14.8	7.5	36.2	14.1	17.7	10.1	5.7	23.1	28.1	20.5	25.2	21.3	12.9	8.3	17.3	15.3	54.6	27.9	48.3	27.5	43.4	11.5	11.5	12.2	15.9	9.0	26.1	8.1	0.7	1.6	1.9	0.4	0.5	0.6	0.5	1.5	0.3	0.4	0.6	0.5	1.6	0.2	4.0	1.7	0.0	0.4	21.3	19.0	33.8	28.4	22.0	14.8	19.0	15.6	28.3	22.0	107.2	54.1	4.5	21.5	29.7	63.3	27.7	20.4	18.7	56.9	17.4	37.3	6.7	3.3	19.2	1.6	21.0	23.6	0.0	24.0	33.5	32.5	20.3	39.5	16.3	25.4	114.4	18.0	14.7	40.3	4.8	57.5	32.4	15.1	18.0	18.7	30.6	26.9	17.3	61.2	7.0	57.9	6.5	30.6	1.7	10.3	21.3	10.5	13.1	20.4	17.9
NDRG1	"CAP43, DRG1, NDR1, RTP, TDD5"	ENSG00000104419	"N-myc downstream regulated 1"	Q92597	8	133237171-133302022	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Charcot-Marie-Tooth disease, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 508.1;Horizontal cells: 556.2;Suprabasal keratinocytes: 583.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 70.6;hTERT-HME1: 142.3;U-87 MG: 95.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006881	Approved		Supported	Microtubules,Cytosol		NA	NA			Cytosol	Microtubules	"HPA006881: AB_1078392"	"unprognostic (6.96e-3)"	"unprognostic (3.31e-3)"	"unprognostic (8.53e-2)"	"unprognostic (1.41e-3)"	"unprognostic (1.54e-3)"	"unprognostic (2.60e-2)"	"prognostic unfavorable (1.47e-4)"	"unprognostic (3.04e-3)"	"unprognostic (5.33e-2)"	"unprognostic (4.29e-2)"	"unprognostic (9.09e-2)"	"unprognostic (2.46e-1)"	"prognostic unfavorable (4.13e-4)"	"unprognostic (7.27e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.47e-3)"	"unprognostic (4.28e-2)"	43.9	23.6	42.0	17.0	80.9	18.0	29.8	6.4	36.2	33.1	47.7	73.2	24.2	74.2	20.9	20.6	83.0	24.7	26.8	22.2	48.7	32.9	62.6	12.1	31.0	11.4	96.3	19.8	37.5	16.7	17.8	18.6	32.5	50.0	115.0	22.4	16.2	29.0	26.4	13.2	56.9	78.2	19.2	102.0	11.5	45.7	15.0	74.3	10.3	21.4	40.0	34.9	58.7	64.9	1.9	12.2	8.9	4.1	1.3	9.3	2.9	22.0	2.7	0.2	0.1	14.0	9.8	3.0	1.6	12.1	1.1	6.2	1.4	3.1	0.1	15.8	6.6	2.6	7.1	0.2	34.8	2.4	1.4	26.1	0.2	5.6	1.6	5.3	0.7	0.5	9.1	70.6	5.9	142.3	13.4	5.2	2.9	0.2	15.4	2.0	1.3	2.0	2.1	0.4	8.1	18.3	0.2	2.4	10.2	3.6	3.2	1.6	1.6	3.4	36.5	8.8	6.1	0.1	2.4	6.8	9.9	5.1	4.3	1.2	11.5	30.3	0.1	95.8	8.3	19.5	8.9	4.1	0.0	6.3	3.7	9.3	1.7	5.9	7.5	6.1	1.9	4.6	3.1	4.2	1.3	4.0	12.2	8.0	2.9	42.0	80.9	6.4	36.2	48.7	32.9	96.3	19.8	50.0	74.3	134.0	42.5	17.1	123.5	508.1	21.1	16.5	73.9	9.4	26.1	177.9	2.0	8.9	28.2	21.1	5.4	137.1	330.3	0.0	11.8	79.9	76.6	236.9	21.9	52.2	15.9	556.2	21.2	77.3	31.9	4.3	45.5	36.0	96.2	19.0	134.0	72.1	84.1	91.2	41.4	59.7	33.2	45.3	59.4	0.9	6.4	583.4	36.3	25.4	80.8	209.3
NF1		ENSG00000196712	"Neurofibromin 1"	P21359	17	31094927-31382116	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"GTPase activation"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Early spermatids: 149.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"B-cells: 2.3;granulocytes: 6.5;T-cells: 8.4"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA045502	Uncertain		Approved	Mitochondria		No	No			Mitochondria		"HPA045502: AB_2679352"	"unprognostic (6.69e-2)"	"unprognostic (8.73e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.76e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.30e-2)"	"unprognostic (3.14e-2)"	"unprognostic (3.88e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.40e-1)"	"unprognostic (3.70e-1)"	12.9	15.9	22.6	13.3	25.9	5.5	18.5	30.2	26.0	17.6	13.6	19.8	12.2	11.0	16.9	17.0	10.5	15.2	13.1	17.3	21.6	19.6	20.0	15.1	12.7	11.5	19.4	25.6	22.9	16.5	34.1	19.0	19.4	20.9	16.1	14.7	12.1	14.4	20.5	14.8	12.0	12.1	14.5	21.4	11.9	13.0	15.4	21.5	11.6	31.1	7.6	12.4	15.3	19.5	2.3	0.7	6.5	0.4	0.9	8.4	1.0	9.8	12.9	15.7	8.4	13.4	17.5	7.9	8.6	15.5	12.7	14.4	11.6	6.7	9.5	2.5	16.0	15.0	17.3	14.2	12.0	21.5	4.6	8.9	8.4	12.1	5.9	9.5	15.0	7.0	13.8	7.7	13.5	16.5	14.4	6.1	10.1	12.0	9.5	12.1	7.8	12.5	5.5	4.6	6.1	4.3	9.8	24.0	7.6	9.6	14.2	6.5	9.8	15.9	5.3	8.8	11.6	16.2	9.6	8.9	10.2	14.2	12.0	3.2	8.7	4.2	10.5	8.3	6.3	10.5	6.5	0.4	0.9	2.3	0.2	1.6	2.3	4.4	3.9	0.5	2.1	3.3	3.2	1.0	0.9	0.4	0.7	8.4	1.0	22.6	25.9	30.2	23.5	21.6	19.6	19.4	25.6	20.9	21.5	29.8	23.6	12.7	38.9	34.3	61.1	39.2	40.8	29.4	20.5	38.4	129.6	44.8	19.9	23.9	149.0	31.8	28.2	0.0	19.3	22.1	28.2	47.4	10.4	31.7	18.9	66.7	19.0	31.9	24.3	70.0	34.5	21.8	20.3	16.2	26.8	49.7	28.6	35.4	47.4	23.7	66.0	45.3	36.7	28.2	25.6	29.6	41.2	18.5	22.6	60.1
NF2	"ACN, BANF, merlin, SCH"	ENSG00000186575	"Neurofibromin 2"	P35240	22	29603556-29698598	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Deafness, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Early spermatids: 61.9;Late spermatids: 86.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003097, CAB005385"	Supported		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"CAB005385: AB_2298548, HPA003097: AB_1079473"	"unprognostic (3.27e-1)"	"unprognostic (1.34e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.62e-1)"	"unprognostic (5.76e-3)"	"unprognostic (1.61e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.16e-2)"	"unprognostic (2.01e-3)"	"unprognostic (4.66e-1)"	"prognostic favorable (2.89e-5)"	"unprognostic (7.73e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.24e-1)"	"unprognostic (9.62e-2)"	11.8	12.4	23.6	11.1	20.1	10.0	15.4	20.8	28.1	10.8	9.7	9.0	11.8	7.8	10.5	11.3	14.2	11.3	8.0	19.7	26.6	16.4	13.5	11.1	11.9	24.1	18.0	13.5	11.0	12.9	46.8	8.6	6.9	11.4	10.2	8.7	9.5	9.3	15.4	25.7	12.1	8.5	11.9	10.7	10.4	8.8	21.6	10.1	14.9	15.6	11.5	9.9	10.6	10.2	8.5	13.6	6.6	17.3	11.6	15.0	9.8	26.6	10.8	3.8	24.6	7.4	7.4	3.6	21.7	12.2	23.8	20.6	10.6	6.6	7.1	18.0	22.3	16.5	9.5	7.8	12.6	21.3	10.3	6.1	8.4	8.1	7.6	7.9	12.0	10.0	6.8	5.7	16.9	20.6	8.1	16.7	4.6	4.1	6.6	23.1	11.2	7.3	4.8	2.8	6.3	10.2	7.6	20.3	6.8	24.2	12.5	5.8	4.0	12.4	8.4	4.9	4.0	5.4	4.8	31.0	35.5	40.5	15.4	36.6	10.3	8.2	8.5	9.4	4.7	22.6	6.6	9.5	3.6	15.0	13.5	12.8	8.2	11.3	10.1	13.6	8.5	9.8	9.2	2.3	11.6	17.3	9.3	9.4	9.8	23.6	20.1	20.8	28.1	26.6	16.4	18.0	13.5	11.4	10.1	6.0	16.1	9.0	9.6	12.6	16.5	19.9	17.8	6.7	7.9	14.0	9.8	9.9	18.3	42.9	61.9	9.8	8.4	0.0	21.5	6.3	12.6	9.5	23.0	12.5	12.4	28.6	12.6	10.4	10.0	86.8	6.6	7.2	8.5	6.4	7.5	17.3	28.7	15.6	11.7	16.2	8.5	6.5	14.9	21.4	7.2	12.5	3.2	10.9	9.8	8.6
NFATC2	"NF-ATP, NFAT1, NFATp"	ENSG00000101096	"Nuclear factor of activated T cells 2"	Q13469	20	51386957-51562831	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 44.6"	"Cell type enhanced"	"Detected in many"	8	"Melanocytes: 59.1;T-cells: 40.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 14.4;HMC-1: 16.6;WM-115: 25.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA008789, CAB018567, HPA024369"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB018567: AB_628012, HPA008789: AB_1079474, HPA024369: AB_1854413"	"unprognostic (2.69e-3)"	"unprognostic (2.92e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.26e-2)"	"unprognostic (3.94e-2)"	"unprognostic (4.05e-2)"	"unprognostic (9.26e-2)"	"unprognostic (3.74e-3)"	"unprognostic (2.17e-2)"	"unprognostic (4.86e-2)"	"prognostic unfavorable (1.57e-4)"	"unprognostic (9.25e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.59e-2)"	8.6	2.4	4.1	44.6	8.2	4.4	9.8	1.1	5.1	8.4	7.8	6.8	3.9	8.4	7.0	7.6	4.0	5.6	19.4	8.5	4.1	3.3	3.4	6.7	6.1	25.2	8.4	0.7	5.0	8.7	3.9	3.7	8.1	10.4	5.4	4.1	6.2	7.9	7.2	5.4	7.0	11.7	5.9	6.5	16.0	11.0	4.5	6.5	8.6	7.0	13.2	18.7	4.5	4.9	1.6	1.7	3.8	0.7	7.6	7.7	1.6	1.6	1.7	0.0	2.2	0.0	0.0	4.6	0.2	1.1	0.7	0.3	8.3	1.5	11.1	1.3	0.5	1.6	0.0	0.5	0.0	0.6	14.4	0.2	4.7	1.2	2.1	0.0	1.3	16.6	0.0	0.0	0.6	0.0	0.1	5.1	3.9	4.6	7.4	0.0	1.8	1.9	7.8	0.1	1.0	4.0	0.8	0.0	4.9	0.3	0.0	0.1	0.0	5.2	1.3	12.1	1.1	2.0	3.1	0.5	1.0	1.9	2.5	0.1	6.3	4.1	11.5	1.1	5.2	25.0	0.3	0.0	3.8	7.7	0.7	3.2	1.6	4.3	6.1	1.7	1.6	2.4	4.4	0.2	7.6	0.2	0.6	2.3	1.6	4.1	8.2	1.1	5.1	4.1	3.3	8.4	0.7	10.4	6.5	6.0	4.8	3.9	10.4	12.8	0.0	2.8	5.1	10.7	9.1	0.0	0.0	2.4	1.7	3.6	1.5	16.9	1.1	0.0	4.9	0.5	28.2	7.4	15.0	6.0	28.1	0.0	7.5	9.2	21.2	0.4	2.0	16.7	59.1	3.6	6.2	0.0	8.0	0.0	0.4	0.2	0.0	0.0	12.2	0.5	0.9	11.3	0.8	40.6	7.1	5.6
NFE2L2	NRF2	ENSG00000116044	"Nuclear factor, erythroid 2 like 2"	Q16236	2	177227595-177392697	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002990, CAB020317, HPA043438"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Plasma membrane"	Cytosol	"CAB020317: , HPA002990: AB_1079476, HPA043438: AB_2678482"	"unprognostic (2.11e-1)"	"unprognostic (3.12e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.95e-2)"	"unprognostic (3.90e-1)"	"unprognostic (5.27e-2)"	"unprognostic (9.58e-2)"	"unprognostic (3.48e-2)"	"unprognostic (9.86e-2)"	"unprognostic (4.86e-2)"	"unprognostic (1.83e-1)"	"prognostic favorable (2.26e-4)"	"unprognostic (1.97e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.26e-1)"	"unprognostic (9.77e-3)"	30.9	24.4	25.4	19.3	34.7	15.0	24.6	36.4	29.7	31.7	28.3	25.8	22.2	28.1	27.7	30.9	82.5	27.0	28.9	32.3	28.0	16.9	44.8	49.3	29.0	19.7	49.0	18.7	53.1	16.3	21.7	52.5	29.4	33.5	39.0	25.4	21.7	34.7	28.1	25.9	48.1	29.2	42.1	42.7	26.8	45.9	21.9	41.6	21.1	49.5	35.8	25.5	43.7	47.1	23.5	41.1	42.4	35.6	25.8	43.2	22.6	10.6	12.3	11.2	12.0	37.8	40.8	12.8	18.2	25.3	16.6	18.8	16.2	20.4	10.5	19.8	20.6	31.6	19.8	13.1	27.7	23.3	8.1	8.0	13.5	21.6	31.6	48.4	8.0	12.8	28.1	65.2	23.6	35.1	39.4	16.4	8.3	14.0	20.6	22.8	10.6	8.1	21.1	12.2	55.2	11.6	6.7	9.8	10.6	25.4	40.1	14.6	9.5	41.2	13.3	43.1	33.7	10.3	21.6	24.7	17.2	11.5	19.1	11.1	14.5	8.7	8.8	17.2	8.9	33.0	42.4	35.6	21.4	23.0	34.1	26.6	23.5	26.9	23.6	41.1	19.9	43.2	28.2	39.9	25.8	31.9	15.5	25.0	22.6	25.4	34.7	36.4	29.7	28.0	16.9	49.0	18.7	33.5	41.6	145.9	85.8	49.5	216.1	262.7	59.6	57.4	96.8	143.2	127.4	146.5	15.7	88.4	333.2	126.2	58.6	116.1	96.6	0.0	147.7	27.7	204.6	118.5	212.0	76.9	78.0	54.0	72.6	97.6	100.1	19.8	266.3	164.9	91.1	213.8	57.7	176.6	122.9	89.2	201.2	56.4	47.1	38.8	169.0	50.5	33.8	275.8	155.7	62.3	90.2	201.5
NFIB	"NFI-RED, NFIB2, NFIB3"	ENSG00000147862	"Nuclear factor I B"	O00712	9	14081843-14398983	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"DNA replication, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 55.0;HBEC3-KT: 22.3;HUVEC TERT2: 22.2;TIME: 21.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003956	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			"Nucleoplasm, Nucleoli fibrillar center"		"HPA003956: AB_1854424"	"unprognostic (1.93e-1)"	"unprognostic (3.18e-2)"	"unprognostic (4.00e-1)"	"unprognostic (2.16e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.55e-2)"	"unprognostic (1.32e-1)"	"unprognostic (4.72e-3)"	"unprognostic (7.46e-2)"	"unprognostic (9.35e-2)"	"unprognostic (3.68e-1)"	"unprognostic (1.12e-1)"	"prognostic favorable (3.53e-4)"	"unprognostic (4.69e-1)"	"unprognostic (2.39e-1)"	"unprognostic (1.87e-2)"	"unprognostic (1.62e-1)"	29.3	9.5	22.6	9.2	12.9	1.0	39.7	30.0	22.9	14.8	17.0	13.6	34.1	11.3	16.8	22.3	11.5	17.0	18.0	24.1	22.0	9.3	18.8	22.3	16.3	9.8	10.8	15.5	18.7	17.5	8.2	6.0	14.7	13.7	21.3	10.4	9.2	40.0	41.3	20.8	23.6	16.8	24.2	14.9	10.4	14.2	7.6	15.6	2.7	18.8	13.9	7.7	27.4	23.4	0.3	0.3	2.4	0.4	0.5	1.0	1.3	6.4	4.6	2.9	55.0	13.9	8.1	0.1	0.1	0.0	1.3	4.8	0.0	2.6	0.1	4.3	0.4	4.2	1.4	2.7	22.3	2.4	0.9	2.6	19.8	10.4	0.6	4.6	0.5	0.1	7.0	3.1	5.0	18.5	5.2	22.2	0.0	0.6	0.1	1.8	3.0	0.0	0.1	1.0	2.9	5.4	0.0	2.6	0.0	4.1	2.4	4.6	17.2	4.7	5.8	1.9	0.1	11.7	0.0	21.7	4.3	6.4	3.3	4.0	0.5	0.4	1.6	3.8	0.1	5.4	1.3	0.1	0.2	0.3	0.2	1.0	0.2	0.2	0.2	0.1	0.3	0.2	0.1	2.4	0.5	0.4	0.3	0.5	1.3	22.6	12.9	30.0	18.8	22.0	9.3	10.8	15.5	13.7	15.6	47.6	31.8	8.5	155.7	238.9	30.8	173.3	203.8	49.5	63.7	43.6	0.0	4.1	33.2	58.5	2.9	193.3	44.6	0.0	108.3	1.6	65.3	158.3	3.5	91.3	1.9	0.0	21.9	176.8	10.2	2.3	124.0	9.2	89.4	2.8	28.6	261.1	66.5	55.8	45.6	159.0	8.8	84.1	186.4	0.7	0.9	147.9	1.4	2.2	68.3	55.3
NFKB2	"LYT-10, NF-kB2, p105, p49/p100, p52"	ENSG00000077150	"Nuclear factor kappa B subunit 2"	Q00653	10	102394110-102402529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"monocytes: 115.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 50.5;Karpas-707: 55.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008422, CAB022098, HPA023900"	Enhanced		Approved	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"CAB022098: , HPA008422: AB_1854434, HPA023900: AB_1854435"	"unprognostic (1.10e-2)"	"unprognostic (1.43e-1)"	"prognostic unfavorable (3.86e-4)"	"unprognostic (1.53e-2)"	"unprognostic (8.08e-3)"	"unprognostic (2.15e-1)"	"unprognostic (2.38e-3)"	"unprognostic (3.98e-2)"	"prognostic favorable (8.45e-5)"	"unprognostic (4.04e-1)"	"unprognostic (8.34e-2)"	"unprognostic (4.14e-2)"	"prognostic unfavorable (6.69e-12)"	"unprognostic (2.37e-3)"	"unprognostic (1.63e-1)"	"unprognostic (4.90e-2)"	"unprognostic (1.56e-1)"	14.9	10.8	5.6	43.6	7.1	40.6	18.7	2.0	4.9	12.5	20.1	4.2	9.4	11.3	18.8	11.0	12.9	10.8	20.4	10.9	4.6	2.5	15.5	14.5	20.6	34.2	6.6	2.5	15.1	17.4	5.2	6.3	12.8	7.9	19.6	5.2	7.3	16.7	15.1	13.6	10.4	14.1	24.0	7.7	28.0	13.1	6.6	5.8	19.5	11.5	14.8	39.2	21.9	24.4	5.2	1.4	7.5	3.4	1.3	2.0	0.9	21.4	13.4	2.7	10.7	3.3	5.1	6.4	6.1	19.6	6.2	9.0	8.0	17.6	9.9	15.3	3.7	15.5	13.0	6.1	8.4	2.5	50.5	3.6	2.5	3.2	4.6	9.4	1.6	14.4	7.0	4.1	10.4	10.3	8.6	2.2	5.2	2.3	55.2	2.4	7.3	2.5	6.7	3.4	4.7	4.8	5.4	7.4	7.8	10.5	6.3	0.5	3.0	5.0	12.2	8.6	2.9	9.4	4.8	6.4	6.5	9.5	9.1	16.3	36.5	33.8	10.4	10.6	4.2	3.4	0.3	2.4	0.1	1.4	1.5	1.4	5.2	1.7	1.5	1.4	4.5	1.8	1.5	7.5	1.3	3.4	0.9	2.0	0.9	5.6	7.1	2.0	4.9	4.6	2.5	6.6	2.5	7.9	5.8	8.9	9.1	51.9	51.4	38.6	1.9	2.2	17.8	1.4	18.2	17.4	15.7	4.7	5.0	29.4	1.1	15.8	40.4	0.0	18.1	14.3	9.4	46.1	72.5	3.4	19.0	0.0	15.6	9.8	13.8	0.9	6.9	24.3	28.7	115.4	13.1	4.9	35.6	14.0	4.6	9.2	5.1	0.0	25.6	1.7	10.2	39.0	19.3	24.9	10.6	38.3
NFKBIE	IKBE	ENSG00000146232	"NFKB inhibitor epsilon"	O00221	6	44258166-44265788	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"monocytes: 85.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002692, HPA005941, CAB010272"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"		NA	NA			"Nucleoli fibrillar center"	"Nucleoplasm, Cytosol"	"CAB010272: AB_2235977, HPA002692: AB_1079479, HPA005941: AB_1079478"	"prognostic favorable (1.72e-5)"	"unprognostic (1.43e-1)"	"unprognostic (1.39e-2)"	"unprognostic (2.37e-2)"	"unprognostic (6.32e-3)"	"unprognostic (1.28e-1)"	"prognostic unfavorable (3.50e-4)"	"unprognostic (4.88e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.43e-2)"	"unprognostic (3.36e-1)"	"unprognostic (2.60e-1)"	"prognostic unfavorable (1.37e-6)"	"unprognostic (2.61e-2)"	"unprognostic (8.83e-2)"	"unprognostic (1.37e-2)"	"prognostic favorable (8.07e-4)"	5.8	5.2	7.6	24.6	5.4	24.0	5.2	9.4	7.8	3.7	8.0	4.2	3.2	6.7	4.7	5.5	6.9	3.0	9.8	4.6	7.9	5.5	11.5	8.7	15.9	17.1	6.0	4.1	6.1	7.1	3.5	4.1	6.0	4.8	7.1	5.9	3.6	7.7	4.1	3.7	7.4	9.5	3.6	5.0	29.6	6.3	7.9	3.7	14.5	5.5	4.6	22.7	6.7	6.7	8.1	8.2	7.1	10.2	0.8	3.5	1.6	13.9	3.5	4.9	7.7	1.9	1.4	2.6	2.5	12.2	7.7	8.1	7.5	6.6	7.5	8.9	2.5	20.7	3.0	5.2	7.8	8.7	12.9	2.9	3.9	1.5	8.4	6.0	12.8	11.8	3.7	3.4	7.1	4.4	6.5	5.2	3.6	3.6	20.2	1.9	7.1	2.5	26.1	2.6	22.0	1.9	4.7	4.4	6.9	17.7	15.2	3.1	4.0	1.7	6.4	10.1	4.3	4.4	15.0	9.1	4.4	5.1	2.7	7.7	12.9	5.4	13.9	3.9	14.2	8.2	7.1	8.1	3.8	1.8	9.4	3.5	8.1	2.4	1.6	6.8	7.3	1.1	1.7	3.2	0.8	10.2	8.2	3.0	1.6	7.6	5.4	9.4	7.8	7.9	5.5	6.0	4.1	4.8	3.7	0.0	11.9	25.1	19.3	34.0	3.3	3.4	15.3	0.0	3.4	3.5	2.0	4.3	14.9	42.8	13.7	8.7	11.0	0.0	18.4	6.2	6.8	25.5	33.3	1.6	52.3	3.2	14.3	4.9	17.8	25.0	1.7	66.3	45.5	85.6	7.0	2.6	39.6	24.6	2.5	10.3	4.0	6.5	16.9	21.4	8.7	34.4	4.5	9.6	6.6	32.1
NIN		ENSG00000100503	Ninein	Q8N4C6	14	50719763-50831121	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Muller glia cells: 87.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA005939, HPA070691"	Approved		Enhanced	"Nucleoplasm,Nucleoli,Nucleoli rim,Centrosome"		NA	NA			Centrosome	"Nucleoplasm, Nucleoli, Nucleoli rim"	"HPA005939: AB_2667474, HPA070691: AB_2686296"	"unprognostic (1.98e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.96e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.43e-2)"	"unprognostic (3.41e-2)"	"unprognostic (3.31e-1)"	"unprognostic (5.81e-3)"	"unprognostic (1.78e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.06e-1)"	"unprognostic (2.46e-2)"	"unprognostic (2.67e-1)"	"unprognostic (1.28e-1)"	"unprognostic (2.58e-2)"	"unprognostic (7.66e-3)"	13.0	6.1	15.1	24.9	10.3	34.8	9.7	12.6	14.0	8.0	9.2	7.6	4.5	5.0	11.8	6.1	11.8	8.2	7.6	16.4	11.7	4.9	6.7	5.2	10.7	30.2	7.6	10.0	11.0	5.4	9.1	12.3	20.2	7.1	6.5	7.7	6.2	8.2	5.1	16.9	10.9	8.3	12.0	7.1	18.2	9.3	4.6	9.0	16.4	7.8	5.1	25.8	11.7	10.3	6.8	6.3	18.4	2.3	1.5	6.0	1.3	12.3	8.7	18.3	15.5	7.0	11.4	7.6	10.6	9.1	8.9	7.5	5.6	6.6	29.1	7.3	14.3	8.5	13.0	14.7	6.7	18.9	14.0	4.5	10.7	5.4	5.3	4.1	18.6	30.9	7.8	5.4	15.7	6.4	5.3	14.2	15.1	2.6	11.9	13.5	13.5	14.1	7.5	2.5	3.9	9.7	16.0	33.8	2.1	8.0	14.0	8.5	9.6	13.3	4.0	11.4	4.2	7.6	16.6	20.7	22.8	31.7	8.7	11.7	9.6	4.8	20.1	5.9	15.2	12.3	12.6	2.3	18.4	3.3	1.7	3.5	6.8	2.2	6.0	1.5	5.5	4.4	3.8	8.3	1.5	1.5	6.3	1.9	1.3	15.1	10.3	12.6	14.0	11.7	4.9	7.6	10.0	7.1	9.0	6.0	7.7	41.0	7.0	16.4	7.5	37.9	12.7	26.8	36.4	10.4	58.9	9.2	3.3	6.9	22.3	24.1	4.1	0.0	3.5	8.9	27.9	13.0	30.1	3.9	20.1	6.4	12.1	27.0	40.6	7.8	7.8	47.2	21.9	12.6	3.9	87.7	4.7	5.8	8.9	5.1	18.0	32.3	20.8	0.0	0.4	18.3	8.1	37.4	4.6	14.5
NKX2-1	"BCH, NKX2A, TITF1, TTF-1, TTF1"	ENSG00000136352	"NK2 homeobox 1"	P43699	14	36516392-36521149	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	18	"lung: 51.5;thyroid gland: 122.8"	"Group enriched"	"Detected in some"	6	"Alveolar cells type 1: 128.1;Alveolar cells type 2: 108.1;Club cells: 46.6"	"Group enriched"	"Detected in some"	39	"lung cancer: 30.9;thyroid cancer: 103.2"	"Group enriched"	"Detected in some"	6	"basal ganglia: 2.4;hypothalamus: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	10	"SCLC-21H: 48.7"	"Group enriched"	"Detected in some"	5	"basal ganglia: 3.4;hypothalamus: 12.0"	"Group enriched"	"Detected in some"	13	"basal ganglia: 6.4;hypothalamus: 16.1"	"CAB000078, CAB053633, HPA074316"	Enhanced		Uncertain	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"CAB000078: , CAB053633: AB_442138, HPA074316: "		"unprognostic (3.79e-1)"		"unprognostic (4.25e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.79e-2)"		"unprognostic (1.26e-2)"				"unprognostic (2.23e-1)"		"unprognostic (1.18e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.83e-2)"	"unprognostic (4.18e-1)"	0.1	0.1	0.0	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	2.5	0.0	0.0	51.5	0.1	0.0	0.1	0.0	0.0	0.0	4.9	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.4	0.0	122.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	48.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.4	0.0	0.1	0.2	2.5	0.0	0.1	0.1	0.4	128.1	108.1	0.0	0.0	0.0	0.0	0.6	0.0	14.7	46.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
NONO	"NMT55, NRB54, P54, P54NRB, PPP1R114"	ENSG00000147140	"Non-POU domain containing octamer binding"	Q15233	X	71283192-71301168	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022069, HPA054094, HPA054559"	Enhanced		Enhanced	"Nucleoplasm,Nucleoli fibrillar center,Nuclear speckles"		NA	NA		150000	Nucleoplasm	"Nucleoli fibrillar center, Nuclear speckles"	"CAB022069: , HPA054094: AB_2682376, HPA054559: AB_2682522"	"unprognostic (2.39e-3)"	"unprognostic (2.22e-2)"	"unprognostic (2.64e-1)"	"prognostic unfavorable (9.29e-4)"	"unprognostic (8.87e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.02e-3)"	"unprognostic (9.34e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.41e-2)"	"unprognostic (3.12e-1)"	"unprognostic (2.07e-1)"	"unprognostic (7.29e-3)"	"unprognostic (6.79e-2)"	"unprognostic (5.73e-3)"	"unprognostic (2.76e-2)"	"unprognostic (3.04e-2)"	37.2	55.9	30.2	37.7	30.8	51.2	37.2	54.8	38.6	45.4	33.4	36.0	38.4	29.9	52.4	40.5	41.0	40.5	37.2	30.5	27.5	29.0	40.1	43.3	37.3	45.7	28.8	31.7	69.2	61.0	39.4	48.2	42.4	27.5	40.8	37.5	42.5	39.8	41.4	37.2	38.4	35.2	40.5	38.3	45.9	40.3	34.4	29.0	98.4	51.0	39.1	57.4	43.6	36.8	44.1	47.3	35.3	51.8	45.4	51.8	58.9	59.7	66.1	91.5	50.2	37.3	38.6	50.1	49.0	45.6	66.3	58.6	52.4	44.4	68.0	54.6	45.1	45.8	44.7	136.6	42.6	73.1	51.7	91.2	55.8	69.4	52.2	31.7	78.1	49.0	40.8	30.4	67.1	45.0	55.0	54.5	49.3	71.1	71.3	61.2	53.0	101.1	71.2	114.0	60.3	53.7	90.9	96.0	58.3	50.9	52.9	63.5	78.9	63.5	41.5	56.3	55.5	39.0	50.6	50.0	42.9	64.5	60.0	56.7	41.2	77.9	77.4	32.1	90.9	61.4	35.3	44.8	34.9	45.8	47.6	51.8	43.7	46.6	44.9	47.3	44.1	50.8	50.2	20.8	45.4	51.8	41.2	50.1	58.9	30.2	30.8	54.8	38.6	27.5	29.0	28.8	31.7	27.5	29.0	71.5	74.4	79.8	78.6	112.2	63.2	53.3	94.3	53.5	84.2	41.8	39.3	104.8	48.0	113.5	9.9	89.5	55.4	70.0	96.7	148.6	89.4	78.5	84.5	108.5	99.0	50.9	134.1	70.0	136.1	12.1	98.7	83.7	54.0	104.6	95.9	77.6	111.2	84.2	120.2	93.8	45.1	64.7	107.2	22.8	62.3	107.0	108.8	84.7	122.4	84.4
NOTCH1	TAN1	ENSG00000148400	"Notch 1"	P46531	9	136494433-136545786	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters"	"Angiogenesis, Differentiation, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Endothelial cells: 41.3;Ito cells: 68.2;Muller glia cells: 50.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 8.8"	"Group enriched"	"Detected in many"	4	"granulocytes: 8.8;NK-cells: 2.7"	"Cell line enhanced"	"Detected in many"		"HaCaT: 25.0;HMC-1: 21.7;hTCEpi: 24.0;MOLT-4: 38.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008112, CAB022466, HPA067168"	Supported		Approved	Nucleoplasm		NA	NA		8100000	Nucleoplasm		"CAB008112: AB_2153490, CAB022466: , HPA067168: AB_2685795"	"unprognostic (1.77e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.16e-1)"	"unprognostic (8.38e-3)"	"unprognostic (3.04e-1)"	"unprognostic (1.13e-1)"	"unprognostic (7.56e-2)"	"unprognostic (1.02e-1)"	"unprognostic (5.74e-3)"	"unprognostic (5.50e-3)"	"unprognostic (8.78e-2)"	"unprognostic (8.50e-2)"	"prognostic unfavorable (5.45e-4)"	"unprognostic (2.14e-2)"	"unprognostic (1.92e-1)"	"unprognostic (5.65e-2)"	"unprognostic (8.84e-2)"	20.0	4.0	10.0	14.5	10.4	14.6	12.8	3.8	18.8	12.8	14.2	19.9	8.2	9.8	11.2	5.1	13.3	9.6	13.1	9.6	10.7	5.8	9.4	7.2	17.4	13.7	11.6	7.5	9.2	17.8	3.7	5.6	8.5	9.3	12.1	5.7	10.4	14.2	11.8	8.2	32.3	10.8	7.7	6.6	20.7	8.6	4.1	9.9	34.8	9.4	10.2	10.9	12.3	22.2	0.6	1.1	8.8	1.0	2.7	1.3	0.9	4.4	7.5	6.2	3.1	0.2	0.5	7.8	2.2	0.6	1.3	0.4	1.1	0.5	6.1	4.7	1.7	1.6	25.0	2.0	10.3	0.2	13.8	1.1	3.4	3.0	0.4	3.4	3.6	21.7	0.4	24.0	1.8	3.8	1.5	8.0	2.7	1.5	1.1	0.9	8.1	38.1	5.8	5.2	3.2	3.4	7.9	5.0	11.2	0.9	3.8	0.0	0.4	3.3	3.5	1.4	1.9	2.1	5.8	11.8	3.3	4.8	3.2	2.4	1.3	1.1	2.4	2.2	2.5	16.9	0.7	1.0	2.8	1.3	0.4	0.8	0.4	0.6	1.0	0.6	0.6	0.4	1.1	8.8	2.7	0.4	1.1	0.4	0.9	10.0	10.4	3.8	11.7	10.7	5.8	11.6	7.5	9.3	9.9	8.9	28.2	13.8	10.6	22.0	0.3	7.3	7.6	0.0	6.8	1.8	2.0	0.7	0.0	4.8	0.3	41.3	4.9	0.0	3.4	1.8	4.8	6.6	34.6	6.8	8.0	1.6	2.4	68.2	10.5	0.0	1.1	17.1	6.8	1.0	11.0	50.6	2.2	7.0	0.7	4.1	1.7	6.5	11.5	0.2	3.2	26.1	0.9	12.9	24.7	14.1
NOTCH2		ENSG00000134250	"Notch 2"	Q04721	1	119911553-120069626	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Paneth cells: 129.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048743	Approved		Supported	"Nucleoplasm,Plasma membrane"		NA	NA		67000000	"Nucleoplasm, Plasma membrane"		"HPA048743: AB_2680508"	"unprognostic (1.33e-1)"	"unprognostic (1.43e-2)"	"unprognostic (2.66e-1)"	"unprognostic (1.40e-3)"	"unprognostic (7.98e-2)"	"unprognostic (4.01e-2)"	"unprognostic (1.22e-1)"	"unprognostic (7.32e-2)"	"unprognostic (1.18e-2)"	"prognostic unfavorable (5.24e-4)"	"prognostic unfavorable (9.48e-4)"	"unprognostic (3.86e-2)"	"unprognostic (6.12e-3)"	"unprognostic (1.55e-2)"	"unprognostic (2.65e-2)"	"unprognostic (1.12e-2)"	"unprognostic (7.35e-3)"	12.0	7.3	6.0	9.4	6.8	4.4	10.6	3.0	5.6	14.5	7.6	4.4	11.3	1.6	12.3	11.8	13.4	11.4	12.8	7.9	6.8	2.3	5.5	11.4	10.6	5.7	5.3	7.6	15.5	27.6	6.1	3.3	10.3	6.5	9.9	5.2	9.4	17.7	10.0	9.3	17.2	6.1	12.4	6.2	11.5	5.8	15.7	4.4	8.0	11.4	8.6	6.6	9.6	13.0	4.2	5.2	7.7	9.6	1.5	1.7	2.0	15.0	5.1	7.9	6.1	33.0	28.3	7.9	11.5	15.9	15.4	16.7	4.7	4.1	0.3	9.7	21.8	13.7	5.7	12.5	10.2	24.6	18.1	8.0	8.7	13.7	0.4	12.3	9.1	2.3	22.7	6.6	46.1	30.7	23.3	7.8	4.1	0.1	19.2	18.5	16.9	3.8	2.6	10.2	1.4	5.7	2.5	27.9	9.7	8.1	9.6	0.3	4.0	15.6	14.7	8.3	16.7	8.1	3.1	27.4	20.1	13.9	30.1	18.0	8.0	3.9	4.4	29.5	8.4	19.1	5.6	6.4	6.4	1.5	6.6	1.7	4.2	1.3	1.1	5.2	3.9	1.0	1.7	7.7	1.5	9.6	4.2	0.8	2.0	6.0	6.8	3.0	5.6	6.8	2.3	5.3	7.6	6.5	4.4	32.8	21.6	24.1	40.5	41.1	3.5	11.2	25.5	2.7	13.6	17.4	5.9	1.2	0.0	37.1	15.7	3.7	3.0	0.0	11.3	6.7	53.5	36.6	15.1	35.0	29.9	3.2	5.8	5.5	68.6	9.3	50.9	36.3	37.1	13.6	7.5	46.7	22.9	129.8	80.2	4.3	10.2	19.4	32.3	4.8	3.6	77.8	1.4	13.6	13.8	52.7
NPM1	"B23, NPM"	ENSG00000181163	"Nucleophosmin 1"	P06748	5	171387116-171411137	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Host-virus interaction"	"Chaperone, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA011384, CAB012983"	Supported		Enhanced	"Nucleoplasm,Nucleoli rim"		Yes	No		810000	"Nucleoli rim"	Nucleoplasm	"CAB012983: AB_2533084, HPA011384: AB_1854692"	"unprognostic (1.84e-3)"	"unprognostic (2.59e-1)"	"unprognostic (2.23e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.65e-1)"	"prognostic unfavorable (7.48e-4)"	"prognostic unfavorable (4.82e-6)"	"unprognostic (1.86e-2)"	"unprognostic (5.25e-3)"	"unprognostic (1.39e-1)"	"unprognostic (2.26e-3)"	"unprognostic (1.27e-1)"	"prognostic unfavorable (2.89e-6)"	"unprognostic (2.19e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.24e-2)"	56.8	44.7	29.9	61.1	33.6	76.0	67.0	37.7	34.6	113.5	57.8	24.8	39.3	36.7	78.2	50.5	81.6	65.0	44.0	48.5	28.8	31.6	64.9	78.8	59.5	128.1	36.1	27.9	177.4	102.0	27.1	57.9	65.2	36.1	87.2	49.3	29.5	47.3	48.2	67.9	42.7	52.8	92.4	43.2	85.9	54.0	56.7	31.3	111.3	112.6	66.5	82.1	116.8	65.7	85.3	54.1	12.3	29.1	59.0	126.6	91.4	119.9	81.3	98.8	139.9	60.4	110.3	147.3	109.2	99.8	148.0	133.3	193.9	84.8	321.2	86.8	63.1	99.7	70.4	137.0	248.2	192.8	100.0	108.7	113.3	79.7	142.8	89.5	228.2	94.0	97.3	87.5	100.4	198.1	116.7	110.3	74.8	137.8	73.9	107.4	149.0	148.9	162.3	123.6	64.0	99.9	133.7	109.0	164.6	126.2	84.6	77.9	62.6	65.2	106.8	197.6	72.0	131.0	101.3	68.9	49.5	109.2	56.9	183.8	59.2	107.6	193.2	74.9	185.8	98.7	12.3	26.9	8.4	45.7	29.1	84.6	85.3	85.1	66.2	54.1	62.8	126.6	99.0	4.0	59.0	23.1	48.7	73.2	91.4	29.9	33.6	37.7	34.6	28.8	31.6	36.1	27.9	36.1	31.3	321.6	347.3	775.5	994.0	1243.7	166.1	228.8	387.3	346.6	597.1	307.1	41.2	1400.5	630.0	839.1	64.3	646.8	150.8	116.8	796.2	1641.6	855.4	473.8	427.8	235.7	952.5	120.8	347.6	298.3	500.7	53.0	902.7	605.7	578.6	960.4	654.2	214.7	840.7	333.1	610.9	657.5	112.2	426.9	861.0	695.1	635.2	890.7	1286.9	674.9	783.2	797.7
NR4A3	"CHN, CSMF, MINOR, NOR1"	ENSG00000119508	"Nuclear receptor subfamily 4 group A member 3"	Q92570	9	99821855-99866891	"Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"seminal vesicle: 80.6"	"Cell type enhanced"	"Detected in many"	11	"Cardiomyocytes: 218.8;granulocytes: 120.9;Melanocytes: 84.4;Smooth muscle cells: 116.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"eosinophil: 1.3;NK-cell: 1.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 1.3;NK-cells: 1.3"	"Group enriched"	"Detected in some"	5	"BJ hTERT+: 21.5;HeLa: 7.4;SK-MEL-30: 14.8;U-266/70: 8.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA043360	Uncertain					NA	NA					"HPA043360: AB_10961186"	"prognostic favorable (5.97e-4)"	"unprognostic (6.92e-3)"	"unprognostic (5.34e-2)"	"unprognostic (2.78e-3)"	"unprognostic (1.40e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.65e-3)"	"unprognostic (1.40e-2)"	"unprognostic (2.28e-1)"	"unprognostic (3.30e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.29e-3)"	"unprognostic (6.11e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.69e-1)"	19.9	46.5	3.5	10.2	4.5	22.1	5.9	1.6	5.0	9.7	4.8	9.5	6.3	0.8	10.7	6.1	3.1	15.7	16.6	37.3	4.1	2.5	3.8	7.1	12.4	1.2	1.6	3.1	37.2	4.0	4.0	12.2	4.7	5.0	12.0	3.2	7.0	1.6	80.6	28.5	1.5	4.2	23.0	5.1	2.6	9.0	1.3	3.4	7.6	4.2	15.5	1.9	23.5	7.5	0.0	0.2	1.3	0.0	1.3	0.0	0.0	0.1	0.1	0.6	0.1	1.2	0.4	1.0	1.3	21.5	0.2	0.3	0.2	0.1	0.1	0.3	0.5	0.4	0.1	0.4	0.0	0.1	1.8	0.3	0.1	7.4	0.0	0.1	0.1	2.1	0.3	0.0	0.5	0.1	0.1	0.0	0.0	0.0	0.5	0.1	0.6	0.0	0.2	0.0	0.1	0.6	0.0	1.0	0.0	0.0	0.1	0.4	0.4	2.4	1.7	14.8	0.2	0.0	0.0	0.1	1.4	0.4	1.7	0.1	8.8	0.1	0.0	0.9	0.0	0.8	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	1.3	0.0	0.0	0.0	0.0	3.5	4.5	1.6	5.0	4.1	2.5	1.6	3.1	5.0	3.4	11.9	22.4	0.9	7.4	70.6	0.7	218.8	2.5	18.7	14.8	15.7	9.8	1.8	0.0	0.1	1.3	7.3	0.6	0.0	1.4	1.2	43.7	5.1	120.9	0.5	10.3	0.0	26.1	8.6	16.8	1.2	1.4	35.2	84.4	74.9	2.2	1.0	0.2	0.3	1.1	0.0	0.8	0.0	116.4	0.3	1.4	51.9	4.7	5.0	0.9	2.3
NRAS	N-ras	ENSG00000213281	"NRAS proto-oncogene, GTPase"	P01111	1	114704469-114716894	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB010157, HPA049830, CAB079912"	Uncertain		Supported	"Plasma membrane"		NA	NA		4800000	"Plasma membrane"		"CAB010157: AB_632073, CAB079912: AB_2784586, HPA049830: AB_2680903"	"unprognostic (4.75e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.09e-3)"	"unprognostic (2.11e-2)"	"unprognostic (8.59e-3)"	"unprognostic (1.14e-1)"	"prognostic unfavorable (3.03e-7)"	"unprognostic (7.76e-3)"	"unprognostic (1.57e-2)"	"unprognostic (1.01e-3)"	"prognostic unfavorable (1.36e-4)"	"unprognostic (6.60e-3)"	"prognostic unfavorable (7.87e-4)"	"unprognostic (2.68e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.16e-1)"	"unprognostic (3.33e-2)"	18.0	9.7	13.1	16.5	14.4	33.5	12.4	9.7	16.6	10.0	18.4	15.8	3.8	14.4	9.8	6.2	19.7	8.7	11.8	7.1	11.7	13.8	24.0	23.9	13.4	18.7	15.3	9.6	10.3	14.2	8.3	7.6	27.4	19.0	9.2	18.5	8.4	12.4	5.2	7.9	16.1	23.4	9.6	20.9	19.5	14.4	9.8	9.7	45.0	11.1	14.0	19.6	13.2	10.5	11.0	9.9	23.7	15.0	12.1	11.1	10.1	24.7	6.7	18.1	6.8	7.5	16.1	12.9	11.8	13.2	22.2	25.0	13.5	9.3	18.8	15.7	15.9	15.5	7.1	24.1	19.2	31.9	25.6	9.4	12.7	10.2	16.0	14.9	31.6	19.8	14.5	15.6	25.4	18.6	7.0	28.2	14.9	20.2	21.7	19.5	66.1	21.8	12.3	30.7	8.1	4.9	16.7	32.2	11.7	19.6	13.4	11.0	16.5	12.1	10.0	28.4	22.0	8.8	25.7	21.5	12.1	23.2	22.6	24.2	38.4	26.4	22.1	24.2	17.3	43.6	23.7	10.0	9.6	9.8	15.0	8.9	11.0	8.0	9.7	9.9	8.8	8.7	11.1	2.7	12.1	12.7	7.7	10.4	10.1	13.1	14.4	9.7	16.6	11.7	13.8	15.3	9.6	19.0	9.7	14.9	13.9	22.5	24.9	27.2	4.4	4.0	25.5	18.7	12.5	21.0	7.9	18.9	11.6	31.0	2.9	23.3	32.2	0.0	27.3	39.9	16.8	25.2	31.1	24.5	43.1	4.8	23.6	40.5	41.2	4.4	7.5	27.8	21.9	41.5	29.5	7.1	39.8	29.4	6.0	27.8	2.2	6.5	10.8	6.5	14.1	31.7	26.1	20.3	24.7	34.0
NRG1	"GGF, HGL, HRG, NDF, NRG1-IT2"	ENSG00000157168	"Neuregulin 1"	Q02297	8	31639386-32767959	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Growth factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 28.3"	"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 1: 35.7;Basal glandular cells: 36.6;Early spermatids: 31.2;Horizontal cells: 27.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 4.4"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"classical monocyte: 22.8"	"Lineage enriched"	"Detected in many"	5	"monocytes: 22.8"	"Cell line enhanced"	"Detected in many"		"A549: 38.0;BJ: 26.0;fHDF/TERT166: 29.1;GAMG: 40.0;HBF TERT88: 25.6;hTEC/SVTERT24-B: 27.3;hTERT-HME1: 28.6"	"Low region specificity"	"Detected in all"							HPA010964	Uncertain		Approved	Nucleoplasm	"Secreted to blood"	NA	NA			Nucleoplasm		"HPA010964: AB_1854641"	"unprognostic (5.76e-3)"	"unprognostic (8.60e-2)"	"unprognostic (1.96e-4)"	"unprognostic (2.67e-1)"	"unprognostic (1.94e-4)"	"unprognostic (4.99e-2)"	"unprognostic (6.69e-2)"	"unprognostic (7.72e-2)"	"unprognostic (2.98e-1)"	"unprognostic (5.65e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.49e-2)"	"unprognostic (4.47e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.88e-1)"	"unprognostic (5.40e-2)"	"unprognostic (7.83e-2)"	0.7	2.1	4.6	5.0	3.3	1.2	8.8	14.8	8.1	10.6	4.2	0.3	2.1	3.5	2.5	1.1	3.7	2.0	4.8	2.2	4.7	15.4	11.5	23.6	5.7	0.6	6.2	3.5	2.9	0.9	0.8	23.9	0.2	28.3	3.2	5.4	3.6	2.5	1.6	0.2	4.3	5.7	1.1	2.5	1.7	3.1	6.4	0.8	0.2	13.8	7.2	2.2	7.2	3.5	0.0	4.9	0.8	22.8	0.0	0.0	4.6	0.1	38.0	0.6	0.0	0.3	0.7	0.0	26.0	18.4	21.6	16.6	0.0	0.8	0.0	4.8	29.1	40.0	20.5	0.1	10.4	25.6	0.0	0.2	0.5	0.5	0.5	0.1	0.0	0.0	0.3	1.1	27.3	28.6	1.9	12.4	0.0	0.0	0.1	7.7	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	16.0	1.1	1.1	1.3	1.9	0.0	0.0	2.1	0.0	0.0	9.0	15.0	4.6	23.9	14.5	0.0	0.0	0.2	7.7	0.0	1.8	0.0	22.8	0.2	0.0	2.1	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	4.6	4.6	3.3	14.8	8.1	4.7	15.4	6.2	3.5	28.3	0.8	35.7	2.4	0.5	36.6	23.1	11.2	1.7	10.2	4.0	13.6	3.5	7.9	0.0	8.3	1.8	31.2	1.4	0.0	0.0	0.2	0.0	0.7	14.3	1.1	6.6	0.5	27.0	0.0	6.7	16.0	14.6	0.3	1.8	1.7	0.0	0.0	4.8	0.8	0.0	0.4	14.6	3.0	0.0	0.9	1.4	1.0	5.4	0.0	0.0	0.0	5.6
NSD1	"ARA267, FLJ22263, KMT3B, STO"	ENSG00000165671	"Nuclear receptor binding SET domain protein 1"	Q96L73	5	177133025-177300215	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cone photoreceptor cells: 141.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048431, HPA070333, HPA073705"	Supported		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA048431: AB_2680388, HPA070333: AB_2686255, HPA073705: AB_2732239"	"unprognostic (3.48e-2)"	"unprognostic (7.46e-2)"	"unprognostic (7.14e-3)"	"unprognostic (2.64e-3)"	"unprognostic (1.38e-1)"	"unprognostic (9.67e-2)"	"unprognostic (2.29e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.68e-3)"	"unprognostic (8.04e-2)"	"unprognostic (1.48e-1)"	"unprognostic (2.09e-1)"	"unprognostic (7.77e-3)"	"unprognostic (3.53e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.51e-2)"	"unprognostic (7.32e-2)"	11.8	13.2	11.9	25.4	15.7	23.9	14.0	28.9	16.7	15.6	14.2	18.5	17.0	10.6	19.0	13.9	17.8	13.6	15.8	11.7	12.8	11.5	14.4	10.5	12.3	19.4	12.9	11.7	16.6	27.1	24.6	19.3	16.0	13.4	14.2	14.3	13.8	13.5	18.7	20.6	16.1	14.5	15.6	13.2	16.1	13.1	28.1	16.1	27.3	20.1	10.6	22.7	13.4	20.2	10.2	8.9	18.7	10.8	10.9	7.8	2.9	9.9	12.8	13.3	11.5	6.6	8.5	0.4	9.0	9.0	12.7	11.8	2.8	8.3	20.5	10.2	12.4	11.7	8.5	21.2	20.0	15.4	34.7	12.8	9.1	14.5	0.1	10.9	19.6	10.8	8.0	12.1	15.0	14.1	9.0	18.4	13.0	12.4	7.2	12.7	20.8	13.6	6.3	14.5	6.7	11.3	15.1	1.7	6.3	8.2	12.1	16.3	11.2	23.4	10.2	7.0	12.9	10.2	16.3	13.5	8.8	12.9	5.6	11.1	8.5	7.4	14.7	5.1	9.6	9.4	10.7	9.1	9.4	7.5	6.1	6.3	8.5	6.3	5.0	6.7	10.2	7.8	6.3	18.7	10.9	10.8	8.9	5.7	2.9	11.9	15.7	28.9	16.7	12.8	11.5	12.9	11.7	13.4	16.1	20.8	26.1	42.4	26.2	15.0	91.7	37.5	33.1	13.4	36.4	52.4	141.4	34.8	14.9	22.8	25.5	31.5	21.9	0.0	18.5	20.4	23.3	24.0	39.4	16.3	24.2	84.2	40.3	31.3	29.2	33.9	47.2	39.1	15.1	50.5	19.4	35.7	20.1	24.6	31.1	13.9	100.0	51.8	19.6	63.2	47.7	18.1	29.6	51.1	21.5	23.5
NSD2	"KMT3G, MMSET, WHSC1"	ENSG00000109685	"Nuclear receptor binding SET domain protein 2"	O96028	4	1871424-1982207	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 1: 11.9;Alveolar cells type 2: 17.3;Ciliated cells: 13.4;Club cells: 14.8;Collecting duct cells: 12.2;Hofbauer cells: 11.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015801, CAB068246, CAB068247"	Enhanced		Supported	Nucleoplasm		No	No			Nucleoplasm		"CAB068246: AB_2665690, CAB068247: AB_2665689, HPA015801: AB_1858830"	"unprognostic (3.70e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.33e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.01e-1)"	"unprognostic (1.31e-2)"	"prognostic unfavorable (2.61e-4)"	"unprognostic (3.24e-2)"	"unprognostic (6.22e-2)"	"unprognostic (7.66e-2)"	"unprognostic (2.09e-1)"	"unprognostic (9.25e-3)"	"prognostic unfavorable (7.19e-4)"	"unprognostic (3.89e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.31e-1)"	"unprognostic (6.15e-2)"	8.7	7.6	17.6	11.5	16.2	35.1	8.5	20.6	18.2	7.0	14.8	12.4	6.3	14.0	9.5	7.4	12.7	6.8	6.9	11.9	15.1	10.9	8.4	7.5	11.1	18.8	14.7	16.1	7.0	11.7	10.7	11.8	9.8	14.6	8.7	17.7	9.4	10.2	7.4	11.8	12.1	14.6	10.5	15.3	13.5	11.0	26.3	13.4	46.7	13.8	5.5	17.7	8.6	9.4	4.9	3.9	4.1	1.8	2.7	4.3	0.6	27.7	14.0	42.3	18.5	4.6	6.8	12.3	22.4	19.9	27.5	30.8	12.4	33.0	29.9	7.7	18.5	36.0	12.1	27.3	18.5	47.3	14.3	11.3	35.6	19.4	7.3	5.8	21.8	18.7	2.6	4.7	24.1	23.2	15.2	21.6	30.2	19.3	31.4	22.5	10.9	58.1	22.9	17.8	14.1	16.2	33.2	27.6	10.3	11.3	13.2	26.3	21.0	18.4	6.9	8.4	19.2	16.3	14.6	16.7	27.5	20.5	17.4	45.1	14.7	15.5	27.1	16.5	21.6	25.5	2.1	1.7	1.7	2.9	1.8	3.2	1.8	3.2	3.2	1.5	4.9	2.8	2.3	4.1	2.7	1.4	3.9	4.3	0.6	17.6	16.2	20.6	18.2	15.1	10.9	14.7	16.1	14.6	13.4	11.9	17.3	0.0	0.0	0.0	0.0	0.0	0.0	13.4	14.8	12.2	0.0	10.0	3.3	10.2	0.0	0.0	0.0	0.0	6.1	7.3	0.0	0.0	2.3	0.0	11.6	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	10.0	0.0	0.0	10.2	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0
NSD3	"FLJ20353, KMT3F, WHISTLE, WHSC1L1"	ENSG00000147548	"Nuclear receptor binding SET domain protein 3"	Q9BZ95	8	38269697-38382272	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Methyltransferase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Cytotrophoblasts: 85.7;Extravillous trophoblasts: 142.9;monocytes: 86.6;Syncytiotrophoblasts: 109.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005659, CAB013721, HPA018893"	Uncertain		Approved	Nucleoplasm,Mitochondria		NA	NA			Mitochondria	Nucleoplasm	"CAB013721: , HPA005659: AB_1080596, HPA018893: AB_1858833"	"unprognostic (6.21e-2)"	"unprognostic (3.73e-2)"	"unprognostic (2.18e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.53e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.97e-2)"	"unprognostic (2.49e-1)"	"unprognostic (5.72e-2)"	"prognostic unfavorable (7.48e-4)"	"unprognostic (5.06e-2)"	"unprognostic (5.60e-3)"	"unprognostic (6.69e-2)"	"unprognostic (4.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.60e-2)"	19.2	11.3	31.1	15.8	31.4	36.3	20.1	51.5	37.7	18.5	15.5	16.7	14.0	16.2	16.0	12.5	17.0	16.8	17.0	12.7	24.4	16.6	14.2	11.2	17.9	22.3	25.0	26.8	26.5	16.3	21.0	24.2	22.5	21.9	16.4	18.7	12.3	18.3	17.9	12.3	16.2	17.7	16.0	15.3	17.2	19.7	9.3	25.6	16.7	19.2	6.9	20.4	19.6	23.3	26.7	5.6	26.2	5.1	8.6	18.0	2.9	24.1	13.9	23.9	16.1	16.8	19.3	17.7	20.3	22.4	17.6	20.5	7.4	13.4	28.8	18.7	13.8	17.1	14.6	18.9	16.2	25.2	11.4	11.1	36.7	11.2	8.6	17.2	16.1	13.3	10.3	16.5	15.9	32.4	16.5	20.1	31.9	26.0	19.2	16.7	8.7	47.1	13.7	16.2	18.8	6.6	21.6	26.1	9.1	12.5	18.7	13.5	18.2	16.5	14.5	14.1	16.0	18.2	12.3	19.2	18.3	19.0	27.2	11.9	17.1	20.4	27.8	15.5	16.3	13.2	13.9	5.1	9.1	8.0	2.4	5.3	16.5	12.0	7.1	4.1	26.7	15.0	6.3	26.2	8.6	1.5	5.6	18.0	2.9	31.1	31.4	51.5	37.7	24.4	16.6	25.0	26.8	21.9	25.6	62.5	52.3	0.0	0.0	0.0	0.0	0.0	0.0	62.9	55.7	48.8	0.0	85.7	19.9	60.6	0.0	0.0	0.0	0.0	53.3	142.9	0.0	0.0	8.1	0.0	39.1	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.0	86.6	0.0	0.0	50.3	0.0	0.0	28.5	0.0	0.0	0.0	0.0	0.0	0.0	109.4	0.0	0.0	0.0
NT5C2	"cN-II, GMP, NT5B, PNT5, SPG65"	ENSG00000076685	"5'-nucleotidase, cytosolic II"	P49902	10	103088017-103193306	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Nucleotide metabolism"	"Allosteric enzyme, Hydrolase"	"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003751	Approved					NA	NA					"HPA003751: AB_1854664"	"unprognostic (8.18e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.55e-2)"	"unprognostic (2.46e-1)"	"unprognostic (5.54e-2)"	"unprognostic (4.87e-3)"	"unprognostic (2.24e-2)"	"unprognostic (1.72e-1)"	"unprognostic (6.41e-2)"	"unprognostic (9.59e-2)"	"unprognostic (2.93e-3)"	"unprognostic (6.20e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.70e-2)"	"unprognostic (6.40e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.50e-1)"	15.0	17.0	17.6	18.2	21.2	31.6	19.7	22.5	19.6	17.5	20.7	25.4	24.5	10.9	24.6	19.6	38.6	14.8	17.0	16.5	16.7	20.7	19.6	15.5	18.8	16.8	21.8	17.3	24.8	19.4	18.7	29.5	16.9	29.1	22.9	17.0	26.2	67.2	21.6	41.6	11.7	13.9	20.4	19.1	20.5	15.9	21.7	14.5	29.7	39.2	16.3	31.5	21.1	31.1	6.7	9.7	23.8	14.5	10.5	8.7	7.1	50.7	20.7	14.4	32.3	12.7	14.1	8.3	25.5	24.8	12.4	12.9	15.0	40.7	24.3	19.8	17.6	10.8	26.0	9.5	13.1	14.6	14.6	8.9	17.5	8.8	14.5	22.7	25.3	8.7	21.7	14.6	10.8	17.5	30.2	11.4	11.8	11.3	17.0	21.5	30.0	22.6	32.8	13.6	15.5	25.6	36.9	12.4	7.0	17.8	29.0	4.3	10.8	13.4	10.6	20.0	20.4	16.1	19.7	11.6	9.9	10.0	14.1	18.6	14.9	24.7	32.6	10.0	29.3	2.8	19.8	11.7	23.8	8.1	11.9	8.7	6.7	7.0	6.5	9.7	4.2	6.0	6.2	21.4	10.5	14.5	7.3	6.5	7.1	17.6	21.2	22.5	18.0	16.7	20.7	21.8	17.3	29.1	14.5	77.4	27.5	10.4	26.3	6.5	19.9	2.4	20.4	32.1	67.1	26.2	43.2	16.3	10.0	27.7	82.0	15.7	21.6	0.0	22.4	10.0	11.0	32.1	8.1	14.9	17.8	44.5	11.1	12.3	30.0	49.8	23.0	20.7	25.3	13.6	16.7	78.8	41.7	14.2	12.7	13.9	53.0	32.3	12.6	23.0	21.5	6.6	29.3	16.6	13.3	73.2
NTRK1	"MTC, TRK, TRKA"	ENSG00000198400	"Neurotrophic receptor tyrosine kinase 1"	P04629	1	156815640-156881850	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"adrenal gland: 15.8;blood: 32.3;brain: 28.3"	"Group enriched"	"Detected in some"	8	"granulocytes: 56.4;Horizontal cells: 54.0"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Region enriched"	"Detected in many"	5	"pons and medulla: 28.3"	"Cell type enriched"	"Detected in single"	127	"basophil: 32.3"	"Lineage enriched"	"Detected in single"	323	"granulocytes: 32.3"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 42.1"	"Region enhanced"	"Detected in some"		"basal ganglia: 8.2"	"Low region specificity"	"Detected in all"			"CAB004606, HPA035799, HPA076570"	Approved		Approved	Vesicles,Cytosol		NA	NA		140000	"Vesicles, Cytosol"		"CAB004606: AB_628397, HPA035799: AB_2674788, HPA076570: "	"unprognostic (5.89e-3)"	"unprognostic (7.56e-2)"	"unprognostic (2.74e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.26e-2)"	"unprognostic (1.43e-3)"	"unprognostic (1.56e-1)"	"unprognostic (7.42e-3)"	"unprognostic (7.63e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.73e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.18e-11)"	"unprognostic (2.18e-3)"	"unprognostic (3.79e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.89e-1)"	1.0	15.8	0.5	0.8	6.0	0.9	0.4	0.0	0.7	0.9	1.1	0.1	0.0	0.8	1.6	2.0	0.7	0.6	2.1	1.5	0.0	1.2	2.9	0.2	1.9	0.3	2.1	0.6	0.3	0.3	0.3	1.1	0.5	28.3	2.2	0.2	3.1	1.2	0.5	0.7	0.2	0.4	1.1	1.2	0.2	1.0	2.4	1.5	0.4	0.3	0.0	0.4	0.7	0.8	0.0	0.0	32.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	6.8	0.0	0.0	0.0	0.0	42.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.8	0.0	0.0	0.0	1.2	0.0	0.0	0.6	1.2	0.0	0.1	0.0	0.0	0.8	9.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.0	1.6	0.2	0.0	0.0	0.0	0.0	32.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.0	0.0	0.6	0.0	1.2	2.1	0.6	28.3	1.5	0.0	2.2	0.0	0.0	0.0	6.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	56.4	0.0	0.1	54.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.2	2.5	0.1	0.0	0.0	0.0	0.0
NTRK3	TRKC	ENSG00000140538	"Neurotrophic receptor tyrosine kinase 3"	Q16288	15	87859751-88256768	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 41.8"	"Cell type enhanced"	"Detected in many"	13	"Bipolar cells: 58.9;Early spermatids: 85.5;Late spermatids: 103.3;Sertoli cells: 51.8;Smooth muscle cells: 37.7"	"Cancer enhanced"	"Detected in some"		"glioma: 2.5"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	8	"U-138 MG: 48.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009233, HPA027484, HPA048065"	Approved		Supported	"Nuclear membrane,Nucleoli,Nucleoli rim"		NA	NA		11000000	"Nucleoli, Nucleoli rim"	"Nuclear membrane"	"CAB009233: AB_632555, HPA027484: AB_2672297, HPA048065: AB_2680245"	"unprognostic (1.27e-3)"	"unprognostic (1.24e-2)"	"unprognostic (1.98e-2)"	"unprognostic (2.04e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.34e-1)"	"unprognostic (3.18e-2)"	"unprognostic (2.23e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.91e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.09e-1)"	"unprognostic (5.78e-3)"	"unprognostic (6.45e-3)"	"unprognostic (1.06e-2)"	"unprognostic (1.26e-2)"	"unprognostic (2.49e-3)"	20.8	7.4	22.0	2.5	28.1	1.5	6.2	30.4	41.8	7.0	4.0	8.4	1.3	2.0	12.4	6.7	3.4	9.5	3.9	5.5	22.0	11.1	5.1	2.0	5.7	3.1	11.2	18.7	5.1	2.9	1.6	7.9	2.8	14.7	6.8	4.7	8.0	11.5	8.7	1.9	2.9	2.5	7.7	13.7	4.1	3.0	13.8	13.7	0.0	2.5	0.7	4.3	7.1	4.8	0.7	0.4	1.3	0.5	0.5	0.8	0.0	0.0	6.1	1.3	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	48.6	0.9	0.0	0.6	0.0	0.0	0.0	1.4	0.0	0.1	1.2	0.5	0.4	0.3	0.1	0.2	0.4	0.3	0.3	0.1	0.7	0.4	0.4	1.3	0.5	0.1	0.4	0.8	0.0	22.0	28.1	30.4	28.9	22.0	11.1	11.2	18.7	14.7	13.7	0.0	0.0	0.0	5.9	0.5	58.9	5.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	85.5	0.7	0.0	0.0	0.0	0.0	1.7	0.6	0.0	0.0	0.9	1.6	0.0	1.8	0.0	103.3	3.1	0.2	0.0	0.0	0.0	8.9	0.0	0.0	25.8	0.0	2.7	51.8	37.7	8.8	1.9	0.1	0.1	0.0	0.0	0.1
NUMA1		ENSG00000137497	"Nuclear mitotic apparatus protein 1"	Q14980	11	72002864-72080693	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Mitosis"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019841, HPA019859, HPA029912"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	Yes			Nucleoplasm	Cytosol	"HPA019841: AB_1854708, HPA019859: AB_1854709, HPA029912: AB_10602811"	"unprognostic (1.60e-2)"	"unprognostic (3.31e-1)"	"unprognostic (2.06e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.14e-1)"	"unprognostic (6.47e-2)"	"unprognostic (5.75e-2)"	"unprognostic (8.74e-3)"	"unprognostic (5.91e-2)"	"unprognostic (9.45e-2)"	"unprognostic (1.60e-2)"	"unprognostic (2.51e-2)"	"prognostic favorable (7.92e-4)"	"unprognostic (1.28e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.39e-1)"	29.7	33.5	23.6	20.6	28.1	26.8	33.1	38.4	31.8	51.9	37.7	55.6	40.1	25.5	58.3	30.9	34.1	37.8	31.2	21.2	21.6	19.4	23.0	13.1	28.3	23.3	37.6	24.8	51.4	30.0	70.7	29.5	26.0	28.3	50.3	24.2	41.2	35.3	40.1	43.7	41.9	30.2	45.3	29.5	23.0	31.2	25.9	39.5	39.4	32.6	22.5	31.8	50.5	37.2	10.3	12.9	4.9	5.7	7.0	9.7	6.6	18.5	23.6	29.6	19.9	26.4	27.5	15.1	25.1	29.1	26.2	22.9	24.5	34.4	25.3	22.0	30.7	18.8	39.9	27.0	25.4	24.0	26.0	12.7	31.0	37.1	18.6	21.2	23.4	22.6	29.0	16.8	25.6	25.9	40.7	22.1	22.9	18.2	30.6	17.9	35.8	30.2	13.1	18.4	35.6	17.1	37.1	51.7	19.5	19.6	29.1	35.8	50.8	40.1	37.1	37.3	13.4	49.9	13.7	30.5	27.8	21.7	39.3	16.6	19.9	19.6	35.6	18.6	11.1	15.8	4.9	5.6	2.5	9.7	3.5	7.4	5.2	6.0	7.5	4.9	10.3	7.5	5.2	4.6	7.0	5.7	12.9	7.2	6.6	23.6	28.1	38.4	31.8	21.6	19.4	37.6	24.8	28.3	39.5	38.7	32.9	12.4	27.2	23.0	61.9	5.2	35.7	32.1	30.7	50.6	68.7	24.3	14.9	24.4	28.1	29.2	50.4	0.0	27.8	11.2	25.5	31.2	30.1	20.3	24.6	49.3	45.5	31.3	31.9	14.3	63.9	23.2	18.6	20.8	58.2	49.2	27.3	31.6	47.7	22.6	57.0	38.8	21.7	11.9	20.4	24.6	37.6	28.4	48.3	21.6
NUP214	"CAIN, CAN, D9S46E, N214"	ENSG00000126883	"Nucleoporin 214"	P35658	9	131125561-131234670	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 131.5"	"Cell type enhanced"	"Detected in many"	9	"Early spermatids: 225.7;Kupffer cells: 255.0;Late spermatids: 282.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 43.7;neutrophil: 131.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 131.5;monocytes: 43.7"	"Cell line enhanced"	"Detected in all"		"K-562: 73.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048789			Approved	"Nucleoplasm,Vesicles,Focal adhesion sites"		NA	NA		100000	Nucleoplasm	"Vesicles, Focal adhesion sites"	"HPA048789: AB_2680521"	"unprognostic (1.30e-1)"	"unprognostic (9.51e-3)"	"unprognostic (9.92e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.42e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.10e-2)"	"unprognostic (3.35e-1)"	"unprognostic (4.95e-1)"	"unprognostic (6.60e-3)"	"unprognostic (1.08e-1)"	"prognostic favorable (2.39e-5)"	"unprognostic (5.49e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.53e-1)"	16.9	10.3	11.5	13.8	13.9	29.4	12.9	13.0	14.4	10.2	11.4	19.8	10.4	9.0	15.0	13.7	16.1	12.1	10.2	9.7	9.5	8.1	19.0	15.1	11.7	13.3	13.2	8.8	14.2	17.0	16.7	16.9	13.0	11.3	11.1	10.8	15.3	13.0	11.1	15.5	17.5	11.7	11.1	14.3	35.8	12.3	63.7	13.3	27.4	11.8	7.6	16.8	10.7	11.2	1.2	16.8	131.5	43.7	1.2	0.8	17.9	6.8	9.8	8.4	5.0	6.8	6.6	8.8	6.1	6.3	8.0	6.5	8.0	5.0	11.1	4.9	8.4	8.3	15.7	11.3	8.0	7.8	8.0	5.5	6.9	14.0	15.6	6.0	10.8	7.5	7.1	7.4	10.2	8.3	5.1	8.1	7.4	73.0	6.4	8.2	12.8	14.2	16.4	9.1	9.9	8.6	5.0	10.6	11.1	9.2	6.3	7.1	7.4	10.2	9.4	5.3	6.3	12.4	27.0	7.0	14.1	7.9	9.2	9.9	5.6	10.9	10.8	6.9	6.5	8.5	3.5	43.7	17.3	0.7	18.4	0.8	1.2	0.7	0.6	16.8	1.1	0.7	0.7	131.5	1.2	15.0	1.5	0.4	17.9	11.5	13.9	13.0	14.4	9.5	8.1	13.2	8.8	11.3	13.3	17.9	19.9	15.2	9.5	7.7	29.6	24.0	15.3	16.0	15.9	22.7	43.2	10.9	8.3	9.1	225.7	14.6	13.6	0.0	13.1	9.3	11.4	11.4	8.1	11.9	75.5	15.9	19.5	18.4	255.0	282.5	21.6	77.0	10.1	15.4	14.3	14.8	12.0	5.8	19.1	6.7	31.6	6.5	8.1	90.1	44.5	9.5	9.2	11.8	16.3	9.3
NUP98	NUP96	ENSG00000110713	"Nucleoporin 98"	P52948	11	3671083-3797792	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Early spermatids: 93.4;Late spermatids: 116.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA074810			Supported	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA074810: AB_2686714"	"unprognostic (1.11e-1)"	"unprognostic (1.49e-1)"	"unprognostic (7.41e-2)"	"unprognostic (2.13e-1)"	"unprognostic (7.71e-3)"	"unprognostic (3.40e-1)"	"unprognostic (4.08e-3)"	"unprognostic (6.47e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.83e-2)"	"unprognostic (7.76e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.23e-1)"	"unprognostic (5.09e-1)"	"unprognostic (1.91e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.21e-1)"	20.2	13.5	8.7	23.5	11.7	40.8	23.5	14.2	13.2	18.0	15.3	14.6	17.8	11.2	19.2	17.5	18.6	17.3	17.1	18.2	7.8	8.0	12.8	20.1	20.7	17.4	11.4	8.7	25.5	19.0	25.7	23.6	20.7	12.7	18.6	15.2	17.8	17.4	25.0	35.2	18.5	15.7	20.8	10.4	18.3	16.0	57.0	10.6	27.5	20.9	15.0	26.6	22.6	19.3	8.9	9.9	24.9	10.0	6.1	13.2	8.7	29.8	23.4	19.3	21.3	21.4	17.6	17.0	21.3	24.9	29.3	26.4	25.7	37.1	29.2	10.1	25.5	29.6	32.2	33.9	21.0	40.0	20.7	24.5	31.3	19.2	17.6	18.0	39.9	26.4	20.0	14.5	16.1	29.4	13.0	22.7	33.4	38.9	23.5	31.1	12.2	40.1	13.0	24.4	32.8	18.0	24.5	23.5	14.0	16.7	23.6	17.8	11.9	30.9	25.1	14.2	21.0	15.4	15.7	16.6	23.5	20.4	25.5	19.4	14.2	24.2	31.0	15.9	17.2	24.7	19.1	7.9	15.5	11.0	10.0	11.0	8.9	10.7	9.7	9.9	7.8	12.2	10.5	24.9	6.1	6.3	2.7	13.2	8.7	8.7	11.7	14.2	13.2	7.8	8.0	11.4	8.7	12.7	10.6	26.8	25.1	21.4	28.7	44.3	14.4	14.3	25.5	13.4	22.7	7.0	15.7	18.8	3.3	11.1	93.4	20.3	12.8	23.3	10.3	14.1	19.3	22.7	17.4	20.2	15.1	14.3	20.6	16.5	15.1	116.3	15.8	20.9	15.1	27.9	14.0	12.4	10.6	12.7	13.4	7.4	14.9	32.3	23.7	48.2	32.6	44.2	38.9	20.2	16.2	23.9
NUTM1	"C15orf55, DKFZp434O192, FAM22H, NUT"	ENSG00000184507	"NUT midline carcinoma family member 1"	Q86Y26	15	34343315-34357737	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	127	"testis: 48.9"	"Group enriched"	"Detected in some"	5	"Early spermatids: 35.9;Spermatogonia: 9.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 1.1;NTERA-2: 2.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA040421	Enhanced					NA	NA					"HPA040421: AB_10793965"	"unprognostic (4.14e-2)"	"unprognostic (3.61e-1)"	"unprognostic (2.11e-1)"	"unprognostic (7.38e-2)"	"unprognostic (1.99e-1)"	"unprognostic (8.37e-2)"		"unprognostic (8.66e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.34e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.34e-2)"	"unprognostic (5.97e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.77e-1)"	"unprognostic (4.27e-2)"	"unprognostic (4.79e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.1	48.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.2	0.0	0.1	0.4	0.4	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.0	0.3	0.5	0.3	0.0	0.0	0.4	0.5	0.1	0.2	0.1	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.1	0.3	0.1	2.2	0.6	0.3	0.2	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.6	0.2	0.6	0.2	0.0	0.7	0.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	9.2	0.0	0.0	0.0	0.0	0.0
NUTM2A	FAM22A	ENSG00000184923	"NUT family member 2A"	Q8IVF1	10	87225448-87236908	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Low tissue specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"eosinophil: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HMC-1: 14.5"									HPA064635			Approved	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"HPA064635: "	"unprognostic (1.75e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.03e-1)"	"unprognostic (8.29e-2)"	"unprognostic (5.67e-2)"	"unprognostic (8.08e-2)"	"unprognostic (1.75e-2)"	"unprognostic (6.84e-2)"	"unprognostic (2.46e-3)"	"unprognostic (1.75e-2)"	"unprognostic (7.24e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.24e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.65e-1)"	3.5	1.8	2.8	0.4	2.5	1.7	1.1	1.5	2.9	1.1	1.8			1.3	1.7	2.1	0.9	1.9	0.8	3.0	3.4	2.2	1.5	1.3	1.6	0.9	2.9		3.0	2.4	2.9	2.0	1.3		2.5	1.0		5.9	0.8	2.3	4.4	2.0	0.7	3.6	1.7	1.8	2.4			2.6		0.2	1.4	1.2	0.4	0.0	1.3	0.2	0.0	0.2	0.2	1.4	0.2	0.7	0.0	1.9	0.9	0.9	0.7	1.8	0.8	0.5	0.2	0.8	1.4	0.1	0.0	0.2	1.4	0.0	1.0	0.1	0.3	1.5	1.7	0.4	0.2	0.7	0.6	14.5	0.5	4.2	1.0	1.2	1.1	0.0	2.5	1.8	0.4	0.2	0.7	1.2	2.5	3.2	0.0	0.5	1.7	0.2	0.0	0.5	0.1	1.8	2.8	0.7	0.6	0.6	0.0	0.3	0.9	1.5	0.0	0.2	0.8	0.1	0.0	0.1	0.7	0.9	1.5	0.0	0.0	0.2	1.3	0.1	0.2	0.0	0.4	0.0	0.1	0.0	0.0	0.1	0.2	0.4	0.0	0.2	0.0	0.0	0.2											0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0
NUTM2B	"bA119F19.1, FAM22B"	ENSG00000188199	"NUT family member 2B"	A6NNL0	10	79703227-79714681	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"No human protein/transcript evidence"	"No human protein/transcript evidence"		"Low tissue specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"eosinophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"HMC-1: 6.2"									HPA064635			Approved	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"HPA064635: "	"unprognostic (9.51e-2)"	"unprognostic (6.09e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.10e-1)"	"unprognostic (3.63e-1)"	"unprognostic (6.60e-2)"	"unprognostic (2.47e-2)"	"unprognostic (7.66e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.95e-1)"	"unprognostic (7.79e-3)"	"unprognostic (1.15e-1)"	"unprognostic (9.70e-2)"	"unprognostic (9.97e-2)"	"unprognostic (5.72e-2)"	"unprognostic (5.37e-2)"	"unprognostic (2.32e-2)"	0.9	1.8	2.8	1.6	2.6	3.6	0.6	2.2	3.0	1.1	1.0			0.6	0.9	1.6	0.4	2.3	0.3	2.1	2.8	1.9	1.6	1.1	1.9	1.6	1.7		2.0	2.1	2.2	2.7	0.7		1.6	0.4		3.0	0.7	2.3	2.2	1.2	0.2	1.9	2.0	0.9	4.6			1.1		1.6	0.4	0.7	0.5	0.4	1.0	0.8	0.1	0.1	0.1	1.4	1.4	2.9	2.3	1.0	0.9	1.5	0.6	1.1	0.9	0.9	0.2	3.2	3.2	0.5	0.5	1.3	1.4	0.2	1.4	0.5	2.0	1.2	2.3	0.5	0.8	1.2	1.7	6.2	2.0	1.0	0.4	0.7	2.7	0.0	4.8	3.3	1.8	0.6	2.7	0.4	4.7	3.4	0.0	1.8	0.7	0.5	0.4	1.2	0.4	1.6	3.9	2.1	2.6	3.6	1.1	0.5	3.0	1.7	0.3	0.6	0.5	1.0	0.7	0.2	0.8	0.0	0.3	0.0	0.0	0.0	1.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.5	0.1	0.0	0.4	0.1	0.8	0.4	0.0	0.1											0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0
OLIG2	"BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17"	ENSG00000205927	"Oligodendrocyte transcription factor 2"	Q13516	21	33025845-33029196	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 66.2"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in some"	52	"glioma: 46.9"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	8	"eosinophil: 15.4"	"Lineage enriched"	"Detected in single"	154	"granulocytes: 15.4"	"Cell line enhanced"	"Detected in some"		"HMC-1: 30.0;NB-4: 21.7;THP-1: 18.8;WM-115: 6.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003254, CAB019381"	Enhanced		Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"CAB019381: , HPA003254: AB_1854795"		"unprognostic (5.14e-1)"	"unprognostic (4.56e-1)"		"unprognostic (1.44e-2)"	"unprognostic (8.27e-2)"		"unprognostic (3.24e-2)"	"unprognostic (4.34e-2)"	"unprognostic (4.81e-2)"	"unprognostic (5.41e-2)"		"unprognostic (1.39e-1)"	"unprognostic (5.78e-5)"	"unprognostic (2.76e-1)"			1.3	1.3	24.1	1.4	19.1	1.4	1.3	4.2	66.2	1.3	1.3	41.4	0.0	1.7	1.3	1.3	1.3	1.3	1.3	1.3	23.6	15.6	1.3	1.3	1.3	1.3	20.9	15.5	1.3	1.3	1.3	0.0	1.3	17.1	1.3	1.3	0.0	1.3	1.3	1.3	1.3	1.5	1.3	16.8	1.3	1.4	1.3	16.6	0.0	1.3	0.0	1.3	1.4	0.0	0.0	0.0	15.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.5	0.0	0.0	0.0	0.6	4.3	0.0	0.0	0.0	0.8	30.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	21.7	1.9	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	18.8	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.8	0.0	6.1	1.8	0.0	15.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.1	19.1	4.2	27.6	23.6	15.6	20.9	15.5	17.1	16.6	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
P2RY8	P2Y8	ENSG00000182162	"P2Y receptor family member 8"	Q86VZ1	X	1462572-1537107	"Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 26.7;lymphoid tissue: 19.0"	"Group enriched"	"Detected in some"	5	"B-cells: 29.8;Kupffer cells: 10.2;monocytes: 20.8;T-cells: 20.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 33.9;MOLT-4: 16.7;NB-4: 16.7;RPMI-8226: 20.8;THP-1: 20.8;U-266/70: 28.5;U-698: 55.5;U-937: 17.2"					"Not detected"	"Not detected"			HPA003631	Enhanced					NA	NA					"HPA003631: AB_1079543"	"unprognostic (4.32e-2)"	"unprognostic (3.22e-5)"	"unprognostic (6.31e-2)"	"unprognostic (2.51e-2)"	"unprognostic (1.17e-1)"	"prognostic favorable (7.80e-5)"	"prognostic favorable (1.73e-4)"	"unprognostic (5.27e-3)"	"unprognostic (5.76e-3)"	"unprognostic (5.52e-3)"	"prognostic favorable (6.54e-4)"	"unprognostic (4.29e-2)"	"unprognostic (8.45e-3)"	"unprognostic (2.90e-1)"	"unprognostic (4.00e-2)"	"unprognostic (3.55e-1)"	"unprognostic (2.80e-1)"	2.9	4.8	0.5	8.9	2.2	13.9	8.2	0.9	1.8	4.7	1.6	0.5	0.5	1.3	7.1	0.5	0.8	0.8	1.6	11.8	0.9	0.2	13.5	0.8	2.1	19.0	3.6	1.7	5.8	1.1	1.0	6.9	3.4	2.7	1.6	1.3	0.5	1.6	0.5	1.1	0.4	7.8	0.5	3.9	16.6	2.0	0.5	2.0	0.5	8.1	0.5	16.7	2.7	2.8	18.5	5.8	17.8	7.3	15.6	26.7	18.3	0.1	0.1	0.1	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.2	33.9	0.1	0.0	0.1	0.1	0.0	0.0	0.0	1.3	0.1	0.3	0.3	1.7	0.0	14.8	3.6	0.0	0.0	0.0	0.0	0.3	0.0	10.1	0.3	14.3	0.0	0.0	16.7	16.7	0.2	0.0	0.3	15.1	0.1	20.8	0.0	0.2	0.0	0.2	0.1	0.3	0.1	0.3	0.1	20.8	0.0	0.3	0.3	0.1	0.0	28.5	5.3	55.5	0.0	17.2	0.0	17.8	7.3	12.4	26.7	5.5	24.6	15.4	20.2	25.1	5.8	18.5	16.1	16.5	4.7	15.6	2.2	1.5	15.9	18.3	0.5	2.2	0.9	1.8	0.9	0.2	3.6	1.7	2.7	2.0	0.0	2.6	29.8	0.0	0.3	0.0	0.8	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.2	0.0	0.4	0.1	1.1	0.0	1.9	0.0	0.0	4.3	10.2	0.0	0.0	1.6	1.7	20.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4	0.0	20.1	0.0	0.0
PAFAH1B2		ENSG00000168092	"Platelet activating factor acetylhydrolase 1b catalytic subunit 2"	P68402	11	117144267-117176894	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051836	Approved		Supported	"Nucleoli,Plasma membrane,Cytosol"		NA	NA		1600000	Cytosol	"Nucleoli, Plasma membrane"	"HPA051836: AB_2681630"	"unprognostic (1.08e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.07e-2)"	"unprognostic (3.88e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.21e-3)"	"prognostic unfavorable (9.44e-4)"	"prognostic unfavorable (3.07e-4)"	"unprognostic (1.01e-1)"	"prognostic favorable (4.25e-4)"	"prognostic unfavorable (7.79e-5)"	"unprognostic (8.18e-2)"	"unprognostic (1.11e-2)"	"unprognostic (9.97e-2)"	"unprognostic (3.25e-1)"	"unprognostic (2.46e-1)"	"unprognostic (1.34e-1)"	21.5	34.1	30.6	19.2	29.7	33.5	32.3	43.5	41.3	21.6	20.2	33.3	12.7	21.1	23.4	22.8	23.3	20.8	19.3	26.2	31.9	36.8	24.6	22.5	20.5	17.7	39.3	31.6	23.6	23.0	23.1	24.2	26.9	39.6	22.2	19.6	17.3	19.3	17.4	14.1	20.8	18.0	19.9	51.6	18.3	21.4	29.9	26.3	15.1	30.9	10.8	20.4	25.9	20.3	26.8	21.6	36.8	35.7	18.9	31.4	26.9	15.0	17.2	19.9	28.7	22.2	15.6	15.5	25.3	22.1	14.1	12.9	31.4	33.2	16.2	36.3	30.3	14.1	24.1	28.9	32.7	18.6	14.5	11.1	41.8	15.7	20.1	19.9	14.4	16.0	17.2	25.9	28.1	35.5	15.4	23.0	9.1	22.1	12.4	21.5	9.6	13.9	21.2	18.2	20.9	13.6	15.6	22.5	17.8	21.5	23.5	22.2	29.4	29.2	22.1	9.6	17.6	24.6	12.4	36.8	25.8	17.1	12.6	17.9	3.9	6.0	21.8	10.4	27.7	21.6	32.1	30.8	26.7	24.2	33.3	28.2	26.8	28.0	25.3	21.6	25.4	29.3	31.4	36.8	18.9	35.7	15.8	19.5	26.9	30.6	29.7	43.5	37.8	31.9	36.8	39.3	31.6	39.6	26.3	26.8	33.3	41.0	38.7	108.6	36.9	31.1	68.8	17.4	26.1	62.8	45.2	36.3	39.7	52.6	7.3	54.4	31.6	0.0	34.5	77.2	42.9	53.9	18.5	39.2	38.5	44.5	79.3	57.7	59.6	8.9	42.0	55.7	47.2	49.5	37.2	33.5	72.8	46.7	32.2	44.8	33.5	12.9	46.4	45.1	75.6	101.4	45.7	38.5	39.1	38.8
PALB2	"FANCN, FLJ21816"	ENSG00000083093	"Partner and localizer of BRCA2"	Q86YC2	16	23603160-23641310	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes, Fanconi anemia, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Spermatocytes: 20.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB014895, HPA057000"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB014895: , HPA057000: AB_2683307"	"unprognostic (1.11e-1)"	"unprognostic (5.67e-3)"	"prognostic favorable (2.83e-5)"	"unprognostic (1.43e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.61e-2)"	"unprognostic (2.00e-3)"	"unprognostic (5.18e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.00e-2)"	"prognostic unfavorable (2.35e-5)"	"unprognostic (2.05e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.25e-1)"	"unprognostic (7.20e-2)"	"unprognostic (3.21e-1)"	12.4	9.9	10.7	19.6	11.9	6.8	15.2	16.5	14.1	12.4	14.0	10.8	9.1	14.8	10.9	13.5	17.6	9.6	7.8	10.5	10.0	10.6	13.7	16.1	9.2	13.4	9.7	12.5	15.3	10.6	13.7	16.1	9.1	14.9	10.9	12.7	8.6	11.0	14.7	10.3	17.0	14.1	12.8	10.8	14.1	11.0	16.9	10.5	12.9	12.1	12.0	15.3	13.6	13.3	3.7	3.9	7.2	7.7	3.9	5.5	2.0	12.0	9.3	11.3	7.9	9.4	7.4	10.1	8.7	13.4	14.4	17.5	7.9	12.6	12.7	6.4	6.1	11.1	10.8	10.0	14.7	17.2	7.5	5.8	7.8	12.9	22.4	8.7	14.3	12.7	8.4	15.0	13.6	15.5	8.0	7.6	12.3	16.0	6.9	12.6	11.9	14.7	14.9	25.1	8.8	5.5	17.1	13.8	17.4	11.0	10.8	8.3	8.3	8.9	10.2	11.4	10.3	9.4	9.8	5.5	17.3	6.6	8.5	9.3	8.1	13.1	13.0	11.3	10.5	10.3	7.2	3.3	3.0	4.4	4.2	5.3	3.7	4.9	5.3	3.9	3.1	5.5	4.3	0.2	3.9	7.7	2.8	3.1	2.0	10.7	11.9	16.5	14.1	10.0	10.6	9.7	12.5	14.9	10.5	11.9	3.4	9.4	3.5	0.8	6.2	4.2	5.1	12.0	10.3	3.5	3.9	2.3	3.3	4.3	3.0	2.3	2.6	0.0	4.4	1.7	1.4	1.5	4.7	4.7	3.2	1.6	1.2	3.1	7.0	2.9	4.4	4.0	1.7	9.0	2.6	4.7	6.9	3.4	6.0	4.6	7.1	6.5	2.1	20.2	14.4	2.4	1.0	2.5	4.3	3.7
PATZ1	"dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG"	ENSG00000100105	"POZ/BTB and AT hook containing zinc finger 1"	Q9HBE1	22	31325804-31346232	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047893, HPA048315"	Approved		Supported	Nucleoplasm		No	No			Nucleoplasm		"HPA047893: AB_2680201, HPA048315: AB_2680353"	"unprognostic (3.25e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.88e-3)"	"prognostic favorable (1.06e-4)"	"unprognostic (1.77e-1)"	"unprognostic (8.34e-3)"	"prognostic favorable (8.71e-5)"	"unprognostic (1.14e-1)"	"unprognostic (1.41e-2)"	"unprognostic (1.99e-3)"	"unprognostic (1.76e-1)"	"prognostic favorable (8.54e-8)"	"unprognostic (9.22e-2)"	"unprognostic (2.15e-1)"	"unprognostic (1.51e-1)"	"prognostic favorable (7.79e-6)"	9.6	11.2	13.0	12.7	12.9	12.9	12.1	16.8	16.0	14.2	13.0	21.7	21.8	9.4	19.6	14.4	7.3	22.2	14.1	10.4	14.0	11.8	11.4	11.0	17.4	30.3	15.3	13.4	27.7	16.6	25.4	11.0	8.9	13.6	14.0	6.8	17.5	17.5	17.8	9.1	7.5	11.9	15.6	12.5	14.3	10.5	13.0	15.5	38.5	18.9	8.2	13.8	17.4	14.2	4.7	7.1	4.8	1.8	3.5	5.7	2.0	8.4	10.6	21.8	12.8	5.8	5.3	11.4	2.6	6.6	10.6	9.7	7.4	8.2	18.1	9.4	4.8	3.7	6.6	14.7	7.9	5.4	10.5	13.5	7.6	7.4	15.1	9.5	25.5	10.3	8.3	9.6	6.7	7.5	8.4	8.3	8.9	3.2	7.3	6.7	25.8	16.3	17.5	14.6	15.5	12.6	27.6	9.3	5.9	7.1	18.0	28.5	22.9	6.5	7.9	14.2	7.5	15.7	16.3	5.8	7.1	13.4	4.4	8.7	9.5	6.2	16.5	3.0	3.3	12.1	0.0	1.8	4.8	3.4	1.1	3.5	4.7	2.6	4.4	2.5	3.8	5.7	4.1	0.8	3.5	0.6	7.1	3.7	2.0	13.0	12.9	16.8	16.0	14.0	11.8	15.3	13.4	13.6	15.5	3.0	12.2	2.9	5.4	1.4	15.6	12.2	10.2	10.7	10.3	19.2	7.9	4.3	16.6	11.3	0.4	4.5	2.9	0.0	5.2	1.4	4.9	8.2	5.8	11.3	7.6	20.6	19.7	9.2	6.4	1.3	8.9	5.0	3.3	3.6	9.1	13.3	7.4	3.5	8.1	6.8	14.2	6.5	3.3	0.7	7.2	1.4	0.7	7.4	10.8	5.6
PAX3	"HUP2, WS1"	ENSG00000135903	"Paired box 3"	P23760	2	222199888-222298996	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Deafness, Disease mutation, Proto-oncogene, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 19.1;retina: 39.6"	"Group enriched"	"Detected in some"	8	"Early spermatids: 10.9;Late spermatids: 19.5;Melanocytes: 32.1"	"Cancer enriched"	"Detected in some"	24	"melanoma: 20.3"	"Group enriched"	"Detected in some"	6	"cerebellum: 19.1;pons and medulla: 7.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+ SV40 Large T+: 7.6;BJ hTERT+ SV40 Large T+ RasG12V: 9.1;HBF TERT88: 6.7;RH-30: 13.1;SK-MEL-30: 23.1"	"Group enriched"	"Detected in some"	7	"cerebellum: 3.9;midbrain: 1.6;pons and medulla: 1.4"	"Group enriched"	"Detected in many"	5	"cerebellum: 10.0;midbrain: 11.7;pons and medulla: 3.5"	"HPA063659, HPA069000"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA063659: AB_2685080, HPA069000: AB_2686067"	"unprognostic (2.57e-2)"				"unprognostic (1.48e-2)"	"unprognostic (1.27e-2)"		"unprognostic (1.65e-1)"	"unprognostic (2.61e-2)"	"unprognostic (3.70e-1)"		"unprognostic (6.18e-2)"		"unprognostic (1.41e-1)"	"unprognostic (2.26e-1)"		"unprognostic (9.70e-2)"	0.8	0.1	0.0	0.1	0.8	0.1	2.9	19.1	0.2	0.3	0.1	0.1	0.3	0.1	0.2	0.1	0.1	0.1	0.1	0.3	0.0	0.2	0.1	0.1	0.1	0.2	2.2	0.0	0.1	0.2	0.1	0.0	0.1	7.8	0.4	0.1	39.6	7.9	0.2	8.6	7.9	0.1	0.1	4.2	0.1	0.2	2.9	0.8	0.0	0.1	3.9	0.5	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	5.2	5.1	7.6	9.1	0.0	0.5	0.0	0.0	3.5	0.1	0.0	0.0	0.0	6.7	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	5.4	0.1	0.0	0.0	0.0	13.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	23.1	5.9	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	2.9	0.0	6.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.8	19.1	0.1	0.0	0.2	2.2	0.0	7.8	0.8	0.0	0.0	0.0	0.0	2.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.5	0.9	0.0	32.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.9	0.3	0.4	0.0	0.0	0.0	0.0
PAX5	BSAP	ENSG00000196092	"Paired box 5"	Q02548	9	36833275-37034185	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Spermatogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 21.6;lymphoid tissue: 33.4"	"Cell type enriched"	"Detected in some"	27	"B-cells: 57.6"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	5	"midbrain: 1.6"	"Group enriched"	"Detected in some"	209	"memory B-cell: 20.1;naive B-cell: 21.6"	"Lineage enriched"	"Detected in single"	216	"B-cells: 21.6"	"Group enriched"	"Detected in some"	8	"Daudi: 21.5;REH: 62.5;U-698: 28.2"	"Region enriched"	"Detected in single"	11	"midbrain: 4.7"	"Group enriched"	"Detected in some"	6	"hippocampal formation: 3.8;midbrain: 10.8;pons and medulla: 3.2"	"CAB026269, CAB026869, HPA056394, HPA068498"	Enhanced	Supported	Supported	Nucleoplasm,Vesicles,Cytosol		NA	NA			Nucleoplasm	"Vesicles, Cytosol"	"CAB026269: , CAB026869: , HPA056394: AB_2683116, HPA068498: AB_2685997"	"unprognostic (4.69e-4)"	"unprognostic (3.83e-1)"	"unprognostic (9.13e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.15e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.95e-2)"	"unprognostic (2.48e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.46e-2)"	"unprognostic (1.11e-3)"	"unprognostic (3.15e-1)"	"unprognostic (8.96e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.01e-1)"	0.4	0.2	0.2	33.4	0.2	5.5	0.2	0.2	0.2	0.2	0.7	0.1	0.0	0.0	0.2	0.0	0.7	0.2	0.4	0.2	0.2	0.3	0.5	0.3	0.3	23.2	1.6	0.0	0.2	0.2	0.0	0.5	0.1	0.2	0.3	0.3	0.4	2.5	0.0	0.6	0.2	8.7	0.0	0.3	16.5	0.7	0.9	0.0	2.3	0.4	0.2	30.1	1.3	0.2	21.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.6	0.1	0.1	62.5	0.1	0.1	0.0	0.0	4.4	1.0	0.0	0.2	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.2	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.1	0.0	0.0	0.0	21.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.2	0.2	0.2	0.3	1.6	0.0	0.2	0.0	0.0	0.0	57.6	0.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1
PAX7	Hup1	ENSG00000009709	"Paired box 7"	P23759	1	18631006-18748866	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"skeletal muscle: 12.9;tongue: 12.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"breast cancer: 0.5;cervical cancer: 1.5;lung cancer: 1.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"A549: 3.4;CAPAN-2: 3.8;U-2 OS: 8.2"	"Region enriched"	"Detected in single"	17	"midbrain: 5.5"	"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (8.41e-4)"	"unprognostic (2.07e-1)"			"unprognostic (5.35e-2)"	"unprognostic (3.96e-2)"		"unprognostic (4.21e-1)"						"unprognostic (1.96e-1)"	"unprognostic (1.34e-1)"			0.4	0.1	0.6	0.0	0.6	0.0	0.0	0.0	3.4	0.1	0.0	0.0	0.0	0.1	0.0	2.3	0.5	0.1	0.0	0.0	0.8	0.8	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	2.4	0.0	3.4	0.3	0.0	0.0	0.1	0.1	12.9	0.0	0.1	0.0	1.0	0.0	0.0	0.3	0.0	0.0	0.0	12.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.6	0.0	3.4	0.8	0.8	2.4	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PAX8		ENSG00000125618	"Paired box 8"	Q06710	2	113215997-113278950	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"kidney: 69.3;thyroid gland: 120.5"	"Group enriched"	"Detected in many"	4	"Collecting duct cells: 233.8;Proximal tubular cells: 100.4"	"Group enriched"	"Detected in many"	12	"endometrial cancer: 60.6;ovarian cancer: 63.5;renal cancer: 33.2;thyroid cancer: 122.2"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	8	"EFO-21: 27.1;GAMG: 16.8;RPTEC TERT1: 63.8"	"Region enriched"	"Detected in some"	4	"pons and medulla: 5.8"					"HPA030062, CAB055097, CAB061888, HPA064554"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB055097: AB_2236705, CAB061888: AB_10895719, HPA030062: AB_10603982, HPA064554: AB_2685283"	"unprognostic (2.63e-3)"	"unprognostic (3.80e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavorable (1.75e-5)"	"unprognostic (7.24e-2)"	"unprognostic (5.16e-5)"	"unprognostic (1.56e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.16e-1)"	"unprognostic (4.13e-2)"	"unprognostic (4.00e-2)"	"unprognostic (3.37e-2)"	"unprognostic (3.27e-1)"	"unprognostic (2.37e-1)"	"unprognostic (8.93e-3)"	"unprognostic (1.02e-1)"	0.9	1.4	1.1	0.5	0.4	0.0	0.6	0.2	0.8	3.8	0.4	0.2	11.7	0.1	2.2	15.2	0.6	9.6	0.8	0.6	0.5	0.5	69.3	0.4	0.5	0.7	0.4	0.3	3.8	0.6	0.1	0.7	0.8	1.5	1.1	0.1	0.5	0.5	10.0	0.3	0.5	0.6	0.4	0.8	0.3	0.4	1.9	0.2	0.4	120.5	0.0	0.2	0.8	1.9	4.4	2.8	1.5	3.4	1.9	2.5	1.1	2.9	0.2	0.1	0.0	0.1	0.0	1.0	0.8	2.7	0.2	0.4	1.8	0.5	0.5	27.1	0.2	16.8	0.0	0.5	0.8	0.2	1.2	0.0	0.4	0.2	1.0	0.3	0.0	0.0	0.7	0.1	0.2	0.6	3.3	0.0	0.0	0.4	2.0	0.8	0.6	0.3	1.2	0.1	0.7	1.8	0.0	0.2	0.6	63.8	4.7	0.5	0.0	3.4	0.0	1.8	0.0	0.0	1.1	0.9	4.6	0.1	0.8	2.3	0.4	1.4	0.1	4.0	0.6	0.0	1.5	3.4	0.0	0.6	1.8	1.5	4.4	1.5	1.1	2.8	1.9	2.5	1.5	0.5	1.9	1.3	1.1	0.8	1.1	1.1	0.4	0.2	0.8	0.5	0.5	0.4	0.3	1.5	0.2	3.0	1.3	0.8	1.7	0.6	0.6	0.8	2.5	0.0	4.5	233.8	0.0	2.1	39.7	9.6	1.5	0.5	5.8	0.0	2.6	2.0	1.9	1.0	0.0	0.0	4.5	0.0	4.6	1.3	1.3	3.1	4.6	2.6	0.0	2.8	2.3	3.3	17.3	7.0	0.4	100.4	0.7	6.5	0.1	4.2	5.8	0.6	0.7	1.0	3.7	1.7
PBRM1	"BAF180, PB1"	ENSG00000163939	"Polybromo 1"	Q86U86	3	52545352-52685917	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015629, HPA059373"	Uncertain		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA015629: AB_1855012, HPA059373: AB_2683994"	"unprognostic (1.87e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.91e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.15e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.02e-2)"	"unprognostic (9.54e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.99e-2)"	"unprognostic (4.32e-2)"	"unprognostic (2.89e-3)"	"unprognostic (3.06e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.06e-1)"	24.3	14.8	13.8	20.6	15.9	17.2	24.4	19.1	13.8	18.9	18.5	14.0	22.9	12.2	25.9	13.9	19.9	18.9	13.7	15.9	11.1	10.0	11.7	14.5	14.9	16.5	16.5	8.2	25.1	15.4	14.4	30.6	28.0	14.7	16.1	15.3	12.7	17.5	16.2	21.8	17.2	14.3	21.1	15.6	19.1	14.8	13.1	13.7	51.0	22.0	10.5	17.1	22.4	23.0	6.6	10.7	11.1	8.7	4.6	7.4	1.9	12.5	8.1	29.0	14.2	14.3	14.6	20.3	17.3	11.9	20.0	17.6	9.1	8.5	30.4	2.4	20.3	16.6	8.6	25.1	13.1	24.4	32.5	13.5	28.8	15.3	7.0	20.5	24.0	21.9	13.6	15.2	22.4	14.5	15.8	19.3	24.1	16.4	16.7	20.1	4.2	39.5	7.2	17.6	8.5	13.3	20.7	18.2	15.5	8.3	24.5	19.7	21.8	20.8	5.0	16.5	18.4	9.4	13.9	22.2	18.8	14.3	16.2	21.1	12.1	19.0	28.9	11.6	19.5	18.7	10.1	5.0	11.1	4.8	3.2	4.9	3.6	4.8	5.3	4.8	6.6	7.4	4.7	2.7	4.6	8.7	10.7	4.5	1.9	13.8	15.9	19.1	13.8	11.1	10.0	16.5	8.2	14.7	13.7	38.7	54.1	19.5	31.0	35.9	42.0	48.4	28.1	53.5	38.7	22.7	45.2	31.3	16.6	31.4	28.7	40.3	25.3	23.3	40.4	28.9	31.5	35.3	27.8	37.0	45.9	28.6	33.8	35.0	63.3	14.7	31.7	46.6	45.5	50.5	30.6	28.5	42.9	28.1	54.8	13.9	43.3	25.8	45.3	41.9	32.8	45.0	42.6	34.1	34.5	33.3
PBX1		ENSG00000185630	"PBX homeobox 1"	P40424	1	164555584-164899296	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Sexual differentiation, Steroidogenesis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 2.9"	"Lineage enriched"	"Detected in single"	9	"granulocytes: 2.9"	"Cell line enhanced"	"Detected in many"		"HEL: 30.9;NTERA-2: 30.3;SK-BR-3: 62.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003505, HPA003881, CAB018768"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies,Cytosol"		NA	NA			Nucleoplasm	"Nuclear bodies, Cytosol"	"CAB018768: AB_675783, HPA003505: AB_1855019, HPA003881: AB_1855020"	"unprognostic (2.26e-2)"	"unprognostic (1.95e-1)"	"unprognostic (9.09e-2)"	"unprognostic (2.14e-2)"	"unprognostic (5.21e-3)"	"unprognostic (6.94e-3)"	"unprognostic (5.95e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.65e-1)"	"unprognostic (2.24e-3)"	"unprognostic (2.30e-1)"	"unprognostic (8.81e-2)"	"unprognostic (1.34e-2)"	"unprognostic (2.13e-1)"	"unprognostic (5.07e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.25e-1)"	13.2	17.3	14.9	8.3	15.0	1.4	16.4	14.1	17.4	73.4	26.3	11.2	15.9	13.6	67.2	15.3	20.8	35.1	25.8	12.6	10.9	9.7	15.4	4.2	10.4	2.3	11.6	14.6	35.2	29.4	21.3	12.4	9.6	8.1	27.6	9.3	10.2	19.6	25.1	16.8	6.0	14.6	56.8	8.0	5.1	13.9	9.7	8.7	2.7	17.4	8.5	6.6	32.2	24.7	0.0	0.1	2.9	0.0	0.3	0.2	2.5	1.1	22.6	22.3	6.0	15.1	7.3	1.3	9.5	6.1	2.6	1.8	4.3	4.0	0.0	2.0	12.9	1.4	7.9	8.8	2.5	1.0	1.1	9.4	30.9	18.2	0.0	10.0	0.0	7.9	7.2	0.0	1.6	0.7	5.6	0.1	0.0	0.0	0.0	0.7	14.9	0.0	0.1	30.3	1.3	1.1	0.0	7.4	9.0	1.8	13.5	0.8	13.2	10.9	62.4	0.0	21.3	23.7	0.0	0.1	1.3	3.1	8.8	2.7	2.8	21.3	0.0	0.1	0.0	0.1	2.9	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.7	0.3	0.0	0.1	0.0	2.5	14.9	15.0	14.1	17.4	10.9	9.7	11.6	14.6	8.1	8.7	20.8	15.2	0.9	91.3	20.3	27.6	44.2	91.7	25.4	21.6	31.4	104.1	89.0	28.2	41.5	72.1	39.2	28.0	0.0	58.9	4.5	75.2	44.0	71.4	17.3	8.6	4.8	87.2	60.8	1.6	78.2	59.0	6.8	15.1	1.8	35.4	34.9	31.8	59.6	97.6	49.4	28.8	38.8	62.7	0.9	11.5	24.6	87.5	3.2	39.4	82.1
PCM1	PTC4	ENSG00000078674	"Pericentriolar material 1"	Q15154	8	17922840-18029944	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Cilium biogenesis/degradation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Spermatocytes: 451.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023370, HPA023374, CAB058695"	Enhanced		Enhanced	"Nuclear membrane,Centrosome,Cytosol"		NA	NA			Centrosome	"Nuclear membrane, Cytosol"	"CAB058695: AB_2665588, HPA023370: AB_1855072, HPA023374: AB_1855073"	"unprognostic (1.52e-2)"	"unprognostic (1.77e-2)"	"unprognostic (6.54e-3)"	"unprognostic (3.35e-2)"	"unprognostic (9.52e-2)"	"unprognostic (1.62e-2)"	"unprognostic (1.40e-1)"	"unprognostic (7.74e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.26e-1)"	"unprognostic (2.84e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.76e-2)"	"unprognostic (2.16e-1)"	"unprognostic (4.60e-1)"	"unprognostic (1.34e-1)"	"unprognostic (2.45e-1)"	19.6	19.0	26.2	26.7	40.4	25.1	25.1	29.2	29.0	25.0	21.1	21.6	22.8	12.4	23.3	27.3	16.4	26.4	17.8	23.0	22.9	18.4	18.8	22.0	19.1	21.1	24.5	24.9	29.1	27.0	42.0	35.8	19.8	26.4	20.2	16.3	16.2	19.4	25.3	63.1	17.6	18.3	26.7	27.2	20.8	17.9	80.0	28.0	40.2	28.2	19.1	20.4	27.0	22.6	11.5	14.9	19.9	7.5	11.2	13.0	4.3	20.6	22.1	34.0	45.0	19.2	20.0	17.6	17.5	21.5	18.7	21.1	14.9	12.4	27.1	12.1	17.4	16.1	15.0	21.7	16.1	31.9	8.9	8.4	46.6	15.6	30.3	21.4	20.4	12.0	17.4	17.2	21.7	24.1	16.4	21.4	28.4	31.4	21.1	22.8	10.3	43.6	33.7	28.0	17.3	6.4	26.3	30.4	9.7	15.5	28.8	26.0	19.6	18.7	10.3	26.8	15.2	16.2	29.7	19.1	17.1	14.0	20.8	14.7	9.0	19.9	24.3	14.4	22.5	17.4	19.9	6.0	14.4	11.5	3.8	12.0	11.1	10.4	13.0	5.9	11.5	11.6	11.6	6.4	11.2	7.5	14.9	10.3	4.3	26.2	40.4	29.2	29.0	22.9	18.4	24.5	24.9	26.4	28.0	119.1	118.7	34.0	55.5	30.0	182.6	220.7	38.2	392.1	177.5	82.0	329.9	42.5	24.9	61.5	377.1	62.9	27.3	70.0	51.3	30.8	46.8	39.6	133.4	45.3	37.2	122.3	68.3	61.4	51.5	176.2	85.4	63.1	52.3	59.5	45.1	137.5	50.9	39.3	91.9	20.6	207.3	122.9	58.7	451.7	165.6	33.4	50.6	87.1	43.7	42.1
PDCD1LG2	"B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2"	ENSG00000197646	"Programmed cell death 1 ligand 2"	Q9BQ51	9	5510570-5571254	"Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"Extravillous trophoblasts: 15.1;monocytes: 45.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 25.9;BJ hTERT+: 40.8;HDLM-2: 31.1;TIME: 18.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA013411	Approved		Uncertain	Cytosol	"Secreted - unknown location"	NA	NA		34000000	Cytosol		"HPA013411: AB_1855102"	"unprognostic (3.93e-2)"	"unprognostic (1.90e-1)"	"unprognostic (3.51e-3)"	"unprognostic (6.68e-3)"	"unprognostic (7.66e-2)"	"unprognostic (6.77e-2)"	"unprognostic (5.72e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.37e-3)"	"unprognostic (5.79e-2)"	"unprognostic (5.29e-2)"	"prognostic unfavorable (1.15e-4)"	"unprognostic (5.00e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.01e-1)"	"unprognostic (7.51e-3)"	15.2	1.8	1.2	7.7	1.4	0.2	9.5	0.7	1.2	7.0	1.9	2.3	0.0	0.8	2.9	7.2	3.9	3.8	4.0	5.8	1.2	1.3	2.5	6.4	13.3	10.8	1.6	0.5	4.1	1.8	0.5	1.1	12.9	1.9	5.0	2.5	2.4	2.9	1.7	5.5	3.6	2.5	4.6	3.7	19.5	1.9	4.2	1.2	8.1	3.5	3.5	8.1	6.0	5.4	0.5	0.9	4.1	3.6	0.0	3.0	0.7	2.1	0.0	0.0	0.0	1.8	2.1	0.0	25.9	40.8	12.5	15.2	0.0	0.1	0.0	0.1	10.5	1.8	0.2	0.0	3.5	12.5	31.1	0.0	0.0	0.0	0.0	10.1	0.0	0.0	1.9	0.0	5.8	6.9	3.6	8.2	0.0	0.0	3.1	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.5	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	18.0	9.0	0.5	4.3	7.1	0.4	0.0	0.0	5.1	0.0	1.1	4.1	0.9	0.0	1.4	3.6	1.9	0.5	2.2	0.9	0.9	0.3	0.0	1.0	2.0	0.0	0.5	0.0	3.0	0.7	1.2	1.4	0.7	1.2	1.2	1.3	1.6	0.5	1.9	1.2	6.0	0.3	0.8	0.0	0.9	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.1	0.0	1.9	0.0	0.0	0.2	15.1	2.1	0.1	3.5	0.0	2.8	0.0	0.0	6.7	4.3	0.0	5.5	2.2	1.7	45.9	0.0	0.0	2.1	0.0	2.1	0.0	0.0	0.0	1.4	0.0	0.0	0.9	0.7	0.0	0.0	0.0
PDE4DIP	"CMYA2, KIAA0454, KIAA0477, MMGL"	ENSG00000178104	"Phosphodiesterase 4D interacting protein"	Q5VU43	1	148808181-149048286	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	10	"heart muscle: 106.0;skeletal muscle: 276.2"	"Cell type enhanced"	"Detected in many"	11	"Cardiomyocytes: 631.5;Rod photoreceptor cells: 241.6;Syncytiotrophoblasts: 258.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 63.3;ASC TERT1: 51.5;K-562: 51.7"	"Low region specificity"	"Detected in all"							HPA012678			Supported	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA012678: AB_1855123"	"unprognostic (2.14e-1)"	"unprognostic (3.27e-1)"	"unprognostic (5.31e-2)"	"unprognostic (6.73e-2)"	"unprognostic (7.82e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.17e-1)"	"unprognostic (9.72e-2)"	"unprognostic (7.65e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.23e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.70e-3)"	"unprognostic (1.82e-1)"	"unprognostic (4.14e-2)"	"unprognostic (9.13e-2)"	"unprognostic (2.28e-1)"	4.8	2.9	9.2	4.3	8.3	2.3	9.0	12.1	15.1	4.8	6.2	8.3	5.6	3.8	3.1	11.8	6.1	3.3	5.0	106.0	9.7	7.8	6.6	9.3	5.5	3.8	15.6	8.1	2.3	3.4	13.6	7.7	10.2	9.3	4.6	4.1	7.2	5.4	4.5	276.2	4.1	7.7	3.1	18.5	2.9	4.4	1.7	11.2	1.5	3.1	18.1	3.8	3.6	6.1	12.0	6.7	7.4	5.9	4.7	13.2	4.3	7.9	1.5	2.2	2.4	63.3	51.5	13.2	9.3	8.9	9.1	12.0	7.3	5.0	4.0	2.9	13.4	26.1	4.1	5.4	6.6	15.5	3.0	7.7	2.0	3.3	2.9	16.7	1.8	2.2	36.6	13.2	38.8	21.1	20.9	3.5	3.4	51.7	9.5	16.2	13.5	1.3	1.1	7.9	6.6	3.3	2.9	5.7	1.5	5.4	8.2	10.9	1.0	9.1	26.7	7.3	10.0	7.9	2.3	4.7	10.6	2.4	26.5	20.7	4.2	5.9	6.0	43.3	1.6	6.5	7.4	5.3	4.1	5.4	5.9	5.5	12.0	10.9	7.2	6.7	11.7	8.4	4.6	1.2	4.7	1.9	2.9	13.2	4.3	9.2	8.3	12.1	10.2	9.7	7.8	15.6	8.1	9.3	11.2	47.6	46.3	21.7	9.6	25.5	78.0	631.5	35.7	121.8	61.4	66.3	108.0	166.9	53.0	10.9	30.1	5.7	27.3	0.0	6.1	103.0	37.0	5.3	12.8	70.6	41.3	31.8	41.5	6.2	35.7	38.7	9.8	70.6	52.3	22.6	33.0	44.3	4.9	20.7	9.2	14.7	241.6	32.3	42.4	6.7	16.8	14.3	258.6	12.8	17.8	3.8
PDGFB	"SIS, SSV"	ENSG00000100311	"Platelet derived growth factor subunit B"	P01127	22	39223359-39244751	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Developmental protein, Growth factor, Mitogen"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Endothelial cells: 22.4;Ito cells: 20.9;Pancreatic endocrine cells: 35.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 10.8"	"Lineage enriched"	"Detected in single"	12	"T-cells: 10.8"	"Cell line enhanced"	"Detected in many"		"A-431: 13.6;EFO-21: 29.7;HUVEC TERT2: 22.9;SK-BR-3: 22.7;TIME: 28.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011604, HPA011972, CAB018341"	Supported		Approved	Vesicles	"Secreted to blood"	NA	NA	4390000	98000	Vesicles		"CAB011604: AB_2162180, CAB018341: AB_2162187, HPA011972: AB_1855134"	"unprognostic (4.96e-2)"	"unprognostic (8.94e-3)"	"unprognostic (8.41e-2)"	"unprognostic (2.66e-1)"	"unprognostic (9.84e-2)"	"unprognostic (4.46e-3)"	"unprognostic (4.34e-1)"	"prognostic unfavorable (3.67e-5)"	"unprognostic (3.22e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.05e-1)"	"unprognostic (8.68e-2)"	"unprognostic (1.84e-3)"	"unprognostic (5.12e-3)"	"unprognostic (7.47e-2)"	"unprognostic (6.50e-2)"	"unprognostic (1.03e-1)"	23.5	6.4	10.4	6.4	9.3	0.6	22.5	5.7	13.0	8.3	14.3	12.4	4.2	4.7	10.8	6.5	6.5	5.6	10.8	13.8	9.7	6.1	10.9	3.8	20.8	6.1	14.7	7.3	4.0	8.3	9.2	3.5	37.3	9.6	5.8	3.7	12.1	7.9	8.6	15.2	7.5	6.7	8.9	11.4	5.6	6.2	5.2	10.3	0.8	12.6	8.6	2.3	6.9	5.0	0.0	0.9	0.1	0.4	0.0	10.8	2.3	13.6	1.1	3.6	0.0	0.0	0.0	4.2	0.0	0.1	0.0	0.0	5.4	4.3	0.0	29.7	0.0	1.3	5.1	0.2	1.2	0.0	0.0	0.1	0.3	0.4	1.9	2.0	0.0	7.7	0.0	0.1	0.0	0.2	0.4	22.9	0.0	0.5	2.6	0.8	5.6	0.0	0.0	1.3	3.4	1.4	0.0	0.1	9.2	12.4	0.0	0.1	0.0	0.2	22.7	0.1	2.8	10.3	0.0	28.4	0.0	2.8	0.0	3.1	0.0	0.1	0.1	0.0	0.6	13.1	0.0	0.0	0.0	8.1	0.1	10.8	0.0	4.7	6.1	0.0	0.0	4.1	2.2	0.1	0.0	0.4	0.9	2.4	2.3	10.4	9.3	5.7	13.0	9.7	6.1	14.7	7.3	9.6	10.3	0.0	1.4	0.0	1.1	2.5	0.8	2.8	0.0	1.4	0.0	7.0	0.0	5.6	0.0	12.5	1.1	22.4	0.0	0.0	3.1	5.3	1.3	1.4	0.0	0.8	6.1	0.0	1.7	20.9	1.9	0.0	0.6	8.7	1.7	1.8	0.5	0.3	35.1	0.0	0.0	1.3	0.0	6.5	2.0	0.0	0.2	1.3	3.8	1.3	0.0	0.1
PDGFRA	"CD140a, GAS9, PDGFR2"	ENSG00000134853	"Platelet derived growth factor receptor alpha"	P16234	4	54229097-54298247	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 81.5"	"Group enriched"	"Detected in many"	9	"Fibroblasts: 171.4;Leydig cells: 416.6;Peritubular cells: 384.4"	"Cancer enhanced"	"Detected in all"		"glioma: 30.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"ASC diff: 82.8;ASC TERT1: 38.8;BJ hTERT+: 48.0;fHDF/TERT166: 33.4;HHSteC: 28.0;HSkMC: 70.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004947, CAB018143"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Intracellular and membrane"	NA	NA		150000	"Nucleoplasm, Plasma membrane, Cell Junctions"		"CAB018143: AB_2162351, HPA004947: AB_2732399"	"unprognostic (1.67e-1)"	"unprognostic (9.35e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.60e-1)"	"unprognostic (8.92e-2)"	"prognostic favorable (9.33e-4)"	"unprognostic (1.24e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (7.01e-2)"	"prognostic unfavorable (9.79e-6)"	"unprognostic (9.58e-3)"	"unprognostic (9.87e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.72e-3)"	35.0	12.4	12.6	16.1	7.6	0.9	17.2	2.4	20.1	33.2	19.1	9.2	6.4	9.6	27.6	14.6	21.9	22.5	16.2	15.3	8.9	7.4	22.8	8.4	24.1	26.9	9.2	4.0	81.5	6.8	1.6	2.1	25.1	7.2	18.6	15.2	19.2	8.5	8.3	11.9	7.0	17.4	19.7	8.8	51.6	13.6	19.0	9.3	0.5	11.3	12.8	4.3	35.9	24.6	0.9	0.4	2.5	0.4	0.3	0.8	0.3	0.0	0.0	0.2	0.1	82.8	38.8	0.1	4.3	48.0	0.0	0.1	11.5	0.0	0.1	0.1	33.4	0.1	0.1	3.3	0.0	0.0	0.4	0.1	0.1	0.1	0.2	28.0	0.0	0.0	70.4	0.0	5.5	0.0	0.9	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.2	0.6	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.1	6.7	0.0	0.1	0.0	0.3	0.1	0.0	0.1	15.2	0.5	16.6	0.0	0.0	0.0	0.1	0.4	0.0	0.3	2.5	0.4	0.2	0.5	0.2	0.2	0.6	0.8	0.4	0.0	0.9	0.7	0.4	2.3	0.3	0.3	0.4	0.2	0.3	12.6	7.6	2.4	7.3	8.9	7.4	9.2	4.0	7.2	9.3	0.0	0.3	0.9	0.3	15.1	0.7	4.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	2.9	1.6	3.3	0.0	0.0	5.8	1.2	171.4	0.4	0.0	0.8	2.8	0.0	0.0	38.1	0.6	3.7	416.6	1.6	21.9	8.2	0.0	18.3	12.2	0.0	384.4	0.0	0.4	0.0	13.2	1.1	3.5	13.8	1.1	0.0	0.0	0.8
PDGFRB	"CD140b, JTK12, PDGFR, PDGFR1"	ENSG00000113721	"Platelet derived growth factor receptor beta"	P09619	5	150113837-150155872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Chemotaxis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"Sertoli cells: 1267.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.9;non-classical monocyte: 4.1"	"Group enriched"	"Detected in many"	8	"monocytes: 4.1;T-cells: 2.9"	"Group enriched"	"Detected in some"	4	"ASC diff: 173.0;ASC TERT1: 59.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003842, CAB018144, HPA028499"	Enhanced		Supported	"Golgi apparatus,Vesicles"		NA	NA		35000000	Vesicles	"Golgi apparatus"	"CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018"	"unprognostic (4.75e-2)"	"unprognostic (2.48e-1)"	"unprognostic (5.21e-2)"	"unprognostic (3.60e-2)"	"unprognostic (3.27e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.36e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.57e-3)"	"unprognostic (6.72e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (5.87e-8)"	"unprognostic (3.13e-3)"	"unprognostic (1.25e-2)"	"unprognostic (5.47e-2)"	"prognostic unfavorable (8.11e-4)"	61.8	10.4	8.3	11.0	9.1	0.5	66.1	4.6	10.4	73.1	15.7	6.7	6.9	5.1	44.3	17.3	21.7	26.1	51.7	24.2	8.2	3.9	17.0	4.6	28.9	21.5	7.9	8.1	46.5	7.5	10.4	7.7	46.4	7.7	24.2	6.3	22.9	11.2	19.3	29.8	20.3	11.2	29.8	5.0	19.6	9.2	21.5	6.7	1.4	21.4	16.0	7.3	23.6	35.1	0.4	0.1	0.0	4.1	0.0	2.9	0.6	0.0	0.0	1.0	0.0	173.0	59.9	0.4	6.0	25.1	4.2	7.1	0.6	0.0	0.0	0.8	17.3	2.4	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.4	0.4	24.5	0.0	0.0	27.0	0.0	5.8	0.0	13.5	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	5.0	0.0	0.0	0.0	6.8	2.2	2.9	0.3	0.0	0.0	0.0	4.2	0.0	0.1	0.0	0.0	0.0	2.9	0.6	0.0	0.4	0.1	0.8	0.1	0.1	0.0	1.3	0.0	0.0	4.1	0.0	0.0	0.6	8.3	9.1	4.6	10.4	8.2	3.9	7.9	8.1	7.7	6.7	0.0	0.6	0.0	0.5	21.3	5.0	13.4	0.0	1.4	0.0	1.8	3.9	0.6	0.0	0.0	0.8	16.2	0.0	0.0	0.0	1.0	68.8	0.6	0.0	1.5	1.4	0.0	0.0	6.7	0.0	4.7	153.1	2.2	23.6	1.0	0.0	74.9	0.1	0.0	191.6	0.0	1.1	1267.6	273.4	1.1	1.5	13.4	0.7	1.0	0.4	0.9
PER1	"PER, RIGUI"	ENSG00000179094	"Period circadian regulator 1"	O15534	17	8140472-8156506	"Cancer-related genes, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 23.7;hTCEpi: 27.6;hTERT-HME1: 27.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047947, HPA067064"			Supported	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"HPA047947: AB_2680219, HPA067064: AB_2685774"	"unprognostic (7.64e-2)"	"prognostic favorable (3.89e-4)"	"unprognostic (5.54e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.44e-2)"	"prognostic favorable (2.56e-4)"	"unprognostic (5.28e-2)"	"unprognostic (6.67e-2)"	"unprognostic (6.21e-3)"	"unprognostic (6.87e-2)"	"unprognostic (4.68e-2)"	"unprognostic (7.09e-3)"	"prognostic unfavorable (1.94e-4)"	"unprognostic (2.08e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.34e-2)"	39.4	33.4	13.2	21.6	15.0	27.3	31.3	19.5	23.9	27.8	24.6	20.9	27.8	6.9	19.5	17.2	31.6	25.2	36.9	24.0	13.3	6.3	14.2	18.6	25.8	10.8	15.6	11.3	50.1	61.8	19.3	29.8	12.7	20.1	23.1	8.1	36.6	23.3	43.5	70.3	47.9	16.9	29.3	17.5	16.7	23.6	13.8	17.1	4.6	28.5	33.1	12.1	30.2	25.0	1.6	4.9	3.3	3.6	0.5	2.1	1.2	1.0	3.9	4.5	6.5	14.8	10.9	2.5	1.5	2.8	2.0	2.4	3.9	2.5	7.3	1.2	2.2	2.2	3.1	4.5	23.7	1.4	2.3	5.6	3.8	8.5	1.1	20.4	1.5	5.8	16.3	27.6	3.4	27.0	2.6	4.3	5.6	4.7	10.1	3.6	3.5	4.4	3.0	3.8	1.2	2.6	6.1	2.5	3.8	4.7	0.8	1.9	4.8	3.3	3.8	3.1	1.9	2.8	1.1	7.3	2.3	4.3	0.8	1.3	6.0	2.2	2.5	3.1	1.9	1.6	0.0	3.6	1.7	1.9	2.5	2.1	1.0	1.7	1.2	4.9	1.6	1.6	1.1	3.3	0.5	1.2	0.7	1.1	1.2	13.2	15.0	19.5	23.9	13.3	6.3	15.6	11.3	20.1	17.1	50.6	66.2	20.2	37.2	47.3	37.1	20.0	33.1	30.8	42.1	26.2	92.3	5.0	5.0	4.0	27.7	50.9	21.9	23.3	3.5	3.3	40.1	42.6	67.1	35.2	17.4	19.1	48.1	36.2	45.9	38.0	38.0	57.8	45.5	7.2	12.9	31.6	7.5	14.4	31.8	3.3	48.6	32.3	42.8	5.2	7.8	52.2	11.3	20.8	9.3	9.3
PHF6	"BFLS, BORJ, CENP-31, KIAA1823, MGC14797"	ENSG00000156531	"PHD finger protein 6"	Q8IWS0	X	134373253-134428791	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Epilepsy, Hypotrichosis, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001023	Enhanced		Supported	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA001023: AB_1079606"	"unprognostic (2.38e-3)"	"unprognostic (8.21e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.04e-3)"	"unprognostic (6.03e-3)"	"unprognostic (5.20e-3)"	"prognostic unfavorable (3.38e-4)"	"unprognostic (1.81e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.08e-1)"	"prognostic unfavorable (9.96e-4)"	"unprognostic (1.09e-1)"	"unprognostic (5.96e-2)"	"unprognostic (4.84e-2)"	"unprognostic (7.45e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.29e-2)"	7.4	19.3	10.2	14.1	12.2	6.5	9.7	18.2	13.5	8.7	8.0	11.6	20.3	7.8	9.0	30.1	11.5	7.3	6.1	7.2	11.0	11.1	9.9	7.5	8.4	20.4	12.5	9.3	30.7	10.4	24.1	18.1	8.2	13.3	8.6	9.5	5.4	11.3	16.8	6.2	7.4	10.2	8.1	17.1	17.8	8.1	8.3	14.4	30.2	11.8	6.0	25.0	8.9	9.8	18.4	11.0	5.3	7.4	9.6	9.9	5.0	11.5	9.6	42.3	17.3	7.9	10.1	8.0	11.6	9.3	12.5	15.5	5.7	12.0	18.6	26.7	7.0	12.2	10.4	29.5	13.1	21.1	15.1	13.7	18.0	16.5	6.6	8.4	17.9	10.0	6.7	10.0	13.6	17.0	12.6	17.4	18.2	13.2	9.2	15.3	7.6	28.9	8.9	12.9	15.8	13.0	28.5	15.4	14.1	13.3	14.0	14.7	17.2	8.9	8.2	12.2	13.1	7.7	9.9	13.2	11.7	8.4	14.6	17.8	4.7	10.9	25.1	7.6	21.4	14.5	5.3	6.1	3.7	7.9	6.0	8.5	18.4	8.2	7.1	8.8	12.8	9.9	8.2	2.5	9.6	7.4	11.0	8.3	5.0	10.2	12.2	18.2	13.5	11.0	11.1	12.5	9.3	13.3	14.4	20.8	17.3	24.1	12.5	11.6	21.9	13.7	7.6	16.0	13.6	15.7	17.7	9.9	19.9	12.5	2.6	14.3	7.9	0.0	11.8	6.8	11.3	10.2	23.2	12.7	13.2	17.5	10.9	19.6	12.6	2.1	19.2	15.3	6.8	19.0	13.4	25.6	12.4	15.0	14.5	16.5	18.2	25.8	9.2	4.6	17.9	10.0	3.9	22.0	16.6	11.0
PHOX2B	"NBPhox, Phox2b, PMX2B"	ENSG00000109132	"Paired like homeobox 2b"	Q99453	4	41744082-41748970	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 14.5;brain: 24.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	99	"pons and medulla: 24.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	91	"SH-SY5Y: 53.6"	"Region enriched"	"Detected in single"	17	"pons and medulla: 5.9"	"Region enriched"	"Detected in single"	27	"pons and medulla: 2.0"	"HPA074325, HPA074941"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA074325: AB_2686678, HPA074941: AB_2732272"			"unprognostic (1.01e-1)"								"unprognostic (2.47e-1)"			"unprognostic (5.27e-2)"				0.0	14.5	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.2	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.4	0.0	0.0	0.0	24.8	0.2	1.4	0.8	0.0	0.0	0.0	0.0	3.2	0.5	0.4	0.0	0.9	0.1	0.0	0.1	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	53.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	24.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PICALM	"CALM, CLTH"	ENSG00000073921	"Phosphatidylinositol binding clathrin assembly protein"	Q13492	11	85957684-86069882	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 25.8"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019053, HPA019061"	Enhanced		Enhanced	Vesicles		NA	NA		28000	Vesicles		"HPA019053: AB_1855361, HPA019061: AB_1855362"	"unprognostic (9.27e-3)"	"unprognostic (7.29e-2)"	"unprognostic (3.51e-1)"	"unprognostic (6.83e-2)"	"unprognostic (5.13e-2)"	"unprognostic (1.93e-1)"	"unprognostic (5.36e-3)"	"unprognostic (9.02e-3)"	"unprognostic (9.80e-2)"	"unprognostic (6.27e-3)"	"prognostic unfavorable (6.61e-4)"	"unprognostic (4.31e-1)"	"prognostic favorable (2.02e-6)"	"unprognostic (1.26e-2)"	"unprognostic (5.21e-3)"	"unprognostic (2.52e-1)"	"unprognostic (1.02e-1)"	72.9	24.2	35.6	43.1	51.4	37.1	51.3	30.2	39.7	38.7	35.9	60.0	27.7	39.6	41.6	26.0	41.3	31.5	48.1	41.4	43.7	34.2	63.9	53.8	45.1	35.2	52.0	33.5	38.2	29.7	70.6	23.8	76.7	50.7	29.9	32.0	26.7	31.8	37.0	35.5	35.0	45.3	49.9	70.7	49.5	30.7	22.9	55.1	31.0	30.8	28.5	34.8	44.0	49.2	2.1	7.1	25.8	8.5	3.9	5.3	3.1	29.2	13.9	22.1	15.5	33.9	35.7	41.7	37.7	48.9	29.8	26.3	54.9	39.9	22.8	38.9	60.3	31.2	24.2	23.1	27.5	43.1	6.7	8.3	64.7	19.0	17.4	34.6	15.2	29.2	30.9	29.8	55.8	46.5	50.6	32.2	15.4	41.4	18.8	56.0	17.2	17.7	14.0	12.1	47.2	7.9	12.3	33.4	16.2	57.8	24.7	13.4	10.9	46.2	15.6	12.4	29.0	21.2	12.3	34.9	55.1	19.2	64.9	30.0	6.7	17.7	20.9	13.0	12.0	37.1	3.6	8.5	4.2	3.9	7.2	3.3	2.1	2.9	5.3	7.1	1.4	3.0	2.7	25.8	3.9	7.2	2.5	3.8	3.1	35.6	51.4	30.2	39.7	43.7	34.2	52.0	33.5	50.7	55.1	32.8	63.6	25.0	34.9	103.0	19.5	39.7	33.1	32.1	25.0	68.0	11.8	37.0	26.6	54.1	51.3	74.2	54.8	70.0	32.6	99.4	46.2	37.9	47.3	49.9	74.3	38.1	24.1	74.3	121.6	73.1	33.1	105.1	57.3	46.9	31.2	20.9	64.7	45.6	41.1	65.4	16.5	77.6	77.5	17.1	12.0	84.3	34.6	40.6	25.2	76.6
PIK3CA	PI3K	ENSG00000121879	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha"	P42336	3	179148114-179240093	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Angiogenesis, Phagocytosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009985, CAB017804"	Approved		Supported	Mitochondria,Cytosol		NA	NA			Cytosol	Mitochondria	"CAB017804: , HPA009985: AB_1079610"	"unprognostic (1.81e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.69e-3)"	"unprognostic (6.49e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.57e-3)"	"unprognostic (5.21e-2)"	"unprognostic (4.50e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.48e-1)"	"unprognostic (9.74e-2)"	"unprognostic (3.82e-2)"	20.1	12.3	13.7	11.5	13.4	25.7	22.4	17.1	24.5	12.9	14.0	5.2	5.7	6.5	15.3	7.9	11.6	11.1	13.2	14.2	18.4	9.7	11.7	10.8	13.2	13.8	9.8	15.7	15.4	9.2	24.7	11.6	16.5	16.3	10.7	8.9	7.2	10.9	10.9	15.2	12.0	10.5	12.8	14.4	16.2	10.6	9.3	9.8	29.6	11.0	7.3	13.9	15.1	15.7	6.2	2.6	7.8	3.8	2.4	5.0	1.1	14.6	5.0	8.0	7.4	19.0	22.2	5.9	9.4	12.7	9.3	14.7	4.3	10.9	13.4	16.1	11.2	13.2	6.0	6.6	8.1	13.5	22.4	5.8	18.4	5.5	3.8	9.1	10.3	10.5	14.0	8.6	10.2	11.7	10.4	13.3	9.7	9.1	15.0	13.3	5.8	7.9	9.3	6.4	7.3	6.8	12.0	8.1	16.1	7.3	9.0	4.5	7.7	10.2	9.1	12.2	7.3	15.2	8.9	14.0	8.7	5.7	13.7	9.3	7.3	10.3	24.1	7.9	7.8	5.1	2.1	3.8	1.6	5.0	2.9	3.9	5.8	4.2	2.8	2.2	6.2	4.6	3.8	7.8	2.4	3.0	2.6	4.1	1.1	13.7	13.4	17.1	24.5	18.4	9.7	9.8	15.7	16.3	9.8	29.8	23.2	13.7	15.2	13.1	26.3	15.4	7.6	18.7	17.0	7.0	29.5	8.1	1.7	9.8	1.7	21.4	4.9	0.0	11.9	5.0	18.3	27.3	30.1	17.4	9.5	36.5	2.4	29.4	21.2	1.6	30.2	16.4	13.5	16.2	9.6	15.6	13.1	12.7	37.1	11.2	26.2	25.8	22.1	9.6	7.6	13.0	7.3	14.0	9.2	27.6
PIK3CB	PIK3C1	ENSG00000051382	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta"	P42338	3	138652699-138834938	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Autophagy, Cell adhesion, Endocytosis"	"Kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HEL: 42.0;HMC-1: 66.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB031938, HPA042288, HPA064207"	Approved		Supported	Nucleoplasm,Nucleoli,Vesicles,Midbody		Yes	No			Nucleoplasm	"Nucleoli, Vesicles, Midbody"	"CAB031938: AB_2165408, HPA042288: , HPA064207: AB_2685212"	"unprognostic (4.89e-2)"	"unprognostic (1.42e-2)"	"unprognostic (5.97e-2)"	"unprognostic (7.85e-2)"	"unprognostic (4.89e-2)"	"unprognostic (6.01e-2)"	"prognostic unfavorable (6.42e-4)"	"unprognostic (3.98e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.28e-1)"	"prognostic unfavorable (3.99e-5)"	"unprognostic (2.15e-1)"	"unprognostic (6.18e-3)"	"unprognostic (9.33e-2)"	"unprognostic (7.82e-2)"	"unprognostic (2.79e-1)"	"unprognostic (4.59e-2)"	12.5	9.9	10.6	9.7	20.6	17.4	11.5	29.9	25.0	12.4	14.6	11.9	11.7	13.7	9.6	6.9	15.2	10.9	8.7	12.7	12.2	14.2	22.6	9.3	9.5	9.1	11.9	15.2	8.8	20.3	20.2	10.9	18.1	24.1	13.4	15.7	12.2	14.9	15.9	33.4	19.6	16.4	8.3	12.5	9.9	11.0	6.4	10.7	14.4	37.4	7.1	11.9	13.4	11.0	4.6	9.1	11.3	7.8	1.3	6.5	2.6	23.0	10.0	4.3	3.6	3.9	5.3	29.3	5.4	5.2	5.5	5.9	10.7	8.8	9.3	14.8	5.3	10.6	9.9	5.6	8.6	9.9	11.8	6.3	42.0	6.8	6.4	4.0	10.2	66.6	4.5	6.6	3.8	7.8	9.8	8.3	4.5	16.0	6.9	6.9	10.6	5.9	7.2	6.2	17.0	9.4	4.3	4.5	6.6	8.5	12.8	3.7	2.7	15.0	6.5	19.3	13.2	16.3	24.4	8.7	3.5	4.5	7.7	7.6	11.7	7.6	8.5	8.6	9.9	4.9	7.0	7.8	11.3	4.0	4.5	2.7	4.6	5.2	3.0	9.1	4.1	6.5	4.4	10.0	1.3	4.3	1.4	2.2	2.6	10.6	20.6	29.9	25.0	12.2	14.2	11.9	15.2	24.1	10.7	8.9	14.7	4.7	12.9	16.9	15.4	30.2	12.7	14.7	21.6	17.4	23.6	29.1	5.0	9.4	0.9	8.5	21.3	0.0	16.5	46.3	6.5	23.0	13.9	15.8	13.4	20.6	15.6	11.6	28.8	1.1	3.4	19.7	6.8	14.4	14.9	8.2	15.2	21.8	6.3	18.9	17.9	6.5	6.1	10.7	14.9	20.5	40.0	6.1	12.7	15.3
PIK3R1	"GRB1, p85, p85-ALPHA"	ENSG00000145675	"Phosphoinositide-3-kinase regulatory subunit 1"	P27986	5	68215720-68301821	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction, Protein transport, Stress response, Transport"		"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cardiomyocytes: 241.2;Leydig cells: 159.3;Muller glia cells: 180.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 73.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001216, CAB004268"	Approved		Supported	Cytosol		NA	NA			Cytosol		"CAB004268: AB_628126, HPA001216: AB_1079612"	"unprognostic (5.74e-2)"	"unprognostic (6.58e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.31e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.33e-2)"	"prognostic favorable (8.09e-4)"	"unprognostic (3.78e-3)"	"unprognostic (1.78e-1)"	"unprognostic (2.71e-1)"	"unprognostic (6.10e-2)"	"unprognostic (1.32e-1)"	"unprognostic (4.59e-3)"	"unprognostic (5.66e-3)"	"unprognostic (1.27e-1)"	"unprognostic (5.92e-2)"	"unprognostic (1.54e-1)"	26.2	13.4	26.0	13.0	24.3	51.6	42.3	15.3	50.3	27.1	20.3	12.8	12.8	8.1	41.3	22.1	20.8	33.0	18.1	33.9	24.0	13.4	17.9	46.5	16.3	12.0	22.0	40.8	25.8	6.8	22.3	9.4	15.0	18.2	15.2	10.8	8.7	54.6	16.2	48.9	19.1	16.1	36.3	17.6	18.8	13.1	7.6	23.6	16.2	12.8	8.5	10.8	25.2	24.4	2.2	2.1	10.6	4.1	8.2	14.8	4.0	1.1	2.1	6.4	19.1	73.1	21.4	2.8	6.1	2.8	2.3	2.5	5.3	1.9	5.6	10.5	8.4	1.1	2.6	1.8	12.4	3.0	23.5	2.3	6.7	1.8	4.3	24.6	6.9	5.4	22.6	28.2	4.3	22.9	1.1	3.1	6.6	1.0	4.3	2.1	2.9	16.7	2.7	1.8	3.8	1.1	15.8	3.0	4.4	3.1	12.6	1.2	5.8	1.0	1.6	4.0	3.9	9.2	4.9	3.7	2.8	2.8	4.6	3.8	4.8	7.1	6.5	3.0	8.6	2.0	10.6	1.2	5.9	9.2	1.7	12.7	1.2	11.5	8.4	2.1	2.2	14.8	10.8	1.5	8.2	4.1	0.9	8.5	4.0	26.0	24.3	15.3	50.3	24.0	13.4	22.0	40.8	18.2	23.6	47.6	25.6	14.3	14.9	12.8	45.1	241.2	28.1	12.0	27.3	5.2	23.6	12.3	61.3	13.7	9.4	23.1	20.0	0.0	8.1	13.0	36.6	8.2	66.0	142.1	25.9	46.1	9.2	39.9	52.0	6.8	159.3	29.5	32.1	21.6	24.8	180.6	9.7	19.3	114.9	31.6	85.9	19.4	26.7	0.9	2.6	8.9	8.4	132.3	21.7	6.0
PIM1	PIM	ENSG00000137193	"Pim-1 proto-oncogene, serine/threonine kinase"	P11309	6	37170203-37175426	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Cell cycle"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Suprabasal keratinocytes: 199.7;Urothelial cells: 399.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 64.6"	"Group enriched"	"Detected in all"	5	"granulocytes: 64.6;T-cells: 19.0"	"Cell line enhanced"	"Detected in many"		"HEL: 35.7;HMC-1: 66.4;K-562: 30.6;U-698: 119.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003941, CAB017040"	Uncertain		Supported	Nucleoli,Cytosol		NA	NA			Cytosol	Nucleoli	"CAB017040: , HPA003941: AB_1079618"	"unprognostic (1.25e-2)"	"unprognostic (4.77e-1)"	"unprognostic (3.61e-2)"	"prognostic unfavorable (9.73e-4)"	"unprognostic (1.91e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.75e-1)"	"unprognostic (4.64e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.65e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.14e-3)"	"unprognostic (8.16e-3)"	"unprognostic (1.04e-1)"	"unprognostic (5.26e-3)"	"unprognostic (2.90e-1)"	39.3	5.4	7.4	18.5	8.9	80.9	20.1	8.1	9.9	23.0	17.9	4.7	4.2	17.9	15.4	9.8	56.3	21.6	24.7	20.8	8.2	3.7	7.5	24.5	14.5	35.7	7.4	2.2	20.0	9.6	2.0	5.6	28.7	12.7	15.6	8.8	6.9	12.8	4.5	26.5	31.3	26.1	31.6	10.7	21.4	12.1	6.8	7.6	15.0	7.2	20.1	28.8	32.6	31.2	1.7	1.4	64.6	1.7	8.4	19.0	8.5	3.0	1.3	2.0	1.1	4.7	2.5	24.0	1.1	3.4	2.3	3.6	4.6	4.3	6.2	1.7	1.3	5.1	3.6	2.1	3.3	2.1	28.1	1.4	35.7	1.3	5.9	4.8	0.6	66.4	8.5	4.1	2.1	1.4	2.5	0.6	1.5	30.6	10.0	0.3	0.8	1.9	3.2	3.8	5.7	2.0	4.8	3.7	7.3	0.6	18.8	10.0	2.0	2.4	0.3	0.6	4.9	0.5	1.0	1.2	1.3	4.0	6.0	1.3	4.7	2.5	119.4	0.5	9.0	1.3	64.6	1.7	24.4	14.7	1.6	19.0	1.7	13.1	12.9	1.4	1.3	11.9	9.0	14.1	8.4	0.9	0.4	9.4	8.5	7.4	8.9	8.1	9.9	8.2	3.7	7.4	2.2	12.7	7.6	20.8	23.1	27.2	134.9	113.6	4.2	17.3	12.7	4.0	22.7	8.7	0.0	27.3	5.0	30.7	3.8	14.3	33.2	46.7	15.5	92.9	73.9	69.5	46.4	27.1	44.8	14.3	35.6	9.2	40.0	10.4	7.5	45.8	42.2	101.0	11.9	4.3	37.7	17.5	2.8	13.0	0.9	0.0	57.5	3.3	34.5	199.7	67.5	126.4	6.6	399.5
PLAG1	ZNF912	ENSG00000181690	"PLAG1 zinc finger"	Q6DJT9	8	56160904-56211324	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Bipolar cells: 24.0;Horizontal cells: 30.2;Rod photoreceptor cells: 28.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 13.1;ASC TERT1: 17.5;HSkMC: 12.3;hTERT-HME1: 12.8"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA072290			Supported	"Nucleoplasm,Nuclear speckles,Centrosome,Cytosol"		NA	NA			"Nucleoplasm, Nuclear speckles"	"Centrosome, Cytosol"	"HPA072290: AB_2686508"	"unprognostic (1.89e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.22e-3)"	"unprognostic (1.63e-4)"	"unprognostic (6.81e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.63e-3)"	"unprognostic (8.56e-2)"	"unprognostic (1.18e-1)"	"unprognostic (7.99e-2)"	"unprognostic (3.42e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.32e-3)"	"unprognostic (2.83e-2)"	"unprognostic (3.94e-1)"	"unprognostic (1.21e-2)"	"unprognostic (6.14e-2)"	1.9	3.6	2.4	3.5	2.9	2.1	2.5	11.0	2.7	7.6	3.8	4.1	9.0	3.4	3.4	9.8	2.0	7.5	2.1	6.8	1.9	1.8	3.7	1.2	4.6	6.7	4.8	2.1	11.6	2.2	2.1	17.8	8.0	4.6	5.1	1.6	7.9	7.5	9.2	1.4	3.4	5.5	2.5	6.3	6.2	3.0	5.2	4.5	11.7	3.5	1.5	5.2	4.8	7.0	3.5	0.2	1.1	0.5	0.7	4.6	1.0	1.5	0.0	9.6	0.1	13.1	17.5	3.0	4.3	5.5	2.0	0.9	0.6	5.0	0.2	4.2	2.3	0.5	0.3	2.7	5.7	2.1	0.1	5.9	6.1	0.5	1.4	2.8	2.0	1.9	12.3	3.2	1.1	12.8	5.6	3.8	4.3	2.6	0.1	4.2	0.0	0.5	3.6	2.8	0.4	1.4	4.7	0.7	3.7	2.6	0.5	0.1	0.0	0.1	0.0	0.3	6.8	0.1	1.9	5.7	3.0	3.8	4.8	1.0	1.5	1.1	2.3	3.4	0.7	0.8	1.1	0.1	1.1	0.3	0.1	0.2	3.5	1.0	0.6	0.1	2.0	4.6	4.3	1.0	0.7	0.5	0.2	0.2	1.0	2.4	2.9	11.0	2.7	1.9	1.8	4.8	2.1	4.6	4.5	6.0	2.7	6.2	2.3	0.9	24.0	9.4	2.5	1.4	2.3	5.2	23.6	6.8	0.0	0.6	4.6	3.3	2.1	0.0	1.2	3.6	3.7	2.8	1.1	0.5	4.5	30.2	5.2	19.6	1.3	4.5	14.1	1.9	15.1	0.0	3.0	18.4	1.2	0.9	9.6	0.5	28.0	0.0	0.7	4.3	6.8	0.6	5.9	1.0	1.6	5.3
PLCG1	"NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1"	ENSG00000124181	"Phospholipase C gamma 1"	P19174	20	41136960-41196801	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction, Lipid degradation, Lipid metabolism"	"Hydrolase, Transducer"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	7	"gdT-cell: 5.9;MAIT T-cell: 8.0;memory CD4 T-cell: 5.2;memory CD8 T-cell: 4.9;naive CD4 T-cell: 5.7;naive CD8 T-cell: 5.4;NK-cell: 4.0;T-reg: 4.4"	"Group enriched"	"Detected in many"	8	"NK-cells: 4.0;T-cells: 8.0"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004277, HPA036681, HPA036682"	Approved		Enhanced	Cytosol		NA	NA			Cytosol		"CAB004277: AB_628119, HPA036681: AB_2675245, HPA036682: AB_2675246"	"unprognostic (2.77e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.65e-1)"	"unprognostic (4.31e-2)"	"unprognostic (5.82e-2)"	"unprognostic (2.09e-2)"	"unprognostic (4.45e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.16e-1)"	"prognostic favorable (4.72e-4)"	"unprognostic (3.32e-1)"	"unprognostic (2.73e-3)"	"unprognostic (1.82e-1)"	"unprognostic (2.65e-1)"	"unprognostic (9.27e-2)"	"unprognostic (2.79e-2)"	20.2	15.1	25.1	20.9	22.1	8.3	34.9	52.6	26.8	19.9	13.9	23.4	12.5	16.5	27.6	13.9	13.5	17.0	18.7	20.9	25.4	13.6	15.3	6.8	19.3	30.7	18.5	20.5	28.7	9.1	16.9	14.2	22.2	18.7	18.4	13.2	20.0	13.2	20.6	13.4	22.3	17.1	22.2	15.4	20.1	12.4	19.9	23.9	48.1	28.5	11.9	21.9	17.1	21.1	0.7	0.0	0.0	0.0	4.0	8.0	3.3	5.4	6.9	33.2	24.3	13.3	9.3	10.6	8.9	11.5	18.0	15.3	16.6	1.8	12.1	11.0	9.7	18.9	10.1	14.4	16.0	10.5	3.4	7.7	0.8	11.5	19.5	10.1	4.7	3.3	11.9	9.0	13.3	10.4	16.3	20.0	26.0	9.0	8.0	16.2	40.4	29.2	3.7	12.3	7.0	12.7	23.3	24.2	5.9	9.9	10.0	11.8	22.5	16.0	7.5	16.0	19.4	8.7	5.6	21.6	43.1	14.0	13.7	10.8	8.9	3.9	10.0	10.2	5.2	17.8	0.0	0.0	0.0	5.9	0.0	8.0	0.3	5.2	4.9	0.0	0.7	5.7	5.4	0.0	4.0	0.0	0.0	4.4	3.3	25.1	22.1	52.6	26.8	25.4	13.6	18.5	20.5	18.7	23.9	14.9	6.5	0.8	1.8	4.9	3.7	9.2	0.0	1.4	3.4	3.5	9.8	1.3	0.0	2.7	5.1	15.8	6.4	0.0	1.4	1.6	6.1	1.9	1.1	2.5	3.2	3.2	1.7	13.5	2.2	5.3	14.1	1.7	3.3	1.0	9.8	7.2	2.8	3.7	17.3	2.4	4.6	12.9	5.1	11.6	11.5	6.0	0.7	6.9	5.1	0.9
PML	"MYL, RNF71, TRIM19"	ENSG00000140464	"Promyelocytic leukemia"	P29590	15	73994673-74047812	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Antiviral defense, Apoptosis, Biological rhythms, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008312, CAB010194, CAB016304"	Supported		Enhanced	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"CAB010194: AB_2166848, CAB016304: AB_628162, HPA008312: AB_1079643"	"prognostic favorable (3.24e-4)"	"unprognostic (4.83e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.58e-3)"	"unprognostic (7.53e-3)"	"unprognostic (1.58e-1)"	"unprognostic (2.35e-2)"	"unprognostic (5.30e-3)"	"unprognostic (4.54e-3)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (3.29e-4)"	"unprognostic (2.67e-2)"	"prognostic unfavorable (6.27e-8)"	"unprognostic (1.58e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.02e-1)"	"unprognostic (8.99e-2)"	46.2	15.4	13.5	29.9	13.0	30.0	50.0	11.4	17.2	24.7	21.9	8.3	22.1	16.9	29.4	22.1	19.3	23.0	25.6	17.6	10.7	7.5	20.5	12.9	37.2	27.3	11.9	12.4	21.2	11.0	9.6	15.0	22.4	16.1	21.2	8.7	14.6	38.0	27.7	18.7	24.2	19.6	20.1	14.3	25.9	21.4	8.7	13.1	25.3	25.9	23.3	23.0	20.7	35.6	11.8	12.9	19.1	18.2	12.7	13.2	7.8	13.8	5.3	4.6	4.5	13.3	18.8	16.0	7.2	12.9	22.4	26.0	5.5	25.2	6.2	25.5	12.9	21.5	25.7	6.3	14.5	3.2	21.8	9.7	13.5	8.3	6.0	15.4	12.8	12.4	35.3	10.5	15.1	7.9	16.6	15.6	10.3	11.3	11.2	13.2	6.5	10.4	20.0	5.0	2.9	9.6	8.1	5.6	11.6	25.1	23.2	4.0	4.4	11.5	6.4	17.2	4.3	5.0	10.7	25.9	22.7	6.2	11.3	14.4	11.7	7.3	3.0	15.7	16.3	7.3	5.4	12.7	19.1	12.4	18.0	9.6	11.8	9.9	13.2	12.9	9.8	8.1	8.2	11.0	12.7	18.2	8.3	12.9	7.8	13.5	13.0	11.4	17.2	10.7	7.5	11.9	12.4	16.1	13.1	14.9	13.5	14.1	13.0	20.4	7.6	8.9	7.6	8.1	5.7	5.2	2.0	7.9	6.6	21.2	3.3	33.9	11.5	0.0	16.4	12.5	16.8	16.3	11.5	8.9	25.8	7.9	13.7	28.3	18.0	3.6	25.6	16.2	6.8	25.2	12.1	10.3	42.2	9.3	22.6	11.4	5.2	38.8	18.4	1.1	3.6	17.1	4.1	15.7	10.8	22.2
PMS2	"H_DJ0042M02.9, HNPCC4, MLH4, PMSL2"	ENSG00000122512	"PMS1 homolog 2, mismatch repair system component"	P54278	7	5973239-6009125	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes, Disease mutation, Hereditary nonpolyposis colorectal cancer, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010235, HPA066490, HPA070310"	Approved		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB010235: AB_2167281, HPA066490: AB_2685677, HPA070310: AB_2686250"	"unprognostic (5.13e-2)"	"unprognostic (6.55e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.43e-3)"	"unprognostic (5.14e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.02e-1)"	"unprognostic (7.43e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.86e-1)"	"unprognostic (7.38e-2)"	"prognostic favorable (1.23e-5)"	"unprognostic (5.31e-2)"	"unprognostic (2.01e-2)"	"unprognostic (3.67e-2)"	"unprognostic (2.81e-2)"	6.3	7.4	8.7	6.0	19.8	3.6	8.1	15.5	21.2	6.2	6.0	11.5	6.9	6.4	6.4	6.3	7.5	7.5	5.0	5.3	9.0	10.3	14.2	5.8	5.5	9.1	8.4	9.5	7.5	7.1	16.6	7.1	5.9	16.2	7.0	6.2	8.0	7.1	7.8	5.7	14.8	6.8	7.1	7.5	6.9	6.1	4.8	5.8	7.5	12.4	5.7	10.7	7.7	6.5	6.2	5.8	7.2	7.9	4.0	9.3	6.3	9.7	10.6	8.5	21.2	6.7	9.9	7.3	5.2	4.0	5.1	4.1	9.2	7.0	18.3	6.2	7.5	11.5	13.4	12.7	3.4	5.5	7.2	5.2	8.0	8.6	6.6	11.4	9.8	5.5	10.4	9.7	4.0	15.2	7.3	9.4	8.7	14.9	8.9	8.4	9.0	2.9	7.0	8.6	4.4	6.5	10.0	10.3	9.3	10.7	7.3	7.8	16.8	10.2	14.9	11.2	13.2	18.5	6.9	8.0	6.5	14.5	9.5	9.4	12.0	20.0	18.5	4.5	9.7	14.8	7.2	5.4	3.1	8.4	7.9	9.3	6.2	6.6	7.2	5.8	5.6	8.8	6.2	2.4	4.0	3.2	5.3	6.4	6.3	8.7	19.8	15.5	21.2	9.0	10.3	8.4	9.5	16.2	5.8	11.9	5.1	17.2	8.2	4.4	12.6	2.8	5.1	6.7	7.9	10.4	21.6	7.8	29.9	4.7	6.9	7.4	2.0	0.0	2.9	5.4	5.5	8.4	4.7	9.6	4.5	28.6	5.2	7.4	7.3	5.6	11.8	4.9	6.8	5.4	2.3	5.2	3.5	2.9	9.6	32.0	14.2	25.8	6.6	24.2	10.2	7.0	10.6	8.5	2.6	10.2
POLD1	"CDC2, POLD"	ENSG00000062822	"DNA polymerase delta 1, catalytic subunit"	P28340	19	50384204-50418016	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA excision, DNA repair, DNA replication"	"DNA-binding, DNA-directed DNA polymerase, Exonuclease, Hydrolase, Nuclease, Nucleotidyltransferase, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Paneth cells: 38.7;Spermatogonia: 26.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004375, HPA046524"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB004375: AB_675487, HPA046524: AB_2679684"	"unprognostic (2.45e-1)"	"unprognostic (7.02e-3)"	"unprognostic (1.59e-1)"	"unprognostic (4.35e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.85e-2)"	"prognostic unfavorable (2.87e-6)"	"unprognostic (4.12e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.83e-1)"	"unprognostic (5.08e-1)"	"unprognostic (3.92e-3)"	"unprognostic (4.01e-3)"	"unprognostic (1.28e-2)"	"unprognostic (1.61e-1)"	"unprognostic (2.89e-1)"	"unprognostic (3.70e-2)"	7.9	5.7	5.4	18.3	9.9	31.6	6.6	9.4	5.4	8.2	10.0	6.1	5.9	6.8	9.5	7.2	11.3	6.9	5.2	5.5	4.4	3.2	7.6	9.3	10.9	15.7	7.0	3.6	8.2	8.4	5.2	5.1	10.9	6.7	6.3	5.2	4.9	8.1	5.4	7.2	13.1	9.9	6.2	7.7	14.1	6.5	13.2	6.5	27.4	12.1	8.1	14.2	5.9	7.8	9.3	10.5	2.1	8.5	5.4	7.3	5.6	18.2	25.2	13.8	7.9	1.8	1.5	14.2	11.4	5.0	14.1	17.9	13.7	14.5	26.2	6.4	3.4	6.3	15.0	16.3	12.4	4.8	22.1	43.8	22.8	24.4	18.0	1.6	21.7	20.1	2.9	3.8	12.7	3.8	3.0	7.2	22.0	24.5	20.4	5.8	12.3	33.5	33.9	16.3	11.8	18.3	33.3	23.2	23.0	4.5	17.5	14.4	13.0	11.3	13.9	2.6	5.2	7.6	20.6	5.6	7.1	23.2	7.7	20.0	19.2	31.6	28.0	7.8	24.5	7.0	1.6	6.2	2.1	7.3	7.8	6.2	7.8	6.5	5.9	5.7	9.3	6.5	5.9	1.1	5.4	8.5	10.5	4.5	5.6	5.4	9.9	9.4	5.4	4.4	3.2	7.0	3.6	6.7	6.5	3.0	3.8	3.7	1.7	5.7	3.3	2.8	2.5	2.7	3.4	3.5	5.9	12.2	0.0	4.4	1.7	2.6	4.6	0.0	3.4	11.7	4.1	1.3	0.0	2.1	13.6	0.0	6.9	1.8	6.3	1.1	2.8	5.0	5.0	3.6	5.3	1.2	3.9	38.7	4.9	2.2	4.1	0.0	2.1	10.9	26.7	4.5	6.4	4.3	10.0	0.6
POLE	POLE1	ENSG00000177084	"DNA polymerase epsilon, catalytic subunit"	Q07864	12	132623753-132687365	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Sertoli cells: 25.8;Spermatocytes: 25.4"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 34.8"	"Cell type enhanced"	"Detected in some"		"NK-cell: 4.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA058210, HPA067385"			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"HPA058210: AB_2683639, HPA067385: AB_2685830"	"unprognostic (1.60e-1)"	"unprognostic (1.77e-3)"	"unprognostic (2.00e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.01e-2)"	"unprognostic (3.96e-3)"	"unprognostic (2.23e-1)"	"prognostic unfavorable (1.44e-4)"	"unprognostic (7.12e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavorable (3.19e-8)"	"unprognostic (8.60e-2)"	"unprognostic (3.18e-1)"	"unprognostic (1.28e-1)"	"unprognostic (9.95e-2)"	6.1	3.4	6.7	10.2	4.4	29.3	6.2	34.8	14.4	7.0	6.6	2.0	7.6	7.3	6.1	4.4	7.5	6.2	6.5	4.7	5.6	1.6	3.8	8.6	5.4	8.2	3.3	4.3	8.7	6.8	3.6	3.1	6.5	5.1	6.8	7.7	4.3	8.7	7.4	8.9	17.9	8.5	6.8	3.7	16.7	7.8	25.6	4.4	29.8	5.1	6.0	10.3	6.7	8.7	0.5	1.7	0.8	0.8	4.8	0.7	0.5	11.2	15.0	22.3	10.6	4.7	3.7	19.9	11.5	5.2	13.8	10.1	18.2	6.7	12.9	4.9	6.2	5.3	15.7	15.5	7.8	8.4	6.0	19.6	20.4	19.4	8.9	0.9	15.9	11.7	2.8	3.1	14.4	4.7	3.8	4.8	16.6	22.8	7.3	6.8	18.2	26.1	29.2	17.3	5.3	9.0	21.7	12.6	5.8	4.4	18.4	18.6	10.7	13.4	11.0	2.5	11.2	16.2	9.9	4.4	12.6	12.9	9.5	11.6	9.7	6.5	20.3	6.9	22.0	8.9	0.0	0.3	0.8	0.5	0.1	0.7	0.5	0.3	0.4	0.7	0.3	0.5	0.3	0.1	4.8	0.8	1.7	0.6	0.5	6.7	4.4	34.8	14.4	5.6	1.6	3.3	4.3	5.1	4.4	0.0	7.9	4.5	3.5	5.0	8.1	5.6	0.0	2.7	0.0	1.8	0.0	6.2	0.0	2.1	6.5	3.0	4.7	0.0	2.7	9.0	4.7	3.7	2.3	8.9	10.4	0.0	6.9	12.9	7.9	7.0	6.4	3.2	5.0	1.0	6.7	3.7	2.4	5.8	3.2	0.8	5.0	25.8	3.3	25.4	7.9	6.8	3.3	5.7	9.8	2.5
POLQ	POLH	ENSG00000051341	"DNA polymerase theta"	O75417	3	121431427-121546641	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 9.5;lymphoid tissue: 21.4"	"Cell type enhanced"	"Detected in some"	10	"Club cells: 3.4;Extravillous trophoblasts: 2.8;Spermatocytes: 7.0;Spermatogonia: 3.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.6"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"cerebellum: 5.2"	HPA053359			Supported	"Nucleoplasm,Golgi apparatus,Cytosol"		NA	Yes			Nucleoplasm	"Golgi apparatus, Cytosol"	"HPA053359: "	"unprognostic (1.59e-1)"	"unprognostic (4.18e-2)"	"unprognostic (2.66e-2)"	"prognostic unfavorable (5.46e-5)"	"unprognostic (2.70e-1)"	"unprognostic (6.23e-3)"	"unprognostic (3.09e-5)"	"unprognostic (8.55e-3)"	"unprognostic (1.09e-4)"	"unprognostic (2.86e-1)"	"unprognostic (5.59e-5)"	"unprognostic (2.06e-3)"	"unprognostic (0.00e+0)"	"prognostic favorable (1.04e-4)"	"unprognostic (1.76e-1)"	"unprognostic (6.01e-2)"	"unprognostic (5.76e-2)"	0.5	0.8	0.2	8.2	0.7	9.5	0.6	0.6	0.4	0.9	3.5	0.2	0.8	2.0	0.9	0.6	6.0	0.3	0.4	0.8	0.3	0.2	0.4	0.6	0.9	4.7	0.3	0.0	0.4	0.4	0.0	0.2	2.8	0.3	0.4	3.7	0.1	1.1	0.8	1.2	2.4	3.9	0.5	0.4	2.6	1.1	5.8	0.6	21.4	0.3	5.6	7.5	0.6	1.7	0.5	1.1	1.6	0.4	0.0	0.4	0.0	13.5	9.2	7.9	5.6	0.7	0.9	7.2	6.4	2.5	7.6	10.2	7.3	5.0	16.1	2.9	3.5	9.2	10.7	9.3	4.1	12.9	4.7	5.1	10.3	5.7	4.5	0.0	11.1	9.5	0.1	0.3	6.9	4.3	1.3	3.7	6.0	6.8	12.3	7.9	5.2	10.0	6.5	7.5	4.1	4.5	8.5	9.5	5.7	2.4	7.8	4.3	3.9	7.4	4.0	2.6	7.2	3.7	11.1	2.9	6.7	8.8	2.6	8.3	6.2	5.0	16.7	3.2	8.3	4.9	1.6	0.2	0.0	0.3	0.2	0.0	0.3	0.4	0.3	0.4	0.5	0.0	0.2	0.0	0.0	0.4	1.1	0.1	0.0	0.2	0.7	0.6	0.4	0.3	0.2	0.3	0.0	0.3	0.6	0.0	0.3	0.0	0.4	0.8	0.3	1.4	0.0	1.4	3.4	0.0	0.0	0.9	0.0	0.1	0.3	0.0	0.4	0.0	0.0	2.8	0.7	0.3	0.0	0.0	1.9	0.0	0.0	0.0	0.6	0.2	0.3	1.5	0.0	1.0	0.4	0.5	0.3	0.3	0.0	0.1	0.1	0.0	0.5	7.0	3.3	0.1	0.2	0.9	0.9	0.9
POT1	"DKFZp586D211, hPot1"	ENSG00000128513	"Protection of telomeres 1"	Q9NUX5	7	124822386-124929983	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Spermatocytes: 27.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											HPA068538			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA068538: AB_2686001"	"unprognostic (1.39e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.04e-1)"	"unprognostic (5.71e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.38e-3)"	"unprognostic (7.88e-2)"	"unprognostic (2.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.48e-2)"	"unprognostic (9.89e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.75e-2)"	"unprognostic (4.77e-3)"	"unprognostic (7.42e-2)"	12.0	13.2	11.1	8.3	14.3	6.2	15.8	13.0	16.6	13.4	10.1	16.0	12.0	7.8	17.0	13.4	10.1	12.6	11.3	11.2	15.5	11.3	16.6	14.7	9.9	14.0	15.0	12.4	15.7	9.4	15.5	29.6	11.1	16.4	12.0	9.7	12.2	8.7	10.1	9.5	8.0	8.8	13.1	16.4	13.6	9.5	15.8	14.8	17.9	21.5	9.3	12.9	13.6	9.8	4.8	3.6	2.7	3.3	5.2	7.4	2.7	12.9	5.5	8.2	6.3	5.5	10.3	5.8	7.3	8.6	8.3	12.6	4.5	13.1	11.7	5.9	5.5	11.6	5.1	9.0	7.4	13.2	15.1	13.1	11.4	5.5	4.8	12.4	11.0	6.8	7.3	8.9	7.7	12.1	9.6	10.5	4.8	20.2	28.1	9.3	2.5	14.6	11.6	9.3	8.4	9.1	8.7	8.6	16.7	7.2	7.2	8.8	11.7	7.4	9.9	10.3	13.2	4.4	10.6	3.4	10.0	4.4	12.1	9.6	15.6	15.9	16.6	10.1	12.6	12.4	0.9	3.1	2.7	4.3	3.3	6.3	4.8	4.5	5.0	3.1	3.4	7.4	5.5	0.7	5.2	3.0	3.6	4.4	2.7	11.1	14.3	13.0	16.6	15.5	11.3	15.0	12.4	16.4	14.8	6.0	5.5	4.2	5.9	4.0	7.0	8.2	7.6	2.7	2.3	12.2	9.8	5.8	16.6	4.2	13.5	4.3	0.8	0.0	3.9	6.8	6.0	3.8	3.5	10.4	5.6	7.9	8.6	6.2	10.0	6.8	8.1	6.1	15.1	4.6	3.2	12.6	3.0	0.0	4.2	8.6	9.3	0.0	8.2	27.5	12.0	2.3	3.8	6.2	4.0	1.8
POU2AF1	"BOB1, OBF1"	ENSG00000110777	"POU class 2 associating factor 1"	Q16633	11	111352252-111455630	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 21.2;lymphoid tissue: 84.0"	"Cell type enhanced"	"Detected in many"	13	"B-cells: 67.0;Ciliated cells: 73.6;Erythroid cells: 46.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	11	"memory B-cell: 19.9;naive B-cell: 14.2"	"Lineage enriched"	"Detected in many"	13	"B-cells: 19.9"	"Cell line enhanced"	"Detected in some"		"Daudi: 46.5;Karpas-707: 53.2;U-266/70: 51.9;U-266/84: 23.4;U-698: 95.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB011193	Enhanced					NA	NA					"CAB011193: AB_532299"	"prognostic favorable (1.68e-4)"	"prognostic favorable (1.63e-4)"	"unprognostic (1.04e-2)"	"unprognostic (5.50e-3)"	"unprognostic (1.88e-1)"	"prognostic favorable (3.59e-4)"	"unprognostic (2.09e-1)"	"unprognostic (3.63e-3)"	"unprognostic (7.15e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.34e-1)"	"unprognostic (4.81e-2)"	"unprognostic (8.51e-8)"	"unprognostic (2.35e-1)"	"unprognostic (3.90e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.23e-1)"	0.9	0.5	0.6	62.7	0.7	2.0	1.4	0.4	0.6	1.9	7.8	1.8	0.0	6.7	0.7	0.3	8.7	1.1	1.4	0.5	0.8	0.7	2.1	1.0	2.6	42.6	1.0	0.5	1.2	0.5	0.0	0.4	0.5	1.2	1.3	4.1	1.2	8.4	0.9	0.4	0.4	21.2	0.0	1.4	74.2	12.2	1.0	0.9	5.0	1.7	1.4	84.0	5.0	1.4	19.9	0.1	1.5	0.2	0.3	0.7	0.6	0.1	0.1	0.0	0.0	0.8	0.8	0.1	0.0	0.0	0.0	0.0	0.1	0.0	46.5	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.5	1.7	53.2	0.0	0.1	0.2	0.2	0.0	0.0	0.0	9.9	0.1	12.5	0.0	0.1	0.1	0.9	0.1	0.0	0.0	0.4	0.2	0.1	0.4	0.0	0.4	0.0	0.0	51.9	23.4	95.5	0.0	0.1	0.0	1.5	0.1	0.3	0.1	0.1	0.1	19.9	0.2	0.1	0.0	14.2	0.2	0.1	0.9	0.3	0.2	0.1	0.7	0.6	0.6	0.7	0.4	0.6	0.8	0.7	1.0	0.5	1.2	0.9	0.0	5.1	67.0	6.0	0.2	0.0	1.6	12.7	73.6	18.2	0.0	0.0	0.0	0.0	0.0	6.0	0.0	0.0	46.7	5.0	0.0	0.6	1.1	0.0	0.0	0.1	0.0	2.9	1.3	0.3	7.9	0.3	0.2	8.5	0.0	0.1	0.0	0.4	0.2	0.4	0.3	0.0	0.0	0.0	5.9	0.7	0.0	0.0	0.5	0.0	7.3
POU5F1	"MGC22487, OCT3, Oct4, OTF3"	ENSG00000204531	"POU class 5 homeobox 1"	Q01860	6	31164337-31180731	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Cholangiocytes: 15.3;Collecting duct cells: 8.7;Enterocytes: 8.4;Pancreatic endocrine cells: 8.5"	"Cancer enriched"	"Detected in many"	34	"testis cancer: 355.9"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"HAP1: 49.8;NTERA-2: 132.5;SuSa: 87.3"									"CAB025600, CAB026380, HPA058267, CAB079773"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB025600: , CAB026380: , CAB079773: AB_2687916, HPA058267: AB_2683659"	"unprognostic (3.25e-2)"	"unprognostic (3.12e-1)"	"unprognostic (2.87e-1)"	"unprognostic (1.06e-2)"	"unprognostic (3.02e-2)"	"unprognostic (2.11e-2)"	"unprognostic (2.62e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.27e-2)"	"unprognostic (2.27e-2)"	"unprognostic (4.79e-2)"	"unprognostic (1.19e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.86e-2)"	"prognostic favorable (2.04e-5)"	1.2	0.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	2.3	2.3	1.2	1.2	4.9	3.1	5.7	1.2	5.2	4.3	1.2	1.2	0.0	11.1	5.0	2.0	1.2	1.2	1.2	1.2	8.8	0.0	1.2	1.2	1.2	4.7	1.0	1.2	1.2	3.0	1.2	1.8	5.9	1.2	1.2	1.2	6.3	2.2	1.2	1.2	1.2	1.2	1.2	11.2	1.2	3.0	1.8	1.8	1.0	1.1	0.9	0.3	0.5	0.2	7.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.2	0.0	0.0	0.6	49.8	0.6	0.0	0.0	0.2	0.0	0.4	0.6	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	132.5	0.2	0.0	0.1	0.1	0.1	1.0	1.0	0.0	0.0	0.2	0.0	0.0	87.3	0.1	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.1	0.1	0.0	0.1	0.0	1.4	1.0	0.5	0.8	0.7	0.5	1.0	0.4	0.4	0.2	3.0	0.9	0.6	1.8	1.1	0.5	1.8	0.3	0.3	1.2	1.2	1.2	1.2	1.2	0.0	1.2	1.2	1.2	1.2	0.0	1.4	0.5	2.4	4.6	0.7	0.4	15.3	1.4	1.2	8.7	2.0	0.0	0.0	4.8	0.0	0.7	8.4	0.0	5.8	0.1	0.5	3.6	0.0	1.5	0.1	0.0	1.2	0.6	0.0	0.0	0.0	0.8	1.7	1.0	3.1	0.0	8.5	3.7	0.7	2.1	0.9	0.0	1.2	0.0	0.4	3.3	0.1	0.0	2.9	3.8
PPARG	"NR1C3, PPARG1, PPARG2, PPARgamma"	ENSG00000132170	"Peroxisome proliferator activated receptor gamma"	P37231	3	12287368-12434356	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 97.6;breast: 102.1"	"Cell type enhanced"	"Detected in many"	11	"Cytotrophoblasts: 90.9;Extravillous trophoblasts: 187.1;Urothelial cells: 210.8"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 33.5"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.8;intermediate monocyte: 2.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC diff: 47.9;ASC TERT1: 27.3;BEWO: 56.5;CAPAN-2: 25.2;HSkMC: 28.1;RT4: 34.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB004282, HPA051239, HPA063663"	Approved		Enhanced	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"CAB004282: AB_628115, HPA051239: AB_2681400, HPA063663: AB_2685081"	"unprognostic (7.35e-3)"	"unprognostic (3.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavorable (3.41e-5)"	"unprognostic (9.13e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.77e-1)"	"prognostic favorable (1.59e-8)"	"unprognostic (1.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.68e-3)"	"prognostic favorable (5.52e-5)"	97.6	1.6	1.9	17.1	1.2	0.7	102.1	1.5	1.3	3.1	24.9	0.8	2.1	7.5	3.5	2.2	2.8	2.4	8.7	12.5	1.4	0.9	6.7	5.9	24.8	11.4	1.1	0.9	6.7	1.2	2.8	0.3	26.8	0.9	10.4	13.9	1.1	5.8	1.5	5.0	2.7	9.6	7.4	1.2	7.0	11.9	3.5	0.6	0.9	6.2	4.3	2.1	30.2	14.1	0.0	0.4	0.0	2.3	0.0	0.7	0.3	9.7	8.7	0.0	0.0	47.9	27.3	56.5	0.9	10.5	1.3	0.5	1.8	25.2	0.0	0.0	0.9	17.1	4.0	3.5	0.1	0.2	23.5	4.9	0.0	1.9	2.3	12.8	0.0	0.0	28.1	2.3	2.4	9.1	5.0	0.1	0.2	0.0	0.0	2.0	2.5	0.0	0.1	0.1	22.7	25.2	0.0	0.0	0.0	7.2	34.5	0.0	0.2	4.1	1.5	0.5	1.7	0.0	7.8	7.9	1.8	2.6	1.0	0.0	0.0	0.0	0.0	0.8	0.1	0.2	0.0	1.8	0.0	0.0	2.3	0.0	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.3	1.9	1.2	1.5	1.3	1.4	0.9	1.1	0.9	0.9	0.6	3.0	7.4	0.0	33.7	0.9	0.5	5.2	2.5	2.7	3.4	5.2	0.0	90.9	1.7	0.1	2.6	17.7	47.1	0.0	0.6	187.1	4.3	35.2	9.2	3.8	46.3	0.0	8.1	19.6	14.5	0.8	3.7	8.6	3.3	2.8	20.5	0.5	10.2	42.1	0.0	11.3	0.0	12.9	5.7	7.9	21.8	1.0	74.4	1.3	16.6	210.8
PPFIBP1	"hSGT2, hSgt2p, L2, SGT2"	ENSG00000110841	"PPFIA binding protein 1"	Q86W92	12	27523431-27695564	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cardiomyocytes: 154.9;Endothelial cells: 139.6;Ito cells: 144.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 7.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"SuSa: 53.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA001924	Uncertain		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA001924: AB_1079665"	"unprognostic (5.27e-2)"	"unprognostic (5.71e-2)"	"unprognostic (3.10e-2)"	"prognostic unfavorable (6.29e-4)"	"unprognostic (4.73e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.47e-1)"	"prognostic unfavorable (5.11e-4)"	"unprognostic (7.33e-2)"	"unprognostic (3.84e-2)"	"prognostic unfavorable (2.56e-4)"	"unprognostic (1.92e-2)"	"prognostic favorable (5.11e-7)"	"unprognostic (8.54e-2)"	"unprognostic (7.54e-2)"	"unprognostic (2.64e-1)"	"unprognostic (4.09e-2)"	21.3	17.1	15.5	8.0	16.8	2.2	22.6	4.9	25.0	18.3	15.4	13.3	13.0	7.1	28.1	9.3	17.1	16.5	12.2	43.3	17.1	9.0	23.8	15.7	25.0	7.8	13.1	16.4	53.1	13.7	12.7	22.2	34.5	15.3	15.3	11.1	8.1	14.2	18.4	13.7	17.8	10.0	20.5	11.2	16.6	15.1	7.1	13.3	6.2	23.9	14.9	6.2	17.2	18.4	7.0	2.0	1.5	0.6	0.3	1.8	0.6	4.4	8.9	7.3	6.2	12.1	33.8	13.0	16.1	18.1	9.5	13.7	23.4	13.5	3.3	18.8	32.6	12.7	11.1	3.9	14.7	17.1	7.6	2.2	7.4	6.8	3.4	5.3	2.2	4.1	26.2	10.3	27.6	28.4	18.6	32.4	4.5	3.8	3.4	33.7	3.4	2.1	0.6	13.0	6.3	6.9	3.4	18.1	1.2	14.1	9.8	0.6	3.0	8.0	4.3	22.4	53.2	5.5	3.4	31.5	26.8	9.0	14.6	16.4	0.0	0.0	0.2	29.8	3.2	42.2	1.5	0.6	0.3	0.7	0.2	1.4	0.7	1.3	0.7	0.6	7.0	1.3	1.3	1.5	0.3	0.2	2.0	1.8	0.6	15.5	16.8	4.9	25.0	17.1	9.0	13.1	16.4	15.3	13.3	92.3	20.3	24.3	55.3	36.5	2.3	154.9	2.5	9.4	14.8	76.8	3.9	28.5	10.0	37.2	2.6	139.6	7.0	0.0	21.6	18.9	41.3	34.7	3.5	12.7	8.3	42.9	17.9	144.9	21.5	3.1	19.5	6.4	59.1	3.6	14.6	7.5	26.9	14.4	39.6	16.6	1.7	19.4	44.8	1.7	9.1	24.1	76.9	5.9	11.5	75.3
PPM1D	"PP2C-DELTA, Wip1"	ENSG00000170836	"Protein phosphatase, Mg2+/Mn2+ dependent 1D"	O15297	17	60600183-60666280	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Cell cycle"	"Hydrolase, Protein phosphatase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 51.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 26.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA022277, HPA061848"	Approved		Supported	Nucleoplasm,Nucleoli		NA	NA			Nucleoplasm	Nucleoli	"HPA022277: AB_1858839, HPA061848: "	"unprognostic (1.48e-1)"	"unprognostic (1.36e-2)"	"prognostic favorable (3.52e-4)"	"unprognostic (1.76e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.12e-2)"	"prognostic unfavorable (4.27e-4)"	"unprognostic (5.50e-2)"	"unprognostic (1.70e-2)"	"unprognostic (6.07e-2)"	"unprognostic (2.52e-3)"	"unprognostic (3.46e-2)"	"unprognostic (1.95e-3)"	"unprognostic (7.33e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.98e-1)"	12.2	7.0	6.1	5.7	9.2	13.6	11.9	30.8	6.6	11.1	10.0	10.6	7.8	7.6	12.0	8.3	8.6	11.1	8.3	5.8	7.7	4.4	7.4	7.4	9.2	7.9	10.3	4.6	17.3	12.3	8.1	8.9	18.5	8.8	9.3	9.4	8.2	8.1	6.8	9.7	8.1	8.1	8.2	7.3	9.2	7.3	16.2	12.5	15.5	8.7	6.9	7.0	7.8	11.3	7.3	13.1	20.5	13.2	6.8	8.3	6.8	2.7	5.5	6.2	5.3	4.2	2.6	8.0	4.3	2.9	2.8	4.0	5.6	1.6	7.9	3.6	3.0	1.1	3.0	4.0	1.8	3.8	1.4	8.8	5.7	5.4	6.5	3.5	2.3	4.4	2.3	2.9	4.2	2.5	2.3	6.4	3.4	4.1	3.3	3.0	26.9	6.2	3.4	2.7	2.6	4.3	7.6	7.9	4.7	2.5	3.4	8.5	6.2	5.7	1.9	1.3	6.9	2.3	3.1	4.7	3.7	10.1	2.8	2.3	5.4	5.7	6.0	1.5	2.3	2.8	8.2	13.2	14.1	6.7	10.2	5.9	7.3	5.6	6.1	13.1	5.9	6.1	6.2	20.5	6.8	6.1	5.8	8.3	6.8	6.1	9.2	30.8	6.6	7.7	4.4	10.3	4.6	8.8	12.5	29.8	7.7	13.7	4.0	18.7	12.0	5.6	5.1	2.7	4.5	5.2	3.9	13.6	3.3	6.0	51.4	15.8	10.1	0.0	6.0	5.1	11.2	6.9	1.1	2.8	7.5	3.2	13.8	20.3	23.0	8.1	12.7	9.8	3.3	6.4	9.0	6.4	5.1	8.6	7.1	4.2	10.1	0.0	12.0	24.5	13.9	15.7	32.3	7.5	10.5	5.5
PPP2R1A	"PP2A-Aalpha, PP2AA, PR65A"	ENSG00000105568	"Protein phosphatase 2 scaffold subunit Aalpha"	P30153	19	52190039-52229533	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Chromosome partition"		"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB018599			Approved	Cytosol		NA	NA		3400000	Cytosol		"CAB018599: AB_628178"	"unprognostic (1.78e-1)"	"unprognostic (2.31e-2)"	"unprognostic (4.52e-2)"	"unprognostic (2.87e-1)"	"unprognostic (6.67e-2)"	"unprognostic (7.82e-2)"	"prognostic unfavorable (1.76e-4)"	"prognostic unfavorable (2.50e-4)"	"unprognostic (4.30e-2)"	"unprognostic (3.06e-1)"	"unprognostic (6.48e-3)"	"unprognostic (8.28e-2)"	"prognostic favorable (1.20e-4)"	"unprognostic (1.97e-1)"	"unprognostic (3.57e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.19e-2)"	25.3	57.3	60.7	20.5	71.0	18.0	21.4	47.5	82.1	29.6	31.2	26.6	21.5	33.4	26.4	37.9	37.7	47.0	39.9	74.7	70.2	44.8	31.0	29.3	20.0	27.5	44.0	50.9	45.8	24.3	37.8	29.5	24.6	51.0	31.0	29.8	31.0	24.3	35.6	50.6	33.5	25.3	34.5	25.2	20.5	19.8	21.7	18.1	29.0	28.9	35.9	30.6	27.3	23.1	52.8	62.8	51.9	67.2	69.8	56.3	67.8	30.9	52.6	42.0	37.3	34.2	35.8	22.1	26.1	34.2	34.9	30.6	26.4	24.5	27.1	18.8	41.5	19.2	22.4	45.0	39.4	20.3	20.0	121.9	19.9	29.0	29.7	31.3	21.5	19.0	48.0	32.6	32.7	30.1	32.8	33.1	18.2	23.1	19.1	38.7	35.8	30.0	41.0	41.5	31.2	46.5	29.5	24.4	30.3	56.1	51.0	31.7	33.9	32.0	32.0	19.5	28.6	28.9	38.0	31.4	27.7	25.1	13.5	29.8	19.8	29.0	31.8	29.8	21.8	34.9	45.0	55.3	51.9	50.4	67.2	45.8	48.4	45.1	47.1	62.8	52.8	37.7	43.0	33.7	69.8	59.8	39.0	56.3	67.8	60.7	71.0	47.5	82.1	70.2	44.8	44.0	50.9	51.0	18.1	41.7	30.7	69.2	78.9	62.5	111.3	81.8	68.8	52.2	36.4	113.4	23.6	183.6	99.5	195.0	3.8	51.7	133.3	0.0	136.1	214.1	70.0	78.9	68.0	44.8	127.2	136.7	102.6	66.9	55.1	6.8	67.0	47.0	50.6	131.7	108.9	97.9	137.7	175.6	80.2	103.3	48.5	77.6	81.4	14.8	54.1	55.3	152.2	70.3	147.4	93.1
PPP6C	PP6	ENSG00000119414	"Protein phosphatase 6 catalytic subunit"	O00743	9	125146573-125189939	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Cell cycle, Immunity, Innate immunity"	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							HPA050940	Uncertain					NA	NA					"HPA050940: AB_2681283"	"unprognostic (6.45e-2)"	"unprognostic (4.01e-3)"	"unprognostic (7.12e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.78e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.57e-3)"	"unprognostic (1.53e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.71e-2)"	"unprognostic (2.28e-2)"	"prognostic favorable (4.50e-6)"	"unprognostic (1.54e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.12e-1)"	21.7	20.1	20.1	15.7	24.5	24.8	21.2	20.8	26.2	17.0	19.1	25.9	15.1	13.9	15.6	17.2	21.2	14.0	12.9	15.3	19.8	16.6	22.8	17.8	16.3	21.5	20.1	16.1	17.5	27.7	21.3	17.3	17.6	17.8	14.5	21.8	16.8	26.9	14.6	50.5	19.3	17.3	16.3	22.6	19.4	16.5	22.8	23.7	34.1	22.2	20.5	24.0	13.8	15.6	17.3	14.8	32.2	19.5	13.9	23.3	13.8	14.1	10.3	18.8	17.8	20.2	16.9	19.0	15.0	16.3	22.2	18.6	16.5	15.0	20.4	11.7	20.1	18.9	28.9	25.4	16.3	25.8	18.2	12.3	16.7	16.2	14.6	16.6	29.1	23.2	13.9	22.4	18.2	17.4	17.1	20.7	23.4	19.5	23.7	23.9	21.0	27.4	18.4	17.5	39.6	19.2	22.4	28.5	27.2	18.8	14.3	19.5	19.3	26.8	21.6	17.4	16.7	33.4	18.4	20.0	13.7	13.1	26.5	19.9	26.2	47.2	27.0	18.4	19.1	22.2	27.2	13.2	21.4	14.7	17.4	18.0	17.3	18.9	16.6	14.8	13.3	18.9	17.5	32.2	13.9	19.5	10.7	23.3	13.8	20.1	24.5	20.8	26.2	19.8	16.6	20.1	16.1	17.8	23.7	38.7	27.8	41.7	45.6	68.7	15.2	30.8	35.7	21.4	23.9	26.2	7.9	40.2	48.0	40.6	102.7	41.4	34.6	23.3	47.6	45.3	30.1	41.0	43.9	36.1	46.7	14.3	46.0	46.6	52.3	56.7	27.6	48.9	42.2	46.9	41.6	28.7	41.6	38.6	33.9	54.9	12.9	51.8	44.8	93.3	43.0	76.5	72.9	49.0	37.9	48.2
PRCC	RCCP1	ENSG00000143294	"Papillary renal cell carcinoma (translocation-associated)"	Q92733	1	156750610-156800817	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017151, HPA019463, HPA019481"	Supported		Enhanced	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"CAB017151: , HPA019463: AB_1855672, HPA019481: AB_1855673"	"unprognostic (6.12e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.68e-3)"	"prognostic unfavorable (5.55e-4)"	"unprognostic (3.19e-1)"	"unprognostic (1.72e-1)"	"prognostic unfavorable (8.63e-4)"	"unprognostic (3.03e-1)"	"unprognostic (9.16e-2)"	"unprognostic (3.27e-3)"	"unprognostic (1.14e-1)"	"unprognostic (6.80e-2)"	"prognostic unfavorable (8.99e-15)"	"unprognostic (1.72e-1)"	"unprognostic (2.74e-1)"	"prognostic unfavorable (3.72e-4)"	"unprognostic (1.02e-2)"	31.3	24.9	28.5	25.8	29.7	33.7	23.7	33.2	43.5	29.8	30.0	35.9	21.8	24.6	35.1	22.8	30.3	25.6	28.7	23.8	28.0	24.5	26.1	33.1	22.0	30.1	22.1	25.2	30.1	23.7	31.0	22.7	38.8	22.6	25.6	21.5	25.6	37.2	24.0	47.4	33.6	30.1	25.7	20.4	29.7	24.1	26.2	19.2	51.9	27.5	29.8	30.7	25.4	23.8	21.4	27.1	36.9	23.1	19.3	22.1	16.9	20.1	17.4	13.8	15.8	11.6	9.2	24.0	14.1	13.8	15.7	13.6	27.3	17.0	20.7	24.4	11.1	9.1	21.0	19.6	14.8	12.3	25.8	25.6	15.1	12.9	17.6	14.3	20.8	17.9	13.0	17.2	13.7	12.5	12.3	14.4	13.7	24.9	19.3	11.0	35.9	23.7	24.4	33.3	28.1	21.7	20.8	12.2	27.8	16.5	19.4	24.5	43.8	14.9	37.6	23.3	23.7	27.0	33.5	13.2	16.0	16.8	17.6	23.1	49.7	74.3	32.0	15.8	13.5	14.8	26.9	20.0	36.9	20.5	20.6	19.6	18.0	18.5	22.1	22.4	21.4	18.4	18.9	19.3	19.3	23.1	27.1	18.5	16.9	28.5	29.7	33.2	43.5	28.0	24.5	22.1	25.2	22.6	19.2	8.9	16.0	27.9	32.9	46.5	17.3	10.6	20.4	12.0	15.9	19.2	21.6	54.4	18.3	35.7	5.8	27.0	25.1	0.0	28.1	52.6	29.2	25.0	16.2	15.3	37.9	27.0	33.0	23.4	18.7	7.1	28.1	25.4	20.3	51.3	23.1	16.5	29.8	27.4	26.9	23.7	16.8	32.3	32.5	33.6	48.1	44.8	84.6	34.1	27.7	31.8
PRDM1	"BLIMP1, PRDI-BF1"	ENSG00000057657	"PR/SET domain 1"	O75626	6	106086320-106109939	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Immunity, Innate immunity, Transcription, Transcription regulation"	"DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 49.9"	"Cell type enhanced"	"Detected in many"	8	"Cone photoreceptor cells: 49.1;T-cells: 100.2;Urothelial cells: 77.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"eosinophil: 5.6;gdT-cell: 12.6;MAIT T-cell: 19.3;memory CD4 T-cell: 12.0;memory CD8 T-cell: 11.6;naive CD8 T-cell: 6.8;neutrophil: 6.8;T-reg: 15.4"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.8;T-cells: 19.3"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 68.5;RPMI-8226: 12.8;U-266/70: 25.7;U-266/84: 16.6"	"Region enriched"	"Detected in single"	6	"olfactory region: 4.4"	"Low region specificity"	"Detected in all"			"HPA030033, HPA075427"	Approved		Approved	Nucleoplasm,Nucleoli		NA	NA			Nucleoli	Nucleoplasm	"HPA030033: AB_10601050, HPA075427: "	"unprognostic (9.60e-2)"	"unprognostic (3.28e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.98e-2)"	"unprognostic (4.03e-1)"	"unprognostic (3.77e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.50e-2)"	"unprognostic (7.56e-2)"	"prognostic unfavorable (9.81e-5)"	"unprognostic (1.52e-1)"	"unprognostic (3.51e-1)"	"unprognostic (2.45e-3)"	"unprognostic (7.90e-2)"	11.6	1.5	1.6	26.3	3.2	10.4	7.0	5.3	1.6	14.0	16.5	1.9	1.4	5.4	11.6	2.2	33.4	3.8	8.1	2.3	1.9	2.0	3.1	2.4	18.8	33.3	2.1	0.5	4.2	1.8	1.2	2.1	9.0	4.9	3.6	11.0	4.3	10.6	3.0	2.0	8.9	18.2	3.4	7.4	24.2	8.6	3.0	1.5	3.1	7.7	35.7	49.9	12.8	18.0	1.5	0.2	6.8	0.6	2.5	19.3	1.3	0.4	0.1	0.3	0.0	0.5	0.7	0.0	2.3	7.2	0.7	1.3	0.4	2.8	0.6	0.1	4.6	0.1	0.1	0.0	1.1	0.8	6.4	0.0	0.1	1.4	0.0	1.1	0.2	0.5	0.7	3.6	1.0	3.0	0.2	0.9	0.3	0.4	68.5	0.1	0.0	0.0	0.1	0.2	0.4	0.0	0.1	0.0	12.8	0.6	0.1	0.0	0.0	0.3	0.3	0.0	0.5	0.3	0.7	0.4	1.1	0.6	0.6	2.1	25.7	16.6	1.5	1.6	0.4	0.6	1.2	0.4	5.6	12.6	0.6	19.3	1.5	12.0	11.6	0.2	0.5	1.1	6.8	6.8	2.5	0.1	0.2	15.4	1.3	1.6	3.2	5.3	1.6	1.9	2.0	2.1	0.5	4.9	1.5	0.0	9.0	19.7	8.0	17.3	0.8	1.4	0.0	2.7	7.9	3.5	49.1	0.4	0.0	0.3	0.8	20.4	7.3	23.3	0.2	0.5	5.1	3.1	3.5	1.5	19.3	0.0	1.7	8.0	24.7	0.0	0.0	38.5	35.4	47.7	3.1	0.5	4.8	4.3	1.1	0.1	0.4	0.0	16.4	0.3	1.3	36.3	0.6	100.2	2.5	77.0
PRDM16	"KIAA1675, KMT8F, MEL1, MGC166915, PFM13"	ENSG00000142611	"PR/SET domain 16"	Q9HAZ2	1	3069168-3438621	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, DNA-binding, Methyltransferase, Repressor, Transferase"	"Cancer-related genes, Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	13	"Alveolar cells type 1: 32.8;Cholangiocytes: 17.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	13	"NK-cell: 5.4"	"Lineage enriched"	"Detected in single"	13	"NK-cells: 5.4"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 2.5;HEK 293: 2.9;HHSteC: 3.4;hTERT-RPE1: 11.5;MCF7: 2.6;OE19: 5.7"	"Region enriched"	"Detected in many"	5	"basal ganglia: 16.1"	"Low region specificity"	"Detected in many"			"HPA050343, HPA060467"			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA050343: AB_2681099, HPA060467: AB_2684287"	"unprognostic (2.44e-1)"	"unprognostic (1.44e-1)"	"unprognostic (5.31e-4)"	"unprognostic (1.27e-1)"	"unprognostic (1.14e-1)"	"unprognostic (3.95e-2)"	"unprognostic (9.15e-3)"	"unprognostic (5.68e-4)"	"unprognostic (2.58e-1)"	"unprognostic (2.07e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.71e-1)"	"unprognostic (7.80e-6)"	"unprognostic (2.14e-1)"	"unprognostic (1.73e-1)"	"prognostic unfavorable (4.70e-5)"	"unprognostic (4.06e-2)"	2.7	0.7	5.3	1.4	5.6	0.5	1.6	0.5	4.7	2.1	6.2	3.3	12.8	14.1	1.5	4.5	1.1	2.0	11.7	5.1	5.2	1.9	7.0	0.6	4.2	1.4	2.9	3.1	3.6	12.7	1.2	1.1	0.6	3.3	1.1	0.9	16.1	1.3	15.0	1.2	0.9	8.0	1.5	2.5	4.2	14.8	1.4	4.8	0.0	10.7	0.0	0.9	1.1	1.5	0.3	0.1	0.0	0.0	5.4	0.4	0.0	0.0	0.0	0.9	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.4	0.5	0.0	0.4	0.0	0.4	0.0	2.2	0.0	0.0	0.2	2.9	0.0	0.0	0.5	3.4	0.0	1.2	0.0	0.0	0.0	0.0	11.5	0.0	0.2	0.0	0.0	0.0	2.6	0.2	0.0	0.3	5.7	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.6	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.4	0.0	5.4	0.0	0.0	0.0	0.0	5.3	5.6	0.5	4.7	5.2	1.9	2.9	3.1	3.3	4.8	32.8	8.0	0.0	0.2	0.6	0.0	4.8	17.8	2.7	9.1	7.0	0.0	0.0	5.0	7.6	0.0	0.7	0.0	0.0	4.3	2.9	0.0	0.3	0.0	0.0	0.0	1.6	5.2	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.3	1.3	5.3	0.0	1.8	0.2	0.0	0.0	5.3	0.2	1.1	0.0	0.0	0.0	1.2	0.1
PREX2	"DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129"	ENSG00000046889	"Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2"	Q70Z35	8	67952118-68237030	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Guanine-nucleotide releasing factor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	11	"Early spermatids: 31.5;Endothelial cells: 35.0;Ito cells: 52.8;Muller glia cells: 74.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"AF22: 12.8;HUVEC TERT2: 17.4;JURKAT: 7.5;NTERA-2: 11.1;RH-30: 5.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015234, HPA075956"	Enhanced		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA015234: AB_1847604, HPA075956: AB_2686769"	"unprognostic (2.25e-1)"	"unprognostic (3.32e-2)"	"unprognostic (1.30e-2)"	"unprognostic (3.39e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.37e-2)"	"unprognostic (4.19e-1)"	"unprognostic (8.27e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.98e-2)"	"unprognostic (2.53e-2)"	"unprognostic (8.77e-2)"	"prognostic unfavorable (1.61e-7)"	"unprognostic (8.30e-3)"	"unprognostic (2.79e-1)"	"unprognostic (3.67e-2)"	"unprognostic (6.64e-2)"	18.8	3.0	14.1	3.3	17.9	1.0	8.5	11.4	16.4	10.8	4.4	13.1	3.0	4.3	6.2	4.5	4.4	12.4	7.6	7.6	15.5	8.1	4.1	3.2	9.1	2.4	12.4	10.0	5.2	3.1	3.7	4.4	17.5	17.2	6.3	4.4	2.6	3.0	5.7	4.9	4.4	4.0	6.1	12.7	3.5	4.1	2.7	16.2	0.0	12.1	3.9	2.9	5.9	15.8	1.1	0.3	0.8	0.1	0.2	0.4	0.0	0.0	0.0	12.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.4	7.5	0.0	0.0	0.0	0.0	2.6	0.0	11.1	0.0	0.0	0.0	5.0	0.0	0.6	0.0	3.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	1.2	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.8	0.1	0.1	0.4	0.1	0.2	0.5	0.2	0.2	0.0	1.1	0.2	0.3	0.5	0.2	0.1	0.3	0.0	0.0	14.1	17.9	11.4	13.6	15.5	8.1	12.4	10.0	17.2	16.2	3.0	5.3	0.0	3.2	3.5	24.6	4.4	0.0	1.4	5.7	1.8	2.0	0.0	0.0	0.0	31.5	35.0	0.0	0.0	0.0	0.0	5.5	0.5	1.1	0.4	0.1	4.8	0.0	52.8	3.1	4.9	10.3	0.2	8.5	0.0	0.0	74.9	0.0	0.0	9.9	0.0	3.0	25.8	3.4	0.7	0.7	2.3	0.0	0.0	0.0	1.4
PRF1	"HPLH2, P1, PFP"	ENSG00000180644	"Perforin 1"	P14222	10	70597348-70602775	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters"	Cytolysis		"Cancer-related genes, Disease mutation, Familial hemophagocytic lymphohistiocytosis"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 100.3;lymphoid tissue: 38.7"	"Cell type enriched"	"Detected in some"	9	"T-cells: 203.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	4	"gdT-cell: 100.3;MAIT T-cell: 70.9;memory CD8 T-cell: 54.9;naive CD8 T-cell: 36.1;NK-cell: 65.1"	"Group enriched"	"Detected in many"	48	"NK-cells: 65.1;T-cells: 100.3"	"Cell line enriched"	"Detected in some"	11	"HDLM-2: 72.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB002436, HPA037940"	Approved		Approved	Cytosol	"Intracellular and membrane"	NA	NA		960000	Cytosol		"CAB002436: AB_563955, HPA037940: AB_2675747"	"unprognostic (6.11e-3)"	"unprognostic (1.26e-2)"	"unprognostic (1.71e-1)"	"prognostic favorable (2.09e-4)"	"unprognostic (1.87e-2)"	"prognostic favorable (3.54e-4)"	"unprognostic (6.98e-3)"	"unprognostic (2.62e-1)"	"unprognostic (1.44e-3)"	"unprognostic (1.69e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.45e-1)"	"prognostic unfavorable (1.08e-5)"	"unprognostic (7.38e-2)"	"unprognostic (2.70e-1)"	"unprognostic (7.97e-3)"	"unprognostic (5.22e-3)"	8.8	1.3	0.9	5.5	1.1	15.3	2.4	0.5	0.7	1.7	3.8	0.4	0.2	1.4	4.4	2.9	2.7	1.7	5.3	4.1	0.8	0.9	1.8	6.5	19.6	11.3	2.5	0.3	2.1	1.6	0.0	1.1	3.1	1.2	3.3	0.8	3.9	2.5	3.3	2.6	0.9	5.1	1.2	1.4	38.7	3.1	1.6	0.2	12.7	2.8	1.0	10.3	3.2	1.7	0.4	0.3	1.7	0.2	65.1	100.3	46.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	72.7	0.0	0.4	0.0	2.2	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.2	0.0	100.3	0.1	70.9	0.4	14.6	54.9	0.2	0.2	6.2	36.1	1.7	65.1	0.2	0.3	11.1	46.7	0.9	1.1	0.5	0.7	0.8	0.9	2.5	0.3	1.2	0.2	3.0	22.3	6.5	0.0	0.3	0.0	0.8	0.0	2.7	4.5	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.4	0.1	8.1	2.1	0.1	0.0	0.0	8.6	5.4	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	0.0	0.6	0.6	203.1	0.0	0.0
PRKACA	PKACa	ENSG00000072062	"Protein kinase cAMP-activated catalytic subunit alpha"	P17612	19	14091688-14118084	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cardiomyocytes: 110.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010361, HPA071185"	Approved		Approved	"Cytokinetic bridge,Cytosol"		NA	NA		1300000	Cytosol	"Cytokinetic bridge"	"CAB010361: AB_2268772, HPA071185: AB_2686356"	"unprognostic (1.08e-1)"	"prognostic favorable (6.28e-6)"	"unprognostic (2.09e-2)"	"prognostic unfavorable (6.26e-5)"	"unprognostic (1.38e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.64e-1)"	"unprognostic (9.36e-3)"	"unprognostic (7.01e-2)"	"unprognostic (3.41e-1)"	"prognostic favorable (6.47e-4)"	"unprognostic (2.86e-1)"	"unprognostic (1.17e-1)"	"unprognostic (4.68e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.66e-2)"	"unprognostic (6.14e-3)"	25.6	43.4	19.6	17.8	22.7	9.1	34.1	29.1	39.6	20.6	17.5	16.0	16.2	13.4	19.8	15.6	20.9	18.8	16.4	91.6	20.7	29.4	14.7	34.5	16.5	28.2	21.6	27.5	47.0	15.6	20.8	24.6	15.4	26.9	16.6	16.2	18.4	15.5	24.9	92.4	13.4	14.4	29.0	16.2	28.1	13.9	24.4	11.1	15.2	15.7	26.2	14.8	21.1	17.3	1.7	2.4	8.6	5.3	0.7	1.7	1.2	26.2	15.3	34.7	41.3	30.7	32.7	6.3	28.0	25.9	39.8	36.5	18.6	9.4	11.4	22.7	44.3	19.4	17.2	24.4	26.5	37.8	20.7	12.3	20.9	28.9	18.0	26.3	12.9	22.2	31.1	12.8	31.6	11.0	24.6	33.5	18.7	19.6	29.8	40.6	38.9	29.0	9.7	12.4	26.6	34.1	26.2	32.0	26.3	19.4	16.7	27.4	17.5	25.3	15.5	11.5	17.5	22.1	12.5	25.9	47.0	13.1	62.9	26.1	20.6	21.1	16.8	31.5	19.6	17.6	0.3	3.4	0.4	1.7	5.3	0.8	1.7	0.9	1.1	2.4	1.3	1.2	1.7	8.6	0.7	4.6	1.6	0.8	1.2	19.6	22.7	29.1	39.6	20.7	29.4	21.6	27.5	26.9	11.1	6.0	4.3	11.5	6.1	7.8	40.4	110.4	28.1	4.0	2.3	14.0	25.5	5.8	6.6	10.7	25.7	21.6	16.0	0.0	16.2	4.8	14.3	7.3	0.0	30.1	29.0	3.2	16.8	31.9	44.8	12.8	45.5	32.4	13.5	7.2	14.3	24.1	13.5	7.0	48.8	9.6	23.0	19.4	17.3	25.7	6.4	9.8	6.8	7.2	11.4	6.4
PRKAR1A	"CNC1, PRKAR1, TSE1"	ENSG00000108946	"Protein kinase cAMP-dependent type I regulatory subunit alpha"	P10644	17	68511780-68551319	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cardiomyocytes: 608.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019378, HPA049979"	Approved		Approved	Cytosol		NA	NA		11000000	Cytosol		"CAB019378: , HPA049979: AB_2680980"	"unprognostic (8.69e-2)"	"unprognostic (6.97e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.68e-1)"	"unprognostic (4.39e-2)"	"unprognostic (2.61e-1)"	"unprognostic (6.42e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.19e-2)"	"unprognostic (5.55e-2)"	"unprognostic (8.56e-3)"	"unprognostic (6.26e-2)"	"unprognostic (6.92e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.11e-1)"	47.1	48.0	41.7	34.5	54.8	14.6	38.7	40.4	57.4	48.2	23.8	44.9	31.4	15.1	43.6	37.7	29.6	43.2	37.4	122.7	42.5	52.3	49.2	43.4	47.3	29.5	50.1	43.6	62.5	19.1	107.8	41.9	47.3	57.7	35.6	24.2	32.2	47.5	43.6	99.8	22.8	19.3	39.4	52.8	35.3	25.1	36.9	40.1	28.2	51.8	23.6	29.2	33.8	33.4	11.3	26.9	52.6	28.7	18.5	13.0	22.9	16.6	32.1	41.2	24.6	55.0	62.5	6.2	22.5	46.5	35.2	31.2	12.5	22.5	16.9	15.5	49.1	36.1	13.8	30.4	36.5	50.6	11.4	10.9	26.2	27.9	40.8	39.9	20.0	29.4	44.6	38.0	40.6	34.3	39.6	58.4	14.5	11.8	26.7	42.6	31.6	22.0	10.7	15.2	17.2	21.9	15.4	68.2	18.7	53.4	36.3	15.0	20.3	20.6	37.7	86.7	40.0	29.5	28.3	41.4	49.7	23.7	22.4	20.9	22.3	15.8	25.2	30.1	19.1	30.9	31.1	26.1	46.3	13.0	25.5	13.0	11.3	9.8	11.6	26.9	8.5	8.9	9.8	52.6	18.5	28.7	8.8	12.3	22.9	41.7	54.8	40.4	57.4	42.5	52.3	50.1	43.6	57.7	40.1	137.0	210.8	75.1	77.8	126.8	93.4	608.0	89.2	258.3	168.4	239.0	62.8	66.4	150.9	74.2	287.1	138.4	34.9	23.3	45.5	74.3	135.4	82.7	180.2	101.7	123.8	131.9	131.3	160.2	157.1	53.4	123.7	102.2	182.2	93.8	51.5	115.8	62.1	52.9	179.3	150.9	56.6	84.1	208.1	100.7	40.5	115.2	69.0	106.6	36.6	95.0
PRRX1	"PHOX1, PMX1"	ENSG00000116132	"Paired related homeobox 1"	P54821	1	170662728-170739419	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"Early spermatids: 327.5;Late spermatids: 303.2;Leydig cells: 237.3;Peritubular cells: 98.3;Smooth muscle cells: 139.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 73.9;ASC TERT1: 59.0;BJ: 20.9;BJ hTERT+: 41.3;HSkMC: 30.1;U-138 MG: 29.0;U-2197: 27.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA051084, HPA063566"	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA051084: AB_2681338, HPA063566: AB_2732702"	"unprognostic (2.03e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.00e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.97e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.88e-2)"	"unprognostic (2.94e-3)"	"unprognostic (1.13e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.29e-1)"	"prognostic unfavorable (6.60e-10)"	"unprognostic (4.23e-3)"	"unprognostic (4.48e-2)"	"unprognostic (2.68e-3)"	"unprognostic (1.69e-3)"	44.8	4.4	5.2	7.2	6.3	0.0	21.0	4.0	9.2	58.5	4.1	6.7	10.6	0.4	31.4	19.4	10.8	17.9	14.5	19.5	6.8	4.5	1.8	0.7	10.4	13.0	6.1	5.3	27.6	1.9	3.4	3.1	2.7	7.7	17.3	2.5	17.4	18.4	34.1	58.6	11.9	2.2	23.0	6.6	1.0	2.3	17.6	6.8	5.0	21.7	28.7	14.9	19.4	31.2	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	73.9	59.0	0.0	20.9	41.3	2.9	2.9	0.0	0.0	0.0	0.0	17.2	0.0	0.0	3.6	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	30.1	0.0	14.4	0.0	5.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	29.0	0.5	27.6	3.2	0.0	0.0	0.0	15.2	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	5.2	6.3	4.0	3.9	6.8	4.5	6.1	5.3	7.7	6.8	0.0	0.3	0.0	0.4	14.4	0.0	29.7	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.9	327.5	6.4	0.0	0.0	0.2	0.2	42.1	1.3	0.0	0.0	0.7	0.0	0.0	0.0	0.0	303.2	237.3	3.9	13.5	0.0	0.0	0.3	0.9	0.0	98.3	0.0	0.1	51.8	139.5	6.0	1.4	10.3	0.1	0.0	0.0	1.3
PSIP1	"DFS70, LEDGF, p52, p75, PSIP2"	ENSG00000164985	"PC4 and SFRS1 interacting protein 1"	O75475	9	15464066-15511019	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Spermatocytes: 273.8;Spermatogonia: 282.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 132.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013718, HPA019697"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB013718: , HPA019697: AB_1852779"	"unprognostic (8.54e-2)"	"unprognostic (3.70e-2)"	"unprognostic (1.31e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.23e-1)"	"unprognostic (2.89e-3)"	"unprognostic (5.10e-2)"	"unprognostic (5.93e-2)"	"unprognostic (2.53e-2)"	"unprognostic (6.49e-3)"	"unprognostic (5.49e-2)"	"unprognostic (6.98e-2)"	"unprognostic (2.04e-1)"	"unprognostic (2.99e-1)"	"unprognostic (7.14e-2)"	"unprognostic (1.39e-1)"	15.1	20.3	42.7	20.8	48.8	24.9	12.2	65.3	49.4	22.6	16.1	19.0	11.5	10.8	27.9	18.2	12.9	20.0	14.9	16.0	38.7	42.7	16.1	10.5	15.6	35.4	34.1	30.2	43.6	8.1	18.8	24.9	18.7	32.4	18.3	15.3	12.3	9.0	21.1	16.3	12.3	14.2	21.3	37.7	24.6	12.5	37.2	29.3	70.4	18.1	6.5	31.9	17.0	16.1	11.4	2.6	8.5	4.3	8.0	16.4	1.9	17.9	11.9	40.7	29.8	8.8	10.7	9.1	21.7	15.5	19.5	23.3	5.0	9.3	38.3	5.0	11.4	10.9	5.0	25.3	11.7	28.3	25.1	15.3	132.4	31.3	9.3	10.7	15.4	14.7	8.9	3.4	16.3	12.0	19.5	17.0	18.1	21.8	21.3	12.6	6.5	31.9	38.4	63.1	0.4	18.6	29.8	22.2	7.7	10.9	6.3	25.9	28.5	19.4	8.6	10.1	26.5	8.6	20.8	12.0	14.2	14.4	10.6	20.5	9.1	12.8	34.5	11.4	15.6	8.1	8.5	2.1	4.2	5.5	1.6	6.7	8.4	11.0	7.6	2.4	11.4	16.4	10.1	7.2	8.0	4.3	2.6	9.8	1.9	42.7	48.8	65.3	46.6	38.7	42.7	34.1	30.2	32.4	29.3	50.6	32.2	51.9	42.9	28.3	223.7	37.1	20.4	58.9	36.4	45.4	62.8	99.5	53.0	8.4	62.0	69.9	10.7	46.7	7.5	66.4	50.7	20.2	15.0	16.3	26.7	130.3	36.5	55.3	27.7	44.5	116.5	31.1	38.8	43.3	27.2	149.7	3.6	23.2	126.2	41.8	252.4	122.9	61.2	273.8	282.5	18.4	34.6	73.4	41.7	15.4
PTCH1	"BCNS, NBCCS, PTCH"	ENSG00000185920	"Patched 1"	Q13635	9	95442980-95517057	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Receptor	"Cancer-related genes, Disease mutation, Holoprosencephaly, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	17	"Late spermatids: 165.3;Leydig cells: 176.9;Peritubular cells: 417.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.9"	"Lineage enriched"	"Detected in many"	8	"T-cells: 8.9"	"Cell line enhanced"	"Detected in many"		"NTERA-2: 15.8;WM-115: 37.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013717, HPA075072"	Uncertain		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"CAB013717: , HPA075072: AB_2686733"	"unprognostic (1.46e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.16e-1)"	"unprognostic (1.79e-2)"	"unprognostic (3.22e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.13e-1)"	"unprognostic (3.54e-3)"	"unprognostic (2.63e-1)"	"unprognostic (8.66e-3)"	"unprognostic (1.52e-2)"	"unprognostic (2.82e-1)"	"unprognostic (1.13e-6)"	"unprognostic (8.63e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.76e-1)"	"unprognostic (2.82e-1)"	4.1	3.8	6.7	6.0	9.5	0.7	7.9	21.0	6.4	28.5	12.5	6.1	8.0	7.8	16.2	4.2	3.0	7.4	13.2	2.8	7.0	6.6	4.9	2.2	7.1	4.5	9.5	3.2	5.2	10.8	3.4	4.0	3.7	6.9	6.9	12.3	11.2	6.9	9.5	2.7	4.3	10.9	8.5	5.1	3.8	12.1	14.3	7.9	1.0	6.3	1.9	3.2	11.3	6.9	1.0	0.0	0.0	0.0	0.3	8.9	1.8	5.1	2.5	10.9	6.8	1.6	2.7	6.2	1.0	0.9	1.2	0.7	2.5	2.5	4.1	1.8	1.9	2.3	11.8	6.2	0.8	0.7	4.0	4.1	0.0	2.5	1.1	1.5	0.1	2.3	2.5	1.3	1.1	0.8	2.3	2.2	1.8	3.6	4.8	0.5	1.0	0.0	1.6	15.8	3.7	1.0	0.0	8.3	2.1	0.8	0.7	7.5	3.7	3.7	3.6	1.6	10.6	0.9	1.1	0.5	1.4	7.2	7.3	0.7	9.7	8.4	2.7	2.0	2.0	37.6	0.0	0.0	0.0	8.9	0.0	5.3	1.0	1.7	3.8	0.0	0.3	2.8	3.2	0.0	0.3	0.0	0.0	1.4	1.8	6.7	9.5	21.0	6.4	7.0	6.6	9.5	3.2	6.9	7.9	0.0	5.4	0.9	2.8	3.5	17.4	5.1	10.2	1.4	2.3	0.0	39.3	2.0	5.0	2.5	80.9	3.7	1.3	0.0	3.5	1.6	6.9	5.8	1.1	1.0	0.7	19.1	20.8	3.1	0.8	165.3	176.9	0.8	11.8	0.0	11.2	71.0	2.6	3.5	417.9	1.1	13.5	38.8	4.2	3.3	33.2	3.9	1.1	4.3	5.0	1.1
PTEN	"BZS, MHAM, MMAC1, PTEN1, TEP1"	ENSG00000171862	"Phosphatase and tensin homolog"	P60484	10	87863113-87971930	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins"	"Apoptosis, Lipid metabolism, Neurogenesis"	"Hydrolase, Protein phosphatase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 29.6"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB004076, HPA031335"	Approved		Supported	Nucleoplasm,Cytosol	"Secreted - unknown location"	NA	NA			Nucleoplasm	Cytosol	"CAB004076: AB_390810, HPA031335: AB_2797221"	"unprognostic (8.72e-2)"	"unprognostic (2.45e-1)"	"unprognostic (5.43e-1)"	"unprognostic (1.50e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.07e-1)"	"unprognostic (6.87e-2)"	"unprognostic (9.77e-2)"	"unprognostic (2.71e-1)"	"prognostic unfavorable (7.35e-4)"	"unprognostic (1.57e-1)"	"unprognostic (2.73e-1)"	"unprognostic (6.54e-3)"	"unprognostic (2.41e-1)"	42.4	24.1	17.7	20.9	17.7	13.5	32.8	39.9	19.7	43.1	26.7	9.9	19.0	15.1	29.8	22.8	26.8	30.3	21.0	19.1	16.0	17.4	19.6	32.4	27.2	30.4	15.7	19.5	29.1	21.3	16.4	23.6	36.4	14.2	35.3	17.7	21.6	16.8	20.8	16.8	20.4	25.4	26.0	11.7	40.9	17.8	18.7	12.5	49.7	25.2	13.3	18.6	29.6	30.9	4.3	5.1	29.6	11.0	4.3	4.7	2.0	10.2	4.8	5.5	5.0	12.8	8.8	5.0	5.5	12.2	6.5	9.1	4.9	12.6	12.1	3.7	9.0	3.8	6.2	7.4	6.3	10.3	6.0	2.1	4.0	12.5	6.0	13.7	13.5	6.9	6.0	17.6	8.2	10.6	27.6	9.1	7.7	3.0	32.9	5.9	7.8	7.6	24.6	2.0	8.9	0.0	11.8	2.9	8.9	10.1	5.8	2.0	9.0	7.3	3.5	9.2	4.6	9.7	19.6	7.9	21.4	5.0	8.3	4.4	10.8	14.0	13.8	6.6	12.8	1.2	8.3	7.9	12.2	3.6	11.0	3.9	4.3	4.0	3.5	5.1	3.7	4.7	4.5	29.6	4.3	7.2	4.2	3.5	2.0	17.7	17.7	39.9	19.7	16.0	17.4	15.7	19.5	14.2	12.5	32.8	55.3	40.2	50.0	49.8	113.3	39.2	40.8	25.4	28.4	27.9	37.3	22.6	28.2	23.2	57.0	44.4	33.9	0.0	25.8	44.5	52.3	36.9	25.3	58.6	31.3	42.9	30.0	47.9	167.4	70.7	52.6	69.1	59.1	27.9	44.1	54.1	30.2	24.6	51.2	30.8	55.8	90.5	118.8	24.9	24.0	52.6	47.9	35.7	39.2	51.2
PTK6	BRK	ENSG00000101213	"Protein tyrosine kinase 6"	Q13882	20	63528001-63537370	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 44.0;intestine: 24.2;skin 1: 24.2"	"Cell type enhanced"	"Detected in many"	12	"Alveolar cells type 2: 34.1;Enterocytes: 90.1;Mucus-secreting cells: 39.1;Paneth cells: 65.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A-431: 10.6;CAPAN-2: 20.4;HaCaT: 16.6;hTCEpi: 22.5;OE19: 27.4;RT4: 13.0;T-47d: 12.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB032952, HPA036070, HPA036071"	Approved		Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane,Cytosol"		NA	NA			Nucleoplasm	"Nuclear bodies, Plasma membrane, Cytosol"	"CAB032952: AB_634461, HPA036070: AB_10602292, HPA036071: AB_10669982"	"unprognostic (2.32e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.29e-1)"	"unprognostic (3.03e-1)"	"unprognostic (3.72e-2)"	"prognostic unfavorable (1.96e-4)"	"unprognostic (1.28e-1)"	"prognostic unfavorable (1.26e-9)"	"unprognostic (4.19e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.73e-1)"	"unprognostic (4.24e-2)"	0.7	0.0	0.4	5.3	0.4	0.0	1.7	0.4	0.4	7.6	18.1	0.5	0.8	13.6	0.6	0.5	44.0	0.0	11.7	0.4	0.4	0.0	0.8	1.7	1.1	0.4	0.4	0.4	0.4	1.4	0.0	0.4	0.6	0.4	2.2	7.4	0.4	7.6	0.4	0.4	24.2	24.2	0.9	0.4	0.4	12.5	0.4	0.4	0.4	0.4	18.9	17.2	6.5	15.0	1.3	4.5	1.2	2.4	0.3	1.9	0.9	10.6	1.2	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	20.4	0.0	3.6	0.0	0.0	16.6	0.0	0.0	0.0	2.6	0.2	0.0	4.3	0.0	0.0	0.0	3.4	0.0	22.5	0.0	0.1	0.1	0.0	0.0	0.1	1.2	0.1	5.9	0.0	0.1	0.1	27.4	7.7	0.0	0.6	0.2	0.0	13.0	0.1	1.1	1.2	4.0	0.0	0.0	12.5	0.8	0.1	0.1	0.2	0.4	0.1	0.2	0.0	0.0	0.2	0.2	0.5	1.2	2.4	0.4	0.5	1.7	1.9	1.2	0.4	0.1	4.5	1.3	0.4	0.6	1.2	0.3	1.3	0.3	0.5	0.9	0.4	0.4	0.4	0.4	0.4	0.0	0.4	0.4	0.4	0.4	11.9	34.1	0.0	2.8	5.3	2.0	0.4	12.7	9.4	17.0	0.0	2.0	0.2	0.0	1.4	0.0	0.3	90.1	0.0	1.4	0.1	0.4	1.3	9.2	1.5	0.7	0.0	5.2	0.6	4.1	0.0	0.3	2.8	0.0	0.0	39.1	2.4	10.3	65.1	0.0	0.1	3.9	0.0	0.4	0.2	0.2	13.6	0.1	0.0	18.8	13.8
PTPN11	"BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2"	ENSG00000179295	"Protein tyrosine phosphatase, non-receptor type 11"	Q06124	12	112418351-112509913	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes, Deafness, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cardiomyocytes: 136.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005377	Approved		Supported	"Nucleoplasm,Nucleoli rim,Actin filaments,Cytosol"		NA	NA		160000	"Nucleoli rim"	"Nucleoplasm, Actin filaments, Cytosol"	"CAB005377: AB_632401"	"unprognostic (2.18e-3)"	"unprognostic (1.73e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.27e-1)"	"unprognostic (6.05e-2)"	"unprognostic (4.25e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.22e-2)"	"unprognostic (8.85e-2)"	"unprognostic (3.75e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.62e-2)"	"unprognostic (1.80e-2)"	25.4	16.8	38.6	14.4	39.0	17.7	30.8	17.5	39.5	18.3	14.7	26.9	9.9	11.9	19.1	13.3	17.6	11.1	13.1	30.1	38.0	32.2	18.0	23.1	15.1	14.5	45.3	22.5	13.1	14.0	29.3	12.9	16.6	26.2	16.2	13.9	9.4	12.0	20.0	34.0	14.1	11.1	28.0	45.7	10.9	12.8	7.6	32.1	10.9	21.2	8.2	13.7	17.4	15.4	17.3	17.1	22.0	11.8	11.3	15.4	6.3	35.4	33.8	24.7	23.4	36.0	35.2	29.2	43.1	47.0	34.0	25.6	33.7	13.7	37.5	22.5	39.8	21.5	21.2	31.7	38.2	56.5	28.4	26.1	54.5	31.5	18.4	35.9	43.7	34.8	28.4	38.5	36.5	51.9	32.8	28.0	29.0	41.4	13.2	32.8	25.6	30.7	21.3	29.9	34.7	22.2	31.6	36.4	21.5	31.3	39.9	17.2	21.1	41.5	31.8	26.5	26.1	36.6	30.3	34.1	40.0	35.9	23.7	37.6	25.6	42.2	37.5	33.3	30.7	37.3	22.0	11.0	15.0	14.8	9.5	14.1	15.5	13.4	12.1	12.6	17.3	15.4	11.8	10.3	11.3	11.8	17.1	9.8	6.3	38.6	39.0	17.5	39.5	38.0	32.2	45.3	22.5	26.2	32.1	56.6	53.2	13.4	22.8	22.8	27.6	136.3	30.6	20.1	50.0	34.9	15.7	20.0	28.2	34.0	65.9	35.8	17.2	0.0	36.7	21.0	25.9	57.9	26.7	93.6	22.8	12.7	12.6	27.0	32.4	19.0	47.8	23.7	13.5	16.2	19.6	59.0	45.4	20.4	75.0	29.8	21.4	32.3	31.9	7.7	5.3	24.0	29.4	19.8	18.7	65.6
PTPN13	"PTP-BAS, PTP-BL, PTP1E, PTPL1"	ENSG00000163629	"Protein tyrosine phosphatase, non-receptor type 13"	Q12923	4	86594315-86815171	"Cancer-related genes, Enzymes, Predicted intracellular proteins"		"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 2: 152.9;Basal keratinocytes: 97.1;Rod photoreceptor cells: 171.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"intermediate monocyte: 3.0;MAIT T-cell: 2.3;memory CD4 T-cell: 2.2;non-classical monocyte: 4.9"	"Group enriched"	"Detected in many"	7	"monocytes: 4.9;T-cells: 2.3"	"Cell line enhanced"	"Detected in many"		"AF22: 45.2;RT4: 21.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002213, HPA063119"	Approved		Supported	"Nucleoplasm,Nucleoli fibrillar center,Cytosol"		NA	NA			Nucleoplasm	"Nucleoli fibrillar center, Cytosol"	"CAB002213: AB_564089, HPA063119: "	"unprognostic (5.36e-2)"	"unprognostic (4.46e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.54e-3)"	"unprognostic (4.02e-1)"	"unprognostic (9.03e-3)"	"unprognostic (4.43e-2)"	"unprognostic (4.38e-2)"	"unprognostic (2.46e-1)"	"unprognostic (7.05e-2)"	"unprognostic (3.69e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.28e-3)"	"unprognostic (3.95e-3)"	"unprognostic (2.26e-1)"	"unprognostic (2.66e-1)"	"unprognostic (2.85e-2)"	10.3	5.9	10.8	2.7	16.9	0.7	9.9	5.7	11.6	15.9	4.1	13.0	7.6	1.2	10.8	21.2	18.7	11.4	6.5	5.3	10.4	5.7	22.1	1.6	18.0	4.3	16.9	7.9	24.1	4.3	26.6	38.3	3.0	14.2	12.0	2.4	39.0	5.9	9.4	1.0	43.0	2.3	8.7	10.3	3.5	3.6	12.2	17.6	1.9	16.9	12.4	11.8	15.7	17.6	0.0	0.5	0.1	4.9	0.1	2.3	0.1	5.1	2.6	45.2	4.4	19.1	16.7	0.0	9.5	19.4	3.6	4.6	0.0	2.6	0.0	2.1	10.5	1.3	17.0	7.8	14.3	7.0	0.1	5.8	4.3	5.6	0.0	2.3	7.5	0.0	10.7	4.6	2.6	8.7	7.6	0.0	0.0	0.0	7.4	0.0	2.3	0.6	2.7	10.3	0.0	1.9	1.5	0.0	0.0	13.8	21.5	2.6	3.8	2.8	6.3	5.2	7.6	3.7	0.2	0.0	3.5	2.7	0.0	1.2	7.7	0.0	0.0	3.7	0.0	1.5	0.0	0.2	0.0	0.2	3.0	2.3	0.0	2.2	0.3	0.5	0.0	0.0	0.0	0.1	0.1	4.9	0.0	0.1	0.1	10.8	16.9	5.7	11.6	10.4	5.7	16.9	7.9	14.2	17.6	44.7	152.9	0.0	21.0	97.1	9.8	1.7	10.2	32.1	75.1	45.4	86.4	0.2	3.3	4.3	20.2	2.2	0.0	0.0	3.0	0.1	20.2	12.1	4.7	0.0	0.2	1.6	4.6	1.8	2.2	14.8	42.3	5.7	18.6	0.0	0.5	14.1	4.3	3.5	30.8	9.2	171.6	12.9	12.5	24.4	21.6	86.9	0.2	4.4	0.2	45.5
PTPRB	PTPB	ENSG00000127329	"Protein tyrosine phosphatase, receptor type B"	P23467	12	70515866-70637440	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Angiogenesis	"Hydrolase, Protein phosphatase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 113.4;Ito cells: 448.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	7	"memory B-cell: 3.5"	"Lineage enriched"	"Detected in single"	7	"B-cells: 3.5"	"Cell line enhanced"	"Detected in some"		"EFO-21: 11.3;hTERT-RPE1: 9.1;HUVEC TERT2: 28.0;TIME: 40.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004782, HPA067868"	Uncertain		Approved	"Vesicles,Plasma membrane,Cell Junctions"		NA	NA		6700000	"Plasma membrane"	"Vesicles, Cell Junctions"	"CAB004782: , HPA067868: AB_2685911"	"unprognostic (3.18e-1)"	"unprognostic (2.99e-6)"	"unprognostic (1.56e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.55e-2)"	"unprognostic (1.77e-2)"	"prognostic favorable (6.05e-4)"	"unprognostic (4.59e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.40e-1)"	"prognostic favorable (1.02e-4)"	"unprognostic (2.91e-2)"	"unprognostic (7.18e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.38e-1)"	23.5	7.0	4.5	5.5	7.0	0.1	22.9	3.6	6.1	11.3	8.0	4.3	7.1	5.3	17.1	8.5	5.8	8.2	11.4	17.6	6.2	5.1	18.7	12.0	39.9	3.3	6.9	4.6	5.5	4.4	4.9	5.7	23.3	7.8	6.1	8.2	16.0	3.6	7.1	11.8	4.7	7.4	13.3	7.3	22.9	5.2	3.7	4.3	0.7	14.0	12.2	2.6	6.5	14.7	3.5	0.1	0.2	0.0	0.4	0.3	0.2	1.9	0.1	0.8	0.1	0.0	0.0	0.4	0.4	1.9	1.0	2.4	0.0	1.5	0.7	11.3	0.3	0.1	6.9	0.1	0.3	3.6	0.6	0.3	0.1	0.8	0.5	0.1	0.3	0.0	0.0	0.3	2.8	0.0	9.1	28.0	0.0	1.5	0.5	0.6	0.0	0.0	0.0	1.0	1.9	0.4	0.0	0.7	0.4	5.2	0.8	0.0	0.4	0.7	0.0	1.6	0.2	0.0	0.6	40.9	0.4	0.4	0.1	2.4	0.5	0.4	0.3	0.2	0.5	0.0	0.2	0.0	0.0	0.2	0.0	0.0	3.5	0.0	0.3	0.0	0.3	0.1	0.0	0.1	0.4	0.0	0.1	0.0	0.2	4.5	7.0	3.6	6.1	6.2	5.1	6.9	4.6	7.8	4.3	0.0	19.9	13.7	0.8	3.3	5.4	9.2	17.8	0.0	1.2	3.5	0.0	0.0	0.0	1.4	4.3	113.4	4.3	46.7	0.8	0.0	1.9	0.6	23.3	2.0	0.3	4.8	0.0	448.7	26.3	2.5	1.1	2.0	5.0	0.0	4.8	0.3	7.2	14.4	0.0	0.0	0.8	0.0	0.9	0.7	0.5	1.4	0.0	1.7	5.2	0.6
PTPRC	"CD45, GP180, LCA, T200"	ENSG00000081237	"Protein tyrosine phosphatase, receptor type C"		1	198638457-198757476	"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Group enriched"	"Detected in many"	4	"blood: 116.9;lymphoid tissue: 172.5"	"Cell type enhanced"	"Detected in many"	12	"B-cells: 266.4;granulocytes: 232.9;Kupffer cells: 338.8;Macrophages: 290.3;T-cells: 539.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 47.1;HEL: 26.6;HL-60: 24.0;JURKAT: 61.5;MOLT-4: 35.5;THP-1: 19.7;U-266/70: 22.0;U-266/84: 20.0;U-698: 28.2;U-937: 21.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000052, HPA000440, CAB002800, CAB056154, CAB068221"	Enhanced		Uncertain	Nucleoplasm,Vesicles	"Intracellular and membrane"	NA	NA			"Nucleoplasm, Vesicles"		"CAB000052: AB_2314143, CAB002800: AB_2237910, CAB056154: AB_2665572, CAB068221: AB_2665571, HPA000440: AB_611377"	"unprognostic (1.51e-2)"	"unprognostic (1.24e-2)"	"unprognostic (5.10e-3)"	"unprognostic (2.33e-3)"	"unprognostic (1.30e-1)"	"unprognostic (2.40e-3)"	"unprognostic (1.62e-1)"	"unprognostic (3.17e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.18e-2)"	"unprognostic (8.08e-2)"	"unprognostic (3.95e-1)"	"prognostic unfavorable (2.42e-4)"	"unprognostic (2.31e-1)"	"unprognostic (3.43e-2)"	"unprognostic (6.41e-2)"	"unprognostic (7.06e-2)"	9.8	2.9	3.4	48.0	6.2	36.1	4.3	1.3	3.5	3.1	5.6	2.8	0.5	4.9	2.9	3.9	4.8	5.6	8.8	4.9	3.9	4.5	4.4	5.2	27.5	93.2	7.9	1.3	2.9	2.1	0.3	2.5	4.5	5.3	4.2	5.8	3.3	10.7	1.0	1.7	2.5	22.2	4.5	13.2	89.3	6.5	2.3	5.3	172.5	4.6	3.9	53.2	13.1	3.7	28.5	42.8	94.7	103.8	53.7	76.1	116.9	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	47.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	26.6	0.0	0.0	0.0	24.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	61.5	0.5	0.7	0.0	0.0	35.5	14.5	0.1	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.3	0.4	0.0	0.1	0.1	0.0	0.0	19.7	0.3	0.0	0.2	0.1	0.1	22.0	20.0	28.2	0.0	21.5	0.1	20.8	52.0	56.3	76.1	99.7	64.5	28.5	52.9	72.7	42.8	26.8	60.2	60.3	94.7	53.7	103.8	6.4	54.6	116.9	3.4	6.2	1.3	3.5	3.9	4.5	7.9	1.3	5.3	5.3	41.7	86.9	266.4	0.7	14.1	0.0	4.1	7.6	21.4	26.1	1.8	0.0	0.4	0.0	0.0	2.0	11.9	0.1	23.3	0.0	0.5	8.9	0.9	232.9	3.0	90.3	0.0	1.2	14.1	338.8	1.5	1.1	290.3	20.3	120.0	0.2	0.0	0.1	0.0	0.0	1.7	0.2	6.5	4.3	0.2	0.2	13.2	0.7	539.1	0.5	0.9
PTPRK	R-PTP-kappa	ENSG00000152894	"Protein tyrosine phosphatase, receptor type K"	Q15262	6	127968779-128520674	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"memory B-cell: 2.3;naive B-cell: 4.8;naive CD8 T-cell: 1.6"	"Group enriched"	"Detected in many"	7	"B-cells: 4.8;T-cells: 1.6"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054056, HPA054822"	Uncertain		Supported	"Vesicles,Plasma membrane,Cell Junctions"		NA	NA		13000000	"Cell Junctions"	"Vesicles, Plasma membrane"	"HPA054056: AB_2682359, HPA054822: AB_2682614"	"unprognostic (3.15e-2)"	"unprognostic (1.07e-2)"	"unprognostic (5.79e-3)"	"unprognostic (4.95e-3)"	"unprognostic (1.89e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.27e-1)"	"unprognostic (6.06e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavorable (1.99e-4)"	"unprognostic (1.46e-1)"	"prognostic favorable (9.33e-5)"	"unprognostic (2.10e-1)"	"unprognostic (1.55e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.32e-2)"	12.0	5.2	18.6	10.7	20.3	1.2	20.9	4.7	24.4	12.2	21.9	25.6	11.2	25.7	12.1	10.3	9.1	13.2	29.6	11.4	17.2	12.6	13.3	23.6	17.4	5.7	20.5	19.3	15.6	25.7	11.4	12.2	17.4	14.9	16.3	23.4	3.9	18.3	17.5	9.1	13.5	27.4	14.6	17.1	6.4	24.6	2.7	23.7	15.3	10.1	6.5	7.6	18.4	15.1	4.8	0.0	0.0	0.0	0.4	1.6	0.2	4.5	4.9	2.9	0.2	6.2	8.3	3.0	12.3	23.8	5.1	4.6	8.1	3.8	0.0	3.7	11.3	14.8	12.9	3.1	9.7	7.2	13.6	4.9	0.1	7.5	11.2	7.6	0.0	0.4	6.1	9.0	10.6	14.5	13.3	13.8	4.4	0.0	0.2	12.4	9.1	6.9	0.0	3.1	8.3	6.3	24.8	6.3	0.8	12.6	9.3	15.5	0.0	12.7	14.2	0.7	3.5	3.9	0.3	23.4	8.0	5.6	15.5	11.1	0.1	1.6	0.0	10.2	0.0	8.4	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.1	0.1	0.0	4.8	0.4	1.6	0.0	0.4	0.0	0.0	0.1	0.2	18.6	20.3	4.7	24.4	17.2	12.6	20.5	19.3	14.9	23.7	23.8	27.4	9.7	78.6	56.3	3.1	19.3	76.5	18.7	33.0	17.4	3.9	21.8	0.0	51.8	3.4	46.7	63.1	0.0	53.2	4.5	30.5	99.0	1.1	36.5	5.1	9.5	42.2	8.0	1.0	2.1	15.8	1.8	16.9	2.8	41.3	7.0	84.8	57.5	17.0	11.2	0.6	58.2	35.8	3.6	5.8	33.2	22.4	1.0	48.9	100.5
PTPRT	"KIAA0283, RPTPrho"	ENSG00000196090	"Protein tyrosine phosphatase, receptor type T"	O14522	20	42072752-43189970	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protein phosphatase, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 23.5;fallopian tube: 17.0"	"Cell type enhanced"	"Detected in some"	17	"Bipolar cells: 40.8;Ciliated cells: 33.5;Early spermatids: 10.0;Late spermatids: 9.9"	"Cancer enhanced"	"Detected in many"		"breast cancer: 5.1"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 4.6;RPMI-8226: 1.2;SCLC-21H: 2.9;U-266/70: 1.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017336, CAB069423"	Approved					NA	NA					"CAB069423: AB_1622602, HPA017336: AB_1855943"	"unprognostic (7.17e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.61e-3)"	"unprognostic (1.08e-2)"	"unprognostic (5.95e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.31e-2)"	"unprognostic (6.93e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.37e-6)"	"unprognostic (3.16e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.81e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.17e-1)"	0.6	0.8	5.0	0.6	11.1	0.5	4.6	1.6	23.5	1.6	0.7	0.9	0.0	1.2	0.5	1.8	0.5	17.0	0.7	0.8	4.7	6.5	0.6	0.9	2.1	1.0	2.2	12.6	0.5	0.9	0.5	4.1	4.6	5.1	0.8	0.6	0.5	2.0	4.6	0.5	0.8	1.0	0.5	1.4	0.7	1.8	2.8	0.9	4.9	0.5	0.0	1.1	0.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.2	0.0	0.0	2.9	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	11.1	1.6	22.6	4.7	6.5	2.2	12.6	5.1	0.9	0.0	0.6	0.0	0.0	0.8	40.8	1.1	0.0	33.5	1.2	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.2	4.8	0.0	7.4	0.3	9.9	0.0	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.1
QKI	QK3	ENSG00000112531	"QKI, KH domain containing RNA binding"	Q96PU8	6	163414000-163578596	"Cancer-related genes, Predicted intracellular proteins"	"Differentiation, mRNA processing, mRNA splicing, mRNA transport, Translation regulation, Transport"	"Developmental protein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 100.3"	"Cell type enhanced"	"Detected in many"	5	"Cardiomyocytes: 308.9"	"Cancer enriched"	"Detected in all"	6	"glioma: 42.0"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"AF22: 64.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019123, CAB022602"	Enhanced	Supported	Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB022602: , HPA019123: AB_1855980"	"unprognostic (2.42e-1)"	"unprognostic (5.81e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.06e-2)"	"unprognostic (8.57e-2)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (1.27e-4)"	"unprognostic (1.34e-1)"	"unprognostic (7.06e-2)"	"unprognostic (1.76e-3)"	"unprognostic (1.08e-1)"	"unprognostic (5.15e-2)"	"prognostic unfavorable (2.31e-5)"	"prognostic unfavorable (3.69e-4)"	"unprognostic (1.16e-1)"	"unprognostic (3.86e-1)"	"unprognostic (4.09e-2)"	32.4	12.4	37.5	16.2	63.5	27.1	14.6	15.1	100.3	14.9	12.2	83.9	3.7	4.0	14.7	4.9	16.0	12.3	15.7	64.0	43.7	18.1	11.1	18.4	24.9	11.4	72.5	31.9	18.4	7.6	7.8	4.7	23.4	46.5	7.9	8.4	7.1	10.2	11.1	59.9	12.4	7.1	21.1	68.8	16.9	8.9	20.5	74.3	5.0	10.4	10.8	11.4	15.8	17.7	1.7	7.3	10.8	8.4	7.4	3.8	1.3	4.3	18.2	64.8	21.5	19.6	21.9	15.1	11.8	27.9	19.3	23.4	12.3	4.0	5.2	9.9	29.5	13.2	6.5	34.3	12.2	31.4	10.5	11.1	20.6	10.1	13.8	24.0	11.0	6.3	25.6	5.0	20.7	32.9	18.9	26.6	7.8	30.2	12.4	12.4	8.2	7.3	2.3	8.3	4.3	9.2	11.3	40.4	10.5	10.6	13.7	1.3	7.5	12.6	6.8	5.2	27.5	2.6	18.0	27.0	13.4	11.3	14.4	21.6	7.9	9.6	6.4	11.5	9.7	31.4	3.4	8.4	3.8	2.3	5.4	3.8	1.4	1.6	2.0	4.3	1.7	1.5	2.5	10.8	7.4	5.5	7.3	1.1	1.3	37.5	63.5	15.1	41.4	43.7	18.1	72.5	31.9	46.5	74.3	140.0	54.6	32.8	29.3	136.6	56.8	308.9	40.8	21.4	36.4	19.2	55.0	41.8	18.3	21.6	45.5	100.3	0.0	46.7	10.3	40.7	66.9	33.8	60.0	61.0	75.9	30.2	0.0	146.1	189.4	77.1	80.3	114.7	108.0	31.5	0.0	113.1	17.4	0.0	92.6	25.9	30.1	45.3	91.7	34.4	14.6	118.9	46.1	25.8	0.0	35.3
RABEP1	"neurocrescin, RAB5EP, rabaptin-5, RABPT5"	ENSG00000029725	"Rabaptin, RAB GTPase binding effector protein 1"	Q15276	17	5282265-5385812	"Cancer-related genes, Predicted intracellular proteins"	"Apoptosis, Endocytosis, Protein transport, Transport"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004549, HPA019669, HPA024235, HPA024691"	Supported		Supported	Vesicles		NA	NA			Vesicles		"CAB004549: AB_628192, HPA019669: AB_1856019, HPA024235: AB_1856020, HPA024691: AB_1856021"	"unprognostic (3.22e-1)"	"unprognostic (2.90e-2)"	"unprognostic (2.45e-1)"	"unprognostic (8.75e-3)"	"unprognostic (1.64e-1)"	"unprognostic (8.25e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.60e-2)"	"unprognostic (7.73e-2)"	"prognostic favorable (6.43e-4)"	"unprognostic (1.14e-1)"	"unprognostic (6.09e-3)"	"unprognostic (7.67e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.00e-1)"	"unprognostic (9.00e-3)"	19.2	16.7	29.6	18.8	31.1	10.3	31.8	24.1	32.7	16.3	14.2	19.0	12.5	10.9	18.1	18.3	12.7	12.9	15.0	27.4	29.7	25.9	16.6	21.8	13.1	21.1	36.2	24.4	15.5	12.1	38.4	16.3	20.2	31.3	22.2	14.2	10.0	14.8	16.0	41.2	11.6	13.4	20.8	35.6	17.7	15.7	11.8	29.0	21.4	17.6	13.5	25.5	14.5	13.0	37.6	14.2	12.6	19.3	9.1	11.2	6.4	18.1	22.4	23.6	13.2	24.8	24.9	13.0	23.6	17.6	24.7	23.7	19.9	7.6	38.3	19.8	23.8	13.9	14.3	34.5	19.6	35.0	25.2	31.6	23.4	27.8	15.0	23.4	15.3	15.5	19.2	13.5	23.8	30.9	15.0	21.4	19.5	19.9	18.9	21.4	12.6	25.3	12.6	10.9	9.9	10.9	24.0	28.3	12.7	12.5	16.6	10.2	16.0	20.9	20.8	19.8	21.8	37.8	7.0	18.8	21.3	9.9	21.4	27.6	11.1	12.1	20.6	16.5	25.1	14.5	4.9	9.0	8.7	11.2	9.2	9.8	30.2	8.7	10.6	9.2	37.6	11.1	9.7	12.6	9.1	19.3	14.2	8.0	6.4	29.6	31.1	24.1	32.5	29.7	25.9	36.2	24.4	31.3	29.0	32.8	42.6	30.0	28.5	21.3	46.6	80.2	15.3	24.1	45.5	17.4	37.3	31.8	34.9	26.0	5.7	28.5	14.6	0.0	20.5	27.9	29.4	43.8	11.6	25.1	71.8	33.4	15.6	34.4	30.4	4.6	31.4	35.3	28.7	27.1	14.3	85.2	23.9	31.6	26.5	29.4	49.0	25.8	29.9	70.4	72.8	17.8	21.6	29.6	14.6	29.3
RAC1	"p21-Rac1, Rac-1, TC-25"	ENSG00000136238	"Rac family small GTPase 1"	P63000	7	6374523-6403977	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"		Hydrolase	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB035994, HPA047820"	Approved		Approved	Nucleoplasm,Nucleoli,Cytosol		NA	NA		44000000	"Nucleoplasm, Cytosol"	Nucleoli	"CAB035994: , HPA047820: AB_2680167"	"unprognostic (8.66e-3)"	"unprognostic (2.47e-1)"	"unprognostic (4.00e-1)"	"unprognostic (2.40e-2)"	"unprognostic (1.88e-3)"	"unprognostic (4.06e-2)"	"prognostic unfavorable (1.74e-5)"	"prognostic unfavorable (4.59e-4)"	"unprognostic (1.59e-1)"	"unprognostic (2.04e-1)"	"prognostic unfavorable (4.57e-5)"	"unprognostic (3.63e-1)"	"prognostic unfavorable (2.11e-4)"	"unprognostic (1.95e-1)"	"unprognostic (2.11e-2)"	"unprognostic (4.13e-2)"	"unprognostic (8.72e-3)"	45.2	35.0	71.0	28.4	64.0	24.4	46.5	42.1	93.0	48.7	58.9	75.5	22.5	51.6	48.7	49.5	93.4	47.2	40.0	48.4	73.8	59.8	47.8	42.9	45.6	38.3	76.7	60.9	45.1	29.2	51.0	25.2	55.8	54.9	40.5	64.0	37.2	43.3	48.9	57.4	58.6	49.8	57.3	88.2	35.0	49.7	28.1	47.1	41.3	40.9	42.8	50.7	52.2	54.0	11.0	32.0	49.1	31.9	7.3	11.8	10.7	75.1	34.1	35.3	38.3	41.9	53.5	21.1	42.4	52.1	56.6	57.7	33.5	71.1	21.2	27.5	59.1	58.6	53.6	37.6	51.4	72.5	9.9	31.2	21.3	27.6	24.1	50.4	19.2	17.4	35.6	46.0	40.7	45.7	43.1	49.8	21.0	38.0	16.8	60.9	54.8	10.5	45.2	63.2	38.3	40.9	18.7	35.9	31.1	72.7	47.7	26.8	45.1	29.9	109.6	34.0	42.1	61.8	57.8	52.2	37.2	56.0	45.5	48.9	12.8	14.0	20.0	34.3	36.7	70.4	7.6	31.9	16.4	7.2	22.2	4.5	11.0	8.1	9.2	32.0	11.0	9.8	6.5	49.1	7.3	22.1	18.2	11.8	10.7	71.0	64.0	42.1	93.0	73.8	59.8	76.7	60.9	54.9	47.1	137.0	112.5	192.8	745.4	829.8	84.3	183.1	481.6	92.3	104.6	338.5	23.6	691.3	454.3	121.1	58.5	522.9	706.2	303.7	149.3	914.8	466.9	1152.5	132.3	288.4	738.1	138.2	323.2	535.2	736.9	43.7	441.0	745.3	435.3	408.4	531.5	280.9	231.2	471.0	444.5	611.5	54.4	472.1	495.6	210.1	328.6	1004.1	707.0	194.1	436.1	1582.5
RAD21	"hHR21, KIAA0078, SCC1"	ENSG00000164754	"RAD21 cohesin complex component"	O60216	8	116845935-116874866	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Apoptosis, Cell cycle, Cell division, Chromosome partition, DNA damage, DNA repair, Mitosis, Transcription, Transcription regulation"	"Activator, Developmental protein, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020044, CAB022065"	Supported		Enhanced	Nucleoplasm		NA	Yes			Nucleoplasm		"CAB022065: , HPA020044: AB_1856035"	"unprognostic (7.85e-2)"	"unprognostic (4.92e-1)"	"unprognostic (3.05e-1)"	"unprognostic (5.43e-3)"	"unprognostic (9.56e-2)"	"unprognostic (3.50e-1)"	"prognostic unfavorable (1.71e-4)"	"unprognostic (1.86e-3)"	"unprognostic (8.99e-2)"	"unprognostic (8.80e-2)"	"unprognostic (5.58e-3)"	"unprognostic (3.56e-2)"	"unprognostic (4.40e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.95e-1)"	31.6	40.9	48.2	30.5	52.2	78.5	37.7	58.8	55.3	24.2	36.3	37.5	21.5	24.8	30.5	25.3	32.1	23.1	22.0	37.8	45.6	44.1	30.5	27.9	29.6	49.2	54.3	35.4	33.5	18.2	29.1	30.0	38.9	45.5	26.5	37.3	19.0	25.3	31.0	37.8	24.0	26.0	33.4	49.7	31.2	31.5	37.6	56.2	58.3	41.9	20.9	50.4	37.1	36.0	8.7	5.4	17.9	7.1	8.0	25.4	6.2	41.6	20.5	40.2	22.5	20.2	17.5	18.0	29.0	27.5	32.2	29.8	16.8	39.3	61.6	16.0	20.6	17.2	23.3	34.2	18.7	37.8	81.7	21.9	62.8	25.2	21.3	12.7	20.1	37.0	14.9	15.4	18.8	22.8	21.3	25.1	89.9	25.2	86.3	27.7	25.1	92.1	11.9	23.6	53.8	25.9	33.8	29.2	30.9	19.2	24.5	50.8	26.2	30.4	82.1	19.6	22.0	34.4	24.9	18.4	22.8	33.4	23.8	30.3	45.7	52.5	55.5	19.5	29.0	27.2	17.2	4.5	15.5	11.0	5.3	11.2	8.7	12.9	13.0	5.4	8.3	13.5	13.0	17.9	8.0	7.1	4.5	25.4	6.2	48.2	52.2	58.8	55.3	45.6	44.1	54.3	35.4	45.5	56.2	238.2	123.7	70.9	67.0	84.9	73.4	149.3	48.4	87.0	138.8	52.4	29.5	106.6	36.5	47.5	247.8	88.8	56.4	70.0	38.8	119.7	73.7	80.6	143.9	61.8	58.9	63.5	81.0	64.4	91.5	303.2	107.9	82.3	65.8	97.4	62.9	99.6	49.1	57.5	100.0	50.1	60.7	71.1	54.7	31.6	81.6	87.8	95.1	93.8	69.2	65.3
RAD51B	"hREC2, R51H2, RAD51L1, REC2"	ENSG00000182185	"RAD51 paralog B"	O15315	14	67819779-68730218	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA recombination, DNA repair"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB016191, HPA051869"	Enhanced		Approved	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nuclear bodies"	Nucleoplasm	"CAB016191: AB_2238209, HPA051869: AB_2681644"	"unprognostic (9.10e-3)"	"unprognostic (5.45e-2)"	"unprognostic (4.92e-1)"	"unprognostic (6.65e-2)"	"unprognostic (2.38e-2)"	"unprognostic (4.85e-2)"	"unprognostic (6.42e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.08e-1)"	"unprognostic (6.80e-3)"	"unprognostic (1.47e-1)"	"unprognostic (6.25e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.49e-2)"	"unprognostic (6.79e-2)"	"unprognostic (8.13e-3)"	5.1	4.9	4.2	4.6	10.1	9.2	8.2	2.0	5.6	8.2	4.3	11.6	11.2	1.7	10.8	13.8	7.0	6.0	6.4	3.4	5.6	3.2	4.3	3.2	5.0	6.6	9.2	4.0	10.0	5.7	8.0	10.0	8.0	7.5	7.0	4.0	9.4	18.7	3.8	2.4	7.1	5.8	6.7	7.3	6.9	3.7	3.4	7.3	12.6	4.9	4.6	12.1	7.7	8.3	13.6	6.6	14.0	5.9	7.8	10.1	4.8	12.2	4.9	5.4	3.3	5.1	8.7	3.4	6.2	4.8	6.9	8.9	3.4	16.7	15.2	4.1	3.8	8.0	11.1	3.4	10.0	9.5	6.7	3.5	7.2	4.4	2.7	2.7	6.1	7.3	4.4	7.7	7.9	8.4	3.2	6.2	11.3	5.8	7.1	5.6	9.6	11.8	2.1	3.2	11.9	4.9	13.4	6.5	5.5	5.4	3.5	3.7	2.4	5.0	1.8	10.8	6.7	8.4	5.5	1.6	8.5	8.2	6.6	5.1	3.4	3.5	12.0	4.7	10.7	4.8	14.0	5.9	5.4	8.6	4.7	7.1	13.6	8.2	9.2	6.5	11.5	10.1	9.7	0.7	7.8	4.5	6.6	9.1	4.8	4.2	10.1	2.0	5.6	5.6	3.2	9.2	4.0	7.5	7.3	0.0	0.6	3.9	4.8	6.0	1.3	1.5	0.0	1.4	2.3	1.8	7.9	4.8	3.3	1.8	1.5	3.6	1.4	0.0	1.2	5.5	2.5	3.4	4.6	0.6	5.7	1.6	4.6	0.6	4.3	1.3	3.4	3.6	8.5	10.0	2.7	5.1	1.1	0.0	4.2	1.6	5.9	0.0	2.0	3.8	3.2	6.0	3.3	2.5	1.3	3.1
RAF1	"c-Raf, CRAF, Raf-1"	ENSG00000132155	"Raf-1 proto-oncogene, serine/threonine kinase"	P04049	3	12583601-12664226	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 53.9"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 53.9"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002640, CAB019291"	Approved		Approved	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"CAB019291: , HPA002640: AB_1856047"	"unprognostic (6.33e-2)"	"unprognostic (1.29e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.17e-3)"	"unprognostic (6.51e-3)"	"unprognostic (7.66e-3)"	"unprognostic (2.66e-3)"	"unprognostic (1.53e-2)"	"unprognostic (2.72e-1)"	"unprognostic (7.66e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.64e-2)"	"unprognostic (2.36e-2)"	19.5	15.6	15.1	14.7	17.1	32.2	17.5	35.2	18.9	19.9	20.3	21.1	19.6	18.4	24.9	15.7	24.6	18.6	20.2	39.3	15.3	11.0	21.7	36.2	19.7	15.7	16.0	13.4	24.9	31.3	30.7	16.9	24.8	14.3	18.8	19.2	25.0	18.3	18.4	79.7	23.9	29.6	23.7	13.8	22.1	23.7	16.7	17.8	27.7	26.9	27.9	26.1	20.5	20.4	6.6	9.3	53.9	9.9	8.5	8.6	7.7	15.4	17.8	27.1	21.0	23.6	19.1	54.6	23.6	40.0	31.3	35.5	13.9	12.8	16.2	11.3	36.5	16.9	9.9	28.5	20.9	32.6	28.3	22.4	21.8	21.4	12.9	23.9	21.2	20.7	17.6	21.2	32.2	26.1	21.6	22.4	24.9	15.8	42.6	30.1	26.4	27.2	15.7	27.6	19.3	24.2	22.0	23.8	20.4	18.7	23.4	8.5	17.8	19.3	18.7	12.5	22.0	31.0	28.1	16.0	21.5	20.5	18.0	26.2	33.2	52.9	34.9	18.5	24.8	22.8	11.3	9.7	18.4	7.4	9.9	7.5	6.6	7.3	7.2	9.3	6.3	7.5	7.6	53.9	8.5	9.6	4.2	8.6	7.7	15.1	17.1	35.2	18.9	15.3	11.0	16.0	13.4	14.3	17.8	20.8	36.5	39.7	31.1	30.6	51.6	25.8	28.1	25.4	21.6	26.2	62.8	34.3	11.6	22.9	7.1	29.1	32.5	0.0	32.0	39.8	32.9	38.2	33.5	36.5	25.2	41.3	28.2	31.3	36.8	3.4	36.2	34.2	25.3	29.7	29.6	32.1	28.8	34.8	38.9	15.7	84.2	32.3	33.0	17.7	27.4	38.0	52.1	38.3	29.5	36.9
RANBP2	"ADANE, ANE1, NUP358"	ENSG00000153201	"RAN binding protein 2"	P49792	2	108719481-108785811	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"mRNA transport, Protein transport, Translocation, Transport, Ubl conjugation pathway"	"RNA-binding, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564"	Supported		Supported	"Nucleoplasm,Nuclear membrane,Vesicles"		NA	NA			"Nuclear membrane"	"Nucleoplasm, Vesicles"	"CAB034063: AB_2176784, HPA018437: AB_2620151, HPA023960: AB_2671385, HPA049497: AB_2680794, HPA051675: AB_2681570, HPA067564: AB_2685862"	"unprognostic (2.51e-1)"	"unprognostic (3.99e-2)"	"unprognostic (1.22e-1)"	"unprognostic (4.37e-2)"	"unprognostic (1.28e-2)"	"unprognostic (9.30e-2)"	"unprognostic (5.47e-2)"	"unprognostic (2.91e-1)"	"unprognostic (4.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (4.23e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.62e-2)"	"unprognostic (8.74e-2)"	"unprognostic (3.08e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.53e-1)"	20.5	24.3	14.4	17.0	18.6	35.5	24.4	23.1	22.2	19.8	17.1	12.8	25.5	13.3	19.9	21.5	17.0	19.1	14.8	20.2	12.9	12.5	18.9	19.5	17.7	19.2	15.1	17.0	32.4	24.1	48.5	37.5	18.8	16.5	21.8	15.8	14.3	20.0	31.6	37.5	17.3	17.4	23.2	17.8	16.3	20.9	20.6	15.9	26.6	28.7	18.0	17.5	20.5	19.7	5.6	5.1	8.3	6.3	4.2	8.7	2.3	18.4	11.3	16.3	14.7	19.0	17.0	15.8	16.6	13.2	13.8	12.1	28.1	8.9	29.1	12.9	17.3	17.0	15.6	27.8	17.3	20.1	17.7	13.5	30.3	14.0	19.8	11.1	35.3	10.2	14.3	13.2	21.5	16.8	13.6	21.0	12.7	32.4	16.1	18.2	10.2	15.6	14.4	20.5	9.3	13.6	14.8	25.0	14.0	12.2	23.1	23.7	10.9	14.7	12.7	16.1	10.2	8.1	16.3	25.0	14.4	19.1	10.1	18.5	13.4	19.8	26.4	11.2	16.0	11.1	8.3	5.3	5.1	7.6	3.4	8.7	5.5	6.3	6.9	4.2	5.6	6.2	6.7	8.3	4.2	6.3	5.1	5.1	2.3	14.4	18.6	23.1	22.2	12.9	12.5	15.1	17.0	16.5	15.9	71.5	71.1	34.9	25.8	49.5	43.3	85.9	33.1	57.6	70.5	55.8	68.7	22.7	1.7	31.3	59.8	43.8	25.7	0.0	44.1	15.0	32.3	38.2	83.1	49.9	41.1	30.2	102.2	27.0	44.0	22.0	35.6	64.2	45.5	49.5	50.9	18.7	36.5	25.9	52.6	15.4	37.7	45.3	62.9	74.1	59.2	59.2	34.0	44.5	31.5	31.5
RAP1GDS1	SmgGDS	ENSG00000138698	"Rap1 GTPase-GDP dissociation stimulator 1"	P52306	4	98261384-98443861	"Cancer-related genes, Predicted intracellular proteins"		"GTPase activation"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Early spermatids: 332.5;Late spermatids: 174.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019060	Approved		Supported	Cytosol		NA	NA		120000	Cytosol		"HPA019060: AB_1856068"	"unprognostic (8.12e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.69e-3)"	"unprognostic (1.66e-1)"	"unprognostic (9.11e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.57e-3)"	"unprognostic (3.44e-1)"	"unprognostic (6.31e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.60e-1)"	"prognostic favorable (2.00e-4)"	"unprognostic (7.11e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.76e-1)"	11.3	9.7	25.8	12.9	28.2	9.0	13.1	28.0	43.6	9.3	12.0	20.0	9.0	7.3	8.9	8.7	13.7	6.1	8.6	6.8	29.7	28.0	12.3	15.2	10.1	15.3	36.9	20.5	7.9	13.8	8.4	15.3	9.6	30.1	8.0	14.0	8.0	8.6	11.9	3.6	10.5	9.0	16.3	37.0	12.5	8.2	15.5	26.2	16.2	13.0	4.8	17.0	12.5	7.6	13.9	31.9	16.0	14.7	19.5	22.7	8.4	17.9	10.5	13.4	11.5	17.3	20.7	5.4	30.6	17.0	18.3	14.4	7.8	23.3	21.3	10.0	22.8	8.9	10.3	16.5	28.0	24.8	21.8	6.8	13.2	13.5	10.2	34.3	21.9	9.2	24.1	17.1	16.1	25.0	15.2	23.9	21.9	8.7	18.3	45.2	9.4	36.2	10.9	4.9	14.7	7.6	15.1	8.0	7.2	18.6	14.1	19.9	12.1	12.8	28.8	16.9	7.7	6.5	14.3	23.5	19.0	13.6	8.7	18.1	6.3	11.0	18.0	15.7	16.5	24.6	16.0	10.6	5.7	14.2	14.6	14.3	13.9	14.5	13.6	16.7	11.0	7.8	11.9	1.6	19.5	14.7	31.9	22.7	8.4	25.8	28.2	28.0	30.5	29.7	28.0	36.9	20.5	30.1	26.2	14.9	9.8	23.0	8.8	12.4	41.4	10.1	20.4	5.3	15.9	15.7	47.1	5.8	19.9	16.8	332.5	13.5	11.1	23.3	18.3	13.9	11.6	11.1	15.0	16.3	22.1	14.3	20.1	16.0	29.4	174.5	8.6	23.3	16.9	29.7	13.9	15.6	19.2	16.7	10.3	15.9	66.0	0.0	11.8	14.6	22.5	14.6	3.8	30.8	17.4	12.8
RARA	"NR1B1, RAR"	ENSG00000131759	"Retinoic acid receptor alpha"	P10276	17	40309192-40357643	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 26.6"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 63.9;SK-BR-3: 40.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058282, HPA071548"			Supported	"Nucleoplasm,Nucleoli,Actin filaments,Cytosol"		NA	NA			Nucleoplasm	"Nucleoli, Actin filaments, Cytosol"	"HPA058282: AB_2683666, HPA071548: "	"unprognostic (8.05e-3)"	"unprognostic (1.89e-1)"	"unprognostic (9.48e-3)"	"prognostic favorable (2.60e-4)"	"unprognostic (8.67e-3)"	"unprognostic (4.87e-3)"	"unprognostic (2.77e-1)"	"unprognostic (5.73e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.29e-3)"	"unprognostic (1.59e-2)"	"unprognostic (5.60e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.09e-2)"	27.6	13.5	5.0	18.6	7.6	32.3	23.7	11.5	15.2	30.2	29.6	5.0	16.8	18.0	23.8	23.9	17.3	23.3	30.2	24.3	5.9	6.1	14.6	24.0	32.0	23.4	4.6	7.8	50.0	9.3	7.4	18.1	16.6	6.5	22.9	8.5	26.8	12.1	32.7	43.1	14.3	31.6	18.6	3.7	31.1	14.3	21.8	2.9	9.7	16.3	15.4	20.2	31.5	20.3	1.0	6.1	26.6	9.3	2.5	2.6	1.9	5.1	12.1	3.6	6.1	7.1	10.9	3.6	4.2	6.4	6.2	4.0	8.3	4.4	2.7	6.6	9.5	5.7	15.0	4.1	10.0	3.6	20.5	6.1	7.8	6.1	8.1	11.4	2.8	24.7	15.3	2.9	6.6	8.4	23.7	9.2	2.4	4.9	6.0	7.0	63.9	1.8	9.5	3.1	4.7	3.8	3.6	21.3	10.3	3.6	4.1	1.5	12.4	9.0	40.6	12.4	3.6	38.2	11.2	10.7	7.8	13.3	13.6	4.6	14.4	4.8	2.3	13.1	5.5	23.0	8.7	4.2	15.7	1.6	6.9	2.6	1.0	1.7	1.7	6.1	0.9	0.8	1.3	26.6	2.5	9.3	1.8	1.4	1.9	5.0	7.6	11.5	15.2	5.9	6.1	4.6	7.8	6.5	2.9	3.0	9.5	5.6	22.6	17.3	24.2	3.2	10.2	4.0	2.3	7.0	5.9	1.9	11.6	14.3	58.0	20.4	52.7	0.0	16.9	5.1	23.8	11.2	34.6	22.8	11.3	3.2	9.2	22.7	35.4	50.8	38.6	37.4	27.0	0.0	14.2	9.3	16.8	24.6	21.5	11.8	8.2	32.3	33.0	2.9	6.9	16.6	4.3	11.5	13.2	19.2
RB1	"OSRC, PPP1R130, RB"	ENSG00000139687	"RB transcriptional corepressor 1"	P06400	13	48303726-48599436	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"monocytes: 107.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"MOLT-4: 58.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000095, CAB016687, HPA050082"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000095: , CAB016687: AB_1622010, HPA050082: AB_2681008"	"unprognostic (4.24e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.62e-2)"	"unprognostic (4.67e-2)"	"unprognostic (2.04e-2)"	"unprognostic (3.86e-1)"	"unprognostic (4.69e-2)"	"unprognostic (7.08e-2)"	"unprognostic (1.59e-1)"	"prognostic unfavorable (6.92e-4)"	"unprognostic (4.06e-2)"	"unprognostic (9.40e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.79e-1)"	"unprognostic (9.99e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.70e-1)"	19.6	21.5	14.9	23.2	18.4	14.7	28.1	25.6	19.4	18.0	13.2	11.5	19.0	12.3	16.8	19.5	27.9	12.7	15.3	19.5	15.4	15.3	18.1	12.1	25.4	30.1	17.0	11.8	15.2	11.6	12.8	17.2	21.5	16.0	15.5	15.3	11.6	20.0	17.4	27.9	20.3	14.3	16.8	23.6	29.4	13.7	14.4	15.3	39.1	19.9	15.8	25.3	17.4	23.6	20.5	10.3	13.2	12.2	3.6	4.6	4.0	9.1	4.9	13.5	14.5	6.7	7.8	6.1	18.0	15.0	19.0	16.2	4.2	16.2	11.8	4.2	12.0	10.5	12.7	17.5	14.5	29.0	16.5	6.7	21.7	10.2	7.2	7.1	18.6	20.6	4.3	8.9	12.3	15.8	15.9	13.1	29.2	7.2	9.7	21.7	4.3	58.2	9.4	6.6	20.8	5.4	25.0	13.5	13.5	19.7	8.9	0.6	13.8	17.8	8.9	14.7	12.5	9.7	24.3	10.1	11.8	7.7	14.3	16.2	4.3	1.2	0.1	6.2	11.7	15.9	11.0	9.7	5.0	4.6	12.2	3.7	17.4	3.8	4.6	9.3	20.5	3.2	3.8	13.2	3.6	12.1	10.3	4.5	4.0	14.9	18.4	25.6	19.4	15.4	15.3	17.0	11.8	16.0	15.3	3.0	18.7	56.5	18.3	25.2	14.4	15.9	17.8	20.1	14.8	29.6	27.5	5.9	13.3	15.8	20.6	33.6	15.9	0.0	10.4	8.0	15.4	21.4	11.5	14.7	64.6	17.5	16.8	38.6	83.9	10.6	24.2	88.8	25.3	107.4	18.5	21.8	13.3	9.9	26.9	21.1	18.5	19.4	20.6	27.9	14.3	33.4	3.7	20.8	15.0	14.4
RBM10	"DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5"	ENSG00000182872	"RNA binding motif protein 10"	P98175	X	47144869-47186813	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA034972, HPA057372"	Approved		Enhanced	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA034972: AB_10602919, HPA057372: AB_2683421"	"unprognostic (9.07e-2)"	"prognostic favorable (6.71e-4)"	"unprognostic (7.83e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.86e-1)"	"unprognostic (3.04e-2)"	"unprognostic (4.47e-3)"	"unprognostic (8.11e-2)"	"unprognostic (9.86e-3)"	"unprognostic (1.76e-1)"	"prognostic favorable (2.86e-6)"	"unprognostic (1.18e-1)"	"unprognostic (6.23e-3)"	"unprognostic (3.33e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.40e-2)"	"unprognostic (1.20e-3)"	18.1	22.2	19.8	38.0	21.9	34.0	17.1	41.2	22.9	19.9	20.5	25.7	22.7	21.8	22.1	17.3	23.7	26.2	29.1	21.7	19.8	18.3	18.4	21.6	17.1	27.2	20.1	19.2	36.4	27.4	20.1	28.3	24.9	17.9	23.5	14.2	18.5	25.1	28.8	20.6	23.8	23.7	18.9	17.2	24.7	20.5	8.7	21.4	32.9	26.8	18.0	22.7	17.6	20.9	15.9	14.6	14.4	19.2	12.3	18.3	11.5	20.9	22.7	21.8	25.8	11.7	9.6	25.3	16.0	9.4	16.5	16.1	19.8	17.2	25.6	9.8	11.0	21.1	20.5	28.4	20.1	9.1	26.0	25.7	19.1	27.6	20.7	17.1	19.3	23.1	12.6	9.7	27.3	22.2	11.9	17.7	24.8	15.9	20.6	10.0	32.0	35.4	32.8	35.9	15.8	25.5	31.3	18.2	26.4	12.2	18.6	25.9	19.7	24.1	18.1	15.3	13.5	22.2	19.3	15.4	19.5	24.8	21.0	16.7	21.7	17.5	21.1	17.3	14.0	27.2	14.0	10.8	14.4	18.3	14.5	17.0	15.9	14.7	15.3	12.3	15.6	14.8	14.1	10.1	12.3	19.2	14.6	16.6	11.5	19.8	21.9	41.2	21.9	19.8	18.3	20.1	19.2	17.9	21.4	38.7	44.1	14.3	20.3	9.8	26.5	30.9	25.5	30.8	36.4	8.7	13.7	27.7	10.0	17.2	0.6	18.8	24.8	0.0	15.2	23.9	18.1	14.5	23.1	19.8	16.9	20.6	34.3	14.7	12.9	1.6	16.7	11.8	15.1	18.0	24.9	14.0	16.8	18.6	24.1	11.5	25.3	0.0	16.9	5.7	6.1	9.3	38.6	17.5	23.4	16.5
RBM15	"OTT, OTT1"	ENSG00000162775	"RNA binding motif protein 15"	Q96T37	1	110338506-110346681	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	RNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 48.7"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB015201, HPA019824, HPA049642"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB015201: , HPA019824: AB_1856113, HPA049642: AB_2680839"	"unprognostic (1.70e-1)"	"unprognostic (1.63e-1)"	"unprognostic (9.39e-2)"	"unprognostic (7.57e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.11e-2)"	"prognostic unfavorable (7.61e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.84e-2)"	"unprognostic (4.91e-2)"	"unprognostic (9.67e-2)"	"unprognostic (2.76e-2)"	"prognostic unfavorable (1.37e-4)"	"prognostic favorable (7.97e-4)"	"unprognostic (2.88e-1)"	"unprognostic (2.46e-2)"	"unprognostic (2.12e-1)"	8.5	7.6	6.3	12.2	7.6	48.7	7.9	18.6	8.3	6.6	8.8	7.6	8.3	7.3	8.5	7.2	8.0	7.3	6.6	8.8	5.2	4.3	6.3	11.0	10.5	13.7	8.3	6.0	8.6	7.5	7.1	8.1	7.1	5.9	5.7	5.7	8.1	7.4	6.4	17.2	7.2	11.3	5.5	5.0	12.5	8.3	14.0	7.9	21.8	7.0	5.3	13.4	6.5	8.6	10.5	4.8	9.8	6.9	5.0	9.9	5.5	7.1	7.8	7.0	7.2	4.5	4.7	11.1	3.8	5.0	6.0	7.9	9.5	6.5	13.5	6.1	4.3	4.9	10.1	11.0	9.5	8.9	14.0	10.1	10.9	11.8	6.9	6.2	11.8	11.6	4.3	6.6	8.3	7.8	3.1	6.3	10.3	15.4	23.7	6.0	7.3	10.6	9.3	15.0	6.3	4.4	12.6	10.6	9.2	4.9	7.2	8.5	4.3	8.3	10.5	8.0	7.9	7.2	14.3	4.4	5.7	10.4	6.2	6.9	18.3	9.2	29.3	8.6	12.0	7.1	8.2	6.9	9.4	7.0	6.0	9.9	10.5	7.7	6.0	4.8	10.0	6.8	8.2	9.8	5.0	6.4	4.7	7.5	5.5	6.3	7.6	18.6	8.3	5.2	4.3	8.3	6.0	5.9	7.9	6.0	3.0	15.3	8.2	29.5	5.4	10.8	7.6	9.4	2.3	3.5	13.7	7.6	0.0	3.4	6.2	9.8	7.5	0.0	3.1	6.2	8.9	8.6	28.8	13.5	5.6	0.0	9.2	10.4	5.7	4.1	3.7	5.5	8.5	1.8	8.4	5.6	4.2	2.9	4.9	3.3	7.1	0.0	13.3	24.4	14.5	29.5	3.9	12.5	7.6	6.7
RECQL4	RecQ4	ENSG00000160957	"RecQ like helicase 4"		8	144511288-144517845	"Cancer-related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"				"Tissue enhanced"	"Detected in many"		"bone marrow: 21.0;lymphoid tissue: 18.9"	"Cell type enhanced"	"Detected in many"	13	"Extravillous trophoblasts: 7.1;Spermatocytes: 12.6;Spermatogonia: 21.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Group enriched"	"Detected in many"	14	"B-cells: 1.9;monocytes: 1.0;T-cells: 1.6"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB017800, HPA025821"	Supported		Enhanced	Nucleoplasm		NA	Yes			Nucleoplasm		"CAB017800: , HPA025821: AB_1856168"	"unprognostic (5.92e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.05e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.17e-2)"	"unprognostic (3.17e-2)"	"prognostic unfavorable (1.91e-4)"	"unprognostic (1.12e-2)"	"unprognostic (4.12e-2)"	"unprognostic (7.53e-2)"	"unprognostic (2.65e-2)"	"unprognostic (4.26e-2)"	"unprognostic (1.12e-3)"	"unprognostic (8.82e-3)"	"unprognostic (1.74e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.34e-1)"	2.0	1.6	2.6	12.3	5.6	21.0	2.8	11.5	3.7	1.8	4.3	1.5	1.6	5.6	2.5	4.9	9.4	1.5	1.9	1.9	2.3	1.7	1.6	1.9	1.6	5.9	1.5	2.2	1.9	3.5	0.3	2.4	2.7	2.2	7.7	1.5	1.4	5.4	0.9	2.1	9.4	4.8	1.1	1.7	4.7	3.0	18.1	1.8	18.9	2.5	5.3	8.0	1.6	1.8	1.9	0.1	0.0	1.0	0.0	1.6	0.2	10.4	18.7	8.7	18.4	0.5	0.9	15.3	10.6	1.9	7.9	6.6	18.4	15.5	7.1	7.1	1.7	4.6	12.7	5.8	4.5	2.2	12.5	22.0	25.7	32.0	13.7	0.1	6.5	21.5	1.1	0.6	8.8	1.8	1.1	2.2	14.6	25.5	9.3	2.7	32.4	23.7	17.7	6.1	8.7	22.4	24.9	6.9	11.9	2.1	11.3	17.3	10.4	14.4	12.1	3.7	2.5	14.7	14.4	2.9	12.8	38.7	15.3	19.5	5.2	5.4	12.1	7.3	20.2	12.8	0.0	0.1	0.0	1.1	1.0	0.0	1.9	0.5	1.1	0.1	0.0	0.9	1.6	0.0	0.0	0.0	0.1	0.0	0.2	2.6	5.6	11.5	3.7	2.3	1.7	1.5	2.2	2.2	1.8	0.0	0.0	2.2	0.4	1.3	2.5	1.6	2.5	0.0	0.0	0.0	3.9	1.2	0.0	0.4	3.1	0.0	0.4	0.0	0.4	7.1	0.8	0.5	0.0	0.6	3.0	0.0	0.0	0.0	0.3	6.2	1.1	0.6	0.0	0.0	1.4	0.2	0.3	0.0	1.4	0.3	1.6	0.0	0.4	12.6	21.1	0.9	1.3	0.0	3.1	0.4
REL	"c-Rel, I-Rel"	ENSG00000162924	"REL proto-oncogene, NF-kB subunit"	Q04864	2	60881521-60931610	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Basal keratinocytes: 459.8;monocytes: 666.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 27.2;U-698: 52.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB004404	Uncertain					NA	NA					"CAB004404: AB_670194"	"unprognostic (2.77e-1)"	"unprognostic (2.05e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.20e-1)"	"unprognostic (2.23e-1)"	"unprognostic (4.41e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.15e-2)"	"unprognostic (2.15e-1)"	"unprognostic (5.87e-2)"	"unprognostic (4.38e-2)"	"unprognostic (4.37e-1)"	"unprognostic (2.82e-2)"	"unprognostic (2.91e-2)"	"unprognostic (3.53e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.66e-2)"	11.2	4.7	3.5	25.9	5.4	35.1	7.7	9.8	5.0	9.7	8.4	4.3	6.2	4.8	8.7	6.6	11.9	6.9	10.1	5.7	3.2	3.1	4.5	8.0	20.5	15.3	5.5	1.8	13.3	7.1	10.8	9.1	6.3	4.7	10.8	5.3	6.0	7.9	6.9	5.0	14.2	9.3	7.7	10.6	22.5	6.0	5.0	5.2	15.3	7.2	6.4	23.8	21.3	14.1	20.8	9.5	11.2	12.9	6.5	7.2	5.5	3.0	1.9	1.4	1.9	1.1	1.1	3.1	1.0	1.6	1.0	1.2	1.4	2.7	27.2	2.7	0.9	2.1	3.7	2.5	1.8	2.1	7.4	2.4	2.7	2.9	1.4	0.6	5.4	3.3	1.1	4.8	2.2	3.4	1.3	2.5	3.0	3.6	1.8	0.7	1.6	3.9	2.2	1.8	2.0	0.7	5.5	4.0	1.1	1.1	12.3	1.4	1.5	3.0	3.3	1.0	2.2	1.9	2.4	2.6	2.3	2.6	1.5	1.6	2.3	1.1	52.8	1.3	4.7	1.1	6.5	9.6	6.0	7.2	10.9	5.0	14.4	3.8	5.5	9.5	20.8	2.4	5.4	11.2	6.5	12.9	6.7	4.6	5.5	3.5	5.4	9.8	5.0	3.2	3.1	5.5	1.8	4.7	5.2	297.8	270.0	109.1	108.9	459.8	79.2	3.5	30.6	224.9	226.3	48.8	80.5	23.7	3.3	27.0	2.4	35.8	37.1	23.3	25.4	48.8	168.6	77.4	397.7	17.9	49.4	55.6	40.8	30.1	118.1	1.5	14.4	236.3	128.2	666.4	32.4	20.3	28.9	43.2	22.3	5.5	51.9	12.9	114.0	28.3	27.0	404.9	64.9	103.8	41.6	203.1
RET	"CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51"	ENSG00000165731	"Ret proto-oncogene"	P07949	10	43077027-43130351	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 63.9"	"Cell type enriched"	"Detected in some"	44	"Horizontal cells: 74.7"	"Cancer enhanced"	"Detected in many"		"breast cancer: 11.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 6.7"	"Group enriched"	"Detected in many"	13	"dendritic cells: 2.1;monocytes: 6.7"	"Cell line enhanced"	"Detected in some"		"MCF7: 18.0;NB-4: 11.8;SH-SY5Y: 91.8;THP-1: 27.4"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in all"	6	"midbrain: 95.5"	"CAB002581, HPA008356, HPA008495"	Approved	Supported	Approved	"Golgi apparatus,Plasma membrane,Cytosol"		No	NA		260000	"Golgi apparatus, Cytosol"	"Plasma membrane"	"CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: "	"unprognostic (7.94e-2)"	"unprognostic (3.68e-2)"	"unprognostic (4.49e-1)"	"prognostic unfavorable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (9.13e-4)"	"unprognostic (1.27e-2)"	"unprognostic (3.62e-2)"	"unprognostic (2.86e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.54e-3)"	"unprognostic (4.43e-1)"	"unprognostic (9.35e-5)"	"unprognostic (1.64e-3)"	"unprognostic (8.28e-2)"	"unprognostic (3.67e-3)"	"unprognostic (2.02e-2)"	1.8	15.2	1.1	1.8	1.3	0.7	1.2	4.1	9.0	1.9	3.1	0.9	1.1	1.5	0.9	0.6	1.2	0.7	1.0	1.2	1.5	5.8	1.0	11.7	0.7	0.8	17.5	1.2	0.8	1.3	63.9	6.3	0.8	16.8	2.2	1.5	2.8	13.6	2.0	4.5	1.1	2.6	1.1	2.8	0.6	2.1	2.0	0.0	0.1	0.8	5.1	0.6	1.9	1.4	0.2	2.1	0.0	6.7	0.0	0.3	0.4	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.0	0.0	11.8	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	91.8	0.0	0.0	0.0	0.1	1.3	27.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.2	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	6.7	2.1	0.3	0.4	1.1	1.3	4.1	9.0	1.5	5.8	17.5	1.2	16.8	0.0	0.0	0.3	0.0	0.5	0.2	0.1	1.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.1	0.0	0.0	0.2	1.7	1.0	1.2	1.1	0.8	0.1	74.7	0.0	0.0	0.0	1.4	0.3	0.0	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.4	0.0	1.4	0.4	1.1	0.5	0.0	0.0	0.0	0.1
RHOA	"ARH12, ARHA, Rho12, RhoA, RHOH12"	ENSG00000067560	"Ras homolog family member A"	P61586	3	49359145-49412998	"Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins"	"Cell cycle, Cell division, Host-virus interaction"	Hydrolase	"Cancer-related genes, Disease mutation, Ectodermal dysplasia, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB005052	Approved		Supported	"Plasma membrane,Cytosol"		NA	NA		65000000	"Plasma membrane, Cytosol"		"CAB005052: AB_562216"	"unprognostic (1.50e-1)"	"unprognostic (3.38e-1)"	"prognostic favorable (3.08e-4)"	"unprognostic (8.75e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.24e-1)"	"prognostic unfavorable (9.15e-4)"	"unprognostic (1.39e-1)"	"unprognostic (8.83e-2)"	"unprognostic (9.44e-3)"	"unprognostic (2.21e-2)"	"unprognostic (4.29e-2)"	"prognostic favorable (3.21e-6)"	"unprognostic (5.14e-2)"	"unprognostic (7.50e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.52e-2)"	141.1	89.5	63.0	79.8	60.6	91.4	93.1	34.3	77.3	80.3	79.1	100.4	48.9	63.6	84.4	66.4	116.7	67.8	74.2	72.5	57.6	54.8	104.0	80.7	104.6	102.4	74.0	43.8	102.7	64.9	45.8	48.2	105.3	68.8	76.0	80.3	81.6	66.5	72.0	86.0	73.9	90.8	88.9	97.3	116.0	73.4	57.3	60.3	127.1	108.1	80.1	99.8	103.4	75.7	42.6	78.4	124.2	125.7	38.3	50.5	151.5	55.7	43.0	54.0	57.9	62.0	94.0	42.2	121.4	77.8	84.9	78.3	36.4	58.5	81.8	34.9	145.8	49.3	31.8	59.3	66.2	87.2	63.1	35.3	78.1	57.9	42.7	66.5	77.0	58.6	73.4	47.1	69.4	55.9	85.8	108.6	43.5	41.6	51.5	100.6	26.6	83.8	75.1	51.6	56.0	54.8	38.8	54.3	64.3	73.4	63.7	19.8	45.1	72.9	52.8	54.7	55.8	34.2	86.8	117.2	68.2	61.8	89.9	87.2	51.2	103.7	93.9	66.4	75.8	77.8	52.5	99.7	106.8	49.1	125.7	41.6	42.6	41.4	47.6	78.4	37.5	32.2	40.1	124.2	38.3	120.4	58.7	50.5	151.5	63.0	60.6	34.3	77.3	57.6	54.8	74.0	43.8	68.8	60.3	360.3	233.2	266.1	228.8	240.6	42.2	113.5	155.4	182.0	182.0	171.0	5.9	328.4	288.5	303.4	30.3	372.7	339.7	93.5	302.0	572.5	345.6	260.3	251.7	153.0	691.2	77.9	225.0	312.5	712.8	42.2	310.4	490.6	310.4	582.5	261.8	172.7	313.0	270.7	383.3	255.4	33.0	271.7	354.1	227.5	221.8	244.4	439.3	304.1	267.8	270.4
RHOH	"ARHH, RhoH, TTF"	ENSG00000168421	"Ras homolog family member H"	Q15669	4	40191053-40246967	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 54.8;lymphoid tissue: 94.7"	"Group enriched"	"Detected in many"	5	"B-cells: 118.6;granulocytes: 136.5;Melanocytes: 54.0;T-cells: 125.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 34.9;HMC-1: 26.8;JURKAT: 35.1;MOLT-4: 48.5;U-266/70: 18.8;U-266/84: 15.1;U-698: 32.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA030345, HPA061314"	Uncertain		Approved	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"HPA030345: AB_10601607, HPA061314: "	"unprognostic (4.00e-2)"	"unprognostic (1.83e-4)"	"unprognostic (1.24e-2)"	"unprognostic (2.22e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.16e-1)"	"unprognostic (2.73e-2)"	"unprognostic (2.30e-2)"	"unprognostic (4.30e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.38e-1)"	"unprognostic (3.31e-6)"	"unprognostic (2.96e-1)"	"unprognostic (3.91e-2)"	"unprognostic (4.46e-2)"	"unprognostic (2.44e-2)"	1.8	0.6	0.6	33.8	1.1	21.7	5.2	0.4	0.4	1.3	2.4	0.5	0.4	1.6	2.0	0.9	2.5	1.5	4.1	1.1	0.6	0.7	1.6	1.7	4.8	43.2	0.8	0.2	0.7	0.8	0.0	0.9	0.3	0.8	2.1	2.0	1.0	7.8	0.6	0.5	1.2	15.1	0.7	1.2	33.1	2.7	0.7	0.6	94.7	1.6	1.9	41.0	5.1	1.5	41.2	4.7	32.2	0.2	12.3	54.8	21.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	34.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	5.2	0.0	0.0	0.0	5.7	26.8	0.4	0.0	0.0	0.0	0.0	0.0	35.1	0.4	0.3	0.0	0.0	48.5	3.6	0.6	0.0	0.1	5.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.6	0.1	0.1	0.0	0.1	0.0	0.0	18.8	15.1	32.2	0.0	1.2	0.0	32.2	0.2	29.6	21.6	0.1	19.4	30.5	34.6	29.1	0.3	41.2	54.8	43.3	1.6	12.3	0.2	4.7	47.0	21.1	0.6	1.1	0.4	0.4	0.6	0.7	0.8	0.2	0.8	0.6	3.0	16.4	118.6	1.4	6.4	0.0	0.8	2.5	1.4	4.5	0.0	0.0	0.1	0.0	0.0	0.4	0.7	0.0	23.3	0.0	0.1	4.1	1.1	136.5	0.0	2.2	0.0	0.0	1.8	4.6	0.0	0.0	12.1	54.0	10.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.2	0.0	6.0	0.2	125.8	0.0	1.8
RMI2	"BLAP18, C16orf75, MGC24665"	ENSG00000175643	"RecQ mediated genome instability 2"	Q96E14	16	11249619-11351762	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA replication"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 31.7;testis: 29.6"	"Cell type enhanced"	"Detected in many"	11	"Cytotrophoblasts: 100.7;Peritubular cells: 40.0;Spermatogonia: 42.9;Syncytiotrophoblasts: 39.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 6.5"	"Group enriched"	"Detected in many"	5	"B-cells: 6.5;T-cells: 3.0"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA040995	Uncertain		Supported	"Nuclear speckles,Cytosol"		NA	Yes			"Nuclear speckles"	Cytosol	"HPA040995: AB_10795531"	"unprognostic (2.76e-1)"	"prognostic favorable (5.69e-5)"	"unprognostic (1.17e-1)"	"unprognostic (3.09e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.80e-3)"	"prognostic unfavorable (2.77e-5)"	"unprognostic (3.98e-1)"	"unprognostic (1.16e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.44e-3)"	"unprognostic (3.89e-1)"	"unprognostic (2.18e-1)"	"unprognostic (5.50e-2)"	"unprognostic (3.68e-2)"	"unprognostic (3.60e-3)"	"unprognostic (1.03e-1)"	1.0	1.8	4.2	18.0	5.1	4.8	2.8	0.7	4.1	2.8	7.3	1.0	0.4	4.3	2.5	3.2	11.8	1.0	2.6	1.9	2.5	1.5	3.1	2.3	2.9	17.9	1.6	5.6	3.6	1.6	0.7	1.1	13.2	1.2	2.6	9.0	0.8	2.9	1.7	1.1	8.7	5.6	1.1	1.4	4.2	4.0	29.6	1.2	31.7	1.4	2.8	20.4	3.6	4.5	6.5	0.6	0.9	0.0	0.3	3.0	0.3	19.2	12.9	25.4	10.8	1.1	5.5	10.6	11.2	8.9	10.6	17.7	4.9	22.9	26.7	9.7	5.2	12.0	11.3	10.8	10.7	17.3	5.2	10.1	14.6	7.6	32.6	0.4	5.6	6.6	1.2	2.1	4.6	4.4	4.2	5.8	11.8	20.1	21.3	5.5	22.2	19.3	26.2	21.3	26.9	5.1	23.5	27.4	28.5	6.3	12.5	14.6	11.6	9.5	15.9	8.3	15.3	27.0	8.4	1.8	8.5	8.0	16.3	1.6	5.8	9.6	31.7	7.9	18.5	15.7	0.0	0.0	0.9	0.6	0.0	0.0	6.5	0.2	0.0	0.4	2.5	1.8	0.7	0.2	0.3	0.0	0.6	3.0	0.3	4.2	5.1	0.7	4.1	2.5	1.5	1.6	5.6	1.2	1.2	0.0	0.3	4.9	6.4	6.1	0.1	0.8	5.1	0.0	2.3	7.0	0.0	100.7	5.0	2.3	2.2	0.7	1.1	23.3	0.4	27.0	2.6	1.6	0.0	0.8	15.8	0.0	2.4	1.3	1.0	4.3	14.7	3.4	3.3	1.8	5.9	0.0	1.1	3.5	40.0	0.0	0.5	32.3	0.9	31.4	42.9	4.6	39.9	0.0	7.0	2.8
RNF213	"C17orf27, KIAA1554, KIAA1618, MYMY2, NET57"	ENSG00000173821	"Ring finger protein 213"	Q63HN8	17	80260866-80398786	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Angiogenesis, Ubl conjugation pathway"	"Hydrolase, Transferase"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 36.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003347, HPA026790"	Approved		Supported	Cytosol		NA	NA			Cytosol		"HPA003347: AB_1079204, HPA026790: AB_10602296"	"unprognostic (8.98e-2)"	"unprognostic (1.60e-1)"	"unprognostic (8.97e-3)"	"prognostic unfavorable (4.65e-5)"	"unprognostic (7.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (2.23e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.57e-2)"	"unprognostic (3.85e-1)"	"unprognostic (1.96e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.52e-3)"	"unprognostic (8.92e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.56e-2)"	17.0	15.1	7.4	16.9	10.3	22.4	10.2	4.7	7.5	11.0	12.2	15.6	14.9	8.5	16.6	13.0	13.2	9.7	12.1	8.5	7.8	7.8	17.1	11.6	15.4	17.9	10.9	5.6	11.5	9.0	41.1	11.4	15.1	10.0	11.2	8.0	12.3	11.7	12.5	9.0	8.7	14.8	13.6	14.3	17.0	10.6	5.9	8.7	24.5	15.9	7.5	18.2	13.6	15.4	7.2	13.9	37.9	9.6	11.4	12.1	1.8	16.2	28.9	2.9	2.0	10.6	16.2	2.2	4.1	9.0	18.6	15.9	3.1	7.5	1.0	3.5	8.6	19.9	9.5	3.9	5.3	6.3	36.8	1.8	2.5	11.7	5.4	4.5	2.7	2.6	8.9	3.6	10.4	4.5	5.8	14.3	11.8	4.7	6.1	6.9	3.9	10.6	1.1	2.1	3.0	6.7	7.3	6.7	1.2	5.2	14.1	2.8	3.9	10.0	21.2	7.6	6.8	4.8	3.4	18.5	10.4	8.3	6.1	4.2	2.7	2.5	2.9	7.8	3.2	3.7	6.9	9.6	4.2	12.1	8.0	8.1	6.2	8.6	9.7	2.3	7.2	6.9	8.5	37.9	11.4	6.9	13.9	6.4	1.8	7.4	10.3	4.7	7.5	7.8	7.8	10.9	5.6	10.0	8.7	83.4	56.5	111.7	32.9	31.8	18.0	28.5	79.0	38.8	38.7	96.0	47.1	18.7	11.6	100.5	1.1	68.4	78.6	23.3	139.5	24.8	43.3	49.8	44.1	45.9	84.7	22.3	44.2	79.2	104.8	2.0	56.4	97.6	28.7	162.3	61.5	23.6	181.0	73.7	48.4	56.6	71.2	64.7	34.9	1.4	4.4	30.1	18.2	168.3	34.5	65.7
RNF43	"DKFZp781H0392, FLJ20315, URCC"	ENSG00000108375	"Ring finger protein 43"	Q68DV7	17	58352500-58417595	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"	"Ubl conjugation pathway, Wnt signaling pathway"	"Developmental protein, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Enterocytes: 33.4;Mucus-secreting cells: 39.0;Undifferentiated cells: 47.8"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 41.7"	"Region enriched"	"Detected in many"	7	"cerebellum: 30.6"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CACO-2: 13.4;Hep G2: 26.2;OE19: 29.2"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA008079	Uncertain					NA	NA					"HPA008079: AB_1856371"	"unprognostic (2.53e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.46e-2)"	"unprognostic (2.56e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.33e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.93e-1)"	"unprognostic (1.05e-1)"	"unprognostic (5.69e-2)"	"unprognostic (3.79e-1)"	"prognostic favorable (6.04e-9)"	"unprognostic (3.61e-3)"	"unprognostic (2.56e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.04e-2)"	0.4	9.4	2.2	6.2	3.5	1.9	4.5	30.6	4.3	3.4	26.4	0.9	21.3	18.5	1.7	9.1	10.0	3.9	8.1	3.3	1.9	1.3	8.0	7.0	6.1	2.7	0.8	1.1	1.6	13.2	3.0	13.3	8.7	4.1	8.0	16.3	3.8	13.7	19.0	0.5	8.9	29.0	0.9	0.8	0.9	4.9	3.1	0.7	3.0	1.8	5.7	6.6	4.0	4.4	0.9	1.1	1.7	1.8	5.6	3.6	1.2	0.6	9.3	1.7	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	13.4	4.5	3.8	4.8	0.0	1.1	2.6	0.3	3.6	0.0	7.9	6.5	3.0	0.4	26.2	0.0	3.7	2.7	0.0	7.4	0.0	1.1	0.5	0.0	1.2	0.2	3.3	0.0	0.1	2.0	3.5	0.2	29.2	0.6	6.2	0.0	2.0	3.3	5.1	1.0	0.3	0.8	0.4	0.3	3.2	1.1	1.0	0.0	0.1	1.1	0.0	0.0	3.4	1.6	2.9	0.3	0.4	2.2	1.7	0.2	1.6	3.1	0.8	3.2	0.9	2.5	3.6	0.4	0.9	2.3	3.0	0.8	5.6	1.8	1.1	1.2	1.2	2.2	3.5	30.6	4.3	1.9	1.3	0.8	1.1	4.1	0.7	3.0	6.2	0.5	15.7	8.5	2.4	3.5	10.2	4.0	3.4	17.4	2.0	19.4	13.3	5.6	1.2	0.7	33.4	0.0	2.4	2.2	0.6	8.7	0.0	8.7	2.3	4.8	14.9	0.6	0.6	1.3	0.3	0.7	13.5	2.8	39.0	11.7	4.5	24.6	0.4	2.2	2.8	0.0	0.4	1.1	0.5	5.4	4.9	3.9	47.8	5.4
ROS1	"c-ros-1, MCF3, ROS"	ENSG00000047936	"ROS proto-oncogene 1, receptor tyrosine kinase"	P08922	6	117288300-117425855	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"epididymis: 38.6;lung: 20.2"	"Group enriched"	"Detected in some"	5	"Alveolar cells type 1: 14.9;Alveolar cells type 2: 56.7"	"Cancer enriched"	"Detected in some"	13	"lung cancer: 6.9"	"Group enriched"	"Detected in some"	10	"cerebral cortex: 7.4;olfactory region: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"GAMG: 16.3;HSkMC: 8.7;hTCEpi: 18.1;LHCN-M2: 12.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA049098, HPA072424"	Uncertain		Approved	Vesicles		NA	NA			Vesicles		"HPA049098: AB_2680628, HPA072424: AB_2686519"	"unprognostic (8.18e-2)"	"unprognostic (4.64e-3)"	"unprognostic (1.60e-1)"	"unprognostic (2.37e-2)"	"unprognostic (7.57e-2)"	"unprognostic (2.05e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.79e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.42e-1)"	"unprognostic (5.20e-2)"	"unprognostic (1.56e-12)"	"unprognostic (1.09e-2)"	"unprognostic (2.81e-1)"	"unprognostic (1.91e-1)"	"unprognostic (2.12e-1)"	0.3	0.2	0.2	0.0	0.4	0.0	0.2	0.2	7.4	0.2	0.4	0.0	7.9	0.0	0.2	38.6	0.2	0.2	0.0	0.2	0.2	0.2	0.4	0.2	20.2	0.0	0.2	2.5	0.2	0.2	0.0	0.3	0.7	0.0	0.2	0.3	0.0	0.2	2.3	0.2	0.7	0.3	0.0	0.2	0.2	0.3	0.7	0.0	0.0	0.2	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.3	0.2	0.0	0.0	0.1	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	8.7	18.1	0.2	1.6	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	1.6	0.0	2.2	1.4	0.1	1.7	0.0	0.0	0.0	1.6	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.2	7.4	0.2	0.2	0.2	2.5	0.0	0.0	14.9	56.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
RPL10	"DXS648, DXS648E, FLJ23544, L10, NOV, QM"	ENSG00000147403	"Ribosomal protein L10"	P27635	X	154389955-154409168	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"	"Translation regulation"	"Developmental protein, Ribonucleoprotein, Ribosomal protein"	"Autism, Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB010339, HPA011311"	Enhanced		Enhanced	"Endoplasmic reticulum,Cytosol"		NA	NA		130000	"Endoplasmic reticulum, Cytosol"		"CAB010339: AB_2181277, HPA011311: AB_1856431"	"unprognostic (2.46e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.72e-1)"	"unprognostic (2.14e-2)"	"unprognostic (1.25e-2)"	"unprognostic (2.06e-1)"	"unprognostic (6.11e-2)"	"unprognostic (9.01e-3)"	"unprognostic (1.91e-1)"	"unprognostic (2.21e-1)"	"unprognostic (5.39e-2)"	"unprognostic (3.37e-1)"	"prognostic unfavorable (7.67e-6)"	"unprognostic (6.84e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.65e-2)"	"unprognostic (5.68e-2)"	103.6	65.3	41.4	108.0	48.5	103.7	152.6	82.4	70.7	118.2	80.6	44.6	107.8	51.3	100.4	75.5	105.2	122.3	52.6	82.5	38.2	31.9	112.1	155.0	97.6	190.2	48.2	37.4	223.5	242.3	35.0	51.9	87.4	53.1	83.6	77.1	66.7	109.9	101.5	125.9	121.8	108.9	78.7	51.4	93.9	90.5	33.9	47.2	158.9	198.9	137.9	134.4	86.9	119.3	252.9	168.6	64.4	124.1	149.1	304.9	445.3	190.6	88.4	88.6	67.9	201.2	381.1	78.4	73.4	170.1	141.3	179.7	78.4	85.8	378.1	177.6	122.3	139.8	74.1	173.4	175.7	121.4	83.0	137.5	51.0	63.4	85.9	236.7	109.5	75.5	287.6	278.2	84.9	265.3	244.2	221.6	161.8	71.8	120.9	137.9	95.7	119.3	106.6	69.8	188.1	152.9	143.1	84.0	210.1	154.1	68.1	71.1	118.8	17.7	156.2	216.7	89.4	56.8	153.2	106.6	49.4	94.0	111.2	162.3	287.9	207.9	376.0	75.1	158.2	61.7	64.4	124.1	18.1	149.9	107.7	256.2	252.9	251.6	186.2	151.2	243.2	304.9	231.1	13.0	149.1	94.9	168.6	178.0	445.3	41.4	48.5	82.4	70.7	38.2	31.9	48.2	37.4	53.1	47.2	1664.5	2043.1	10322.4	11239.3	10721.6	451.7	309.0	3949.0	1271.5	2545.5	1934.9	233.7	5960.7	5721.4	3854.4	49.9	6113.6	2058.8	1915.6	11641.3	8484.3	6948.0	9869.1	2815.7	3204.1	6194.0	254.3	2785.1	5085.5	7653.2	131.8	7835.9	9465.3	7747.1	9437.5	6244.9	793.3	8332.0	5018.5	3353.3	5769.1	609.3	2942.7	9122.3	99.1	315.1	12724.6	6324.6	8194.7	7230.3	10693.0
RPL22	"EAP, L22"	ENSG00000116251	"Ribosomal protein L22"	P35268	1	6181269-6209389	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Heparin-binding, Ribonucleoprotein, Ribosomal protein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA068294			Approved	Nucleoplasm,Nucleoli		NA	NA		320000	Nucleoli	Nucleoplasm	"HPA068294: AB_2732781"	"unprognostic (3.16e-3)"	"unprognostic (1.28e-1)"	"unprognostic (3.13e-1)"	"unprognostic (3.62e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.29e-3)"	"unprognostic (4.40e-2)"	"unprognostic (7.06e-2)"	"unprognostic (3.26e-1)"	"unprognostic (1.48e-1)"	"unprognostic (4.24e-2)"	"unprognostic (1.46e-3)"	"unprognostic (3.83e-1)"	"unprognostic (3.88e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.98e-1)"	75.5	71.5	54.3	79.7	42.8	124.7	75.0	46.7	39.5	95.8	73.9	39.2	53.9	66.5	133.6	63.9	103.9	59.1	61.8	50.8	47.4	38.6	58.8	90.2	55.3	142.6	50.6	39.7	163.1	154.8	30.4	57.0	49.8	37.4	90.8	46.4	57.0	140.3	66.8	114.0	79.7	62.6	106.6	58.3	79.1	62.0	38.2	35.0	95.3	91.0	112.8	81.1	101.5	91.9	75.6	62.3	11.0	38.9	42.2	98.8	73.9	89.4	25.5	54.4	55.5	38.3	60.3	43.0	78.2	31.5	28.8	24.6	50.6	77.8	138.9	64.4	28.9	19.9	51.8	40.8	40.6	38.0	68.0	66.5	135.0	58.1	62.8	38.0	178.6	54.2	53.1	33.7	25.6	53.1	59.6	35.9	39.0	111.2	84.2	33.0	39.5	78.0	145.7	33.8	59.9	56.7	75.3	112.8	107.6	42.1	31.1	75.2	69.0	63.6	184.4	143.1	49.3	59.3	141.6	87.7	41.1	45.3	54.2	73.4	67.7	92.9	210.2	27.2	184.7	25.4	11.0	38.9	8.8	38.0	34.3	66.9	75.6	71.1	52.3	59.8	72.4	98.8	78.1	2.9	42.2	27.8	62.3	54.0	73.9	54.3	42.8	46.7	39.5	47.4	38.6	50.6	39.7	37.4	35.0	413.9	647.4	2117.2	1742.6	1617.7	195.0	241.8	1080.3	472.4	833.7	554.8	123.7	1561.4	1614.8	1042.5	368.7	1236.7	707.2	537.3	1569.0	2352.9	1052.3	1320.4	878.8	1234.2	1317.3	133.5	877.3	1218.4	1697.8	247.8	1877.2	1676.9	1020.7	1556.4	1647.3	322.2	1580.5	1090.7	1160.1	1724.2	283.7	763.2	1114.2	317.0	420.5	1692.2	1548.7	1448.0	2302.5	1714.3
RPL5	"L5, PPP1R135"	ENSG00000122406	"Ribosomal protein L5"	P46777	1	92831983-92841924	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein, RNA-binding, rRNA-binding"	"Cancer-related genes, Diamond-Blackfan anemia, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"HPA043717, HPA054444"	Approved		Supported	"Nucleoli,Nucleoli rim,Endoplasmic reticulum,Cytosol"		NA	NA		130000	"Endoplasmic reticulum, Cytosol"	"Nucleoli, Nucleoli rim"	"HPA043717: AB_10964719, HPA054444: AB_2732584"	"unprognostic (5.81e-3)"	"unprognostic (3.96e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.52e-1)"	"unprognostic (9.44e-3)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-3)"	"unprognostic (9.95e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.98e-2)"	"unprognostic (3.48e-1)"	"prognostic unfavorable (6.81e-5)"	"unprognostic (2.26e-2)"	"unprognostic (3.12e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.97e-1)"	119.4	80.3	50.0	70.0	50.1	113.8	140.5	46.9	46.8	158.6	111.4	45.0	75.1	61.7	135.2	114.6	159.4	100.5	73.1	73.0	43.5	43.1	99.7	114.9	89.9	148.2	54.5	36.2	296.8	306.5	40.8	90.3	90.2	44.3	175.4	78.8	64.3	121.5	73.2	109.1	97.8	95.3	153.4	61.9	130.1	90.0	68.8	45.7	156.6	210.0	97.7	118.9	191.2	146.6	104.5	85.2	12.8	45.9	72.4	143.0	142.1	118.8	51.1	91.0	76.7	118.4	239.2	146.0	71.1	95.2	88.5	63.5	135.2	52.0	224.2	114.2	79.8	84.0	76.0	104.3	133.2	113.2	71.0	142.8	116.3	85.0	124.4	142.0	178.1	49.1	195.6	210.2	78.6	173.1	160.6	122.3	118.5	144.0	118.2	101.4	67.4	141.8	201.9	140.6	90.4	96.5	130.3	176.3	144.8	107.4	99.0	77.6	92.9	46.3	129.2	206.7	78.2	71.2	245.0	74.2	44.7	81.8	84.6	128.1	73.2	69.5	151.7	30.3	153.6	30.3	12.8	45.9	7.2	60.9	44.8	122.1	104.5	111.5	91.6	85.2	88.4	143.0	123.9	4.4	72.4	38.3	71.1	83.2	142.1	50.0	50.1	46.9	46.8	43.5	43.1	54.5	36.2	44.3	45.7	607.4	848.7	2690.4	3540.6	2525.4	316.8	352.2	1200.0	674.6	1189.7	390.8	84.4	2237.8	1689.4	1278.7	1159.8	1643.6	564.1	537.3	2338.5	3530.6	1572.9	2535.7	1002.7	856.3	1297.7	138.2	1189.1	1198.2	1468.3	888.7	2620.2	1565.9	1334.5	1646.5	1585.6	343.0	1936.2	1164.3	2027.0	1766.3	226.7	1034.8	1885.9	531.9	457.4	2528.9	2185.2	1965.9	2487.8	3230.9
RPN1	OST1	ENSG00000163902	"Ribophorin I"	P04843	3	128619970-128681075	"Cancer-related genes, Plasma proteins, Predicted membrane proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009748, HPA026828, HPA051520"	Enhanced		Enhanced	"Endoplasmic reticulum,Cytosol"		NA	NA		8200000	"Endoplasmic reticulum"	Cytosol	"CAB009748: AB_2182230, HPA026828: AB_10610418, HPA051520: AB_2681521"	"unprognostic (4.83e-2)"	"unprognostic (5.92e-2)"	"unprognostic (1.10e-1)"	"unprognostic (7.67e-2)"	"unprognostic (2.36e-1)"	"unprognostic (2.12e-2)"	"prognostic unfavorable (4.80e-4)"	"unprognostic (2.71e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.28e-2)"	"unprognostic (4.58e-3)"	"unprognostic (2.87e-1)"	"unprognostic (7.68e-2)"	"unprognostic (7.86e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.44e-1)"	"unprognostic (9.74e-2)"	52.3	37.5	22.2	26.6	23.8	24.4	48.2	20.9	31.4	45.8	40.8	31.9	58.8	28.5	38.3	110.2	32.2	38.3	38.8	47.1	23.0	28.0	55.4	174.0	47.4	50.6	26.4	18.3	37.8	62.9	43.5	36.9	58.3	24.3	31.4	41.1	28.6	54.1	55.5	34.4	24.0	37.0	33.5	31.8	48.0	33.7	26.9	23.3	34.3	69.1	27.3	36.5	32.7	39.7	26.7	53.1	64.4	43.5	23.4	45.1	53.3	60.5	33.0	27.6	50.7	74.7	50.1	62.5	52.2	68.7	69.4	80.9	68.4	57.1	37.9	49.3	75.3	64.7	61.0	44.5	46.5	68.0	27.2	28.6	66.8	24.6	56.2	82.4	54.2	35.2	41.5	54.4	45.6	67.5	46.5	54.2	28.7	27.5	50.9	45.5	55.4	30.0	59.6	35.0	81.1	30.3	32.9	37.1	91.2	48.1	36.4	42.5	24.5	42.9	44.5	52.8	36.9	47.6	56.1	35.2	35.9	28.1	52.5	38.7	54.9	43.2	40.5	58.9	40.4	51.8	38.8	43.5	35.7	37.3	40.0	45.1	26.7	30.7	33.8	43.5	18.3	19.1	29.2	64.4	23.4	40.2	53.1	30.5	53.3	22.2	23.8	20.9	31.4	23.0	28.0	26.4	18.3	24.3	23.3	56.6	71.5	37.3	71.3	44.0	11.5	35.3	61.1	66.9	47.8	106.4	7.9	108.3	13.3	99.9	13.7	58.2	107.9	46.7	81.2	161.1	79.3	88.0	42.7	155.3	122.7	19.1	41.6	107.4	134.1	20.7	87.2	73.4	55.6	36.9	102.4	27.5	98.9	83.4	60.5	80.2	11.7	45.3	39.6	49.9	59.8	46.7	131.0	50.0	106.2	66.4
RSPO2	MGC35555	ENSG00000147655	"R-spondin 2"	Q6UXX9	8	107899316-108083648	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Sensory transduction, Wnt signaling pathway"	"Developmental protein, Heparin-binding"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 27.0;placenta: 20.1"	"Cell type enhanced"	"Detected in some"	13	"Early spermatids: 1.4;Late spermatids: 2.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	5	"intermediate monocyte: 1.6"	"Lineage enriched"	"Detected in single"	17	"monocytes: 1.6"	"Cell line enhanced"	"Detected in some"		"HEK 293: 3.6;HEL: 3.3;NTERA-2: 2.0;U-138 MG: 3.6;U-266/70: 10.7"	"Group enriched"	"Detected in some"	7	"amygdala: 8.2;cerebral cortex: 18.2;hippocampal formation: 23.2"	"Group enriched"	"Detected in many"	5	"amygdala: 23.3;cerebral cortex: 18.0;hippocampal formation: 24.1;midbrain: 33.2"	"HPA024764, CAB025900, HPA053068"	Uncertain				"Secreted in other tissues"	NA	NA					"CAB025900: , HPA024764: AB_10603236, HPA053068: AB_2682031"	"unprognostic (1.10e-2)"		"unprognostic (2.18e-1)"	"unprognostic (3.97e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.19e-1)"	"unprognostic (8.33e-3)"		"unprognostic (1.82e-1)"	"unprognostic (9.48e-2)"	"unprognostic (1.31e-1)"		"unprognostic (1.40e-1)"	"unprognostic (8.45e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.17e-2)"	0.4	0.5	3.9	1.4	6.3	0.5	0.2	1.9	27.0	3.6	12.0	4.2	3.6	5.1	0.3	3.6	8.9	0.2	4.8	0.5	5.8	10.5	0.2	1.1	9.3	0.2	15.7	5.4	1.1	0.2	0.2	2.8	20.1	2.0	11.6	10.1	15.5	0.2	3.4	0.3	0.3	5.8	0.7	1.3	0.2	8.3	2.0	1.7	0.0	0.2	0.0	0.2	2.2	1.2	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	3.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.2	0.3	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.3	0.0	0.2	0.0	3.6	0.2	0.1	0.0	10.7	0.0	0.0	1.1	0.4	0.0	0.0	0.3	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	6.3	1.9	27.0	5.8	10.5	15.7	5.4	2.0	1.7	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.2	0.3	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.8	0.0	0.0	0.0
RSPO3	"FLJ14440, THSD2"	ENSG00000146374	"R-spondin 3"	Q9BXY4	6	127118604-127197765	"Cancer-related genes, Predicted secreted proteins"	"Sensory transduction, Wnt signaling pathway"	Heparin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"Early spermatids: 10.8;Fibroblasts: 10.4;Ito cells: 16.0;Leydig cells: 25.3;Sertoli cells: 6.5"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"cerebellum: 5.7;hippocampal formation: 20.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 23.5;BJ hTERT+: 4.1;hTERT-RPE1: 7.8;U-138 MG: 5.2;U-87 MG: 5.1"	"Low region specificity"	"Detected in all"			"Region enhanced"	"Detected in many"		"hippocampal formation: 32.5"	HPA029957	Uncertain				"Secreted to blood"	NA	NA					"HPA029957: AB_10602087"	"unprognostic (4.77e-2)"	"unprognostic (3.95e-2)"	"unprognostic (1.27e-2)"	"unprognostic (2.27e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.99e-1)"	"unprognostic (9.71e-2)"	"unprognostic (1.49e-2)"	"unprognostic (3.77e-2)"	"unprognostic (3.21e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.37e-1)"	"unprognostic (1.07e-3)"	"unprognostic (7.94e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.64e-2)"	"unprognostic (7.89e-3)"	18.5	10.5	2.8	12.1	0.8	0.0	40.7	5.7	2.3	12.9	8.5	0.0	23.8	1.2	50.3	32.5	23.7	14.9	7.6	4.2	20.5	1.7	3.3	4.2	3.8	10.2	0.8	2.4	13.2	1.5	0.0	2.6	24.1	0.8	10.2	4.7	8.6	3.9	15.3	19.7	2.2	6.7	34.1	0.6	1.4	10.8	12.4	0.0	0.2	2.9	2.1	0.9	9.3	39.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.5	0.0	0.0	1.4	0.0	0.0	0.0	4.1	0.2	0.5	0.0	0.0	0.0	0.5	0.2	0.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	7.8	2.6	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.2	0.0	0.0	0.2	0.0	0.0	0.0	5.2	2.0	0.7	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.8	5.7	2.2	20.5	1.7	0.8	2.4	0.8	0.0	0.0	0.0	0.0	0.0	0.8	1.7	0.4	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	10.8	2.8	0.0	0.0	0.0	1.0	10.4	0.6	0.0	0.0	1.3	0.0	0.0	16.0	0.3	1.1	25.3	0.0	1.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.5	2.7	0.0	0.1	0.1	1.4	0.0	0.0	0.1
RUNX1	"AML1, AMLCR1, CBFA2, PEBP2A2"	ENSG00000159216	"Runt related transcription factor 1"	Q01196	21	34787801-36004667	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 54.3;lymphoid tissue: 58.6"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 17.0"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEL: 61.2;HMC-1: 36.9;JURKAT: 56.6"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA004176, HPA037912"	Enhanced		Enhanced	Nucleoplasm,Vesicles		No	No			Nucleoplasm	Vesicles	"HPA004176: AB_1078412, HPA037912: AB_2675733"	"unprognostic (4.06e-3)"	"unprognostic (2.35e-2)"	"unprognostic (1.42e-2)"	"unprognostic (1.52e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.62e-1)"	"unprognostic (5.87e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.12e-3)"	"unprognostic (2.33e-2)"	"unprognostic (3.47e-2)"	"prognostic unfavorable (3.44e-15)"	"unprognostic (1.48e-1)"	"unprognostic (1.50e-1)"	"unprognostic (6.17e-2)"	"unprognostic (5.47e-2)"	11.5	3.2	5.2	14.8	7.3	29.8	54.3	1.0	4.3	12.5	4.7	3.8	4.0	3.8	2.9	7.4	6.5	4.6	12.4	7.6	6.1	2.0	4.2	6.7	17.9	13.9	8.5	1.1	6.5	5.8	1.6	5.5	6.4	6.0	9.9	5.1	3.5	29.8	8.8	14.4	8.3	5.1	6.8	12.3	10.6	12.7	2.9	6.6	58.6	4.6	5.7	14.2	11.0	9.1	3.2	3.4	17.0	3.9	1.3	4.8	2.0	12.2	0.9	0.0	0.0	3.2	4.1	8.1	6.9	7.1	3.9	2.9	0.6	9.4	6.1	0.4	6.1	6.5	11.1	0.7	8.3	5.6	9.3	0.9	61.2	2.4	2.8	5.9	7.0	36.9	8.0	5.0	11.8	11.7	5.4	2.2	56.6	4.1	3.5	8.2	2.6	28.5	11.2	0.5	6.7	3.6	28.9	21.4	3.7	5.2	4.9	0.3	0.0	7.2	1.8	2.5	1.8	3.7	16.6	9.1	6.4	8.3	9.5	10.4	11.8	4.8	5.7	8.0	15.5	9.3	17.0	3.2	6.3	3.4	1.4	3.3	3.2	3.1	3.2	0.9	3.1	4.8	3.8	3.5	1.3	3.9	3.4	4.0	2.0	5.2	7.3	1.0	4.3	6.1	2.0	8.5	1.1	6.0	6.6	50.6	30.7	14.5	44.6	37.0	2.1	2.2	38.2	56.2	39.8	19.2	0.0	0.8	1.7	35.7	16.8	5.8	12.0	0.0	24.4	19.6	25.7	45.4	16.3	4.3	57.2	0.0	5.8	4.9	79.5	21.7	4.4	63.0	27.0	31.5	10.8	0.5	63.1	12.7	4.2	1.2	0.6	0.0	31.5	23.0	24.9	17.7	2.1	37.4	14.4	53.7
RUNX1T1	"AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2"	ENSG00000079102	"RUNX1 translocation partner 1"	Q06455	8	91954967-92103286	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 57.8"	"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 122.4;Ito cells: 87.8;Leydig cells: 89.2;Peritubular cells: 93.0;Sertoli cells: 64.7"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in all"	4	"cerebellum: 57.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"Daudi: 13.2;fHDF/TERT166: 11.2;HEL: 24.1;HSkMC: 9.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049852, HPA070951"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA049852: AB_2680914, HPA070951: AB_2686326"	"unprognostic (2.37e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.62e-1)"	"unprognostic (3.37e-4)"	"unprognostic (2.29e-4)"	"unprognostic (5.56e-3)"	"unprognostic (1.24e-2)"	"unprognostic (1.62e-2)"	"unprognostic (2.11e-2)"	"unprognostic (2.37e-1)"	"unprognostic (5.70e-4)"	"unprognostic (8.98e-3)"	"unprognostic (6.78e-2)"	"unprognostic (1.51e-1)"	"unprognostic (7.80e-3)"	9.6	4.6	7.7	4.5	11.5	0.4	6.9	57.8	13.0	14.0	7.8	1.1	2.0	2.0	11.8	5.9	4.1	7.7	7.8	12.3	5.8	4.0	2.5	1.3	6.0	2.0	3.6	9.6	7.7	1.8	1.7	8.6	8.7	4.2	4.2	4.0	5.3	4.7	4.1	5.5	3.6	3.6	10.3	3.0	2.9	4.2	5.6	3.7	0.0	5.2	3.3	1.8	5.7	5.9	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	1.3	3.5	5.1	0.0	5.2	7.9	3.5	5.4	0.0	0.0	13.2	0.0	11.2	0.0	0.0	2.8	0.3	2.3	0.0	2.2	24.1	0.0	0.0	1.4	0.0	0.0	9.7	0.0	5.8	0.3	0.0	7.4	0.0	0.1	0.0	0.9	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	4.2	0.0	0.0	0.0	5.7	0.0	0.0	0.8	0.3	0.0	0.6	0.0	2.6	0.0	4.2	0.5	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	7.7	11.5	57.8	13.0	5.8	4.0	3.6	9.6	4.2	3.7	0.0	0.6	0.0	0.1	5.6	122.4	43.1	0.0	0.0	1.2	0.0	15.7	1.1	1.7	0.0	2.0	49.6	0.0	0.0	0.2	0.2	62.1	0.3	1.1	0.5	1.7	33.4	45.7	87.8	4.9	4.0	89.2	0.8	10.1	0.0	0.0	3.9	0.3	0.0	93.0	0.0	7.1	64.7	41.5	3.0	13.0	4.3	0.9	0.0	0.0	0.0
SALL4	"dJ1112F19.1, ZNF797"	ENSG00000101115	"Spalt like transcription factor 4"	Q9UJQ4	20	51782331-51802520	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"parathyroid gland: 8.8;testis: 11.7;thyroid gland: 8.6"	"Cell type enriched"	"Detected in some"	7	"Horizontal cells: 25.4"	"Cancer enriched"	"Detected in many"	11	"testis cancer: 22.7"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	9	"NK-cell: 6.3"	"Lineage enriched"	"Detected in single"	9	"NK-cells: 6.3"	"Cell line enhanced"	"Detected in some"		"AF22: 13.1;AN3-CA: 9.1;BEWO: 17.5;NTERA-2: 31.5;SiHa: 8.0;SuSa: 22.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA015291, HPA015791"	Enhanced		Enhanced	Nucleoplasm		Yes	No			Nucleoplasm		"HPA015291: AB_1856548, HPA015791: AB_1856547"	"unprognostic (1.30e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.09e-3)"	"unprognostic (3.55e-2)"	"unprognostic (7.43e-2)"	"unprognostic (3.63e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.20e-1)"	"unprognostic (9.23e-2)"	"unprognostic (2.50e-2)"	"unprognostic (2.39e-2)"	"unprognostic (2.42e-8)"	"unprognostic (5.90e-3)"	"unprognostic (1.82e-1)"	"unprognostic (5.00e-5)"	"unprognostic (7.41e-2)"	0.3	0.4	0.3	0.3	0.9	1.2	0.3	0.8	0.9	0.4	0.7	0.3	2.2	0.1	0.3	0.8	0.3	0.2	0.3	0.3	0.3	0.1	0.5	1.9	0.3	0.3	0.3	0.3	0.3	4.6	8.8	0.6	0.3	0.9	3.1	0.2	4.5	2.2	0.4	0.3	0.3	0.7	0.3	0.3	0.8	0.3	11.7	0.3	0.3	8.6	0.3	0.3	0.9	0.3	0.1	0.1	0.6	0.1	6.3	0.2	0.0	0.0	0.8	13.1	9.1	0.0	0.0	17.5	0.0	0.1	0.0	0.1	4.5	0.1	0.0	0.1	0.1	0.1	2.2	0.1	0.0	0.1	0.2	0.0	0.0	3.0	0.2	0.1	0.0	1.0	0.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	31.5	0.1	0.2	1.2	0.0	0.0	0.0	0.2	3.0	1.6	8.0	0.0	0.7	22.0	0.0	0.5	0.0	0.5	1.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.6	6.3	0.1	0.1	0.0	0.0	0.3	0.9	0.8	0.9	0.3	0.1	0.3	0.3	0.9	0.3	0.0	1.3	0.0	0.7	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.2	0.0	0.4	1.1	0.0	0.0	0.2	25.4	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.5	1.7	0.0	0.0	0.0	0.0	1.0
SBDS	"CGI-97, FLJ10917, SDS, SWDS"	ENSG00000126524	"SBDS, ribosome maturation factor"	Q9Y3A5	7	66987677-66995601	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Ribosome biogenesis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"Late spermatids: 1381.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028891	Approved		Supported	Nucleoplasm,Cytosol		NA	NA		55000	"Nucleoplasm, Cytosol"		"HPA028891: AB_10601500"	"prognostic unfavorable (1.49e-4)"	"unprognostic (1.87e-2)"	"unprognostic (5.73e-2)"	"unprognostic (1.71e-3)"	"unprognostic (8.06e-3)"	"prognostic unfavorable (3.65e-4)"	"unprognostic (1.07e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.44e-1)"	"unprognostic (6.99e-2)"	"unprognostic (7.84e-3)"	"unprognostic (4.59e-1)"	"unprognostic (1.04e-2)"	"unprognostic (9.38e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.30e-1)"	"unprognostic (5.06e-3)"	40.9	34.5	37.7	18.7	44.0	41.7	44.5	23.6	43.2	30.7	37.5	35.3	20.2	39.1	35.6	27.3	40.8	27.7	34.0	70.0	39.2	40.9	36.9	38.4	32.1	16.7	50.6	36.6	31.9	27.5	50.4	26.9	38.6	44.6	35.1	35.7	20.1	23.5	40.5	130.7	26.1	34.4	52.0	63.2	16.7	32.8	15.9	48.2	7.2	33.9	38.7	15.6	54.0	38.0	21.6	15.5	20.8	12.6	16.6	39.1	19.4	31.4	13.3	11.8	10.7	43.2	32.3	13.2	53.5	44.1	41.0	31.5	27.4	16.2	11.7	40.6	48.9	27.1	15.3	19.9	31.8	44.1	11.1	26.3	5.7	24.9	16.4	38.5	14.6	8.0	29.1	42.8	31.1	54.2	21.2	25.2	7.7	42.2	12.8	63.6	18.8	7.7	21.2	13.1	43.4	31.7	5.9	25.5	24.4	43.2	14.1	18.2	12.5	26.8	46.4	35.5	27.3	34.6	12.4	33.5	55.4	18.9	28.0	39.0	7.9	9.3	26.7	19.0	24.0	30.6	20.8	11.1	20.2	23.4	12.6	29.6	21.6	30.6	27.2	11.3	18.7	39.1	31.5	4.7	16.6	11.2	15.5	25.9	19.4	37.7	44.0	23.6	43.2	39.2	40.9	50.6	36.6	44.6	48.2	282.9	101.3	66.6	339.3	412.4	74.2	273.7	79.0	58.9	128.5	87.2	11.8	116.1	222.2	161.5	544.8	139.6	267.8	46.7	145.1	193.1	210.9	212.5	144.6	97.2	95.0	55.6	97.9	127.7	39.0	1381.2	117.6	84.1	243.0	99.2	183.0	124.0	212.7	199.9	158.4	222.6	46.7	161.7	333.7	75.3	45.3	375.9	333.3	96.2	134.2	299.8
SDC4	"amphiglycan, ryudocan, SYND4"	ENSG00000124145	"Syndecan 4"	P31431	20	45325288-45348424	"Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 141.1"	"Cell type enhanced"	"Detected in many"	4	"Exocrine glandular cells: 450.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 75.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005716, CAB013240"	Enhanced		Approved	"Golgi apparatus,Plasma membrane"	"Secreted to blood"	NA	NA			"Golgi apparatus"	"Plasma membrane"	"CAB013240: AB_2533250, HPA005716: AB_1080160"	"unprognostic (1.34e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.71e-2)"	"unprognostic (2.16e-1)"	"unprognostic (5.39e-2)"	"unprognostic (6.59e-3)"	"unprognostic (1.16e-1)"	"unprognostic (5.93e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.95e-2)"	"prognostic unfavorable (4.20e-4)"	"unprognostic (1.97e-1)"	"prognostic favorable (2.44e-7)"	"unprognostic (3.00e-1)"	"unprognostic (2.18e-1)"	"prognostic favorable (2.67e-4)"	"unprognostic (7.42e-2)"	15.9	26.2	19.9	15.7	24.3	3.5	40.5	6.9	20.1	20.4	24.8	19.2	9.0	13.3	17.6	14.7	42.4	27.4	26.2	19.5	19.8	12.1	56.6	141.1	56.7	4.8	23.5	20.5	14.7	36.6	6.2	12.5	23.0	30.9	19.5	22.3	21.8	47.6	17.5	25.5	45.5	13.8	38.7	23.0	9.0	46.9	33.7	15.7	2.0	26.5	25.2	23.5	34.4	16.4	0.7	2.8	2.0	3.1	1.4	8.1	1.2	23.0	3.0	1.6	0.1	41.2	25.4	71.1	29.5	40.3	33.5	24.0	35.1	58.9	0.0	13.2	37.1	33.8	30.0	1.2	75.0	40.8	6.6	1.1	0.7	2.4	13.7	44.9	0.1	1.2	34.1	50.4	13.8	33.8	18.6	4.4	0.5	1.1	0.0	19.2	22.9	0.0	2.0	3.0	20.1	9.3	0.0	14.9	0.0	55.0	30.8	0.6	2.3	40.6	25.2	7.2	19.6	18.2	1.4	8.2	25.6	21.3	2.5	19.0	1.2	0.9	0.1	40.2	2.3	15.2	2.0	3.1	0.7	1.3	1.1	4.1	0.6	4.1	1.6	2.8	0.7	0.9	1.1	1.6	1.4	1.1	2.5	8.1	1.2	19.9	24.3	6.9	20.1	19.8	12.1	23.5	20.5	30.9	15.7	271.0	364.7	7.8	299.2	332.0	10.3	49.5	201.2	113.8	195.7	179.7	11.8	27.4	54.7	239.6	0.5	9.0	87.8	0.0	450.4	202.4	50.9	254.2	12.8	232.3	18.5	0.0	52.9	14.7	15.1	2.9	3.7	36.5	72.6	56.9	103.4	8.5	443.3	93.4	4.9	128.2	23.3	0.0	42.6	0.9	2.8	413.3	56.3	18.8	79.5	364.0
SDHA	"FP, SDH2, SDHF"	ENSG00000073578	"Succinate dehydrogenase complex flavoprotein subunit A"	P31040	5	218241-256700	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 100.1;skeletal muscle: 114.0"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034929, HPA041981, HPA064582"	Enhanced		Supported	Nucleoli,Mitochondria		No	No		780000	Mitochondria	Nucleoli	"CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293"	"prognostic unfavorable (6.00e-4)"	"unprognostic (1.93e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.80e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.67e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (9.53e-8)"	"unprognostic (1.11e-2)"	"unprognostic (2.62e-1)"	"unprognostic (3.57e-1)"	"unprognostic (1.79e-1)"	17.6	31.4	15.3	11.5	20.3	10.6	12.8	18.8	29.0	10.2	29.4	17.3	10.0	44.3	11.3	12.1	15.3	12.6	14.8	100.1	15.8	14.5	36.5	55.4	10.7	11.7	19.6	19.3	14.5	14.7	23.2	9.5	9.2	29.7	10.7	24.6	14.5	17.3	12.0	114.0	11.5	39.9	16.5	13.2	13.9	21.2	14.6	14.8	15.7	12.5	39.6	12.5	13.2	11.1	28.3	31.9	29.1	29.2	27.1	48.9	32.4	18.7	30.4	12.5	20.4	21.6	16.2	34.0	14.5	18.4	25.0	25.5	32.9	25.6	23.2	45.8	16.5	18.9	24.3	22.1	29.6	14.8	49.4	20.2	11.8	84.1	42.8	13.4	14.7	15.4	16.1	19.0	18.6	9.9	19.9	27.0	16.6	19.0	19.3	11.7	28.7	19.4	39.7	4.3	20.5	38.6	25.1	18.2	45.0	53.1	24.9	13.8	7.9	68.2	44.1	17.9	8.1	26.7	18.6	19.5	18.5	18.2	11.0	11.9	20.6	8.8	17.1	17.9	21.2	11.7	17.8	24.4	29.1	36.4	29.2	32.1	28.3	34.8	35.1	31.9	24.5	34.5	31.7	5.9	27.1	24.1	20.5	48.9	32.4	15.3	20.3	18.8	29.0	15.8	14.5	19.6	19.3	29.7	14.8	32.8	63.8	52.9	58.0	54.4	45.7	238.2	76.5	58.9	40.9	71.5	96.2	94.1	121.0	78.8	32.8	37.6	207.8	0.0	39.4	87.2	53.2	29.4	42.7	135.6	60.4	95.3	45.6	43.0	39.1	20.2	63.3	43.9	86.0	78.5	75.8	40.3	44.9	92.8	52.3	129.8	77.8	77.6	45.0	66.5	55.1	31.5	129.4	59.9	128.8	78.3
SDHAF2	"C11orf79, FLJ20487, PGL2, SDH5"	ENSG00000167985	"Succinate dehydrogenase complex assembly factor 2"	Q9NX18	11	61430042-61447529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		Chaperone	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039464, HPA039732"	Supported		Approved	Nucleoli,Mitochondria,Cytosol		NA	NA			"Mitochondria, Cytosol"	Nucleoli	"HPA039464: AB_10962146, HPA039732: AB_10962868"	"unprognostic (5.31e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.13e-1)"	"unprognostic (1.30e-2)"	"unprognostic (1.40e-1)"	"unprognostic (6.71e-2)"	"unprognostic (1.98e-3)"	"unprognostic (9.06e-2)"	"unprognostic (2.17e-1)"	"unprognostic (2.09e-3)"	"unprognostic (4.21e-3)"	"unprognostic (1.50e-1)"	"unprognostic (1.81e-2)"	"unprognostic (3.61e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.48e-2)"	23.7	33.0	22.2	22.4	27.2	34.1	24.8	19.9	33.8	20.5	22.1	23.4	21.0	22.3	23.3	33.5	25.3	25.8	21.1	32.5	20.8	26.9	26.8	39.1	19.9	36.7	24.3	25.0	25.7	22.7	23.3	38.4	26.7	25.2	26.1	24.9	32.0	28.1	21.5	31.4	22.9	27.9	26.6	20.8	32.2	24.3	19.2	21.1	36.1	27.0	20.2	30.9	24.0	19.2	31.3	23.2	44.6	25.4	32.7	43.7	26.7	15.4	22.3	13.2	9.2	19.2	15.7	10.3	12.0	17.4	16.3	12.5	20.8	16.7	15.6	22.1	17.4	22.2	16.8	17.2	17.1	17.5	23.1	16.3	13.4	18.3	30.0	20.0	15.8	18.8	19.4	20.9	17.7	17.3	11.6	26.2	16.8	15.4	20.1	19.6	34.2	16.1	35.9	20.4	15.9	32.8	17.4	17.1	28.8	23.2	23.0	14.2	17.7	16.5	19.3	33.4	14.1	30.1	18.9	16.3	16.6	13.5	19.7	14.2	12.4	19.3	19.9	16.1	14.1	17.4	41.9	25.4	44.6	32.4	22.8	38.4	31.3	35.9	34.7	20.3	29.9	39.5	38.4	37.0	32.7	17.9	23.2	43.7	26.7	22.2	27.2	19.9	33.8	20.8	26.9	24.3	25.0	25.2	21.1	32.8	38.1	35.3	31.0	18.3	14.0	20.5	12.7	32.1	21.6	27.9	5.9	61.5	46.4	50.2	11.4	29.8	27.1	23.3	52.7	47.1	28.8	26.8	31.2	37.0	45.9	14.3	32.8	36.8	33.7	13.8	29.1	32.1	42.2	81.2	28.5	36.7	49.4	31.7	29.0	38.3	14.1	32.3	24.7	15.8	23.5	19.6	83.3	44.5	23.9	29.9
SDHB	"SDH, SDH1"	ENSG00000117118	"Succinate dehydrogenase complex iron sulfur subunit B"	P21912	1	17018722-17054170	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Cardiomyocytes: 395.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002868, CAB009822, CAB068233, CAB068234, CAB068235"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Mitochondria"	"Intracellular and membrane"	NA	NA			Mitochondria	"Nucleoplasm, Plasma membrane"	"CAB009822: AB_2183458, CAB068233: AB_2665638, CAB068234: AB_2665639, CAB068235: AB_2665640, HPA002868: AB_1079889"	"unprognostic (1.06e-1)"	"unprognostic (2.86e-2)"	"unprognostic (2.19e-2)"	"unprognostic (2.93e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.79e-3)"	"unprognostic (1.58e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.19e-1)"	"unprognostic (8.45e-2)"	"unprognostic (5.51e-2)"	"unprognostic (3.93e-2)"	"prognostic favorable (2.93e-7)"	"unprognostic (1.46e-1)"	"unprognostic (2.75e-1)"	"unprognostic (7.82e-2)"	"unprognostic (3.82e-2)"	17.8	25.6	19.8	16.6	21.7	17.0	26.4	18.0	29.1	13.9	30.8	12.3	15.1	34.0	14.2	15.7	19.8	13.6	15.1	86.9	18.2	16.4	51.0	75.1	16.8	24.6	20.1	18.9	10.5	30.7	20.0	11.3	15.6	16.7	13.0	31.5	11.7	15.9	19.5	96.2	13.2	31.4	21.3	16.5	17.2	21.7	18.7	15.7	14.2	15.5	52.2	18.0	15.4	17.1	22.2	45.9	48.5	48.7	18.9	26.7	25.0	26.0	25.8	14.7	18.8	28.7	28.5	16.8	22.8	29.3	52.3	47.2	36.3	31.3	35.7	28.5	30.7	33.8	30.7	58.7	45.4	59.0	20.9	48.1	32.1	26.9	27.8	35.1	50.2	23.9	29.3	30.0	45.2	76.6	27.8	36.9	31.4	26.8	41.4	36.3	21.5	33.3	28.7	12.2	41.9	51.9	24.0	28.4	44.2	48.1	14.8	27.8	15.2	30.9	38.7	64.9	16.3	22.7	28.4	18.3	20.1	22.7	36.9	30.0	17.3	21.3	36.5	30.8	76.6	22.2	16.6	38.4	37.4	18.3	48.7	18.3	22.2	21.2	19.5	45.9	18.3	19.3	19.5	48.5	18.9	42.2	21.5	26.7	25.0	19.8	21.7	18.0	29.1	18.2	16.4	20.1	18.9	16.7	15.7	59.6	39.6	77.3	79.1	46.2	28.1	395.8	109.5	78.9	40.9	45.4	13.7	93.2	300.1	104.4	146.0	54.0	212.4	116.8	130.5	121.6	58.6	70.1	65.7	198.8	162.9	35.0	46.7	41.7	81.2	13.8	53.5	90.6	60.8	125.4	89.5	52.1	97.2	192.9	63.6	355.3	35.5	38.8	60.4	85.9	68.4	47.7	101.8	52.3	135.8	97.0
SDHC	"CYB560, cybL, PGL3"	ENSG00000143252	"Succinate dehydrogenase complex subunit C"	Q99643	1	161314257-161375340	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Distal tubular cells: 658.2;Proximal tubular cells: 706.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"													NA	NA						"unprognostic (1.48e-2)"	"unprognostic (6.88e-2)"	"unprognostic (6.38e-3)"	"unprognostic (1.86e-2)"	"unprognostic (1.90e-2)"	"unprognostic (5.02e-2)"	"unprognostic (7.08e-2)"	"unprognostic (2.33e-1)"	"unprognostic (7.38e-2)"	"unprognostic (1.35e-1)"	"unprognostic (2.43e-2)"	"unprognostic (1.29e-1)"	"prognostic favorable (2.20e-4)"	"unprognostic (9.14e-2)"	"unprognostic (1.52e-1)"	"unprognostic (4.19e-3)"	"unprognostic (3.77e-1)"	36.8	49.7	25.6	17.1	27.3	14.1	24.1	14.4	36.2	20.6	29.1	31.2	17.0	34.3	22.1	19.7	35.2	21.4	19.3	35.5	21.5	21.8	65.9	75.3	17.8	20.9	28.6	20.1	20.1	17.2	28.8	17.0	19.2	28.0	20.8	28.4	23.9	28.5	21.9	98.0	21.6	33.4	23.2	24.9	21.2	24.3	17.0	16.2	25.7	35.9	45.4	22.4	20.6	19.2	31.3	60.4	28.3	48.2	29.0	38.6	47.9	29.6	21.7	30.6	26.4	40.4	32.3	33.8	32.9	26.2	25.5	19.8	32.1	36.9	8.8	42.8	33.2	22.9	34.7	40.8	34.6	29.7	31.5	40.0	20.4	20.8	32.9	23.0	37.7	21.9	34.1	28.5	29.7	20.0	31.6	26.6	31.4	28.7	8.3	41.1	28.6	26.8	21.8	30.1	66.8	23.0	28.1	29.9	37.4	53.8	29.5	21.4	36.4	39.6	74.6	47.0	38.0	60.9	47.3	23.4	17.8	27.2	25.1	28.4	43.4	53.0	52.2	26.0	24.7	34.4	27.7	48.2	28.3	36.0	44.9	38.6	31.3	32.3	35.5	60.4	30.6	36.3	35.7	23.9	29.0	38.8	44.8	35.2	47.9	25.6	27.3	14.4	36.2	21.5	21.8	28.6	20.1	28.0	16.2	41.7	50.7	84.8	120.9	55.0	71.4	87.7	163.1	97.7	59.1	143.1	60.9	207.5	658.2	185.1	14.4	65.2	106.6	23.3	127.6	211.0	62.7	94.7	56.6	206.9	208.7	68.3	64.2	75.5	101.7	25.9	95.3	83.6	123.2	205.6	95.6	90.0	123.2	105.2	102.6	706.4	61.9	51.8	92.0	89.9	105.2	66.9	257.2	81.0	139.7	129.5
SDHD	"cybS, PGL, PGL1"	ENSG00000204370	"Succinate dehydrogenase complex subunit D"	O14521	11	112086773-112120013	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"		"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Distal tubular cells: 449.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											HPA045727	Approved				"Intracellular and membrane"	NA	NA					"HPA045727: AB_10963114"	"unprognostic (9.13e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.47e-3)"	"unprognostic (4.21e-2)"	"unprognostic (1.93e-1)"	"unprognostic (4.98e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.83e-3)"	"unprognostic (7.10e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.80e-1)"	"prognostic favorable (1.99e-10)"	"unprognostic (5.14e-2)"	"unprognostic (1.58e-2)"	"unprognostic (1.56e-2)"	"unprognostic (7.51e-2)"	20.9	23.1	17.1	21.7	19.4	10.9	19.6	14.1	18.4	18.1	33.6	14.2	23.9	36.0	22.7	17.5	35.2	17.3	17.9	42.5	15.1	13.7	66.6	75.4	19.1	23.3	17.1	15.1	18.6	23.2	22.5	16.1	20.1	18.0	23.7	33.9	15.7	32.6	21.7	65.4	15.5	61.2	24.0	15.3	22.8	22.2	8.8	14.8	21.7	46.2	33.9	24.6	23.5	20.3	55.5	74.7	62.1	91.7	46.1	53.7	68.9	16.7	17.2	11.7	17.7	43.8	35.2	19.7	20.4	29.0	21.4	26.9	59.4	43.9	30.4	63.1	27.5	31.7	42.0	36.5	28.9	26.3	27.0	18.3	28.9	12.8	31.5	34.1	45.5	22.0	38.8	32.0	25.5	40.8	25.6	30.1	22.0	29.8	42.0	26.5	21.0	27.3	41.2	15.8	64.5	42.6	25.3	31.1	56.7	43.8	40.9	16.9	11.2	28.6	38.7	20.3	17.7	39.8	32.8	23.5	20.9	27.4	23.2	18.7	12.5	16.0	55.7	11.9	59.6	19.9	46.1	73.0	48.7	41.4	91.7	44.1	55.5	44.5	43.1	74.7	45.6	53.7	49.8	62.1	46.1	70.7	36.8	44.2	68.9	17.1	19.4	14.1	18.4	15.1	13.7	17.1	15.1	18.0	14.8	74.5	39.0	90.1	83.6	72.5	10.9	198.1	91.7	68.3	63.7	85.5	7.9	134.7	449.3	67.9	8.3	67.1	194.1	46.7	51.2	94.9	111.1	52.7	63.6	160.7	147.1	11.1	48.5	66.9	103.7	21.8	96.4	98.5	72.6	129.8	105.1	39.2	45.9	122.4	93.7	350.8	18.5	90.5	100.9	53.9	50.7	65.1	149.7	72.6	141.2	82.2
SET	"2PP2A, IPP2A2, PHAPII"	ENSG00000119335	"SET nuclear proto-oncogene"	Q01105	9	128683424-128696400	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Chaperone, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB005232, HPA063683"	Supported		Enhanced	"Nucleoplasm,Lipid droplets"		NA	NA		880000	Nucleoplasm	"Lipid droplets"	"CAB005232: AB_2185634, HPA063683: AB_2685088"	"unprognostic (1.92e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.77e-1)"	"unprognostic (7.15e-2)"	"unprognostic (4.37e-3)"	"prognostic unfavorable (9.41e-7)"	"unprognostic (2.00e-2)"	"unprognostic (1.88e-2)"	"unprognostic (3.62e-1)"	"unprognostic (3.78e-2)"	"unprognostic (3.27e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.57e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.09e-1)"	"unprognostic (1.54e-2)"	47.2	49.7	66.5	59.3	65.8	71.8	56.5	64.2	61.2	54.4	51.3	55.3	45.6	40.1	64.8	33.1	71.6	51.6	48.9	81.6	63.6	57.3	51.7	57.8	51.2	91.1	65.4	56.1	76.5	61.3	55.0	38.7	65.4	47.3	59.2	56.4	36.3	52.1	46.9	76.3	53.6	45.7	59.0	73.5	62.8	46.8	34.8	58.6	152.9	69.1	46.2	92.7	74.4	84.1	72.2	66.4	43.2	56.5	78.8	77.9	69.7	51.4	58.8	84.6	66.9	25.2	39.6	78.0	42.5	47.1	61.5	42.4	80.7	63.2	133.1	36.0	43.7	48.1	96.5	124.9	63.9	70.3	60.7	53.2	76.6	91.4	65.6	56.5	139.7	50.2	33.0	50.1	52.3	105.0	49.5	57.5	71.6	148.6	54.0	50.3	86.8	117.0	51.6	141.2	78.7	62.6	107.0	105.1	107.8	47.4	58.1	86.2	54.1	93.6	62.9	50.8	62.8	78.4	43.6	55.0	72.7	54.5	44.8	70.3	42.5	122.1	158.5	34.6	74.5	69.2	34.5	53.9	43.2	58.9	56.5	72.1	72.2	67.9	62.8	52.7	66.3	65.8	77.9	35.4	78.8	45.6	66.4	52.3	69.7	66.5	65.8	64.2	61.2	63.6	57.3	65.4	56.1	47.3	58.6	113.2	124.3	265.7	328.1	598.4	174.9	190.6	209.0	89.7	129.7	186.7	41.2	273.8	330.0	223.2	30.8	200.0	100.9	93.5	188.0	401.9	250.8	373.4	128.3	164.3	210.2	117.6	245.8	160.2	212.7	25.3	151.8	217.3	310.4	235.4	230.5	205.1	229.0	108.7	163.0	257.3	97.8	129.4	279.5	127.7	287.7	613.8	263.1	219.3	275.8	519.4
SETBP1	"KIAA0437, SEB"	ENSG00000152217	"SET binding protein 1"	Q9Y6X0	18	44680173-45068510	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		DNA-binding	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Leydig cells: 58.1;Peritubular cells: 37.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 4.9;naive B-cell: 7.5"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"AF22: 9.5;Karpas-707: 37.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA049022, HPA057259"	Uncertain		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"		NA	NA			Nucleoplasm	"Nuclear bodies, Cytosol"	"HPA049022: AB_2680602, HPA057259: AB_2683384"	"unprognostic (1.25e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.97e-2)"	"unprognostic (4.63e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.91e-1)"	"unprognostic (3.57e-2)"	"unprognostic (3.49e-1)"	"unprognostic (2.01e-2)"	"unprognostic (2.71e-3)"	"unprognostic (6.52e-2)"	"prognostic favorable (6.34e-8)"	"unprognostic (2.18e-2)"	"unprognostic (2.29e-1)"	"unprognostic (6.06e-2)"	"unprognostic (7.81e-5)"	10.6	2.9	3.8	13.2	8.7	2.1	9.8	16.0	12.6	16.9	14.6	4.2	19.9	2.5	14.0	17.5	6.6	11.0	7.9	6.8	3.6	3.5	15.0	7.2	9.8	7.0	2.9	7.4	12.8	8.2	9.1	5.1	10.2	3.2	12.2	5.3	14.0	6.9	21.3	14.5	6.6	6.9	19.9	3.7	5.9	9.1	5.5	1.2	3.4	8.4	8.7	8.8	11.9	13.3	7.5	4.3	0.2	1.6	0.0	0.6	0.2	0.0	1.7	9.5	0.0	2.7	0.7	0.6	0.8	1.7	0.9	0.7	0.1	0.0	0.5	0.3	1.0	0.5	2.8	1.0	3.0	0.6	0.8	0.5	0.0	1.0	0.6	0.0	0.0	0.0	2.3	1.1	0.0	1.8	1.6	0.3	0.0	0.0	37.9	0.2	0.5	0.0	0.0	1.3	0.0	0.6	3.1	0.0	3.3	3.2	2.2	4.8	2.5	0.0	0.0	0.5	4.5	1.3	0.0	0.0	5.6	2.1	0.0	4.4	5.0	0.3	0.0	3.4	0.1	3.2	0.2	0.0	0.0	0.6	1.1	0.0	4.9	0.1	0.5	0.1	7.5	0.0	0.2	0.0	0.0	1.6	4.3	0.0	0.2	3.8	8.7	16.0	12.6	3.6	3.5	2.9	7.4	3.2	1.2	0.0	2.6	26.0	8.5	13.7	11.5	3.6	10.2	2.7	3.4	15.7	17.7	1.3	3.3	4.1	0.9	9.5	0.4	0.0	2.9	1.2	27.4	6.4	0.0	13.5	1.6	3.2	11.5	12.3	1.6	1.8	58.1	2.7	3.3	0.0	2.5	9.1	3.3	8.4	37.4	6.8	19.3	6.5	30.7	0.0	0.1	13.2	0.7	4.9	4.6	1.0
SETD2	"FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A"	ENSG00000181555	"SET domain containing 2"	Q9BYW2	3	47016429-47163967	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Antiviral defense, Differentiation, DNA damage, DNA repair, Host-virus interaction, Immunity, Innate immunity, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Developmental protein, Methyltransferase, Transferase"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042451	Approved		Approved	"Nuclear speckles,Cytosol"		NA	NA			"Nuclear speckles"	Cytosol	"HPA042451: AB_10806239"	"unprognostic (2.78e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.08e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.01e-2)"	"prognostic unfavorable (8.19e-4)"	"unprognostic (6.19e-2)"	"unprognostic (2.45e-1)"	"unprognostic (7.84e-2)"	"prognostic favorable (7.99e-6)"	"unprognostic (1.03e-1)"	"unprognostic (1.91e-1)"	"unprognostic (8.79e-2)"	"unprognostic (5.43e-2)"	13.2	10.5	12.2	15.2	15.4	20.0	11.7	22.4	16.4	13.4	14.0	9.1	12.9	9.5	15.8	7.5	10.8	11.4	8.7	8.8	10.6	6.8	11.4	10.3	10.4	11.8	11.7	9.5	16.0	13.4	21.4	16.3	10.7	11.3	12.4	10.9	7.7	12.7	14.8	27.6	12.5	11.5	11.9	9.8	13.8	10.4	12.8	12.8	23.2	15.8	5.5	12.8	16.1	15.5	4.8	2.6	6.0	2.3	7.1	3.9	1.0	11.6	9.2	15.4	7.9	9.3	10.7	6.5	10.7	10.4	12.6	11.5	9.7	7.6	25.7	6.7	14.8	12.3	7.1	16.7	10.2	17.1	14.7	6.6	26.4	15.3	7.5	7.0	19.7	15.3	9.2	9.9	12.4	15.4	10.2	11.6	13.3	16.9	9.7	10.3	6.1	14.5	2.6	11.7	5.6	7.7	9.6	15.0	13.3	6.4	15.3	6.7	10.6	18.1	7.1	6.7	11.5	7.5	14.7	14.8	13.9	10.4	11.8	17.1	12.5	13.9	26.0	8.0	11.3	8.1	2.4	2.2	5.2	3.9	2.3	2.4	3.7	2.4	3.0	2.5	4.8	3.5	3.0	6.0	7.1	1.9	2.6	1.0	1.0	12.2	15.4	22.4	16.4	10.6	6.8	11.7	9.5	11.3	12.8	44.7	53.3	20.6	20.5	29.7	33.4	58.5	22.9	66.9	80.8	10.4	39.3	16.3	10.0	17.4	24.0	29.3	26.5	0.0	19.3	10.1	20.8	25.9	55.6	26.7	14.3	25.4	21.2	23.4	27.2	20.8	28.1	21.6	16.9	20.8	27.8	21.7	20.0	17.5	31.1	9.3	37.0	12.9	21.7	78.1	18.9	31.1	15.4	27.7	24.8	34.2
SF3B1	"Hsh155, Prp10, PRPF10, SAP155, SF3b155"	ENSG00000115524	"Splicing factor 3b subunit 1"	O75533	2	197389784-197435091	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA050275	Approved		Enhanced	"Nuclear speckles"		NA	NA		840000	"Nuclear speckles"		"HPA050275: AB_2681071"	"unprognostic (6.86e-2)"	"unprognostic (2.78e-1)"	"unprognostic (2.14e-1)"	"unprognostic (3.51e-1)"	"unprognostic (4.42e-2)"	"unprognostic (1.25e-3)"	"unprognostic (2.44e-3)"	"unprognostic (3.31e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.20e-1)"	"unprognostic (6.79e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.57e-2)"	"unprognostic (9.15e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.79e-1)"	"unprognostic (3.41e-2)"	53.9	49.9	36.5	54.5	44.9	88.0	57.9	60.8	47.3	72.3	54.2	44.3	45.6	36.8	64.6	72.0	50.5	53.3	43.1	39.6	34.7	26.0	49.7	50.7	53.1	65.3	56.5	27.7	73.6	60.5	66.2	81.4	64.6	46.7	50.0	51.0	37.0	54.4	45.4	49.3	48.5	67.8	41.2	50.2	88.1	48.8	33.3	53.5	113.0	53.3	38.0	65.7	62.4	56.0	32.7	41.9	41.1	37.8	39.6	45.9	29.4	30.2	27.8	62.7	34.2	48.6	49.7	52.6	42.4	43.4	37.0	45.5	53.0	32.7	57.9	28.6	43.1	38.4	29.4	62.6	34.4	58.0	44.3	38.9	61.2	68.0	62.3	36.7	65.0	44.7	51.9	33.7	38.6	47.5	63.1	43.1	38.6	43.8	40.0	41.0	26.6	59.7	62.6	49.3	34.3	44.0	52.7	53.6	38.4	51.5	77.0	35.2	43.6	40.5	24.8	29.0	81.0	24.5	49.8	43.4	29.1	25.0	29.3	30.1	36.4	59.2	83.1	27.9	39.3	32.1	27.7	33.1	39.1	37.5	37.8	40.6	32.7	32.5	35.3	41.9	30.8	33.9	33.9	41.1	39.6	36.1	23.8	45.9	29.4	36.5	44.9	60.8	47.3	34.7	26.0	56.5	27.7	46.7	53.5	166.7	222.4	88.0	131.1	105.8	96.4	104.9	73.9	257.0	221.8	87.2	68.7	93.6	48.0	91.8	6.7	106.2	77.2	46.7	82.1	86.2	104.2	87.4	231.0	63.5	87.0	89.0	106.0	112.3	145.9	14.9	111.4	119.2	72.6	130.8	98.8	119.0	91.7	60.4	98.3	63.2	88.9	116.4	99.9	81.4	93.6	103.8	119.3	119.3	74.2	125.4
SFPQ	"PPP1R140, PSF"	ENSG00000116560	"Splicing factor proline and glutamine rich"	P23246	1	35176378-35193148	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, DNA damage, DNA recombination, DNA repair, Immunity, Innate immunity, mRNA processing, mRNA splicing, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009886, HPA047513, HPA054689"	Enhanced		Enhanced	Nucleoplasm		NA	NA		280000	Nucleoplasm		"CAB009886: AB_2186937, HPA047513: AB_2680073, HPA054689: AB_2682574"	"prognostic favorable (9.56e-5)"	"unprognostic (1.01e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.99e-1)"	"unprognostic (5.53e-2)"	"unprognostic (1.86e-2)"	"prognostic unfavorable (7.91e-13)"	"unprognostic (3.10e-1)"	"unprognostic (4.00e-3)"	"unprognostic (3.85e-2)"	"unprognostic (2.20e-2)"	"unprognostic (8.03e-3)"	"unprognostic (1.25e-3)"	"unprognostic (1.16e-2)"	"unprognostic (3.97e-3)"	"unprognostic (3.07e-1)"	"unprognostic (3.77e-3)"	40.5	35.7	31.5	39.4	31.4	122.5	48.3	53.0	38.5	39.0	31.4	37.8	32.9	30.0	45.3	36.5	45.5	43.0	28.1	34.0	29.1	24.6	36.4	34.2	47.6	48.8	26.3	32.6	59.9	40.2	45.8	46.3	35.5	31.9	35.5	38.0	35.7	39.6	38.0	44.9	42.9	34.1	36.5	32.8	42.4	35.5	37.5	32.9	95.2	35.3	24.1	60.6	35.9	38.6	6.9	11.2	4.4	8.8	4.9	8.9	3.3	36.4	30.5	53.2	30.1	13.1	19.7	49.9	20.0	20.3	34.2	25.0	33.1	26.4	66.6	27.8	23.1	21.4	33.4	57.8	39.1	46.6	35.5	38.4	50.0	32.9	39.3	17.7	52.0	29.8	15.7	15.2	29.6	14.4	15.2	29.7	35.3	56.5	31.8	33.2	31.7	60.8	44.6	63.4	22.0	29.5	61.9	36.1	43.3	33.0	44.3	38.4	42.7	28.8	22.5	28.9	38.9	26.3	37.1	31.6	27.4	40.3	17.9	42.7	36.5	31.0	67.8	19.5	34.5	38.9	2.6	6.5	4.4	7.7	8.8	8.9	6.2	7.6	6.1	5.8	6.9	7.2	7.9	3.4	4.9	6.4	11.2	8.2	3.3	31.5	31.4	53.0	38.5	29.1	24.6	26.3	32.6	31.9	32.9	157.8	233.8	123.2	218.3	317.6	223.2	127.3	68.8	123.1	187.7	104.7	180.6	178.4	69.6	106.2	101.7	173.0	92.7	46.7	119.2	185.7	204.4	133.7	151.3	95.2	121.1	162.1	210.6	114.8	123.3	250.0	132.3	139.5	133.3	108.2	106.4	182.5	126.2	101.2	109.6	66.5	219.0	51.8	200.9	192.3	171.1	286.1	255.5	127.5	133.5	143.0
SFRP4	"FRP-4, frpHE, FRZB-2"	ENSG00000106483	"Secreted frizzled related protein 4"	Q6FHJ7	7	37905932-38025695	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Differentiation, Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 144.9;endometrium 1: 100.7;retina: 123.0"	"Cell type enriched"	"Detected in some"	5	"Peritubular cells: 177.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 14.1;HSkMC: 5.5;U-937: 5.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA009712, HPA050585"	Enhanced				"Secreted in female reproductive system"	NA	NA		1500000			"HPA009712: AB_1856778, HPA050585: AB_2681183"	"unprognostic (5.93e-2)"	"unprognostic (5.84e-3)"	"unprognostic (2.75e-2)"	"unprognostic (1.58e-3)"	"unprognostic (2.61e-1)"	"unprognostic (2.35e-2)"	"unprognostic (4.02e-2)"	"unprognostic (2.60e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.76e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavorable (1.36e-5)"	"unprognostic (7.37e-3)"	"unprognostic (1.61e-1)"	"unprognostic (4.35e-3)"	"unprognostic (1.89e-3)"	4.6	2.3	0.5	0.9	0.9	0.0	12.5	0.3	0.4	144.9	0.8	1.7	5.4	0.0	100.7	11.5	3.2	35.1	2.5	5.5	0.4	0.4	1.2	0.2	3.9	0.8	0.8	0.7	42.7	1.4	0.1	4.0	0.4	1.3	4.9	0.2	123.0	2.3	7.1	1.4	0.3	0.5	14.5	3.3	4.1	0.5	5.8	0.3	0.4	3.3	2.5	0.5	8.8	14.8	0.4	0.8	0.4	0.6	0.1	0.1	0.0	0.0	2.6	2.9	0.0	14.1	0.6	0.1	0.0	0.1	0.0	0.0	0.4	0.0	0.1	0.1	3.0	0.4	0.1	0.0	0.3	0.3	0.0	0.0	0.2	0.2	2.0	0.1	0.4	0.0	5.5	0.7	0.6	0.0	1.0	0.2	0.2	0.0	0.3	0.2	0.4	0.0	1.7	0.1	0.0	0.0	0.2	1.7	0.0	0.1	0.3	0.1	0.3	0.0	0.0	0.3	0.6	0.0	0.0	0.9	0.0	1.2	1.7	0.2	0.5	0.1	0.2	0.3	5.3	0.9	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.0	0.0	0.1	0.1	0.1	0.0	0.4	0.1	0.0	0.8	0.0	0.0	0.5	0.9	0.3	0.4	0.4	0.4	0.8	0.7	1.3	0.3	0.0	2.6	0.0	1.7	0.9	0.0	0.4	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.8	0.5	0.0	0.0	0.4	0.1	8.6	1.6	0.0	0.0	0.2	0.0	0.0	4.3	0.0	0.9	38.6	0.8	0.0	0.0	0.0	2.7	0.1	0.0	177.1	2.1	0.1	0.0	3.1	0.2	0.5	1.4	0.2	0.0	0.0	0.0
SH2B3	"IDDM20, LNK"	ENSG00000111252	"SH2B adaptor protein 3"	Q9UQQ2	12	111405948-111451623	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Ito cells: 49.7;Kupffer cells: 110.0;Macrophages: 49.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 32.3;hTEC/SVTERT24-B: 37.0;U-87 MG: 56.2;WM-115: 42.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005483	Approved		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA005483: AB_1079260"	"unprognostic (2.77e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.18e-1)"	"unprognostic (9.09e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.65e-2)"	"unprognostic (8.17e-3)"	"unprognostic (9.08e-2)"	"prognostic unfavorable (6.20e-4)"	"unprognostic (2.86e-1)"	"unprognostic (3.89e-3)"	"unprognostic (1.11e-1)"	"unprognostic (2.24e-2)"	17.6	9.0	7.9	13.7	7.9	34.4	19.8	3.8	9.3	8.9	7.5	7.2	3.1	5.3	8.0	7.1	5.6	7.5	12.7	15.3	5.8	5.5	9.2	12.5	17.6	27.8	6.6	4.0	8.2	11.0	4.7	7.6	16.1	5.2	8.4	9.3	8.7	5.0	4.2	10.2	3.6	10.3	9.1	7.8	31.7	5.5	13.3	6.8	9.5	10.2	3.2	11.8	10.0	5.8	1.8	6.1	3.8	10.3	2.3	1.7	1.9	2.3	1.4	1.8	1.9	6.4	9.6	1.2	7.5	20.6	5.7	6.2	2.1	1.3	3.9	5.4	11.4	19.5	0.4	1.4	4.3	9.4	3.3	0.7	13.4	0.6	1.5	6.3	5.8	32.3	5.7	1.0	37.0	3.3	12.8	30.9	3.3	9.6	1.6	20.9	0.8	2.4	11.7	2.8	0.6	5.4	2.4	4.2	2.5	2.7	0.9	1.2	1.3	1.3	0.1	10.7	1.7	0.9	8.4	23.9	5.3	3.0	4.5	12.1	3.6	3.8	4.5	56.2	4.2	42.8	1.1	4.3	1.5	1.6	10.3	1.4	1.8	1.4	1.7	5.9	0.7	1.0	1.3	3.8	2.3	7.6	6.1	0.5	1.9	7.9	7.9	3.8	9.3	5.8	5.5	6.6	4.0	5.2	6.8	3.0	31.9	11.5	1.3	6.1	4.1	14.9	5.1	0.0	2.3	1.8	2.0	0.4	1.7	3.1	9.6	32.1	3.8	0.0	7.5	1.1	9.8	2.4	37.0	9.4	35.5	3.2	3.4	49.7	110.0	4.0	2.6	49.7	15.1	34.3	2.6	0.9	6.9	7.0	3.9	1.4	3.1	0.0	17.6	9.4	4.0	3.6	0.8	11.8	1.7	0.8
SH3GL1	"CNSA1, EEN, MGC111371, SH3D2B, SH3P8"	ENSG00000141985	"SH3 domain containing GRB2 like 1, endophilin A2"	Q99961	19	4360370-4400547	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	Endocytosis		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Extravillous trophoblasts: 128.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA021485	Approved		Enhanced	Cytosol		NA	NA			Cytosol		"HPA021485: AB_1856816"	"unprognostic (1.32e-1)"	"prognostic favorable (1.50e-4)"	"unprognostic (6.85e-2)"	"prognostic favorable (1.86e-4)"	"unprognostic (1.84e-1)"	"unprognostic (1.02e-1)"	"prognostic unfavorable (1.10e-4)"	"unprognostic (1.92e-2)"	"unprognostic (1.21e-1)"	"unprognostic (1.42e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.54e-1)"	"prognostic unfavorable (9.36e-8)"	"unprognostic (5.48e-3)"	"unprognostic (2.45e-1)"	"unprognostic (1.02e-3)"	"unprognostic (4.10e-2)"	20.5	22.4	12.8	17.7	14.5	28.9	17.5	19.1	25.9	21.6	18.7	13.3	11.9	25.4	16.9	12.1	66.0	15.0	16.1	13.2	13.0	8.0	13.8	19.7	14.8	13.0	11.4	13.0	23.5	20.5	5.6	17.3	33.9	9.4	17.1	6.2	14.9	22.1	16.8	8.6	40.4	29.8	18.8	9.0	19.5	16.4	13.7	11.3	10.1	14.2	19.1	33.0	22.2	30.0	6.1	6.5	9.7	5.1	3.8	7.4	3.4	31.7	14.4	15.0	19.8	17.6	27.5	27.7	27.7	24.0	24.8	24.7	22.5	16.8	7.2	11.8	27.5	12.0	26.3	10.6	30.5	6.6	9.5	17.7	8.6	19.9	29.4	25.5	7.7	9.8	23.0	21.3	20.8	12.9	12.3	29.1	7.0	22.3	16.4	19.8	26.6	7.5	8.1	37.6	11.6	16.1	5.9	20.9	12.5	19.5	28.2	14.8	22.8	24.5	24.5	17.4	7.4	16.8	12.3	43.8	23.9	17.4	49.9	28.1	10.5	6.4	7.6	34.3	20.2	32.7	1.0	3.8	4.8	5.0	1.9	4.8	6.1	7.4	6.9	5.0	4.5	4.2	4.5	9.7	3.8	5.1	6.5	6.6	3.4	12.8	14.5	19.1	25.9	13.0	8.0	11.4	13.0	9.4	11.3	8.9	22.1	14.3	32.2	54.0	16.6	3.3	7.6	6.7	9.1	8.7	5.9	32.6	11.6	31.4	5.6	21.5	32.5	23.3	25.4	128.0	43.2	30.1	9.2	18.8	42.1	9.5	9.8	33.7	15.9	4.9	30.2	14.3	21.9	16.2	16.3	12.4	36.0	15.0	22.6	17.9	8.0	12.9	23.1	13.3	12.4	75.0	37.0	13.8	16.4	59.9
SIX1	DFNA23	ENSG00000126778	"SIX homeobox 1"	Q15475	14	60643415-60658259	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Deafness, Disease mutation, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pituitary gland: 39.1;salivary gland: 55.1;skeletal muscle: 59.0"	"Cell type enhanced"	"Detected in some"	19	"Basal glandular cells: 23.3;Ciliated cells: 65.6;Club cells: 33.0;Glandular cells: 24.0;Urothelial cells: 14.9"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"olfactory region: 1.2;pons and medulla: 4.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 14.3;LHCN-M2: 53.4;RH-30: 29.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001893, CAB058690"	Enhanced		Supported	Nucleoplasm,Nucleoli		No	No			Nucleoplasm	Nucleoli	"CAB058690: AB_2665581, HPA001893: AB_1079991"	"unprognostic (3.62e-1)"	"unprognostic (5.44e-2)"	"unprognostic (5.09e-2)"	"prognostic unfavorable (8.92e-6)"	"unprognostic (1.33e-2)"	"unprognostic (1.44e-2)"	"unprognostic (2.04e-3)"	"prognostic favorable (3.94e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.15e-2)"	"unprognostic (6.45e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.06e-8)"	"unprognostic (8.61e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.94e-1)"	"unprognostic (3.86e-1)"	7.1	0.4	0.3	0.1	0.5	0.1	4.7	0.3	0.6	7.4	0.2	0.2	0.0	0.1	0.2	2.1	1.3	0.5	0.4	0.4	0.3	0.3	0.3	0.2	1.8	0.3	0.4	1.2	0.3	0.3	16.8	39.1	0.1	4.5	8.7	0.1	2.0	55.1	0.2	59.0	0.4	0.2	0.7	0.5	0.2	0.5	1.6	0.0	6.5	2.4	22.5	3.0	1.4	9.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	8.3	1.9	0.2	11.9	6.9	8.1	0.1	2.0	4.5	2.3	2.0	0.0	3.8	0.0	1.1	0.4	1.1	2.7	3.9	3.6	0.8	0.0	9.5	0.9	0.8	2.7	0.0	0.0	0.1	6.0	1.8	1.6	0.3	14.3	0.1	0.7	2.6	0.0	53.4	1.3	0.0	0.2	0.0	0.0	4.8	0.0	29.2	0.0	2.3	6.5	1.1	0.1	2.3	0.1	2.4	0.2	1.4	0.2	6.8	3.2	3.2	3.7	3.0	0.2	0.0	0.0	0.8	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.3	0.5	0.3	0.3	0.4	1.2	4.5	0.0	3.0	1.0	0.0	23.3	0.1	0.0	0.8	0.0	65.6	33.0	1.8	0.0	0.0	1.7	0.0	0.2	0.0	0.0	0.0	0.7	0.4	0.8	24.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.8	0.2	0.0	1.1	0.0	0.3	0.0	0.2	0.0	2.5	0.1	0.2	0.0	0.0	14.9
SLC34A2	NAPI-3B	ENSG00000157765	"Solute carrier family 34 member 2"	O95436	4	25648011-25678748	"Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"lung: 259.9;seminal vesicle: 69.1"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 443.7;Alveolar cells type 2: 1050.6"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 585.2"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.9"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	81	"BEWO: 12.6;EFO-21: 47.7;RPTEC TERT1: 34.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA037989, HPA066474"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA037989: AB_10670536, HPA066474: "	"unprognostic (1.60e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.38e-1)"	"unprognostic (4.25e-2)"	"unprognostic (7.33e-2)"	"unprognostic (9.83e-2)"	"unprognostic (2.37e-2)"	"unprognostic (6.60e-3)"	"unprognostic (6.27e-2)"	"unprognostic (1.89e-2)"	"unprognostic (5.77e-2)"	"unprognostic (2.24e-1)"	"unprognostic (7.08e-3)"	"unprognostic (3.25e-1)"	"unprognostic (6.75e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.93e-1)"	0.1	0.1	0.1	0.0	0.1	0.0	3.2	0.2	0.1	13.0	0.1	0.0	24.7	2.9	6.9	2.1	0.5	13.0	3.4	0.1	0.1	0.1	10.8	0.5	259.9	0.0	0.1	0.0	2.9	4.4	0.0	0.6	2.6	0.8	0.3	0.0	1.6	27.4	69.1	0.1	0.7	2.1	0.0	0.1	0.1	0.4	0.5	0.0	0.4	27.9	0.1	1.9	0.0	0.1	0.4	0.2	1.9	0.5	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.0	0.0	0.1	0.0	0.1	47.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	34.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.3	0.0	0.2	0.1	0.1	0.0	0.0	0.0	1.9	0.5	0.2	0.3	0.3	0.1	0.2	0.1	0.1	0.0	0.4	0.3	0.2	1.5	0.4	0.1	0.2	0.0	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.8	0.0	443.7	1050.6	0.0	0.1	0.0	0.0	0.6	40.8	125.8	178.6	19.2	0.0	1.6	5.0	57.7	3.5	0.0	0.0	0.0	7.1	0.0	0.0	3.5	26.7	0.0	0.2	0.0	0.0	0.0	0.0	14.0	1.1	0.0	0.0	0.0	0.0	0.0	14.4	0.0	0.0	2.9	0.0	0.0	0.1	0.5	0.1	0.0	0.2	0.0	0.0	0.1
SLC45A3	"IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein"	ENSG00000158715	"Solute carrier family 45 member 3"	Q96JT2	1	205657851-205680459	"Cancer-related genes, Predicted membrane proteins, Transporters"	Transport		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"prostate: 115.0"	"Group enriched"	"Detected in many"	11	"Glandular cells: 50.8;granulocytes: 117.6"	"Cancer enriched"	"Detected in all"	49	"prostate cancer: 539.9"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	226	"basophil: 22.6"	"Lineage enriched"	"Detected in single"	226	"granulocytes: 22.6"	"Cell line enriched"	"Detected in some"	30	"HMC-1: 141.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA019073, HPA019075"	Enhanced		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA019073: AB_1857177, HPA019075: AB_1857179"	"unprognostic (1.80e-1)"	"unprognostic (1.08e-3)"	"unprognostic (3.13e-2)"	"prognostic unfavorable (4.04e-5)"	"unprognostic (6.93e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.10e-1)"	"unprognostic (2.90e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.03e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.55e-1)"	"unprognostic (1.96e-1)"	"prognostic favorable (7.33e-5)"	0.8	1.5	2.5	1.5	6.2	0.7	0.8	0.4	5.8	1.9	2.1	19.0	0.0	2.1	0.9	0.6	0.9	1.1	1.8	0.7	4.2	2.0	1.1	4.0	1.7	1.6	13.2	1.6	1.0	0.7	0.5	1.9	0.6	7.2	115.0	1.6	0.2	0.9	0.7	2.2	0.9	2.1	0.8	12.4	5.0	6.4	1.4	11.1	0.0	0.5	0.7	0.7	1.5	0.4	0.0	0.0	22.6	0.0	0.0	0.0	0.2	1.5	0.5	0.4	0.4	0.0	0.0	0.3	0.2	0.0	0.5	0.4	1.1	2.9	0.4	0.7	0.0	0.5	0.5	0.2	0.5	0.0	0.6	0.4	4.7	0.1	0.3	0.3	0.8	141.5	0.0	0.1	0.3	0.0	0.3	1.6	0.7	0.7	0.2	0.2	0.3	0.1	1.3	2.0	2.7	1.7	0.1	0.7	0.2	0.6	2.2	0.2	0.5	0.2	3.5	0.6	0.4	0.8	0.2	1.5	0.2	1.6	0.5	1.1	0.0	0.1	0.0	0.3	0.2	1.1	22.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.5	6.2	0.4	5.8	4.2	2.0	13.2	1.6	7.2	11.1	0.0	5.6	1.3	1.1	0.0	0.2	1.7	5.1	2.7	1.2	1.8	0.0	0.4	0.0	1.8	0.1	0.6	3.4	0.0	0.5	0.1	0.6	50.8	117.6	4.9	2.0	0.0	0.0	0.0	0.6	0.0	1.7	0.9	0.0	1.0	7.4	0.2	2.4	7.0	1.4	1.8	0.0	6.5	1.0	0.0	1.5	0.1	0.0	0.0	4.4	0.8
SMAD2	"JV18-1, MADH2, MADR2"	ENSG00000175387	"SMAD family member 2"	Q15796	18	47808957-47931146	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Cone photoreceptor cells: 200.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB025507, HPA067203, CAB073546"	Approved		Supported	Nucleoplasm,Nucleoli,Cytosol		NA	NA			"Nucleoplasm, Nucleoli, Cytosol"		"CAB025507: , CAB073546: , HPA067203: AB_2685803"	"unprognostic (1.55e-1)"	"unprognostic (2.49e-1)"	"unprognostic (1.43e-2)"	"unprognostic (9.82e-3)"	"unprognostic (9.88e-2)"	"unprognostic (1.06e-1)"	"prognostic unfavorable (9.44e-5)"	"unprognostic (1.91e-2)"	"unprognostic (7.59e-2)"	"unprognostic (1.41e-3)"	"unprognostic (6.46e-2)"	"unprognostic (4.91e-2)"	"unprognostic (9.20e-3)"	"unprognostic (2.68e-1)"	"unprognostic (6.13e-2)"	"unprognostic (3.20e-2)"	"unprognostic (6.28e-2)"	38.5	39.2	29.0	26.2	25.9	19.6	31.4	19.5	28.9	28.8	34.2	29.4	28.9	21.5	26.6	26.3	33.5	28.8	25.7	31.1	26.1	27.1	26.4	20.9	28.3	23.8	30.9	24.3	36.6	28.1	25.7	24.4	34.8	28.6	27.8	29.8	31.7	29.7	28.7	33.9	28.0	26.4	34.6	35.4	34.1	26.3	29.2	26.2	60.7	46.1	23.6	31.5	35.1	35.7	12.0	21.8	28.9	24.7	24.5	25.9	19.7	22.2	32.0	19.5	18.9	31.2	38.2	22.3	24.3	29.2	25.4	29.7	12.2	21.4	34.6	17.5	30.8	35.6	24.6	21.9	27.1	34.1	37.6	11.2	29.4	48.3	19.8	36.4	40.8	30.1	28.2	35.0	21.7	50.3	29.6	28.0	28.2	13.6	29.0	31.2	14.5	28.0	19.6	9.6	1.1	7.6	20.5	28.5	23.6	57.0	38.4	18.1	21.2	29.2	20.1	23.8	19.9	15.2	27.2	31.3	37.7	21.8	10.2	17.6	28.5	27.3	30.2	26.1	27.9	27.5	28.9	22.6	25.0	16.9	24.7	21.2	12.0	23.1	20.9	21.8	9.4	25.8	19.8	22.7	24.5	20.8	15.5	25.9	19.7	29.0	25.9	19.5	28.9	26.1	27.1	30.9	24.3	28.6	26.2	41.7	29.7	22.0	39.2	48.3	44.4	40.0	40.8	30.8	45.5	73.3	200.3	37.8	33.2	31.7	53.8	44.7	32.0	46.7	38.2	33.2	34.3	51.4	20.8	22.6	38.9	33.4	49.0	57.7	52.1	97.0	38.6	38.2	49.0	44.1	42.5	37.9	37.5	24.6	50.2	32.1	82.1	32.3	35.9	26.3	39.6	54.1	58.1	38.1	35.7	55.8
SMAD3	"HsT17436, JV15-2, MADH3"	ENSG00000166949	"SMAD family member 3"	P84022	15	67063763-67195195	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	DNA-binding	"Aortic aneurysm, Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Glandular cells: 111.1;Urothelial cells: 247.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008094, HPA046386, HPA067203, CAB069409"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB008094: AB_2302271, CAB069409: AB_1622941, HPA046386: AB_2679647, HPA067203: AB_2685803"	"unprognostic (1.04e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.99e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.98e-2)"	"unprognostic (8.40e-3)"	"unprognostic (1.80e-2)"	"unprognostic (7.62e-2)"	"unprognostic (6.82e-2)"	"prognostic unfavorable (2.48e-4)"	"unprognostic (2.93e-1)"	"unprognostic (2.14e-2)"	"unprognostic (3.10e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.15e-1)"	"unprognostic (5.97e-2)"	25.3	4.6	12.2	18.5	12.4	12.4	21.6	5.0	12.7	20.9	17.9	7.6	9.5	12.7	19.9	16.6	35.3	14.3	27.7	19.7	7.5	4.8	15.6	13.6	13.9	14.0	6.0	7.5	23.0	12.6	7.0	10.8	11.5	8.2	20.5	9.2	30.8	12.5	10.8	37.3	19.6	19.0	23.2	5.5	11.2	15.8	7.0	7.7	10.5	21.8	23.4	29.7	31.4	24.6	4.8	2.5	3.2	1.9	0.4	6.3	1.8	12.2	41.2	7.7	3.7	13.6	31.4	6.1	7.1	29.3	9.9	8.0	8.5	32.9	4.1	9.6	20.2	44.6	29.1	8.0	30.0	9.9	3.2	3.0	0.4	11.6	6.4	10.2	1.6	0.7	28.4	7.0	8.7	7.4	22.0	33.3	1.3	9.9	11.5	12.3	6.3	0.3	6.2	4.5	6.5	12.9	0.4	2.3	1.5	6.6	39.5	0.2	2.6	9.4	5.2	8.1	15.7	1.4	7.6	28.0	13.4	12.6	9.6	8.0	4.4	1.2	5.1	12.1	1.7	12.0	0.0	1.9	3.2	5.5	1.5	5.7	2.1	6.2	6.3	1.8	4.8	2.8	2.4	0.1	0.4	1.5	2.5	3.1	1.8	12.2	12.4	5.0	12.7	7.5	4.8	6.0	7.5	8.2	7.7	44.7	14.5	13.6	67.6	79.0	8.3	9.5	15.3	24.1	30.7	34.9	5.9	0.8	3.3	53.0	0.9	20.1	34.4	0.0	44.0	4.0	34.3	111.1	24.2	11.3	8.4	0.0	3.4	9.8	4.8	3.7	24.7	13.8	20.3	3.6	11.9	9.7	71.0	21.0	19.4	12.2	0.4	25.8	14.6	0.3	0.7	42.8	1.4	12.5	15.7	247.9
SMAD4	"DPC4, MADH4"	ENSG00000141646	"SMAD family member 4"	Q13485	18	51028394-51085045	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019154	Approved		Supported	Nucleoplasm,Centrosome,Cytosol		NA	NA			"Nucleoplasm, Cytosol"	Centrosome	"HPA019154: AB_1853480"	"unprognostic (1.58e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.25e-2)"	"unprognostic (4.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (4.05e-1)"	"unprognostic (7.29e-3)"	"unprognostic (9.00e-2)"	"unprognostic (4.01e-2)"	"unprognostic (2.51e-2)"	"unprognostic (1.03e-3)"	"unprognostic (4.40e-2)"	"prognostic favorable (1.92e-5)"	"unprognostic (2.62e-2)"	"unprognostic (4.23e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.44e-1)"	25.6	17.5	16.0	14.0	16.7	11.4	24.9	29.7	16.0	27.9	22.6	17.9	21.3	15.1	28.2	18.8	21.7	20.5	17.5	19.6	15.3	11.5	21.0	22.0	20.1	16.0	17.2	13.3	30.5	25.0	30.0	28.9	30.6	14.2	27.8	17.4	18.4	23.1	22.8	39.7	18.2	23.4	27.6	13.9	21.7	19.3	17.6	18.4	38.8	35.0	13.9	18.1	29.0	24.1	3.6	3.6	3.4	1.8	2.9	4.7	1.3	8.5	11.4	30.9	8.9	12.8	19.8	17.4	15.1	16.6	20.3	25.5	7.0	2.0	14.3	4.5	13.0	10.4	14.2	17.3	6.8	21.6	12.4	9.8	9.9	11.4	8.0	12.7	17.2	7.8	8.9	11.5	10.0	14.7	19.6	14.7	7.3	11.1	13.2	12.0	4.5	10.2	5.0	16.1	4.6	7.1	13.3	15.7	14.0	9.7	3.7	19.1	11.3	14.1	2.6	9.4	13.7	7.0	10.0	11.0	17.2	8.0	4.3	10.0	19.9	13.8	12.4	11.2	6.7	11.3	0.8	1.8	1.8	3.2	1.1	3.7	2.2	3.3	2.6	3.6	3.6	4.0	4.7	3.4	2.9	1.3	2.9	4.3	1.3	16.0	16.7	29.7	16.0	15.3	11.5	17.2	13.3	14.2	18.4	20.8	23.2	11.8	18.4	22.8	13.2	33.5	40.8	16.0	19.4	21.0	19.6	15.5	10.0	16.2	7.3	23.2	15.6	0.0	10.8	16.8	23.8	31.7	4.6	40.0	13.2	14.3	38.1	23.9	26.1	11.4	30.8	16.7	27.0	5.4	33.8	18.9	18.1	24.3	28.7	18.5	20.8	25.8	29.2	13.9	16.2	23.8	10.5	13.8	26.2	22.5
SMARCA4	"BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2"	ENSG00000127616	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4"	P51532	19	10960825-11079426	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Neurogenesis, Transcription, Transcription regulation"	"Activator, Chromatin regulator, Helicase, Hydrolase, Repressor, RNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cardiomyocytes: 219.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB004208	Supported		Supported	Nucleoplasm		NA	NA		260000	Nucleoplasm		"CAB004208: AB_626762"	"unprognostic (2.68e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.71e-1)"	"unprognostic (3.43e-3)"	"unprognostic (1.40e-1)"	"unprognostic (6.33e-3)"	"prognostic unfavorable (1.11e-4)"	"unprognostic (7.19e-2)"	"unprognostic (7.29e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.15e-2)"	"unprognostic (6.80e-3)"	"unprognostic (6.83e-3)"	"unprognostic (5.44e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.29e-1)"	10.3	12.4	15.5	18.0	21.3	20.5	10.9	29.1	28.0	13.2	12.8	16.6	9.7	14.3	16.6	9.4	24.7	15.7	12.8	11.6	14.4	17.7	13.0	9.9	13.0	18.1	17.1	16.8	13.6	13.4	18.1	11.5	14.6	16.1	13.3	9.4	17.3	18.2	12.5	21.9	20.4	12.0	10.6	16.1	13.2	14.5	22.2	12.4	58.2	15.5	10.1	21.5	15.2	12.6	9.8	11.2	8.6	13.5	11.4	13.7	5.9	20.5	1.1	36.7	34.7	7.2	6.1	16.1	14.3	8.6	17.5	13.0	28.7	0.9	48.3	22.2	12.5	0.7	15.1	28.6	17.7	9.7	19.8	21.4	38.4	18.2	33.3	10.9	27.8	19.2	10.2	8.6	14.7	15.2	7.8	15.6	21.1	34.4	18.2	13.7	41.9	46.2	23.9	37.2	10.0	31.1	49.2	23.2	25.0	11.2	26.1	41.8	37.9	15.2	19.6	16.3	12.3	16.6	20.9	20.6	26.1	13.6	23.8	23.6	37.7	41.8	47.9	14.8	26.7	22.1	8.1	8.3	8.6	13.7	9.5	12.2	7.4	10.4	11.6	8.5	9.8	11.4	11.2	5.2	11.4	13.5	11.2	8.8	5.9	15.5	21.3	29.1	28.0	14.4	17.7	17.1	16.8	16.1	12.4	62.5	67.7	32.7	32.8	32.7	82.3	219.1	43.3	46.8	51.2	41.8	66.8	57.1	34.9	75.0	39.4	30.8	34.6	23.3	53.1	46.8	38.0	38.3	29.0	19.2	36.4	95.3	60.6	22.7	21.0	29.3	24.2	23.3	15.1	57.7	37.3	37.2	60.6	38.6	12.7	19.3	63.8	12.9	30.3	93.0	96.0	45.2	51.0	28.4	50.9	40.7
SMARCB1	"BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1"	ENSG00000099956	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1"	Q12824	22	23786931-23838008	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Host-virus interaction, Neurogenesis, Transcription, Transcription regulation"	"Activator, Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Hypotrichosis, Mental retardation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 19.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009196, HPA018248, HPA019127"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			Nucleoplasm	"Nucleoli fibrillar center"	"CAB009196: AB_2191983, HPA018248: AB_1851162, HPA019127: AB_1851165"	"unprognostic (2.15e-1)"	"unprognostic (5.62e-2)"	"unprognostic (6.60e-3)"	"unprognostic (1.63e-2)"	"unprognostic (4.01e-3)"	"unprognostic (2.14e-1)"	"prognostic unfavorable (6.52e-4)"	"unprognostic (4.10e-1)"	"unprognostic (1.86e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.10e-2)"	"unprognostic (4.43e-3)"	"prognostic favorable (1.14e-6)"	"unprognostic (1.24e-1)"	"unprognostic (4.58e-2)"	"unprognostic (4.57e-2)"	"unprognostic (7.04e-2)"	11.0	15.2	14.6	33.2	15.4	16.9	12.1	30.4	21.9	13.4	25.1	16.4	11.4	41.1	17.2	11.0	15.6	12.3	15.0	12.6	13.2	14.2	14.6	11.7	14.0	32.8	13.0	13.8	21.3	16.1	7.9	15.7	20.8	12.8	11.0	9.4	16.7	40.9	13.1	28.1	14.7	27.4	10.6	12.8	19.8	24.1	37.7	12.9	29.4	15.7	12.0	16.0	21.1	12.2	19.5	9.9	4.8	11.6	7.0	7.5	5.9	1.5	1.0	19.2	1.8	1.8	0.5	3.9	6.1	1.8	1.8	2.9	2.2	1.8	15.7	5.3	0.8	2.0	2.9	4.6	3.0	3.0	2.6	6.7	13.0	1.8	1.3	2.1	13.8	3.8	1.1	2.2	2.1	4.7	0.9	0.9	1.9	3.5	8.7	1.1	3.9	11.2	3.2	5.7	4.7	3.8	7.0	15.5	7.0	1.6	3.0	9.1	6.9	1.4	0.4	10.3	10.4	1.5	2.1	1.6	1.6	6.7	2.6	1.7	9.6	8.8	10.4	1.3	7.6	4.6	4.0	10.0	4.8	3.8	10.2	5.2	19.5	4.6	4.6	9.3	6.4	3.8	2.5	0.8	7.0	11.6	9.9	7.5	5.9	14.6	15.4	30.4	21.9	13.2	14.2	13.0	13.8	12.8	12.9	6.0	10.4	102.1	57.3	44.6	51.7	3.7	38.2	18.7	6.8	45.4	19.6	106.2	71.3	80.0	26.9	31.5	31.9	23.3	67.3	185.0	45.7	53.3	33.5	17.7	66.6	63.5	68.9	36.8	19.7	12.4	33.1	35.4	54.0	63.1	50.5	72.3	62.0	51.8	30.1	65.4	36.9	19.4	58.2	125.7	116.1	46.3	133.9	35.0	61.6	56.7
SMARCD1	"BAF60A, CRACD1, Rsc6p"	ENSG00000066117	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1"	Q96GM5	12	50084972-50100712	"Cancer-related genes, Predicted intracellular proteins"	Neurogenesis	"Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004101	Supported		Supported	Nucleoplasm,Vesicles		NA	NA			Nucleoplasm	Vesicles	"HPA004101: AB_1080026"	"unprognostic (1.88e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.11e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.76e-1)"	"prognostic unfavorable (2.53e-8)"	"unprognostic (3.62e-2)"	"unprognostic (1.44e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.10e-2)"	"unprognostic (1.20e-3)"	"unprognostic (2.18e-1)"	"unprognostic (3.45e-1)"	"unprognostic (1.38e-1)"	"unprognostic (5.04e-2)"	21.3	24.5	16.4	22.6	22.7	29.9	21.3	27.8	28.2	19.8	19.9	29.5	17.6	18.8	23.6	23.4	23.3	19.9	18.2	15.6	16.3	13.8	25.1	18.3	19.4	26.1	15.7	20.4	24.7	19.6	44.3	17.8	24.7	18.8	20.4	22.4	20.3	21.4	25.9	16.6	19.7	24.0	23.8	18.5	28.1	17.4	34.4	14.9	64.3	24.3	17.9	36.7	19.3	18.2	6.0	6.7	4.4	3.4	3.1	6.9	2.3	8.1	13.8	40.7	23.5	12.7	12.0	20.2	10.1	18.0	29.9	17.5	37.7	12.8	31.8	15.3	19.4	13.6	10.5	34.3	26.7	25.9	24.6	25.3	31.4	13.9	21.8	15.1	27.7	12.6	12.1	17.9	17.7	32.0	20.1	35.2	34.0	26.5	19.8	15.1	19.1	40.2	14.9	50.8	12.5	22.6	48.3	10.6	27.8	17.0	19.1	21.9	36.6	21.3	10.9	42.5	31.6	24.5	23.3	21.1	15.4	17.3	9.7	20.7	27.9	24.5	28.3	12.5	11.2	17.4	4.4	2.3	4.1	6.1	2.1	5.8	6.0	3.3	3.9	3.6	5.6	2.1	6.9	1.1	3.1	3.4	6.7	5.0	2.3	16.4	22.7	27.8	28.2	16.3	13.8	15.7	20.4	18.8	14.9	0.0	8.1	33.4	17.8	14.7	31.0	5.7	15.3	9.4	25.0	26.2	19.6	17.5	44.7	25.2	3.2	21.0	17.7	0.0	24.9	16.2	12.9	16.7	16.1	12.7	15.1	25.4	29.9	14.1	10.7	6.6	15.3	11.0	16.9	34.3	18.6	26.7	27.6	14.0	15.2	30.4	26.0	32.3	13.3	21.9	31.5	17.1	9.3	16.0	15.7	14.4
SMARCE1	BAF57	ENSG00000073584	"SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1"	Q969G3	17	40624962-40648864	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	Neurogenesis	"Chromatin regulator, DNA-binding"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003916, CAB037318"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB037318: AB_476780, HPA003916: AB_1857279"	"unprognostic (7.91e-2)"	"unprognostic (2.68e-2)"	"unprognostic (2.09e-2)"	"unprognostic (8.06e-3)"	"unprognostic (1.87e-1)"	"unprognostic (2.55e-2)"	"unprognostic (4.48e-1)"	"unprognostic (1.25e-2)"	"unprognostic (2.20e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.04e-1)"	"unprognostic (9.80e-2)"	"unprognostic (5.93e-2)"	"unprognostic (7.63e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.27e-2)"	25.1	20.2	14.4	17.2	18.8	18.4	20.2	17.0	16.7	37.6	25.1	18.0	12.6	18.4	42.8	19.5	31.0	21.1	20.6	19.6	13.3	12.0	23.0	22.6	20.1	22.3	16.5	14.3	39.5	16.9	13.3	20.4	34.8	15.2	32.4	19.2	17.9	20.6	21.9	32.0	21.3	22.6	33.4	15.8	30.3	19.1	22.0	17.5	53.9	23.8	18.9	25.1	31.2	21.0	40.3	32.0	34.0	30.3	47.2	44.0	39.2	20.7	34.5	42.3	31.5	22.4	32.3	20.8	26.1	36.0	30.7	23.1	22.6	18.0	32.9	37.7	35.2	20.5	28.3	26.2	27.6	36.9	30.8	34.0	23.5	18.6	39.6	22.6	42.9	23.9	28.0	21.8	24.5	35.7	31.0	33.0	26.6	34.2	13.1	29.3	23.3	78.5	8.9	23.6	17.1	17.1	44.0	47.7	25.0	37.0	35.6	33.9	32.8	23.2	67.3	21.7	48.0	40.3	26.9	27.0	25.0	27.5	22.5	32.1	24.6	28.6	49.2	25.4	19.7	38.4	31.8	26.0	34.0	39.1	26.8	40.5	38.4	35.8	40.9	31.3	40.3	30.2	34.9	11.0	47.2	30.3	32.0	44.0	39.2	14.4	18.8	17.0	16.7	13.3	12.0	16.5	14.3	15.2	17.5	44.7	30.1	53.5	36.0	33.9	46.7	46.8	38.2	73.6	60.3	19.2	15.7	85.1	13.3	34.9	18.3	60.7	37.1	23.3	27.8	65.4	59.9	34.1	70.6	38.4	44.7	77.9	92.7	48.5	34.8	7.7	83.7	37.7	23.6	49.5	51.9	65.5	27.8	51.0	77.4	21.6	34.7	38.8	52.6	40.8	46.0	35.0	96.0	60.9	54.8	33.5
SMO	"FZD11, SMOH"	ENSG00000128602	"Smoothened, frizzled class receptor"	Q99835	7	129188872-129213545	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"		"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Collecting duct cells: 10.4;Leydig cells: 19.2;Muller glia cells: 15.1;Peritubular cells: 20.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 20.3;AN3-CA: 37.6;NTERA-2: 28.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB011446	Approved					NA	NA					"CAB011446: "	"unprognostic (2.48e-2)"	"unprognostic (2.69e-2)"	"unprognostic (7.09e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.16e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.63e-1)"	"unprognostic (5.89e-2)"	"unprognostic (5.38e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.17e-2)"	"unprognostic (8.74e-3)"	"unprognostic (1.62e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.09e-1)"	"unprognostic (2.25e-1)"	"unprognostic (2.61e-2)"	4.0	4.1	4.2	3.8	4.8	0.5	7.4	5.3	4.6	18.2	5.8	5.1	9.2	2.5	20.9	18.7	10.3	11.4	10.0	5.2	8.4	3.7	10.6	13.7	2.4	2.0	4.3	4.5	23.0	7.1	14.4	13.5	2.6	9.0	18.4	2.2	17.2	9.4	12.8	3.5	16.6	3.5	9.8	7.0	2.0	4.2	7.9	3.4	5.3	9.2	6.8	4.6	6.3	17.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	8.0	20.3	37.6	0.5	0.1	6.4	2.2	2.9	4.5	2.6	6.1	0.1	0.0	6.2	4.5	10.2	12.4	12.2	0.7	1.7	0.0	9.9	3.9	0.0	9.8	2.5	0.1	0.0	7.4	5.0	1.4	0.0	9.0	2.6	11.2	0.6	0.0	1.4	0.0	10.3	0.0	28.8	0.0	2.3	15.0	8.7	0.0	2.3	0.0	0.6	13.6	0.0	0.0	5.3	8.1	4.9	2.6	0.0	0.3	6.5	7.8	4.3	0.4	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	4.8	5.3	4.6	8.4	3.7	4.3	4.5	9.0	3.4	0.0	0.0	0.0	2.3	1.6	0.6	1.2	2.5	0.0	4.5	10.4	0.0	0.3	1.7	3.2	0.3	0.4	0.0	0.0	1.0	0.3	4.4	2.8	0.0	5.1	3.3	0.0	0.0	1.3	1.3	0.9	19.2	0.4	0.0	1.0	0.0	15.1	1.9	0.0	20.5	3.7	0.3	6.5	2.1	0.0	0.4	2.5	0.5	0.0	0.0	0.4
SND1	"p100, TDRD11"	ENSG00000197157	"Staphylococcal nuclease and tudor domain containing 1"	Q7KZF4	7	127652180-128092609	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Transcription, Transcription regulation"	"Endonuclease, Hydrolase, Nuclease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cytotrophoblasts: 195.0;Syncytiotrophoblasts: 223.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002529, HPA002632, CAB019323"	Enhanced		Enhanced	Cytosol		NA	NA		1200000	Cytosol		"CAB019323: , HPA002529: AB_1857317, HPA002632: AB_1857316"	"unprognostic (2.06e-1)"	"unprognostic (8.27e-3)"	"unprognostic (2.21e-1)"	"prognostic favorable (1.95e-4)"	"unprognostic (5.10e-3)"	"unprognostic (6.83e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.91e-2)"	"unprognostic (4.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.36e-2)"	"unprognostic (9.96e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.42e-2)"	"unprognostic (2.26e-3)"	21.5	29.8	25.3	25.3	19.8	22.5	45.4	28.1	28.1	33.3	20.0	13.0	57.7	21.3	36.1	38.4	24.8	26.7	25.3	28.3	20.9	16.6	17.3	39.6	38.8	64.2	20.2	19.0	39.7	130.3	22.2	30.3	33.7	27.6	24.5	20.2	13.9	37.5	66.7	20.5	21.5	19.2	41.0	40.1	24.9	30.8	37.0	18.0	22.3	26.6	13.5	24.9	26.5	24.2	28.1	34.9	16.1	30.0	21.0	30.9	28.5	28.5	25.9	19.8	35.9	30.1	31.5	27.2	33.6	39.8	30.8	34.6	33.4	24.8	37.9	17.0	41.2	26.0	24.0	27.9	36.4	30.1	20.7	23.6	20.9	30.9	32.0	54.8	32.3	20.6	46.3	40.7	26.3	44.1	35.1	38.2	15.7	23.1	38.1	30.7	21.3	35.1	24.2	22.2	29.0	32.3	24.5	17.7	84.8	24.1	20.1	25.0	27.0	24.3	113.2	38.9	31.1	14.1	23.0	37.9	25.1	16.4	45.5	26.1	47.0	17.6	39.8	50.3	27.9	45.3	16.1	30.0	5.9	26.1	28.1	30.9	28.1	19.8	21.0	32.3	16.2	14.3	15.8	2.2	21.0	22.8	34.9	15.8	28.5	25.3	19.8	28.1	28.1	20.9	16.6	20.2	19.0	27.6	18.0	14.9	43.1	29.8	20.4	17.4	11.2	26.2	38.2	14.7	20.5	27.9	19.6	195.0	14.9	60.6	12.9	28.0	32.8	23.3	83.7	91.7	29.4	34.2	34.6	43.3	73.2	28.6	70.2	26.4	48.3	40.2	42.3	43.7	32.1	80.2	55.0	15.6	63.2	31.6	38.9	25.1	32.0	32.3	19.5	19.2	29.2	24.0	223.8	27.7	53.0	21.3
SOCS1	"Cish1, JAB, SOCS-1, SSI-1, TIP3"	ENSG00000185338	"Suppressor of cytokine signaling 1"	O15524	16	11254405-11256200	"Cancer-related genes, Predicted intracellular proteins"	"Growth regulation, Ubl conjugation pathway"	"Signal transduction inhibitor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 42.3;lymphoid tissue: 58.3"	"Cell type enhanced"	"Detected in many"	5	"T-cells: 63.1"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	6	"cerebellum: 15.2"	"Cell type enhanced"	"Detected in many"		"basophil: 12.9"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	5	"HDLM-2: 48.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB010355, HPA074108"	Approved		Supported	"Nucleoplasm,Cytoplasmic bodies"		NA	NA			Nucleoplasm	"Cytoplasmic bodies"	"CAB010355: AB_2193144, HPA074108: AB_2686661"	"unprognostic (4.50e-3)"	"unprognostic (3.30e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.25e-2)"	"prognostic favorable (1.10e-4)"	"unprognostic (1.71e-2)"	"unprognostic (4.09e-3)"	"unprognostic (5.31e-3)"	"unprognostic (4.82e-2)"	"unprognostic (1.17e-1)"	"unprognostic (5.39e-2)"	"prognostic unfavorable (1.08e-6)"	"unprognostic (1.56e-1)"	"unprognostic (5.68e-2)"	"unprognostic (6.08e-2)"	"unprognostic (1.67e-1)"	10.9	2.8	0.7	19.2	1.5	13.9	37.9	15.2	1.1	15.8	6.3	0.3	2.2	3.3	4.9	7.6	5.6	4.2	11.0	3.6	0.6	1.0	11.1	42.3	9.6	25.8	0.8	0.0	9.3	3.8	0.7	16.8	9.3	2.4	5.3	1.8	3.2	3.7	3.9	2.3	6.0	11.0	6.5	1.1	14.7	6.6	7.1	0.4	58.3	5.1	4.8	14.7	5.4	8.3	4.4	1.3	12.9	0.1	5.5	2.7	0.4	1.2	0.2	0.5	0.1	1.6	0.2	1.9	1.0	7.5	0.4	0.6	0.3	0.2	2.9	2.2	0.4	1.4	0.5	0.2	0.1	0.1	48.3	0.3	0.8	0.0	3.9	0.7	0.0	8.9	0.7	0.1	1.0	0.1	0.2	0.1	0.3	6.4	0.8	0.0	1.1	3.2	1.8	5.4	0.0	0.8	0.3	0.3	0.3	0.5	0.2	0.7	0.1	0.2	1.7	0.5	1.5	0.0	0.4	0.0	0.6	3.2	0.4	0.6	0.2	0.2	4.5	1.2	0.3	0.6	12.9	0.1	8.8	2.2	0.0	2.0	1.4	2.5	2.7	0.0	4.4	2.7	2.5	0.3	5.5	0.0	1.3	2.6	0.4	0.7	1.5	15.2	0.6	0.6	1.0	0.8	0.0	2.4	0.4	0.0	4.1	11.5	14.7	10.9	1.9	9.2	5.1	2.7	0.0	48.8	5.9	21.5	19.9	11.3	40.7	3.6	23.6	0.0	7.3	4.3	30.9	5.9	54.0	2.4	4.0	0.0	25.0	10.4	6.5	17.6	6.6	8.4	28.7	24.4	12.9	7.4	6.9	9.1	39.3	7.0	4.2	0.0	16.5	0.9	2.0	5.9	48.3	63.1	6.6	10.8
SOX2		ENSG00000181449	"SRY-box 2"	P48431	3	181711924-181714436	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Microphthalmia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 80.1"	"Cell type enriched"	"Detected in some"	9	"Muller glia cells: 455.6"	"Cancer enhanced"	"Detected in many"		"glioma: 136.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 68.9;HAP1: 29.3;NTERA-2: 56.2;U-251 MG: 12.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045725, HPA062851, HPA071379, CAB079745"	Enhanced	Supported	Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB079745: , HPA045725: AB_2679431, HPA062851: , HPA071379: "	"unprognostic (1.80e-2)"	"unprognostic (3.18e-3)"	"unprognostic (5.69e-2)"	"unprognostic (6.96e-2)"	"unprognostic (2.74e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.79e-2)"	"unprognostic (4.48e-3)"	"unprognostic (1.71e-1)"	"unprognostic (4.38e-3)"	"unprognostic (1.83e-1)"	"unprognostic (7.68e-2)"	"unprognostic (3.81e-9)"	"unprognostic (1.12e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.26e-1)"	"unprognostic (1.12e-2)"	1.8	2.5	30.3	2.0	25.8	1.5	1.6	13.9	80.1	1.8	2.3	24.3	0.0	2.0	1.5	1.8	15.9	5.0	1.8	1.7	36.0	19.2	1.5	1.5	3.4	1.5	19.4	18.5	1.7	1.6	1.5	5.8	1.5	18.6	3.9	2.0	1.0	6.3	1.9	1.6	1.8	2.3	1.7	18.4	1.6	9.7	3.0	22.4	0.0	1.5	2.1	6.9	2.3	1.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.2	68.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.1	29.3	0.7	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	56.2	2.9	0.1	0.0	0.1	0.0	7.6	0.1	0.1	0.3	0.0	0.0	0.0	11.9	0.4	0.0	0.0	0.0	1.0	0.0	12.9	0.0	0.0	0.0	0.0	0.0	8.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30.3	25.8	13.9	20.0	36.0	19.2	19.4	18.5	18.6	22.4	0.0	5.9	0.0	41.2	0.2	3.5	0.4	0.0	52.2	38.7	3.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	4.9	1.1	0.0	0.1	0.0	0.0	1.3	0.0	0.0	0.6	0.2	3.3	0.0	0.0	455.6	0.0	0.0	0.0	0.0	8.2	0.0	0.1	1.5	0.2	0.4	0.2	0.0	0.0	7.0
SPEN	"KIAA0929, MINT, RBM15C, SHARP"	ENSG00000065526	"Spen family transcriptional repressor"	Q96T58	1	15847864-15940460	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015825, HPA050257"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA015825: AB_1856823, HPA050257: AB_2681065"	"unprognostic (3.91e-1)"	"unprognostic (1.74e-1)"	"unprognostic (3.76e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.48e-1)"	"unprognostic (3.06e-2)"	"unprognostic (6.93e-3)"	"unprognostic (2.26e-1)"	"unprognostic (4.26e-2)"	"unprognostic (4.88e-3)"	"unprognostic (1.71e-1)"	"unprognostic (5.98e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.49e-1)"	"unprognostic (1.66e-1)"	"unprognostic (2.26e-1)"	"unprognostic (1.83e-1)"	18.2	11.2	18.2	18.2	22.2	27.2	17.3	38.2	25.9	18.5	13.4	20.7	17.7	11.9	19.0	12.7	16.7	19.4	11.8	13.5	17.6	11.5	14.4	13.2	17.8	16.6	23.4	17.5	31.2	23.9	35.1	17.5	16.2	19.0	14.9	13.3	11.6	16.2	16.2	24.0	22.8	16.0	15.1	22.0	16.5	13.7	13.6	23.3	18.3	20.1	8.7	18.0	17.1	41.9	5.0	2.7	7.7	2.4	1.3	1.7	0.6	12.7	10.8	13.5	10.1	13.6	8.3	7.3	6.6	8.7	7.2	6.1	9.8	10.0	18.0	7.9	13.0	8.5	18.5	12.7	11.8	11.6	16.2	35.2	22.6	9.6	6.2	6.1	18.5	10.8	6.1	8.5	10.7	15.6	6.8	8.2	13.8	23.5	18.6	5.8	7.1	15.3	7.3	6.1	7.4	8.3	14.8	13.2	11.1	4.0	11.5	10.5	10.6	18.6	9.1	7.9	6.4	3.2	9.1	14.7	6.6	8.2	12.8	9.4	11.2	7.3	20.6	6.5	15.0	9.2	7.7	1.5	0.9	1.6	2.4	1.3	1.8	1.7	1.4	0.7	5.0	0.9	1.3	4.2	1.3	1.2	2.7	1.1	0.6	18.2	22.2	38.2	25.9	17.6	11.5	23.4	17.5	19.0	23.3	74.5	74.0	31.3	47.9	93.0	64.6	48.1	20.4	38.8	66.0	5.2	49.1	10.9	3.3	16.9	3.4	55.5	30.7	23.3	15.0	12.0	46.5	43.4	59.1	26.3	13.3	90.6	30.4	13.5	30.8	3.6	25.3	30.1	20.3	25.2	24.4	29.6	18.0	23.2	33.6	6.5	54.5	19.4	54.6	34.9	51.9	88.8	13.2	20.2	18.7	49.2
SPOP	"BTBD32, TEF2"	ENSG00000121067	"Speckle type BTB/POZ protein"	O43791	17	49598884-49678234	"Cancer-related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.96e-2)"	"unprognostic (1.43e-2)"	"unprognostic (8.83e-2)"	"unprognostic (3.23e-1)"	"unprognostic (2.15e-2)"	"unprognostic (4.51e-2)"	"prognostic unfavorable (6.88e-4)"	"unprognostic (1.89e-2)"	"unprognostic (7.20e-2)"	"unprognostic (1.17e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.67e-2)"	"unprognostic (2.81e-1)"	"unprognostic (3.45e-2)"	"unprognostic (1.10e-2)"	"unprognostic (3.29e-1)"	22.0	16.5	22.5	16.9	24.9	7.9	18.6	39.8	26.9	27.5	59.5	25.0	25.1	15.2	36.2	21.2	35.4	25.2	17.2	22.7	22.7	18.8	17.0	20.2	19.1	19.6	20.9	21.4	26.0	18.5	15.1	28.5	18.2	23.2	38.8	23.5	21.8	22.8	49.5	29.2	15.2	24.1	45.1	18.4	18.8	28.4	10.5	26.8	28.6	26.4	14.3	23.3	35.6	22.3	43.2	55.6	59.6	43.1	40.7	58.4	50.8	14.2	16.1	18.6	7.0	20.9	22.3	12.6	18.8	19.4	24.9	25.9	32.8	15.7	23.6	36.0	17.0	17.2	11.5	21.1	13.7	29.8	43.7	23.3	27.4	16.4	18.7	24.0	17.9	22.4	16.7	17.6	19.4	21.1	18.1	25.3	17.6	28.3	24.3	16.7	13.9	32.9	16.5	4.9	33.7	19.7	18.7	27.1	30.5	13.5	8.5	28.0	13.0	11.8	6.0	15.4	10.5	23.2	18.7	22.2	27.0	18.7	21.1	15.4	24.4	20.3	20.6	15.8	16.1	13.5	57.0	41.8	50.6	36.2	37.1	36.1	42.4	40.6	39.2	55.6	43.2	58.4	45.3	59.6	40.7	43.1	37.2	36.0	50.8	22.5	24.9	39.8	26.9	22.7	18.8	20.9	21.4	23.2	26.8	44.7	34.5	45.7	39.5	38.0	59.7	46.4	22.9	33.5	30.7	27.9	41.2	19.1	24.9	30.3	13.7	56.0	23.9	0.0	24.6	19.6	43.7	25.3	30.1	39.9	33.5	71.5	49.4	54.6	50.5	4.5	52.0	43.8	37.1	65.9	43.6	94.4	23.0	36.5	68.9	22.7	54.6	71.1	58.6	30.9	46.6	38.3	30.2	43.7	32.2	18.0
SRC	"ASV, c-src, SRC1"	ENSG00000197122	"SRC proto-oncogene, non-receptor tyrosine kinase"	P12931	20	37344685-37406050	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell adhesion, Cell cycle, Host-virus interaction, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 5.3;non-classical monocyte: 4.4"	"Group enriched"	"Detected in many"	6	"dendritic cells: 3.0;monocytes: 5.3"	"Cell line enhanced"	"Detected in many"		"A549: 35.9;HBEC3-KT: 33.4;RT4: 34.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004023, HPA030875"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol"		NA	NA		20000000	"Plasma membrane, Cell Junctions"	"Nucleoplasm, Cytosol"	"CAB004023: AB_2106059, HPA030875: AB_2673640"	"unprognostic (5.58e-2)"	"unprognostic (9.83e-2)"	"unprognostic (3.56e-1)"	"unprognostic (4.54e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (4.90e-5)"	"unprognostic (3.89e-2)"	"unprognostic (7.04e-2)"	"unprognostic (8.13e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (1.63e-4)"	"prognostic unfavorable (1.22e-4)"	"unprognostic (2.33e-2)"	"unprognostic (4.72e-2)"	"unprognostic (3.65e-2)"	"prognostic favorable (5.22e-5)"	6.9	17.5	12.8	11.1	12.0	5.4	9.9	6.4	16.0	16.0	16.4	3.5	15.1	29.5	20.3	9.7	16.2	14.2	42.1	5.8	11.3	6.6	13.4	2.9	10.4	7.0	3.3	9.9	15.8	19.1	6.6	11.3	6.3	5.1	19.9	13.1	13.1	7.5	22.5	3.4	7.7	28.1	27.2	3.6	12.2	29.8	27.3	4.8	4.0	6.6	10.5	10.4	26.4	20.0	0.3	3.0	0.1	5.3	0.6	0.1	1.6	7.7	35.9	8.3	7.4	3.1	5.0	17.2	7.2	6.2	8.8	5.6	13.5	7.0	0.2	4.5	13.0	10.0	14.2	4.9	33.4	3.4	0.0	4.5	2.0	1.3	20.9	7.5	0.1	3.1	5.3	11.4	5.7	7.7	9.8	8.0	4.6	0.2	0.0	1.4	5.3	1.9	0.2	3.9	21.5	32.6	8.4	2.2	0.2	3.7	34.4	7.7	27.9	8.1	11.4	8.9	6.6	10.2	2.8	11.6	10.5	7.1	3.8	6.4	0.1	0.2	0.1	7.4	0.0	7.8	0.0	2.6	0.0	0.0	5.3	0.0	0.3	0.0	0.1	1.1	0.3	0.0	0.0	0.1	0.6	4.4	3.0	0.1	1.6	12.8	12.0	6.4	16.0	11.3	6.6	3.3	9.9	5.1	4.8	3.0	1.7	4.4	10.8	7.2	5.4	1.6	15.3	1.4	0.0	12.2	2.0	1.6	1.7	9.7	1.3	1.4	30.0	0.0	16.2	7.0	8.2	11.2	0.0	0.9	5.8	3.2	16.1	1.3	6.9	1.5	10.0	12.1	1.7	7.2	25.9	4.1	29.0	18.1	16.3	9.5	4.7	12.9	6.4	0.2	0.7	8.0	1.9	0.0	14.9	27.7
SRSF2	"PR264, SC-35, SC35, SFRS2, SFRS2A"	ENSG00000161547	"Serine and arginine rich splicing factor 2"	Q01130	17	76734115-76737374	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049905	Supported		Approved	Nucleoplasm,Cytosol		NA	NA		140000	Nucleoplasm	Cytosol	"HPA049905: AB_2680945"	"unprognostic (2.50e-1)"	"unprognostic (2.16e-3)"	"unprognostic (2.73e-3)"	"prognostic unfavorable (8.73e-4)"	"unprognostic (1.75e-2)"	"unprognostic (4.19e-2)"	"prognostic unfavorable (3.53e-8)"	"unprognostic (1.19e-1)"	"unprognostic (7.79e-3)"	"unprognostic (7.03e-3)"	"unprognostic (1.92e-1)"	"unprognostic (1.07e-3)"	"prognostic unfavorable (1.05e-7)"	"unprognostic (3.85e-2)"	"unprognostic (8.05e-2)"	"unprognostic (1.95e-1)"	"prognostic favorable (9.87e-4)"	35.4	40.2	20.6	56.6	30.3	73.1	35.3	33.3	36.2	42.1	37.7	34.0	19.5	41.8	37.0	33.6	51.1	35.1	34.8	32.4	19.9	22.6	36.9	66.7	37.3	64.3	21.6	24.0	47.1	34.2	29.1	33.8	51.2	29.5	31.3	36.5	35.5	35.6	40.5	44.9	41.1	46.6	25.5	23.9	52.5	35.6	29.2	18.9	105.3	41.1	41.3	64.5	30.6	35.7	11.1	30.2	4.2	23.5	15.6	12.7	12.2	48.2	38.9	46.2	32.2	11.3	9.6	48.0	31.2	23.1	36.2	33.6	40.8	33.8	74.4	22.8	29.3	26.1	43.7	45.8	36.0	36.5	31.1	79.8	55.8	37.7	47.4	12.9	61.6	33.4	10.6	8.2	30.0	8.7	14.7	28.2	33.3	56.7	32.9	28.3	38.6	67.6	67.3	54.1	28.1	55.5	68.5	49.7	54.9	24.2	34.8	39.4	56.3	35.6	30.6	16.8	25.4	37.5	45.0	29.5	33.5	43.1	22.2	50.4	43.3	32.5	86.0	30.1	49.0	27.6	1.0	17.5	4.2	12.3	23.5	12.6	11.1	8.5	12.7	30.2	9.8	9.8	9.0	2.1	15.6	14.7	22.4	10.6	12.2	20.6	30.3	33.3	36.2	19.9	22.6	21.6	24.0	29.5	18.9	110.2	104.2	263.7	359.4	409.3	143.7	75.1	117.2	84.3	119.4	83.7	86.4	268.2	132.6	175.8	190.8	186.2	246.5	140.2	136.4	478.7	232.5	241.3	217.7	110.3	220.7	93.8	255.6	111.1	135.5	118.5	147.3	197.1	268.2	218.2	170.4	153.0	146.8	241.8	119.9	87.2	188.9	116.4	279.5	292.6	343.6	387.6	264.3	196.1	264.9	438.8
SRSF3	"SFRS3, SRp20"	ENSG00000112081	"Serine and arginine rich splicing factor 3"	P84103	6	36594353-36605600	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, mRNA transport, Transport"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012986, HPA056981"	Supported		Supported	Nucleoplasm		NA	NA		1600000	Nucleoplasm		"CAB012986: AB_2533150, HPA056981: AB_2683299"	"unprognostic (3.25e-1)"	"unprognostic (1.08e-3)"	"prognostic favorable (2.56e-4)"	"unprognostic (8.19e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.77e-2)"	"prognostic unfavorable (6.22e-5)"	"unprognostic (2.92e-2)"	"prognostic unfavorable (1.95e-4)"	"prognostic favorable (1.37e-4)"	"unprognostic (9.61e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (2.02e-4)"	"unprognostic (9.88e-2)"	"unprognostic (3.33e-2)"	"unprognostic (8.33e-2)"	"unprognostic (1.06e-2)"	45.3	27.4	37.4	42.1	38.3	69.5	43.5	42.6	39.1	36.4	41.7	32.9	34.0	25.5	37.2	31.8	42.9	40.8	27.4	37.5	33.0	28.1	34.3	36.9	32.3	51.8	35.8	27.0	53.9	31.3	22.4	47.2	37.4	38.1	40.1	46.6	30.1	30.2	33.0	29.2	36.2	35.8	43.1	31.9	36.4	35.2	27.2	36.7	67.5	35.9	46.7	67.0	49.6	38.6	28.0	73.9	12.9	38.0	37.6	37.6	53.9	52.3	35.0	61.8	47.2	23.9	18.8	38.2	37.5	31.5	63.3	48.8	41.1	37.7	88.1	27.1	41.0	41.4	41.6	81.1	59.7	67.7	41.1	49.9	52.9	27.8	46.2	29.2	70.9	44.8	16.6	20.3	41.2	46.1	20.2	48.0	53.7	63.7	37.4	45.9	40.9	87.1	67.2	65.1	61.6	36.8	77.8	59.2	52.8	44.8	43.7	47.8	45.2	41.7	41.0	56.7	46.2	41.5	76.3	31.3	32.4	47.3	32.4	56.3	36.9	54.6	120.8	27.8	66.1	44.9	12.9	38.0	11.5	32.9	36.2	37.1	28.0	31.1	34.5	73.9	24.0	31.4	32.3	3.7	37.6	24.4	43.7	37.6	53.9	37.4	38.3	42.6	39.1	33.0	28.1	35.8	27.0	38.1	36.7	187.6	233.6	318.3	350.5	417.2	149.0	207.3	150.3	167.3	258.2	118.7	51.1	416.8	308.4	279.1	130.6	291.5	222.5	70.0	281.9	659.0	372.0	205.6	389.0	176.1	317.5	93.8	319.4	203.1	270.2	235.9	196.2	343.3	317.2	322.0	216.3	322.7	247.9	247.6	161.9	198.3	123.9	200.5	442.5	331.9	315.7	389.7	439.9	330.0	297.7	236.4
SS18	"SSXT, SYT"	ENSG00000141380	"SS18, nBAF chromatin remodeling complex subunit"	Q15532	18	26016253-26091217	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA055741, HPA059539"	Supported		Approved	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA055741: AB_2682901, HPA059539: AB_2684055"	"unprognostic (2.03e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.48e-2)"	"unprognostic (1.95e-2)"	"unprognostic (3.39e-1)"	"unprognostic (8.74e-2)"	"unprognostic (4.59e-2)"	"unprognostic (1.53e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (2.47e-1)"	"prognostic favorable (4.86e-4)"	"unprognostic (1.03e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.30e-1)"	26.1	40.5	18.7	30.4	26.4	15.5	26.6	17.6	20.2	24.8	21.4	31.8	32.1	14.0	31.7	32.7	29.8	27.2	23.4	22.4	21.6	16.1	30.0	30.9	21.9	25.8	32.6	16.3	39.4	20.6	39.4	41.8	43.2	25.3	28.6	18.7	26.1	26.0	33.5	10.3	31.3	22.6	31.0	23.7	24.7	22.5	28.3	32.6	27.8	35.6	24.7	35.2	25.5	25.9	15.9	13.1	19.9	17.1	20.7	17.6	13.1	19.2	14.0	34.4	16.8	27.4	24.8	17.4	23.7	21.6	21.0	20.1	9.2	16.0	33.7	19.0	27.7	19.0	25.3	18.6	23.0	26.0	21.5	8.9	16.7	20.5	14.8	21.7	25.5	25.9	31.8	27.2	26.3	28.9	21.0	15.7	9.8	12.2	17.3	28.9	19.4	10.4	14.8	6.5	18.1	13.5	12.1	26.7	16.2	22.2	22.8	14.7	22.2	36.2	16.8	10.2	25.8	17.1	15.1	18.0	44.2	8.8	10.2	23.2	31.3	20.8	24.3	20.7	17.8	23.4	19.9	11.7	16.5	15.1	17.1	17.6	15.9	14.6	15.7	13.1	13.0	15.5	17.4	5.6	20.7	16.7	7.4	15.7	13.1	18.7	26.4	17.6	20.2	21.6	16.1	32.6	16.3	25.3	32.6	26.8	21.3	28.3	27.1	7.9	28.5	14.1	17.8	36.1	23.9	22.7	15.7	57.3	18.3	26.4	40.7	25.3	17.2	0.0	22.5	41.2	19.5	22.9	36.8	30.1	23.9	82.6	23.7	24.5	20.0	31.2	30.8	17.1	5.0	12.6	21.1	51.6	26.7	14.0	38.5	23.8	29.7	38.8	27.1	23.4	19.0	11.5	71.2	25.4	14.5	21.7
SS18L1	"CREST, KIAA0693"	ENSG00000184402	"SS18L1, nBAF chromatin remodeling complex subunit"	O75177	20	62143795-62182484	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Hepatocytes: 33.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB011827, HPA059046"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB011827: AB_778216, HPA059046: AB_2683888"	"unprognostic (4.12e-2)"	"unprognostic (5.82e-2)"	"unprognostic (1.54e-1)"	"unprognostic (3.03e-2)"	"unprognostic (6.57e-2)"	"prognostic favorable (8.00e-5)"	"unprognostic (1.39e-1)"	"prognostic favorable (3.74e-4)"	"unprognostic (1.01e-1)"	"unprognostic (1.87e-1)"	"unprognostic (2.47e-3)"	"unprognostic (6.43e-2)"	"unprognostic (2.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.66e-1)"	"unprognostic (1.01e-1)"	"unprognostic (9.94e-3)"	6.6	8.9	11.9	7.7	12.7	7.7	8.6	35.9	15.8	7.0	7.0	9.9	12.2	9.5	9.7	10.9	9.3	6.9	7.2	6.4	11.5	10.9	11.5	33.3	8.2	7.4	11.2	14.5	10.0	10.4	8.4	10.7	8.8	13.1	8.7	7.8	7.4	8.6	11.8	19.2	23.7	9.0	7.7	9.9	9.2	8.8	10.7	10.9	6.0	8.3	6.7	7.1	6.8	8.6	3.6	1.3	2.5	2.7	1.6	2.8	0.5	6.5	7.8	10.9	9.9	4.9	5.7	7.9	6.2	2.4	10.4	5.2	26.8	6.1	4.0	8.3	3.5	5.4	17.0	6.7	5.9	9.5	2.7	4.4	17.8	16.4	13.8	3.6	6.5	15.9	3.4	13.0	5.3	4.4	6.1	4.7	6.9	11.9	7.7	5.8	7.8	9.8	10.1	4.4	6.6	9.0	10.9	14.1	4.5	7.8	8.3	20.7	11.5	11.1	13.6	9.3	7.2	12.7	10.4	5.5	19.9	12.0	7.3	8.6	8.6	7.7	3.6	9.9	6.4	6.5	0.3	1.6	0.6	1.7	1.1	1.1	0.7	0.9	1.4	1.3	3.6	2.8	0.9	2.5	1.6	2.7	0.8	0.8	0.5	11.9	12.7	35.9	15.8	11.5	10.9	11.2	14.5	13.1	10.9	8.9	6.5	6.0	4.4	14.5	14.4	7.7	2.5	4.0	11.4	7.0	21.6	4.5	3.3	4.1	8.6	7.4	6.8	0.0	2.3	2.7	10.4	7.3	1.1	33.3	4.2	14.3	13.7	8.0	11.9	16.0	6.9	7.4	11.8	3.6	6.6	4.9	6.3	7.0	3.2	7.3	17.7	6.5	8.9	3.9	10.6	15.3	6.4	5.0	5.3	4.7
SSX1	CT5.1	ENSG00000126752	"SSX family member 1"	Q16384	X	48255317-48267444	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	14	"testis: 12.6"	"Group enriched"	"Detected in some"	12	"Sertoli cells: 6.5;Spermatocytes: 9.8;Spermatogonia: 22.6"	"Cancer enhanced"	"Detected in many"		"liver cancer: 7.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Daudi: 28.8;Karpas-707: 41.8;U-2197: 9.7"									HPA045683	Supported		Approved	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA045683: AB_2679418"					"unprognostic (2.25e-1)"		"unprognostic (3.51e-3)"		"unprognostic (2.36e-1)"	"unprognostic (4.32e-3)"				"unprognostic (3.38e-1)"	"unprognostic (5.41e-2)"	"unprognostic (6.94e-2)"		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.6	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.2	0.9	0.4	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.8	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	41.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	9.7	0.0	0.0	2.0	0.0	2.4	0.0	0.0	0.9	0.4	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.3	0.5	0.5	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	9.8	22.6	0.0	0.0	0.0	0.0	0.0
SSX2	"CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX"	ENSG00000241476	"SSX family member 2"	Q16385	X	52696896-52707189	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	57	"testis: 24.1"	"Cell type enriched"	"Detected in single"	28	"Spermatogonia: 2.8"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"PC-3: 3.2;U-2197: 1.9"									"HPA045683, CAB046020"	Enhanced		Approved	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"CAB046020: AB_2194010, HPA045683: AB_2679418"																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.1			0.4		0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.9	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.3	0.0	0.0	0.0	0.2	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.9	0.0	0.6	0.1	0.6	1.9	0.0	0.0	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0
SSX4	CT5.4	ENSG00000268009	"SSX family member 4"	O60224	X	48383516-48393347	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"		"Tissue enriched"	"Detected in single"	14	"testis: 6.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	10	"BEWO: 3.6;Karpas-707: 8.8;U-266/70: 5.2;U-266/84: 9.5"									HPA045683	Approved		Approved	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA045683: AB_2679418"																		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.3	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.1	0.7	0.3	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	8.8	0.0	0.0	0.0	0.0	0.3	0.2	0.3	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.1	0.0	0.0	0.0	5.2	9.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STAG2	"SA-2, SA2, SCC3B"	ENSG00000101972	"Stromal antigen 2"	Q8N3U4	X	123960212-124422664	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Chromosome partition, Meiosis, Mitosis"		"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA002857	Supported					NA	NA					"HPA002857: AB_1079861"	"unprognostic (1.62e-1)"	"unprognostic (1.01e-2)"	"unprognostic (6.75e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.70e-2)"	"unprognostic (3.77e-2)"	"unprognostic (9.67e-3)"	"unprognostic (4.68e-2)"	"unprognostic (1.86e-1)"	"unprognostic (1.24e-1)"	"unprognostic (3.38e-1)"	"unprognostic (1.59e-3)"	"unprognostic (2.81e-1)"	"unprognostic (2.77e-2)"	"unprognostic (1.63e-1)"	"unprognostic (3.97e-1)"	24.0	18.8	21.5	23.9	23.7	39.7	30.1	35.4	23.5	28.1	25.1	16.4	25.2	14.9	24.3	21.0	24.3	20.0	16.3	15.7	21.4	17.9	22.2	18.1	23.4	26.2	24.9	17.5	31.1	19.7	46.1	27.6	25.5	20.6	25.9	18.3	14.2	20.7	27.8	27.6	18.9	21.9	25.9	30.6	26.7	17.6	9.3	26.4	69.3	32.0	19.7	27.1	37.7	37.8	12.8	12.5	30.3	14.4	12.1	15.5	6.7	17.5	16.5	24.9	15.7	10.7	16.2	16.1	16.6	17.9	17.3	21.8	15.4	18.8	32.4	23.6	14.9	19.4	16.0	50.9	14.1	24.5	23.0	21.7	29.9	33.1	10.1	11.1	39.1	23.6	12.7	14.0	20.5	33.1	15.0	14.5	33.1	29.2	34.6	12.7	19.1	50.0	17.6	13.0	16.1	24.6	35.5	32.9	27.1	13.4	33.5	22.5	17.9	37.5	14.0	19.7	18.6	8.4	18.0	17.6	0.1	9.3	20.3	18.9	14.9	22.5	40.7	10.9	24.1	17.4	16.8	10.2	18.1	10.8	13.1	12.6	10.0	11.2	10.1	12.5	12.8	15.5	12.4	30.3	12.1	14.4	11.2	8.7	6.7	21.5	23.7	35.4	23.5	21.4	17.9	24.9	17.5	20.6	26.4	59.6	44.6	53.3	44.3	49.9	49.3	38.4	28.1	60.2	64.8	41.8	56.9	28.0	18.3	37.3	0.9	53.4	25.6	46.7	33.1	27.7	48.0	69.8	54.5	35.8	31.4	42.9	55.8	46.6	58.6	1.6	60.9	61.9	32.1	38.7	36.8	54.0	42.5	20.1	65.0	27.0	60.0	64.7	43.2	7.0	11.3	49.1	59.7	50.7	37.9	72.3
STAT3	APRF	ENSG00000168610	"Signal transducer and activator of transcription 3"	P40763	17	42313324-42388568	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Diabetes mellitus, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001671, CAB003859, HPA058603, CAB068241, CAB068242"	Supported		Supported	Nucleoplasm,Cytosol		NA	NA		220000	"Nucleoplasm, Cytosol"		"CAB003859: AB_347629, CAB068241: AB_2665663, CAB068242: AB_2665662, HPA001671: AB_1080102, HPA058603: AB_2683772"	"unprognostic (1.83e-2)"	"unprognostic (2.42e-1)"	"unprognostic (9.23e-3)"	"unprognostic (2.91e-1)"	"unprognostic (5.59e-3)"	"unprognostic (1.78e-2)"	"unprognostic (8.26e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.26e-1)"	"unprognostic (6.47e-3)"	"unprognostic (7.75e-3)"	"unprognostic (2.21e-2)"	"unprognostic (7.63e-2)"	"unprognostic (1.61e-1)"	44.6	30.7	23.2	34.4	27.5	35.3	49.3	15.7	23.5	25.1	31.5	18.4	21.7	20.5	33.2	27.4	36.4	32.7	34.0	82.9	20.1	14.7	34.5	90.0	45.7	45.5	26.0	11.1	40.6	32.1	18.6	27.9	24.6	27.6	28.9	21.8	24.3	29.3	22.9	53.4	28.4	28.6	49.7	25.1	41.4	29.4	15.4	25.7	16.8	38.0	31.2	28.8	40.4	53.1	10.8	13.7	69.7	20.2	13.9	21.7	26.7	17.0	32.3	14.3	14.1	30.5	29.2	10.4	20.0	25.4	17.3	16.9	8.5	16.5	5.3	19.8	19.8	26.2	26.0	12.9	20.4	14.2	43.9	8.9	36.9	19.6	17.4	22.6	9.0	24.1	45.5	20.1	13.8	20.0	18.2	23.5	9.8	22.6	17.0	11.4	12.0	33.3	9.0	8.3	17.4	0.0	7.4	38.2	7.8	27.4	22.1	13.1	8.5	23.0	54.6	8.2	17.9	28.7	13.5	19.7	26.9	13.7	15.9	16.3	26.2	20.4	4.5	16.6	9.5	11.9	26.2	19.4	24.9	21.7	20.2	17.3	10.8	16.0	16.8	13.7	10.4	16.6	15.8	69.7	13.9	18.7	7.5	12.0	26.7	23.2	27.5	15.7	23.5	20.1	14.7	26.0	11.1	27.6	25.7	86.4	150.9	56.2	91.3	115.1	87.1	46.2	43.3	85.6	108.1	127.4	265.1	21.1	14.9	68.7	27.3	107.9	156.0	0.0	83.8	34.3	140.9	148.0	138.6	102.5	60.4	23.8	119.1	104.3	64.9	11.1	66.4	84.8	69.2	88.4	68.1	108.0	75.8	94.7	57.3	38.3	352.3	64.7	221.4	32.2	15.1	139.9	26.1	86.3	72.7	78.8
STAT5B		ENSG00000173757	"Signal transducer and activator of transcription 5B"	P51692	17	42199168-42276707	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"Early spermatids: 85.5;Late spermatids: 113.5;Peritubular cells: 70.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 43.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004298, CAB005418, HPA042128, HPA049883, HPA051156"	Approved		Approved	Cytosol		NA	NA		170000	Cytosol		"CAB004298: AB_2197067, CAB005418: AB_632445, HPA042128: AB_2677864, HPA049883: AB_2680931, HPA051156: AB_2681366"	"unprognostic (1.49e-1)"	"unprognostic (3.60e-2)"	"unprognostic (4.06e-2)"	"prognostic favorable (9.37e-4)"	"unprognostic (2.68e-1)"	"unprognostic (4.29e-1)"	"unprognostic (2.23e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.06e-2)"	"unprognostic (7.98e-2)"	"prognostic favorable (1.63e-4)"	"unprognostic (1.36e-1)"	"prognostic favorable (2.39e-5)"	"unprognostic (9.19e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.13e-1)"	25.7	24.0	13.5	19.5	16.3	21.8	26.2	32.1	15.9	21.6	21.0	13.7	16.3	8.6	31.9	12.0	11.6	24.5	18.1	12.8	11.9	20.1	12.4	13.5	15.8	24.6	16.0	13.9	34.4	12.1	12.0	22.6	55.4	17.2	20.8	10.3	16.4	12.9	21.7	38.3	12.2	14.8	33.1	10.6	22.1	14.4	13.2	15.7	21.7	15.4	9.6	19.8	21.5	33.1	2.5	2.4	18.8	2.8	3.5	8.3	3.8	5.3	8.4	12.5	3.3	15.6	7.9	6.0	5.5	9.8	7.9	6.9	3.6	4.5	17.4	8.3	6.3	15.7	6.9	7.4	4.8	6.3	43.9	8.6	17.0	15.8	5.6	8.6	7.5	27.5	9.7	7.4	5.9	7.6	6.8	12.5	11.8	30.6	3.8	3.2	5.2	35.1	19.7	3.1	12.4	0.0	15.1	7.8	6.0	5.0	8.6	9.2	5.4	10.1	12.9	7.7	2.9	9.1	8.8	9.5	11.1	3.9	5.7	7.6	7.5	3.4	8.7	4.4	7.9	5.7	8.8	2.8	4.6	5.9	2.5	6.4	2.5	8.3	6.7	2.4	2.5	5.9	5.0	18.8	3.5	2.8	1.8	6.9	3.8	13.5	16.3	32.1	15.9	11.9	20.1	16.0	13.9	17.2	15.7	6.0	17.9	3.7	4.7	7.9	18.0	17.3	10.2	5.3	9.1	3.5	19.6	5.9	5.0	7.2	85.5	23.3	6.2	23.3	10.1	5.7	10.8	8.0	15.1	10.2	8.1	9.5	9.8	16.0	14.2	113.5	43.7	11.1	10.1	10.0	7.2	8.4	10.7	7.8	70.0	8.1	13.8	38.8	22.8	4.2	4.1	8.5	10.6	24.5	7.5	5.4
STAT6	"D12S1644, IL-4-STAT"	ENSG00000166888	"Signal transducer and activator of transcription 6"	P42226	12	57095408-57132139	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001861	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"HPA001861: AB_1080106"	"unprognostic (3.43e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.37e-1)"	"prognostic favorable (1.69e-4)"	"unprognostic (4.14e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	"unprognostic (6.70e-2)"	"unprognostic (1.88e-2)"	"unprognostic (3.65e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.00e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.55e-1)"	"prognostic favorable (7.76e-4)"	"prognostic favorable (1.14e-4)"	33.6	34.9	10.4	35.9	12.8	12.8	27.9	4.6	11.6	37.8	47.3	6.2	28.4	23.9	44.5	26.6	40.8	31.8	33.8	20.9	10.2	3.9	35.0	31.0	34.9	25.2	13.3	12.0	41.9	21.2	18.1	9.2	22.0	9.8	42.3	26.2	23.3	30.1	26.5	11.4	39.1	59.4	43.8	12.2	48.4	32.1	13.3	7.9	29.3	31.1	24.4	42.8	43.1	34.0	6.2	9.6	27.6	13.0	4.7	5.9	14.0	16.7	16.7	4.1	6.8	40.8	39.7	11.9	13.3	29.4	14.9	10.9	7.5	22.8	40.2	20.9	29.6	0.1	23.4	5.1	25.9	11.0	18.0	1.9	9.2	17.8	9.4	24.4	10.7	30.4	55.3	21.5	18.0	16.0	39.3	26.2	13.2	6.5	5.7	19.1	5.7	11.7	12.0	6.3	20.9	3.4	13.6	0.3	13.7	25.7	28.0	0.1	0.4	12.5	10.4	12.6	5.9	15.5	24.6	21.7	0.3	8.7	15.5	0.2	0.1	0.4	10.0	13.4	10.4	17.9	9.8	12.5	6.8	5.9	13.0	5.2	6.2	4.8	4.8	9.6	6.2	4.7	4.3	27.6	4.7	11.0	4.6	4.9	14.0	10.4	12.8	4.6	11.6	10.2	3.9	13.3	12.0	9.8	7.9	44.7	57.5	34.4	35.4	26.6	1.0	12.0	22.9	45.5	46.6	47.1	0.0	1.6	13.3	32.2	6.4	29.9	63.9	0.0	31.0	8.4	26.5	42.7	55.6	33.4	31.9	0.0	31.8	38.6	76.0	8.6	55.0	54.0	20.3	52.3	38.2	3.3	38.1	49.1	47.7	21.9	1.0	25.8	27.8	0.9	1.1	28.7	5.3	29.9	37.3	48.9
STIL	"MCPH7, SIL"	ENSG00000123473	"STIL, centriolar assembly protein"	Q15468	1	47250139-47314147	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes, Disease mutation, Mental retardation, Primary microcephaly, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 36.0;testis: 23.8"	"Cell type enhanced"	"Detected in many"	9	"Spermatocytes: 18.6;Spermatogonia: 17.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA046543			Approved	"Plasma membrane,Cytosol"		NA	Yes			"Plasma membrane, Cytosol"		"HPA046543: AB_2679692"	"unprognostic (2.07e-1)"	"unprognostic (6.29e-2)"	"unprognostic (5.54e-3)"	"unprognostic (2.67e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.56e-2)"	"unprognostic (2.90e-5)"	"unprognostic (7.35e-3)"	"unprognostic (4.04e-3)"	"unprognostic (1.41e-1)"	"prognostic unfavorable (1.33e-4)"	"unprognostic (5.81e-2)"	"unprognostic (3.36e-14)"	"unprognostic (5.76e-3)"	"unprognostic (2.58e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.28e-1)"	1.2	1.4	1.3	10.8	2.4	11.0	2.9	1.4	2.2	1.2	4.1	0.9	2.5	3.6	1.5	2.2	5.8	0.9	1.7	2.0	1.4	1.2	1.5	1.6	1.7	5.0	1.3	1.5	1.2	1.5	0.9	0.9	5.5	1.1	1.7	6.4	0.8	3.6	0.5	0.8	4.2	4.0	1.3	1.2	3.4	2.2	23.8	1.0	36.0	1.1	3.5	7.1	1.3	2.1	1.9	1.6	5.4	0.7	3.3	1.2	0.5	16.9	9.1	13.1	11.7	0.9	2.3	8.4	15.0	7.2	16.8	17.7	9.8	8.4	20.0	7.1	7.5	17.3	11.3	15.3	7.9	18.1	14.9	6.9	22.5	11.3	8.6	0.5	18.2	11.5	0.8	1.3	14.4	9.4	2.1	11.1	15.3	15.9	19.1	12.6	7.7	17.6	5.7	15.9	9.4	7.5	11.5	21.4	9.6	4.7	10.2	11.7	7.0	16.1	11.9	7.8	16.3	7.7	10.4	6.5	15.9	16.1	11.4	20.3	6.3	13.1	19.7	7.4	13.9	14.7	4.3	0.7	1.1	1.1	0.4	0.5	1.7	1.2	1.0	0.5	1.9	0.8	0.8	5.4	3.3	0.3	1.6	1.1	0.5	1.3	2.4	1.4	2.2	1.4	1.2	1.3	1.5	1.1	1.0	3.0	0.3	2.2	0.5	0.8	1.2	0.5	0.0	6.7	2.3	0.0	3.9	1.2	0.0	1.2	0.7	0.9	1.8	0.0	0.4	3.8	0.8	1.2	2.3	0.5	2.3	0.0	1.7	1.8	1.9	1.3	0.3	1.2	0.0	4.6	4.3	0.8	1.8	1.5	0.7	0.3	0.7	0.0	0.0	18.6	17.8	2.0	0.7	0.8	3.4	1.4
STK11	"LKB1, PJS"	ENSG00000118046	"Serine/threonine kinase 11"	Q15831	19	1177558-1228435	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Autophagy, Cell cycle, Differentiation, DNA damage, Spermatogenesis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	11	"Early spermatids: 124.0;Late spermatids: 234.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 11.7"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB016231, HPA017254, CAB022105, HPA067481"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB016231: AB_627890, CAB022105: , HPA017254: AB_1852924, HPA067481: AB_2685847"	"unprognostic (8.60e-2)"	"unprognostic (1.68e-1)"	"unprognostic (5.00e-2)"	"prognostic favorable (3.69e-5)"	"unprognostic (2.04e-2)"	"prognostic favorable (1.96e-4)"	"unprognostic (9.11e-3)"	"unprognostic (3.19e-1)"	"unprognostic (9.08e-2)"	"unprognostic (1.26e-1)"	"unprognostic (1.95e-3)"	"unprognostic (7.70e-3)"	"unprognostic (3.54e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.60e-1)"	"unprognostic (3.31e-1)"	"unprognostic (3.12e-3)"	13.4	13.7	13.5	11.8	12.4	19.3	16.7	17.8	16.0	12.2	16.1	8.3	19.8	18.1	10.8	8.7	15.1	10.0	11.8	15.3	12.6	9.8	10.7	22.1	9.4	12.5	9.7	10.4	11.0	16.8	10.7	11.6	12.2	9.9	12.2	5.3	11.9	16.0	12.2	49.2	16.8	18.0	7.7	7.6	16.9	15.5	59.8	7.5	11.8	12.4	14.5	19.0	11.4	9.8	2.7	1.9	11.7	6.3	1.9	1.8	0.5	21.2	10.3	7.8	14.8	7.4	6.7	16.5	10.4	10.9	9.8	10.4	8.4	14.9	13.9	11.5	10.8	4.4	13.8	7.7	16.0	3.0	26.0	18.8	14.2	0.6	10.5	16.0	14.3	23.9	12.2	11.7	7.5	11.2	8.9	9.8	11.1	26.6	19.2	5.5	15.9	13.7	14.5	15.0	7.3	12.7	21.8	8.4	15.6	8.8	15.6	18.1	13.1	0.0	7.7	11.2	4.7	12.1	23.5	13.2	10.1	11.5	19.8	16.5	37.8	15.9	10.4	10.1	19.1	10.4	2.0	4.2	4.5	0.6	6.0	0.4	2.7	1.0	1.8	1.9	1.0	1.0	0.9	11.7	1.9	6.3	1.0	0.7	0.5	13.5	12.4	17.8	16.0	12.6	9.8	9.7	10.4	9.9	7.5	6.0	13.6	11.1	6.4	14.8	23.6	11.8	17.8	2.7	6.8	22.7	17.7	6.7	6.6	8.1	124.0	14.7	29.5	0.0	11.9	4.5	10.4	14.2	2.3	25.2	12.9	17.5	14.5	16.0	22.2	234.7	22.7	10.4	15.1	17.2	29.2	19.3	13.0	25.9	19.4	8.6	19.8	12.9	20.8	49.9	19.4	13.6	7.3	8.6	33.0	10.9
STRN	"PPP2R6A, STRN1"	ENSG00000115808	Striatin	O43815	2	36843640-36966472	"Cancer-related genes, Predicted intracellular proteins"		Calmodulin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cardiomyocytes: 51.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA017286	Approved		Approved	Nucleoplasm,Cytosol		No	No		11000	Cytosol	Nucleoplasm	"HPA017286: AB_1857618"	"unprognostic (1.65e-1)"	"unprognostic (1.65e-1)"	"unprognostic (3.57e-3)"	"unprognostic (2.23e-2)"	"unprognostic (3.25e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.63e-3)"	"unprognostic (7.37e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.77e-3)"	"unprognostic (1.33e-1)"	"prognostic favorable (2.27e-4)"	"unprognostic (1.13e-1)"	"unprognostic (6.43e-2)"	"unprognostic (2.11e-1)"	"unprognostic (3.43e-2)"	11.8	8.1	11.4	11.0	22.1	17.4	13.3	16.4	14.2	11.2	14.0	10.9	8.9	10.1	8.6	7.1	25.9	6.8	8.4	25.7	16.2	10.2	11.6	10.2	10.3	9.6	16.9	9.4	9.9	7.1	11.3	6.3	12.6	10.5	8.1	13.7	5.6	16.2	6.9	16.0	16.1	13.2	11.1	34.3	10.9	11.4	9.8	14.8	18.6	8.1	15.5	16.7	11.3	14.4	1.5	0.8	3.7	1.5	0.5	2.1	0.4	23.3	11.8	15.8	6.6	8.7	12.2	15.8	9.5	8.9	9.2	8.5	12.0	7.6	15.5	7.6	11.9	13.2	11.1	13.3	10.4	11.4	17.5	10.2	25.1	10.4	6.2	8.3	15.0	14.1	7.3	9.1	14.7	11.6	6.8	11.7	6.2	18.7	12.3	11.3	6.7	14.9	6.6	12.6	9.5	6.0	9.7	25.0	6.7	7.6	19.3	2.9	9.6	14.1	10.9	8.9	9.2	7.8	5.8	15.5	16.5	16.7	10.2	12.4	12.5	18.8	13.7	8.4	15.1	11.4	3.4	0.8	1.4	2.1	1.5	0.7	1.5	1.5	1.3	0.4	0.9	0.8	0.9	3.7	0.5	1.4	0.8	0.3	0.4	11.4	22.1	16.4	13.0	16.2	10.2	16.9	9.4	10.5	14.8	8.9	7.7	5.2	9.0	18.3	11.7	51.7	10.2	1.4	17.0	22.7	19.6	6.9	8.3	8.8	1.7	17.5	17.3	0.0	7.2	7.9	7.9	14.5	4.7	7.3	7.6	17.5	10.9	15.4	22.2	0.9	8.9	11.0	8.5	10.8	16.4	9.3	12.8	10.5	11.7	7.7	15.4	0.0	10.3	10.3	18.1	29.1	13.6	10.2	13.8	29.3
SUFU	"PRO1280, SUFUH, SUFUXL"	ENSG00000107882	"SUFU negative regulator of hedgehog signaling"	Q9UMX1	10	102503987-102633535	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"		"Developmental protein"	"Cancer-related genes, Ciliopathy, Disease mutation, Joubert syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	8	"Early spermatids: 126.0;Late spermatids: 78.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008700	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA008700: AB_1080125"	"unprognostic (1.55e-1)"	"unprognostic (4.00e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.33e-1)"	"unprognostic (4.69e-2)"	"unprognostic (5.68e-2)"	"unprognostic (3.69e-2)"	"unprognostic (5.99e-2)"	"unprognostic (1.64e-1)"	"unprognostic (3.15e-3)"	"unprognostic (9.60e-2)"	"unprognostic (2.13e-1)"	"unprognostic (3.72e-3)"	"unprognostic (1.82e-1)"	"unprognostic (1.44e-1)"	"unprognostic (5.10e-2)"	"unprognostic (3.82e-3)"	10.7	12.8	15.0	15.2	12.8	3.9	18.3	23.0	15.3	13.4	10.4	11.3	12.1	7.7	14.4	13.3	14.7	14.2	16.2	11.0	11.8	7.8	10.8	10.0	21.4	20.5	11.9	11.0	18.0	8.9	20.0	7.8	13.9	10.0	15.4	8.8	11.9	12.6	16.7	14.1	23.1	9.4	14.3	10.7	13.1	7.9	21.1	13.1	19.9	6.2	12.7	15.0	15.2	15.0	2.3	4.5	6.2	5.5	2.8	3.1	2.8	6.3	6.7	10.9	15.7	11.3	9.5	5.3	6.6	12.8	9.6	8.7	6.2	4.7	6.5	18.8	7.3	3.9	4.5	13.4	7.3	6.3	4.0	10.4	15.5	3.9	5.9	5.4	5.6	11.2	10.9	5.8	7.1	5.8	17.6	12.3	6.4	3.4	6.0	5.8	5.3	10.6	8.5	3.1	4.1	5.1	11.5	11.8	3.4	6.3	9.5	3.7	5.9	5.2	4.9	5.9	10.5	10.8	3.7	13.5	4.3	6.1	4.5	7.2	4.9	3.2	4.7	5.3	11.0	2.9	4.2	4.5	6.2	2.5	5.5	2.0	2.3	3.1	2.8	4.5	2.1	2.2	2.5	1.1	2.8	5.5	2.5	1.9	2.8	15.0	12.8	23.0	15.3	11.8	7.8	11.9	11.0	10.0	13.1	0.0	3.0	0.9	2.2	2.7	3.4	3.6	0.0	4.0	4.5	3.5	7.9	6.9	1.7	3.9	126.0	4.3	4.0	0.0	2.6	3.1	5.4	1.9	3.5	4.9	10.4	1.6	1.2	12.9	10.2	78.9	4.6	5.6	0.0	7.2	2.2	2.9	3.5	0.0	6.3	4.4	3.9	0.0	3.4	4.2	4.5	5.6	5.8	5.1	2.8	1.1
SUZ12	"CHET9, JJAZ1, KIAA0160"	ENSG00000178691	"SUZ12 polycomb repressive complex 2 subunit"	Q15022	17	31937018-32001045	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA057436	Approved		Supported	"Nucleoplasm,Nucleoli,Nucleoli rim,Nuclear bodies"		Yes	No			"Nucleoplasm, Nucleoli, Nucleoli rim, Nuclear bodies"		"HPA057436: AB_2683439"	"unprognostic (1.23e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.65e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.49e-1)"	"unprognostic (7.31e-2)"	"unprognostic (2.66e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.27e-2)"	"unprognostic (3.06e-2)"	"unprognostic (6.29e-2)"	"unprognostic (8.70e-2)"	"unprognostic (3.28e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.91e-2)"	"unprognostic (1.31e-1)"	10.1	10.8	13.4	15.4	10.4	25.5	33.5	16.0	13.8	11.2	11.4	7.5	13.6	10.1	12.5	8.1	12.3	9.8	7.7	9.7	9.1	7.6	10.9	11.5	10.6	19.9	9.3	9.9	10.0	10.1	15.5	10.4	15.3	9.5	10.7	10.9	6.9	10.1	9.6	8.7	9.9	12.2	9.6	7.7	15.2	10.7	17.1	12.5	31.8	12.0	6.5	18.9	10.8	19.5	5.5	4.6	4.1	2.6	4.4	5.5	1.2	14.3	12.7	12.0	13.7	6.9	8.9	12.3	14.0	12.4	17.2	20.8	9.6	8.1	31.3	10.8	8.7	14.7	12.7	17.8	8.0	28.0	11.0	17.3	21.7	10.8	6.9	8.2	34.1	22.3	6.2	9.1	17.1	13.2	10.4	10.5	15.0	20.9	43.6	14.7	5.0	40.5	19.8	6.8	10.1	7.8	24.2	30.8	25.4	10.1	14.0	15.4	12.0	22.5	7.3	13.5	8.7	21.1	28.5	7.7	13.7	12.5	16.3	21.5	23.8	29.6	38.8	10.0	21.1	12.3	1.4	1.9	3.8	3.8	2.6	3.0	5.5	4.1	4.0	1.4	4.4	3.9	5.5	4.1	4.4	1.8	4.6	4.2	1.2	13.4	10.4	16.0	13.8	9.1	7.6	9.3	9.9	9.5	12.5	38.7	37.9	23.1	41.1	52.0	74.2	24.8	35.7	28.1	37.5	33.2	102.1	49.4	14.9	23.6	8.9	34.9	15.6	23.3	19.1	45.9	33.8	46.2	15.1	37.5	27.9	58.8	28.3	38.6	41.9	10.7	24.7	37.6	23.6	86.6	31.9	41.7	22.6	10.5	24.1	24.5	76.3	12.9	32.5	100.7	141.1	62.7	58.1	39.9	33.0	48.2
SYK		ENSG00000165025	"Spleen associated tyrosine kinase"	P43405	9	90801787-90898549	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Adaptive immunity, Angiogenesis, Host-virus interaction, Immunity, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 38.5"	"Cell type enhanced"	"Detected in many"	6	"B-cells: 53.8;Hofbauer cells: 63.0;Kupffer cells: 79.3;Macrophages: 66.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	15	"classical monocyte: 21.4;eosinophil: 23.3;intermediate monocyte: 19.0;memory B-cell: 23.1;myeloid DC: 24.9;naive B-cell: 17.5;neutrophil: 32.8;NK-cell: 8.7;non-classical monocyte: 16.4;plasmacytoid DC: 18.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Daudi: 39.4;HEL: 22.7;HL-60: 31.3;HMC-1: 20.9;REH: 26.2;THP-1: 24.1;U-698: 18.6;U-937: 22.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001384, CAB007773"	Enhanced		Approved	"Vesicles,Plasma membrane,Cytosol"		No	NA		1000000	"Plasma membrane, Cytosol"	Vesicles	"CAB007773: AB_562232, HPA001384: AB_1080144"	"unprognostic (1.01e-1)"	"unprognostic (5.45e-2)"	"unprognostic (2.10e-1)"	"unprognostic (2.69e-2)"	"unprognostic (2.31e-1)"	"unprognostic (7.92e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.34e-1)"	"unprognostic (6.41e-2)"	"unprognostic (1.78e-2)"	"unprognostic (7.20e-2)"	"unprognostic (9.93e-2)"	"unprognostic (2.55e-3)"	"unprognostic (8.77e-2)"	"unprognostic (5.36e-3)"	"unprognostic (3.41e-2)"	"unprognostic (1.06e-2)"	7.2	3.3	6.0	38.1	9.6	18.2	6.7	1.1	4.5	3.7	10.3	6.7	1.5	12.3	2.3	6.7	16.2	6.9	6.6	5.5	7.2	3.2	8.6	2.5	13.7	36.4	9.1	2.5	2.1	8.9	25.9	3.1	5.0	6.1	4.1	8.3	2.8	8.9	1.8	1.4	8.3	22.2	3.5	11.3	38.5	7.4	5.5	7.9	30.5	18.1	7.8	32.2	8.6	7.5	23.1	24.9	32.8	21.4	8.7	0.1	10.2	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	39.4	1.1	0.0	1.3	6.1	0.8	3.2	0.0	0.0	5.4	22.7	0.0	0.0	0.0	31.3	20.9	0.0	4.5	0.0	0.4	0.0	0.0	4.9	0.6	3.2	0.0	4.8	0.0	13.7	0.2	14.8	0.0	26.2	0.0	10.8	0.8	5.9	2.1	1.8	0.0	2.8	0.0	0.1	2.5	24.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	18.6	0.0	22.1	0.0	1.4	21.4	23.3	0.1	19.0	0.1	23.1	0.0	0.0	24.9	17.5	0.0	0.0	32.8	8.7	16.4	18.5	0.0	10.2	6.0	9.6	1.1	4.5	7.2	3.2	9.1	2.5	6.1	7.9	11.9	22.7	53.8	3.7	3.1	0.9	1.6	12.7	12.0	17.0	14.0	0.0	1.2	13.3	12.6	5.5	1.1	18.4	0.0	10.9	1.3	1.1	1.8	40.6	0.9	63.0	0.0	9.9	4.9	79.3	4.7	0.6	66.0	11.8	24.4	23.8	0.0	15.3	28.1	0.0	0.3	0.1	6.5	1.0	0.7	0.7	5.0	1.1	5.3	24.7	6.5
TAF15	"hTAFII68, Npl3, RBP56, TAF2N"	ENSG00000270647	"TATA-box binding protein associated factor 15"	Q92804	17	35713791-35864615	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"DNA-binding, RNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA052059, HPA063647"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA052059: AB_2681711, HPA063647: AB_2685072"	"unprognostic (1.26e-1)"	"unprognostic (2.66e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.63e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.27e-1)"	"unprognostic (8.48e-3)"	"unprognostic (4.75e-2)"	"unprognostic (8.06e-3)"	"unprognostic (2.08e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.39e-2)"	"unprognostic (5.41e-2)"	"unprognostic (3.35e-2)"	"unprognostic (2.99e-1)"	14.0	12.9	12.7	15.3	16.2	13.9	11.0	13.7	14.1	10.5	11.7	15.0	13.2	12.7	10.2	11.0	12.6	8.0	11.5	13.1	11.8		9.8	15.0	8.9	19.4	14.7	8.3	10.7	11.3	14.6	18.1	11.1	11.1	11.4	10.1	9.2	9.8	15.3	26.9	14.7	13.4	17.5	15.9	12.7	11.0	11.3	15.5	21.1	9.4	12.8	15.8	12.0	9.8	3.7	3.2	3.8	3.6	4.7	7.2	2.2	29.2	48.1	25.7	24.9	20.6	11.7	16.9	33.4	11.4	15.3	15.0	32.2	21.2	58.2	24.1	21.6	18.3	31.1	34.1	33.7	22.0	16.4	44.7	33.5	34.9	33.7	20.4	54.0	22.5	18.6	17.7	23.1	36.3	17.7	20.6	36.2	31.4	24.1	17.2	34.9	58.8	13.1	15.9	27.3	13.8	35.1	38.3	21.8	19.3	52.6	19.5	19.2	41.6	12.6	13.2	31.4	29.5	18.6	27.7	11.8	25.8	16.9	40.1	22.8	27.8	42.4	23.3	26.7	19.3	3.8	3.5	3.5	4.9	3.4	7.2	3.0	3.5	3.8	2.5	3.7	3.3	3.7	2.0	4.7	3.6	3.2	3.9	2.2											14.9	50.3	37.4	49.0	32.1	54.1	35.5	43.3	50.9	64.8	57.6	39.3	72.7	3.3	35.9	4.6	49.6	37.7	46.7	25.7	39.3	25.9	36.3	54.3	53.9	37.4	57.2	47.1	33.2	42.9	8.9	28.4	36.7	32.1	34.3	49.4	55.6	28.8	28.1	38.2	26.6	42.8	45.3	31.9	60.1	72.8	32.5	65.2	42.4	50.6	42.6
TAL1	"bHLHa17, SCL, TCL5"	ENSG00000162367	"TAL bHLH transcription factor 1, erythroid differentiation factor"	P17542	1	47216290-47232220	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 33.1"	"Cell type enhanced"	"Detected in some"	22	"Endothelial cells: 18.0;Erythroid cells: 93.5;granulocytes: 35.8;Ito cells: 30.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"basophil: 3.2;neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 3.2"	"Cell line enhanced"	"Detected in some"		"HEL: 52.8;HMC-1: 25.4;HUVEC TERT2: 11.0;JURKAT: 21.1;K-562: 16.5;TIME: 12.0"	"Region enriched"	"Detected in some"	5	"midbrain: 17.1"	"Low region specificity"	"Detected in many"			"CAB017805, HPA047866, HPA073983"	Approved		Enhanced	Nucleoplasm		Yes	NA			Nucleoplasm		"CAB017805: , HPA047866: AB_2680192, HPA073983: AB_2732246"	"unprognostic (2.63e-1)"	"unprognostic (2.62e-2)"	"unprognostic (1.22e-1)"	"unprognostic (2.40e-2)"	"unprognostic (1.59e-1)"	"unprognostic (8.80e-3)"	"unprognostic (3.95e-3)"	"unprognostic (1.33e-1)"	"unprognostic (4.15e-2)"	"unprognostic (1.99e-2)"	"unprognostic (5.42e-3)"	"unprognostic (3.68e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.76e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.18e-2)"	9.1	2.7	7.0	1.8	5.7	33.1	7.1	1.6	6.9	3.3	2.4	12.0	2.3	1.6	3.7	3.3	2.5	4.1	4.2	3.9	8.8	3.5	4.5	2.4	14.6	2.2	11.1	4.4	1.5	1.3	2.2	2.1	9.8	7.3	2.4	2.4	2.1	1.4	3.0	3.1	2.0	3.3	4.4	9.4	8.5	2.1	1.8	9.2	0.0	6.7	4.1	1.5	2.5	5.5	0.3	0.1	3.2	0.3	0.4	0.4	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	52.8	0.0	0.0	0.0	0.0	25.4	0.0	0.0	0.0	0.0	0.0	11.0	21.1	16.5	0.0	0.0	0.0	8.8	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	12.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.1	0.2	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.3	0.4	0.1	1.2	0.4	0.1	0.1	0.1	2.2	7.0	5.7	1.6	6.9	8.8	3.5	11.1	4.4	7.3	9.2	0.0	0.0	0.0	0.0	0.8	0.0	1.7	2.5	0.0	2.3	1.8	0.0	0.1	0.0	0.0	4.8	18.0	0.0	93.5	0.0	0.1	0.9	0.0	35.8	0.0	7.9	0.0	0.0	30.7	2.1	10.2	0.0	0.2	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.4	0.9	0.0	0.0	0.0	0.0
TAL2	bHLHa19	ENSG00000186051	"TAL bHLH transcription factor 2"	Q16559	9	105662457-105663112	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	11	"blood: 8.8;kidney: 4.6;skeletal muscle: 17.3"	"Cell type enhanced"	"Detected in some"	16	"Cone photoreceptor cells: 3.9;Distal tubular cells: 6.6;Intestinal endocrine cells: 3.4;Muller glia cells: 1.8"	"Cancer enhanced"	"Detected in some"		"renal cancer: 1.6"					"Group enriched"	"Detected in some"	21	"memory B-cell: 8.8;naive B-cell: 7.9;plasmacytoid DC: 2.2"	"Group enriched"	"Detected in many"	18	"B-cells: 8.8;dendritic cells: 2.2"	"Cell line enhanced"	"Detected in some"		"CACO-2: 3.4;HAP1: 4.9;K-562: 12.9"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA030886	Uncertain		Approved	Cytosol		NA	NA			Cytosol		"HPA030886: AB_10601596"	"unprognostic (3.89e-2)"	"unprognostic (1.45e-1)"	"unprognostic (8.51e-2)"	"unprognostic (5.54e-2)"	"unprognostic (2.24e-1)"	"unprognostic (9.06e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.70e-3)"	"unprognostic (2.63e-1)"	"unprognostic (7.00e-4)"	"unprognostic (2.84e-2)"	"prognostic favorable (2.69e-4)"	"unprognostic (2.70e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.29e-1)"	"unprognostic (7.39e-2)"	0.1	0.3	0.5	0.1	0.7	0.0	0.0	0.3	0.6	0.2	0.0			0.0	0.2	0.9	0.1	0.2	0.0	0.3	0.4	0.5	4.6	0.3	0.0	0.2	0.7		0.3	0.1	0.0	0.8	0.1		0.1	0.1		0.0	0.2	17.3	0.1	0.1	0.0	0.8	0.3	0.0	0.6			0.1		0.4	0.1	0.0	8.8	2.2	0.0	0.0	0.3	0.0	0.1	0.0	0.7	2.5	0.7	0.3	0.0	0.3	0.1	0.3	0.1	0.4	3.4	0.2	0.1	0.3	0.0	0.7	0.1	4.9	0.0	0.2	0.6	0.5	1.1	0.0	0.0	0.2	0.6	1.9	0.3	0.6	0.1	0.2	0.2	0.0	0.8	12.9	0.3	0.4	0.3	0.8	0.7	0.2	0.0	0.2	0.1	0.1	0.0	0.0	0.0	2.9	1.2	0.2	0.3	0.2	0.1	0.2	2.1	0.5	0.3	0.8	0.7	1.1	1.0	2.0	0.1	0.2	2.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	8.8	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.3	0.0	2.2	0.0	0.1											0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	3.9	0.0	6.6	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.2	0.0	0.4	1.1	0.9	0.0	0.0	0.3	1.3	0.0	0.0	0.0	0.0	0.0
TBL1XR1	"C21, DC42, FLJ12894, IRA1, TBLR1"	ENSG00000177565	"Transducin beta like 1 X-linked receptor 1"	Q9BZK7	3	177019340-177228000	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"Activator, Chromatin regulator, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-698: 71.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA019182	Supported		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA019182: AB_1857800"	"unprognostic (4.11e-2)"	"unprognostic (3.00e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.27e-3)"	"prognostic favorable (5.16e-5)"	"unprognostic (4.44e-2)"	"prognostic unfavorable (1.08e-7)"	"unprognostic (3.75e-1)"	"unprognostic (4.84e-2)"	"unprognostic (3.04e-1)"	"unprognostic (3.13e-3)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (4.25e-5)"	"unprognostic (5.83e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.17e-1)"	20.7	26.0	27.4	24.3	26.8	27.3	20.3	27.5	28.1	28.9	29.9	22.6	15.4	24.0	23.9	20.5	23.8	21.9	22.7	30.3	26.2	20.7	19.9	21.8	30.8	27.8	21.4	25.9	26.5	19.9	30.6	11.3	24.0	19.7	24.4	23.2	24.7	21.3	17.7	21.1	17.8	24.3	21.9	19.6	24.7	21.3	17.4	22.3	28.4	45.6	14.9	32.1	29.1	25.5	7.4	13.3	12.9	4.6	6.8	8.3	4.1	23.9	12.3	16.0	9.0	13.6	14.8	9.6	7.6	11.8	6.6	9.1	14.1	19.9	24.6	35.9	10.9	17.5	14.8	11.9	15.8	13.3	25.8	3.7	13.8	21.0	8.4	11.7	21.9	8.2	21.8	8.2	9.7	24.1	13.0	10.3	17.3	10.3	43.6	8.5	8.6	20.4	3.0	10.1	15.4	8.3	11.7	20.4	26.2	5.9	34.0	5.8	9.2	10.2	8.0	9.5	10.5	29.3	16.8	15.7	10.8	9.1	6.0	16.4	23.8	30.5	71.1	7.3	16.4	12.3	11.4	3.0	3.8	5.8	4.6	5.1	7.3	5.7	6.6	4.0	7.4	5.0	6.4	12.9	6.8	3.9	13.3	8.3	4.1	27.4	26.8	27.5	28.1	26.2	20.7	21.4	25.9	19.7	22.3	68.5	47.1	43.4	46.9	81.4	116.0	84.2	48.4	61.6	62.6	99.5	117.8	22.3	24.9	43.8	5.7	62.9	42.8	23.3	37.3	28.5	65.8	123.0	24.3	58.7	32.8	109.7	81.9	55.9	85.4	5.2	59.2	54.6	62.4	31.5	74.5	41.8	53.4	23.0	68.6	46.2	81.2	45.3	41.5	8.4	53.9	97.7	23.0	49.8	75.7	61.8
TBX3	"TBX3-ISO, UMS, XHL"	ENSG00000135111	"T-box 3"	O15119	12	114670254-114684164	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"seminal vesicle: 117.7"	"Cell type enriched"	"Detected in many"	6	"Syncytiotrophoblasts: 513.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"BJ: 34.0;BJ hTERT+: 32.4;RT4: 42.4"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA005799, HPA075876"			Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA005799: AB_1857817, HPA075876: "	"unprognostic (3.27e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.84e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.40e-2)"	"unprognostic (5.97e-3)"	"unprognostic (1.56e-1)"	"unprognostic (2.99e-2)"	"unprognostic (9.43e-2)"	"unprognostic (1.15e-1)"	"unprognostic (3.35e-1)"	"unprognostic (3.06e-1)"	"unprognostic (3.64e-3)"	"unprognostic (1.09e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.01e-1)"	"prognostic favorable (3.28e-4)"	4.3	60.5	0.9	3.3	1.9	0.0	19.9	0.7	2.3	18.2	12.2	1.7	69.6	14.2	13.1	18.7	1.9	7.5	5.0	6.2	1.2	1.5	4.1	15.1	12.6	0.8	1.2	0.5	15.6	1.1	0.3	5.3	67.8	1.6	32.3	1.5	2.6	7.3	117.7	4.2	4.8	19.4	9.7	1.4	2.6	2.2	3.5	1.2	0.5	36.3	7.3	3.5	24.6	25.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	6.0	0.0	0.0	9.0	12.4	13.5	34.0	32.4	13.2	13.1	5.3	1.4	0.0	0.5	5.9	0.8	1.5	2.8	1.2	16.3	0.0	4.1	0.0	1.5	15.5	2.9	0.0	0.0	5.5	0.8	4.4	9.1	0.0	0.1	0.0	1.2	0.0	1.1	0.5	0.0	0.1	0.0	17.2	1.8	0.0	0.0	0.8	0.0	42.4	2.2	6.6	4.8	2.2	1.1	15.8	1.7	0.0	0.0	4.0	2.6	2.3	11.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.9	0.7	2.3	1.2	1.5	1.2	0.5	1.6	1.2	0.0	3.4	0.9	88.0	8.8	6.3	9.8	0.0	0.0	0.0	33.2	3.9	39.8	0.0	0.4	1.3	26.5	25.4	0.0	0.0	5.9	9.5	74.0	0.0	31.0	5.4	1.6	4.7	0.6	1.6	1.8	4.9	0.8	3.3	0.0	13.8	1.5	0.5	23.0	5.6	0.0	2.0	38.8	34.1	0.1	4.7	8.5	513.4	0.7	4.5	62.6
TCEA1	"GTF2S, SII, TCEA, TF2S, TFIIS"	ENSG00000187735	"Transcription elongation factor A1"	P23193	8	53966552-54022529	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043786	Approved		Supported	Nucleoplasm,Nucleoli		NA	NA			Nucleoplasm	Nucleoli	"HPA043786: AB_10959468"	"unprognostic (5.35e-2)"	"unprognostic (9.90e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.11e-3)"	"unprognostic (3.34e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.72e-2)"	"unprognostic (1.77e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (3.75e-5)"	"unprognostic (3.80e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.13e-1)"	"unprognostic (3.05e-2)"	26.7	25.3	30.7	40.5	31.5	29.6	31.1	26.1	27.4	26.0	28.3	21.9	26.6	20.3	27.3	20.9	27.5	23.6	24.7	21.4	27.8	24.2	26.5	56.8	22.3	39.2	29.7	17.6	28.5	38.4	32.2	28.7	21.1	27.1	31.3	22.5	20.6	25.4	25.4	21.8	22.8	22.4	38.9	36.8	30.0	26.1	17.3	31.3	39.9	54.6	18.6	46.9	39.6	37.3	60.0	31.9	20.5	17.8	25.2	40.1	17.8	27.3	27.7	24.8	25.5	17.6	21.9	17.8	21.7	25.5	25.7	28.7	15.8	22.9	67.2	24.7	24.9	27.4	21.1	31.3	19.9	37.5	38.4	15.7	50.8	13.5	23.3	55.3	19.9	21.9	15.7	53.8	24.2	106.8	21.3	21.9	23.2	32.2	58.4	23.3	13.0	41.1	13.9	40.3	44.5	8.3	31.9	8.7	12.0	35.4	18.7	23.3	16.9	17.9	15.8	58.3	24.2	22.8	22.3	19.4	18.9	17.4	21.2	19.5	36.1	22.6	45.5	33.3	22.8	26.6	18.1	17.8	20.5	30.1	16.8	28.6	60.0	31.4	27.7	22.1	44.4	28.0	29.1	6.4	25.2	15.6	31.9	40.1	17.8	30.7	31.5	26.1	27.4	27.8	24.2	29.7	17.6	27.1	31.3	83.4	82.6	150.6	116.2	120.3	70.8	20.7	79.0	139.2	124.0	94.2	84.4	99.1	142.6	96.9	85.2	85.7	52.6	93.5	95.8	104.8	89.7	121.1	94.9	140.5	76.9	54.0	83.7	48.5	68.2	129.1	124.8	89.2	111.3	118.2	83.8	139.0	101.0	71.9	124.8	130.8	97.6	77.6	122.7	77.9	84.3	131.6	93.7	107.1	78.7	109.8
TCF12	"bHLHb20, HEB, HsT17266, HTF4"	ENSG00000140262	"Transcription factor 12"	Q99081	15	56918623-57299281	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	"Developmental protein, DNA-binding"	"Cancer-related genes, Craniosynostosis, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 89.4"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004432, HPA065827"	Approved		Supported	"Nucleoplasm,Nuclear speckles"		NA	NA			"Nucleoplasm, Nuclear speckles"		"CAB004432: AB_671267, HPA065827: AB_2685564"	"unprognostic (1.19e-1)"	"unprognostic (1.11e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.65e-1)"	"unprognostic (2.07e-3)"	"unprognostic (1.11e-1)"	"unprognostic (6.63e-2)"	"unprognostic (1.85e-1)"	"prognostic unfavorable (8.89e-4)"	"unprognostic (7.83e-2)"	"unprognostic (7.26e-3)"	"unprognostic (5.57e-3)"	"prognostic unfavorable (5.24e-5)"	"unprognostic (2.03e-1)"	"unprognostic (2.93e-1)"	"unprognostic (3.15e-2)"	"unprognostic (1.41e-1)"	20.9	14.3	24.9	12.6	37.5	10.9	18.4	32.7	41.8	48.2	16.5	33.6	14.0	16.0	28.1	15.0	14.8	28.2	21.4	15.7	28.4	16.4	17.0	14.4	17.3	13.7	33.9	15.3	26.2	12.5	29.2	15.7	19.1	27.9	26.3	17.9	14.7	20.1	17.5	18.1	16.0	15.8	25.8	25.3	13.6	17.3	14.7	41.3	89.4	17.0	9.6	15.8	23.3	21.2	11.8	15.9	16.0	19.3	12.2	17.6	10.2	6.5	12.3	54.1	17.4	24.7	21.7	9.5	13.5	23.7	12.0	15.9	7.9	5.3	9.0	11.1	20.4	8.6	7.9	21.1	9.7	15.3	11.8	7.9	18.0	13.3	9.5	17.0	11.3	9.5	19.0	17.6	11.0	29.2	16.0	21.4	40.5	20.1	11.3	16.2	2.2	26.7	6.3	14.6	6.8	5.3	36.5	62.8	8.4	16.5	12.2	11.0	32.0	14.5	5.3	13.1	18.0	8.2	22.3	16.4	19.3	14.8	8.2	19.6	6.5	11.6	15.0	10.8	22.1	23.1	16.0	11.2	8.7	15.0	14.3	12.4	10.8	12.2	13.6	15.9	11.8	14.1	12.7	1.3	12.2	19.3	6.6	17.6	10.2	24.9	37.5	32.7	26.9	28.4	16.4	33.9	15.3	27.9	41.3	50.6	15.8	14.2	18.0	23.7	12.8	14.5	20.4	16.0	27.3	15.7	33.4	8.5	11.6	15.2	19.4	27.4	15.8	0.0	10.3	12.7	31.5	19.7	22.0	16.0	23.5	12.7	8.6	22.7	34.0	15.6	23.9	26.0	13.5	10.0	16.5	26.9	13.8	17.5	32.5	13.6	25.1	45.3	20.6	18.9	12.5	29.5	10.9	16.0	16.4	15.6
TCF3	"bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR"	ENSG00000071564	"Transcription factor 3"	P15923	19	1609290-1652605	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Differentiation, Neurogenesis, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Daudi: 76.6;REH: 76.2;U-698: 96.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018351, HPA049808, HPA062476"	Approved		Enhanced	Nucleoplasm		No	No			Nucleoplasm		"CAB018351: AB_675504, HPA049808: AB_2680892, HPA062476: AB_2684775"	"unprognostic (8.82e-2)"	"unprognostic (4.74e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.91e-2)"	"unprognostic (8.25e-3)"	"prognostic unfavorable (2.46e-4)"	"unprognostic (2.07e-2)"	"unprognostic (7.99e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.42e-1)"	"unprognostic (9.29e-3)"	"prognostic unfavorable (1.53e-4)"	"unprognostic (4.87e-3)"	"unprognostic (1.88e-1)"	"unprognostic (3.07e-1)"	"unprognostic (8.05e-2)"	13.0	8.8	12.8	31.6	9.8	33.2	17.4	8.3	11.9	15.5	16.2	11.9	9.4	18.1	16.6	11.3	16.7	12.1	19.0	9.4	11.2	6.2	11.9	8.9	13.2	42.0	10.7	6.0	18.2	13.5	6.3	13.9	10.8	11.0	17.1	9.7	12.4	13.6	6.9	11.2	16.7	23.0	8.8	10.4	33.1	14.9	36.0	11.2	63.2	15.9	11.6	38.0	15.2	13.9	11.3	12.1	2.9	2.8	2.3	4.2	1.6	15.9	8.2	22.6	20.3	3.2	8.6	10.1	9.9	7.8	11.4	10.1	16.2	12.6	76.6	11.3	8.1	2.1	16.6	13.8	10.8	6.7	46.4	9.2	7.2	10.3	17.6	7.4	17.6	10.1	5.5	12.5	8.9	6.9	10.2	13.7	28.5	29.6	26.6	7.2	28.2	48.6	17.1	31.4	9.7	8.6	76.2	10.4	17.3	7.7	14.1	21.6	30.3	9.4	9.3	11.5	8.8	11.8	31.4	16.4	15.0	17.8	18.5	16.9	64.8	31.6	96.6	9.8	22.5	13.4	2.9	1.3	0.9	3.5	1.4	3.7	10.8	2.2	3.2	2.7	11.3	3.2	4.2	0.4	2.3	2.8	12.1	2.1	1.6	12.8	9.8	8.3	11.9	11.2	6.2	10.7	6.0	11.0	11.2	6.0	7.8	26.7	4.5	12.4	10.7	8.9	2.5	0.0	10.3	1.8	25.5	3.4	1.7	9.4	6.7	9.5	13.5	0.0	5.9	7.4	11.5	8.0	6.9	3.9	6.7	4.8	15.5	8.6	7.2	3.9	12.7	6.5	10.1	5.4	13.0	9.0	14.7	14.0	9.6	4.5	13.6	19.4	10.5	3.7	15.8	11.5	2.4	8.6	18.4	6.7
TCF7L2	"TCF-4, TCF4"	ENSG00000148737	"Transcription factor 7 like 2"	Q9NQB0	10	112950250-113167678	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Wnt signaling pathway"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Diabetes mellitus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Extravillous trophoblasts: 184.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"intermediate monocyte: 12.1;non-classical monocyte: 33.1"	"Lineage enriched"	"Detected in many"	13	"monocytes: 33.1"	"Low cell line specificity"	"Detected in many"			"Group enriched"	"Detected in many"	8	"midbrain: 84.5;thalamus: 98.3"	"Group enriched"	"Detected in all"	5	"midbrain: 190.1;pons and medulla: 104.8;thalamus: 169.1"	"CAB013535, HPA038800"	Supported		Approved	"Nucleoplasm,Nuclear bodies,Cytosol"		Yes	No			Nucleoplasm	"Nuclear bodies, Cytosol"	"CAB013535: AB_2533167, HPA038800: "	"unprognostic (1.79e-2)"	"unprognostic (3.36e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.31e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.72e-1)"	"unprognostic (2.09e-1)"	"unprognostic (9.84e-2)"	"unprognostic (5.09e-1)"	"unprognostic (7.10e-2)"	"unprognostic (6.10e-3)"	"unprognostic (3.46e-2)"	"unprognostic (7.25e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.64e-1)"	"unprognostic (7.36e-3)"	27.4	10.3	8.7	18.7	10.0	7.3	46.4	5.4	10.3	27.4	34.2	15.4	28.1	21.0	26.6	14.9	12.6	18.2	15.3	13.5	8.1	17.9	10.2	22.9	26.9	13.9	8.5	9.0	25.6	13.9	16.5	17.9	24.0	10.2	14.4	23.7	13.9	14.9	52.8	13.7	17.6	40.4	18.0	13.9	27.3	24.0	10.6	10.1	6.6	14.3	9.3	7.0	21.5	16.3	0.0	1.7	2.5	33.1	0.0	0.6	1.1	7.1	18.6	20.4	19.7	10.7	7.1	24.4	5.1	9.9	3.5	4.3	12.3	21.6	0.0	5.7	9.5	4.8	5.1	6.9	8.8	4.5	0.8	6.4	5.0	12.4	11.3	11.4	1.9	1.8	12.6	3.2	5.5	9.4	15.1	5.9	4.2	5.2	0.3	4.1	13.9	3.2	1.2	14.6	8.0	10.7	9.0	15.0	3.2	7.7	9.9	0.4	6.3	7.7	7.6	8.1	16.5	4.9	1.1	13.7	3.3	9.6	8.5	10.4	1.3	0.1	0.1	3.3	4.2	7.4	0.1	1.8	0.1	0.6	12.1	0.4	0.0	0.1	0.5	1.7	0.0	0.1	0.3	2.5	0.0	33.1	0.0	0.0	1.1	8.7	10.0	5.4	10.3	8.1	17.9	8.5	9.0	10.2	10.1	20.8	21.6	4.7	23.8	37.8	2.4	10.6	35.7	20.1	34.2	38.4	5.9	36.9	10.0	28.5	5.5	37.0	121.0	0.0	38.6	184.2	40.4	33.1	0.0	57.7	15.1	4.8	19.0	55.3	68.7	2.7	54.7	21.0	30.4	1.0	68.2	36.6	41.7	91.2	45.6	13.4	5.7	90.5	44.3	3.0	23.4	34.8	23.8	4.3	42.7	42.0
TCL1A	TCL1	ENSG00000100721	"T cell leukemia/lymphoma 1A"	P56279	14	95709967-95714196	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	12	"blood: 179.4;lymphoid tissue: 63.7"	"Group enriched"	"Detected in some"	5	"B-cells: 166.3;Spermatogonia: 48.5"	"Cancer enriched"	"Detected in many"	18	"testis cancer: 64.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	381	"memory B-cell: 45.6;naive B-cell: 179.4;plasmacytoid DC: 79.8"	"Group enriched"	"Detected in many"	487	"B-cells: 179.4;dendritic cells: 79.8"	"Group enriched"	"Detected in some"	157	"Daudi: 71.1;REH: 92.4;U-698: 94.4"					"Not detected"	"Not detected"			"CAB004045, HPA016604"	Enhanced		Enhanced	"Nucleoplasm,Endoplasmic reticulum,Cytosol"		NA	NA			"Endoplasmic reticulum, Cytosol"	Nucleoplasm	"CAB004045: AB_2179419, HPA016604: AB_1857859"	"unprognostic (1.27e-3)"	"unprognostic (3.12e-4)"	"unprognostic (2.61e-4)"	"unprognostic (2.01e-2)"	"unprognostic (1.27e-1)"	"unprognostic (4.75e-4)"	"unprognostic (7.70e-2)"	"unprognostic (9.67e-3)"	"unprognostic (1.03e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.14e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.87e-1)"	"unprognostic (3.94e-1)"	"unprognostic (2.06e-1)"	"unprognostic (4.55e-1)"	0.4	0.2	0.2	53.4	0.2	4.8	0.3	0.2	0.2	0.2	0.9	0.0	0.2	0.0	0.3	0.0	0.8	0.3	0.6	0.3	0.2	0.2	1.1	0.4	3.2	63.7	0.2	0.0	0.3	0.2	0.0	0.2	0.6	0.0	0.4	0.2	0.1	2.9	0.0	0.2	0.2	10.4	0.1	0.2	33.5	0.5	5.3	0.0	4.7	0.8	1.2	53.6	3.6	0.3	179.4	79.8	0.2	0.1	0.0	0.1	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	71.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	92.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.4	0.1	0.0	0.0	0.5	94.4	0.0	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.1	45.6	0.0	0.0	0.1	179.4	0.1	0.0	0.2	0.0	0.1	79.8	0.0	6.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	2.2	166.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.3	0.0	1.2	0.0	0.0	0.9	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	20.6	48.5	0.0	0.0	0.0	0.0	0.0
TERT	"EST2, hEST2, TCS1, TP2, TRT"	ENSG00000164362	"Telomerase reverse transcriptase"	O14746	5	1253147-1295069	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins"		"DNA-binding, Nucleotidyltransferase, Ribonucleoprotein, RNA-directed DNA polymerase, Transferase"	"Cancer-related genes, Disease mutation, Dyskeratosis congenita"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"bone marrow: 3.4;lymphoid tissue: 12.0;testis: 5.0"	"Cell type enhanced"	"Detected in some"	24	"Cardiomyocytes: 1.2;Spermatogonia: 1.9"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 62.6;fHDF/TERT166: 59.4;HBEC3-KT: 120.8;hTEC/SVTERT24-B: 76.3;LHCN-M2: 34.4;TIME: 98.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA054641, HPA065897"	Supported		Supported	"Nucleoplasm,Nuclear speckles,Cytosol"		NA	NA			Nucleoplasm	"Nuclear speckles, Cytosol"	"HPA054641: AB_2682554, HPA065897: AB_2685576"	"unprognostic (1.21e-2)"	"unprognostic (2.88e-2)"	"unprognostic (1.24e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.43e-3)"	"unprognostic (6.42e-3)"	"unprognostic (1.85e-2)"	"unprognostic (2.21e-1)"	"unprognostic (6.91e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.59e-1)"	"unprognostic (9.16e-4)"	"unprognostic (8.84e-11)"	"unprognostic (1.92e-1)"	"unprognostic (2.15e-1)"		"unprognostic (3.35e-1)"	0.0	0.0	0.0	7.1	0.9	3.4	0.0	0.0	0.2	0.1	1.1	0.0	0.0	1.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	2.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.9	0.0	0.0	1.0	0.4	5.0	0.0	12.0	0.0	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	31.3	62.6	0.5	0.0	23.8	4.3	8.0	0.1	0.1	0.7	0.0	59.4	0.0	0.0	0.2	120.8	5.1	0.0	0.3	0.0	0.0	0.1	0.0	0.3	0.3	0.0	3.1	76.3	0.8	0.1	0.2	0.5	0.6	0.1	34.4	0.0	0.2	1.7	0.4	0.0	0.2	0.9	0.0	0.8	3.5	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	98.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.9	0.0	0.0	0.0	0.2	0.0
TET1	"bA119F7.1, CXXC6, KIAA1676, LCX"	ENSG00000138336	"Tet methylcytosine dioxygenase 1"	Q8NFU7	10	68560656-68694482	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Extravillous trophoblasts: 59.1;Horizontal cells: 33.4;Leydig cells: 23.9"	"Cancer enriched"	"Detected in some"	15	"testis cancer: 10.4"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BEWO: 15.3;HAP1: 17.4;K-562: 9.7;NTERA-2: 10.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019032, HPA057273"			Supported	"Nucleoplasm,Nuclear membrane"		NA	NA			Nucleoplasm	"Nuclear membrane"	"HPA019032: AB_1847363, HPA057273: AB_2683391"	"unprognostic (1.60e-1)"	"unprognostic (8.30e-2)"	"unprognostic (9.85e-2)"	"unprognostic (1.67e-2)"	"unprognostic (1.27e-1)"	"unprognostic (8.15e-2)"	"unprognostic (3.60e-3)"	"unprognostic (1.12e-1)"	"unprognostic (2.00e-1)"	"unprognostic (7.90e-3)"	"unprognostic (1.83e-1)"	"unprognostic (1.71e-1)"	"unprognostic (1.18e-3)"	"unprognostic (2.88e-4)"	"unprognostic (4.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (9.52e-3)"	4.4	1.6	3.3	4.3	2.6	1.6	3.1	4.4	4.3	5.1	2.4	5.8	3.2	1.2	6.0	3.4	2.4	2.9	3.5	2.4	3.5	2.3	1.8	1.5	1.6	1.7	2.5	2.6	6.1	1.6	7.4	2.2	5.8	2.9	3.2	2.0	8.1	15.9	4.8	4.0	2.2	1.8	6.5	3.6	1.7	2.2	1.4	5.9	1.2	3.2	3.2	1.8	5.1	5.4	1.3	1.1	1.0	0.0	0.9	2.3	0.2	0.6	0.7	6.9	7.8	0.7	0.6	15.3	0.4	0.8	0.6	1.1	4.6	0.2	0.0	0.2	0.7	0.1	0.0	17.4	0.0	0.7	0.2	2.8	1.8	0.0	4.1	1.0	1.6	0.9	0.9	0.1	0.4	0.0	1.4	0.1	2.9	9.7	1.2	0.6	0.5	2.7	1.2	10.2	0.0	0.9	2.7	2.2	0.2	0.3	0.7	1.9	3.1	0.3	0.4	1.4	7.2	0.9	1.2	0.2	0.6	1.4	0.0	0.5	0.5	0.5	2.7	0.1	0.0	0.1	0.0	0.0	1.0	1.5	0.0	2.0	1.3	0.8	1.3	0.2	0.5	1.4	1.1	0.0	0.9	0.0	1.1	2.3	0.2	3.3	2.6	4.4	2.6	3.5	2.3	2.5	2.6	2.9	5.9	3.0	3.8	0.0	1.9	1.0	2.2	4.5	2.5	1.4	4.5	0.0	9.8	16.6	0.0	1.4	0.4	3.3	0.0	0.0	0.3	59.1	11.8	2.1	0.0	2.1	3.3	33.4	13.2	7.4	0.0	0.6	23.9	0.1	1.7	0.0	0.0	17.3	0.9	0.0	19.4	0.8	10.8	6.5	3.8	0.5	0.7	1.0	23.3	1.7	0.4	0.3
TET2	"FLJ20032, KIAA1546"	ENSG00000168769	"Tet methylcytosine dioxygenase 2"	Q6N021	4	105145875-105279816	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle"	"Chromatin regulator, Dioxygenase, DNA-binding, Oxidoreductase"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 29.0"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 29.0"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA043135	Supported		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA043135: AB_10794177"	"unprognostic (6.83e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.69e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.15e-2)"	"unprognostic (5.88e-2)"	"unprognostic (6.12e-2)"	"unprognostic (1.19e-3)"	"unprognostic (1.15e-2)"	"unprognostic (1.57e-2)"	"unprognostic (5.77e-2)"	"unprognostic (7.29e-2)"	"unprognostic (2.70e-3)"	"unprognostic (6.10e-2)"	"unprognostic (1.89e-1)"	"unprognostic (9.15e-2)"	"unprognostic (7.84e-2)"	9.9	6.1	8.7	11.9	11.4	26.3	8.0	4.1	10.0	9.6	7.4	10.1	5.8	8.2	10.1	7.4	16.2	9.2	6.6	6.8	9.0	4.2	6.7	5.5	9.9	9.8	13.7	5.7	8.5	7.0	7.4	29.0	12.4	9.1	6.5	8.0	4.7	13.5	8.2	9.8	16.0	10.2	7.8	15.5	12.9	6.8	3.2	14.6	9.3	7.2	6.9	8.7	9.8	12.3	2.8	5.1	29.0	7.0	2.6	2.1	1.4	4.8	3.1	10.6	10.8	1.9	4.3	4.3	3.5	4.7	5.0	4.9	3.1	6.5	0.5	4.0	4.3	2.4	4.6	10.2	6.1	5.7	6.2	2.7	6.8	6.0	1.1	5.4	15.4	11.3	3.7	8.3	4.8	6.2	8.1	6.6	3.7	7.2	12.7	4.3	3.6	2.5	4.2	2.3	6.4	1.9	7.9	5.3	1.0	4.6	10.2	7.6	6.2	3.8	9.9	0.6	6.0	4.5	11.1	8.5	7.6	6.9	2.2	5.9	8.5	6.1	6.4	4.6	3.8	7.4	10.8	7.0	7.2	2.1	5.5	0.8	2.6	1.2	1.2	5.1	2.8	1.0	1.6	29.0	2.6	6.4	4.5	1.5	1.4	8.7	11.4	4.1	10.0	9.0	4.2	13.7	5.7	9.1	14.6	23.8	26.1	5.6	9.4	12.8	21.1	21.6	7.6	21.4	20.5	8.7	15.7	16.9	6.6	5.6	0.2	12.9	15.8	0.0	6.6	4.8	7.5	10.8	26.6	6.6	13.0	33.4	22.3	9.2	49.2	0.4	7.5	43.4	5.0	11.8	15.9	5.6	6.6	17.3	6.7	2.4	23.8	12.9	8.2	0.2	0.6	31.5	28.6	17.5	12.7	22.5
TFE3	"bHLHe33, TFEA"	ENSG00000068323	"Transcription factor binding to IGHM enhancer 3"	P19532	X	49028726-49043486	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 10.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023881	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA023881: AB_1857931"	"unprognostic (2.68e-2)"	"unprognostic (2.89e-3)"	"unprognostic (2.40e-2)"	"unprognostic (5.36e-2)"	"unprognostic (2.71e-2)"	"unprognostic (1.81e-1)"	"prognostic unfavorable (6.03e-5)"	"unprognostic (2.40e-1)"	"unprognostic (1.26e-1)"	"unprognostic (4.32e-2)"	"unprognostic (5.41e-2)"	"unprognostic (1.16e-1)"	"prognostic unfavorable (2.19e-8)"	"unprognostic (1.93e-1)"	"unprognostic (8.77e-2)"	"unprognostic (4.19e-2)"	"unprognostic (6.25e-1)"	31.3	20.9	12.6	18.2	14.4	22.6	53.1	16.5	18.1	22.6	17.7	16.6	30.0	9.9	22.8	21.9	20.5	18.8	16.4	15.1	11.3	11.8	21.6	14.1	22.8	10.3	13.2	9.4	24.4	15.9	16.5	16.3	22.0	15.9	21.2	10.4	15.7	12.6	30.6	13.6	14.1	13.5	21.2	14.8	23.0	14.7	10.4	15.2	4.2	21.7	10.8	10.5	28.6	20.5	1.2	1.9	10.5	4.4	0.4	1.4	1.6	11.8	15.3	5.1	14.7	16.6	15.1	5.1	15.7	18.2	16.0	13.7	9.3	9.5	4.5	6.7	23.0	17.7	9.8	9.6	14.1	13.0	9.8	5.2	4.1	11.3	8.7	22.4	4.3	10.2	13.0	9.1	26.3	18.8	14.9	7.7	3.1	7.9	19.6	13.6	7.0	2.8	4.0	13.9	3.5	13.8	4.3	8.8	10.1	10.2	5.5	4.9	4.8	16.7	7.2	5.5	18.0	10.2	3.9	16.2	17.6	18.8	17.5	8.6	12.1	11.3	3.7	21.0	5.3	12.0	0.0	3.5	1.6	0.5	4.3	0.9	0.6	0.9	0.5	1.9	1.2	0.6	0.4	10.5	0.4	4.4	0.4	1.4	1.6	12.6	14.4	16.5	14.9	11.3	11.8	13.2	9.4	15.9	15.2	14.9	9.1	5.2	18.6	17.5	6.5	6.2	17.8	4.0	11.4	19.2	3.9	13.6	8.3	16.6	0.6	14.6	11.8	0.0	13.7	7.4	16.4	16.4	5.7	13.9	19.2	17.5	12.0	9.8	23.8	1.3	25.3	13.0	8.5	10.0	8.5	9.6	17.6	14.0	23.0	8.6	5.3	12.9	13.3	2.6	0.9	19.3	31.0	8.6	6.5	15.8
TFEB	"bHLHe35, TCFEB"	ENSG00000112561	"Transcription factor EB"	P19484	6	41683978-41736259	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Adaptive immunity, Autophagy, Immunity, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Syncytiotrophoblasts: 100.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 29.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BEWO: 30.2;Daudi: 19.1;OE19: 25.5;U-698: 28.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA049532			Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA049532: AB_2680807"	"unprognostic (3.63e-3)"	"unprognostic (1.51e-3)"	"unprognostic (1.75e-2)"	"unprognostic (4.48e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.64e-1)"	"unprognostic (4.22e-3)"	"unprognostic (1.39e-2)"	"unprognostic (4.13e-2)"	"prognostic favorable (4.77e-4)"	"unprognostic (2.12e-2)"	"prognostic favorable (1.06e-5)"	"unprognostic (1.44e-1)"	"unprognostic (3.51e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.31e-2)"	8.6	6.4	10.2	16.8	20.7	8.9	6.8	8.6	15.0	6.4	10.5	34.4	8.2	6.8	7.1	4.3	9.3	7.2	9.1	19.3	14.6	8.2	12.2	5.0	8.3	24.1	30.0	6.8	6.7	11.4	26.1	14.9	18.5	16.2	10.7	5.3	6.9	18.0	8.6	45.2	7.9	15.5	8.4	27.4	27.3	7.9	2.5	24.0	2.8	11.1	10.9	18.3	10.8	11.1	22.2	8.5	29.0	9.6	0.8	2.6	4.4	1.7	1.8	0.4	7.0	2.4	1.4	30.2	2.7	5.5	2.4	1.8	4.0	2.0	19.1	3.7	2.9	1.8	4.8	1.1	2.8	0.6	17.5	1.9	0.0	6.9	7.3	4.7	0.5	2.6	0.5	5.4	2.8	1.8	5.8	1.8	2.1	2.3	4.7	0.9	1.2	1.1	1.4	0.1	25.5	0.9	12.6	0.2	2.6	4.3	1.4	7.9	2.3	2.3	4.9	0.6	1.8	1.4	9.5	3.8	0.9	1.9	0.1	1.9	12.3	1.9	28.2	1.4	8.1	0.9	0.1	9.6	8.8	2.6	9.3	0.4	22.2	0.7	1.0	8.5	15.1	0.2	0.9	29.0	0.8	6.5	1.7	0.4	4.4	10.2	20.7	8.6	15.0	14.6	8.2	30.0	6.8	16.2	24.0	8.9	9.4	20.8	7.5	12.6	5.8	16.4	12.7	4.0	1.2	12.2	11.8	37.8	18.3	3.0	0.7	7.7	14.0	0.0	6.2	3.4	5.2	6.4	1.1	3.9	25.2	25.4	12.7	8.6	22.7	4.0	3.1	12.9	0.0	4.6	8.4	16.7	6.9	17.3	10.3	2.4	4.7	6.5	6.2	0.5	0.9	12.7	100.7	5.4	7.9	6.0
TFG	"FLJ36137, SPG57, TF6"	ENSG00000114354	"TRK-fused gene"	Q92734	3	100709331-100748966	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"ER-Golgi transport, Transport"		"Cancer-related genes, Disease mutation, Hereditary spastic paraplegia, Neurodegeneration, Neuropathy, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019473, HPA052206"	Approved		Supported	Vesicles,Cytosol		No	No			Vesicles	Cytosol	"HPA019473: AB_1857936, HPA052206: AB_2681760"	"unprognostic (1.14e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.46e-1)"	"unprognostic (4.14e-2)"	"prognostic unfavorable (5.48e-4)"	"unprognostic (3.31e-3)"	"unprognostic (1.42e-1)"	"unprognostic (3.73e-2)"	"prognostic unfavorable (1.50e-4)"	"unprognostic (4.58e-3)"	"unprognostic (3.72e-2)"	"unprognostic (2.82e-1)"	"unprognostic (8.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (8.45e-2)"	36.4	40.3	27.2	21.9	33.8	29.7	31.0	28.1	40.5	31.2	34.7	33.3	44.2	52.5	31.2	45.8	46.7	29.0	40.8	46.2	28.1	30.7	44.6	68.6	29.9	25.4	28.2	21.5	33.5	49.2	52.3	45.1	63.3	33.7	27.5	40.7	31.9	39.6	45.8	38.6	31.0	67.1	37.5	31.7	28.3	28.9	33.5	23.0	27.6	43.6	42.9	41.2	29.5	30.1	25.8	27.8	43.2	28.4	27.7	26.8	21.8	48.7	26.6	33.1	21.0	41.8	47.4	40.9	35.3	47.5	46.2	55.1	33.5	24.4	6.5	26.0	43.8	35.8	36.6	35.6	40.3	55.0	30.0	20.9	24.5	20.5	31.1	46.8	18.1	14.7	38.8	54.4	27.6	48.8	42.9	40.8	11.5	17.6	18.1	47.6	34.1	15.9	14.3	31.5	45.4	40.0	14.0	19.4	21.2	56.0	32.9	26.2	24.0	23.2	30.2	41.1	28.7	35.6	24.6	27.3	27.9	33.8	12.8	25.5	15.5	15.6	23.4	44.6	19.8	32.7	43.2	28.3	27.0	21.8	28.4	26.4	25.8	22.6	24.4	27.8	22.9	21.6	21.6	18.7	27.7	26.4	19.4	26.8	21.8	27.2	33.8	28.1	40.5	28.1	30.7	28.2	21.5	33.7	23.0	56.6	28.8	33.5	90.7	121.3	43.5	83.1	53.5	36.1	40.9	34.9	23.6	186.8	116.0	161.1	64.7	63.1	162.1	23.3	94.6	171.9	101.9	94.0	76.1	59.6	75.5	54.0	50.5	51.0	25.1	36.9	65.6	40.7	60.8	142.5	99.4	86.6	108.9	83.4	69.6	72.7	59.0	38.8	84.4	49.9	48.5	104.0	237.9	28.8	82.9	98.7
TGFBR2	"MFS2, TBR-ii, TBRII"	ENSG00000163513	"Transforming growth factor beta receptor 2"	P37173	3	30606502-30694142	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins"	"Apoptosis, Differentiation, Growth regulation"	"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Aortic aneurysm, Cancer-related genes, Craniosynostosis, Disease mutation, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	14	"Endothelial cells: 188.8;Ito cells: 564.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 54.5;ASC TERT1: 82.2;HSkMC: 70.9;LHCN-M2: 67.2;TIME: 61.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB073537			Supported	"Plasma membrane"		NA	NA		560000	"Plasma membrane"		"CAB073537: "	"unprognostic (1.74e-1)"	"unprognostic (1.84e-2)"	"unprognostic (3.70e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.26e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.62e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.24e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.81e-2)"	"unprognostic (8.81e-2)"	"unprognostic (8.02e-2)"	91.8	24.6	6.7	24.6	10.3	7.3	88.3	3.6	7.3	36.5	42.6	9.8	18.6	13.2	42.6	23.3	36.2	28.4	42.6	73.5	6.9	5.2	32.6	21.9	52.6	75.7	12.6	3.7	22.2	26.0	17.4	10.3	24.2	9.9	35.2	17.5	27.9	22.5	19.5	34.9	17.0	31.3	37.2	12.0	68.7	26.8	15.4	8.2	19.3	40.9	16.8	26.9	48.0	82.0	5.3	6.8	20.0	6.6	1.4	19.7	3.9	2.5	14.7	0.9	0.0	54.5	82.2	2.5	12.8	18.0	4.4	4.4	3.3	13.6	0.3	46.2	17.1	5.2	5.1	0.6	18.7	7.3	1.0	1.3	1.4	1.7	16.5	23.3	2.3	12.1	70.9	16.6	19.0	18.4	20.2	47.6	1.7	0.3	0.0	67.2	0.2	2.3	1.7	0.4	12.8	5.9	2.1	5.9	0.3	23.6	6.0	0.0	0.9	3.8	1.0	3.6	1.2	0.0	2.5	61.6	21.7	5.4	9.8	4.8	0.5	0.0	2.0	13.0	2.5	8.7	6.9	2.9	20.0	3.5	3.0	3.2	4.0	5.4	4.2	2.6	5.3	19.7	9.1	12.6	1.4	6.6	6.8	1.2	3.9	6.7	10.3	3.6	7.3	6.9	5.2	12.6	3.7	9.9	8.2	134.0	83.8	41.5	14.2	33.2	1.9	64.1	48.4	12.0	53.4	26.2	0.0	5.3	3.3	11.4	2.0	188.8	9.7	0.0	13.8	4.3	48.1	7.3	28.9	45.3	27.1	0.0	8.1	564.1	139.2	2.0	30.5	46.1	28.7	1.8	11.9	0.2	25.3	10.8	44.6	5.6	0.9	32.3	36.0	0.3	1.1	26.7	3.1	39.4	13.0	9.0
TLX1	"HOX11, TCL3"	ENSG00000107807	"T cell leukemia homeobox 1"	P31314	10	101130505-101137789	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"lymphoid tissue: 59.5;salivary gland: 19.5"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HAP1: 5.4;HEK 293: 3.0;K-562: 15.4;SCLC-21H: 2.6;SH-SY5Y: 3.8;SiHa: 2.5"	"Region enriched"	"Detected in single"	13	"pons and medulla: 0.5"	"Not detected"	"Not detected"									NA	NA						"unprognostic (8.67e-2)"	"unprognostic (2.23e-1)"	"prognostic unfavorable (7.32e-4)"	"unprognostic (1.06e-5)"	"unprognostic (1.06e-1)"	"unprognostic (1.60e-1)"	"unprognostic (5.07e-1)"	"unprognostic (1.57e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.69e-2)"	"unprognostic (2.52e-3)"	"unprognostic (1.81e-1)"		"unprognostic (2.63e-1)"	"unprognostic (3.26e-1)"	"unprognostic (3.06e-1)"	"unprognostic (7.35e-2)"	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.1	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.1	0.1	0.2	0.0	0.0	19.5	0.0	0.1	0.0	0.6	0.0	0.0	59.5	0.0	0.1	0.1	0.0	0.0	4.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.1	0.0	5.4	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.6	3.8	2.5	0.0	0.0	0.3	0.2	0.5	0.2	0.0	1.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0
TLX3	"HOX11L2, RNX"	ENSG00000164438	"T cell leukemia homeobox 3"	O43711	5	171309284-171312134	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"		"Developmental protein, DNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	59	"brain: 46.6"	"Cell type enriched"	"Detected in some"	5	"Extravillous trophoblasts: 5.2"	"Cancer enhanced"	"Detected in some"		"cervical cancer: 1.7"	"Region enriched"	"Detected in some"	22	"cerebellum: 46.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"SH-SY5Y: 24.6"	"Region enriched"	"Detected in single"	7	"cerebellum: 2.5"	"Region enriched"	"Detected in some"	10	"cerebellum: 48.1"	"HPA030504, HPA060957, HPA069359"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA030504: AB_2732458, HPA060957: AB_2732655, HPA069359: AB_2732130"		"unprognostic (3.52e-2)"		"unprognostic (2.43e-2)"					"unprognostic (2.09e-1)"	"unprognostic (3.11e-1)"				"unprognostic (9.80e-2)"	"unprognostic (2.76e-2)"		"unprognostic (4.48e-2)"	0.4	0.5	0.0	0.0	0.0	0.0	0.0	46.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	1.6	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.3	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.2	0.0	0.0	24.6	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.6	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0
TMEM127	"FLJ20507, FLJ22257"	ENSG00000135956	"Transmembrane protein 127"	O75204	2	96248516-96265994	"Cancer-related genes, Disease related genes, Predicted membrane proteins"			"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (5.15e-3)"	"unprognostic (2.67e-1)"	"unprognostic (1.72e-2)"	"unprognostic (6.51e-2)"	"unprognostic (5.82e-2)"	"unprognostic (2.05e-1)"	"prognostic unfavorable (6.59e-4)"	"unprognostic (6.73e-2)"	"unprognostic (4.25e-1)"	"unprognostic (1.06e-2)"	"unprognostic (7.50e-2)"	"unprognostic (2.17e-1)"	"prognostic favorable (6.69e-5)"	"unprognostic (3.59e-1)"	"unprognostic (1.52e-1)"	"unprognostic (5.15e-2)"	"unprognostic (3.65e-2)"	27.6	27.8	16.4	18.7	22.6	31.8	26.1	20.2	40.6	22.9	27.2	18.7	27.3	22.2	24.8	18.9	29.3	18.2	24.2	45.6	15.6	16.5	29.3	43.3	22.9	19.8	14.8	13.1	23.4	26.2	50.7	23.7	21.6	21.4	20.5	21.5	26.5	29.8	31.5	18.7	24.0	41.8	24.4	11.2	28.5	20.0	12.7	12.8	19.6	22.4	19.3	26.9	26.1	22.3	2.4	4.5	14.7	6.7	1.5	3.4	2.9	11.7	15.9	8.5	13.0	37.5	19.0	15.7	15.5	27.8	16.5	15.2	15.7	16.8	7.4	22.7	30.4	29.1	18.9	9.7	14.3	11.6	14.8	7.7	12.8	7.6	15.3	24.3	10.8	23.2	23.0	20.5	20.5	15.2	22.1	18.7	5.1	7.8	15.9	16.7	13.4	7.0	6.8	11.6	13.9	17.2	6.7	10.7	10.9	18.4	20.2	9.5	10.0	11.3	27.0	13.0	18.0	10.0	11.6	21.9	27.6	15.8	23.8	10.6	12.1	11.6	5.8	18.4	12.8	14.6	4.1	6.5	7.9	3.1	6.7	3.4	2.1	2.3	3.3	4.5	2.4	1.8	2.4	14.7	1.5	5.3	2.7	1.6	2.9	16.4	22.6	20.2	40.6	15.6	16.5	14.8	13.1	21.4	12.8	17.9	18.3	14.9	12.0	15.2	18.1	33.9	22.9	9.4	19.4	26.2	25.5	9.8	13.3	28.6	3.4	19.5	45.9	0.0	30.1	11.2	11.8	20.0	12.8	31.6	33.4	20.6	15.6	24.5	48.8	3.9	12.7	30.3	15.1	25.2	19.6	8.0	31.4	28.1	15.9	11.4	14.5	6.5	13.7	5.6	2.9	20.5	20.3	13.8	15.0	31.4
TMPRSS2	PRSS10	ENSG00000184012	"Transmembrane serine protease 2"	O15393	21	41464551-41531116	"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 75.6;pancreas: 64.5;prostate: 68.2"	"Cell type enhanced"	"Detected in many"	10	"Enterocytes: 190.3;Glandular cells: 290.4;Paneth cells: 127.7;Urothelial cells: 115.9"	"Cancer enriched"	"Detected in many"	7	"prostate cancer: 250.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 14.1;MCF7: 6.1;OE19: 20.6;RT4: 33.9;SK-BR-3: 6.9"	"Not detected"	"Not detected"							"HPA034493, HPA035787"	Enhanced		Approved	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	Nucleoplasm	"HPA034493: , HPA035787: AB_2674782"	"unprognostic (4.80e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.16e-1)"	"prognostic favorable (2.56e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.05e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.51e-3)"	"unprognostic (9.43e-2)"	"unprognostic (9.02e-3)"	"unprognostic (6.24e-2)"	"unprognostic (6.43e-2)"	"prognostic favorable (7.86e-6)"	"unprognostic (2.00e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.15e-2)"	0.2	0.1	0.2	15.5	0.4	0.0	6.1	0.2	0.5	1.3	38.7	0.4	24.4	17.5	0.5	0.9	10.7	2.2	17.3	0.2	0.3	0.1	19.4	18.4	20.7	0.2	0.2	0.2	0.7	64.5	0.0	1.3	1.0	0.4	68.2	18.5	0.3	52.3	35.7	0.2	2.1	75.6	0.9	0.2	0.3	36.7	0.8	0.3	0.5	19.9	3.9	10.2	5.9	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	14.1	1.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.1	0.5	1.2	20.6	0.0	0.0	0.0	1.3	0.5	33.9	0.0	0.4	0.0	6.9	0.1	0.2	5.2	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.4	0.2	0.5	0.3	0.1	0.2	0.2	0.4	0.3	47.6	88.6	0.0	31.0	0.2	0.0	0.6	25.5	14.7	38.7	45.4	0.0	0.5	19.9	30.0	19.4	0.0	190.3	0.0	52.6	0.1	0.6	290.4	6.9	28.7	0.1	0.0	17.3	0.0	0.8	3.5	0.0	1.5	10.1	1.0	79.6	0.0	53.4	127.7	0.0	3.7	0.0	0.0	1.0	0.2	0.0	0.1	0.2	0.0	73.2	115.9
TNFAIP3	"A20, OTUD7C"	ENSG00000118503	"TNF alpha induced protein 3"	P21580	6	137867188-137883312	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Apoptosis, Inflammatory response, Ubl conjugation pathway"	"DNA-binding, Hydrolase, Multifunctional enzyme, Protease, Thiol protease, Transferase"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 112.4"	"Cell type enhanced"	"Detected in many"	10	"Basal keratinocytes: 688.4;Suprabasal keratinocytes: 651.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"GAMG: 31.8;Karpas-707: 48.1;REH: 41.8;U-266/84: 35.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA002116	Approved		Approved	Centrosome,Cytosol		NA	NA			"Centrosome, Cytosol"		"HPA002116: AB_1858162"	"unprognostic (5.50e-3)"	"unprognostic (9.98e-3)"	"unprognostic (3.06e-2)"	"unprognostic (1.01e-2)"	"unprognostic (4.01e-2)"	"unprognostic (9.47e-2)"	"unprognostic (5.01e-3)"	"unprognostic (4.40e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.06e-1)"	"prognostic unfavorable (6.05e-4)"	"unprognostic (6.06e-2)"	"unprognostic (3.55e-3)"	"unprognostic (1.27e-1)"	"unprognostic (6.29e-2)"	27.4	6.0	1.5	58.6	1.8	112.4	17.2	0.4	1.5	7.7	15.7	3.2	2.6	5.1	9.7	7.3	12.7	12.1	17.0	11.7	2.1	1.3	6.8	8.1	45.1	38.8	2.1	2.6	37.5	7.2	2.1	3.7	14.5	4.6	13.8	6.3	7.2	8.2	3.5	10.7	20.5	17.2	8.2	3.8	25.9	8.0	9.3	2.1	38.6	5.7	9.2	31.4	23.3	9.5	7.1	18.6	10.0	9.7	7.5	20.5	9.0	8.9	1.4	0.5	0.8	3.0	5.1	2.1	5.1	19.9	1.4	1.8	9.9	2.9	2.0	13.1	5.8	31.8	6.8	0.3	14.7	2.6	14.5	0.5	2.0	5.1	5.8	3.3	2.7	3.6	4.6	2.1	16.8	16.0	1.7	0.8	5.3	4.0	48.1	2.4	0.5	14.7	11.5	0.3	0.6	0.4	41.8	10.4	1.4	4.3	4.3	0.2	0.0	1.0	1.5	4.3	2.1	1.0	3.3	4.0	14.4	1.7	12.9	2.9	15.5	35.9	4.1	5.2	3.4	1.7	5.6	9.7	5.5	14.8	7.1	20.5	6.2	15.1	13.3	10.3	7.1	10.0	7.4	10.0	7.5	3.7	18.6	14.7	9.0	1.5	1.8	0.4	1.5	2.1	1.3	2.1	2.6	4.6	2.1	35.7	83.1	25.1	141.6	688.4	1.0	4.2	30.6	41.5	26.1	0.0	27.5	5.5	1.7	50.3	2.3	27.0	39.0	0.0	23.4	88.6	55.5	117.9	248.4	10.2	45.4	0.0	11.3	45.4	74.2	2.4	6.4	241.1	123.2	82.0	12.5	1.7	27.9	8.2	5.6	2.2	13.3	6.5	87.3	0.9	2.3	651.8	19.3	101.2	8.5	60.3
TNFRSF14	"ATAR, CD270, HVEA, HVEM, LIGHTR, TR2"	ENSG00000157873	"TNF receptor superfamily member 14"	Q92956	1	2555639-2565382	"Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity, Innate immunity"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 14.6;HDLM-2: 14.8;HHSteC: 17.3;Karpas-707: 13.6;SK-MEL-30: 28.5"									"HPA006404, CAB026150, CAB030007"	Approved					NA	NA					"CAB026150: , CAB030007: AB_2303380, HPA006404: AB_1851348"	"prognostic favorable (4.39e-5)"	"unprognostic (3.48e-2)"	"unprognostic (1.53e-2)"	"prognostic favorable (8.01e-6)"	"unprognostic (1.11e-2)"	"unprognostic (6.83e-3)"	"unprognostic (9.62e-3)"	"unprognostic (2.32e-1)"	"unprognostic (3.25e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.86e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.58e-1)"	"prognostic favorable (7.79e-6)"	15.9	24.9	4.9	38.9	2.8	11.0	21.9	2.0	4.5	16.8	36.3	3.2	18.5	36.3	15.2	20.5	13.7	12.3	36.7	12.7	4.9	2.5	19.3	20.5	30.3	33.2	3.6	5.7	12.8	7.3	3.5	9.3	8.3	3.9	21.5	8.2	44.1	20.9	22.6	5.2	8.4	41.9	14.6	4.1	36.7	16.7	5.9	2.7	23.5	10.8	10.6	25.0	15.4	17.2	18.2	9.7	30.2	25.8	8.1	25.1	14.2	1.3	0.1	0.1	2.4	5.2	2.8	0.8	0.7	2.4	1.4	1.9	0.2	14.6	0.8	0.1	2.2	1.4	1.3	0.0	0.9	0.2	14.8	0.0	8.5	0.4	2.7	17.3	1.1	10.6	2.7	1.4	0.7	0.1	2.1	3.8	0.8	1.2	13.6	1.3	0.0	4.7	1.3	0.0	4.6	1.3	3.8	0.0	4.2	0.2	2.1	0.4	0.0	0.6	0.1	28.5	0.0	0.4	0.3	9.6	0.2	0.6	0.3	0.1	11.1	2.7	0.4	2.4	1.2	1.0	3.0	15.1	8.2	17.2	25.8	14.9	16.6	18.0	14.8	9.7	18.2	17.3	14.9	30.2	8.1	24.1	8.7	25.1	14.2	4.9	2.8	2.0	4.5	4.9	2.5	3.6	5.7	3.9	2.7	17.9	38.9	54.7	30.5	14.5	1.5	6.7	56.0	26.8	31.8	33.2	0.0	1.0	3.3	16.7	0.3	48.4	116.5	0.0	29.0	0.8	16.0	32.4	50.9	18.3	78.8	0.0	34.7	35.0	60.9	1.3	19.2	62.9	43.9	111.0	60.4	15.8	19.7	86.3	13.1	30.9	0.5	19.4	17.5	0.0	0.3	11.7	1.0	77.3	72.2	38.8
TNFRSF17	"BCM, BCMA, CD269, TNFRSF13A"	ENSG00000048462	"TNF receptor superfamily member 17"	Q02223	16	11965107-11968068	"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 34.1;intestine: 17.8;lymphoid tissue: 28.8"	"Group enriched"	"Detected in some"	9	"B-cells: 29.3;Erythroid cells: 46.7;Melanocytes: 101.3"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	59	"memory B-cell: 34.1;naive B-cell: 26.9;plasmacytoid DC: 27.9"	"Group enriched"	"Detected in many"	62	"B-cells: 34.1;dendritic cells: 27.9"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 25.9;RPMI-8226: 40.8;U-266/70: 121.4;U-266/84: 60.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA		2200000				"prognostic favorable (1.35e-5)"	"unprognostic (3.41e-2)"	"unprognostic (4.00e-3)"	"unprognostic (1.41e-2)"	"unprognostic (6.47e-2)"	"prognostic favorable (1.58e-6)"	"unprognostic (9.75e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.13e-2)"	"unprognostic (7.96e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.85e-6)"	"unprognostic (2.06e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.10e-1)"	0.6	0.4	0.4	24.0	0.9	0.3	5.4	0.5	0.4	1.5	17.8	0.2	0.2	12.3	0.5	0.2	3.7	1.1	4.9	0.7	0.4	0.4	1.3	0.8	3.0	22.4	0.4	0.2	0.9	3.1	0.0	0.5	0.3	0.2	1.0	9.4	0.6	14.2	0.2	0.4	0.4	11.7	0.2	0.4	22.2	9.4	2.2	0.3	3.1	1.1	1.4	28.8	7.6	0.7	34.1	27.9	0.5	0.1	0.2	0.1	3.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	25.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	121.4	60.3	9.4	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	34.1	0.0	0.0	0.0	26.9	0.0	0.0	0.5	0.2	0.0	27.9	0.0	3.7	0.4	0.9	0.5	0.4	0.4	0.4	0.4	0.2	0.2	0.3	0.0	0.0	29.3	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	46.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	3.6	0.0	0.0	101.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	6.5	0.0	0.5	0.4	0.5	0.0	0.0	0.0	0.0
TOP1		ENSG00000198900	"DNA topoisomerase I"	P11387	20	41028818-41124487	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction"	"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Syncytiotrophoblasts: 670.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009058, HPA019039"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"		No	Yes			"Nucleoplasm, Nucleoli fibrillar center"		"CAB009058: AB_2303554, HPA019039: AB_1858187"	"unprognostic (1.46e-1)"	"unprognostic (8.65e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.92e-3)"	"unprognostic (5.05e-2)"	"unprognostic (1.49e-3)"	"prognostic unfavorable (6.42e-4)"	"unprognostic (5.86e-2)"	"unprognostic (1.51e-1)"	"unprognostic (4.60e-2)"	"unprognostic (3.74e-3)"	"unprognostic (6.51e-2)"	"unprognostic (8.65e-2)"	"unprognostic (4.70e-2)"	"unprognostic (5.14e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.29e-1)"	26.6	31.0	24.6	46.3	25.3	55.3	37.4	39.6	31.1	21.3	30.0	11.1	26.7	29.7	22.9	22.5	36.0	20.5	29.2	21.0	23.0	18.3	31.8	32.7	37.9	38.6	21.9	20.9	25.5	22.5	22.2	39.9	43.9	25.2	23.3	27.2	13.6	25.3	34.3	26.2	24.6	48.4	23.1	27.4	36.9	26.7	14.2	24.2	54.2	31.5	25.1	40.6	25.2	41.7	9.0	17.2	18.4	11.1	5.8	8.2	4.6	22.0	15.4	28.9	23.7	11.7	14.0	28.7	20.0	17.6	23.2	21.2	40.5	27.8	62.9	21.4	10.3	24.8	21.5	34.7	31.9	34.1	13.6	17.7	80.2	12.4	28.7	30.6	34.5	27.6	15.8	17.0	22.6	37.2	20.8	24.2	23.0	34.7	21.9	26.2	49.0	48.8	21.9	23.3	22.1	28.8	41.7	27.2	33.4	24.8	20.5	24.1	16.7	31.3	19.4	20.3	21.8	21.6	30.9	23.7	18.8	16.0	17.4	21.4	13.9	15.6	73.3	25.3	19.4	17.8	9.1	9.2	14.3	6.5	9.2	8.2	9.0	7.2	6.8	8.6	8.7	7.7	6.9	18.4	5.8	11.1	17.2	7.9	4.6	24.6	25.3	39.6	31.1	23.0	18.3	21.9	20.9	25.2	24.2	110.2	181.3	71.6	274.4	218.4	93.3	38.9	84.1	73.6	228.6	94.2	56.9	139.0	63.0	78.8	6.3	78.8	108.1	210.2	57.1	149.4	129.3	136.7	76.2	114.3	86.4	68.3	88.0	63.8	84.7	6.5	55.3	93.8	69.2	72.1	73.8	94.4	93.7	112.2	65.4	91.4	80.4	84.1	77.1	95.2	57.3	187.2	670.2	61.2	78.0	206.2
TP53	"LFS1, p53"	ENSG00000141510	"Tumor protein p53"	P04637	17	7661779-7687550	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters"	"Apoptosis, Biological rhythms, Cell cycle, Host-virus interaction, Necrosis, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Li-Fraumeni syndrome, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 102.6"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002973, CAB039238, CAB039239, HPA051244, HPA063532, CAB072876"	Enhanced		Enhanced	Nucleoplasm		Yes	No			Nucleoplasm		"CAB002973: AB_2206626, CAB039238: , CAB039239: , CAB072876: AB_2665731, HPA051244: AB_2681403, HPA063532: "	"unprognostic (2.29e-2)"	"unprognostic (8.83e-3)"	"unprognostic (1.26e-2)"	"prognostic favorable (1.35e-4)"	"unprognostic (9.95e-2)"	"unprognostic (4.00e-2)"	"unprognostic (2.79e-3)"	"unprognostic (4.99e-2)"	"unprognostic (2.75e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.30e-1)"	"prognostic unfavorable (5.01e-4)"	"unprognostic (1.86e-3)"	"unprognostic (7.89e-3)"	"unprognostic (8.05e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.08e-1)"	18.5	11.1	6.0	28.6	6.8	9.0	17.5	2.5	7.3	18.5	14.6	6.8	8.3	9.7	20.3	15.0	25.3	16.7	22.6	8.1	5.0	3.8	10.6	20.8	11.2	26.0	6.6	3.1	33.8	13.8	4.9	6.0	22.8	6.9	16.5	14.5	9.9	15.3	16.1	12.5	24.6	14.0	12.8	6.2	24.2	12.0	14.1	6.9	102.6	13.2	23.5	31.2	16.9	15.0	15.2	19.6	2.2	14.1	11.0	11.3	8.2	19.4	36.0	19.7	14.2	9.2	11.0	20.8	7.0	15.8	19.4	24.6	1.0	10.0	45.8	31.9	13.8	18.9	43.0	28.5	19.3	18.2	10.2	19.1	18.5	20.2	17.1	27.7	0.4	9.6	13.9	22.5	9.4	26.1	11.2	19.0	6.2	0.9	1.8	9.9	34.6	31.1	22.7	19.8	2.5	0.7	60.4	13.9	15.9	14.5	21.6	11.7	20.3	23.1	15.6	5.9	10.2	27.0	1.7	24.6	23.3	7.7	0.3	11.8	12.1	8.8	19.7	6.0	2.4	19.6	0.8	13.3	2.2	9.1	14.1	11.1	15.2	9.4	10.2	19.6	14.5	9.9	10.8	1.7	11.0	11.9	17.9	11.3	8.2	6.0	6.8	2.5	6.4	5.0	3.8	6.6	3.1	6.9	6.9	8.9	10.9	24.4	8.9	25.4	2.3	2.0	22.9	8.1	12.5	19.2	0.0	30.5	8.3	19.1	7.8	19.6	10.2	0.0	15.7	35.3	17.1	11.3	1.1	16.1	21.7	0.0	29.6	20.3	27.8	2.1	21.3	14.4	11.8	15.4	37.2	6.1	19.5	0.0	15.9	6.5	2.2	12.9	20.1	0.5	4.2	28.7	18.8	15.7	50.6	7.4
TP63	"EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L"	ENSG00000073282	"Tumor protein p63"	Q9H3D4	3	189631416-189897279	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Notch signaling pathway, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding"	"Cancer-related genes, Disease mutation, Ectodermal dysplasia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 83.2;skin 1: 54.2"	"Group enriched"	"Detected in many"	12	"Basal keratinocytes: 244.6;Suprabasal keratinocytes: 247.4"	"Group enriched"	"Detected in many"	11	"cervical cancer: 37.9;head and neck cancer: 73.3;lung cancer: 37.3;urothelial cancer: 21.2"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"HaCaT: 23.8;HBEC3-KT: 45.6;hTCEpi: 34.6;hTERT-HME1: 33.1;RT4: 50.1"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000083, HPA006288, HPA006289, HPA007009, HPA007010"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000083: AB_2207187, HPA006288: AB_1080334, HPA006289: , HPA007009: , HPA007010: AB_1080336"	"prognostic favorable (1.07e-4)"	"unprognostic (1.30e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.02e-1)"	"unprognostic (4.38e-2)"	"unprognostic (3.50e-1)"	"unprognostic (1.29e-1)"	"unprognostic (5.17e-2)"	"unprognostic (2.78e-1)"	"unprognostic (5.37e-2)"	"unprognostic (2.09e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.87e-5)"	"unprognostic (1.86e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.74e-3)"	2.9	0.1	0.2	0.7	0.1	0.0	7.2	0.1	0.2	9.5	0.1	0.1	5.7	0.0	0.3	8.0	33.7	0.3	0.0	0.2	0.1	0.1	0.4	0.1	1.2	0.2	0.1	0.2	0.1	0.1	0.0	0.3	7.8	0.8	9.6	0.0	0.3	9.0	7.8	83.2	54.2	0.1	2.7	0.6	0.1	0.1	1.2	0.0	9.0	0.4	36.7	26.1	9.6	19.2	3.7	1.3	3.0	0.9	1.2	1.2	0.2	0.6	1.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.1	0.0	0.0	23.8	0.0	45.6	0.0	0.3	0.0	0.5	0.3	0.1	0.0	0.0	0.1	0.0	34.6	0.0	33.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	50.1	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.1	0.3	0.1	0.0	0.2	2.0	0.4	1.1	0.9	0.5	0.7	3.7	1.2	1.0	0.4	1.7	0.8	0.7	3.0	1.2	0.9	1.3	0.8	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.8	0.0	0.0	4.0	0.0	20.4	244.6	0.0	0.6	0.0	1.4	5.7	0.0	0.0	18.7	0.0	0.2	0.7	0.3	0.0	0.0	0.2	1.8	1.0	2.6	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	8.5	1.0	0.0	0.0	1.2	0.0	1.1	0.0	0.0	0.0	0.5	0.3	2.6	247.4	7.4	0.0	0.0	10.1
TPM3	"NEM1, TRK"	ENSG00000143549	"Tropomyosin 3"	P06753	1	154155304-154194648	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes, Disease mutation, Nemaline myopathy, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 738.4;tongue: 203.6"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA000261, HPA009066, HPA047089, HPA053624"	Approved		Approved	"Actin filaments,Cytosol"		NA	NA		410000000	"Actin filaments"	Cytosol	"HPA000261: AB_1080339, HPA009066: AB_1080342, HPA047089: AB_2679928, HPA053624: AB_2682210"	"unprognostic (1.64e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.01e-3)"	"unprognostic (1.07e-1)"	"unprognostic (2.39e-1)"	"unprognostic (2.69e-3)"	"prognostic unfavorable (6.73e-6)"	"prognostic unfavorable (4.01e-4)"	"unprognostic (2.80e-1)"	"prognostic favorable (2.39e-5)"	"prognostic unfavorable (3.65e-4)"	"unprognostic (3.31e-2)"	"prognostic unfavorable (3.12e-5)"	"unprognostic (3.52e-2)"	"unprognostic (1.67e-1)"	"unprognostic (1.98e-2)"	"unprognostic (1.00e-2)"	10.1	7.3	10.8	10.8	10.5	26.5	6.2	6.4	11.2	4.6	9.6	3.9	3.2	7.9	4.1	27.9	18.3	4.4	6.7	29.7	7.7	8.1	7.2	6.8	9.6	12.9	8.9	5.8	4.8	23.2	3.6	3.2	6.7	5.0	5.7	10.7	4.4	20.5	2.5	738.4	5.9	8.2	5.2	7.7	11.7	6.9	5.4	4.4	6.7	9.3	203.6	28.6	6.8	4.9	38.9	72.6	154.8	95.9	35.4	54.4	146.1	66.5	33.2	42.5	27.9	36.0	47.1	42.9	57.2	52.9	75.9	57.3	61.8	62.4	50.1	46.6	64.5	30.5	61.7	42.1	60.2	81.0	34.7	22.9	61.7	32.4	41.6	28.6	90.2	82.0	35.5	33.0	66.9	51.5	34.2	116.7	36.9	46.3	53.9	93.7	39.9	70.2	93.1	95.7	113.6	72.2	60.2	29.5	71.0	54.8	50.8	29.9	56.1	43.5	57.9	56.7	59.2	80.8	107.9	87.2	66.5	48.1	63.7	89.6	45.9	75.4	67.0	60.1	68.0	105.0	70.8	64.7	154.8	54.4	87.8	48.6	38.9	48.5	51.1	72.6	30.1	36.6	47.3	74.9	35.4	95.9	36.0	52.1	146.1	10.8	10.5	6.4	11.2	7.7	8.1	8.9	5.8	5.0	4.4	577.7	334.3	245.8	179.3	132.8	84.5	62.7	104.4	335.9	395.8	92.5	29.5	101.3	89.5	278.9	51.0	357.1	327.9	0.0	302.5	278.2	125.9	137.0	499.8	99.0	485.9	287.6	135.3	175.6	320.5	131.0	43.1	444.6	145.1	764.7	164.6	45.8	384.6	230.6	28.0	130.8	59.1	19.4	73.4	34.9	54.6	125.3	85.2	233.3	208.9	254.0
TPM4		ENSG00000167460	"Tropomyosin 4"	P67936	19	16067021-16103005	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"		"Actin-binding, Muscle protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-2197: 230.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004685, HPA047089, HPA053624"	Approved		Approved	"Actin filaments,Cytosol"		NA	NA		950000000	"Actin filaments"	Cytosol	"CAB004685: AB_425723, HPA047089: AB_2679928, HPA053624: AB_2682210"	"unprognostic (1.27e-1)"	"unprognostic (1.53e-2)"	"unprognostic (3.62e-3)"	"unprognostic (7.38e-3)"	"unprognostic (3.80e-1)"	"unprognostic (2.40e-2)"	"unprognostic (3.11e-2)"	"unprognostic (2.75e-3)"	"unprognostic (1.38e-2)"	"unprognostic (3.61e-1)"	"prognostic unfavorable (3.07e-4)"	"unprognostic (1.03e-1)"	"prognostic unfavorable (1.26e-10)"	"unprognostic (3.85e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.78e-1)"	66.2	17.9	13.3	60.0	13.7	10.8	47.4	46.2	11.5	90.2	40.5	14.6	56.4	17.4	87.1	63.3	149.3	49.4	108.4	39.2	14.5	12.4	32.4	12.2	69.7	27.1	16.0	10.5	102.4	15.4	8.4	16.2	65.0	19.7	84.1	31.8	18.6	47.6	64.6	29.9	39.0	25.2	127.2	22.5	99.7	37.5	30.6	11.7	11.5	20.0	92.2	60.1	177.3	70.5	22.2	35.0	40.7	32.7	24.7	52.5	48.6	59.8	23.7	46.0	28.0	106.9	159.3	57.6	83.9	101.8	71.1	73.4	24.6	62.6	2.7	65.6	104.6	52.4	32.3	19.2	48.1	93.0	39.4	11.0	30.2	34.1	19.7	58.8	5.4	72.2	98.6	15.6	58.1	66.8	82.3	81.3	14.1	3.4	38.0	98.1	20.3	16.2	19.0	24.0	54.9	28.9	22.2	39.5	13.0	16.4	51.3	8.3	26.3	56.4	25.3	29.7	46.3	0.5	8.3	95.2	123.9	15.7	230.2	77.5	6.6	15.6	13.3	85.9	15.9	41.9	40.7	30.1	2.2	34.8	32.7	26.3	22.2	26.9	31.2	35.0	18.8	7.8	18.3	35.2	24.7	16.2	27.4	52.5	48.6	13.3	13.7	46.2	11.5	14.5	12.4	16.0	10.5	19.7	11.7	372.2	149.0	112.7	891.9	382.9	46.3	46.3	96.8	158.0	326.4	230.3	9.8	212.0	11.6	660.1	53.8	384.6	203.3	0.0	501.5	677.9	318.1	567.0	235.4	1.9	313.9	4.8	90.0	275.0	103.4	37.2	160.2	324.4	135.0	331.0	106.2	5.7	698.7	90.9	514.4	15.6	10.7	329.8	423.9	12.0	11.3	300.5	475.8	117.4	88.9	901.5
TPR		ENSG00000047410	"Translocated promoter region, nuclear basket protein"	P12270	1	186311652-186375693	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Cell cycle, Cell division, Mitosis, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"Spermatocytes: 640.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019661, HPA019663, HPA024336"	Enhanced		Enhanced	"Nuclear membrane"		NA	NA			"Nuclear membrane"		"HPA019661: AB_1858215, HPA019663: AB_1858216, HPA024336: AB_1858217"	"unprognostic (4.51e-2)"	"unprognostic (9.87e-3)"	"unprognostic (2.48e-1)"	"unprognostic (7.56e-2)"	"unprognostic (9.88e-3)"	"prognostic favorable (4.71e-4)"	"prognostic unfavorable (1.06e-4)"	"unprognostic (1.71e-1)"	"unprognostic (3.71e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.63e-2)"	"unprognostic (1.31e-3)"	"unprognostic (3.75e-1)"	"unprognostic (4.19e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.98e-2)"	21.5	17.3	14.3	26.7	21.3	21.6	19.0	24.4	17.1	21.7	24.2	7.3	27.1	12.9	20.8	23.5	18.5	16.9	16.8	28.3	13.8	10.5	18.7	20.6	17.9	20.4	14.1	16.6	24.7	17.8	44.2	29.1	29.7	15.1	22.2	17.7	9.1	20.2	30.1	33.1	20.5	21.1	21.2	16.4	26.1	18.8	35.0	17.8	39.5	21.7	19.7	21.4	25.1	19.1	19.1	19.8	50.3	15.2	10.7	16.9	5.2	21.6	18.7	28.1	16.3	22.6	20.2	29.6	24.9	16.7	17.6	16.4	28.2	18.5	25.4	19.3	16.9	12.1	28.4	21.1	17.0	21.8	19.0	23.1	33.8	30.3	19.7	12.1	36.0	22.2	15.4	10.3	26.5	20.6	16.3	20.7	14.6	40.7	22.9	18.7	18.7	17.9	9.6	30.9	19.8	6.5	21.2	22.0	22.0	14.4	26.1	15.3	24.3	29.0	19.3	15.6	40.1	21.4	23.0	29.1	17.6	16.8	19.4	30.1	25.1	29.3	23.2	11.3	18.4	15.7	29.5	12.0	21.9	15.8	10.0	13.3	15.2	13.8	12.7	6.8	19.1	16.9	11.7	50.3	10.7	15.2	19.8	15.3	5.2	14.3	21.3	24.4	17.1	13.8	10.5	14.1	16.6	15.1	17.8	202.5	98.3	78.9	89.1	89.9	87.4	160.6	35.7	133.8	120.6	55.8	74.6	117.3	19.9	88.2	106.7	100.9	41.3	23.3	65.3	89.1	87.0	62.9	77.5	34.3	63.0	93.8	65.1	57.1	60.2	23.6	116.2	74.5	52.3	147.9	49.2	93.4	74.7	52.6	110.3	23.7	104.0	129.4	82.9	640.0	239.5	86.7	126.1	97.0	64.6	75.6
TRAF7	"DKFZp586I021, MGC7807, RFWD1, RNF119"	ENSG00000131653	"TNF receptor associated factor 7"	Q6Q0C0	16	2155698-2178129	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"Apoptosis, Transcription, Transcription regulation, Ubl conjugation pathway"	Transferase	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041229	Approved		Supported	"Vesicles,Plasma membrane"		NA	NA			Vesicles	"Plasma membrane"	"HPA041229: AB_10794194"	"unprognostic (1.94e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.13e-1)"	"unprognostic (4.23e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.65e-2)"	"unprognostic (2.77e-3)"	"unprognostic (7.08e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.08e-1)"	"unprognostic (9.23e-2)"	"unprognostic (6.07e-2)"	"unprognostic (2.99e-2)"	"unprognostic (2.43e-1)"	"unprognostic (8.48e-2)"	16.0	18.2	18.3	22.3	20.6	28.5	39.1	28.7	25.6	22.1	29.4	9.1	21.1	37.3	20.4	18.3	32.9	21.9	36.9	21.0	18.3	14.8	21.3	47.3	18.3	40.9	13.4	14.7	19.3	41.6	17.7	20.3	19.5	12.8	16.2	16.9	13.0	24.4	23.1	25.5	32.2	37.8	28.8	14.1	21.4	25.1	13.2	10.6	26.1	20.3	30.9	21.9	21.9	28.9	6.7	12.3	7.7	13.9	3.0	7.1	5.2	20.7	26.6	15.2	27.2	15.8	29.8	17.9	16.0	20.2	18.9	17.1	32.3	26.8	13.3	19.0	20.4	12.1	24.4	14.2	28.4	7.2	21.0	18.2	19.0	35.4	24.7	20.9	20.2	27.6	29.5	23.8	18.2	23.9	15.6	36.5	26.4	20.3	18.0	18.0	47.5	20.7	23.5	29.9	28.7	13.0	38.7	25.3	26.7	15.2	11.2	30.7	25.5	13.4	25.8	17.5	8.3	29.3	24.9	27.5	23.0	32.4	21.4	17.4	26.1	19.3	17.6	13.1	13.1	17.8	3.7	10.0	7.7	5.4	13.9	5.0	6.7	5.3	5.7	12.3	4.9	3.8	4.5	6.9	3.0	9.4	6.0	7.1	5.2	18.3	20.6	28.7	25.6	18.3	14.8	13.4	14.7	12.8	10.6	0.0	8.6	11.9	15.5	25.5	14.6	3.4	17.8	4.0	4.5	14.0	5.9	20.5	14.9	35.4	3.8	23.9	60.0	0.0	51.6	30.1	20.0	27.8	9.2	26.1	37.6	35.0	32.6	23.4	38.3	9.1	23.0	18.8	10.1	35.1	35.9	10.5	45.1	40.3	20.8	18.9	8.9	6.5	16.0	4.8	21.5	28.4	22.3	12.9	33.8	29.6
TRIM24	"hTIF1, RNF82, TIF1, Tif1a"	ENSG00000122779	"Tripartite motif containing 24"	O15164	7	138460334-138589993	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"AF22: 43.3;HMC-1: 58.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043495, HPA061717"	Approved		Enhanced	Nucleoplasm	"Intracellular and membrane"	NA	NA			Nucleoplasm		"HPA043495: AB_10962915, HPA061717: AB_2684592"	"unprognostic (2.40e-1)"	"unprognostic (9.52e-3)"	"unprognostic (2.23e-1)"	"unprognostic (3.96e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (9.94e-4)"	"prognostic favorable (6.57e-4)"	"unprognostic (4.01e-2)"	"unprognostic (8.93e-2)"	"unprognostic (2.53e-1)"	"unprognostic (2.02e-1)"	"unprognostic (4.62e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.25e-2)"	"unprognostic (5.54e-2)"	"unprognostic (6.34e-2)"	10.3	31.4	10.4	11.2	10.6	8.8	8.8	8.5	10.7	9.4	9.2	14.6	5.7	9.4	9.0	8.5	11.3	7.0	10.3	9.7	8.4	8.5	9.6	21.5	10.7	8.5	10.5	8.0	29.9	11.6	20.7	7.3	13.5	8.4	13.6	9.1	7.5	10.1	7.1	16.0	9.8	14.1	9.4	8.0	8.5	10.8	24.1	11.3	34.8	8.8	9.2	8.9	11.3	11.2	1.3	1.9	3.7	2.5	2.2	2.7	0.8	4.2	5.2	43.3	12.5	2.9	2.7	3.3	3.9	4.2	3.1	3.0	8.2	3.9	8.1	3.9	3.8	6.4	2.3	21.0	3.3	4.6	6.2	5.2	17.9	3.9	25.2	3.9	13.9	58.5	2.4	3.5	2.6	4.1	2.2	7.3	4.5	20.2	5.0	3.7	8.2	23.7	12.6	16.5	22.1	4.7	18.8	5.1	6.8	6.9	12.6	9.0	20.5	7.3	6.6	2.1	15.7	4.5	9.2	3.1	3.6	3.0	6.3	5.4	4.6	5.0	13.8	6.0	9.2	5.2	1.1	2.3	3.6	2.2	2.5	0.4	0.9	1.9	1.2	1.9	1.3	1.8	2.0	3.7	2.2	1.1	1.4	2.7	0.8	10.4	10.6	8.5	9.7	8.4	8.5	10.5	8.0	8.4	11.3	47.6	42.2	4.5	11.6	12.4	13.3	38.8	15.3	17.4	20.5	7.0	15.7	25.9	5.0	6.3	45.5	13.2	8.0	0.0	10.6	11.7	11.8	10.1	38.3	28.4	9.2	38.1	9.7	14.1	11.2	28.3	13.0	12.4	13.5	4.6	8.2	28.0	10.1	9.3	15.2	7.7	20.8	12.9	9.9	43.1	8.5	10.3	18.5	10.2	15.5	12.2
TRIM27	"RFP, RNF76"	ENSG00000204713	"Tripartite motif containing 27"	P14373	6	28903002-28923989	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Transport, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048684, HPA053408"	Approved		Approved	Nucleoplasm,Nucleoli		NA	NA			Nucleoli	Nucleoplasm	"HPA048684: AB_2680493, HPA053408: AB_2682139"	"unprognostic (1.57e-1)"	"unprognostic (1.48e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.14e-2)"	"unprognostic (1.70e-2)"	"unprognostic (2.56e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.17e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.12e-3)"	"unprognostic (4.76e-3)"	"unprognostic (1.16e-2)"	"prognostic unfavorable (3.50e-6)"	"unprognostic (1.27e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.47e-1)"	"prognostic favorable (2.71e-4)"	11.5	10.6	8.8	25.5	9.7	7.9	9.3	10.1	12.2	11.2	10.2	8.7	20.2	23.8	12.1	13.2	7.8	12.1	11.4	8.1	8.2	9.6	10.1	22.5	10.4	17.4	12.6	8.3	14.7	31.0	7.4	13.9	13.7	10.6	13.7	4.6	7.7	17.0	25.2	12.2	9.7	19.4	9.2	8.4	18.6	18.5	9.2	9.2	16.7	12.5	7.9	12.1	9.9	11.8	12.5	12.5	13.8	13.9	11.2	15.9	13.8	3.3	2.3	1.0	6.1	0.8	1.7	0.7	4.6	1.1	1.4	1.7	1.7	1.4	7.7	8.0	1.3	3.0	7.4	1.1	2.7	0.1	3.0	13.1	11.0	0.5	2.3	1.3	4.6	1.7	1.3	1.7	1.2	0.5	0.1	1.2	8.0	10.6	3.3	0.4	1.3	6.4	2.4	0.0	2.1	7.4	9.1	7.0	14.3	1.1	1.1	3.3	13.1	5.6	3.4	7.4	0.3	3.3	3.6	4.0	3.5	7.1	6.3	2.7	12.2	14.6	12.2	1.8	11.7	5.2	12.6	13.8	8.8	12.7	13.9	15.9	12.5	12.6	14.4	12.5	10.5	11.8	12.1	13.8	11.2	12.1	9.8	10.4	13.8	8.8	9.7	10.1	12.2	8.2	9.6	12.6	8.3	10.6	9.2	14.9	21.9	30.9	26.1	25.2	11.0	14.9	30.6	24.1	19.4	27.9	15.7	41.3	18.3	35.7	9.4	29.1	15.7	23.3	37.7	49.1	24.4	31.4	20.8	36.5	36.4	7.9	26.5	25.2	23.8	4.4	22.2	24.5	8.5	25.2	24.4	9.8	42.8	19.5	17.3	24.1	13.1	19.4	21.1	5.1	11.2	17.1	38.1	26.2	24.4	24.0
TRIM33	"FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA"	ENSG00000197323	"Tripartite motif containing 33"	Q9UPN9	1	114392777-114511160	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Early spermatids: 155.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 49.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004345	Supported		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA004345: AB_1858287"	"unprognostic (8.90e-2)"	"unprognostic (5.86e-2)"	"prognostic favorable (6.20e-4)"	"unprognostic (1.09e-2)"	"unprognostic (8.42e-3)"	"prognostic favorable (8.93e-4)"	"unprognostic (1.34e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.75e-2)"	"unprognostic (4.58e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.27e-2)"	"unprognostic (4.84e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.68e-1)"	15.2	12.8	16.9	18.4	19.9	27.1	17.1	38.3	21.8	16.9	14.3	11.0	21.9	10.9	19.8	38.3	16.4	15.0	15.6	10.8	18.1	12.5	17.3	15.0	14.3	15.2	12.1	18.0	19.8	15.7	21.8	22.4	27.2	15.2	16.5	13.0	10.7	16.4	19.1	14.3	19.5	14.8	20.2	12.9	14.9	14.1	29.0	16.3	20.5	17.9	9.8	16.6	17.9	28.7	3.4	4.0	12.2	2.8	4.7	4.4	1.0	13.1	7.1	13.4	10.0	5.7	6.0	22.9	6.7	7.2	9.4	10.0	8.0	5.6	14.1	7.0	7.8	6.1	7.6	12.2	7.8	13.0	10.6	7.2	13.6	9.4	9.3	6.3	17.1	11.3	5.7	5.8	11.1	11.4	7.2	7.8	12.0	16.9	10.0	8.9	49.4	17.2	7.3	18.1	5.0	7.2	14.9	20.5	4.6	6.7	20.7	9.3	9.8	12.7	15.4	12.1	9.0	7.0	9.4	8.8	6.5	10.6	15.1	9.4	7.0	6.5	14.7	9.2	10.0	18.5	12.2	1.6	7.4	3.5	1.8	3.1	3.4	3.7	3.7	2.0	2.2	2.9	4.4	4.8	4.7	2.8	4.0	2.0	1.0	16.9	19.9	38.3	21.8	18.1	12.5	12.1	18.0	15.2	16.3	17.9	29.5	19.1	25.9	46.9	71.6	22.0	25.5	10.7	25.0	52.4	92.3	49.7	1.7	18.3	155.1	31.1	23.6	23.3	20.5	27.8	32.1	38.2	36.9	40.5	26.3	25.4	50.1	37.4	44.7	78.9	45.5	39.2	18.6	17.2	31.4	33.5	25.3	32.6	34.6	12.6	58.2	32.3	23.7	54.0	29.6	48.4	73.3	35.5	28.9	48.8
TRIP11	"CEV14, GMAP-210, GMAP210, Trip230"	ENSG00000100815	"Thyroid hormone receptor interactor 11"	Q15643	14	91965991-92040896	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, Dwarfism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002570, HPA070684"	Supported		Enhanced	"Nucleoplasm,Golgi apparatus"		NA	NA			"Golgi apparatus"	Nucleoplasm	"HPA002570: AB_1078995, HPA070684: AB_2686295"	"unprognostic (1.65e-1)"	"unprognostic (2.81e-2)"	"unprognostic (7.14e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.89e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.49e-3)"	"unprognostic (1.60e-1)"	"unprognostic (1.46e-1)"	"unprognostic (7.33e-3)"	"unprognostic (2.04e-1)"	"unprognostic (1.21e-1)"	"prognostic favorable (1.78e-6)"	"unprognostic (1.78e-1)"	"unprognostic (5.08e-1)"	"unprognostic (7.74e-2)"	"unprognostic (5.55e-2)"	13.0	15.0	10.5	10.8	12.5	7.7	12.1	18.5	14.1	17.4	13.0	8.8	15.2	11.1	13.3	12.7	14.7	11.4	11.2	12.9	9.2	6.7	15.5	16.1	10.6	9.4	12.2	11.1	16.0	27.1	27.1	34.9	24.4	15.2	14.5	11.0	9.4	15.1	15.3	24.0	12.4	15.9	11.2	10.7	15.2	16.2	14.0	13.5	16.4	18.4	11.1	11.9	15.8	12.5	20.0	12.7	17.0	13.0	12.1	14.1	3.9	12.5	12.8	8.3	8.8	14.7	22.8	12.6	20.0	15.4	10.0	11.4	7.7	20.5	8.8	14.8	17.6	7.8	16.6	10.9	9.7	21.8	13.4	3.3	9.9	11.5	7.3	11.2	11.6	9.9	8.7	11.9	17.6	15.1	11.1	15.8	4.9	6.5	10.2	15.5	17.6	6.6	2.9	3.8	12.3	9.2	8.2	16.0	4.4	8.9	20.6	6.1	5.5	16.2	9.5	6.2	8.8	20.8	5.9	20.9	11.6	8.2	12.0	9.0	9.1	13.9	8.0	13.6	6.6	14.5	8.2	8.8	17.0	13.3	8.0	12.8	11.8	14.1	12.1	6.9	20.0	13.5	14.1	8.7	12.1	13.0	12.7	12.2	3.9	10.5	12.5	18.5	14.1	9.2	6.7	12.2	11.1	15.2	13.5	50.6	65.6	24.1	27.5	14.7	56.7	99.6	35.7	71.0	62.6	36.6	68.7	34.2	14.9	55.0	10.9	42.7	24.5	0.0	40.6	23.8	31.0	32.3	35.9	30.6	22.0	41.3	30.9	30.7	25.7	8.5	57.5	21.2	6.8	33.3	38.0	54.1	40.4	28.1	50.9	21.4	64.7	58.2	23.7	107.2	64.1	14.9	60.6	21.0	28.1	33.1
TRRAP	"PAF400, TR-AP, Tra1"	ENSG00000196367	"Transformation/transcription domain associated protein"	Q9Y4A5	7	98877933-99050831	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator"	"Autism spectrum disorder, Cancer-related genes, Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054376			Supported	"Nucleoplasm,Golgi apparatus"		NA	NA			Nucleoplasm	"Golgi apparatus"	"HPA054376: AB_2682467"	"unprognostic (2.10e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.21e-1)"	"unprognostic (4.35e-2)"	"unprognostic (2.02e-1)"	"unprognostic (2.02e-1)"	"prognostic unfavorable (8.77e-4)"	"unprognostic (1.40e-2)"	"unprognostic (2.39e-2)"	"unprognostic (3.99e-2)"	"unprognostic (9.45e-2)"	"unprognostic (7.02e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.96e-1)"	9.6	14.2	10.7	18.4	13.4	18.8	14.9	22.8	14.4	14.1	11.3	15.4	10.0	10.6	15.1	10.1	11.3	17.1	11.4	11.4	10.7	9.5	10.8	11.0	13.1	17.1	12.4	9.4	22.4	16.2	26.7	29.9	12.2	9.6	11.8	10.2	13.7	11.8	16.7	11.7	16.9	13.3	16.9	14.2	14.5	11.5	19.3	12.1	37.1	16.6	7.7	19.3	12.8	11.5	2.7	3.1	5.7	0.9	1.3	2.7	0.3	12.3	14.4	15.0	12.7	7.4	7.6	7.5	5.4	7.3	8.6	8.3	11.2	5.5	17.2	8.7	10.1	16.6	6.4	15.5	7.5	9.5	9.9	15.2	10.5	10.5	6.5	5.5	18.8	7.8	7.1	4.4	14.0	12.0	6.0	11.0	15.6	17.9	32.7	8.0	23.8	23.0	7.5	11.4	7.5	8.9	17.0	8.6	13.1	4.5	13.8	11.9	14.8	13.8	9.1	4.6	12.8	4.6	8.5	11.5	11.6	16.9	15.3	12.7	13.5	15.3	25.5	8.2	9.7	11.4	5.7	0.9	0.6	1.5	0.6	2.7	2.0	2.7	1.3	0.9	2.7	1.9	1.8	2.9	1.3	0.9	3.1	2.0	0.3	10.7	13.4	22.8	14.4	10.7	9.5	12.4	9.4	9.6	12.1	14.9	13.9	4.5	3.7	14.1	13.1	9.2	5.1	4.0	10.3	14.0	25.5	7.7	0.0	6.7	3.0	9.0	6.1	0.0	5.7	4.3	8.0	6.5	5.7	10.9	7.0	20.6	12.1	9.2	8.7	4.0	8.1	8.4	8.5	5.4	10.6	5.8	7.9	3.5	8.1	4.3	8.5	0.0	6.1	14.4	8.0	18.6	9.2	9.2	9.5	6.0
TSC1	"hamartin, KIAA0243, LAM, TSC"	ENSG00000165699	"TSC complex subunit 1"	Q92574	9	132891348-132946874	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Chaperone	"Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Late spermatids: 99.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB011568, CAB012481, HPA074132"	Supported		Enhanced	Cytosol		NA	NA			Cytosol		"CAB011568: AB_732752, CAB012481: , HPA074132: AB_2686666"	"unprognostic (1.88e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.40e-2)"	"unprognostic (2.56e-1)"	"unprognostic (6.67e-2)"	"unprognostic (4.23e-3)"	"prognostic unfavorable (6.03e-6)"	"unprognostic (1.96e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.24e-1)"	"prognostic favorable (8.01e-4)"	"unprognostic (1.84e-2)"	"prognostic favorable (7.91e-4)"	"unprognostic (9.49e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.16e-1)"	10.4	13.6	15.8	8.8	26.8	13.6	11.4	32.1	28.3	12.7	10.8	22.6	7.9	9.1	14.6	12.3	10.9	12.4	9.7	17.6	13.0	12.1	13.1	9.4	11.6	10.2	12.5	15.1	21.2	12.1	15.9	19.5	15.8	21.1	11.8	12.6	13.1	11.6	10.4	20.0	13.8	11.2	14.2	12.4	13.7	10.6	36.2	14.9	10.5	16.2	8.6	14.2	10.9	11.1	2.8	3.1	4.8	7.0	4.9	7.1	2.6	6.2	7.4	10.1	8.3	10.4	9.9	19.0	8.4	13.6	8.8	8.7	12.5	7.3	14.6	3.7	16.0	13.4	16.2	11.9	8.5	9.0	7.0	6.3	4.6	14.7	10.2	12.4	6.8	6.3	10.7	6.4	11.2	13.8	8.8	10.1	13.0	8.1	8.0	10.0	11.5	6.1	5.8	13.9	9.2	6.2	7.4	19.1	8.2	3.9	8.2	5.1	7.8	9.8	6.1	4.8	12.5	11.1	4.0	10.4	14.4	8.7	8.6	5.7	4.5	10.0	14.2	8.2	4.0	6.4	4.1	4.4	4.8	6.5	7.0	7.1	1.9	3.6	5.7	3.1	2.8	5.9	5.3	1.7	4.9	3.2	1.8	5.7	2.6	15.8	26.8	32.1	28.3	13.0	12.1	12.5	15.1	21.1	14.9	20.8	25.6	10.8	4.8	6.6	26.0	26.6	7.6	21.4	12.5	10.4	35.3	12.8	11.6	9.5	39.6	8.7	6.3	0.0	6.2	19.5	9.1	6.5	8.1	5.0	7.8	23.8	16.1	12.3	8.7	99.6	14.4	7.4	11.8	8.2	7.9	10.4	10.9	8.4	10.6	7.5	25.2	19.4	8.0	18.9	17.8	7.5	17.6	7.1	9.9	6.5
TSC2	"LAM, PPP1R160, TSC4, tuberin"	ENSG00000103197	"TSC complex subunit 2"	P49815	16	2047465-2089487	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"GTPase activation"	"Cancer-related genes, Disease mutation, Epilepsy, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cone photoreceptor cells: 88.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002225, HPA030409, HPA049679"	Approved		Enhanced	Cytosol		NA	NA			Cytosol		"CAB002225: AB_564043, HPA030409: AB_10602483, HPA049679: AB_2680848"	"unprognostic (2.80e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.60e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.03e-3)"	"unprognostic (2.04e-2)"	"unprognostic (6.05e-3)"	"unprognostic (3.43e-1)"	"unprognostic (8.94e-2)"	"prognostic favorable (5.06e-4)"	"unprognostic (4.32e-2)"	"unprognostic (3.91e-2)"	"unprognostic (2.14e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.51e-2)"	"unprognostic (8.96e-2)"	13.9	11.9	16.9	12.4	20.0	10.9	13.2	35.1	26.9	20.5	17.0	19.4	17.9	14.0	20.1	12.2	13.0	18.6	15.0	14.0	13.3	8.8	11.8	9.8	12.7	10.1	13.8	14.7	21.1	16.1	20.0	18.1	10.6	14.6	13.8	10.8	16.7	22.9	19.6	31.7	14.5	13.2	13.5	11.4	12.9	16.6	21.4	12.9	14.1	20.1	11.3	10.9	18.0	14.0	4.7	5.6	7.7	4.9	3.6	7.0	3.7	7.2	11.6	16.1	18.2	19.2	16.2	13.6	17.4	11.9	13.1	11.2	13.9	13.8	10.9	15.5	14.3	6.1	12.0	9.6	12.6	9.8	8.3	15.8	10.3	22.5	5.7	13.2	12.8	12.5	19.1	8.0	10.6	7.9	15.8	12.3	7.9	10.0	9.8	11.6	14.4	15.2	3.7	16.7	5.4	11.4	24.2	17.6	13.9	5.3	6.5	12.2	23.1	24.8	16.4	8.8	16.7	15.0	9.5	19.4	13.8	9.4	12.3	8.8	21.9	21.8	21.8	5.7	5.2	16.3	6.2	4.9	5.4	7.0	4.7	6.7	4.4	4.4	4.1	5.6	4.7	3.1	4.8	7.7	3.6	3.7	1.5	3.2	3.7	16.9	20.0	35.1	26.9	13.3	8.8	13.8	14.7	14.6	12.9	23.8	17.6	14.9	7.2	8.1	44.2	38.9	20.4	9.4	10.3	19.2	88.4	10.1	3.3	12.8	11.0	19.5	25.8	0.0	12.2	6.5	14.6	9.4	8.1	29.2	9.8	42.9	31.2	34.4	10.5	22.4	26.2	16.6	8.5	7.2	23.8	24.1	15.9	17.5	24.4	6.7	69.1	12.9	11.8	19.4	39.6	8.5	7.8	20.0	24.7	9.2
TSHR	LGR3	ENSG00000165409	"Thyroid stimulating hormone receptor"	P16473	14	80954989-81146302	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"thyroid gland: 158.0"	"Cell type enhanced"	"Detected in some"	15	"Club cells: 2.3;Intestinal endocrine cells: 1.7"	"Cancer enriched"	"Detected in some"	116	"thyroid cancer: 100.4"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"T-reg: 9.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 9.9"	"Cell line enhanced"	"Detected in some"		"JURKAT: 34.0;MOLT-4: 13.3;SCLC-21H: 13.7;U-266/70: 6.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB000473	Approved				"Intracellular and membrane"	NA	NA					"CAB000473: AB_2303782"	"unprognostic (3.36e-3)"	"unprognostic (1.31e-3)"	"unprognostic (1.02e-2)"	"unprognostic (4.17e-6)"	"unprognostic (3.01e-3)"	"unprognostic (1.85e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.66e-2)"	"unprognostic (3.39e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.70e-1)"	"unprognostic (7.11e-3)"	"unprognostic (5.08e-7)"	"unprognostic (1.32e-1)"	"unprognostic (7.40e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.66e-1)"	0.1	0.2	0.1	0.2	0.4	0.3	0.2	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.3	0.3	0.5	0.1	0.0	0.8	0.2	0.0	0.1	0.3	0.1	0.0	0.2	0.2	0.1	0.1	0.1	27.3	158.0	0.2	0.4	0.1	0.1	1.8	0.8	1.3	0.3	0.1	9.9	0.1	0.2	0.1	0.4	0.3	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.2	0.3	0.4	0.1	0.1	0.2	0.1	0.5	0.0	0.1	0.2	0.1	0.2	0.4	0.2	0.0	0.1	0.2	0.2	0.0	0.1	0.2	0.1	0.0	34.0	0.2	0.4	0.1	0.3	13.3	0.3	0.3	0.1	0.1	0.5	0.1	0.5	0.0	0.3	13.7	0.2	0.1	0.1	0.1	0.3	0.2	0.0	0.1	0.4	0.3	0.3	0.2	6.7	3.5	0.3	0.2	0.1	0.2	0.6	0.2	0.2	0.2	0.1	0.2	1.0	0.8	0.5	0.1	1.8	0.3	0.2	1.3	0.1	0.3	0.8	9.9	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.1	0.0	0.5	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0
U2AF1	"RN, RNU2AF1, U2AF35, U2AFBP"	ENSG00000160201	"U2 small nuclear RNA auxiliary factor 1"	Q01081	21	43092956-43107587	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	RNA-binding	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"Basal keratinocytes: 437.9;Melanocytes: 192.3;Suprabasal keratinocytes: 379.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"HPA044833, HPA052083"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA044833: AB_10960990, HPA052083: AB_2681720"	"unprognostic (1.10e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.98e-2)"	"unprognostic (2.87e-2)"	"unprognostic (1.36e-1)"	"unprognostic (8.06e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.29e-4)"	"unprognostic (4.81e-4)"	"unprognostic (3.42e-2)"	"unprognostic (2.31e-3)"	"unprognostic (8.85e-2)"	"unprognostic (2.14e-6)"	"unprognostic (1.08e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.26e-2)"	20.0	15.1	20.8	19.2	21.1	48.5	61.0	25.6	20.8	16.1	21.5	9.7	12.3	17.6	28.8	26.5	19.3	27.6	17.1	19.5	19.7	15.8	14.6	17.1	35.2	33.5	25.7	2.9	22.1	48.3	15.3	27.8	21.2	20.8	23.9	13.7	9.6	44.5	19.8	33.0	16.6	20.4	38.7	23.9	21.0	17.5	33.9	22.7	20.6	27.3	26.5	20.0	22.9	31.7	58.4	82.8	81.2	54.1	33.1	55.5	53.8	25.3	27.8	15.1	11.4	8.9	6.4	35.5	22.0	15.3	18.0	16.1	64.6	9.3	43.4	12.0	14.3	24.7	12.4	31.6	23.4	9.3	34.0	71.5	70.2	14.2	24.3	21.7	30.2	17.3	8.8	14.4	29.1	18.6	6.5	14.8	26.6	38.5	19.6	12.5	47.7	24.9	33.5	32.1	21.7	32.1	41.2	14.6	21.8	12.0	10.7	23.0	17.6	23.6	14.3	11.7	4.3	17.4	17.6	18.5	15.0	20.4	13.5	23.0	26.3	30.9	35.9	14.4	55.6	23.1	48.4	52.6	50.9	42.2	52.5	41.4	55.9	46.4	42.1	54.1	58.4	46.4	44.8	81.2	33.1	54.1	82.8	55.5	53.8	20.8	21.1	25.6	20.8	19.7	15.8	25.7	2.9	20.8	22.7	17.9	17.8	8.9	29.0	437.9	21.8	2.8	7.6	21.4	27.3	1.8	41.2	16.3	1.7	4.5	1.9	22.2	22.9	0.0	5.1	15.6	26.8	31.7	26.7	17.8	19.6	17.5	17.5	28.8	21.4	2.0	17.0	27.1	192.3	2.8	16.7	13.0	4.0	17.5	21.2	2.8	59.6	6.5	29.2	14.4	17.7	379.0	19.9	20.0	22.2	30.1
UBR5	"DD5, EDD, EDD1, HYD, KIAA0896"	ENSG00000104517	"Ubiquitin protein ligase E3 component n-recognin 5"	O95071	8	102253012-102412841	"Cancer-related genes, Enzymes, Predicted intracellular proteins"	"DNA damage, DNA repair, Host-virus interaction, Ubl conjugation pathway"	Transferase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA053688			Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA053688: AB_2682230"	"unprognostic (3.79e-3)"	"unprognostic (7.44e-3)"	"unprognostic (1.25e-1)"	"unprognostic (2.10e-2)"	"unprognostic (2.44e-2)"	"unprognostic (1.41e-1)"	"prognostic unfavorable (1.26e-4)"	"unprognostic (2.50e-1)"	"unprognostic (1.75e-2)"	"unprognostic (7.54e-3)"	"unprognostic (8.29e-3)"	"unprognostic (3.84e-2)"	"unprognostic (6.64e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.69e-2)"	"unprognostic (2.45e-1)"	27.0	16.7	27.1	29.5	31.7	30.3	29.2	40.8	32.8	24.9	25.0	19.1	21.1	14.4	26.8	24.0	23.8	22.0	17.6	22.7	25.5	15.3	17.9	17.0	24.2	29.6	21.9	20.6	29.7	22.2	32.4	25.5	25.0	23.6	20.2	17.1	19.7	22.9	21.8	39.9	29.7	22.4	29.3	17.5	21.9	21.1	39.7	28.3	37.9	20.3	15.9	27.0	27.5	28.6	5.0	4.0	6.3	5.5	2.4	7.1	2.1	23.6	10.6	20.5	10.4	20.2	20.6	18.9	17.9	15.8	14.0	12.3	10.6	15.9	47.1	15.5	16.7	9.2	14.4	17.5	15.5	19.7	20.4	8.6	39.3	14.5	19.0	18.0	12.2	21.7	23.6	15.5	14.4	25.2	16.0	16.8	13.5	18.9	26.8	13.7	21.4	31.0	14.6	15.4	22.9	12.0	18.1	12.1	22.3	12.8	23.2	15.1	12.6	12.5	12.1	12.4	18.6	19.6	13.0	16.8	15.0	17.5	13.4	12.4	14.4	13.8	48.5	14.8	19.1	12.1	3.1	3.4	5.0	5.6	3.4	5.6	5.0	6.0	5.9	4.0	3.9	4.8	7.1	6.3	2.4	5.5	3.6	7.1	2.1	27.1	31.7	40.8	32.8	25.5	15.3	21.9	20.6	23.6	28.3	23.8	27.7	29.8	38.5	46.4	48.4	35.8	5.1	40.2	63.7	29.6	64.8	19.1	8.3	15.1	25.0	38.3	17.3	0.0	13.1	14.9	48.2	37.7	28.9	15.8	15.4	54.0	32.0	23.4	29.4	20.2	36.8	28.9	42.2	27.1	17.9	31.5	16.2	17.3	34.3	6.7	44.0	12.9	38.7	64.7	30.4	53.3	58.2	30.5	17.7	46.9
USP6	"HRP1, Tre-2, TRE17, Tre2, TRESMCR"	ENSG00000129204	"Ubiquitin specific peptidase 6"	P35125	17	5116438-5175034	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"	"Calmodulin-binding, Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	9	"skeletal muscle: 18.2;testis: 29.0"	"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 19.3;Erythroid cells: 23.3;Spermatocytes: 19.2"	"Cancer enriched"	"Detected in single"	14	"testis cancer: 2.8"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA046969			Uncertain	Vesicles		NA	NA			Vesicles		"HPA046969: "	"unprognostic (3.89e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.50e-1)"	"unprognostic (1.85e-1)"	"unprognostic (9.32e-2)"	"unprognostic (3.50e-3)"	"unprognostic (1.29e-1)"	"unprognostic (1.67e-2)"	"unprognostic (3.45e-2)"	"unprognostic (2.46e-2)"	"unprognostic (7.91e-4)"	"unprognostic (6.28e-3)"	"unprognostic (3.24e-4)"	"unprognostic (3.75e-2)"	"unprognostic (3.13e-1)"	"unprognostic (2.71e-1)"	"unprognostic (7.09e-4)"	0.3	0.3	0.3	0.3	0.6	0.2	0.4	0.5	0.5	0.3	0.5	0.3	1.2	0.0	0.6	0.6	0.3	0.5	0.4	0.3	0.3	0.1	0.3	0.3	0.3	0.3	0.3	0.3	2.6	0.3	0.0	0.4	0.4	0.3	0.4	0.1	0.3	0.3	0.3	18.2	0.6	0.7	0.9	0.3	0.3	0.0	29.0	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.9	1.2	1.9	1.0	0.2	0.4	0.1	2.2	0.9	2.2	1.6	0.4	0.2	2.3	1.9	0.1	0.6	0.4	0.8	1.0	2.2	1.6	1.2	1.9	1.0	0.7	0.8	0.5	1.5	1.3	1.7	1.3	0.9	1.2	0.5	2.8	1.1	0.5	0.1	0.2	2.5	0.3	1.8	0.5	0.3	0.5	2.5	1.8	0.7	1.5	0.7	0.1	1.4	1.9	0.2	0.5	0.7	0.9	2.1	1.0	0.1	3.3	3.7	2.1	2.2	1.2	0.9	3.2	2.0	1.4	2.0	1.6	1.5	0.0	0.1	2.6	0.1	0.4	0.9	0.4	0.3	0.2	0.6	0.3	0.3	0.3	0.9	0.3	0.4	1.9	0.2	1.0	1.2	0.1	0.1	0.3	0.6	0.5	0.3	0.3	0.1	0.3	0.3	0.3	0.3	6.0	9.6	0.5	0.9	9.6	7.9	1.6	7.6	5.3	5.7	3.5	11.8	0.5	3.3	0.0	19.3	2.9	0.0	23.3	0.0	0.8	1.5	2.4	0.0	2.6	2.3	1.6	0.0	4.9	4.9	9.4	1.7	5.7	3.3	0.0	0.0	4.7	0.1	0.0	2.5	2.8	9.8	6.5	0.6	19.2	5.5	9.2	0.6	0.7	0.0	0.9
USP8	"HumORF8, KIAA0055, SPG59, UBPY"	ENSG00000138592	"Ubiquitin specific peptidase 8"	P40818	15	50424380-50514419	"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Cell cycle, Ubl conjugation pathway"	"Hydrolase, Protease, Thiol protease"	"Cancer-related genes, Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA050215	Approved		Supported	"Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	Cytosol	"HPA050215: AB_2681054"	"unprognostic (5.81e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.58e-2)"	"unprognostic (2.35e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.96e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.08e-2)"	"unprognostic (2.94e-1)"	"unprognostic (3.99e-2)"	"prognostic favorable (1.29e-5)"	"unprognostic (4.89e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.79e-1)"	"unprognostic (1.58e-1)"	19.4	21.9	21.0	20.6	20.6	21.6	18.1	27.3	21.6	21.4	23.9	13.8	19.5	20.2	22.1	17.4	22.3	17.4	15.5	17.4	19.7	18.2	28.2	26.4	17.0	25.4	21.8	15.2	21.9	16.7	42.6	43.2	29.1	29.7	16.7	18.9	10.7	19.9	17.9	24.3	17.8	32.1	19.2	29.3	30.3	17.7	27.5	26.1	28.9	24.1	12.7	20.9	22.3	18.4	16.7	10.6	38.1	15.1	9.5	11.9	6.9	11.2	16.2	9.1	16.0	16.6	18.7	12.6	16.2	19.2	15.8	18.7	10.8	7.5	11.9	12.5	18.5	17.8	21.8	12.4	12.1	18.7	10.4	8.2	21.9	15.1	11.0	17.1	14.7	14.9	14.4	14.6	13.9	23.6	14.7	15.3	8.5	12.5	14.5	14.8	23.1	9.4	5.8	10.4	12.9	7.5	8.5	16.9	17.8	15.0	26.5	11.6	10.6	17.0	25.5	21.2	20.1	14.0	18.0	17.3	16.4	9.2	50.5	21.3	11.3	23.4	13.1	13.1	29.7	15.8	38.1	13.3	22.4	11.1	12.4	10.7	16.5	11.4	11.1	10.6	16.7	11.9	10.7	22.7	9.5	15.1	9.9	8.5	6.9	21.0	20.6	27.3	21.6	19.7	18.2	21.8	15.2	29.7	26.1	89.3	104.5	61.4	35.4	25.6	51.6	61.8	48.4	147.2	88.7	45.4	64.8	49.9	21.6	44.4	53.0	44.9	70.6	23.3	44.6	38.3	35.3	38.8	83.3	45.5	40.2	31.8	51.2	53.4	59.1	12.4	49.8	49.2	38.8	52.3	54.2	53.3	45.7	54.3	58.0	40.7	75.6	45.3	42.6	86.1	47.1	36.3	88.0	47.9	55.0	52.6
VHL	VHL1	ENSG00000134086	"Von Hippel-Lindau tumor suppressor"	P40337	3	10141008-10152220	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Cancer-related genes, Congenital erythrocytosis, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"BEWO: 54.7"									"CAB005430, HPA031631, HPA031632"	Uncertain		Enhanced	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB005430: AB_2241850, HPA031631: AB_2673968, HPA031632: AB_2673969"	"prognostic unfavorable (9.02e-5)"	"unprognostic (1.10e-1)"	"unprognostic (4.46e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.33e-1)"	"prognostic unfavorable (1.32e-5)"	"unprognostic (3.55e-1)"	"unprognostic (3.03e-2)"	"unprognostic (4.36e-2)"	"unprognostic (5.82e-3)"	"unprognostic (1.81e-2)"	"unprognostic (2.51e-1)"	"prognostic favorable (7.84e-4)"	"unprognostic (1.46e-1)"	"unprognostic (2.92e-2)"	"unprognostic (1.28e-3)"	13.8	17.4	18.1	29.2	18.4	24.3	15.4	25.8	21.4	13.3	19.8	19.3	14.5	15.9	15.1	13.6	16.4	14.3	18.9	10.5	17.1	18.5	13.7	16.3	14.6	27.9	13.5	12.3	15.2	22.5	13.8	14.6	18.8	12.8	15.1	16.6	12.5	21.8	13.7	14.8	14.0	22.3	13.4	17.0	22.6	16.2	17.9	11.2	39.2	16.9	11.5	29.3	15.4	19.1	5.4	3.9	8.0	4.1	4.4	4.3	1.7	6.8	6.6	14.6	8.9	13.6	10.5	54.7	6.1	8.7	7.8	9.2	7.8	8.6	24.3	8.3	8.2	11.0	5.9	13.5	8.5	9.6	11.6	12.2	18.9	10.8	10.7	12.9	16.6	15.2	10.6	9.7	10.3	13.0	10.4	8.9	15.3	16.8	18.5	7.6	12.4	15.8	12.2	9.8	7.4	8.5	20.1	12.9	12.2	9.5	17.8	5.5	18.3	12.8	6.8	7.3	9.2	13.4	21.1	7.7	7.7	10.4	7.2	9.5	13.2	26.9	38.8	8.6	20.0	7.0	2.6	4.1	3.3	3.8	2.5	3.6	4.1	2.9	4.3	3.9	5.4	2.5	2.7	8.0	4.4	3.2	2.4	3.1	1.7	18.1	18.4	25.8	21.4	17.1	18.5	13.5	12.3	12.8	11.2	11.9	12.2	25.5	15.5	13.1	15.6	5.0	20.4	5.3	5.7	15.7	17.7	13.9	6.6	9.9	7.6	12.1	10.5	0.0	4.5	15.8	9.5	19.0	4.7	12.3	12.9	17.5	13.8	17.2	20.2	6.1	13.0	18.5	11.8	15.4	9.3	10.4	8.5	9.3	10.6	7.3	13.9	6.5	6.2	14.4	25.6	17.9	14.4	17.5	10.7	19.5
WAS	"IMD2, THC, WASP, WASPA"	ENSG00000015285	"Wiskott-Aldrich syndrome"	P42768	X	48676596-48691427	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 30.7;lymphoid tissue: 55.9"	"Cell type enhanced"	"Detected in many"	8	"B-cells: 72.2;Hofbauer cells: 95.2;Kupffer cells: 94.9;Macrophages: 70.0;T-cells: 87.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 20.3"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 21.7;HEL: 19.1;HMC-1: 46.5;MOLT-4: 19.7;NB-4: 21.5;RPMI-8226: 26.5;THP-1: 19.5;U-266/70: 24.6;U-937: 24.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA002022, CAB004290"	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA		320000	"Plasma membrane"	Cytosol	"CAB004290: AB_628445, HPA002022: AB_1080581"	"unprognostic (1.43e-3)"	"unprognostic (2.09e-3)"	"unprognostic (2.36e-2)"	"prognostic favorable (4.95e-4)"	"unprognostic (9.89e-2)"	"prognostic favorable (3.78e-4)"	"unprognostic (5.12e-3)"	"unprognostic (7.60e-2)"	"unprognostic (1.54e-2)"	"unprognostic (2.86e-1)"	"unprognostic (7.40e-2)"	"unprognostic (3.60e-1)"	"prognostic unfavorable (5.58e-6)"	"unprognostic (2.24e-1)"	"unprognostic (2.37e-2)"	"unprognostic (3.55e-2)"	"unprognostic (1.71e-1)"	7.6	4.0	4.9	28.9	7.8	30.7	3.3	2.0	5.1	2.7	4.4	5.9	0.5	4.8	2.4	5.6	3.7	4.5	4.4	3.0	4.6	4.1	4.1	5.0	12.6	29.9	7.6	1.3	2.6	2.2	0.7	2.6	5.4	6.0	3.2	3.2	3.5	5.4	1.9	1.4	2.2	14.3	3.7	12.8	55.9	4.1	1.7	7.3	53.2	2.8	1.4	33.2	5.8	2.5	2.1	3.5	20.3	5.3	2.1	3.2	2.0	0.2	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	21.7	0.1	0.0	0.1	0.7	0.0	0.0	0.0	12.5	0.1	19.1	0.2	0.0	0.2	9.8	46.5	0.0	0.0	0.0	0.0	0.0	0.0	11.7	0.2	13.4	0.0	2.2	19.7	21.5	0.1	0.3	0.1	17.3	0.0	26.5	0.0	0.0	0.1	0.2	0.3	0.2	0.2	0.1	0.1	19.5	0.1	0.0	0.1	0.3	0.0	24.6	12.0	15.2	0.1	24.8	0.0	1.8	4.6	20.3	3.0	5.0	2.2	1.8	2.3	2.5	3.5	2.1	2.1	2.3	18.1	2.1	5.3	1.8	3.2	2.0	4.9	7.8	2.0	5.1	4.6	4.1	7.6	1.3	6.0	7.3	3.0	21.3	72.2	0.1	2.2	0.0	0.8	0.0	2.7	0.0	0.0	0.0	0.8	1.7	0.1	0.5	0.5	0.0	23.3	0.3	0.9	1.5	0.2	46.2	0.9	95.2	0.0	1.2	5.5	94.9	0.8	0.0	70.0	3.3	45.9	0.0	0.2	0.1	0.0	0.0	1.5	0.0	0.0	0.6	1.4	1.1	1.3	1.1	87.0	0.0	0.1
WDCP	"C2orf44, FLJ21945"	ENSG00000163026	"WD repeat and coiled coil containing"	Q9H6R7	2	24029340-24049575	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"			"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"	12	"Collecting duct cells: 8.7;Distal tubular cells: 6.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041054	Approved		Approved	Nucleoli,Cytosol		NA	NA			Nucleoli	Cytosol	"HPA041054: AB_10796566"	"unprognostic (1.07e-1)"	"unprognostic (3.19e-2)"	"unprognostic (3.36e-1)"	"prognostic unfavorable (6.53e-4)"	"unprognostic (1.32e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavorable (5.14e-8)"	"unprognostic (7.69e-2)"	"unprognostic (9.01e-3)"	"unprognostic (2.05e-1)"	"unprognostic (1.07e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.76e-3)"	"unprognostic (1.85e-1)"	"unprognostic (1.97e-1)"	"unprognostic (7.76e-2)"	"unprognostic (3.00e-1)"	11.7	9.6	8.3	7.6	9.4	2.4	9.2	14.6	9.8	9.6	9.3	11.5	8.4	5.3	10.7	8.0	7.4	7.2	5.6	6.8	7.1	6.9	7.5	8.9	5.4	12.4	8.3	4.8	11.6	7.7	11.2	9.4	8.5	8.7	8.7	6.2	7.8	7.1	12.9	13.8	5.9	7.5	7.4	8.0	9.4	7.0	12.5	9.2	17.9	8.9	5.5	13.7	9.4	6.4	4.9	4.3	1.5	3.8	5.0	7.8	4.2	7.3	11.4	12.6	8.7	8.6	6.9	4.5	9.0	4.8	9.4	9.0	10.3	3.4	19.4	3.9	4.6	7.9	5.4	17.8	6.1	9.8	11.6	10.2	11.8	5.7	10.7	5.9	10.7	8.2	4.1	4.8	9.6	4.8	4.9	8.8	11.3	16.3	5.4	9.8	3.3	13.9	6.4	15.1	7.4	8.9	15.4	21.2	7.8	4.4	3.6	9.7	13.4	4.4	4.3	5.5	9.2	3.3	4.8	8.4	7.6	8.4	4.5	8.1	8.9	11.2	27.4	4.8	11.5	5.9	0.0	2.4	1.5	7.5	3.8	7.8	4.9	5.0	5.5	4.3	4.7	6.8	7.5	0.7	5.0	2.6	1.6	7.1	4.2	8.3	9.4	14.6	9.8	7.1	6.9	8.3	4.8	8.7	9.2	3.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.2	8.7	0.0	2.6	6.6	2.1	0.0	0.0	0.0	0.0	1.7	2.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	1.4	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0
WIF1		ENSG00000156076	"WNT inhibitory factor 1"	Q9Y5W5	12	65050626-65121566	"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins"	"Wnt signaling pathway"	"Developmental protein"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 35.2;lung: 67.7;retina: 29.6"	"Cell type enriched"	"Detected in many"	15	"Muller glia cells: 2337.6"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 16.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 5.4;LHCN-M2: 2.5;NTERA-2: 7.0;SCLC-21H: 1.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (5.96e-3)"	"unprognostic (2.00e-1)"	"unprognostic (4.29e-3)"	"unprognostic (3.26e-3)"	"unprognostic (9.66e-2)"	"unprognostic (1.91e-1)"		"unprognostic (1.26e-2)"	"unprognostic (7.94e-2)"	"unprognostic (2.44e-1)"	"unprognostic (2.92e-2)"	"unprognostic (3.17e-1)"	"unprognostic (2.30e-5)"	"unprognostic (3.02e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.22e-1)"	"unprognostic (7.24e-3)"	0.9	2.4	23.3	0.8	35.2	0.6	14.2	1.6	20.6	1.6	0.8	1.0	1.9	0.6	5.5	14.5	3.4	1.5	0.6	0.7	10.4	3.9	1.0	0.6	67.7	0.7	1.4	8.2	0.8	0.8	0.6	21.4	0.6	0.4	9.5	0.8	29.6	24.8	2.3	0.6	4.2	1.8	1.2	0.7	0.7	0.9	1.0	3.5	0.0	0.6	3.6	0.6	0.8	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	2.5	0.1	0.0	0.9	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.3	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	35.2	1.6	20.6	10.4	3.9	1.4	8.2	0.4	3.5	32.8	159.2	0.0	31.4	11.2	20.4	1.1	0.0	62.9	48.9	1.8	7.9	0.0	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.0	1.9	16.0	7.0	0.0	0.0	14.3	0.0	0.0	0.0	0.0	0.0	3.1	21.9	0.0	0.0	2337.6	0.0	0.0	0.4	0.8	66.4	0.0	3.6	0.5	0.2	9.3	0.0	0.0	0.0	0.5
WRN	"RECQ3, RECQL2"	ENSG00000165392	"Werner syndrome RecQ like helicase"	Q14191	8	31033801-31173769	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Exonuclease, Helicase, Hydrolase, Multifunctional enzyme, Nuclease"	"Cancer-related genes, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028661	Approved		Supported	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"HPA028661: AB_10602255"	"unprognostic (8.73e-2)"	"unprognostic (9.33e-2)"	"unprognostic (1.51e-3)"	"unprognostic (3.85e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.85e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.25e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.27e-2)"	"unprognostic (6.63e-2)"	"unprognostic (1.53e-2)"	"unprognostic (6.51e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.00e-2)"	"unprognostic (2.66e-1)"	10.1	9.2	5.6	8.5	6.6	15.6	11.1	10.7	7.3	14.2	8.0	7.7	7.7	5.5	24.4	8.8	7.6	9.7	6.9	7.0	5.9	4.0	5.1	7.7	7.2	6.7	8.2	5.3	12.0	9.9	7.8	28.1	8.5	7.0	8.6	7.8	8.3	10.8	7.8	7.7	10.2	7.0	12.1	14.9	8.9	8.3	10.4	7.3	11.8	7.9	6.3	9.3	10.8	8.7	3.9	2.7	1.3	1.9	2.9	6.2	1.6	6.5	6.4	13.3	8.4	8.0	12.8	8.4	7.4	7.3	9.1	9.5	4.1	4.0	15.4	6.8	7.5	6.9	3.4	8.2	5.3	13.6	4.3	7.0	15.7	6.1	3.4	10.0	9.3	5.8	9.3	5.9	8.6	10.4	4.5	8.7	10.8	24.8	9.7	8.3	4.2	19.3	4.5	11.4	7.1	4.6	11.1	10.1	6.2	3.8	7.2	2.9	7.7	9.0	5.1	7.0	7.8	3.5	4.6	13.9	9.9	6.1	5.0	6.2	2.6	2.8	19.3	7.3	7.3	6.8	1.2	1.9	1.3	3.3	1.9	6.2	3.9	3.8	3.3	2.7	3.5	2.5	3.2	0.5	2.9	0.8	2.0	2.8	1.6	5.6	6.6	10.7	7.3	5.9	4.0	8.2	5.3	7.0	7.3	8.9	8.8	10.8	8.0	11.9	14.2	6.5	12.7	9.4	11.4	15.7	21.6	5.9	1.7	5.1	37.8	8.5	3.2	23.3	8.4	4.7	10.8	8.1	2.3	8.9	4.5	14.3	2.4	6.2	5.1	8.1	17.5	4.9	10.1	5.4	12.1	21.9	7.1	2.9	13.4	2.1	22.1	6.5	9.5	8.7	18.6	8.9	4.7	5.1	7.6	9.8
WT1	"AWT1, GUD, NPHS4, WAGR, WIT-2"	ENSG00000184937	"Wilms tumor 1"	P19544	11	32387775-32435630	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, RNA-binding"	"Cancer-related genes, Disease mutation, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 69.0;fallopian tube: 34.5;ovary: 53.4"	"Cell type enhanced"	"Detected in some"	18	"Collecting duct cells: 19.2;Late spermatids: 5.9;Leydig cells: 7.8;Sertoli cells: 6.5"	"Cancer enriched"	"Detected in many"	14	"ovarian cancer: 55.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEL: 13.5;HMC-1: 17.4;K-562: 12.2;NB-4: 32.6;THP-1: 15.6"	"Region enhanced"	"Detected in single"		"pons and medulla: 0.5"	"Not detected"	"Not detected"			"CAB000327, HPA035717, HPA053848"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB000327: AB_2304486, HPA035717: AB_2674748, HPA053848: AB_2682279"	"unprognostic (3.09e-3)"	"unprognostic (9.97e-4)"	"unprognostic (3.32e-1)"	"unprognostic (8.24e-3)"	"unprognostic (5.20e-2)"	"unprognostic (1.98e-3)"	"unprognostic (2.94e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.23e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.31e-10)"	"unprognostic (2.65e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.96e-3)"	"unprognostic (1.30e-2)"	10.3	0.0	0.2	1.8	0.6	0.0	0.2	0.2	0.5	20.3	1.5	0.2	3.7	0.0	69.0	9.3	0.4	34.5	0.8	2.1	0.9	0.0	5.3	0.2	0.8	0.5	0.2	0.2	53.4	0.2	0.0	0.2	6.9	0.3	0.9	0.0	0.2	0.2	4.2	0.2	0.0	0.4	23.7	0.2	14.6	0.0	24.5	0.2	0.2	0.3	0.2	0.2	1.3	4.1	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.1	0.1	0.0	0.0	0.0	6.3	0.0	0.0	0.0	4.7	13.5	0.0	1.2	3.8	9.0	17.4	0.0	0.0	2.8	0.0	0.0	0.0	2.8	12.2	0.1	2.7	0.0	7.9	32.6	0.7	0.0	3.8	1.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	1.8	15.6	0.1	0.0	2.4	0.0	0.3	0.0	0.0	0.0	0.1	2.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.6	0.2	0.5	0.9	0.0	0.2	0.2	0.3	0.2	0.0	0.0	0.0	0.2	0.0	0.0	1.4	0.0	0.0	0.0	19.2	0.0	0.9	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.7	0.2	0.1	0.0	0.0	0.3	0.0	0.0	2.5	0.0	5.9	7.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.2	0.0	6.5	0.0	1.9	0.9	0.0	0.7	0.0	0.0	0.1
WWTR1	"DKFZp586I1419, TAZ"	ENSG00000018408	"WW domain containing transcription regulator 1"	Q9GZV5	3	149517235-149736714	"Cancer-related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	Activator	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Basal glandular cells: 158.0;Endothelial cells: 172.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.6;memory CD8 T-cell: 2.8"	"Lineage enriched"	"Detected in single"	4	"T-cells: 2.8"	"Cell line enhanced"	"Detected in many"		"EFO-21: 60.9;SK-MEL-30: 42.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007415, CAB017483, CAB068248"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies,Cytosol"		NA	NA			"Nucleoplasm, Nuclear bodies"	Cytosol	"CAB017483: AB_2216639, CAB068248: AB_2665648, HPA007415: AB_1080602"	"unprognostic (1.85e-2)"	"unprognostic (2.24e-2)"	"unprognostic (3.41e-3)"	"unprognostic (1.33e-2)"	"unprognostic (7.94e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.41e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.74e-2)"	"unprognostic (2.34e-1)"	"unprognostic (1.63e-2)"	"unprognostic (3.32e-1)"	"unprognostic (1.17e-3)"	"unprognostic (2.76e-2)"	"unprognostic (2.53e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.01e-3)"	25.1	9.9	9.3	16.0	18.6	0.2	20.4	7.7	10.5	27.2	38.5	18.4	15.0	5.6	27.2	17.6	41.2	16.4	25.8	20.6	14.7	9.0	31.0	13.1	29.8	6.2	15.2	5.6	30.9	21.7	10.4	8.5	29.0	20.7	34.6	9.1	29.4	15.8	22.4	12.1	13.4	11.7	81.5	25.8	13.8	20.8	12.0	16.4	0.7	18.2	13.2	7.1	68.4	31.0	0.2	0.1	0.6	0.1	0.1	2.8	0.4	16.8	20.0	10.6	14.2	12.7	22.7	11.2	9.8	14.4	4.4	4.7	11.2	14.3	0.0	60.9	11.0	13.6	10.0	6.9	7.1	4.4	4.7	5.3	0.0	5.2	9.3	7.2	0.0	0.0	12.0	1.8	15.4	6.8	17.0	34.5	0.0	0.0	0.0	15.3	2.2	0.0	0.0	2.4	0.0	25.3	0.0	14.3	0.1	37.8	2.5	0.0	0.1	6.5	4.6	42.0	8.3	7.8	0.3	28.0	8.7	4.2	7.0	19.1	0.2	0.1	0.2	18.7	0.0	22.2	0.4	0.1	0.1	2.6	0.0	0.0	0.0	0.3	2.8	0.0	0.2	0.1	1.3	0.6	0.1	0.0	0.1	1.9	0.4	9.3	18.6	7.7	10.5	14.7	9.0	15.2	5.6	20.7	16.4	59.6	79.0	0.0	158.0	45.9	2.0	42.0	147.7	60.2	128.5	47.1	3.9	10.5	6.6	55.4	14.8	172.1	0.7	0.0	23.5	70.1	58.9	72.2	7.0	20.3	3.7	0.0	0.0	92.7	6.4	3.6	53.5	8.0	28.7	3.6	0.0	10.4	31.6	0.0	118.8	48.8	2.0	58.2	48.4	1.7	0.7	31.0	12.4	5.3	0.0	80.1
XPA	"XP1, XPAC"	ENSG00000136936	"XPA, DNA damage recognition and repair factor"	P23025	9	97674909-97697357	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"DNA damage, DNA repair"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000155, HPA056856"	Supported		Approved	"Nucleoplasm,Cytokinetic bridge"		Yes	No			Nucleoplasm	"Cytokinetic bridge"	"CAB000155: , HPA056856: AB_2683258"	"unprognostic (8.76e-2)"	"unprognostic (1.05e-3)"	"unprognostic (1.60e-1)"	"unprognostic (2.30e-2)"	"unprognostic (4.17e-1)"	"unprognostic (1.84e-1)"	"unprognostic (5.26e-2)"	"unprognostic (2.38e-1)"	"unprognostic (3.90e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.97e-3)"	"unprognostic (9.55e-3)"	"prognostic favorable (4.28e-5)"	"unprognostic (2.19e-2)"	"unprognostic (1.56e-1)"	"unprognostic (3.03e-2)"	"unprognostic (1.17e-1)"	18.7	17.5	20.1	17.1	21.0	10.6	17.4	26.8	20.8	20.3	25.2	17.2	11.7	20.6	25.5	15.4	18.9	15.0	19.5	12.9	17.2	15.3	24.9	24.2	14.8	16.7	18.6	17.5	17.2	14.5	23.0	23.1	12.8	17.7	20.3	13.6	16.4	16.1	21.7	43.3	16.3	22.2	27.5	17.1	16.2	25.1	6.4	15.8	15.7	31.5	11.9	21.6	22.0	16.4	22.2	23.4	12.7	15.8	19.7	21.6	11.3	23.0	5.4	8.1	10.0	9.9	9.7	5.6	6.3	10.0	11.5	7.8	14.1	19.4	13.0	6.1	6.9	7.7	11.6	6.4	7.6	9.8	8.9	12.9	10.2	11.8	7.8	10.8	12.1	12.4	8.4	8.2	5.3	5.5	7.8	12.8	10.8	14.1	10.2	6.3	7.2	15.7	14.6	5.5	22.0	9.0	16.0	17.3	11.0	18.3	9.0	11.4	11.5	9.0	6.9	8.1	6.4	10.1	7.3	8.0	4.0	10.1	15.9	13.6	18.1	14.5	8.2	10.0	8.7	7.9	6.0	13.3	12.7	16.2	13.1	18.7	19.5	17.7	15.6	13.5	22.2	21.6	18.6	1.5	19.7	15.8	23.4	18.3	11.3	20.1	21.0	26.8	20.8	17.2	15.3	18.6	17.5	17.7	15.8	23.8	31.5	27.5	17.4	15.3	99.5	29.1	50.9	34.8	40.9	21.0	76.6	27.4	102.8	31.2	1.2	29.2	16.9	0.0	33.5	8.3	24.2	16.3	29.0	40.6	30.4	79.4	21.5	17.8	17.5	2.6	40.9	29.8	13.5	49.5	21.3	71.6	24.5	21.0	44.6	38.3	99.8	32.3	31.9	12.8	16.4	16.4	11.7	25.3	26.3	20.2
XPC	"RAD4, XPCC"	ENSG00000154767	"XPC complex subunit, DNA damage recognition and repair factor"	Q01831	3	14145147-14178783	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes, Disease mutation, Xeroderma pigmentosum"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009932, HPA035707, HPA069673"	Supported		Enhanced	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"CAB009932: AB_2241587, HPA035707: AB_2674743, HPA069673: AB_2686167"	"unprognostic (7.46e-2)"	"unprognostic (2.52e-2)"	"unprognostic (4.50e-2)"	"unprognostic (3.01e-1)"	"unprognostic (6.63e-2)"	"unprognostic (2.54e-2)"	"unprognostic (1.97e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.50e-1)"	"unprognostic (7.13e-3)"	"unprognostic (4.39e-2)"	"unprognostic (2.07e-1)"	"prognostic favorable (4.14e-7)"	"unprognostic (1.59e-1)"	"unprognostic (7.88e-2)"	"unprognostic (7.62e-2)"	"prognostic favorable (2.46e-4)"	20.2	17.1	14.2	24.0	30.2	8.4	21.4	16.1	19.3	22.3	18.9	20.8	27.5	18.0	24.6	18.3	16.9	24.9	25.1	12.4	16.2	14.4	24.6	23.4	19.9	21.1	33.4	15.2	35.0	20.9	35.4	26.7	28.0	22.1	20.9	15.9	16.7	17.6	30.3	22.4	30.5	23.6	17.7	22.6	23.3	15.9	12.9	30.6	18.5	25.7	12.4	20.8	22.4	22.3	10.9	7.0	34.6	8.8	8.8	12.2	6.1	4.5	11.6	13.1	8.4	19.7	13.6	44.5	11.3	32.3	10.9	8.5	4.2	5.4	15.1	5.0	13.7	5.1	5.7	8.6	18.0	9.0	6.1	7.4	8.0	12.3	7.8	17.5	6.0	15.3	19.3	21.4	14.5	29.1	12.8	12.9	6.9	11.0	8.2	12.1	9.5	4.9	5.7	7.8	7.4	7.9	6.3	5.9	12.1	13.8	13.5	2.8	10.2	12.3	10.2	8.1	21.5	10.7	4.9	20.2	4.2	11.5	6.4	5.2	18.9	13.7	8.9	10.1	7.0	15.2	12.0	8.2	9.4	9.8	6.3	9.6	10.7	11.2	9.6	7.0	10.9	12.2	8.7	34.6	8.8	8.8	6.7	9.2	6.1	14.2	30.2	16.1	19.3	16.2	14.4	33.4	15.2	22.1	30.6	56.6	54.6	22.2	18.7	12.2	33.8	11.2	33.1	84.3	73.9	15.7	37.3	34.0	29.9	16.3	1.9	24.9	12.3	46.7	16.9	17.1	16.4	15.5	44.1	30.4	16.2	25.4	15.6	22.1	24.3	1.8	28.4	28.4	8.5	38.7	12.2	29.9	15.2	14.8	26.5	34.1	50.6	25.8	18.0	22.7	57.3	9.7	26.8	34.6	13.3	8.7
XPO1	"CRM1, emb"	ENSG00000082898	"Exportin 1"	O14980	2	61477849-61538626	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Transport"	RNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010184, HPA042933"	Supported		Enhanced	"Nucleoplasm,Nuclear membrane,Vesicles,Cytosol"		NA	NA		170000	"Nucleoplasm, Nuclear membrane"	"Vesicles, Cytosol"	"CAB010184: AB_2215817, HPA042933: AB_2678229"	"unprognostic (7.34e-2)"	"unprognostic (7.04e-2)"	"unprognostic (6.37e-2)"	"unprognostic (1.67e-2)"	"unprognostic (5.61e-2)"	"unprognostic (1.28e-1)"	"prognostic unfavorable (1.84e-5)"	"unprognostic (1.84e-1)"	"unprognostic (1.99e-3)"	"unprognostic (4.43e-1)"	"unprognostic (3.53e-3)"	"unprognostic (4.90e-2)"	"prognostic unfavorable (3.74e-4)"	"unprognostic (5.69e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.43e-1)"	"unprognostic (5.55e-2)"	20.7	27.9	36.1	28.1	39.6	21.6	35.1	41.5	36.3	28.2	23.2	19.5	26.0	16.5	35.7	35.3	26.1	36.0	20.3	20.1	33.0	19.2	19.5	22.2	22.0	34.5	42.0	19.5	45.0	34.6	33.4	27.6	30.8	33.6	25.8	24.5	18.0	20.2	29.9	34.9	29.8	25.0	28.4	32.1	24.5	21.9	32.1	39.3	51.1	28.2	16.4	35.7	26.0	57.8	6.1	5.4	12.6	5.1	6.2	5.1	2.5	39.4	35.3	47.9	35.9	21.7	29.2	35.3	43.7	28.2	46.0	39.4	46.9	29.7	57.9	30.6	29.9	46.8	33.5	73.0	30.3	67.7	35.3	26.9	57.0	36.3	29.3	15.7	57.4	39.0	16.4	22.7	36.3	39.6	34.9	37.5	29.2	65.7	33.8	42.3	20.8	47.7	25.2	55.7	47.2	27.1	42.8	54.7	35.2	20.9	30.0	38.3	20.4	42.5	35.9	21.3	50.4	29.4	28.4	25.0	43.2	49.1	35.1	42.9	27.5	45.3	84.0	26.8	49.3	38.9	12.6	5.1	5.8	5.1	5.0	4.7	4.3	3.6	4.5	3.9	6.1	4.3	3.7	12.4	6.2	3.2	5.4	3.2	2.5	36.1	39.6	41.5	36.3	33.0	19.2	42.0	19.5	33.6	39.3	38.7	36.3	31.8	27.6	46.2	69.7	57.0	43.3	46.8	28.4	29.6	90.3	46.3	11.6	24.4	3.2	40.7	19.3	70.0	22.5	42.3	40.9	34.4	40.5	48.0	49.4	68.3	43.4	42.4	46.3	8.0	31.1	53.2	35.4	49.5	31.2	34.0	26.3	17.5	29.0	20.8	102.5	19.4	43.7	64.6	88.2	49.7	25.2	42.9	37.6	38.3
YWHAE	FLJ45465	ENSG00000108953	"Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon"	P62258	17	1344272-1400378	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008445, CAB016200, CAB021109, CAB047350, HPA061603"	Approved		Supported	"Nucleoplasm,Nucleoli rim,Cytosol"		NA	NA		160000000	Cytosol	"Nucleoplasm, Nucleoli rim"	"CAB016200: AB_626619, CAB021109: AB_10060396, CAB047350: , HPA008445: AB_1844336, HPA061603: "	"unprognostic (1.29e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.99e-2)"	"prognostic favorable (6.48e-6)"	"unprognostic (1.59e-1)"	"unprognostic (2.91e-2)"	"unprognostic (2.73e-2)"	"unprognostic (4.77e-3)"	"unprognostic (4.53e-2)"	"unprognostic (5.14e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.92e-3)"	"unprognostic (8.33e-2)"	"unprognostic (2.57e-1)"	"unprognostic (3.24e-2)"	"unprognostic (8.94e-2)"	55.2	54.3	107.5	35.3	87.1	32.7	37.3	71.5	118.4	28.4	40.2	60.9	23.8	40.2	35.9	54.1	43.1	44.2	23.4	57.7	92.3	81.9	64.5	50.9	32.8	25.4	94.1	77.9	40.2	40.2	41.0	37.9	45.1	73.7	35.0	42.5	27.9	42.4	27.7	135.9	36.8	36.2	32.2	101.1	26.2	38.5	46.0	53.6	30.9	47.5	36.5	37.2	31.6	32.1	19.2	41.5	17.2	36.2	15.0	23.3	31.5	79.3	59.3	71.9	60.4	31.8	36.8	69.1	51.3	30.3	45.8	35.6	106.0	32.6	53.9	60.4	42.5	36.3	55.2	60.9	51.9	65.1	37.2	113.5	37.6	49.5	45.3	38.0	36.0	38.6	33.3	38.3	45.9	70.4	41.5	55.1	39.3	43.1	39.0	58.9	38.6	47.6	28.7	65.9	49.5	38.5	57.9	34.0	38.2	46.6	46.0	40.1	60.8	61.8	25.3	40.2	42.5	48.1	33.3	52.1	44.5	37.9	56.2	90.6	24.5	45.2	45.2	53.4	43.1	64.3	17.2	31.8	8.6	12.4	36.2	15.6	19.2	18.7	13.9	41.5	16.1	17.0	14.3	10.8	15.0	30.9	28.8	23.3	31.5	107.5	87.1	71.5	90.2	92.3	81.9	94.1	77.9	73.7	53.6	276.9	161.5	157.1	381.2	509.9	135.0	437.9	257.4	539.4	243.4	352.4	47.1	418.8	631.6	405.9	192.2	338.4	245.3	70.0	366.4	587.8	367.2	359.0	204.6	255.7	335.2	104.9	338.5	239.4	235.4	296.2	260.1	221.5	403.2	401.2	274.5	253.1	384.5	266.5	277.2	497.3	121.5	239.3	263.7	441.4	573.9	512.8	434.5	126.4	277.6	415.5
ZBTB16	"PLZF, ZNF145"	ENSG00000109906	"Zinc finger and BTB domain containing 16"	Q05516	11	114059593-114250676	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation, Ubl conjugation pathway"	"DNA-binding, Repressor"	"Cancer-related genes, Disease mutation, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Leydig cells: 83.1;Peritubular cells: 86.7;Sertoli cells: 103.5"	"Cancer enhanced"	"Detected in many"		"prostate cancer: 5.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 13.7;MAIT T-cell: 23.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 30.6;ASC TERT1: 17.7;HEL: 18.2;HHSteC: 13.2;HSkMC: 14.1;hTCEpi: 13.1;hTERT-HME1: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001499, CAB004540"	Uncertain					NA	NA					"CAB004540: AB_2218941, HPA001499: AB_1079640"	"unprognostic (2.21e-1)"	"unprognostic (2.17e-1)"	"unprognostic (7.30e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.53e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.25e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.09e-1)"	"unprognostic (8.79e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"prognostic favorable (2.21e-4)"	"unprognostic (2.57e-3)"	"unprognostic (2.67e-1)"	"unprognostic (1.00e-1)"	"unprognostic (5.90e-2)"	38.0	16.0	10.0	6.3	14.6	6.3	20.5	18.0	22.8	18.7	14.9	6.7	15.7	1.8	19.6	8.5	24.0	17.3	11.8	25.5	11.8	4.5	8.3	9.3	17.3	6.2	16.1	8.9	41.6	51.5	14.5	9.5	8.3	12.6	10.0	3.0	7.8	10.4	15.1	58.8	17.5	10.4	15.1	10.8	11.1	12.8	4.6	14.2	0.0	24.1	10.9	2.5	21.9	27.5	6.9	0.0	0.6	2.4	5.5	23.5	2.7	0.0	0.0	6.2	0.0	30.6	17.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	18.2	0.0	0.0	13.2	0.3	0.2	14.1	13.1	0.0	11.5	0.0	2.2	2.7	0.0	0.0	0.1	0.0	1.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.4	0.6	13.7	0.6	23.5	0.1	0.6	2.0	0.0	6.9	0.8	0.4	0.2	5.5	0.5	0.0	0.2	2.7	10.0	14.6	18.0	22.8	11.8	4.5	16.1	8.9	12.6	14.2	20.8	4.8	11.1	63.9	9.8	23.7	31.3	25.5	10.7	7.9	8.7	0.0	0.1	1.7	0.7	18.8	27.5	2.0	0.0	0.8	0.2	13.1	36.9	13.9	45.2	0.7	0.0	6.9	57.7	19.6	16.8	83.1	5.8	6.8	2.8	0.7	21.4	0.5	0.0	86.7	5.3	1.9	103.5	50.5	0.3	5.7	5.9	0.2	29.3	0.8	6.3
ZFHX3	"ATBF1, ZNF927"	ENSG00000140836	"Zinc finger homeobox 3"	Q15911	16	72782885-73891871	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Myogenesis, Transcription, Transcription regulation"	"Activator, DNA-binding, Repressor"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Smooth muscle cells: 198.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 2.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA059353	Uncertain		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA059353: AB_2683987"	"prognostic unfavorable (1.55e-4)"	"unprognostic (3.57e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.03e-2)"	"unprognostic (2.81e-2)"	"unprognostic (3.12e-1)"	"unprognostic (4.24e-2)"	"unprognostic (6.36e-2)"	"unprognostic (9.94e-3)"	"unprognostic (2.85e-1)"	"unprognostic (1.06e-1)"	"unprognostic (4.16e-2)"	"prognostic favorable (1.37e-5)"	"unprognostic (6.76e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.11e-1)"	"unprognostic (2.15e-2)"	7.9	6.0	2.5	2.3	4.6	1.1	11.3	1.5	4.1	7.5	7.7	5.4	14.5	2.0	7.4	7.3	4.5	4.9	18.2	4.9	4.3	4.8	4.4	6.5	6.1	1.4	4.0	2.6	4.4	5.7	23.8	6.3	8.1	5.5	12.0	3.5	10.5	5.0	19.5	16.9	3.6	3.6	15.5	9.7	3.9	5.0	2.3	5.2	0.5	10.8	4.0	1.0	16.7	14.7	0.8	1.0	0.2	1.6	2.5	0.1	0.2	4.4	7.9	12.9	10.7	4.8	6.1	13.3	3.4	3.7	2.2	2.5	9.0	2.5	1.9	6.0	6.4	3.0	3.1	8.1	4.0	3.0	7.8	2.0	0.3	10.8	12.8	4.4	1.3	3.2	2.2	2.4	6.4	5.8	2.0	4.1	0.9	0.9	0.5	5.4	9.2	0.4	2.6	2.3	2.3	1.3	5.9	3.5	0.6	3.5	7.5	9.6	3.4	6.0	1.9	4.3	6.2	2.6	0.6	8.8	5.4	6.4	5.7	4.5	4.9	1.6	1.4	2.6	1.2	4.1	0.2	1.6	0.2	0.1	0.9	0.1	0.5	0.0	0.0	0.7	0.8	0.0	0.1	0.2	2.5	1.1	1.0	0.1	0.2	2.5	4.6	1.5	4.1	4.3	4.8	4.0	2.6	5.5	5.2	65.5	26.1	8.1	52.4	15.0	87.0	16.5	43.3	32.1	48.9	45.4	21.6	35.9	5.0	23.2	1.9	28.2	6.0	0.0	20.2	18.1	50.1	96.3	20.7	30.0	55.1	22.3	25.8	42.4	67.6	1.3	9.8	55.4	20.3	24.4	18.0	18.0	20.8	21.0	18.7	6.1	31.2	122.9	198.8	3.4	17.7	15.1	51.9	3.2	29.3	41.2
ZMYM2	"FIM, MYM, RAMP, ZNF198"	ENSG00000121741	"Zinc finger MYM-type containing 2"	Q9UBW7	13	19958670-20091829	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Transcription, Transcription regulation"		"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031765	Approved		Approved	"Nucleoplasm,Endoplasmic reticulum"		NA	NA			"Nucleoplasm, Endoplasmic reticulum"		"HPA031765: AB_10601927"	"unprognostic (2.96e-1)"	"unprognostic (3.42e-3)"	"unprognostic (1.85e-1)"	"unprognostic (1.69e-1)"	"unprognostic (7.71e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.66e-3)"	"unprognostic (1.16e-1)"	"unprognostic (6.78e-2)"	"unprognostic (5.88e-2)"	"unprognostic (4.60e-2)"	"unprognostic (2.80e-2)"	"unprognostic (6.65e-3)"	"unprognostic (2.05e-1)"	"unprognostic (8.74e-2)"	"unprognostic (1.06e-1)"	"prognostic favorable (6.07e-4)"	15.0	17.3	15.9	18.1	23.3	22.2	16.1	23.9	26.8	18.3	16.8	14.0	13.7	13.3	20.0	14.0	18.5	16.1	15.7	17.1	14.4	12.0	17.3	13.7	15.4	14.2	12.9	20.2	21.7	16.2	17.1	32.1	14.0	23.2	19.4	13.8	13.8	18.2	17.6	19.7	18.3	14.5	15.3	16.2	16.3	16.0	44.5	16.5	38.0	24.3	10.4	19.7	19.5	17.2	5.5	6.3	7.4	5.9	5.4	7.9	3.5	6.4	5.8	22.3	9.6	9.9	10.6	10.6	6.7	10.8	8.7	10.4	8.9	13.3	15.4	6.2	9.4	8.3	10.3	16.4	7.2	11.8	6.1	4.6	27.2	8.7	4.4	9.9	22.9	8.3	10.5	13.5	6.9	7.1	13.8	14.7	15.9	10.3	11.0	11.9	9.1	22.1	6.5	20.6	19.5	3.6	24.7	24.3	7.2	6.7	9.4	26.1	26.0	13.0	9.3	12.2	15.7	12.3	16.4	8.6	4.3	6.9	5.2	3.5	8.7	6.8	15.9	3.7	5.4	10.3	0.2	5.2	4.0	5.5	5.9	6.7	5.5	7.5	5.6	6.1	4.5	7.9	6.9	7.4	5.4	4.9	6.3	5.4	3.5	15.9	23.3	23.9	26.8	14.4	12.0	12.9	20.2	23.2	16.5	41.7	35.3	47.7	40.3	48.9	111.9	33.0	28.1	36.1	46.6	48.8	106.0	13.1	5.0	20.1	90.8	35.1	23.6	0.0	15.4	10.5	38.8	45.9	45.1	28.4	19.1	68.3	53.6	43.6	57.0	140.1	51.8	45.1	32.1	20.8	31.0	48.9	25.9	31.6	38.5	13.7	112.6	32.3	39.3	94.3	48.9	39.0	9.5	45.9	27.6	70.2
ZNF331	"RITA, ZNF361, ZNF463"	ENSG00000130844	"Zinc finger protein 331"	Q9NQX6	19	53520981-53580269	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 66.4;ovary: 86.4"	"Cell type enhanced"	"Detected in many"	7	"granulocytes: 234.6;Smooth muscle cells: 196.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HEK 293: 36.4;RT4: 27.8"					"Low region specificity"	"Detected in all"			HPA063157			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA063157: AB_2684951"	"unprognostic (2.19e-1)"	"unprognostic (1.79e-1)"	"unprognostic (5.18e-2)"	"unprognostic (1.55e-2)"	"unprognostic (4.24e-1)"	"unprognostic (8.16e-2)"	"unprognostic (7.62e-3)"	"unprognostic (3.25e-2)"	"unprognostic (1.84e-2)"	"unprognostic (4.40e-2)"	"unprognostic (5.68e-3)"	"unprognostic (2.69e-1)"	"unprognostic (4.73e-2)"	"prognostic unfavorable (4.79e-4)"	"unprognostic (2.08e-1)"	"prognostic unfavorable (7.43e-4)"	"unprognostic (6.74e-2)"	19.1	66.4	6.8	9.0	8.2	18.6	10.5	11.4	9.5	9.4	5.3	8.4	8.9	2.1	9.5	11.6	4.9	19.5	23.8	15.5	5.1	7.7	6.6	6.1	15.6	4.0	6.8	5.5	86.4	9.9	11.3	29.0	23.3	7.2	10.2	4.2	9.9	4.7	31.5	6.3	5.2	4.8	8.5	9.1	4.5	6.3	8.1	6.0	3.8	7.8	4.4	4.8	25.7	9.2	8.1	4.1	6.5	7.4	4.6	14.7	5.2	0.1	5.1	10.3	11.8	8.0	5.9	17.2	7.3	6.5	5.6	10.2	5.5	2.6	4.1	1.9	4.3	2.6	3.0	7.4	5.5	10.0	0.0	36.4	5.1	8.7	3.3	5.8	3.2	7.2	5.9	3.6	6.2	3.0	3.1	2.5	6.4	0.2	1.6	5.5	3.6	7.2	6.8	4.6	0.1	7.6	8.9	6.5	4.2	3.3	27.8	7.3	7.4	3.4	9.7	2.4	21.4	1.7	2.9	2.6	7.9	7.0	4.6	4.8	20.3	13.2	7.7	0.1	0.4	6.1	0.5	4.9	6.5	8.7	3.8	13.4	8.1	9.4	8.8	3.6	8.1	14.7	9.7	0.7	4.6	7.4	4.1	9.4	5.2	6.8	8.2	11.4	9.5	5.1	7.7	6.8	5.5	7.2	6.0	17.9	70.7	15.9	15.3	39.8	52.9	16.5	7.6	17.4	20.5	73.3	27.5	32.9	8.3	2.9	128.2	19.9	2.1	0.0	3.6	30.4	36.8	11.9	234.6	3.9	60.1	28.6	22.5	14.7	33.7	61.5	22.5	79.8	43.9	3.6	5.1	25.1	2.3	3.5	18.4	3.7	35.8	0.0	196.7	34.4	19.8	44.3	37.2	74.7	3.2	9.4
ZNF384	"CAGH1A, CIZ, NMP4, NP, TNRC1"	ENSG00000126746	"Zinc finger protein 384"	Q8TF68	12	6666477-6689572	"Cancer-related genes, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	DNA-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004051	Supported		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA004051: AB_1859228"	"unprognostic (1.90e-1)"	"unprognostic (5.11e-3)"	"unprognostic (1.76e-1)"	"unprognostic (6.16e-2)"	"unprognostic (1.79e-1)"	"unprognostic (3.04e-2)"	"unprognostic (1.87e-2)"	"unprognostic (9.94e-2)"	"unprognostic (1.35e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.25e-1)"	"unprognostic (1.24e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.06e-1)"	"unprognostic (8.13e-2)"	20.5	22.8	18.9	30.9	19.9	33.4	22.1	36.1	23.0	23.2	23.3	19.5	16.8	22.1	29.8	17.6	21.1	24.2	25.3	16.1	16.0	10.8	20.7	19.9	19.7	21.9	19.7	17.7	31.3	25.8	25.8	20.5	23.9	14.8	22.7	21.4	18.6	22.4	20.6	22.7	24.1	29.4	24.8	14.2	33.6	21.3	20.5	18.7	39.7	27.0	17.5	29.7	25.2	28.9	10.2	11.1	14.2	13.3	15.6	17.3	7.3	10.5	20.3	25.0	16.7	17.7	12.6	33.6	15.3	14.3	14.9	15.9	22.2	22.7	25.0	5.8	17.2	21.6	14.3	18.4	14.1	17.0	45.1	16.7	28.6	26.9	11.5	12.5	27.1	21.2	13.8	13.7	18.3	28.6	28.1	12.8	17.7	14.9	8.7	16.2	16.4	24.4	17.5	48.4	19.3	8.9	24.3	26.8	9.6	13.2	28.5	7.8	25.3	15.9	21.3	13.7	44.0	5.6	22.5	15.9	16.4	22.9	12.8	18.0	12.1	11.4	45.6	16.1	9.8	18.5	3.3	8.0	14.2	17.3	9.7	13.8	10.2	11.0	13.6	11.1	8.8	10.8	12.1	14.2	15.6	13.3	7.4	13.2	7.3	18.9	19.9	36.1	23.0	16.0	10.8	19.7	17.7	14.8	18.7	0.0	8.3	8.0	2.9	7.0	4.7	2.3	12.7	4.0	3.4	1.8	9.8	5.8	0.0	3.8	3.4	5.8	9.7	0.0	4.3	4.4	6.1	4.4	5.7	5.8	6.1	0.0	3.5	9.2	14.1	1.8	7.8	7.2	5.0	6.4	13.6	6.0	5.7	14.1	8.1	3.1	7.6	0.0	3.4	6.7	6.3	8.5	6.1	10.2	11.2	3.8
ZNF521	"EHZF, Evi3"	ENSG00000198795	"Zinc finger protein 521"	Q96K83	18	25061926-25352190	"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors"	"Differentiation, Transcription, Transcription regulation"	"Activator, Developmental protein, DNA-binding, Repressor"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 69.1"	"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 27.9;Endothelial cells: 22.4;Horizontal cells: 14.3;Ito cells: 14.1"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	6	"cerebellum: 69.1"	"Group enriched"	"Detected in some"	5	"basophil: 8.8;plasmacytoid DC: 9.8"	"Group enriched"	"Detected in many"	5	"dendritic cells: 9.8;granulocytes: 8.8"	"Cell line enhanced"	"Detected in many"		"AF22: 32.0;fHDF/TERT166: 15.0;HUVEC TERT2: 21.9;THP-1: 17.8"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in all"	6	"cerebellum: 105.4"	"HPA023056, HPA023849"	Enhanced		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA023056: AB_1859315, HPA023849: AB_1859316"	"unprognostic (8.80e-3)"	"unprognostic (9.68e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.40e-2)"	"unprognostic (5.43e-2)"	"unprognostic (3.73e-3)"	"unprognostic (1.52e-3)"	"unprognostic (6.17e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.18e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.19e-3)"	"unprognostic (1.16e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.52e-3)"	"unprognostic (7.82e-4)"	9.2	11.3	5.2	2.8	7.0	1.9	9.1	69.1	11.5	11.0	3.4	9.1	4.7	1.7	19.8	5.9	3.8	9.0	10.0	7.0	5.8	5.1	3.1	1.2	6.4	4.0	8.4	2.8	20.5	1.4	1.4	16.8	8.0	12.2	4.4	3.5	6.7	8.7	3.0	3.8	4.6	3.2	13.3	12.2	18.5	2.4	3.4	8.9	0.5	5.3	6.9	2.6	7.4	5.4	0.0	9.8	8.8	0.1	1.7	0.0	0.1	0.0	0.0	32.0	0.0	5.1	9.0	0.1	4.6	6.7	1.6	1.0	0.0	0.0	0.0	0.0	15.0	0.0	0.1	0.0	0.0	1.3	0.0	1.9	6.3	0.3	0.2	0.9	0.0	9.6	11.1	0.0	0.1	0.0	0.0	21.9	7.6	0.1	0.0	2.8	0.0	4.1	0.0	2.2	0.0	0.0	0.0	7.2	0.5	0.0	0.0	4.1	2.6	0.4	0.0	0.0	3.0	0.0	17.8	12.4	12.7	1.0	3.7	0.7	0.0	0.0	0.1	4.8	0.0	10.4	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.1	9.8	0.0	0.1	5.2	7.0	69.1	4.3	5.8	5.1	8.4	2.8	12.2	8.9	0.0	4.8	0.0	0.1	3.3	27.9	9.1	0.0	2.7	1.2	0.0	2.0	0.0	0.0	0.0	1.6	22.4	0.0	0.0	0.0	0.0	7.2	0.2	12.7	0.0	0.1	14.3	1.2	14.1	1.6	3.6	9.2	0.9	13.5	0.0	0.0	0.7	0.0	0.0	7.4	3.1	2.7	0.0	3.3	0.1	1.5	3.9	0.1	0.0	0.0	0.1
ZRSR2	"U2AF1-RS2, U2AF1L2, URP, ZC3H22"	ENSG00000169249	"Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2"	Q15696	X	15790472-15823260	"Cancer-related genes, Predicted intracellular proteins"	"mRNA processing, mRNA splicing"	"Ribonucleoprotein, RNA-binding"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"													NA	NA						"prognostic favorable (7.96e-4)"	"unprognostic (1.54e-2)"	"unprognostic (7.31e-2)"	"prognostic favorable (8.50e-5)"	"unprognostic (8.08e-2)"	"unprognostic (1.69e-1)"	"unprognostic (6.14e-3)"	"unprognostic (5.72e-3)"	"unprognostic (8.46e-2)"	"unprognostic (3.47e-3)"	"unprognostic (6.90e-2)"	"unprognostic (2.85e-2)"	"prognostic unfavorable (4.87e-5)"	"unprognostic (8.14e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.65e-2)"	"prognostic favorable (2.97e-4)"	11.4	9.7	16.7	13.4	21.7	32.5	14.2	22.5	22.1	20.7	13.6	7.6	11.2	9.1	17.1	17.7	10.9	11.8	8.8	12.8	16.1	14.4	11.5	8.2	13.9	21.7	18.1	11.6	16.7	9.2	15.7	31.1	9.8	16.0	11.8	10.9	9.4	10.6	10.6	31.7	12.3	12.4	14.5	20.1	21.1	9.5	4.8	17.5	7.9	12.8	5.6	16.5	21.8	16.7	23.8	17.8	22.0	18.8	10.2	20.3	7.6	9.5	6.4	11.0	10.3	15.6	13.5	4.4	7.9	7.4	7.7	7.8	7.5	7.9	10.9	13.6	7.3	19.7	9.4	10.6	13.7	8.0	8.1	14.0	7.2	15.1	7.0	10.7	16.4	16.9	6.7	12.6	14.1	23.0	15.1	13.3	10.5	11.3	10.8	9.2	11.7	8.7	17.3	14.0	5.0	8.9	10.1	15.4	11.1	9.1	7.6	7.7	8.4	18.5	16.5	11.5	15.7	13.0	9.5	9.3	7.7	5.5	20.2	7.4	9.2	7.7	10.4	5.9	11.9	9.9	22.0	18.8	16.6	13.5	16.6	13.1	21.6	17.1	18.0	10.9	23.8	20.3	14.8	21.0	10.2	15.6	17.8	16.0	7.6	16.7	21.7	22.5	22.1	16.1	14.4	18.1	11.6	16.0	17.5	8.9	19.5	19.6	9.7	10.1	13.0	20.2	5.1	25.4	17.0	15.7	13.7	6.1	19.9	11.9	1.0	13.5	12.1	0.0	12.9	6.7	11.0	6.3	31.2	12.5	17.3	7.9	16.1	8.6	25.9	1.1	12.7	29.4	11.8	22.6	11.2	9.0	11.1	9.1	15.6	11.0	18.4	19.4	17.9	3.8	3.8	9.3	6.1	30.8	11.5	6.5
